{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "machine_shape": "hm",
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KjO1baxs_hcr",
        "outputId": "339bd051-0684-4d95-eb58-81599d4e781b",
        "collapsed": true
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting PyMuPDF\n",
            "  Downloading PyMuPDF-1.24.10-cp310-none-manylinux2014_x86_64.whl.metadata (3.4 kB)\n",
            "Collecting PyMuPDFb==1.24.10 (from PyMuPDF)\n",
            "  Downloading PyMuPDFb-1.24.10-py3-none-manylinux2014_x86_64.manylinux_2_17_x86_64.whl.metadata (1.4 kB)\n",
            "Downloading PyMuPDF-1.24.10-cp310-none-manylinux2014_x86_64.whl (3.5 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.5/3.5 MB\u001b[0m \u001b[31m22.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading PyMuPDFb-1.24.10-py3-none-manylinux2014_x86_64.manylinux_2_17_x86_64.whl (15.9 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m15.9/15.9 MB\u001b[0m \u001b[31m67.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: PyMuPDFb, PyMuPDF\n",
            "Successfully installed PyMuPDF-1.24.10 PyMuPDFb-1.24.10\n",
            "Requirement already satisfied: gensim in /usr/local/lib/python3.10/dist-packages (4.3.3)\n",
            "Requirement already satisfied: nltk in /usr/local/lib/python3.10/dist-packages (3.8.1)\n",
            "Requirement already satisfied: matplotlib in /usr/local/lib/python3.10/dist-packages (3.7.1)\n",
            "Requirement already satisfied: numpy<2.0,>=1.18.5 in /usr/local/lib/python3.10/dist-packages (from gensim) (1.26.4)\n",
            "Requirement already satisfied: scipy<1.14.0,>=1.7.0 in /usr/local/lib/python3.10/dist-packages (from gensim) (1.13.1)\n",
            "Requirement already satisfied: smart-open>=1.8.1 in /usr/local/lib/python3.10/dist-packages (from gensim) (7.0.4)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk) (2024.5.15)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from nltk) (4.66.5)\n",
            "Requirement already satisfied: contourpy>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (1.3.0)\n",
            "Requirement already satisfied: cycler>=0.10 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (0.12.1)\n",
            "Requirement already satisfied: fonttools>=4.22.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (4.53.1)\n",
            "Requirement already satisfied: kiwisolver>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (1.4.7)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (24.1)\n",
            "Requirement already satisfied: pillow>=6.2.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (9.4.0)\n",
            "Requirement already satisfied: pyparsing>=2.3.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (3.1.4)\n",
            "Requirement already satisfied: python-dateutil>=2.7 in /usr/local/lib/python3.10/dist-packages (from matplotlib) (2.8.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.7->matplotlib) (1.16.0)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from smart-open>=1.8.1->gensim) (1.16.0)\n",
            "Requirement already satisfied: nltk in /usr/local/lib/python3.10/dist-packages (3.8.1)\n",
            "Requirement already satisfied: spacy in /usr/local/lib/python3.10/dist-packages (3.7.6)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk) (2024.5.15)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from nltk) (4.66.5)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (8.2.5)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.1.3)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (0.4.1)\n",
            "Requirement already satisfied: typer<1.0.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (0.12.5)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.32.3)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.9.1)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.1.4)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy) (71.0.4)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (24.1)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.4.0)\n",
            "Requirement already satisfied: numpy>=1.19.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.26.4)\n",
            "Requirement already satisfied: language-data>=1.2 in /usr/local/lib/python3.10/dist-packages (from langcodes<4.0.0,>=3.2.0->spacy) (1.2.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.3 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (2.23.3)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (4.12.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (2024.8.30)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy) (0.1.5)\n",
            "Requirement already satisfied: shellingham>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from typer<1.0.0,>=0.3.0->spacy) (1.5.4)\n",
            "Requirement already satisfied: rich>=10.11.0 in /usr/local/lib/python3.10/dist-packages (from typer<1.0.0,>=0.3.0->spacy) (13.8.1)\n",
            "Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.5.0,>=0.1.0->spacy) (0.19.0)\n",
            "Requirement already satisfied: smart-open<8.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from weasel<0.5.0,>=0.1.0->spacy) (7.0.4)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy) (2.1.5)\n",
            "Requirement already satisfied: marisa-trie>=0.7.7 in /usr/local/lib/python3.10/dist-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy) (1.2.0)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (2.16.1)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from smart-open<8.0.0,>=5.2.1->weasel<0.5.0,>=0.1.0->spacy) (1.16.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (0.1.2)\n",
            "Collecting bertopic\n",
            "  Downloading bertopic-0.16.3-py3-none-any.whl.metadata (23 kB)\n",
            "Collecting hdbscan>=0.8.29 (from bertopic)\n",
            "  Downloading hdbscan-0.8.38.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (15 kB)\n",
            "Requirement already satisfied: numpy>=1.20.0 in /usr/local/lib/python3.10/dist-packages (from bertopic) (1.26.4)\n",
            "Requirement already satisfied: pandas>=1.1.5 in /usr/local/lib/python3.10/dist-packages (from bertopic) (2.1.4)\n",
            "Requirement already satisfied: plotly>=4.7.0 in /usr/local/lib/python3.10/dist-packages (from bertopic) (5.15.0)\n",
            "Requirement already satisfied: scikit-learn>=0.22.2.post1 in /usr/local/lib/python3.10/dist-packages (from bertopic) (1.3.2)\n",
            "Collecting sentence-transformers>=0.4.1 (from bertopic)\n",
            "  Downloading sentence_transformers-3.1.0-py3-none-any.whl.metadata (23 kB)\n",
            "Requirement already satisfied: tqdm>=4.41.1 in /usr/local/lib/python3.10/dist-packages (from bertopic) (4.66.5)\n",
            "Collecting umap-learn>=0.5.0 (from bertopic)\n",
            "  Downloading umap_learn-0.5.6-py3-none-any.whl.metadata (21 kB)\n",
            "Requirement already satisfied: scipy>=1.0 in /usr/local/lib/python3.10/dist-packages (from hdbscan>=0.8.29->bertopic) (1.13.1)\n",
            "Requirement already satisfied: joblib>=1.0 in /usr/local/lib/python3.10/dist-packages (from hdbscan>=0.8.29->bertopic) (1.4.2)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2024.1)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2024.1)\n",
            "Requirement already satisfied: tenacity>=6.2.0 in /usr/local/lib/python3.10/dist-packages (from plotly>=4.7.0->bertopic) (9.0.0)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from plotly>=4.7.0->bertopic) (24.1)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn>=0.22.2.post1->bertopic) (3.5.0)\n",
            "Requirement already satisfied: transformers<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (4.44.2)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (2.4.0+cu121)\n",
            "Requirement already satisfied: huggingface-hub>=0.19.3 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (0.24.6)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (9.4.0)\n",
            "Requirement already satisfied: numba>=0.51.2 in /usr/local/lib/python3.10/dist-packages (from umap-learn>=0.5.0->bertopic) (0.60.0)\n",
            "Collecting pynndescent>=0.5 (from umap-learn>=0.5.0->bertopic)\n",
            "  Downloading pynndescent-0.5.13-py3-none-any.whl.metadata (6.8 kB)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.16.0)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2024.6.1)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (6.0.2)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2.32.3)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (4.12.2)\n",
            "Requirement already satisfied: llvmlite<0.44,>=0.43.0dev0 in /usr/local/lib/python3.10/dist-packages (from numba>=0.51.2->umap-learn>=0.5.0->bertopic) (0.43.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas>=1.1.5->bertopic) (1.16.0)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (1.13.2)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (3.3)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (3.1.4)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (2024.5.15)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (0.4.5)\n",
            "Requirement already satisfied: tokenizers<0.20,>=0.19 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (0.19.1)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (2.1.5)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2024.8.30)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (1.3.0)\n",
            "Downloading bertopic-0.16.3-py3-none-any.whl (143 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m143.5/143.5 kB\u001b[0m \u001b[31m3.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading hdbscan-0.8.38.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (4.2 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m4.2/4.2 MB\u001b[0m \u001b[31m40.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading sentence_transformers-3.1.0-py3-none-any.whl (249 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m249.1/249.1 kB\u001b[0m \u001b[31m19.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading umap_learn-0.5.6-py3-none-any.whl (85 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m85.7/85.7 kB\u001b[0m \u001b[31m7.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pynndescent-0.5.13-py3-none-any.whl (56 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m56.9/56.9 kB\u001b[0m \u001b[31m4.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pynndescent, hdbscan, umap-learn, sentence-transformers, bertopic\n",
            "Successfully installed bertopic-0.16.3 hdbscan-0.8.38.post1 pynndescent-0.5.13 sentence-transformers-3.1.0 umap-learn-0.5.6\n",
            "Collecting en-core-web-sm==3.7.1\n",
            "  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_sm-3.7.1/en_core_web_sm-3.7.1-py3-none-any.whl (12.8 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m12.8/12.8 MB\u001b[0m \u001b[31m37.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: spacy<3.8.0,>=3.7.2 in /usr/local/lib/python3.10/dist-packages (from en-core-web-sm==3.7.1) (3.7.6)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (8.2.5)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.1.3)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.4.1)\n",
            "Requirement already satisfied: typer<1.0.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.12.5)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (4.66.5)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.32.3)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.9.1)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.1.4)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (71.0.4)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (24.1)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.4.0)\n",
            "Requirement already satisfied: numpy>=1.19.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.26.4)\n",
            "Requirement already satisfied: language-data>=1.2 in /usr/local/lib/python3.10/dist-packages (from langcodes<4.0.0,>=3.2.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.2.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.3 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.23.3)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (4.12.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2024.8.30)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.1.5)\n",
            "Requirement already satisfied: click>=8.0.0 in /usr/local/lib/python3.10/dist-packages (from typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (8.1.7)\n",
            "Requirement already satisfied: shellingham>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.5.4)\n",
            "Requirement already satisfied: rich>=10.11.0 in /usr/local/lib/python3.10/dist-packages (from typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (13.8.1)\n",
            "Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.5.0,>=0.1.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.19.0)\n",
            "Requirement already satisfied: smart-open<8.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from weasel<0.5.0,>=0.1.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (7.0.4)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.1.5)\n",
            "Requirement already satisfied: marisa-trie>=0.7.7 in /usr/local/lib/python3.10/dist-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.2.0)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.16.1)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from smart-open<8.0.0,>=5.2.1->weasel<0.5.0,>=0.1.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.16.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.1.2)\n",
            "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
            "You can now load the package via spacy.load('en_core_web_sm')\n",
            "\u001b[38;5;3m⚠ Restart to reload dependencies\u001b[0m\n",
            "If you are in a Jupyter or Colab notebook, you may need to restart Python in\n",
            "order to load all the package's dependencies. You can do this by selecting the\n",
            "'Restart kernel' or 'Restart runtime' option.\n",
            "Collecting pyLDAvis\n",
            "  Downloading pyLDAvis-3.4.1-py3-none-any.whl.metadata (4.2 kB)\n",
            "Requirement already satisfied: numpy>=1.24.2 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.26.4)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.13.1)\n",
            "Requirement already satisfied: pandas>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (2.1.4)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.4.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (3.1.4)\n",
            "Requirement already satisfied: numexpr in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (2.10.1)\n",
            "Collecting funcy (from pyLDAvis)\n",
            "  Downloading funcy-2.0-py2.py3-none-any.whl.metadata (5.9 kB)\n",
            "Requirement already satisfied: scikit-learn>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.3.2)\n",
            "Requirement already satisfied: gensim in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (4.3.3)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (71.0.4)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2024.1)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2024.1)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn>=1.0.0->pyLDAvis) (3.5.0)\n",
            "Requirement already satisfied: smart-open>=1.8.1 in /usr/local/lib/python3.10/dist-packages (from gensim->pyLDAvis) (7.0.4)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->pyLDAvis) (2.1.5)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas>=2.0.0->pyLDAvis) (1.16.0)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from smart-open>=1.8.1->gensim->pyLDAvis) (1.16.0)\n",
            "Downloading pyLDAvis-3.4.1-py3-none-any.whl (2.6 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.6/2.6 MB\u001b[0m \u001b[31m16.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading funcy-2.0-py2.py3-none-any.whl (30 kB)\n",
            "Installing collected packages: funcy, pyLDAvis\n",
            "Successfully installed funcy-2.0 pyLDAvis-3.4.1\n",
            "Collecting contractions\n",
            "  Downloading contractions-0.1.73-py2.py3-none-any.whl.metadata (1.2 kB)\n",
            "Collecting textsearch>=0.0.21 (from contractions)\n",
            "  Downloading textsearch-0.0.24-py2.py3-none-any.whl.metadata (1.2 kB)\n",
            "Collecting anyascii (from textsearch>=0.0.21->contractions)\n",
            "  Downloading anyascii-0.3.2-py3-none-any.whl.metadata (1.5 kB)\n",
            "Collecting pyahocorasick (from textsearch>=0.0.21->contractions)\n",
            "  Downloading pyahocorasick-2.1.0-cp310-cp310-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_12_x86_64.manylinux2010_x86_64.whl.metadata (13 kB)\n",
            "Downloading contractions-0.1.73-py2.py3-none-any.whl (8.7 kB)\n",
            "Downloading textsearch-0.0.24-py2.py3-none-any.whl (7.6 kB)\n",
            "Downloading anyascii-0.3.2-py3-none-any.whl (289 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m289.9/289.9 kB\u001b[0m \u001b[31m4.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pyahocorasick-2.1.0-cp310-cp310-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_12_x86_64.manylinux2010_x86_64.whl (110 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m110.7/110.7 kB\u001b[0m \u001b[31m9.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pyahocorasick, anyascii, textsearch, contractions\n",
            "Successfully installed anyascii-0.3.2 contractions-0.1.73 pyahocorasick-2.1.0 textsearch-0.0.24\n"
          ]
        }
      ],
      "source": [
        "!pip install PyMuPDF\n",
        "!pip install gensim nltk matplotlib\n",
        "!pip install nltk spacy\n",
        "!pip install bertopic\n",
        "!python -m spacy download en_core_web_sm\n",
        "!pip install pyLDAvis\n",
        "!pip install contractions\n",
        "\n",
        "import os\n",
        "import fitz  # PyMuPDF\n",
        "import nltk\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "from nltk.tokenize import word_tokenize, sent_tokenize\n",
        "from nltk.corpus import stopwords\n",
        "import string\n",
        "import spacy\n",
        "import re # regular expressions\n",
        "import matplotlib.pyplot as plt\n",
        "from google.colab import drive\n",
        "import pyLDAvis.gensim_models as gensimvis\n",
        "import pyLDAvis\n",
        "import gensim\n",
        "import contractions\n",
        "\n",
        "from gensim.corpora import Dictionary\n",
        "from gensim.models.ldamodel import LdaModel\n",
        "from gensim.models.ldaseqmodel import LdaSeqModel\n",
        "from gensim.models import CoherenceModel\n",
        "from gensim import corpora\n",
        "from datetime import datetime\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "os.makedirs('/root/.kaggle/', exist_ok=True)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "d8wI7EuHjgL0",
        "outputId": "0dc59087-d39a-4c35-fcb0-fe8fc0c81fe5"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "nlp = spacy.load('en_core_web_sm')\n",
        "nltk.download('wordnet')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "4Atc7mCVqQ7G",
        "outputId": "274849bd-49ce-40e4-e4e0-5541fce5a08b"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n",
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n",
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 2
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Mount Google Drive\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9ySHONtO_rq8",
        "outputId": "9c747dab-3512-413a-cd74-da8bd6410eeb"
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### LDA"
      ],
      "metadata": {
        "id": "PxA_gpze3-4N"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# convert PDF in text\n",
        "\n",
        "#Tranform PDF to text all accepted documents from 2020 to 2024\n",
        "\n",
        "# Specify the base folder path, modify for either \"accepted_all\" or \"denied_all \"\n",
        "base_folder_path = '/content/drive/My Drive/thesis/nccn_guidelines/submission_requests/denied_all'\n",
        "\n",
        "# List to hold the text from each PDF\n",
        "pdf_texts = []\n",
        "\n",
        "# List to hold the text from each PDF\n",
        "pdf_count=0\n",
        "\n",
        "\n",
        "# Walk through all directories and files within the base folder\n",
        "for root, dirs, files in os.walk(base_folder_path):\n",
        "    for filename in files:\n",
        "        # Check if the file is a PDF\n",
        "        if filename.endswith(\".pdf\"):\n",
        "            # Full path to the PDF file\n",
        "            file_path = os.path.join(root, filename)\n",
        "\n",
        "            # Open the PDF file\n",
        "            doc = fitz.open(file_path)\n",
        "\n",
        "            # Extract text from each page\n",
        "            text = \"\"\n",
        "            for page_num in range(len(doc)):\n",
        "                page = doc.load_page(page_num)\n",
        "                text += page.get_text()\n",
        "\n",
        "            # Append the extracted text to the list\n",
        "            pdf_texts.append({\n",
        "                \"filename\": filename,\n",
        "                \"text\": text,\n",
        "            })\n",
        "\n",
        "            # Increment the counter\n",
        "            pdf_count += 1\n",
        "\n",
        "# Print the total number of PDFs processed\n",
        "print(f\"Total number of PDFs processed: {pdf_count}\")\n",
        "\n",
        "# Display the text and tokenized data extracted from each PDF\n",
        "for pdf in pdf_texts:\n",
        "    print(f\"Text from {pdf['filename']}:\")\n",
        "    print(pdf['text'][:500])  # Print first 500 characters for brevity\n",
        "    print(\"\\n---\\n\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "z9pmqL5Cdj3r",
        "outputId": "4dd5d626-592b-4dcd-a249-608e898e703a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Total number of PDFs processed: 37\n",
            "Text from 2021_05_28_Ilumina.pdf:\n",
            "Name: David Eberhard MD, PhD \n",
            "Company/Organization: Illumina Inc. \n",
            "Address: 5200 Illumina Way, San Diego CA 92122 \n",
            "Phone: 6503769577 \n",
            "Email: deberhard@illumina.com \n",
            "Date of request: May 28, 2021 \n",
            "NCCN Guidelines Cutaneous Melanoma \n",
            " \n",
            "On behalf of Illumina, I respectfully request the NCCN Guideline Panel for Cutaneous Melanoma to \n",
            "consider the enclosed information for the inclusion of liquid biopsy-based DNA testing as a \n",
            "complimentary alternative to tissue testing for the assessment of genetic v\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_07_BrystolMayers.pdf:\n",
            "1 \n",
            "June 07, 2021 \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike  \n",
            "Lawrence, New Jersey 08648 \n",
            "NCCN Guidelines® Panel: Melanoma Panel \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel review the data recently \n",
            "presented at the American Society of Clinical Oncology (ASCO) 2021 Meeting on the use of OPDIVO® \n",
            "(nivolumab) plus YERVOY® (ipilimumab) for the treatment of patients with unresectabl\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_07_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 07, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IV melanoma. \n",
            " \n",
            "Specific Changes: We respectfully req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_Astro.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Email: Submissions@nccn.org  \n",
            " \n",
            "Date of Request: June 11, 2021 \n",
            " \n",
            " \n",
            " \n",
            "The American Society for Radiation Oncology has reviewed the 2021 NCCN cutaneous melanoma guideline \n",
            "for gaps relative to radiation therapy. We offer two major recommendations supported by evidence-based \n",
            "rationales and one minor recommendation for your consideration. \n",
            " \n",
            "We hope you find these recommendations useful to your panel as you review and update the guidelines. \n",
            " \n",
            "Sincerely, \n",
            " \n",
            "Laura I. Thevenot  \n",
            "Chief E\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_Castle.pdf:\n",
            "Castle Biosciences, Inc.  \n",
            "NCCN Guidelines Melanoma Panel \n",
            " \n",
            "1 \n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: Jay Braxton, PharmD \n",
            "Company:  Castle Biosciences, Inc. \n",
            "Address:  505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546 \n",
            "Phone: (336) 944-1365 \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of Submission of Requested Amendments: 11 June 2021  \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "To the Members of the NCCN Guidelines Melanoma Panel: \n",
            "On behalf of Castle Biosciences, thank you for the time and attention\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_PartnerTerapeutics.pdf:\n",
            " \n",
            " \n",
            "Hillard M Lazarus, MD, FACP \n",
            "Partner Therapeutics, Inc. \n",
            " \n",
            "19 Muzzey Street, Lexington, MA 02421 \n",
            "hillard.lazarus@partnertx.com \n",
            "216-978-8003 \n",
            " \n",
            "June 11, 2021 \n",
            " \n",
            "Dear NCCN Cutaneous Melanoma Guideline Panel:  \n",
            " \n",
            "On behalf of Partner Therapeutics, I respectfully request the NCCN Cutaneous Melanoma Guideline \n",
            "Committee review the enclosed data that support adding the combination of ipilimumab and \n",
            "sargramostim (glycosylated yeast-derived rhu GM-CSF) to the Guideline as a second-line or subsequ\n",
            "\n",
            "---\n",
            "\n",
            "Text from 20201_06_01_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 06, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Changes: We resp\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2024_02_21_Iovance.pdf:\n",
            "Prince, Emily\n",
            "emily.prince@iovance.com\n",
            "6143714737\n",
            "February 21, 2024\n",
            "Company: Iovance, Iovance Biotherapeutics, Inc.\n",
            " \n",
            "Guideline: Melanoma: Cutaneous\n",
            " \n",
            "Panel: Melanoma Panel\n",
            " \n",
            "Algorithm Page Number: ME-J 3 of 4 page 100\n",
            " \n",
            "Specific Change Recommended:\n",
            "Please consider the addition of the following bulleted point in the first column under BRAF V600-\n",
            "activating mutation present: “For patients with progression on anti-PD-1 containing therapy and BRAF ± \n",
            "MEK inhibitor combination therapy, consider lifi\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2022_09_29_Castle.pdf:\n",
            "C/&STLH\n",
            "Submitted by\n",
            "Jay Braxton, Pharm. D., Vice President of Medical Affairs\n",
            "Castle Biosciences, lnc\n",
            "505 S. Friendswood Drive, 4m Floor, Friendswood, TX 77546\n",
            "Ph : 28 1 . 853.9357 | | Ema il : jbraxto n@castlebiosciences.com\n",
            "Date of Request: 912912022\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma Subcommittee)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations as well as the panel's willingness to update those recommendations based on th\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_01_13_Merck.pdf:\n",
            " \n",
            "Name: Suzana Giffin, AVP Global Medical Affairs \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd. \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 13, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA (pembrolizumab), in reference to unresectable \n",
            "or metastatic melanoma with brain metastasis. \n",
            " \n",
            "Specif\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_15_Castle.pdf:\n",
            "C/'STLA\n",
            ":\n",
            "Submitted by\n",
            "Jay Braxton, Pharnn. D., Executive Director of MedicalAffairs\n",
            "Castle Biosciences, Inc\n",
            "820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546\n",
            "Ph: 281.853.9357 ll Email: jbraxton@castlebiosciences.com\n",
            "Date of Request: 0611512020\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations, as it is essential that clinical decision-making be based on the highest level of peer-\n",
            "re\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_16_DermTech.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: DermTech, Inc  \n",
            "Name: Burkhard Jansen, MD, Chief Medical Officer \n",
            "Company/Organization: DermTech, Inc. \n",
            "Address: 11099 N Torrey Pines Road, Suite 100, La Jolla, CA 92037 \n",
            "Phone: (858)249-9413 \n",
            "Email: bjansen@dermtech.com \n",
            "Date of request: June 16, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "On behalf of DermTech, Inc., I respectfully request the NCCN Melanoma Panel review the enclosed data on DermTech’s \n",
            "pre-biopsy and biopsy guiding n\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_17_Castle.pdf:\n",
            " \n",
            " \n",
            "Submitted by:  \n",
            "Name:  Jay Braxton, PharmD, Executive Director, Medical Affairs \n",
            "Company:  Castle Biosciences, Inc.  \n",
            "Address:  820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546 \n",
            "Phone:  281-853-9357  \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of request:  6/17/20 \n",
            "NCCN Guidelines Panel:  Melanoma \n",
            " \n",
            "Castle Biosciences Inc. would like to thank the NCCN Panel for updating guidance on gene expression profiling (GEP) in the \n",
            "2020 guideline versions. While we appreciate the fact that\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_21_DermatologicSurgeryWashington.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: Gary L. Peck, MD \n",
            "Company/Organization: Dermatologic Surgery Center of Washington \n",
            "Address: 5530 Wisconsin Avenue, Suite 820, Chevy Chase, MD 20815 \n",
            "Phone: (301) 652-8081 \n",
            "Email: garypeck1@gmail.com  \n",
            "Date of request: June 21, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Re: Clinical Utility of the DermTech Pigmented Lesion Assay \n",
            " \n",
            "My experience as the director, Melanoma Center, Washington Hospital Center, Washington DC from \n",
            "1996 to 2015 included accruing about 2000 \n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_22_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to the evaluation and management of patients with melanoma. \n",
            "Req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_22_SUNY.pdf:\n",
            " \n",
            "1 \n",
            "June 22, 2020 \n",
            " \n",
            "Re: DermTech’s Pigmented Lesion Assay /NCCN \n",
            " \n",
            "Submitted by: \n",
            "Name: Daniel M. Siegel MD, MS \n",
            "Company/Organization: SUNY Downstate \n",
            "Address: Basic Sci Bldg 849 450 Clarkson Avenue, Box46, Brooklyn 11203 \n",
            "Phone: 718 270 1229 \n",
            "Email: Daniel.siegel@downstate.edu \n",
            "Date of Request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            " \n",
            "Dear Cutaneous Melanoma Panel Members: \n",
            " \n",
            "As a clinician and clinical researcher, I’ve not only studied and published, but also incorporate\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_23_Northwestern.pdf:\n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: June K. Robinson, MD – Research Professor of Dermatology \n",
            "Company/Organization: Northwestern University Feinberg School of Medicine, Department of \n",
            "Dermatology \n",
            "Address: 645 N. Michigan Ave, Suite 1050, Chicago, IL 60611 \n",
            "Phone: 312-503-5941 \n",
            "Email: june-robinson@northwestern.edu \n",
            "Date of Request: June 23, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "June 23, 2020 \n",
            "To: NCCN Cutaneous Melanoma Panel; submissions@nccn.org  \n",
            "Re: DermTech’s Pigmented Lesion Assay  \n",
            " \n",
            "D\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_23_UPMC.pdf:\n",
            " \n",
            " \n",
            "NCCN Cutaneous Melanoma Guidelines Panel  \n",
            " \n",
            "Submitted by: \n",
            "Name: Laura K. Ferris, MD, PhD \n",
            "Organization: UPMC \n",
            "Address: Please see above \n",
            "Phone: Please see above \n",
            "Email: ferrlk@UPMC.EDU \n",
            "Date of request: 06232020 \n",
            "NCCN Guidelines Panel – Cutaneous Melanoma \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "Regarding: NCCN Guidelines for Cutaneous Melanoma – Pigmented Lesion Assay \n",
            "Dear NCCN Cutaneous Melanoma Panel Members: \n",
            "I have served as the lead investigator for several clinical studies invol\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_09_15_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: Original submission June 22, 2020; highlighted updates September 15, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to t\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_16_DermTech.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: DermTech, Inc  \n",
            "Name: Burkhard Jansen, MD, Chief Medical Officer \n",
            "Company/Organization: DermTech, Inc. \n",
            "Address: 11099 N Torrey Pines Road, Suite 100, La Jolla, CA 92037 \n",
            "Phone: (858)249-9413 \n",
            "Email: bjansen@dermtech.com \n",
            "Date of request: June 16, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "On behalf of DermTech, Inc., I respectfully request the NCCN Melanoma Panel review the enclosed data on DermTech’s \n",
            "pre-biopsy and biopsy guiding n\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_Castle.pdf:\n",
            "Castle Biosciences, Inc.  \n",
            "NCCN Guidelines Melanoma Panel \n",
            " \n",
            "1 \n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: Jay Braxton, PharmD \n",
            "Company:  Castle Biosciences, Inc. \n",
            "Address:  505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546 \n",
            "Phone: (336) 944-1365 \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of Submission of Requested Amendments: 11 June 2021  \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "To the Members of the NCCN Guidelines Melanoma Panel: \n",
            "On behalf of Castle Biosciences, thank you for the time and attention\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_23_Northwestern.pdf:\n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: June K. Robinson, MD – Research Professor of Dermatology \n",
            "Company/Organization: Northwestern University Feinberg School of Medicine, Department of \n",
            "Dermatology \n",
            "Address: 645 N. Michigan Ave, Suite 1050, Chicago, IL 60611 \n",
            "Phone: 312-503-5941 \n",
            "Email: june-robinson@northwestern.edu \n",
            "Date of Request: June 23, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "June 23, 2020 \n",
            "To: NCCN Cutaneous Melanoma Panel; submissions@nccn.org  \n",
            "Re: DermTech’s Pigmented Lesion Assay  \n",
            " \n",
            "D\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_09_15_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: Original submission June 22, 2020; highlighted updates September 15, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to t\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_Astro.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Email: Submissions@nccn.org  \n",
            " \n",
            "Date of Request: June 11, 2021 \n",
            " \n",
            " \n",
            " \n",
            "The American Society for Radiation Oncology has reviewed the 2021 NCCN cutaneous melanoma guideline \n",
            "for gaps relative to radiation therapy. We offer two major recommendations supported by evidence-based \n",
            "rationales and one minor recommendation for your consideration. \n",
            " \n",
            "We hope you find these recommendations useful to your panel as you review and update the guidelines. \n",
            " \n",
            "Sincerely, \n",
            " \n",
            "Laura I. Thevenot  \n",
            "Chief E\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_21_DermatologicSurgeryWashington.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: Gary L. Peck, MD \n",
            "Company/Organization: Dermatologic Surgery Center of Washington \n",
            "Address: 5530 Wisconsin Avenue, Suite 820, Chevy Chase, MD 20815 \n",
            "Phone: (301) 652-8081 \n",
            "Email: garypeck1@gmail.com  \n",
            "Date of request: June 21, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Re: Clinical Utility of the DermTech Pigmented Lesion Assay \n",
            " \n",
            "My experience as the director, Melanoma Center, Washington Hospital Center, Washington DC from \n",
            "1996 to 2015 included accruing about 2000 \n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_17_Castle.pdf:\n",
            " \n",
            " \n",
            "Submitted by:  \n",
            "Name:  Jay Braxton, PharmD, Executive Director, Medical Affairs \n",
            "Company:  Castle Biosciences, Inc.  \n",
            "Address:  820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546 \n",
            "Phone:  281-853-9357  \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of request:  6/17/20 \n",
            "NCCN Guidelines Panel:  Melanoma \n",
            " \n",
            "Castle Biosciences Inc. would like to thank the NCCN Panel for updating guidance on gene expression profiling (GEP) in the \n",
            "2020 guideline versions. While we appreciate the fact that\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_15_Castle.pdf:\n",
            "C/'STLA\n",
            ":\n",
            "Submitted by\n",
            "Jay Braxton, Pharnn. D., Executive Director of MedicalAffairs\n",
            "Castle Biosciences, Inc\n",
            "820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546\n",
            "Ph: 281.853.9357 ll Email: jbraxton@castlebiosciences.com\n",
            "Date of Request: 0611512020\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations, as it is essential that clinical decision-making be based on the highest level of peer-\n",
            "re\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2022_09_29_Castle.pdf:\n",
            "C/&STLH\n",
            "Submitted by\n",
            "Jay Braxton, Pharm. D., Vice President of Medical Affairs\n",
            "Castle Biosciences, lnc\n",
            "505 S. Friendswood Drive, 4m Floor, Friendswood, TX 77546\n",
            "Ph : 28 1 . 853.9357 | | Ema il : jbraxto n@castlebiosciences.com\n",
            "Date of Request: 912912022\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma Subcommittee)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations as well as the panel's willingness to update those recommendations based on th\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_05_28_Ilumina.pdf:\n",
            "Name: David Eberhard MD, PhD \n",
            "Company/Organization: Illumina Inc. \n",
            "Address: 5200 Illumina Way, San Diego CA 92122 \n",
            "Phone: 6503769577 \n",
            "Email: deberhard@illumina.com \n",
            "Date of request: May 28, 2021 \n",
            "NCCN Guidelines Cutaneous Melanoma \n",
            " \n",
            "On behalf of Illumina, I respectfully request the NCCN Guideline Panel for Cutaneous Melanoma to \n",
            "consider the enclosed information for the inclusion of liquid biopsy-based DNA testing as a \n",
            "complimentary alternative to tissue testing for the assessment of genetic v\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_11_PartnerTerapeutics.pdf:\n",
            " \n",
            " \n",
            "Hillard M Lazarus, MD, FACP \n",
            "Partner Therapeutics, Inc. \n",
            " \n",
            "19 Muzzey Street, Lexington, MA 02421 \n",
            "hillard.lazarus@partnertx.com \n",
            "216-978-8003 \n",
            " \n",
            "June 11, 2021 \n",
            " \n",
            "Dear NCCN Cutaneous Melanoma Guideline Panel:  \n",
            " \n",
            "On behalf of Partner Therapeutics, I respectfully request the NCCN Cutaneous Melanoma Guideline \n",
            "Committee review the enclosed data that support adding the combination of ipilimumab and \n",
            "sargramostim (glycosylated yeast-derived rhu GM-CSF) to the Guideline as a second-line or subsequ\n",
            "\n",
            "---\n",
            "\n",
            "Text from 20201_06_01_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 06, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Changes: We resp\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_07_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 07, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IV melanoma. \n",
            " \n",
            "Specific Changes: We respectfully req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_23_UPMC.pdf:\n",
            " \n",
            " \n",
            "NCCN Cutaneous Melanoma Guidelines Panel  \n",
            " \n",
            "Submitted by: \n",
            "Name: Laura K. Ferris, MD, PhD \n",
            "Organization: UPMC \n",
            "Address: Please see above \n",
            "Phone: Please see above \n",
            "Email: ferrlk@UPMC.EDU \n",
            "Date of request: 06232020 \n",
            "NCCN Guidelines Panel – Cutaneous Melanoma \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "Regarding: NCCN Guidelines for Cutaneous Melanoma – Pigmented Lesion Assay \n",
            "Dear NCCN Cutaneous Melanoma Panel Members: \n",
            "I have served as the lead investigator for several clinical studies invol\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_22_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to the evaluation and management of patients with melanoma. \n",
            "Req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2021_06_07_BrystolMayers.pdf:\n",
            "1 \n",
            "June 07, 2021 \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike  \n",
            "Lawrence, New Jersey 08648 \n",
            "NCCN Guidelines® Panel: Melanoma Panel \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel review the data recently \n",
            "presented at the American Society of Clinical Oncology (ASCO) 2021 Meeting on the use of OPDIVO® \n",
            "(nivolumab) plus YERVOY® (ipilimumab) for the treatment of patients with unresectabl\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_06_22_SUNY.pdf:\n",
            " \n",
            "1 \n",
            "June 22, 2020 \n",
            " \n",
            "Re: DermTech’s Pigmented Lesion Assay /NCCN \n",
            " \n",
            "Submitted by: \n",
            "Name: Daniel M. Siegel MD, MS \n",
            "Company/Organization: SUNY Downstate \n",
            "Address: Basic Sci Bldg 849 450 Clarkson Avenue, Box46, Brooklyn 11203 \n",
            "Phone: 718 270 1229 \n",
            "Email: Daniel.siegel@downstate.edu \n",
            "Date of Request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            " \n",
            "Dear Cutaneous Melanoma Panel Members: \n",
            " \n",
            "As a clinician and clinical researcher, I’ve not only studied and published, but also incorporate\n",
            "\n",
            "---\n",
            "\n",
            "Text from 2020_01_13_Merck.pdf:\n",
            " \n",
            "Name: Suzana Giffin, AVP Global Medical Affairs \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd. \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 13, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA (pembrolizumab), in reference to unresectable \n",
            "or metastatic melanoma with brain metastasis. \n",
            " \n",
            "Specif\n",
            "\n",
            "---\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pdf_texts[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nTcFUA0JPd2t",
        "outputId": "92f9d9c0-80f8-4e59-d00d-46591527084c",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'filename': '2024_02_21_Submission_Melanoma__Cutaneous.pdf',\n",
              " 'text': 'Prince, Emily\\nemily.prince@iovance.com\\n6143714737\\nFebruary 21, 2024\\nCompany: Iovance, Iovance Biotherapeutics, Inc.\\n \\nGuideline: Melanoma: Cutaneous\\n \\nPanel: Melanoma Panel\\n \\nAlgorithm Page Number: MELSYS 1 of 7, page 52\\n \\nSpecific Change Recommended:\\nPlease consider the inclusion of lifileucel in the guideline as a Preferred Regimen for second-line or \\nsubsequent therapy for patients with unresectable or metastatic melanoma along with the accompanying \\nfootnote: \"Includes tumor resection for the manufacture of lifileucel as well as it\\'s infusion.\"  \\n \\nFDA Clearance: On February 16, 2024, the US Food and Drug Administration granted approval of \\nAMTAGVI™ (lifileucel) for the treatment of adult patients with unresectable or metastatic melanoma \\npreviously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor \\nwith or without a MEK inhibitor. This indication is approved under accelerated approval based on objective \\nresponse rate (ORR). Continued approval for this indication may be contingent upon verification and \\ndescription of clinical benefit in a confirmatory trial(s).1\\n \\nRationale for Recommended Changes: Tumor-infiltrating lymphocytes (TIL) are cytotoxic and helper T \\ncells that infiltrate tumors as a component of the immunological response to a patient’s cancer.2 Through a \\nprocess pioneered by researchers at the National Cancer Institute, TIL can be recovered directly from the \\npatient’s tumor tissue, amplified, and reinvigorated to produce billions of polyclonal, patient-specific TIL.3 \\nUpon reinfusion into the patient, these autologous T cells recognize and target a multitude of individualized, \\ntumor-specific neoantigens.2,3 Over decades this process has provided numerous patients long-term durable \\nclinical responses, and has continued to show clinical efficacy despite the dramatic changes in the \\ntherapeutic landscape for melanoma.4,5 This level of validation has occurred not just at the NCI but at \\nexternal centers including in a recent pivotal randomized clinical trial.6  \\n \\nLifileucel is the first and only tumor-derived autologous T cell immunotherapy that is approved by the FDA \\nfor patients with metastatic or unresectable melanoma, representing a new treatment modality and option for \\npatients with disease progression on or after approved therapies.1 Although the exact mechanism of action \\nof lifileucel is unknown, it is thought that the autologous T cells infiltrate the tumor and mediate a cytotoxic \\neffect. Like other cell therapies, lifileucel is given as part of a regimen with lymphodepletion and IL-2. \\nLifileucel manufacturing, which uses a centralized process, relies on existing surgical techniques to provide \\nthe starting material for producing this T cell therapy. Lifileucel can be manufactured using tumor tissue \\nfrom any anatomic location. Close coordination across multidisciplinary teams, including surgeons, is \\nneeded to ensure patient access to this new therapy. \\n \\nStudy Summary: C-144-01 (NCT02360579) is a Phase 2 global, multicenter, multicohort, open-label clinical \\ntrial that evaluated the safety and efficacy of lifileucel in adult patients with unresectable or metastatic \\nmelanoma who received more than one prior therapy, including a PD-1 blocking antibody and, if BRAF \\nV600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor.2 FDA approval is based on 73 \\npatients in Cohort 4 of this trial who received lifileucel at the recommended dose of 7.5 × 109 to 72 × 109 \\nviable cells manufactured at a central facility. The ORR in this population was 31.5% (95% CI 21.1, 43.4). \\nA supporting pooled analysis of Cohorts 2 and 4 (N=153), which had identical eligibility criteria and \\ntreatment regimen, yielded a similar ORR of 31.4% (95% CI: 24.1, 39.4).1 Patients in these cohorts were \\nheavily pretreated with a median of three prior lines of therapy (range 1 to 9).2  \\n \\nIn a four-year efficacy analysis of the pooled population, 79.3% of patients had a reduction in tumor burden \\nand the response to lifileucel was shown to be durable with the median duration of response Not Reached \\n(8.3 months, NR) with a median follow-up of 48.1 months.7 Responses have deepened over time: 7 patients \\n(14.6%) initially assessed as a PR achieved a confirmed CR and 10 patients (20.8%) improved from SD to \\nPR.7,8 Responses to lifileucel were observed in all subgroups analyzed, regardless of age, prior anti-CTLA-\\n4 use, BRAF mutation status, and PD-1 status, as well as in both non-mucosal and mucosal subsets.7  \\n \\nSafety was assessed in 156 patients who received lifileucel. The most common non-laboratory adverse \\nreactions (incidence of =20%) of any grade were chills, pyrexia, fatigue, tachycardia, diarrhea, febrile \\nneutropenia, edema, rash, hypotension, alopecia, infection, hypoxia, and dyspnea. Grade 3 or 4 laboratory \\nabnormalities occurring in =10% of patients were thrombocytopenia, neutropenia, anemia, leukopenia, \\nlymphopenia, and hypophosphatemia.1 Please see attached prescribing information for full safety \\ninformation, including boxed warning and warnings and precautions. \\n \\nThe following resources are enclosed to assist the committee with its review: \\n1. AMTAGVI™ (lifileucel) package insert. Iovance Biotherapeutics Inc, 2024.  \\n2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-\\ninfiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune \\ncheckpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J \\nImmunother Cancer 2022;10(12):e005755. \\n3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with \\ntumor-infiltrating lymphocytes. Science 1986;233:1318-21. \\n4. Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of \\nlymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic \\nmelanoma. J Clin Oncol 2016;34:2389-97. \\n5. Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of \\ntumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res 2021;27:5289-98. \\n6. Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in \\nadvanced melanoma. N Engl J Med 2023;388:859-60. \\n7. Medina T, Chesney JA, Whitman E, et al. Long-term efficacy and safety of lifileucel tumor-infiltrating \\nlymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 \\nstudy. J Immunother Cancer 2023;11(Suppl 1):A873. \\n8. Egger, ME, McCarter M, Olino K, et al Lifileucel TIL cell therapy in patients with advanced melanoma \\nafter progression on immune checkpoint inhibitors (ICI) and targeted therapy: Tumor tissue procurement \\ndata from the C-144-01 study. Ann Surg Oncol 2023;23(Suppl 1):S5. \\n \\nCitations:\\n1. AMTAGVI™ (lifileucel) package insert. Iovance Biotherapeutics Inc, 2024.\\n \\n2. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-\\ninfiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune \\ncheckpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J \\nImmunother Cancer 2022;10(12):e005755.\\n \\n3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with \\ntumor-infiltrating lymphocytes. Science 1986;233:1318-21.\\n \\n4. Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of \\nlymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic \\nmelanoma. J Clin Oncol 2016;34:2389-97.\\n \\n5. Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of \\ntumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res 2021;27:5289-98.\\n \\n6. Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in \\nadvanced melanoma. N Engl J Med 2023;388:859-60.\\n \\n7. Medina T, Chesney JA, Whitman E, et al. Long-term efficacy and safety of lifileucel tumor-infiltrating \\nlymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 \\nstudy. J Immunother Cancer 2023;11(Suppl 1):A873.\\n \\n8. Egger, ME, McCarter M, Olino K, et al Lifileucel TIL cell therapy in patients with advanced melanoma \\nafter progression on immune checkpoint inhibitors (ICI) and targeted therapy: Tumor tissue procurement \\ndata from the C-144-01 study. Ann Surg Oncol 2023;23(Suppl 1):S5.\\n \\n'}"
            ]
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def preprocess_text(pdf_texts):\n",
        "    \"\"\"\n",
        "    Preprocesses text by tokenizing, lowercasing, removing stop words, removing abbreviations, and lemmatizing.\n",
        "\n",
        "    Parameters:\n",
        "    pdf_texts (dict): Dictionary containing \"filename\" and \"text\".\n",
        "\n",
        "    Returns:\n",
        "    dict: Dictionary with the same structure, but the \"text\" field preprocessed.\n",
        "    \"\"\"\n",
        "    lemmatizer = WordNetLemmatizer()\n",
        "    stop_words = set(stopwords.words('english'))\n",
        "\n",
        "    # Define a list of known abbreviations/low information tokens to remove\n",
        "    abbreviations = {'pfs', 'co.', 'co', 'also', 'vs', 'vs.', 'ok', 'etc.', 'v', 'n=', \"''\", 'et.', 'al', 'et', '--', 'o', \"'s\", \"fig\", \"figure\", 'til', 'le'}\n",
        "\n",
        "    processed_texts = {}\n",
        "\n",
        "    for entry in pdf_texts:\n",
        "        text = entry['text']\n",
        "\n",
        "        # Lowercase the text\n",
        "        text = text.lower()\n",
        "\n",
        "        # Expand contractions\n",
        "        text = contractions.fix(text)\n",
        "\n",
        "        # Remove numbers using regular expression\n",
        "        text = re.sub(r'\\d+', '', text)\n",
        "\n",
        "        # Tokenize the text\n",
        "        words = word_tokenize(text)\n",
        "\n",
        "        # Remove stop words, punctuation, abbreviations, and lemmatize the words\n",
        "        processed_words = [\n",
        "            lemmatizer.lemmatize(word) #Lemmas are always actual words, reduces words to their base dictionary form\n",
        "            for word in words\n",
        "            if word not in stop_words and word not in string.punctuation\n",
        "            and word not in abbreviations and len(word) > 1  # Remove abbreviations and single letters\n",
        "        ]\n",
        "\n",
        "        # Add the processed tokenized text back to the dictionary with the filename\n",
        "        processed_texts[entry['filename']] = processed_words\n",
        "\n",
        "    return processed_texts\n"
      ],
      "metadata": {
        "id": "7E4Hemta5hUP",
        "collapsed": true,
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "6287fa47-dd3a-4369-929d-74421aa9ec19"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Preprocess text test\n",
        "processed_texts = preprocess_text(pdf_texts)\n",
        "\n",
        "# Extract the tokenized texts as a list of lists\n",
        "tokenized_texts = list(processed_texts.values())\n"
      ],
      "metadata": {
        "id": "Ob-aAi28gACH",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "b76ba4af-6f6e-4742-a1ad-d1c029ff24e9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a Dictionaty and a Corpus\n",
        "\n",
        "\n",
        "# Create a Dictionary from the tokenized documents\n",
        "dictionary = Dictionary(tokenized_texts)\n",
        "\n",
        "# Print the dictionary to verify\n",
        "#print(dictionary)\n",
        "\n",
        "# Filter out too rare and too common words\n",
        "dictionary.filter_extremes(no_below=5, no_above=0.5)\n",
        "\n",
        "# Convert the tokenized documents into a bag-of-words corpus\n",
        "corpus = [dictionary.doc2bow(doc) for doc in tokenized_texts]\n",
        "#print(corpus)"
      ],
      "metadata": {
        "id": "Bu1z6ipRoBFW",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "386b708c-d28a-477b-dc00-b619dc6ee501"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# build a coherence list and model list to evaluate the number of optimal topics\n",
        "coherence_values = []\n",
        "model_list = []\n",
        "min_topics = 2\n",
        "max_topics = 10\n",
        "\n",
        "for num_topics in range(min_topics, max_topics + 1):\n",
        "    # Build the LDA model\n",
        "    lda_model = gensim.models.LdaModel(corpus, num_topics=num_topics, id2word=dictionary, passes=15)\n",
        "    model_list.append(lda_model)\n",
        "    coherence_model_lda = CoherenceModel(model=lda_model, texts=tokenized_texts, dictionary=dictionary, coherence='c_v')\n",
        "    coherence_lda = coherence_model_lda.get_coherence()\n",
        "    coherence_values.append(coherence_lda)\n",
        "\n",
        "# Plotting the coherence scores\n",
        "x = range(min_topics, max_topics + 1)\n",
        "plt.plot(x, coherence_values)\n",
        "plt.xlabel(\"Number of Topics\")\n",
        "plt.ylabel(\"Coherence Score\")\n",
        "plt.title(\"Coherence Score vs Number of Topics\")\n",
        "plt.show()\n",
        "\n",
        "# Optional: Print the coherence scores for each number of topics\n",
        "for i, num in enumerate(x):\n",
        "    print(f\"Number of Topics: {num}, Coherence Score: {coherence_values[i]}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 683
        },
        "id": "mow1ReO67Kmo",
        "outputId": "c448600e-6051-4e9e-99ed-7778e1939b05"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Number of Topics: 2, Coherence Score: 0.2918662373354328\n",
            "Number of Topics: 3, Coherence Score: 0.6405395283829863\n",
            "Number of Topics: 4, Coherence Score: 0.5702056944992177\n",
            "Number of Topics: 5, Coherence Score: 0.5583917495461822\n",
            "Number of Topics: 6, Coherence Score: 0.4948251035421727\n",
            "Number of Topics: 7, Coherence Score: 0.5389026149258654\n",
            "Number of Topics: 8, Coherence Score: 0.42109736745422943\n",
            "Number of Topics: 9, Coherence Score: 0.4185623712249328\n",
            "Number of Topics: 10, Coherence Score: 0.479435535062687\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Build LDA model with the optimal number of topics based on coherence score\n",
        "\n",
        "# Find the maximum coherence score and the corresponding number of topics\n",
        "max_coherence = max(coherence_values)\n",
        "optimal_topics = coherence_values.index(max_coherence) + min_topics\n",
        "print(f'Optimal Number of Topics: {optimal_topics}')\n",
        "print(f'Max Coherence Score: {max_coherence}')\n",
        "\n",
        "\n",
        "# Build the optimal LDA model using the optimal number of topics\n",
        "optimal_lda_model = LdaModel(corpus, num_topics=3, id2word=dictionary, passes=15)\n",
        "\n",
        "# Print the topics\n",
        "topics = optimal_lda_model.print_topics(num_words=10)\n",
        "for topic in topics:\n",
        "    print(topic)"
      ],
      "metadata": {
        "id": "ZJ7-tLaQpKoN",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f2f9c619-12f8-4137-90df-fd33f3661e3b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Optimal Number of Topics: 3\n",
            "Max Coherence Score: 0.6405395283829863\n",
            "(0, '0.044*\"therapy\" + 0.026*\"pembrolizumab\" + 0.023*\"month\" + 0.022*\"ci\" + 0.022*\"survival\" + 0.019*\"unresectable\" + 0.019*\"overall\" + 0.019*\"advanced\" + 0.017*\"response\" + 0.016*\"disease\"')\n",
            "(1, '0.070*\"pla\" + 0.061*\"lesion\" + 0.056*\"biopsy\" + 0.036*\"pigmented\" + 0.020*\"diagnostic\" + 0.019*\"skin\" + 0.019*\"assay\" + 0.017*\"negative\" + 0.016*\"testing\" + 0.016*\"md\"')\n",
            "(2, '0.041*\"expression\" + 0.039*\"class\" + 0.035*\"prognostic\" + 0.035*\"prospective\" + 0.024*\"profile\" + 0.023*\"stage\" + 0.022*\"outcome\" + 0.021*\"metastasis\" + 0.019*\"testing\" + 0.017*\"independent\"')\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Visualization in pyLDAvis\n",
        "vis_data = gensimvis.prepare(optimal_lda_model, corpus, dictionary)\n",
        "pyLDAvis.display(vis_data)"
      ],
      "metadata": {
        "id": "4krF_7H4VV-k",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 916
        },
        "outputId": "79ed852b-6256-41c0-a1f1-7738abdd6276"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
              "\n",
              "\n",
              "<div id=\"ldavis_el8191348037219406406837783613\" style=\"background-color:white;\"></div>\n",
              "<script type=\"text/javascript\">\n",
              "\n",
              "var ldavis_el8191348037219406406837783613_data = {\"mdsDat\": {\"x\": [-0.007434074774273665, -0.17932375921136645, 0.1867578339856401], \"y\": [-0.1401720386441197, 0.07435576178893388, 0.06581627685518593], \"topics\": [1, 2, 3], \"cluster\": [1, 1, 1], \"Freq\": [39.156474828325, 35.62137924544877, 25.22214592622623]}, \"tinfo\": {\"Term\": [\"pla\", \"lesion\", \"biopsy\", \"therapy\", \"pigmented\", \"class\", \"prognostic\", \"pembrolizumab\", \"prospective\", \"expression\", \"ci\", \"unresectable\", \"profile\", \"month\", \"advanced\", \"response\", \"assay\", \"profiling\", \"phase\", \"skin\", \"diagnostic\", \"randomized\", \"disease\", \"independent\", \"md\", \"mutation\", \"median\", \"negative\", \"dermatology\", \"case\", \"profiling\", \"class\", \"prognostic\", \"profile\", \"independent\", \"prospective\", \"multicenter\", \"expression\", \"imaging\", \"diagnosed\", \"category\", \"shown\", \"follow\", \"s.\", \"used\", \"age\", \"surveillance\", \"factor\", \"decision-making\", \"comparison\", \"inform\", \"outcome\", \"level\", \"multiple\", \"node\", \"superior\", \"finding\", \"biomarkers\", \"stage\", \"al.\", \"metastasis\", \"status\", \"molecular\", \"testing\", \"med\", \"important\", \"impact\", \"oncol\", \"evaluating\", \"using\", \"lymph\", \"demonstrated\", \"biopsy\", \"high\", \"therapy\", \"pembrolizumab\", \"ci\", \"unresectable\", \"advanced\", \"response\", \"phase\", \"randomized\", \"mutation\", \"keytruda\", \"adverse\", \"week\", \"grade\", \"disease\", \"every\", \"reached\", \"median\", \"month\", \"need\", \"observed\", \"nct\", \"resource\", \"indicated\", \"tissue\", \"e.\", \"benefit\", \"combination\", \"plus\", \"mg\", \"society\", \"overall\", \"doi\", \"systemic\", \"survival\", \"received\", \"update\", \"group\", \"medicine\", \"o\", \"oncology\", \"oncol\", \"metastasis\", \"value\", \"pigmented\", \"pla\", \"peer\", \"dermtech\", \"lesion\", \"pre-diagnostic\", \"sample\", \"brouha\", \"case\", \"dermatology\", \"genomic\", \"diagnosis\", \"assay\", \"biopsy\", \"reviewed\", \"care\", \"fewer\", \"diagnostic\", \"ferris\", \"md\", \"see\", \"negative\", \"skin\", \"registry\", \"number\", \"many\", \"guiding\", \"surgical\", \"useful\", \"key\", \"large\", \"publication\", \"performance\", \"testing\", \"accuracy\", \"tool\", \"practice\", \"expression\"], \"Freq\": [63.0, 58.0, 62.0, 55.0, 33.0, 57.0, 51.0, 33.0, 55.0, 67.0, 28.0, 25.0, 36.0, 31.0, 24.0, 22.0, 20.0, 24.0, 20.0, 24.0, 23.0, 19.0, 22.0, 26.0, 19.0, 17.0, 20.0, 21.0, 13.0, 13.0, 23.925708266643312, 54.54740524652087, 48.82372115233546, 33.61335558175912, 24.110255437506478, 48.24588846963926, 10.784231194994634, 57.42585206728228, 7.929553575270587, 6.978335778075638, 13.650351737046106, 7.5732830868076295, 9.834726475905061, 6.0286436607776315, 11.969942955206221, 12.683825444824237, 6.708291082517587, 19.354313785295606, 8.882010139243357, 6.579891645904915, 7.930080228856359, 30.304888030705815, 18.41017964037947, 9.831467039479744, 17.435513803904367, 4.12256737153836, 8.880310631353074, 8.844188657376296, 31.227869441294754, 12.685630929632392, 29.28930605712161, 13.108331498182412, 16.449473542378026, 26.400194339698132, 10.782926515743501, 10.788248624863032, 11.735519428067924, 12.95434574411128, 10.253568579963492, 10.044030888704544, 9.828578522266982, 10.374625237809136, 11.591998248436047, 9.835286731928209, 55.05575127434171, 32.797585448539316, 28.158626877682114, 24.441690518894806, 23.5036314612378, 21.656017545660877, 19.79817720171763, 18.87320745505192, 16.98994330253274, 14.234230072645643, 14.230858102473807, 13.30402836389323, 10.517459490634568, 20.704127296545895, 7.735008583040776, 7.733999813721587, 18.874336147996466, 29.09940890706784, 6.805515834544158, 6.79957902722802, 4.950073963108072, 4.949981668945419, 9.593453835858993, 17.286840102986858, 8.615933438989156, 8.628377278702791, 17.022581340179237, 6.805517598126883, 6.809943602907872, 6.808398704440022, 24.049907089180586, 10.522251732761625, 13.306319845715025, 27.245716509695804, 9.593912367367716, 10.523067683702788, 16.096333583898193, 10.319504383988207, 12.387224005248232, 11.541409729927999, 11.19094704348057, 11.969668753300178, 10.67820770465265, 32.57437185508699, 62.140273176924104, 11.371085034860187, 9.525913450311066, 54.49308541009304, 8.603706022001276, 6.704492075513584, 5.839327697615456, 12.295663377519084, 12.292326781763737, 11.855889567666452, 12.296347679343159, 16.80127141905804, 49.823779385485295, 12.537911218145615, 12.537792172937777, 4.918224143051074, 17.51763553078852, 10.450569213979255, 14.31852117329994, 5.843073875484483, 14.944923737199657, 16.901246084090726, 5.8400665271396255, 9.538049401638768, 4.919458716779911, 4.917576054279732, 11.533245420034735, 4.081111977520185, 6.812514779334895, 9.526887456557011, 10.44690794947526, 7.360140633794803, 14.457474402817859, 7.264460753567962, 6.7590659784675715, 7.060646200425725, 7.674275962760005], \"Total\": [63.0, 58.0, 62.0, 55.0, 33.0, 57.0, 51.0, 33.0, 55.0, 67.0, 28.0, 25.0, 36.0, 31.0, 24.0, 22.0, 20.0, 24.0, 20.0, 24.0, 23.0, 19.0, 22.0, 26.0, 19.0, 17.0, 20.0, 21.0, 13.0, 13.0, 24.728883783947133, 57.04182594105641, 51.3296736605796, 36.10404726298843, 26.590388147362827, 55.040614619423515, 12.334247855211533, 67.29241655356037, 9.472775309130084, 8.520811774115696, 17.03608087336425, 9.469533930347318, 12.299638661288014, 7.574468134378094, 15.142412455748303, 16.095122592484156, 8.513146806548987, 24.61044212800548, 11.358851888909797, 8.516531411995075, 10.395659160122822, 39.742211028641506, 24.569978157729945, 13.222432930218755, 23.64033269279485, 5.664880108773177, 12.281523265558407, 12.286366427444815, 43.46171435384623, 17.9240696556422, 41.57419353922974, 18.891103209448115, 24.50693995669618, 45.130507245555165, 16.048269845272202, 16.965538522123058, 19.757509408650105, 24.458371356201372, 16.023155547842084, 16.016433003642227, 16.024747458934264, 19.746048197469122, 62.19109849490198, 16.930779671793758, 55.71698631152988, 33.43225710080112, 28.789763576022136, 25.07568216388225, 24.147323296259625, 22.29019957373544, 20.433123645756723, 19.50460559915059, 17.64767325349079, 14.86198725691035, 14.862046679517247, 13.933505012639634, 11.148006481971192, 22.313920634133797, 8.362417909889254, 8.362447075282148, 20.456382916614384, 31.592885815491474, 7.433899007045563, 7.433934594825818, 5.576875173376092, 5.576873348816267, 11.171174887576974, 20.454076396515568, 10.213477814110796, 10.243504454689543, 20.50318239519531, 8.356637233389796, 8.385618590579723, 8.385596429332097, 29.812905736785822, 13.051638610924757, 16.789136053156632, 37.351546445764185, 12.093986895098283, 14.003609353493266, 26.209404503562972, 13.945599663935853, 22.524286000862688, 19.68918045374781, 24.458371356201372, 41.57419353922974, 22.471690737001374, 33.235286004426584, 63.717314053680695, 12.008915393595375, 10.163144463830482, 58.1711281869852, 9.240268875952587, 7.394921643941565, 6.47162942058457, 13.860104899150247, 13.883639660432362, 13.889477003390134, 14.835417867629038, 20.40463562541986, 62.19109849490198, 15.762321458350286, 15.762452504886534, 6.477094193897564, 23.13710596473819, 13.941659753422035, 19.419010189124325, 8.351714811439706, 21.40550715810597, 24.209842304143855, 8.375277628083387, 13.923558028331804, 7.428844881475341, 7.452415990103351, 17.648911010970778, 6.505456830825002, 11.131330818532527, 15.874608104930699, 20.60536207866841, 13.08602266091762, 45.130507245555165, 15.945137118859694, 13.105998499680426, 15.802049546473928, 67.29241655356037], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -4.0605, -3.2363, -3.3472, -3.7205, -4.0528, -3.3591, -4.8573, -3.1849, -5.1648, -5.2926, -4.6216, -5.2108, -4.9495, -5.4389, -4.753, -4.6951, -5.3321, -4.2725, -5.0514, -5.3514, -5.1647, -3.8241, -4.3225, -4.9498, -4.3769, -5.8189, -5.0516, -5.0556, -3.7941, -4.6949, -3.8582, -4.6622, -4.4351, -3.962, -4.8574, -4.8569, -4.7728, -4.674, -4.9078, -4.9284, -4.9501, -4.896, -4.7851, -4.9494, -3.1324, -3.6504, -3.8029, -3.9445, -3.9836, -4.0655, -4.1552, -4.203, -4.3082, -4.4851, -4.4854, -4.5527, -4.7878, -4.1105, -5.095, -5.0952, -4.203, -3.7701, -5.2231, -5.2239, -5.5414, -5.5414, -4.8797, -4.2908, -4.9872, -4.9857, -4.3062, -5.2231, -5.2224, -5.2226, -3.9607, -4.7873, -4.5525, -3.8359, -4.8797, -4.7872, -4.3622, -4.8068, -4.6241, -4.6948, -4.7257, -4.6584, -4.7726, -3.312, -2.6662, -4.3645, -4.5415, -2.7975, -4.6434, -4.8928, -5.0309, -4.2863, -4.2866, -4.3227, -4.2863, -3.9741, -2.8871, -4.2668, -4.2668, -5.2026, -3.9324, -4.4489, -4.134, -5.0303, -4.0912, -3.9682, -5.0308, -4.5403, -5.2024, -5.2027, -4.3503, -5.3892, -4.8768, -4.5414, -4.4493, -4.7995, -4.1244, -4.8126, -4.8847, -4.841, -4.7577], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 0.9046, 0.8929, 0.8876, 0.8661, 0.8397, 0.8058, 0.8033, 0.7791, 0.7598, 0.7379, 0.716, 0.7142, 0.714, 0.7093, 0.7025, 0.6994, 0.6993, 0.6973, 0.6916, 0.6796, 0.6669, 0.6665, 0.649, 0.6413, 0.6332, 0.6198, 0.6133, 0.6089, 0.607, 0.5919, 0.5873, 0.5722, 0.5389, 0.4014, 0.54, 0.4849, 0.4167, 0.3021, 0.4912, 0.471, 0.4488, 0.294, -0.7423, 0.3944, 1.0203, 1.0131, 1.0101, 1.0066, 1.0052, 1.0034, 1.0007, 0.9993, 0.9942, 0.9891, 0.9888, 0.986, 0.974, 0.9573, 0.9542, 0.9541, 0.9517, 0.95, 0.9439, 0.943, 0.913, 0.913, 0.88, 0.864, 0.8621, 0.8606, 0.8462, 0.8269, 0.8241, 0.8239, 0.8174, 0.8168, 0.7997, 0.7167, 0.8006, 0.7465, 0.5447, 0.7311, 0.4343, 0.4981, 0.2504, -0.2129, 0.2882, 1.3574, 1.3524, 1.3229, 1.3127, 1.3121, 1.3061, 1.2794, 1.2746, 1.2577, 1.2557, 1.2191, 1.1897, 1.1831, 1.1557, 1.1486, 1.1486, 1.1021, 1.0992, 1.0892, 1.0727, 1.0202, 1.0182, 1.0181, 1.0169, 0.9992, 0.9653, 0.9617, 0.952, 0.9112, 0.8864, 0.8668, 0.6982, 0.802, 0.2391, 0.5913, 0.7153, 0.5718, -0.7937]}, \"token.table\": {\"Topic\": [1, 3, 2, 2, 1, 2, 1, 3, 1, 3, 1, 2, 1, 2, 1, 2, 3, 3, 1, 2, 3, 2, 3, 1, 2, 3, 2, 1, 3, 1, 2, 1, 2, 1, 2, 1, 2, 3, 1, 3, 3, 1, 3, 1, 3, 1, 2, 3, 1, 2, 1, 2, 2, 3, 1, 2, 3, 2, 1, 2, 3, 1, 2, 3, 1, 3, 2, 3, 1, 2, 3, 1, 3, 1, 2, 3, 2, 1, 2, 3, 1, 3, 1, 2, 3, 1, 3, 1, 2, 3, 1, 2, 3, 1, 2, 1, 2, 1, 3, 1, 2, 3, 2, 1, 3, 2, 3, 1, 2, 3, 1, 2, 1, 2, 3, 2, 3, 1, 2, 1, 2, 1, 2, 3, 1, 2, 1, 2, 1, 2, 3, 1, 2, 3, 1, 2, 1, 3, 2, 2, 2, 1, 2, 3, 1, 2, 1, 2, 3, 1, 2, 2, 1, 2, 1, 2, 1, 2, 1, 2, 3, 3, 2, 1, 3, 2, 3, 1, 3, 2, 3, 1, 2, 3, 3, 1, 2, 3, 1, 1, 3, 1, 2, 1, 3, 2, 2, 1, 2, 3, 1, 3, 2, 2, 1, 2, 3, 1, 2, 3, 1, 2, 3, 1, 2, 1, 3, 1, 2, 1, 2, 3, 1, 2, 1, 3, 1, 2, 3, 1, 3, 1, 2, 3, 1, 2, 1, 2, 3, 2, 1, 2, 3, 1, 3, 2, 1, 2, 1, 2, 3, 1, 2, 3, 1, 2, 3, 1, 2, 3, 2], \"Freq\": [0.5017203640436373, 0.43900531853818264, 0.9938989802533333, 0.941996772173693, 0.8076981039007763, 0.18639187013094838, 0.7252817161368158, 0.2789545062064676, 0.14702541398301838, 0.8331440125704375, 0.09762284034954401, 0.878605563145896, 0.7325192564578039, 0.24417308548593464, 0.1929536588099289, 0.016079471567494077, 0.8039735783747038, 0.9271235434024637, 0.12688380817515407, 0.06344190408757704, 0.8247447531385016, 0.07214952608773612, 0.8657943130528335, 0.8217852512011062, 0.058698946514364726, 0.11739789302872945, 0.9725679033821626, 0.964204758396649, 0.0350619912144236, 0.14631874906907213, 0.8291395780580755, 0.8219308614468184, 0.23483738898480525, 0.7923335992070766, 0.17607413315712814, 0.5064304462338806, 0.40514435698710444, 0.050643044623388055, 0.07202722228883159, 0.8643266674659791, 0.9839474422103223, 0.8215179710065209, 0.1173597101437887, 0.13481251541717681, 0.8088750925030609, 0.04322061719923128, 0.17288246879692512, 0.777971109586163, 0.044815073800625216, 0.9411165498131295, 0.15323746386342002, 0.8428060512488101, 0.8811885788370468, 0.09790984209300521, 0.6240967935524253, 0.24963871742097016, 0.12481935871048508, 0.9566611100049586, 0.8470493841550737, 0.029721031022985043, 0.11888412409194017, 0.7720300147870537, 0.1625326346920113, 0.04063315867300282, 0.21518241393487159, 0.7172747131162386, 0.15439022037724207, 0.7719511018862104, 0.7328081220380113, 0.16284624934178027, 0.08142312467089013, 0.813032014629347, 0.16260640292586942, 0.0719969513435186, 0.0719969513435186, 0.8639634161222232, 0.9867235023400326, 0.34338819101275336, 0.6104678951337837, 0.038154243445861484, 0.2683693452775526, 0.6709233631938815, 0.590640253659419, 0.1771920760978257, 0.2362561014637676, 0.8445254678731176, 0.1055656834841397, 0.6073640028103056, 0.1518410007025764, 0.25306833450429395, 0.6483731704511474, 0.2357720619822354, 0.1178860309911177, 0.9025817850793677, 0.07521514875661398, 0.08951609925219779, 0.895160992521978, 0.7695519713350704, 0.1923879928337676, 0.08983651787036122, 0.26950955361108364, 0.6288556250925286, 0.9420005385545225, 0.3779620863923175, 0.6299368106538624, 0.05157197554011337, 0.9282955597220406, 0.7326013838696487, 0.0814001537632943, 0.1628003075265886, 0.6240347952831361, 0.3744208771698817, 0.13461042947519503, 0.13461042947519503, 0.6730521473759752, 0.2574796527374122, 0.720943027664754, 0.6854321435304495, 0.3115600652411134, 0.048884497522179944, 0.9288054529214189, 0.07170720686798857, 0.7170720686798856, 0.14341441373597713, 0.6975481069196295, 0.2886405959667433, 0.11925178675827026, 0.8347625073078919, 0.652876288442051, 0.08160953605525638, 0.24482860816576912, 0.03165269566826507, 0.9179281743796871, 0.03165269566826507, 0.8918257626347456, 0.08107506933043142, 0.7562904688399549, 0.22688714065198645, 0.963299793452223, 0.8965594252261402, 0.9416323780247311, 0.2803016978613321, 0.04671694964355534, 0.7007542446533301, 0.7191100151133362, 0.25380353474588335, 0.14364144537842832, 0.14364144537842832, 0.7182072268921416, 0.4439652382151868, 0.5327582858582242, 0.9416278702360596, 0.5315153576938342, 0.4497437642024751, 0.40631452481188524, 0.6094717872178278, 0.7548648961271816, 0.22645946883815446, 0.13417008175303233, 0.8050204905181939, 0.03354252043825808, 0.915986135256357, 0.9870706575539359, 0.38208706568519646, 0.5349218919592751, 0.9788028666949966, 0.9929205963687134, 0.015694321313630983, 0.9730479214451211, 0.8376575175515322, 0.11966535965021888, 0.12656586059409491, 0.37969758178228474, 0.4429805120793322, 0.973997631543182, 0.9417226759187919, 0.02769772576231741, 0.02769772576231741, 0.97052500265215, 0.954613511163451, 0.03896381678218167, 0.8720832848959699, 0.10901041061199623, 0.4853105692499549, 0.4853105692499549, 0.9741289001417919, 0.9566577734939005, 0.0826857188348122, 0.826857188348122, 0.0826857188348122, 0.23879805408405114, 0.7163941622521534, 0.896559718549335, 0.9869808445287596, 0.12688486307583044, 0.06344243153791522, 0.8247516099928979, 0.7921348263078585, 0.13202247105130974, 0.9465955607163042, 0.11973588928470794, 0.11973588928470794, 0.7184153357082476, 0.84481454513428, 0.21120363628357, 0.28913860371580574, 0.7021937518812426, 0.11925210191395401, 0.834764713397678, 0.7132714496168188, 0.20707880795326994, 0.06902626931775666, 0.6881546226214166, 0.264674854854391, 0.706104970130827, 0.17652624253270674, 0.16998215913351047, 0.16998215913351047, 0.6799286365340419, 0.8222576397502092, 0.11746537710717274, 0.2409538789262268, 0.7228616367786803, 0.026772653214025197, 0.17868697891908208, 0.774310241982689, 0.5761069747905548, 0.08863184227546997, 0.3102114479641449, 0.9871316386797915, 0.09778002004239643, 0.8311301703603696, 0.09778002004239643, 0.4578056376357973, 0.5341065772417635, 0.9571025762389186, 0.21423048331833364, 0.7855117721672233, 0.7924761021447813, 0.13207935035746354, 0.06603967517873177, 0.15371710642389783, 0.15371710642389783, 0.6148684256955913, 0.6243587444049461, 0.18730762332148382, 0.18730762332148382, 0.3560034753783516, 0.4895047786452334, 0.13350130326688184, 0.9330028580897043], \"Term\": [\"accuracy\", \"accuracy\", \"advanced\", \"adverse\", \"age\", \"age\", \"al.\", \"al.\", \"assay\", \"assay\", \"benefit\", \"benefit\", \"biomarkers\", \"biomarkers\", \"biopsy\", \"biopsy\", \"biopsy\", \"brouha\", \"care\", \"care\", \"care\", \"case\", \"case\", \"category\", \"category\", \"category\", \"ci\", \"class\", \"class\", \"combination\", \"combination\", \"comparison\", \"comparison\", \"decision-making\", \"decision-making\", \"demonstrated\", \"demonstrated\", \"demonstrated\", \"dermatology\", \"dermatology\", \"dermtech\", \"diagnosed\", \"diagnosed\", \"diagnosis\", \"diagnosis\", \"diagnostic\", \"diagnostic\", \"diagnostic\", \"disease\", \"disease\", \"doi\", \"doi\", \"e.\", \"e.\", \"evaluating\", \"evaluating\", \"evaluating\", \"every\", \"expression\", \"expression\", \"expression\", \"factor\", \"factor\", \"factor\", \"ferris\", \"ferris\", \"fewer\", \"fewer\", \"finding\", \"finding\", \"finding\", \"follow\", \"follow\", \"genomic\", \"genomic\", \"genomic\", \"grade\", \"group\", \"group\", \"group\", \"guiding\", \"guiding\", \"high\", \"high\", \"high\", \"imaging\", \"imaging\", \"impact\", \"impact\", \"impact\", \"important\", \"important\", \"important\", \"independent\", \"independent\", \"indicated\", \"indicated\", \"inform\", \"inform\", \"key\", \"key\", \"key\", \"keytruda\", \"large\", \"large\", \"lesion\", \"lesion\", \"level\", \"level\", \"level\", \"lymph\", \"lymph\", \"many\", \"many\", \"many\", \"md\", \"md\", \"med\", \"med\", \"median\", \"median\", \"medicine\", \"medicine\", \"medicine\", \"metastasis\", \"metastasis\", \"mg\", \"mg\", \"molecular\", \"molecular\", \"molecular\", \"month\", \"month\", \"month\", \"multicenter\", \"multicenter\", \"multiple\", \"multiple\", \"mutation\", \"nct\", \"need\", \"negative\", \"negative\", \"negative\", \"node\", \"node\", \"number\", \"number\", \"number\", \"o\", \"o\", \"observed\", \"oncol\", \"oncol\", \"oncology\", \"oncology\", \"outcome\", \"outcome\", \"overall\", \"overall\", \"overall\", \"peer\", \"pembrolizumab\", \"performance\", \"performance\", \"phase\", \"pigmented\", \"pla\", \"pla\", \"plus\", \"plus\", \"practice\", \"practice\", \"practice\", \"pre-diagnostic\", \"profile\", \"profile\", \"profile\", \"profiling\", \"prognostic\", \"prognostic\", \"prospective\", \"prospective\", \"publication\", \"publication\", \"randomized\", \"reached\", \"received\", \"received\", \"received\", \"registry\", \"registry\", \"resource\", \"response\", \"reviewed\", \"reviewed\", \"reviewed\", \"s.\", \"s.\", \"sample\", \"see\", \"see\", \"see\", \"shown\", \"shown\", \"skin\", \"skin\", \"society\", \"society\", \"stage\", \"stage\", \"stage\", \"status\", \"status\", \"superior\", \"superior\", \"surgical\", \"surgical\", \"surgical\", \"surveillance\", \"surveillance\", \"survival\", \"survival\", \"survival\", \"systemic\", \"systemic\", \"testing\", \"testing\", \"testing\", \"therapy\", \"tissue\", \"tissue\", \"tissue\", \"tool\", \"tool\", \"unresectable\", \"update\", \"update\", \"used\", \"used\", \"used\", \"useful\", \"useful\", \"useful\", \"using\", \"using\", \"using\", \"value\", \"value\", \"value\", \"week\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [3, 1, 2]};\n",
              "\n",
              "function LDAvis_load_lib(url, callback){\n",
              "  var s = document.createElement('script');\n",
              "  s.src = url;\n",
              "  s.async = true;\n",
              "  s.onreadystatechange = s.onload = callback;\n",
              "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
              "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
              "}\n",
              "\n",
              "if(typeof(LDAvis) !== \"undefined\"){\n",
              "   // already loaded: just create the visualization\n",
              "   !function(LDAvis){\n",
              "       new LDAvis(\"#\" + \"ldavis_el8191348037219406406837783613\", ldavis_el8191348037219406406837783613_data);\n",
              "   }(LDAvis);\n",
              "}else if(typeof define === \"function\" && define.amd){\n",
              "   // require.js is available: use it to load d3/LDAvis\n",
              "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
              "   require([\"d3\"], function(d3){\n",
              "      window.d3 = d3;\n",
              "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "        new LDAvis(\"#\" + \"ldavis_el8191348037219406406837783613\", ldavis_el8191348037219406406837783613_data);\n",
              "      });\n",
              "    });\n",
              "}else{\n",
              "    // require.js not available: dynamically load d3 & LDAvis\n",
              "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
              "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "                 new LDAvis(\"#\" + \"ldavis_el8191348037219406406837783613\", ldavis_el8191348037219406406837783613_data);\n",
              "            })\n",
              "         });\n",
              "}\n",
              "</script>"
            ]
          },
          "metadata": {},
          "execution_count": 39
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Each circle represents a topic.\n",
        "Size: corresponds to the prevalence of that topic across the corpus, larger circles indicate more dominant topics.\n",
        "Distance: indicates topic similarity. Topics that are close to each other share more words and have higher similarity, while those far apart are more distinct.\n",
        "Red bar - TF - frequency of word in selected topic\n",
        "Blue bar - DF - frequency of word in corpus.\n",
        "Saliency - A word that appears frequently in one specific topic but not common in others, helps to differentiate topics effectively"
      ],
      "metadata": {
        "id": "mJJxanwVcG6x"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Dynamic topic modeling"
      ],
      "metadata": {
        "id": "K_ZWJFkqw-IF"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "#Run for loading data, and getting time slices\n",
        "\n",
        "# Specify the base folder path , valid inputs \"accepted_all\"/ 'denied_all\"\n",
        "base_folder_path = '/content/drive/My Drive/thesis/nccn_guidelines/submission_requests/denied_all'\n",
        "\n",
        "# List to hold the text and corresponding timestamps from each PDF\n",
        "pdf_texts = []\n",
        "timestamps = []\n",
        "\n",
        "# Counter to keep track of the number of processed PDFs\n",
        "pdf_count = 0\n",
        "\n",
        "# Regular expression pattern to extract timestamp from filename (assuming format YYYY-MM-DD)\n",
        "timestamp_pattern = r'\\d{4}_\\d{2}_\\d{2}'\n",
        "\n",
        "# Walk through all directories and files within the base folder\n",
        "for root, dirs, files in os.walk(base_folder_path):\n",
        "    for filename in files:\n",
        "        # Check if the file is a PDF\n",
        "        if filename.endswith(\".pdf\"):\n",
        "            # Full path to the PDF file\n",
        "            file_path = os.path.join(root, filename)\n",
        "\n",
        "            # Attempt to extract the timestamp from the filename\n",
        "            match = re.search(timestamp_pattern, filename)\n",
        "            if match:\n",
        "                timestamp = datetime.strptime(match.group(), '%Y_%m_%d')\n",
        "                timestamps.append(timestamp)\n",
        "            else:\n",
        "                # Handle cases where the timestamp isn't found, you can choose to skip or set a default\n",
        "                print(f\"Timestamp not found in filename: {filename}\")\n",
        "                continue  # Skip this file if timestamp is mandatory\n",
        "\n",
        "            # Open the PDF file\n",
        "            doc = fitz.open(file_path)\n",
        "\n",
        "            # Extract text from each page\n",
        "            text = \"\"\n",
        "            for page_num in range(len(doc)):\n",
        "                page = doc.load_page(page_num)\n",
        "                text += page.get_text()\n",
        "\n",
        "            # Append the extracted text and timestamp to the list\n",
        "            pdf_texts.append({\n",
        "                \"filename\": filename,\n",
        "                \"timestamp\": timestamp,\n",
        "                \"text\": text,\n",
        "            })\n",
        "\n",
        "            # Increment the counter\n",
        "            pdf_count += 1\n",
        "\n",
        "# Print the total number of PDFs processed\n",
        "print(f\"Total number of PDFs processed: {pdf_count}\")\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 211
        },
        "id": "u6HEFEovxCXB",
        "outputId": "cb5a869a-0489-40fd-a593-9d83938cdd13"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "error",
          "ename": "NameError",
          "evalue": "name 'os' is not defined",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-2-cb324951a000>\u001b[0m in \u001b[0;36m<cell line: 15>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     14\u001b[0m \u001b[0;31m# Walk through all directories and files within the base folder\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 15\u001b[0;31m \u001b[0;32mfor\u001b[0m \u001b[0mroot\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdirs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfiles\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mos\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwalk\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbase_folder_path\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     16\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mfilename\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mfiles\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m         \u001b[0;31m# Check if the file is a PDF\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mNameError\u001b[0m: name 'os' is not defined"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Preprocess function with timestamp\n",
        "\n",
        "def preprocess_text(pdf_texts):\n",
        "    \"\"\"\n",
        "    Preprocesses text by tokenizing, lowercasing, removing stop words, removing abbreviations, and lemmatizing.\n",
        "\n",
        "    Parameters:\n",
        "    pdf_texts (dict): Dictionary containing \"filename\" and \"text and \"timestamp\"\n",
        "\n",
        "    Returns:\n",
        "    list: List of dictionaries with the same structure, but the \"text\" field preprocessed.\n",
        "    \"\"\"\n",
        "    lemmatizer = WordNetLemmatizer()\n",
        "    stop_words = set(stopwords.words('english'))\n",
        "\n",
        "    # Define a list of known abbreviations/low information tokens to remove\n",
        "    abbreviations = {'pfs', 'co.', 'co', 'also', 'vs', 'vs.', 'ok', 'etc.', 'v', 'n=', \"''\", 'et.', 'al', 'et', '--', 'o', \"'s\", \"fig\", \"figure\", 'til', 'le'}\n",
        "\n",
        "    processed_texts = []\n",
        "\n",
        "    for entry in pdf_texts:\n",
        "        text = entry['text']\n",
        "\n",
        "        # Lowercase the text\n",
        "        text = text.lower()\n",
        "\n",
        "        # Expand contractions\n",
        "        text = contractions.fix(text)\n",
        "\n",
        "        # Remove numbers using regular expression\n",
        "        text = re.sub(r'\\d+', '', text)\n",
        "\n",
        "        # Tokenize the text\n",
        "        words = word_tokenize(text)\n",
        "\n",
        "        # Remove stop words, punctuation, abbreviations, and lemmatize the words\n",
        "        processed_words = [\n",
        "            lemmatizer.lemmatize(word) #Lemmas are always actual words, reduces words to their base dictionary form\n",
        "            for word in words\n",
        "            if word not in stop_words and word not in string.punctuation\n",
        "            and word not in abbreviations and len(word) > 1  # Remove abbreviations and single letters\n",
        "        ]\n",
        "\n",
        "        # Add the processed tokenized text back to the dictionary with the filename and timestamp\n",
        "        processed_texts.append({\n",
        "            'filename': entry['filename'],\n",
        "            'timestamp': entry['timestamp'],\n",
        "            'text': processed_words,  # Storing as a list of words, you can join them if you prefer a single string\n",
        "\n",
        "        })\n",
        "\n",
        "    return processed_texts\n",
        "\n",
        "processed_texts = preprocess_text(pdf_texts)\n",
        "print(processed_texts)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "IUIuBDAXR3iz",
        "outputId": "ade8e7e3-5ede-43dd-f5f5-65eade4bfda0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[{'filename': '2021_05_28_Ilumina.pdf', 'timestamp': datetime.datetime(2021, 5, 28, 0, 0), 'text': ['name', 'david', 'eberhard', 'md', 'phd', 'company/organization', 'illumina', 'inc.', 'address', 'illumina', 'way', 'san', 'diego', 'ca', 'phone', 'email', 'deberhard', 'illumina.com', 'date', 'request', 'may', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'behalf', 'illumina', 'respectfully', 'request', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'consider', 'enclosed', 'information', 'inclusion', 'liquid', 'biopsy-based', 'dna', 'testing', 'complimentary', 'alternative', 'tissue', 'testing', 'assessment', 'genetic', 'variant', 'tumor', 'tissue', 'unavailable', 'specific', 'change', 'red', 'text', 'me-c', 'add', 'new', 'sub-bullet', 'point', 'principle', 'molecular', 'testing', 'section', 'method', 'mutation', 'testing', 'mutation', 'testing', 'may', 'performed', 'using', 'tumor', 'tissue', 'ctdna', 'peripheral', 'blood', 'liquid', 'biopsy', 'liquid', 'biopsy', 'negative', 'tumor', 'tissue', 'testing', 'recommended', 'rationale', 'study', 'demonstrated', 'use', 'ctdna', 'liquid', 'biopsy', 'viable', 'modality', 'molecular', 'biomarker', 'testing', 'tumor', 'tissue', 'unavailable/insufficient', 'patient', 'medically', 'unfit', 'invasive', 'tissue', 'sampling', 'recommendation', 'use', 'ctdna', 'incorporated', 'breast', 'non-', 'small', 'cell', 'lung', 'esophageal', 'gastric', 'cancer', 'guidelines-', 'advanced', 'melanoma', 'patient', 'could', 'benefit', 'le', 'invasive', 'biopsy', 'option', 'tissue', 'available', 'genomic', 'alteration', 'solid', 'cancer', 'may', 'identified', 'evaluating', 'cell-free', 'circulating', 'tumor', 'dna', 'cfdna/ctdna', 'blood', 'le', 'invasive', 'liquid', 'biopsy-based', 'genomic', 'analysis', 'used', 'frequently', 'patient', 'advanced', 'disease', 'may', 'unable', 'clinical', 'biopsy', 'disease', 'surveillance', 'management', 'allows', 'patient', 'matched', 'targeted', 'therapy', 'clinical', 'trial', 'molecular', 'profiling', 'genomic', 'alteration', 'reinforce', 'selection', 'patient', 'targeted', 'therapy', 'braf', 'and/or', 'mek', 'inhibitor', 'clinical', 'trial', 'nras-targeting', 'drug', 'approximately', 'melanoma', 'patient', 'harbor', 'braf', 'nra', 'mutation', 'respectively', 'biomarkers', 'evaluated', 'ctdna', 'testing', 'tumor', 'tissue', 'often', 'unavailable', 'insufficient', 'biomarker', 'testing', 'particularly', 'true', 'cutaneous', 'melanoma', 'patient', 'liquid', 'biopsy', 'assay', 'evaluate', 'spectrum', 'biomarkers', 'including', 'observed', 'melanoma.', 'several', 'melanoma-focused', 'clinical', 'performance', 'study', 'demonstrated', 'good', 'concordance', 'ctdna/cfdna', 'analysis', 'tissue-derived', 'dna', 'testing', 'prospective', 'study', 'metastatic', 'melanoma', 'patient', 'ctdna', 'sequencing', 'braf', 'gene', 'showed', 'sensitivity', 'specificity', 'overall', 'percent', 'agreement', 'respectively', 'compared', 'tissue-based', 'analysis', 'patient', 'braf', 'mutation-positive', 'melanoma', 'comparison', 'cfdna', 'analysis', 'tissue', 'dna', 'testing', 'showed', 'overall', 'positive', 'percent', 'agreement', 'vk', 'overall', 'negative', 'percent', 'agreement', 'vk', 'study', 'stage', 'iii/iv', 'melanoma', 'patient', 'ctdna', 'mutational', 'assessment', 'braf', 'gene', 'showed', 'positive', 'agreement', 'negative', 'agreement', 'overall', 'agreement', 'respectively', 'tissue-based', 'analysis', 'liquid', 'biopsy-based', 'dna', 'sequencing', 'tissue-based', 'method', 'shown', 'good', 'concordance', 'several', 'multi-cancer', 'study', 'ctdna', 'concordance', 'higher', 'tissue', 'metastasis', 'primary', 'tumor', 'ngs-based', 'method', 'used', 'analyze', 'tissue', 'sample', 'observational', 'analysis', 'patient', 'several', 'different', 'cancer', 'melanoma', 'ctdna', 'analysis', 'clinical', 'sensitivity', 'specificity', 'diagnostic', 'accuracy', 'mutated', 'oncogene', 'compared', 'dna', 'sequencing', 'matched', 'tissue', 'similar', 'smaller', 'study', 'showed', 'positive', 'predictive', 'value', 'melanoma', 'total', 'overall', 'concordance', 'melanoma', 'total', 'braf', 'mutational', 'study', 'patient', 'different', 'cancer', 'melanoma', 'overall', 'agreement', 'plasma', 'cfdna', 'tissue', 'dna', 'analysis', 'sensitivity', 'specificity', 'positive', 'predictive', 'value', 'negative', 'predictive', 'value', 'cfdna', 'testing', 'respectively', 'following', 'article', 'submitted', 'support', 'proposed', 'change', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'breast', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/breast.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'esophageal', 'esophagogastric', 'junction', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'gastric', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/gastric.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'non-small', 'cell', 'lung', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/nscl.pdf', 'accessed', 'may', 'rothwell', 'dg', 'ayub', 'cook', 'utility', 'ctdna', 'support', 'patient', 'selection', 'early', 'phase', 'clinical', 'trial', 'target', 'study', 'nature', 'medicine', '//', 'lanman', 'rb', 'mortimer', 'sa', 'zill', 'oa', 'analytical', 'clinical', 'validation', 'digital', 'sequencing', 'panel', 'quantitative', 'highly', 'accurate', 'evaluation', 'cell-free', 'circulating', 'tumor', 'dna', 'plo', 'one', 'e.', 'willis', 'lefterova', 'mi', 'artyomenko', 'validation', 'microsatellite', 'instability', 'detection', 'using', 'comprehensive', 'plasma-based', 'genotyping', 'panel', 'clinical', 'cancer', 'research', 'rowe', 'sp', 'luber', 'makell', 'validity', 'clinical', 'utility', 'influence', 'circulating', 'tumor', 'dna', 'melanoma', 'patient', 'management', 'real-world', 'setting', 'mol', 'oncol', 'boyer', 'cayrefourcq', 'dereure', 'clinical', 'relevance', 'liquid', 'biopsy', 'melanoma', 'merkel', 'cell', 'carcinoma', 'cancer', 'tsao', 'chin', 'garraway', 'la', 'fisher', 'de', 'melanoma', 'mutation', 'medicine', 'gene', 'dev', 'santiago-walker', 'gagnon', 'mazumdar', 'correlation', 'braf', 'mutation', 'status', 'circulating-free', 'dna', 'tumor', 'association', 'clinical', 'outcome', 'across', 'four', 'brafi', 'meki', 'clinical', 'trial', 'clinical', 'cancer', 'research', 'haselmann', 'gebhardt', 'brechtel', 'liquid', 'profiling', 'circulating', 'tumor', 'dna', 'plasma', 'melanoma', 'patient', 'companion', 'diagnostics', 'monitoring', 'braf', 'inhibitor', 'therapy', 'clinical', 'chemistry', 'cheng', 'cao', 'macleay', 'clinical', 'validation', 'cell-free', 'dna', 'gene', 'panel', 'journal', 'molecular', 'diagnostics', 'janku', 'huang', 'hj', 'claes', 'braf', 'mutation', 'testing', 'cell-free', 'dna', 'plasma', 'patient', 'advanced', 'cancer', 'using', 'rapid', 'automated', 'molecular', 'diagnostics', 'system', 'molecular', 'cancer', 'therapeutic', 'tae', 'kim', 'suk', 'lee', 'lanman', 'rb', 'prospective', 'blinded', 'study', 'somatic', 'mutation', 'detection', 'cell-free', 'dna', 'utilizing', 'targeted', '-gene', 'next', 'generation', 'sequencing', 'panel', 'metastatic', 'solid', 'tumor', 'patient', 'oncotarget', 'vol', 'perkins', 'yap', 'ta', 'pope', 'multi-purpose', 'utility', 'circulating', 'plasma', 'dna', 'testing', 'patient', 'advanced', 'cancer', 'plo', 'one', 'e-e.', 'thank', 'consideration', 'david', 'eberhard', 'md', 'phd', 'sr', 'medical', 'director', 'oncology', 'illumina', 'inc']}, {'filename': '2021_06_07_BrystolMayers.pdf', 'timestamp': datetime.datetime(2021, 6, 7, 0, 0), 'text': ['june', 'mary', 'coffey', 'pharmd', 'senior', 'director', 'ww', 'scientific', 'content', 'market', 'capability', 'bristol', 'myers', 'squibb', 'princeton', 'pike', 'lawrence', 'new', 'jersey', 'nccn', 'guidelines®', 'panel', 'melanoma', 'panel', 'behalf', 'bristol', 'myers', 'squibb', 'respectfully', 'request', 'melanoma', 'panel', 'review', 'data', 'recently', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'meeting', 'use', 'opdivo®', 'nivolumab', 'plus', 'yervoy®', 'ipilimumab', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'panel', 'consider', 'following', 'update', 'reflect', 'approximately', 'year', 'minimum', 'follow-up', 'month', 'data', 'checkmate', 'update', 'discussion', 'section', 'ms-', 'ms-', 'ms-', 'ms-', 'm', 'ms-', 'longer-term', 'data', 'update', 'reference', 'me-i', 'pg', 'reflect', 'new', 'longer-term', 'data', 'fda', 'clearance', 'opdivo®', 'indicated', 'adjuvant', 'treatment', 'option', 'patient', 'melanoma', 'lymph', 'node', 'involvement', 'metastatic', 'disease', 'undergone', 'complete', 'resection', 'opdivo®', 'indicated', 'monotherapy', 'combination', 'yervoy®', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma.', 'yervoy®', 'indicated', 'monotherapy', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'adult', 'pediatric', 'patient', 'year', 'older', 'rationale', 'data', 'submitted', 'response', 'standing', 'request', 'nccn®', 'new', 'data', 'please', 'note', 'previous', 'submission', 'nccn', 'regarding', '-year', 'outcome', 'checkmate', 'trial', 'october', 'study', 'summary', 'checkmate', 'phase', 'randomized', 'double-blind', 'study', 'nivolumab', 'combination', 'ipilimumab', 'nivo', 'mg/kg', 'ipi', 'mg/kg', 'qw', 'dos', 'nivo', 'mg/kg', 'qw', 'nivolumab', 'monotherapy', 'nivo', 'mg/kg', 'qw', 'compared', 'ipilimumab', 'monotherapy', 'ipi', 'mg/kg', 'qw', 'dos', 'previously', 'untreated', 'patient', 'unresectable', 'metastatic', 'melanoma', 'co-', 'primary', 'endpoint', 'progression-free', 'survival', 'overall', 'survival', 'nivo+ipi', 'nivo', 'group', 'versus', 'ipi', 'group', 'result', 'minimum', 'follow-up', 'approximately', '.-years', 'recently', 'presented', 'asco', 'meeting', 'median', 'overall', 'survival', 'ci', '.-nr', 'month', 'nivo', 'ipi', '.-', 'month', 'nivo', '.-', 'month', 'ipi', '.-year', 'overall', 'survival', 'rate', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'progression-free', 'survival', 'rate', 'year', 'nivo+ipi', 'nivo', 'ipi', 'respectively', 'additionally', 'patient', 'treated', 'nivo', 'ipi', 'received', 'subsequent', 'therapy', 'compared', 'nivo', 'ipi', 'median', 'time', 'subsequent', 'systemic', 'therapy', 'yet', 'reached', 'compared', 'month', 'nivo', 'month', 'ipi', 'patient', 'alive', 'year', 'treated', 'nivo', 'ipi', 'treated', 'nivo', 'treatment-free', 'study', 'treatment', 'never', 'received', 'subsequent', 'systemic', 'therapy', 'grade', 'treatment-related', 'adverse', 'event', 'reported', 'patient', 'receiving', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'grade', 'adverse', 'event', 'reported', 'patient', 'receiving', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'new', 'safety', 'signal', 'observed', 'additional', 'treatment-related', 'death', 'since', '-month', 'analysis', 'part', 'submission', 'following', 'resource', 'enclosed', 'review', 'product', 'information', 'opdivo®', 'nivolumab', 'injection', 'intravenous', 'infusion', 'bristol', 'myers', 'squibb', 'princeton', 'nj', 'may', 'product', 'information', 'yervoy®', 'ipilimumab', 'injection', 'intravenous', 'infusion', 'bristol', 'myers', 'squibb', 'princeton', 'nj', 'may', 'wolchock', 'jd', 'chiarion-sileni', 'gonzalez', 'checkmate', '.-year', 'outcome', 'patient', 'advanced', 'melanoma', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'anual', 'meeting', 'june', 'thank', 'consideration', 'request', 'sincerely', 'mary', 'coffey', 'pharmd', 'samantha', 'gothelf', 'pharmd', 'senior', 'director', 'vice', 'president', 'ww', 'scientific', 'content', 'market', 'capability', 'u', 'medical', 'oncology']}, {'filename': '2021_06_07_Merck.pdf', 'timestamp': datetime.datetime(2021, 6, 7, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'panel', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda®', 'pembrolizumab', 'reference', 'resected', 'stage', 'iv', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'inclusion', 'pembrolizumab', 'category', 'adjuvant', 'treatment', 'option', 'patient', 'resected', 'stage', 'iv', 'melanoma', 'evidence', 'disease', 'appropriate', 'section', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'v.', 'including', 'page', 'me-', 'me-a', 'fda', 'clearance', 'keytruda', 'pembrolizumab', 'indicated', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'keytruda', 'indicated', 'adjuvant', 'treatment', 'patient', 'melanoma', 'involvement', 'lymph', 'node', 'following', 'complete', 'resection', 'please', 'refer', 'keytruda', 'prescribing', 'information', 'fda-approved', 'indication', 'rationale', 'grossman', 'presented', 'data', 'phase', 'iii', 'trial', 'ass', 'whether', 'pembrolizumab', 'administered', 'year', 'would', 'improve', 'relapse-free-survival', 'rf', 'overall', 'survival', 'o', 'comparison', 'either', 'ipilimumab', 'high-dose', 'interferon', 'patient', 'high-risk', 'resected', 'melanoma', 'eligible', 'patient', 'age', 'year', 'older', 'completely', 'resected', 'melanoma', 'including', 'lymph', 'node', 'dissection', 'sentinel', 'lymph', 'node', 'positive', 'disease', 'previous', 'immunotherapy', 'allowed', 'prior', 'adjuvant', 'radiation', 'permitted', 'patient', 'randomized', 'treatment', 'stage', 'iiia', 'iiib', 'iiic', 'iv', 'melanoma', 'respectively', 'american', 'joint', 'committee', 'cancer', 'th', 'edition', 'patient', 'randomized', 'either', 'experimental', 'arm', 'control', 'arm', 'follows', 'experimental', 'arm', 'pembrolizumab', 'mg', 'intravenously', 'iv', 'every', 'week', 'qw', 'week', 'control', 'arm', 'investigator', 'choice', 'prespecified', 'enrollment', 'interferon', 'alfa-b', 'million', 'unit', 'per', 'square', 'meter', 'mu/m', 'iv', 'day', 'week', 'followed', 'mu/m/day', 'subcutaneously', 'day', 'week', 'ipilimumab', 'mg/kg', 'iv', 'qw', 'dos', 'every', 'week', 'year', 'primary', 'endpoint', 'rf', 'o', 'total', 'population', 'o', 'patient', 'programmed-', 'death', 'ligand', 'positive', 'pd-l+', 'melanoma', 'baseline', 'pre-specified', 'analysis', 'performed', 'per-protocol', 'year', 'date', 'last', 'patient', 'randomized', 'time-driven', 'including', 'event', 'rf', 'event', 'o', 'patient', 'received', 'pembrolizumab', 'statistically', 'significant', 'improvement', 'rf', 'compared', 'high-dose', 'interferon', 'ipilimumab', 'hr', 'ci', '.-', 'statistically', 'significant', 'improvement', 'o', 'total', 'population', 'hr', 'ci', '.-', 'p=', 'patient', 'pd-l', 'positive', 'melanoma', 'hr', 'ci', '.-', 'p=.', 'treatment-related', 'grade', 'adverse', 'event', 'aes', 'occurred', 'patient', 'received', 'pembrolizumab', 'compared', 'ipilimumab', 'high-dose', 'interferon', 'aes', 'led', 'discontinuation', 'patient', 'received', 'pembrolizumab', 'compared', 'ipilimumab', 'high-dose', 'interferon', 'respectively', 'result', 'study', 'support', 'pembrolizumab', 'treatment', 'option', 'patient', 'completely', 'resected', 'stage', 'iiia', 'iiib', 'iiic', 'iv', 'melanoma', 'specifically', 'subgroup', 'patient', 'resected', 'stage', 'iv', 'melanoma', 'rf', 'hr', 'ci', '.-.', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'grossman', 'kf', 'othus', 'patel', 'final', 'analysis', 'overall', 'survival', 'relapse-free', 'survival', 'swog', 'phase', 'iii', 'randomized', 'trial', 'comparing', 'pembrolizumab', 'either', 'high', 'dose', 'interferon', 'ipilimumab', 'patient', 'high', 'risk', 'resected', 'melanoma', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'virtual', 'scientific', 'program', 'june', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}, {'filename': '2021_06_11_Astro.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['email', 'submission', 'nccn.org', 'date', 'request', 'june', 'american', 'society', 'radiation', 'oncology', 'reviewed', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'gap', 'relative', 'radiation', 'therapy', 'offer', 'two', 'major', 'recommendation', 'supported', 'evidence-based', 'rationale', 'one', 'minor', 'recommendation', 'consideration', 'hope', 'find', 'recommendation', 'useful', 'panel', 'review', 'update', 'guideline', 'sincerely', 'laura', 'i.', 'thevenot', 'chief', 'executive', 'officer', 'american', 'society', 'radiation', 'oncology', 'major', 'recommendation', 'treatment', 'metastatic', 'disease', 'recommend', 'removing', 'page', 'me-', 'me-', 'resectable', 'limited', 'unresectable', 'disseminated', 'sbrt', 'listed', 'alongside', 'resection', 'management', 'limited', 'distant', 'metastatic', 'disease', 'rationale', 'cut', 'point', 'widespread', 'disease', 'limited', 'metastatic', 'disease', 'solely', 'discretion', 'surgeon', 'low-volume', 'brain', 'metastasis', 'low-volume', 'extracranial', 'even', 'unresectable', 'disease', 'effectively', 'managed', 'sbrt', 'sbrt', 'listed', 'alongside', 'resection', 'management', 'limited', 'distant', 'metastatic', 'disease', 'randomized', 'data', 'supporting', 'sbrt', 'oligometastatic', 'disease', 'whereas', 'randomized', 'data', 'practice', 'surgical', 'resection', 'strictly', 'speaking', 'sbrt', 'preferred', 'option', 'based', 'level', 'evidence', 'considered', 'guideline', 'randomized', 'data', 'support', 'use', 'stereotactic', 'body', 'radiotherapy', 'sbrt', 'ablative', 'treatment', 'oligometastatic', 'disease', 'lesion', 'demonstrable', 'benefit', 'progression-free', 'survival', 'overall', 'survival', '..', 'sabrt-comet', 'enrolled', 'histology', 'demonstrated', 'sbrt', 'associated', '-year', 'o', 'versus', 'patient', 'managed', 'standard', 'systemic', 'therapy', 'alone', 'p=.', 'standard', 'consideration', 'patient', 'oligometastatic', 'disease', 'furthermore', 'line', 'intracranial', 'control', 'demonstrated', 'radiosurgery', 'dosing', 'melanoma-specific', 'data', 'demonstrates', 'sufficient', 'sbrt', 'dos', 'achieve', 'metastatic', 'lesion', 'control', 'year', 'approximately', 'year', 'countering', 'long-held', 'belief', 'melanoma', 'metastasis', 'insensitive', 'radiotherapy', 'additionally', 'sbrt', 'modeled', 'cost-effective', 'strategy', 'melanoma', 'pulmonary', 'oligometastases', 'surgical', 'resetion', 'reference', 'palma', 'da', 'clin', 'oncol', 'sep', 'pmid', 'palma', 'da', 'lancet', 'may', 'pmid', 'youland', 'r', 'adv', 'radiat', 'oncol', 'feb', 'pmid', 'lester-coll', 'nh', 'int', 'radiat', 'oncol', 'biol', 'phys', 'jun', 'pmdi', 'major', 'recommendation', 'me-l', 'recommend', 'removing', 'section', 'titled', 'selection', 'initial', 'treatment', 'modality', 'instead', 'propose', 'listing', 'best', 'systemic', 'therapy', 'plus', 'brain-directed', 'therapy', 'first', 'step', 'principle', 'brain', 'metastasis', 'management', 'bullet', 'point', 'heading', 'state', 'highly', 'select', 'patient', 'evaluated', 'multidisciplinary', 'setting', 'systemic', 'therapy', 'alone', 'close', 'observation', 'intracranial', 'response', 'may', 'appropriate.', 'rationale', 'neurosurgeon', 'radiation', 'oncologist', 'illusion', 'resection', 'and/or', 'sr', 'displacing', 'need', 'systemic', 'therapy', 'setting', 'intracranial', 'metastasis', 'either/or', 'choice', 'brain-directed', 'therapy', 'performed', 'context', 'best', 'systemic', 'therapy', 'either', 'ongoing', 'planned', 'shortly', 'thereafter', 'framing', 'presented', 'selection', 'initial', 'treatment', 'modality', 'however', 'make', 'seem', 'systemic', 'therapy', 'indicated', 'almost', 'always', 'local', 'therapy', 'considered', 'parallel', 'decade', 'brain', 'metastasis', 'management', 'clearly', 'contradicts', 'presented', 'dichotomy', 'furthermore', 'presence', 'absence', 'symptom', 'key', 'determinant', 'suggested', 'bullet', 'point', 'page', 'lesion', 'becomes', 'symptomatic', 'sr', 'often', 'feasible', 'craniotomy', 'required', 'avoided', 'asymptomatic', 'window', 'usually', 'ideal', 'time', 'intervene', 'randomized', 'study', 'ipi/nivo', 'nivo', 'alone', 'studied', 'brain', 'metastasis', 'resulted', 'intracranial', 'progression', 'rate', 'craniotomy', 'death', 'ascribed', 'intracranial', 'progression', 'patient', 'offered', 'upfront', 'brain-directed', 'therapy', 'study', 'supported', 'omission', 'brain-directed', 'therapy', 'rather', 'study', 'demonstrated', 'danger', 'omitting', 'brain-directed', 'therapy', 'systemic', 'therapy', 'alone', 'randomized', 'study', 'braf/mek', 'inhibition', 'lieu', 'brain-directed', 'therapy', 'similar', 'concerning', 'finding', 'patient', 'afforded', 'radiosurgery', 'requiring', 'craniotomy', 'tucked', 'away', 'appendix', 'overall', 'recommend', 'strengthening', 'need', 'formal', 'cns', 'specialist', 'evaluation', 'weakening', 'option', 'systemic', 'therapy', 'alone', 'practice', 'brain-directed', 'therapy', 'established', 'standard', 'care', 'brain', 'metastatic', 'management', 'per', 'numerous', 'radiation', 'oncology', 'neurosurgical', 'randomized', 'study', 'always', 'context', 'best', 'systemic', 'therapy', 'systemic', 'therapy', 'alone', 'versus', 'standard', 'never', 'examined', 'randomized', 'fashion', 'reference', 'long', 'gv', 'lancet', 'oncol', 'may', 'pmid', 'kruser', 'tj', 'lancet', 'oncol', 'aug', 'e.', 'pmid', 'davy', 'lancet', 'oncol', 'jul', 'pmid', 'minor', 'recommendation', 'me-', 'me-', 'recommend', 'footnote', 'describing', 'role', 'adjuvant', 'rt', 'desmoplastic', 'histology', 'selected', 'patient', 'positive', 'margin', 'surgery…consider…rt', 'rationale', 'agree', 'note', 'page', 'me-h', 'page', 'adjuvant', 'rt', 'may', 'considered', 'high-risk', 'desmoplastic', 'melanoma', 'however', 'preceding', 'footnote', 'pathway', 'would', 'guide', 'surgeon', 'medical', 'oncologist', 'seeing', 'clinical', 'patient', 'find', 'recommendation', 'reference', 'included', 'reference', 'principle', 'rt', 'melanoma', 'page', 'section', 'me-h', 'nicely', 'support', 'recommendation']}, {'filename': '2021_06_11_Castle.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'submitted', 'name', 'jay', 'braxton', 'pharmd', 'company', 'castle', 'bioscience', 'inc.', 'address', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'texas', 'phone', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'submission', 'requested', 'amendment', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'member', 'nccn', 'guideline', 'melanoma', 'panel', 'behalf', 'castle', 'bioscience', 'thank', 'time', 'attention', 'devote', 'developing', 'clinical', 'practice', 'guideline', 'patient', 'cancer', 'respectfully', 'request', 'additional', 'relevant', 'recent', 'publication', 'included', 'update', 'guideline', 'recognize', 'gene', 'expression', 'profile', 'gep', 'testing', 'may', 'add', 'information', 'multidisciplinary', 'decision-making', 'process', 'adjunct', 'replacement', 'traditional', 'staging', 'please', 'find', 'requested', 'change', 'rationale', 'inclusion', 'well', 'relevant', 'publication', 'previously', 'discussed', 'specific', 'recommended', 'change', 'rationale', 'request', 'gene', 'expression', 'profiling', 'risk', 'recurrence', 'page', 'me-a', 'footnote', 'clinical', 'presentation', 'pathology', 'report', 'preliminary', 'workup', 'footnote', 'page', 'me-a', 'footnote', 'workup', 'primary', 'treatment', 'footnote', 'page', 'me-', 'nccn', 'guideline', 'version', 'melanoma', 'cutaneous', 'footnote', 'footnote', 'similar', 'verbiage', 'therefore', 'request', 'verbiage', 'footnote', 'recommended', 'change', 'use', 'gep', 'testing', 'according', 'specific', 'ajcc-', 'melanoma', 'stage', 'slnb', 'requires', 'prospective', 'investigation', 'large', 'contemporary', 'data', 'set', 'unselected', 'patient', 'prognostic', 'gep', 'testing', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'replace', 'pathologic', 'staging', 'procedure', 'may', 'used', 'conjunction', 'staging', 'provide', 'additional', 'risk', 'stratification', 'moreover', 'since', 'low', 'probability', 'metastasis', 'stage', 'melanoma', 'higher', 'proportion', 'false-positive', 'result', 'gep', 'testing', 'guide', 'clinical', 'decision-making', 'subgroup', 'see', 'principle', 'molecular', 'testing', 'me-c', 'page', 'me-c', 'principle', 'molecular', 'testing', 'bullet', 'prognostic', 'testing', 'arrow', 'recommended', 'change', 'commercially', 'available', 'gep', 'test', 'marketed', 'able', 'classify', 'cutaneous', 'melanoma', 'separate', 'category', 'based', 'risk', 'metastasis', 'however', 'remains', 'unclear', 'whether', 'gep', 'platform', 'may', 'provide', 'clinically', 'actionable', 'prognostic', 'information', 'used', 'addition', 'comparison', 'known', 'clinicopathologic', 'factor', 'multivariable', 'nomogram', 'incorporate', 'patient', 'sex', 'age', 'tumor', 'location', 'thickness', 'ulceration', 'mitotic', 'rate', 'lymphovascular', 'invasion', 'microsatellites', 'slnb', 'status', 'part', 'multidisciplinary', 'decision-making', 'process', 'furthermore', 'impact', 'test', 'treatment', 'outcome', 'follow-up', 'schedule', 'established', 'page', 'me-c', 'principle', 'molecular', 'testing', 'bullet', 'prognostic', 'testing', 'arrow', 'recommended', 'change', 'various', 'mostly', 'retrospective', 'study', 'prognostic', 'gep', 'testing', 'suggest', 'role', 'independent', 'predictor', 'worse', 'outcome', 'though', 'superior', 'breslow', 'thickness', 'sln', 'status', 'remains', 'unclear', 'whether', 'available', 'gep', 'platform', 'reliably', 'predictive', 'outcome', 'across', 'risk', 'spectrum', 'melanoma', 'recent', 'pprospective', 'validation', 'study', 'performed', 'breast', 'cancer', 'required', 'define', 'accurately', 'support', 'clinical', 'utility', 'molecular', 'testing', 'prior', 'widespread', 'implementation', 'gep', 'prognostication', 'cutaneous', 'melanoma', 'adjunct', 'traditional', 'staging', 'process', 'part', 'multidisciplinary', 'decision-', 'making', 'process', 'particular', 'determine', 'role', 'guiding', 'surveillance', 'imaging', 'slnb', 'adjuvant', 'treatment', 'decision', 'existing', 'emerging', 'gep', 'platform', 'prognostic', 'technique', 'compared', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'i.e.', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'development', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'rationale', 'recommended', 'change', 'current', 'staging', 'powerful', 'limitation', 'melanoma', 'diagnosed', 'stage', 'ii', 'many', 'death', 'occur', 'patient', 'initially', 'diagnosed', 'stage', 'sentinel', 'node', 'positivity', 'important', 'prognosis', 'two-thirds', 'patient', 'completely', 'staged', 'die', 'melanoma', 'initially', 'node-negative', 'disease.', 'gene', 'expression', 'profile', 'provide', 'independent', 'information', 'identify', 'patient', 'aggressive', 'tumor', 'biology', 'provide', 'improved', 'risk', 'stratification', 'recent', 'independent', 'publication', 'arnot', 'al.', 'reported', 'outcome', 'patient', 'prospectively', 'enrolled', 'database', 'oregon', 'health', 'science', 'university', 'mean', 'follow-up', 'time', 'month', 'patient', 'underwent', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'patient', 'experienced', 'recurrence', 'melanoma', 'within', 'three', 'year', 'recurrence', 'positive', 'slnb', 'decisiondx-melanoma', '-gep', 'class', 'result', 'demonstrating', '-gep', 'identify', 'completely', 'staged', 'patient', 'still', 'risk', 'metastasis', 'note', 'study', 'slnb', 'identified', 'one-third', 'recurrence', 'consistent', 'mslt-', 'overall', 'cohort', '-gep', 'independent', 'predictor', 'rf', 'hr', 'p=', 'dmfs', 'hr', 'p=', 'specifically', 'low', 'risk', 'stage', 'i-iia', 'population', '-gep', 'could', 'stratify', 'patient', 'group', 'low', 'class', 'high', 'class', 'risk', 'relapse', 'hsueh', 'al.', 'another', 'prospective', 'multi-center', 'study', 'examining', 'unselected', 'patient', 'stage', 'i-iii', 'melanoma', 'median', 'follow-up', 'time', 'year', 'patient', '-gep', 'class', 'result', 'excellent', 'outcome', 'distant', 'metastasis-', 'free', 'survival', 'dmfs', 'compared', 'dmfs', 'among', 'patient', 'high-risk', 'class', 'result', 'molecular', 'testing', 'added', 'clinical', 'factor', 'indicated', 'significant', 'hazard', 'ratio', 'multivariable', 'analysis', 'included', 'ajcc', 'stage', 'breslow', 'thickness', 'ulceration', 'status', 'sln', 'status', 'tumor', 'location', 'head', 'neck', 'sex', 'age', 'mitoses', 'determined', 'accuracy', 'metric', 'sensitivity', 'identification', 'patient', 'developed', 'distant', 'metastasis', 'increased', 'using', 'staging', 'factor', 'combining', '-gep', 'test', 'staging', 'factor', 'sensitivity', 'increased', 'endpoint', 'evaluated', 'study', 'following', 'inclusion', '-gep', 'result', 'ajcc', 'prognosis', 'additionally', 'combined', 'ajcc', '-gep', 'prognosis', 'maintained', 'negative', 'predictive', 'value', 'dmfs', 'similar', 'result', 'seen', 'rf', 'o', 'demonstrating', '-gep', 'test', 'significant', 'independent', 'predictor', 'recurrence', 'distant', 'metastasis', 'death', 'data', 'viewed', '-gep', 'subclass', '-year', 'overall', 'survival', 'patient', 'stage', 'i-iia', 'melanoma', 'class', '-gep', 'result', 'similar', 'survival', 'patient', 'stage', 'iib-iii', 'melanoma', 'suggesting', '-gep', 'identify', 'patient', 'traditionally', 'staged', 'low', 'risk', 'may', 'higher', 'recurrence', 'metastasis', 'risk', 'initially', 'thought', 'result', 'reported', 'article', 'described', 'consistent', 'published', 'prospective', 'studies.', 'addition', 'evidence', 'described', 'prospective', 'study', 'two', 'recent', 'systematic', 'review', 'meta-analyses', 'demonstrated', 'consistent', 'prognostic', 'accuracy', '-gep', 'across', 'multiple', 'study', 'greenhaw', 'al.', 'reviewed', 'result', 'patient', 'reporting', 'group', 'stage', 'patient', 'class', 'result', 'dmfs', 'rate', 'compared', 'patient', 'class', 'result', 'similarly', 'significant', 'separation', 'distant', 'metastasis', 'risk', 'reported', 'stage', 'ii', 'patient', 'patient', 'class', 'result', 'patient', 'class', 'result', 'multivariable', 'cox', 'regression', 'analysis', 'showed', '-gep', 'added', 'independent', 'prognostic', 'information', 'model', 'incorporating', 'clinical', 'pathologic', 'factor', 'incorporated', 'ajcc', 'staging', 'patient', 'age', 'similar', 'study', 'described', 'result', 'meta-analysis', 'demonstrated', '-gep', 'high', 'sensitivity', 'increased', 'combined', 'sln', 'status', 'sensitivity', 'sln', 'status', 'alone', 'indicating', 'using', '-gep', 'conjunction', 'staging', 'factor', 'improve', 'prognostic', 'accuracy', 'growing', 'list', 'study', 'build', 'result', 'ferris', 'al.', 'demonstrates', 'added', 'prognostic', 'value', '-gep', 'combined', 'clinicopathologic', 'factor', 'described', 'ajcc', 'th', 'th', 'edition', 'cancer', 'staging', 'manual', 'recommendation', 'nccn', 'important', 'highlight', 'request', 'comparison', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'limited', 'fact', 'cited', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'currently', 'available', 'use', 'believe', 'request', 'comparison', 'included', 'nccn', 'text', 'limited', 'tool', 'available', 'comparison', 'gene', 'expression', 'profiling', 'sentinel', 'lymph', 'node', 'biopsy', 'page', 'me-f', 'principle', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'bullet', 'arrow', 'recommended', 'change', 'prognostic', 'gep', 'testing', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'replace', 'pathologic', 'staging', 'procedure', 'currently', 'available', 'gep', 'test', 'used', 'determine', 'slnb', 'eligibility', 'however', 'clinical', 'scenario', 'wherein', 'gep', 'add', 'additional', 'information', 'regarding', 'risk', 'slnb', 'positivity', 'adjunct', 'traditional', 'staging', 'important', 'part', 'multidisciplinary', 'discussion', 'rationale', 'recommended', 'change', 'recent', 'nccn', 'guideline', 'recommend', 'sentinel', 'lymph', 'node', 'biopsy', 'discussed', 'offered', 'patient', 'likelihood', 'detecting', 'positive', 'sln', 'procedure', 'discussed', 'considered', 'likelihood', 'sln', 'metastasis', 'procedure', 'performed', 'risk', 'sln', 'positivity', 'le', 't-stage', 'melanoma', 'tumor', 'determined', 'time', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'diagnosis', 'determines', 'likelihood', 'sln', 'metastasis', 'factor', 'including', 'lymphovascular', 'invasion', 'age', 'uncertain', 'microstaging', 'recommended', 'considered', 'determining', 'risk', 'nodal', 'metastasis', 'association', '-gep', 'test', 'result', 'low-', 'high-', 'risk', 'sln', 'metastasis', 'demonstrated', 'specifically', 'class', 'patient', 'year', 'age', 'older', 'thickness', 'tumor', 'risk', 'positive', 'slnb', 'equivalent', 'risk', 'current', 'guideline', 'would', 'recommend', 'procedure', 'thus', 'patient', 'may', 'safely', 'avoid', 'surgical', 'intervention', 'ass', 'nodal', 'status', 'given', 'patient', 'risk', 'group', 'positive', 'node', 'following', 'slnb', 'maintained', '-year', 'ms', 'rate', 'additionally', 'patient', 'year', 'age', 'class', 'score', 'likelihood', 'positive', 'node', 'conversely', 'patient', 'class', 'b-b', '-gep', 'test', 'result', 'risk', 'sln', 'positivityabove', 'threshold', 'nccn', 'guideline', 'recommend', 'discussing', 'slnb', 'procedure', '-gep', 'test', 'validated', 'prospective', 'studies-', 'including', 'academic', 'non-industry-sponsored', 'systematic', 'review', 'meta-analyses', 'including', 'patient', 'multiple', 'retrospective', 'study', 'study', 'consistently', 'demonstrated', '-gep', 'test', 'offer', 'added', 'value', 'prognostication', 'used', 'combination', 'ajcc', 'staging', 'slnb', 'positivity', 'across', 'different', 'patient', 'group', 'early-stage', 'melanoma', 'recently', 'two', 'large', 'prospective', 'study', 'contemporary', 'data', 'set', 'demonstrated', 'added', 'prognostic', 'accuracy', 'offered', '-gep.', 'sum', '-gep', 'shown', 'vetto', 'inform', 'slnb', 'decision', 'improve', 'sensitivity', 'regarding', 'recurrence', 'distant', 'metastasis', 'melanoma-', 'specific', 'survival', 'overall', 'survival', 'used', 'combination', 'slnb', 'evidenced', 'systematic', 'review', 'meta-analysis', 'greenhaw', 'literature', 'summary', 'rationale', 'key', 'article', 'arnot', 'ap', 'han', 'fortino', 'utility', '-gene', 'expression', 'profile', 'predicting', 'outcome', 'patient', 'primary', 'cutaneous', 'melanoma', 'referred', 'sentinel', 'node', 'biopsy', 'surg', 'study', 'design', 'prospective', 'independent', 'unselected', 'large', 'contemporary', 'data', 'set', 'patient', 'undergoing', 'slnb', 'finding', 'risk', 'regional', 'recurrence', 'distant', 'metastasis', '-gep', 'added', 'prognostic', 'value', 'clinical', 'information', 'predicted', 'recurrence', 'slnb', 'patient', 'recurrence', 'slnb+', 'versus', 'patient', 'recurrence', 'class', 'result', 'risk-stratified', 'patient', 'entire', 'cohort', 'stage', 'i-iii', 'stage', 'i-iia', 'subgroup', 'additional', 'rationale', 'publication', 'support', 'added', 'prognostic', 'accuracy', 'offered', '-gep', 'addition', 'slnb', 'identified', 'patient', 'went', 'develop', 'recurrence', 'slnb', 'seminal', 'mslt-', 'trial', 'demonstrated', 'important', 'prognostic', 'information', 'provided', 'slnb', 'however', 'given', 'patient', 'died', 'melanoma', 'sln-negative', 'risk', 'underestimated', 'traditional', 'staging', 'castle', 'bioscience', 'assert', 'take', 'position', 'slnb', 'valuable', 'replaced', 'rather', 'recommend', 'gep', 'used', 'adjunct', 'traditional', 'staging', 'finding', 'slnb', '-gep', 'predicted', 'slnb', 'positivity', 'class', 'patient', 'positive', 'slnb', 'class', 'patient', 'positive', 'slnb', '-gep', 'added', 'clinical', 'information', 'shown', 'significant', 'hazard', 'ratio', 'gep', 'multivariable', 'analysis', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'long-term', 'outcome', 'multicenter', 'prospective', 'cohort', 'evaluating', 'prognostic', '-gene', 'expression', 'profile', 'cutaneous', 'melanoma', 'jco', 'precis', 'oncol', 'study', 'design', 'prospective', 'multicenter', 'contemporary', 'data', 'set', 'demonstrating', 'long-term', 'outcome', 'patient', 'stage', 'i-iii', 'stage', 'i-iia', 'cutaneous', 'melanoma', 'finding', 'statistically', 'significant', 'separation', 'risk', 'profile', 'patient', 'class', 'class', 'gep', 'result', 'patient', '-gep', 'subclass', 'result', 'endpoint', 'rf', 'dmfs', 'o', 'patient', 'class', 'result', 'excellent', 'outcome', 'rf', 'dmfs', 'o', 'compared', 'class', 'result', 'rf', 'dmfs', 'o', 'overall', 'cohort', 'stage', 'i-iia', 'melanoma', 'rf', 'class', 'class', 'dmfs', 'class', 'class', 'o', 'class', '-gep', 'added', 'sensitivity', 'staging', 'maintaining', 'specificity', 'consistently', 'high', 'npv', 'additional', 'rationale', 'provider', 'routinely', 'use', 'gep', 'aid', 'multidisciplinary', 'decision-making', 'process', 'provider', 'routinely', 'use', 'factor', 'included', 'staging', 'i.e.', 'age', 'mitotic', 'rate', 'lvi', 'etc', 'prognostication', 'preponderance', 'evidence', 'demonstrates', 'gep', 'factor', 'included', 'traditional', 'staging', 'aid', 'accurate', 'risk', 'stratification', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'study', 'design', 'multicenter', 'study', 'examining', 'slnb', 'positivity', 'patient', 't-t', 'melanoma', 'prospectively', 'tested', '-gep', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'finding', 'developed', 'validated', 'model', 'predict', 'slnb', 'positivity', 'based', 'incorporation', 'age', 'breslow', 'thickness', 'gep', 'score', 'patient', 'aged', '-years', 'older', 't-t', 'tumor', 'received', 'class', '-gep', 'result', 'risk', 'positive', 'sln', 'maintaining', '-year', 'ms', 'rate', 'additional', 'rationale', 'publication', 'established', 'independent', 'predictive', 'value', 'model', 'incorporating', '-gep', 'age', 'breslow', 'thickness', 'slnb', 'positivity', 'risk', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'study', 'design', 'systematic', 'review', 'meta-analysis', 'examining', 'prognostic', 'value', '-gep', 'across', 'study', 'finding', '-gep', 'accurately', 'consistently', 'identifies', 'patient', 'cutaneous', 'melanoma', 'increased', 'risk', 'metastasis', '-gep', 'independent', 'clinicopathologic', 'feature', 'improves', 'risk', 'stratification', 'identifying', 'patient', 'high', 'risk', 'metastasis', 'previously', 'identified', 'low', 'risk', 'additional', 'rationale', 'study', 'demonstrated', '-gep', 'slnb', 'considered', 'together', 'dmfs', 'sensitivity', 'negative', 'predictive', 'value', 'improved', 'compared', 'either', 'alone', 'support', 'request', 'gep', 'considered', 'adjunct', 'traditional', 'staging', 'additionally', 'multiple', 'study', 'demonstrated', 'age', 'anticorrelated', 'slnb', 'positivity', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'study', 'design', 'multicenter', 'retrospective', 'analysis', 'large', 'cohort', 'patient', 'stage', 'i-iii', 'melanoma', 'examine', 'outcome', 'patient', 'low-risk', 'melanoma', 'traditional', 'ajcc', 'staging', 'slnb-', 'stage', 'i-iia', 'melanoma', 'finding', '-gep', 'independently', 'predicted', 'outcome', 'patient', 'considered', 'low-risk', 'melanoma', 'traditional', 'staging', 'test', 'demonstrated', 'dmfs', 'patient', 'stage', 'iia', 'melanoma', 'class', 'result', 'versus', 'dmfs', 'patient', 'stage', 'iia', 'melanoma', 'class', 'result', 'additionally', 'test', 'identified', 'sln-negative', 'patient', 'went', 'metastasize', 'demonstrated', 'reduced', 'recurrence-free', 'survival', 'patient', 'thin', 'tumor', 'class', 'result', 'class', 'result', 'independent', 'predictor', 'risk', 'patient', 'stage', 'iia', 'melanoma', 'hr', 'p=', 'patient', 'thin', 'tumor', 'hr', 'p=', 'additional', 'rationale', 'publication', 'support', 'addition', 'gep', 'traditional', 'staging', 'process', 'added', 'independent', 'prognostic', 'information', 'traditionally', 'low-risk', 'patient', 'group', 'stage', 'i-iia', 'whose', 'recurrence', 'may', 'missed', 'traditional', 'staging', 'alone', 'additionally', 'provider', 'consider', 'outcome', 'ms', 'outcome', 'reported', 'ajcc', 'version', 'staging', 'ms', 'important', 'outcome', 'publication', 'offer', 'additional', 'information', 'regarding', 'rf', 'dmfs', 'ms', 'kwatra', 'sg', 'hines', 'semenov', 'yr', 'dermatologist', 'guide', 'implementation', 'gene', 'expression', 'profiling', 'management', 'melanoma', 'clin', 'aesthet', 'dermatol', 'suppl', 's-s.', 'study', 'design', 'expert', 'panel', '-gep', 'test', 'user', 'sought', 'provide', 'clarification', 'use', 'option', 'rational', 'clinical', 'workflow', 'guide', 'appropriate', 'application', '-gep', 'test', 'everyday', 'practice', 'specifically', 'considered', 'role', 'gep', 'prognostication', 'finding', 'author', 'found', '-gep', 'test', 'useful', 'actionable', 'patient', 'care', 'applied', 'accordance', 'current', 'nccn', 'guideline', 'stratification', 'patient', 'low-', 'class', 'intermediate-', 'class', 'high-', 'class', 'risk', 'category', 'inform', 'multidisciplinary', 'conference', 'discussion', 'assist', 'determining', 'intensity', 'imaging', 'surveillance', 'follow-up', 'care', 'author', 'suggest', 'clinical', 'workflow', 'integrates', '-gep', 'testing', 'umbrella', 'current', 'national', 'guideline', 'application', 'test', 'appropriate', 'patient', 'population', 'improve', 'risk', 'assessment', 'inform', 'clinical', 'decision-making', 'including', 'slnb', 'referral', 'decision', 'additional', 'rationale', 'recently', 'published', 'consensus', 'statement', 'mpwg', 'author', 'noted', 'gep', 'could', 'important', 'aspect', 'multidisciplinary', 'decision-making', 'process', 'patient', 'cutaneous', 'melanoma', 'castle', 'bioscience', 'fully', 'support', 'thoughtful', 'use', 'gep', 'adjunct', 'traditional', 'staging', 'process', 'grossman', 'already', 'referenced', 'guideline', 'request', 'point', 'recognized', 'well', 'considering', 'gep', 'fda', 'status', 'decisiondx-melanoma', 'performed', 'central', 'laboratory', 'castle', 'bioscience', 'regulated', 'clinical', 'laboratory', 'improvement', 'amendment', 'clia', 'fda', 'clearance', 'required', 'note', 'commercially', 'available', 'prognostic', 'gene', 'expression', 'profile', 'test', 'cancer', 'site', 'breast', 'prostate', 'fda', 'approved', 'request', 'amendment', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'respectfully', 'submitted', 'castle', 'bioscience', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'reference', 'morton', 'dl', 'thompson', 'jf', 'cochran', 'aj', 'final', 'trial', 'report', 'sentinel-node', 'biopsy', 'versus', 'nodal', 'observation', 'melanoma', 'engl', 'med', 'seer', 'data', 'release', 'arnot', 'ap', 'han', 'fortino', 'utility', '-gene', 'expression', 'profile', 'predicting', 'outcome', 'patient', 'primary', 'cutaneous', 'melanoma', 'referred', 'sentinel', 'node', 'biopsy', 'surg', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'long-term', 'outcome', 'multicenter', 'prospective', 'cohort', 'evaluating', 'prognostic', '-gene', 'expression', 'profile', 'cutaneous', 'melanoma', 'jco', 'precis', 'oncol', 'greenhaw', 'bn', 'zitelli', 'ja', 'brodland', 'dg', 'estimation', 'prognosis', 'invasive', 'cutaneous', 'melanoma', 'independent', 'study', 'accuracy', 'gene', 'expression', 'profile', 'test', 'dermatol', 'surg', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'interim', 'analysis', 'survival', 'prospective', 'multi-center', 'registry', 'cohort', 'cutaneous', 'melanoma', 'tested', 'prognostic', '-gene', 'expression', 'profile', 'test', 'hematol', 'oncol', 'keller', 'schwartz', 'tl', 'lizalek', 'jm', 'prospective', 'validation', 'prognostic', '-gene', 'expression', 'profiling', 'test', 'primary', 'cutaneous', 'melanoma', 'cancer', 'med', 'podlipnik', 'carrera', 'boada', 'early', 'outcome', '-gene', 'expression', 'profile', 'test', 'ajcc', 'stage', 'ib-ii', 'melanoma', 'patient', 'prospective', 'multicenter', 'cohort', 'study', 'eur', 'acad', 'dermatol', 'venereol', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'berger', 'ac', 'davidson', 'right', 'poitras', 'jk', 'clinical', 'impact', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'prospectively', 'consecutively', 'tested', 'patient', 'curr', 'med', 're', 'opin', 'dillon', 'ld', 'gadzia', 'je', 'davidson', 'r', 'prospective', 'multicenter', 'clinical', 'impact', 'evaluation', '-gene', 'expression', 'profile', 'test', 'management', 'melanoma', 'patient', 'skin', 'cutan', 'med', 'farberg', 'glazer', 'white', 'impact', '-gene', 'expression', 'profiling', 'test', 'cutaneous', 'melanoma', 'dermatologist', 'clinical', 'management', 'decision', 'drug', 'dermatol', 'gastman', 'zager', 'messina', 'performance', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'head', 'neck', 'head', 'neck', 'litchman', 'gh', 'prado', 'teplitz', 'rw', 'rigel', 'd', 'systematic', 'review', 'meta-analysis', 'gene', 'expression', 'profiling', 'primary', 'cutaneous', 'melanoma', 'prognosis', 'skin', 'cutan', 'med', 'mirsky', 'prado', 'svoboda', 'management', 'decision', 'made', 'physician', 'assistant', 'nurse', 'practitioner', 'cutaneous', 'malignant', 'melanoma', 'patient', 'impact', '-gene', 'expression', 'profile', 'test', 'journal', 'drug', 'dermatology', 'drug', 'dermatol', 'schuitevoerder', 'heath', 'cook', 'rw', 'impact', 'gene', 'expression', 'profiling', 'decision-making', 'clinically', 'node', 'negative', 'melanoma', 'patient', 'surgical', 'staging', 'drug', 'dermatol', 'svoboda', 'glazer', 'farberg', 'factor', 'affecting', 'dermatologist', 'use', '-gene', 'expression', 'profiling', 'testa', 'adjunct', 'predicting', 'metastatic', 'risk', 'cutaneous', 'melanoma', 'drug', 'dermatol', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'zager', 'gastman', 'leachman', 'performance', 'prognostic', '-gene', 'expression', 'profile', 'independent', 'cohort', 'cutaneous', 'melanoma', 'patient', 'bmc', 'cancer', 'ferris', 'lk', 'farberg', 'middlebrook', 'identification', 'high-risk', 'cutaneous', 'melanoma', 'tumor', 'improved', 'combining', 'online', 'american', 'joint', 'committee', 'cancer', 'individualized', 'melanoma', 'patient', 'outcome', 'prediction', 'tool', '-gene', 'expression', 'profile-based', 'classification', 'acad', 'dermatol', '-.e', '..', 'rigel', 'ceilley', 'litchman', 'gene', 'expression', 'profile', 'testing', 'skin', 'cancer', 'prognosis', 'data', 'clear', '–it', 'time', 'get', 'board', 'skin', 'cutan', 'med', 'hanna', 'sinnamon', 'aj', 'rose', 'relationship', 'age', 'likelihood', 'lymph', 'node', 'metastasis', 'patient', 'intermediate', 'thickness', 'melanoma', '.-.mm', 'national', 'cancer', 'database', 'study', 'acad', 'dermatol', 'sinnamon', 'aj', 'neuwirth', 'mg', 'yalamanchi', 'association', 'patient', 'age', 'lymph', 'node', 'positivity', 'thin', 'melanoma', 'jama', 'dermatol', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'kwatra', 'sg', 'hines', 'semenov', 'yr', 'dermatologist', 'guide', 'implementation', 'gene', 'expression', 'profiling', 'management', 'melanoma', 'clin', 'aesthet', 'dermatol', 'suppl', 's-s.', 'pmid', 'grossman', 'okwundu', 'bartlett', 'ek', 'prognostic', 'gene', 'expression', 'profiling', 'cutaneous', 'melanoma', 'identifying', 'knowledge', 'gap', 'assessing', 'clinical', 'benefit', 'jama', 'dermatol']}, {'filename': '2021_06_11_PartnerTerapeutics.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['hillard', 'lazarus', 'md', 'facp', 'partner', 'therapeutic', 'inc.', 'muzzey', 'street', 'lexington', 'hillard.lazarus', 'partnertx.com', 'june', 'dear', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'panel', 'behalf', 'partner', 'therapeutic', 'respectfully', 'request', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'committee', 'review', 'enclosed', 'data', 'support', 'adding', 'combination', 'ipilimumab', 'sargramostim', 'glycosylated', 'yeast-derived', 'rhu', 'gm-csf', 'guideline', 'second-line', 'subsequent', 'treatment', 'option', 'metastatic', 'unresectable', 'melanoma', 'today', 'patient', 'metastatic', 'melanoma', 'receive', 'pd-', 'pd-l', 'blockade', 'therapy', 'adjuvant', 'first', 'line', 'setting', 'many', 'patient', 'left', 'option', 'experience', 'disease', 'progression', 'ipilimumab', 'fda', 'approved', 'treatment', 'melanoma', 'whereas', 'sargramostim', 'fda', 'approved', 'yet', 'indicated', 'melanoma', 'believe', 'combined', 'ipilimumab/sargramostim', 'important', 'le', 'toxic', 'option', 'patient', 'merit', 'committee', 'consideration', 'specific', 'request', 'request', 'combination', 'ipilimumab', 'sargramostim', 'listed', 'regimen', 'option', 'second-line', 'subsequent', 'therapy', 'page', 'section', 'me-i', 'systemic', 'therapy', 'metastatic', 'unresectable', 'disease', 'based', 'version', 'cutaneous', 'melanoma', 'guideline', 'rationale', 'melanoma', 'metastasizes', 'distant', 'site', '-year', 'survival', 'seer', 'race', 'sex', 'seer', 'summary', 'stage', 'hence', 'death', 'due', 'advanced', 'melanoma', 'represents', 'persistent', 'unmet', 'medical', 'need', 'treatment', 'option', 'unresectable', 'metastatic', 'melanoma', 'dose-limiting', 'severe', 'adverse', 'event', 'particularly', 'immune-related', 'adverse', 'event', 'associated', 'checkpoint', 'inhibitor', 'including', 'ipilimumab', 'nonetheless', 'ipilimumab', 'remains', 'important', 'treatment', 'patient', 'advanced', 'melanoma', 'dose', 'benefit', 'risk', 'relationship', 'established', 'ipilimumab', 'approved', 'mg/kg', 'mg/kg', 'mg/kg', 'dos', 'across', 'several', 'indication', 'recent', 'long-term', 'follow-up', 'data', 'ascierto', 'report', 'mg/kg', 'dose', 'ipilimumab', 'versus', 'mg/kg', 'showed', 'overall', 'survival', 'month', 'month', 'hazard', 'ratio', 'hr', 'p=', 'patient', 'unresectable', 'metastatic', 'melanoma', 'ascierto', 'improving', 'benefit-risk', 'ratio', 'ipilimumab', 'would', 'represent', 'significant', 'advance', 'treatment', 'address', 'serious', 'unmet', 'medical', 'need', 'preclinical', 'translational', 'study', 'demonstrated', 'antitumor', 'activity', 'gm-csf', 'advanced', 'melanoma', 'additive', 'synergistic', 'activity', 'observed', 'combined', 'immune', 'checkpoint', 'inhibitor', 'van', 'elsas', 'li', 'kwek', 'gm-csf', 'improves', 'antigen', 'presentation', 'mature', 'dendritic', 'cell', 'increasing', 'priming', 'activation', 'tumor-infiltrating', 'lymphocyte', 'tumor', 'draining', 'lymph', 'node', 'tumor', 'microenvironment', 'tarhini', 'clinical', 'data', 'supporting', 'sargramostim', 'usage', 'increase', 'survival', 'ameliorate', 'iraes', 'detailed', 'ecog', 'study', 'prospective', 'randomized', 'phase', 'ii', 'trial', 'compared', 'overall', 'survival', 'sargramostim', 'plus', 'ipilimumab', 'versus', 'ipilimumab', 'alone', 'patient', 'advanced', 'melanoma', 'hodi', 'total', 'patient', 'randomized', 'ipilimumab', 'mg/kg', 'every', 'week', 'cycle', 'every', 'week', 'either', 'sargramostim', 'mcg/day', 'day', '-day', 'cycle', 'alone', 'primary', 'analysis', 'median', 'month', 'follow-up', 'summarized', 'following', 'table', 'outcome', 'ipilimumab', 'sargramostim', 'ipilimumab', 'value', 'number', 'death', 'median', 'overall', 'survival', 'month', 'month', 'ne-year', 'survival', 'mortality', 'hazard', 'ratio', 'significant', 'difference', 'secondary', 'clinical', 'outcome', 'progression-free', 'survival', 'clinical', 'response', 'rate', 'observed', 'treatment', 'arm', 'well', 'established', 'ipilimumab', 'improve', 'overall', 'survival', 'without', 'associated', 'progression-free', 'survival', 'response', 'rate', 'benefit', 'finding', 'may', 'due', 'tumor', 'pseudoprogression', 'i.e', 'increased', 'lesion', 'size', 'resembles', 'progressive', 'disease', 'yet', 'actually', 'treatment', 'related', 'pseudoprogression', 'associated', 'influx', 'inflammatory', 'cell', 'follows', 'immune-modulating', 'therapy', 'including', 'ipilimumab', 'additionally', 'posthoc', 'analysis', 'change', 'cd+', 'icos', 'cell', 'found', 'increase', 'function', 'treatment', 'higher', 'sargramostim', 'arm', 'compared', 'ipilimumab', 'alone', 'p=', 'cd+', 'icos', 'cell', 'greater', 'signicant', 'p=', 'hodi', 'addition', 'increased', 'survival', 'fewer', 'patient', 'sargramostim', 'group', 'grade', 'adverse', 'event', 'compared', 'ipilimumab', 'alone', 'arm', 'p=.', 'reduction', 'grade', 'gastrointestinal', 'p=', 'pulmonary', 'p=', 'toxicity', 'favored', 'sargramostim', 'combination', 'arm', 'ipilimumab', 'alone', 'arm', 'correspondingly', 'colonic', 'perforation', 'occurred', 'patient', 'sargramostim', 'combination', 'arm', 'versus', 'ipilimumab', 'alone', 'arm', 'total', 'patient', 'sargramostim', 'combination', 'arm', 'patient', 'ipilimumab', 'alone', 'arm', 'discontinued', 'treatment', 'due', 'adverse', 'event', 'patient', 'discontinued', 'treatment', 'early', 'due', 'adverse', 'event', 'better', 'overall', 'survival', 'sargramostim', 'combination', 'arm', 'compared', 'ipilimumab', 'alone', 'arm', 'p=.', 'additionally', 'rule', 'improved', 'survival', 'benefit', 'due', 'toxicity', 'benefit', 'alone', 'analysis', 'performed', 'censoring', 'treatment-related', 'lethal', 'adverse', 'event', 'overall', 'survival', 'benefit', 'maintained', 'sargramostim', 'arm', 'median', 'o', 'reached', 'ci', 'month', 'reached', 'compared', 'ipilimumab', 'alone', 'month', 'ci', 'month', 'reached', 'p=', 'hodi', 'study', 'result', 'confirmed', 'additional', 'trial', 'kwek', 'conducted', 'prospective', 'single-arm', 'phase', 'ii', 'trial', 'ipilimumab', 'sargramostim', 'metastatic', 'melanoma', 'patient', 'kwek', 'patient', 'received', 'ipilimumab', 'mg/kg', 'day', 'sargramostim', 'mcg/m/day', 'day', '-day', 'cycle', 'cycle', 'followed', 'month', 'sargramostim', 'alone', 'followed', 'maintenance', 'therapy', 'ipilimumab', 'sargramostim', 'every', 'month', 'year', 'primary', 'endpoint', 'disease', 'control', 'rate', 'week', 'median', 'overall', 'survival', 'month', 'grade', 'adverse', 'event', 'occurred', 'patient', 'luke', 'retrospectively', 'evaluated', 'metastatic', 'melanoma', 'patient', 'received', 'ipilimumab', 'mg/kg', 'day', 'sargramostim', 'mcg/day', 'day', '-day', 'cycle', 'cycle', 'luke', 'overall', 'disease', 'control', 'rate', 'week', 'recist', 'criterion', 'immune-related', 'response', 'criterion', 'median', 'overall', 'survival', 'week', 'overall', 'incidence', 'immune-related', 'adverse', 'event', 'grade', 'event', 'including', 'grade', 'colitis', 'ipilimumab', 'dose', 'lower', 'compared', 'dose', 'used', 'adverse', 'event', 'still', 'plague', 'ipilimumab', 'therapy', 'support', 'addition', 'sargramostim', 'enhance', 'patient', 'tolerance', 'following', 'article', 'included', 'support', 'proposed', 'change', 'ascierto', 'del', 'vecchio', 'mackiewicz', 'overall', 'survival', 'year', 'follow-up', 'phase', 'iii', 'trial', 'comparing', 'ipilimumab', 'mg/kg', 'mg/kg', 'patient', 'advanced', 'melanoma', 'immunother', 'cancer', 'e.', 'doi', './jitc', 'van', 'elsas', 'hurwitz', 'aa', 'allison', 'jp', 'combination', 'immunotherapy', 'melanoma', 'using', 'anti-', 'cytotoxic', 'lymphocyte-associated', 'antigen', 'ctla-', 'granulocyte/macrophage', 'colony-', 'stimulating', 'factor', 'gm-csf', '-producing', 'vaccine', 'induces', 'rejection', 'subcutaneous', 'metastatic', 'tumor', 'accompanied', 'autoimmune', 'depigmentation', 'exp', 'med', 'doi', './jem', '...', 'li', 'vanroey', 'wang', 'anti-programmed', 'death-', 'synergizes', 'granulocyte', 'macrophage', 'colony-stimulating', 'factor', 'secreting', 'tumor', 'cell', 'immunotherapy', 'providing', 'therapeutic', 'benefit', 'mouse', 'established', 'tumor', 'clin', 'cancer', 're', 'doi', './-.ccr', 'kwek', 's', 'kahn', 'greaney', 'sk', 'gm-csf', 'ipilimumab', 'therapy', 'metastatic', 'melanoma', 'clinical', 'outcome', 'immunologic', 'response', 'oncoimmunology', 'e.', 'doi', './x', '..', 'tarhini', 'aa', 'joshi', 'garner', 'f.', 'sargramostim', 'rhu', 'gm-csf', 'immune', 'checkpoint', 'inhibitor', 'combinatorial', 'therapeutic', 'study', 'metastatic', 'melanoma', 'immunotherapy', 'press', 'doi', './imt', 'hodi', 'sf', 'lee', 'mcdermott', 'df', 'ipilimumab', 'plus', 'sargramostim', 'ipilimumab', 'alone', 'treatment', 'metastatic', 'melanoma', 'randomized', 'clinical', 'trial', 'jama', 'doi', './jama', '..', 'luke', 'jj', 'donahue', 'nishino', 'single', 'institution', 'experience', 'ipilimumab', 'mg/kg', 'sargramostim', 'gm-csf', 'metastatic', 'melanoma', 'cancer', 'immunol', 're', 'doi', './-.cir', 'combining', 'sargramostim', 'immune', 'checkpoint', 'inhibitor', 'advanced', 'melanoma', 'remains', 'clinical', 'interest', 'ongoing', 'ecog-acrin', 'phase', 'ii/iii', 'trial', 'evaluating', 'combination', 'ipilimumab', 'nivolumab', 'sargramostim', 'compared', 'ipilimumab', 'plus', 'nivolumab', 'alone', 'unresectable', 'stage', 'iii', 'iv', 'melanoma', 'trial', 'recently', 'resumed', 'accrual', 'phase', 'iii', 'portion', 'meeting', 'prespecified', 'efficacy', 'safety', 'threshold', 'believe', 'evidence', 'support', 'adding', 'ipilimumab/sargramostim', 'combination', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'option', 'second', 'line', 'therapy', 'metastatic', 'unresectable', 'disease', 'given', 'improved', 'toxicity', 'profile', 'impact', 'overall', 'survival', 'compared', 'ipilimumab', 'alone', 'please', 'hesitate', 'reach', 'directly', 'hillard.lazarus', 'partnertx.com', 'question', 'sincerely', 'hillard', 'lazarus', 'md', 'facp', 'consultant', 'partner', 'therapeutic', 'professor', 'medicine', 'case', 'western', 'reserve', 'university', 'editor-in-chief', 'bone', 'marrow', 'transplantation', 'editor-in-chief', 'blood', 'review']}, {'filename': '20201_06_01_Merck.pdf', 'timestamp': datetime.datetime(201, 6, 1, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'january', 'nccn', 'guideline', 'panel', 'melanoma', 'panel', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda®', 'pembrolizumab', 'reference', 'unresectable', 'metastatic', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'inclusion', 'pembrolizumab', 'combination', 'dabrafenib', 'trametinib', 'systemic', 'treatment', 'option', 'patient', 'unresectable', 'metastatic', 'melanoma', 'braf', 'v-activating', 'mutation', 'appropriate', 'section', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'v.', 'including', 'page', 'me-i', 'fda', 'clearance', 'keytruda', 'indicated', 'combination', 'therapy', 'dabrafenib', 'trametinib', 'treatment', 'patient', 'advanced', 'melanoma', 'keytruda', 'pembrolizumab', 'indicated', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'keytruda', 'indicated', 'adjuvant', 'treatment', 'patient', 'melanoma', 'involvement', 'lymph', 'node', 'following', 'complete', 'resection', 'please', 'refer', 'keytruda', 'prescribing', 'information', 'fda-approved', 'indication', 'rationale', 'ferrucci', 'published', 'result', 'part', 'keynote-', 'trial', 'nct', 'randomized', 'double-blind', 'phase', 'portion', 'patient', 'previously', 'untreated', 'advanced', 'melanoma', 'randomly', 'assigned', 'receive', 'pembrolizumab', 'mg/kg', 'intravenously', 'every', 'three', 'week', 'combination', 'dabrafenib', 'mg', 'orally', 'two', 'time', 'daily', 'trametinib', 'mg', 'orally', 'daily', 'triplet', 'therapy', 'placebo', 'combined', 'dabrafenib', 'mg', 'orally', 'two', 'time', 'daily', 'trametinib', 'mg', 'orally', 'daily', 'doublet', 'therapy', 'eligible', 'patient', 'year', 'age', 'unresectable', 'stage', 'iii', 'stage', 'iv', 'cutaneous', 'melanoma', 'brafve/k', 'mutation-positive', 'disease', 'primary', 'endpoint', 'progression-free', 'survival', 'assessed', 'based', 'response', 'evaluation', 'criterion', 'solid', 'tumor', 'version', 'recist', 'v.', 'investigator', 'secondary', 'endpoint', 'objective', 'response', 'rate', 'orr', 'duration', 'response', 'dor', 'overall', 'survival', 'o', 'cutoff', 'date', 'june', 'median', 'follow-up', 'time', 'analysis', 'month', 'result', 'updated', 'analysis', 'considered', 'carry', 'statistical', 'significance', 'trial', 'previously', 'demonstrated', 'median', 'follow-up', 'time', 'month', 'triplet', 'therapy', 'improved', 'compared', 'doublet', 'therapy', 'without', 'reaching', 'statistical', 'significance', 'month', 'month', 'hr', 'p=.', 'updated', 'analysis', 'median', 'month', 'ci', '.-', 'triplet', 'arm', 'month', 'ci', '.-', 'doublet', 'arm', 'hr', 'ci', '.-.', '-month', 'kaplan-meier', 'km', 'estimated', 'rate', 'ci', 'triplet', 'arm', 'ci', 'doublet', 'arm', '-month', 'rate', 'ci', 'ci', 'respectively', 'orr', 'recist', 'v.', 'assessed', 'investigator', 'triplet', 'arm', 'doublet', 'arm', 'median', 'km-estimated', 'dor', 'month', 'triplet', 'arm', 'month', 'doublet', 'arm', 'hr', 'ci', '.-.', 'median', 'o', 'reached', 'triplet', 'arm', 'month', 'doublet', 'arm', 'hr', 'ci', '.-.', '-month', 'km-', 'estimated', 'o', 'rate', 'ci', 'triplet', 'arm', 'ci', 'doublet', 'arm', '-month', 'o', 'rate', 'ci', 'ci', 'respectively', 'treatment-related', 'adverse', 'event', 'traes', 'occurred', 'patient', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'grade', 'traes', 'occurred', 'patient', 'including', 'one', 'death', 'pneumonitis', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'adverse', 'event', 'led', 'treatment', 'discontinuation', 'patient', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'median', 'follow-up', 'year', 'result', 'support', 'antitumor', 'activity', 'pembrolizumab', 'dabrafenib', 'trametinib', 'first-line', 'combination', 'therapy', 'patient', 'unresectable', 'metastatic', 'melanoma', 'brafve/k', 'mutation', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'ferrucci', 'pf', 'di', 'giacomo', 'del', 'vecchio', 'keynote-', 'part', 'randomized', 'double-blind', 'phase', 'study', 'pembrolizumab', 'dabrafenib', 'trametinib', 'braf-mutant', 'melanoma', 'journal', 'immunotherapy', 'cancer', 'e.', 'doi', './jitc', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}, {'filename': '2024_02_21_Iovance.pdf', 'timestamp': datetime.datetime(2024, 2, 21, 0, 0), 'text': ['prince', 'emily', 'emily.prince', 'iovance.com', 'february', 'company', 'iovance', 'iovance', 'biotherapeutics', 'inc.', 'guideline', 'melanoma', 'cutaneous', 'panel', 'melanoma', 'panel', 'algorithm', 'page', 'number', 'me-j', 'page', 'specific', 'change', 'recommended', 'please', 'consider', 'addition', 'following', 'bulleted', 'point', 'first', 'column', 'braf', 'v-', 'activating', 'mutation', 'present', 'patient', 'progression', 'anti-pd-', 'containing', 'therapy', 'braf', 'mek', 'inhibitor', 'combination', 'therapy', 'consider', 'lifileucel', 'fda', 'clearance', 'february', 'u', 'food', 'drug', 'administration', 'granted', 'approval', 'amtagvi™', 'lifileucel', 'treatment', 'adult', 'patient', 'unresectable', 'metastatic', 'melanoma', 'previously', 'treated', 'pd-', 'blocking', 'antibody', 'braf', 'mutation', 'positive', 'braf', 'inhibitor', 'without', 'mek', 'inhibitor', 'indication', 'approved', 'accelerated', 'approval', 'based', 'objective', 'response', 'rate', 'orr', 'continued', 'approval', 'indication', 'may', 'contingent', 'upon', 'verification', 'description', 'clinical', 'benefit', 'confirmatory', 'trial', 'rationale', 'recommended', 'change', 'tumor-infiltrating', 'lymphocyte', 'cytotoxic', 'helper', 'cell', 'infiltrate', 'tumor', 'component', 'immunological', 'response', 'patient', 'cancer', 'process', 'pioneered', 'researcher', 'national', 'cancer', 'institute', 'recovered', 'directly', 'patient', 'tumor', 'tissue', 'amplified', 'reinvigorated', 'produce', 'billion', 'polyclonal', 'patient-specific', 'upon', 'reinfusion', 'patient', 'autologous', 'cell', 'recognize', 'target', 'multitude', 'individualized', 'tumor-specific', 'neoantigens.', 'decade', 'process', 'provided', 'numerous', 'patient', 'long-term', 'durable', 'clinical', 'response', 'continued', 'show', 'clinical', 'efficacy', 'despite', 'dramatic', 'change', 'therapeutic', 'landscape', 'melanoma', 'level', 'validation', 'occurred', 'nci', 'external', 'center', 'including', 'recent', 'pivotal', 'randomized', 'clinical', 'trial', 'lifileucel', 'first', 'tumor-derived', 'autologous', 'cell', 'immunotherapy', 'approved', 'fda', 'patient', 'metastatic', 'unresectable', 'melanoma', 'representing', 'new', 'treatment', 'modality', 'option', 'patient', 'disease', 'progression', 'approved', 'therapy', 'although', 'exact', 'mechanism', 'action', 'lifileucel', 'unknown', 'thought', 'autologous', 'cell', 'infiltrate', 'tumor', 'mediate', 'cytotoxic', 'effect', 'like', 'cell', 'therapy', 'lifileucel', 'given', 'part', 'regimen', 'lymphodepletion', 'il-', 'lifileucel', 'manufacturing', 'us', 'centralized', 'process', 'relies', 'existing', 'surgical', 'technique', 'provide', 'starting', 'material', 'producing', 'cell', 'therapy', 'lifileucel', 'manufactured', 'using', 'tumor', 'tissue', 'anatomic', 'location', 'close', 'coordination', 'across', 'multidisciplinary', 'team', 'including', 'surgeon', 'needed', 'ensure', 'patient', 'access', 'new', 'therapy', 'study', 'summary', 'nct', 'phase', 'global', 'multicenter', 'multicohort', 'open-label', 'clinical', 'trial', 'evaluated', 'safety', 'efficacy', 'lifileucel', 'adult', 'patient', 'unresectable', 'metastatic', 'melanoma', 'received', 'one', 'prior', 'therapy', 'including', 'pd-', 'blocking', 'antibody', 'braf', 'mutation-positive', 'braf', 'inhibitor', 'without', 'mek', 'inhibitor', 'fda', 'approval', 'based', 'patient', 'cohort', 'trial', 'received', 'lifileucel', 'recommended', 'dose', 'viable', 'cell', 'manufactured', 'central', 'facility', 'orr', 'population', 'ci', 'supporting', 'pooled', 'analysis', 'cohort', 'identical', 'eligibility', 'criterion', 'treatment', 'regimen', 'yielded', 'similar', 'orr', 'ci', 'patient', 'cohort', 'heavily', 'pretreated', 'median', 'three', 'prior', 'line', 'therapy', 'range', 'four-year', 'efficacy', 'analysis', 'pooled', 'population', 'patient', 'reduction', 'tumor', 'burden', 'response', 'lifileucel', 'shown', 'durable', 'median', 'duration', 'response', 'reached', 'month', 'nr', 'median', 'follow-up', 'month', 'response', 'deepened', 'time', 'patient', 'initially', 'assessed', 'pr', 'achieved', 'confirmed', 'cr', 'patient', 'improved', 'sd', 'pr.', 'response', 'lifileucel', 'observed', 'subgroup', 'analyzed', 'regardless', 'age', 'prior', 'anti-ctla-', 'use', 'braf', 'mutation', 'status', 'pd-', 'status', 'well', 'non-mucosal', 'mucosal', 'subset', 'safety', 'assessed', 'patient', 'received', 'lifileucel', 'common', 'non-laboratory', 'adverse', 'reaction', 'incidence', 'grade', 'chill', 'pyrexia', 'fatigue', 'tachycardia', 'diarrhea', 'febrile', 'neutropenia', 'edema', 'rash', 'hypotension', 'alopecia', 'infection', 'hypoxia', 'dyspnea', 'grade', 'laboratory', 'abnormality', 'occurring', 'patient', 'thrombocytopenia', 'neutropenia', 'anemia', 'leukopenia', 'lymphopenia', 'hypophosphatemia', 'please', 'see', 'attached', 'prescribing', 'information', 'full', 'safety', 'information', 'including', 'boxed', 'warning', 'warning', 'precaution', 'following', 'resource', 'enclosed', 'assist', 'committee', 'review', 'amtagvi™', 'lifileucel', 'package', 'insert', 'iovance', 'biotherapeutics', 'inc', 'chesney', 'lewis', 'kd', 'kluger', 'efficacy', 'safety', 'lifileucel', 'one-time', 'autologous', 'tumor-', 'infiltrating', 'lymphocyte', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', 'progression', 'immune', 'checkpoint', 'inhibitor', 'targeted', 'therapy', 'pooled', 'analysis', 'consecutive', 'cohort', 'study', 'immunother', 'cancer', 'e.', 'rosenberg', 'sa', 'spy', 'lafreniere', 'r.', 'new', 'approach', 'adoptive', 'immunotherapy', 'cancer', 'tumor-infiltrating', 'lymphocyte', 'science', 'goff', 'sl', 'dudley', 'citrin', 'de', 'randomized', 'prospective', 'evaluation', 'comparing', 'intensity', 'lymphodepletion', 'adoptive', 'transfer', 'tumor-infiltrating', 'lymphocyte', 'patient', 'metastatic', 'melanoma', 'clin', 'oncol', 'seitter', 'sj', 'sherry', 'rm', 'yang', 'jc', 'impact', 'prior', 'treatment', 'efficacy', 'adoptive', 'transfer', 'tumor-infiltrating', 'lymphocyte', 'patient', 'metastatic', 'melanoma', 'clin', 'cancer', 're', 'rohaan', 'mw', 'borch', 'th', 'van', 'den', 'berg', 'jh', 'tumor-infiltrating', 'lymphocyte', 'therapy', 'ipilimumab', 'advanced', 'melanoma', 'engl', 'med', 'medina', 'chesney', 'ja', 'whitman', 'long-term', 'efficacy', 'safety', 'lifileucel', 'tumor-infiltrating', 'lymphocyte', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', '-year', 'analysis', 'study', 'immunother', 'cancer', 'suppl', 'a.', 'egger', 'mccarter', 'olino', 'lifileucel', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', 'progression', 'immune', 'checkpoint', 'inhibitor', 'ici', 'targeted', 'therapy', 'tumor', 'tissue', 'procurement', 'data', 'study', 'ann', 'surg', 'oncol', 'suppl', 's.', 'citation', 'amtagvi™', 'lifileucel', 'package', 'insert', 'iovance', 'biotherapeutics', 'inc', 'chesney', 'lewis', 'kd', 'kluger', 'efficacy', 'safety', 'lifileucel', 'one-time', 'autologous', 'tumor-', 'infiltrating', 'lymphocyte', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', 'progression', 'immune', 'checkpoint', 'inhibitor', 'targeted', 'therapy', 'pooled', 'analysis', 'consecutive', 'cohort', 'study', 'immunother', 'cancer', 'e.', 'rosenberg', 'sa', 'spy', 'lafreniere', 'r.', 'new', 'approach', 'adoptive', 'immunotherapy', 'cancer', 'tumor-infiltrating', 'lymphocyte', 'science', 'goff', 'sl', 'dudley', 'citrin', 'de', 'randomized', 'prospective', 'evaluation', 'comparing', 'intensity', 'lymphodepletion', 'adoptive', 'transfer', 'tumor-infiltrating', 'lymphocyte', 'patient', 'metastatic', 'melanoma', 'clin', 'oncol', 'seitter', 'sj', 'sherry', 'rm', 'yang', 'jc', 'impact', 'prior', 'treatment', 'efficacy', 'adoptive', 'transfer', 'tumor-infiltrating', 'lymphocyte', 'patient', 'metastatic', 'melanoma', 'clin', 'cancer', 're', 'rohaan', 'mw', 'borch', 'th', 'van', 'den', 'berg', 'jh', 'tumor-infiltrating', 'lymphocyte', 'therapy', 'ipilimumab', 'advanced', 'melanoma', 'engl', 'med', 'medina', 'chesney', 'ja', 'whitman', 'long-term', 'efficacy', 'safety', 'lifileucel', 'tumor-infiltrating', 'lymphocyte', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', '-year', 'analysis', 'study', 'immunother', 'cancer', 'suppl', 'a.', 'egger', 'mccarter', 'olino', 'lifileucel', 'cell', 'therapy', 'patient', 'advanced', 'melanoma', 'progression', 'immune', 'checkpoint', 'inhibitor', 'ici', 'targeted', 'therapy', 'tumor', 'tissue', 'procurement', 'data', 'study', 'ann', 'surg', 'oncol', 'suppl']}, {'filename': '2022_09_29_Castle.pdf', 'timestamp': datetime.datetime(2022, 9, 29, 0, 0), 'text': ['c/', 'stlh', 'submitted', 'jay', 'braxton', 'pharm', 'd.', 'vice', 'president', 'medical', 'affair', 'castle', 'bioscience', 'lnc', 's.', 'friendswood', 'drive', 'floor', 'friendswood', 'tx', 'ph', 'ema', 'il', 'jbraxto', 'castlebiosciences.com', 'date', 'request', 'nccn', 'guideline', 'panel', 'melanoma', 'uveal', 'melanoma', 'subcommittee', 'appreciate', 'nccn', 'rigorous', 'criterion', 'assigning', 'evidence', 'category', 'guideline', 'recommendation', 'well', 'panel', 'willingness', 'update', 'recommendation', 'based', 'highest', 'level', 'peer-reviewed', 'evidence', 'available', 'cunent', 'version', 'nccn', 'guideline', 'uveal', 'melanoma', 'v.', 'includes', 'multiple', 'biomarkers', 'elinical', 'risk', 'factor', 'recommended', 'aid', 'follow', 'imaging', 'decision', 'patient', 'diagnosed', 'primary', 'uveal', 'melanoma', 'uiii', 'thank', 'guideline', 'panel', 'recent', 'important', 'update', 'made', 'um', 'guideline', 'including', 'removal', 'several', 'non-evidence-based', 'risk', 'factor', 'listed', 'um-', 'previously', 'submitted', 'request', 'panel', 'increased', 'evidence', 'designation', 'decisiondx-um', 's-gene', 'expression', 'profile', 'gep', 'test', 'believe', 'achieves', 'category', 'evidence', 'according', 'nccn', 'criterion', 'test', 'remains', 'extensively', 'validated', 'test', 'assessing', 'metastatic', 'risk', 'primary', 'um', 'since', 'last', 'submission', 'three', 'new', 'study', 'published', 'supporting', 'test', 'continued', 'clinical', 'performance', 'however', 'note', 'remains', 'distinction', 'level', 'evidence', 'supporting', 'lts', 'use', 'comparison', 'risk', 'factor', 'specific', 'chanoes', 'requested', 'respectfully', 'request', 'thatthe', 'nccn', 'uveal', 'melanoma', 'subcommittee', 'assign', 'evidence', 'category', 'recommendation', 'gep', 'testing', 'follow', 'section', 'guideline', 'uveal', 'melanoma', 'um-', 'based', 'high', 'levelof', 'evidence', 'supporting', 'test', 'including', 'meta-analysis', 'widespread', 'adoption', 'ocular', 'oncologist', 'fda', 'status', 'applicable', 'submission', 'decisiondx-um', 'laboratory', 'developed', 'test', 'exclusively', 'performed', 'castle', 'bioscience', 'laboratory', 'clinical', 'laboratory', 'lmprovement', 'amendment', 'clia', 'certification', 'college', 'american', 'pathologist', 'cap', 'accreditation', 'lt', 'require', 'fda', 'approval', 'clearance', 'test', 'approved', 'new', 'york', 'state', 'department', 'health', 'nysdoh', 'rationale', 'decisiondx-um', 'prognostic', 'test', 'um', 'undergone', 'prospective', 'validation', 'required', 'achieve', 'level', 'evidence', 'according', 'system', 'outlined', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncologyl', 'test', 'extensively', 'utilized', 'across', 'you.s.', 'helping', 'inform', 'management', 'approximately', 'newly', 'diagnosed', 'patient', 'year', 'accurate', 'metastatic', 'risk-stratification', 'essential', 'management', 'um', 'patient', 'prognostic', 'decisiondx-um', 'test', 'multigene', 'expression', 'test', 'us', 'support', 'vector', 'machine', 'learning', 'algorithm', 'classifo', 'patient', 'diagnosed', 'um', 'three', 'risk', 'group', 'increasing', 'probability', 'experiencing', 'distant', 'metastasis', 'within', 'year', 'diagnosis', 'low', 'risk', 'class', 'intermediate', 'risk', 'class', 'high', 'risk', 'class', 'decisiondx-um', 'class', 'result', 'included', 'nccn', 'um', 'guideline', 'since', 'first', 'version', 'released', 'v.', 'method', 'risk', 'stratification', 'may', 'used', 'inform', 'frequency', 'follow-up', 'including', 'systemic', 'imaging', 'blood', 'test', 'determine', 'possible', 'eligibility', 'clinical', 'trial', 'however', 'believe', 'important', 'necessary', 'distinguish', 'decisiondx-um', 'class', 'result', 'risk', 'factor', 'consistently', 'shown', 'independent', '/^/', 'stle', '\\\\vr', 'broscren.es', 'superior', 'method', 'prognostication', 'listed', 'guideline', 'decisiondx-um', 'test', 'test', 'undergone', 'prospective', 'validation', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'outline', 'comprehensive', 'system', 'evaluating', 'evidence', 'support', 'clinical', 'biomarker', 'testsl', 'decisiondx-', 'um', 'test', 'prospectively', 'validated', 'marker', 'primary', 'objective', 'study', 'tt', 'achieves', 'level', 'evidence', 'outlined', 'system', 'table', 'furthermore', 'multiple', 'independent', 'prospective', 'study', 'confirmed', 'test', 'clinicat', 'validity', 'recent', 'meta-analysis', 'found', 'class', 'test', 'result', 'independent', 'predictor', 'metastasis', 'associated', 'increased', 'risk', 'metastasis', 'mortality', 'thus', 'decisiondx-um', 'test', 'surpassed', 'threshold', 'required', 'achieve', 'level', 'evidence', 'according', 'system', 'established', 'nccn', 'table', 'decisiondx-um', 'meet', 'nccn', 'criterion', 'highest', 'level', 'evidence', 'molecular', 'test', 'level', 'ofevidence', 'la', 'prospective', 'mrrker', 'primary', 'obiective', 'well', 'powered', 'meta-analysisl', 'patrents', 'patient', 'data', 'trrospectirel', 'enrolled', 'lreated', 'followed', 'praspe.tive', 'randomrzed', '.ontroi', 'trial', 'stalislical', 'desrln', 'afallsrs', 'studr-', 'forered', 'addrcss', 'lumormarkrr', 'question', 'fe.lc', 'st', 'il', 'ln', 'onken', 'corren', 'augburger', 'plassaraud', 'aaberg', '-r.', 'rr', 'il', 'lprospeatrve', 'studres', 'bold', 'onkenet', 'al.', '.ophthalnology', 'gilj', 'char', 'lla/i', 'lrtjr', 'rarrloi', 'chappell', 'ei', 'a/n', 'odlhalltrci', 'corea', 'auosburger', 'al.', 'araefes', 'arch', 'clin', 'exp', 'ophth', 'correa', 'augsburger', 'al.', 'aphhalmol', 'decalur', 'ai', 'ja/', 'ctrirliarrol', \"'€iter\", 'jaira', '-lltai/no', \"'plasseraud\", 'al.', 'j.', 'oncol', 'demrrc', 'ai', 'ophiharrci', 'cai', 'el', 'arn', 'o/rhtilslrncl', 'afshar', 'etal', 'l/ars/yrsscile.rrci', 'iaaberg', '..', 'acul', 'oncol', 'pathol', 'bin', \"i't\", \"ar'/rlr\", \"-t'ti\", \"'rei/a\", 'roelofs', 'bt', 'plltilaitnci', 'stace', 'ea', 'gcr//or.oi', 'fatilol', 'kher', 'etal', 'ad', 'radialo/iio/', 'ong', 'nz', 'cnteild', 'btaclly', 'ltetanf', 'given', 'physician', 'you.s', 'across', 'world', 'follow', 'nccn', 'recommendation', 'feel', 'important', 'nccn', 'um', 'subcommittee', 'incorporate', 'different', 'level', 'evidence', 'exist', 'biomarkers', 'inform', 'follow', 'surveillance', 'decision', 'um', 'patient', 'described', 'decisiondx-um', 'test', 'supported', 'higher', 'level', 'peer-reviewed', 'evidence', 'prognostic', 'factor', 'extensive', 'evidence', 'led', 'use', 'test', 'guide', 'management', 'um', 'patient', 'ocular', 'oncology', 'center', 'you.s', 'therefore', 'respectfully', 'urge', 'panel', 'assign', 'evidence', 'category', 'recommendation', 'gene', 'expression', 'profiling', 'decisiondx-um', 'question', 'test', 'body', 'scientific', 'evidence', 'associated', 'publication', 'please', 'feelfree', 'contact', 'directly', 'sincerely', 'w-', 'jay', 'braxton', 'pharmd', 'specimen', 'collecljof', 'frocessinq', 'archival', 'resuil', 'unlikei', 'b€', 'pla', 'chance', 'although', 'preferred', 'validatron', 'required', 'validatron', 'c/astle', 'i-', 'reference', 'febbo', 'p.', 'g.', 'nccn', 'task', 'force', 'report', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'journal', 'national', 'comprehensive', 'cancer', 'network', 'jnccn', 'suppl', 's-', 'quiz', 's.', 'onken', 'm.', 'd.', 'collaborative', 'ocular', 'oncology', 'group', 'report', 'number', 'prospective', 'validation', 'multi-gene', 'prognostic', 'assay', 'uveal', 'melanoma', 'ophthalmology', 'corr€a', 'z.', 'm.', 'augsburger', 'j.', 'j.', 'independent', 'prognostic', 'significance', 'gene', 'expression', 'profile', 'class', 'largest', 'basal', 'diameter', 'posterior', 'uveal', 'melanoma', 'ophthalmol', '-e.', 'plasseraud', 'k.', 'm.', 'clinical', 'performance', 'management', 'outcome', 'decisiondx-um', 'gene', 'expression', 'profile', 'test', 'prospective', 'multicenter', 'study', 'oncol', 'aaberg', 't.m', 'gene', 'expression', 'profiling', 'uveal', 'melanoma', 'five-year', 'prospective', 'outcome', 'meta-analysis', 'ocul', 'oncol', 'pathol']}, {'filename': '2020_01_13_Merck.pdf', 'timestamp': datetime.datetime(2020, 1, 13, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'january', 'nccn', 'guideline', 'panel', 'melanoma', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda', 'pembrolizumab', 'reference', 'unresectable', 'metastatic', 'melanoma', 'brain', 'metastasis', 'specific', 'change', 'respectfully', 'request', 'nccn', 'panel', 'consider', 'inclusion', 'keytruda', 'combination', 'bevacizumab', 'treatment', 'option', 'patient', 'disseminated', 'unresectable', 'melanoma', 'brain', 'metastasis', 'appropriate', 'section', 'guideline', 'including', 'section', 'me-', 'me-i', 'well', 'section', 'ms-', 'table', 'based', 'data', 'presented', 'annual', 'meeting', 'society', 'neuro-oncology', 'pembrolizumab', 'plus', 'bevacizumab', 'melanoma', 'patient', 'untreated', 'brain', 'metastasis', 'fda', 'clearance', 'keytruda', 'pembrolizumab', 'approved', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'rationale', 'ongoing', 'prospective', 'single-arm', 'phase', 'study', 'nct', 'pembrolizumab', 'plus', 'bevacizumab', 'melanoma', 'patient', 'brain', 'metastasis', 'patient', 'brain', 'metastasis', 'response', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'kluger', 'hm', 'forsyth', 'khushalani', 'phase', 'trial', 'pembrolizumab', 'bevacizumab', 'melanoma', 'brain', 'met', 'patient', 'neuro-oncology', 'supplement_', 'vi-vi', 'doi', './neuonc/noz', 'kluger', 'km', 'forsyth', 'khushalani', 'phase', 'trial', 'pembrolizumab', 'combination', 'bevacizumab', 'melanoma', 'patient', 'untreated', 'brain', 'metastasis', 'poster', 'presented', 'society', 'neuro-oncology', 'annual', 'meeting', 'november', 'phoenix', 'az', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}, {'filename': '2020_06_15_Castle.pdf', 'timestamp': datetime.datetime(2020, 6, 15, 0, 0), 'text': [\"c/'stla\", 'submitted', 'jay', 'braxton', 'pharnn', 'd.', 'executive', 'director', 'medicalaffairs', 'castle', 'bioscience', 'inc', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'tx', 'ph', '..', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'request', 'nccn', 'guideline', 'panel', 'melanoma', 'uveal', 'melanoma', 'appreciate', 'nccn', 'rigorous', 'criterion', 'assigning', 'evidence', 'category', 'guideline', 'recommendation', 'essential', 'clinical', 'decision-making', 'based', 'highest', 'level', 'peer-', 'reviewed', 'science', 'available', 'appreciate', 'current', 'version', 'nccn', 'guideline', 'uveal', 'melanoma', 'v.', 'includes', 'decisiondx-um', 'test', 'one', 'multiple', 'biomarkers', 'aid', 'follow', 'imaging', 'decision', 'um-', 'however', 'would', 'like', 'point', 'within', 'biomarkers', 'distinction', 'made', 'level', 'evidence', 'supporting', 'use', 'whether', 'independent', 'specifically', 'gene', 'expression', 'profiling', 'gep', 'using', 'decisiondx-um', 'test', 'validated', 'biomarker', 'risk', 'uveal', 'melanoma', 'um', 'patient', 'achieving', 'category', 'level', 'evidence', 'reflected', 'guideline', 'concerned', 'could', 'lead', 'confusion', 'provider', 'histologic', 'feature', 'could', 'judged', 'substitute', 'molecular', 'risk', 'assessment', 'histology', 'shown', 'provide', 'independent', 'prognostic', 'value', 'compared', 'directly', 'molecular', 'feature', 'univariate', 'multivariate', 'analysis', 'addition', 'note', 'nccn', 'biomarkers', 'compendium', 'mistakenly', 'omitted', 'use', 'gep', 'uveal', 'melanoma', 'section', 'specific', 'chanqes', 'requested', 'request', 'nccn', 'uveal', 'melanoma', 'panel', 'assign', 'evidence', 'category', 'recommendation', 'gep', 'testing', 'follow', 'section', 'guideline', 'uveal', 'melanoma', 'um-', 'request', 'nccn', 'biomarkers', 'compendium', 'updated', 'reflect', 'inclusion', 'gep', 'biomarker', 'guide', 'follow', 'systemic', 'imaging', 'uveal', 'melanoma', 'guideline', 'vl', 'fda', 'status', 'applicable', 'submission', 'rationale', 'decisiondx-um', 'prognostic', 'test', 'um', 'undergone', 'prospective', 'validation', 'required', 'achieve', 'category', 'level', 'evidence', 'according', 'system', 'outlined', \"nccn's\", 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncologyl', 'decisiondx-um', 'genomic', 'test', 'classifies', 'patient', 'diagnosed', 'uveal', 'melanoma', 'um', 'low', 'class', 'intermediate', 'class', 'high', 'risk', 'class', 'metastasis', 'based', 'rna', 'expression', 'gene', 'primary', 'tumor', 'tissue', 'decisiondx-um', 'class', 'result', 'included', 'um', 'guideline', 'since', 'first', 'iteration', 'v.', 'method', 'risk', 'stratification', 'may', 'used', 'inform', 'frequency', 'follow-up', 'including', 'systemic', 'imaging', 'blood', 'test', 'determine', 'possible', 'eligibility', 'clinical', 'trial', 'however', 'important', 'distinguish', 'decisiondx-um', 'class', 'result', 'risk', 'factor', 'consistently', 'shown', 'independent', 'superior', 'method', 'prognostication', 'listed', 'guideline', 'test', 'undergone', 'prospective', 'validation', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'outline', 'comprehensive', 'system', 'evaluating', 'evidence', 'support', 'clinical', 'biomarker', 'testsl', 'decisiondx-', 'um', 'test', 'prospectively', 'validated', 'marker', 'primary', 'objective', 'study', 'achieves', 'category', 'level', 'evidence', 'outlined', 'system', 'furthermore', 'multiple', 'independent', '.f', 'prospective', 'study', 'confirmed', 'test', 'clinical', 'validity', 'thus', 'decisiondx-um', 'achieved', 'surpilssed', 'threshold', 'needed', 'meeting', 'category', 'evidence', 'according', 'system', 'adopted', 'nccn', 'table', 'table', 'decisiondx-um', 'meet', 'nccn', 'criterion', 'highest', 'level', 'evidence', 'molecular', 'test', 'level', 'evidence', 'la', 'prospeclive', 'marker', 'primary', 'objective', 'w€ll', 'powerod', 'mela-analysisl', 'clinica', 'trial', 'pro', 'pective', 'cftnrcal', 'kial', 'de', 'rgned', 'addfegs', 'tun', 'nratker', 'prospective', 'enrolled', 'tteated', 'patienls', 'ar', 'palreft', 'data', 'followecj', 'prospective', 'raf', 'dorilized', 'conlrol', 't|al', 'spgc', 'nrencollocnon', 'proceasillg', 'specillensrollccled', 'processcd', 'ano', 'archval', 'assayed', 'spccllic', 'ntarker', 'rl', 'roat', 'lrme', 'slalistical', 'desion', 'ana', 'vsis', 'strdy', 'powcrod', 'ilddress', 'tumol', 'ntarkor', 'qucstion', 'result', 'untikety', 'lo', 'play', 'va|dalion', 'ohance', 'altholrgh', 'preferred', 'validation', 'nol', 'roquired', 'rfrlhbo', 'el', 'onken', 'correa', 'augburger', 'plaeseraud', 'aaberg', 'tt', 'il', '\\\\t', 'i.', 'tt', 'prospective', 'study', 'bold', 'onken', 'ot', 'a.', 'ophthalmology', 'gill', 'char', '..', 'odhthahnol', 'chappell', 'ot', 'a|', 'odthahuol', 'rcorrea', 'augsburger', 'el', 'al.', 'graefes', 'arch', 'clln', 'exp', 'ophth', 'correa', 'augsburger', 'al.', 'ophahalmol', 'decatuf', 'el', 'al.', 'jama', 'aphilnlmol', 'walleretal', 'jamaophlh.ilnel.', 'splasseraud', 'al.', 'j.', 'oncol.', 'demirci', '..', 'o.', 'odhtlnlntol.', 'cai', '..', 'odhlhalrnol', 'oaaberg', 'al.', 'ocul', 'oncol', 'pathol', 'press', 'given', 'physician', 'you.s', 'across', 'world', 'follow', 'nccn', 'recommendation', 'important', 'nccn', 'um', 'panel', 'incorporates', 'different', 'level', 'evidence', 'exist', 'biomarkers', 'inform', 'follow', 'surveillance', 'decision', 'um', 'patient', 'presented', 'decisiondx-', 'um', 'test', 'supportr', 'much', 'higher', 'level', 'published', 'evidence', 'method', 'prognostication', 'lack', 'sanre', 'level', 'validation', 'prognostic', 'accuracy', 'thus', 'serve', 'substitute', 'test', 'therefore', 'respectfully', 'urge', 'panel', 'assign', 'evidence', 'category', 'recommendation', \"i'or\", 'gene', 'expression', 'profiling', 'decisiondx-um', 'addition', 'reason', 'test', 'omitted', 'biomarkers', 'compendium', 'question', 'test', 'body', 'scientific', 'evidence', 'associated', 'publication', 'plea', 'feel', 'free', 'contact', 'directly', 'sincerely', \"r'\", 'r.r', 'ja', 'braxton', 'pharmd', 'reference', 'febbo', 'p.', 'g.', 'nccn', 'task', 'force', 'report', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'journal', 'national', 'comprehensive', 'cancer', 'network', 'jnccn', 'suppl', 's-', 'quiz', 's.', 'onken', 'ttl', 'd.', 'collaborative', 'ocular', 'oncology', 'group', 'report', 'number', 'prospective', 'validation', 'multi-gene', 'prognostic', 'assay', 'uveal', 'merlanoma', 'ophthalmology', 'correa', 'z.', 'm.', 'l\\\\ugsburger', 'j.', 'j.', 'sufficiency', 'fnab', 'aspirate', 'posterior', 'uveal', 'melanoma', 'cytologic', 'versus', 'gep', 'classificertion', 'patient', 'relative', 'prognostic', 'significance', 'classification', 'graefes', 'arch', 'clin', 'exp', 'ophthalmol', 'ti', 'avrarav\\\\r/', \"rv'\", 'corra', 'z.', 'm.', 'gsburger', 'j.', 'j.', 'independent', 'prog', 'nostic', 'sign', 'ificance', 'gene', 'expression', 'profile', 'class', 'largest', 'basal', 'diameter', 'posterrior', 'uveal', 'melanoma', 'ophthalmol', '.-e', 'plasseraud', 'k.', 'm.', 'clinical', 'performance', 'management', 'outcome', 'decisiondx-um', 'gene', 'expression', 'profile', 'test', 'prospective', 'multicenter', 'study', 'oncol', 'aaberg', 't.m.', 'gene', 'expression', 'profiling', 'uveal', 'melanoma', 'five-year', 'prospective', 'outcome', 'meta-analysis', 'ocul', 'onr', 'old', 'pathol', 'press']}, {'filename': '2020_06_16_DermTech.pdf', 'timestamp': datetime.datetime(2020, 6, 16, 0, 0), 'text': ['submitted', 'dermtech', 'inc', 'name', 'burkhard', 'jansen', 'md', 'chief', 'medical', 'officer', 'company/organization', 'dermtech', 'inc.', 'address', 'torrey', 'pine', 'road', 'suite', 'la', 'jolla', 'ca', 'phone', 'email', 'bjansen', 'dermtech.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'sent', 'via', 'email', 'submission', 'nccn.org', 'behalf', 'dermtech', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'data', 'dermtech', 'pre-biopsy', 'biopsy', 'guiding', 'non-invasive', 'melanoma', 'rule-out', 'test', 'pigmented', 'lesion', 'assay', 'pla', 'pla', 'supported', 'peer', 'reviewed', 'publication', 'covered', 'medicare', 'support', 'test', 'treatment', 'deems', 'experimental', 'investigational', 'benefitted', 'u', 'patient', 'date', 'reducing', 'avoidable', 'biopsy', 'missing', 'fewer', 'melanoma', 'based', 'test', 'high', 'negative', 'predictive', 'value', 'test', 'insert', 'simple', 'non-invasive', 'objective', 'step', 'current', 'diagnostic', 'pigmented', 'lesion', 'paradigm', 'visual', 'inspection', 'surgical', 'biopsy', 'case', 'clinician', 'require', 'information', 'guide', 'biopsy', 'decision', 'greatly', 'appreciate', 'consideration', 'available', 'peer', 'reviewed', 'evidence', 'including', 'large', 'real-world', 'utility', 'study', 'demonstrates', 'pla', 'reduces', 'avoidable', 'biopsy', 'clinician', 'following', 'guidance', 'test', 'case', 'pla', 'positive', 'lesion', 'biopsied', 'pla', 'negative', 'lesion', 'clinically', 'followed', 'biopsied', 'well', 'clarification', 'noninvasive', 'genomic', 'patch', 'test', 'fit', 'diagnostic', 'continuum', 'pigmented', 'lesion', 'management', 'specific', 'change', 'recommend', 'pigmented', 'lesion', 'assay', 'pla', 'useful', 'pre-diagnostic', 'tool', 'support', 'clinician', 'decision', 'whether', 'biopsy', 'assessment', 'pigmented', 'skin', 'lesion', 'suspicious', 'melanoma', 'changed', 'requires', 'investigation', 'see', 'v.', 'me-', 'common', 'follow-up', 'recommendation', 'patient', 'moldx', 'coverage', 'february', 'medicare', 'administrative', 'contractor', 'palmetto', 'gba', 'moldx', 'published', 'effective', 'local', 'coverage', 'determination', 'lcd', 'pigmented', 'lesion', 'assay', 'harmonized', 'medicare', 'administrator', 'coverage', 'determination', 'across', 'moldx', 'region', 'rationale', 'support', 'proposed', 'change', 'v.', 'guideline', 'cutaneous', 'melanoma', 'correctly', 'characterized', 'noninvasive', 'genomic', 'adhesive', 'patch', 'test…', 'pre-diagnostic', 'technolog', 'inform', 'decision', 'whether', 'biopsy', 'affirmatively', 'stated', 'noninvasive', 'genomic', 'adhesive', 'patch', 'testing', 'outside', 'guideline', 'purview', 'however', 'reference', 'noninvasive', 'genomic', 'patch', 'testing', 'removed', 'appropriately', 'principle', 'molecular', 'testing', 'section', 'subsequent', 'version', 'guideline', 'designation', 'requiring', 'investigation', 'see', 'v.', 'me-', 'common', 'follow-up', 'recommendation', 'patient', 'ignores', 'overwhelming', 'evidence', 'pla', 'effectively', 'informs', 'clinical', 'decision', 'making', 'whether', 'biopsy', 'pigmented', 'lesion', 'suspicious', 'melanoma', 'important', 'highlight', 'pre-diagnostic', 'biopsy', 'guiding', 'pla', 'distinct', 'discussed', 'prognostic', 'post-biopsy', 'gene', 'expression', 'test', 'reader', 'previous', 'guideline', 'document', 'confuse', 'portfolio', 'peer', 'reviewed', 'pla', 'publication', 'medicare', 'coverage', 'based', 'full', 'moldx', 'review', 'support', 'proposed', 'change', 'ease', 'use', 'include', 'hyperlinked', 'document', 'peer', 'reviewed', 'publication', 'facilitate', 'review', 'panel', 'highlighting', 'key', 'evidence', 'previously', 'considered', 'brouha', 'al.', 'real-world', 'utility', 'non-invasive', 'gene', 'expression', 'test', 'rule', 'primary', 'cutaneous', 'melanoma', 'large', 'u', 'registry', 'study', 'journal', 'drug', 'dermatology', 'study', 'evaluated', 'case', 'pigmented', 'lesion', 'clinically', 'suspicious', 'melanoma', 'affirmed', 'real-world', 'utility', 'pla', 'clinician', 'followed', 'guidance', 'offered', 'pla', 'positive', 'test', 'case', 'unnecessary', 'surgical', 'procedure', 'avoided', 'case', 'overall', 'clinician', 'followed', 'guidance', 'test', 'case', 'ferris', 'al.', 'impact', 'clinical', 'practice', 'noninvasive', 'gene', 'expression', 'melanoma', 'rule-out', 'test', '-month', 'follow-up', 'negative', 'test', 'result', 'utility', 'data', 'large', 'u', 'registry', 'study.', 'dermatol', 'online', 'paper', 'evaluated', 'long-term', 'follow-up', 'case', 'provided', 'evidence', 'pla', 'missed', 'melanoma', '-month', 'follow-up', 'period', 'palmetto', 'gba', 'moldx', 'local', 'coverage', 'determination', 'lcd', 'pigmented', 'lesion', 'assay', 'policy', 'clearly', 'defines', 'pla', 'fit', 'diagnostic', 'paradigm', 'pre-diagnostic', 'biopsy', 'guiding', 'tool', 'capable', 'reducing', 'biopsy', 'rate', 'non-malignant', 'lesion', 'importantly', 'discus', 'limitation', 'current', 'care', 'standard', 'clinician', 'rely', 'visual', 'inspection', 'plus', 'surgical', 'biopsy', 'study', 'berman', 'colleague', 'consensus', 'panel', 'nine', 'expert', 'dermatologists/dermatologic', 'surgeons/dermatopathologists', 'convened', 'almost', 'two', 'year', 'ago', 'august', 'determine', 'individual', 'level', 'evidence', 'selected', 'publication', 'gene', 'expression', 'test', 'used', 'pigmented', 'lesion', 'management', 'berman', 'al.', 'appropriate', 'use', 'criterion', 'integration', 'diagnostic', 'prognostic', 'gene', 'expression', 'profile', 'assay', 'management', 'cutaneous', 'malignant', 'melanoma', 'expert', 'panel', 'consensus-based', 'modified', 'delphi', 'process', 'assessment', 'skin', 'panel', 'assigned', 'highest', 'evidence', 'level', 'level', 'pla', 'clinical', 'validation', 'study', 'reference', 'within', 'provided', 'hyperlinked', 'document', 'available', 'online', 'unable', 'consider', 'two', 'large', 'real-world', 'utility', 'study', 'highlighted', 'study', 'relevant', 'patient-oriented', 'evidence', 'available', 'time', 'consensus', 'panel', 'convened', 'given', 'limitation', 'panel', 'arrived', 'still', 'high', 'strength', 'recommendation', 'taxonomy', 'sort', 'assessment', 'based', 'fraction', 'key', 'evidence', 'inconsistent', 'limited-quality', 'patient-oriented', 'evidence', 'patient', 'atypical', 'lesion', 'requiring', 'assessment', 'beyond', 'visual', 'inspection', 'help', 'selection', 'biopsy', 'clinical', 'validation', 'study', 'address', 'potential', 'pla', 'niche', 'us', 'patient', 'refuse', 'surgical', 'biopsy', 'patient', 'increased', 'infection', 'risk', 'separately', 'studied', 'received', 'lower', 'sort', 'score', 'new', 'consensus', 'assessment', 'considers', 'evidence', 'available', 'warranted', 'thank', 'review', 'consideration', 'please', 'let', 'know', 'answer', 'question', 'sincerely', 'burkhard', 'jansen', 'md', 'chief', 'medical', 'officer', 'dermtech']}, {'filename': '2020_06_17_Castle.pdf', 'timestamp': datetime.datetime(2020, 6, 17, 0, 0), 'text': ['submitted', 'name', 'jay', 'braxton', 'pharmd', 'executive', 'director', 'medical', 'affair', 'company', 'castle', 'bioscience', 'inc.', 'address', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'tx', 'phone', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'request', '//', 'nccn', 'guideline', 'panel', 'melanoma', 'castle', 'bioscience', 'inc.', 'would', 'like', 'thank', 'nccn', 'panel', 'updating', 'guidance', 'gene', 'expression', 'profiling', 'gep', 'guideline', 'version', 'appreciate', 'fact', 'panel', 'recognizes', 'gep', 'adjunct', 'staging', 'evidence', 'supporting', 'gep', 'stronger', 'represented', 'guideline', 'respectfully', 'request', 'following', 'recent', 'publication', 'regarding', 'decisiondx-melanoma', 'test', '-gep', 'considered', 'updating', 'language', 'better', 'reflect', 'available', 'evidence', 'two', 'recent', 'meta-analyses', 'multiple', 'prospective', 'clinical', 'validity', 'study', 'prospective', 'retrospective', 'clinical', 'utility-', 'study', 'suggested', 'change', 'included', 'rationale', 'literature', 'summary', 'rationale', 'literature', 'summary', 'clinical', 'validation', '-gep', 'test', 'validated', 'prospective', 'study', 'including', 'academic', 'non-industry-', 'sponsored', 'systematic', 'review', 'meta-analyses', 'including', 'patients-', 'multiple', 'retrospective', 'studies-', 'study', 'consistently', 'shown', '-gep', 'test', 'added', 'impact', 'prognostication', 'combination', 'ajcc', 'staging', 'slnb', 'across', 'different', 'patient', 'group', 'early-stage', 'melanoma', 'summary', 'finding', '-gep', 'study', 'design', 'class', 'class', 'outcome', 'ref', 'gep', 'add', 'prognostic', 'information', 'current', 'staging', 'factor', 'increase', 'identification', 'high-risk', 'patient', 'including', 'diagnosed', 'early', 'stage', 'disease', 'prospective', '-y', 'rf', '-y', 'dmfs', '-y', 'o', 'academic-sponsored', 'gep', 'class', 'patient', 'time', 'likely', 'develop', 'metastasis', 'author', 'offer', 'gep', 'melanoma', 'patient', 'prospective', '-y', 'rf', '-y', 'o', 'sensitivity', 'npv', 'academic-sponsored', 'gep', 'class', 'result', 'significant', 'independent', 'predictor', 'metastasis', 'context', 'clinicopathologic', 'feature', 'used', 'staging', 'gep', 'class', 'result', 'accurately', 'identified', 'slnb-negative', 'patient', 'experienced', 'recurrence', 'prospective', '-y', 'rf', '-y', 'dmfs', 'academic-sponsored', 'gep', 'identified', 'recurrence', 'risk', 'stage', 'ib-ii', 'patient', 'including', 'low-risk', 'ajcc', 'stage', 'prospective', 'rate', 'recurrence', 'sensitivity', 'large', 'study', 'gep', 'identified', 't-t', 'melanoma', 'low', 'risk', 'slnb', 'positivity', 'prospective', 'sln', 'positivity', 'meta-analysis', 'gep', 'consistently', 'accurately', 'predicts', 'recurrence', 'distant', 'metastasis', 'across', 'ajcc', 'stage', 'i-iii', 'across', 'multiple', 'study', 'augments', 'ability', 'identify', 'high-risk', 'patient', 'meta-analysis', '-y', 'rf', '-y', 'dmfs', 'gep', 'identified', 'patient', 'likely', 'recur', 'within', 'traditionally', 'low-risk', 'patient', 'slnb-negative', 'stage', 'i-iia', '≤mm', 'tumor', 'study', 'reporting', 'combined', 'previous', 'cohort', 'retrospective', 'rf', 'dmfs', 'melanoma', 'o', 'gep', 'improved', 'identification', 'high-risk', 'melanoma', 'combined', 'ajcc', 'prediction', 'stage', 'i-ii', 'patient', 'indicating', 'test', 'provides', 'additional', 'prognostic', 'information', 'traditional', 'staging', 'retrospective', 'ajcc', 'low-risk', '-y', 'rf', '-y', 'dmfs', '-y', 'o', 'ajcc', 'high-risk', '-y', 'rf', 'dmfs', '-y', 'o', 'reported', 'disease-free', 'survival', 'class', 'class', 'b.', 'castle', 'bioscience', 'inc.', 'submission', 'nccn', 'guideline', 'panel', 'melanoma', 'page', 'clinical', 'utility', 'prospective', 'retrospective', 'study', 'including', 'total', 'patient', 'prospectively', 'tested', 'showed', 'impact', '-gep', 'test', 'treatment', 'management', 'decisions.-', 'recently', 'expert', 'consensus', 'panel', 'convened', 'national', 'society', 'cutaneous', 'medicine', 'provided', 'evidence-based', 'recommendation', '-gep', 'testing', 'appropriate', 'use', 'criterion', 'statement', 'suggested', 'change', 'based', 'evidence', 'presented', 'please', 'consider', 'following', 'suggested', 'change', 'me-', 'me-', 'me-', 'footnote', 'prognostic', 'gene', 'expression', 'profiling', '-gep', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'may', 'provide', 'information', 'individual', 'risk', 'recurrence', 'adjunct', 'standard', 'ajcc', 'staging', 'however', 'currently', 'available', 'prognostic', 'molecular', 'technique', 'replace', 'pathologic', 'staging', 'procedures.', 'use', 'gep', 'testing', 'according', 'specific', 'melanoma', 'stage', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'requires', 'prospective', 'investigation', 'large', 'contemporary', 'data', 'set', 'unselected', 'patients.', 'me-c', 'prognostic', 'testing', 'bullet', 'commercially', 'available', 'gep', 'test', 'marketed', 'able', 'classify', 'cutaneous', 'melanoma', 'separate', 'category', 'based', 'risk', 'metastasis', 'however', 'remains', 'unclear', 'whether', 'five', 'prospective', 'study', 'two', 'meta-analyses', 'shown', '-gep', 'test', 'provides', 'clinically', 'actionable', 'prognostic', 'information', 'used', 'addition', 'comparison', 'known', 'clinicopathologic', 'factor', 'multivariable', 'nomogram', 'incorporate', 'patient', 'sex', 'age', 'tumor', 'location', 'thickness', 'ulceration', 'mitotic', 'rate', 'lymphovascular', 'invasion', 'microsatellites', 'slnb', 'status', 'furthermore', 'impact', 'test', 'treatment', 'outcome', 'follow-up', 'schedule', 'established', 'three', 'clinical', 'use', 'study', 'showed', 'physician', 'use', '-gep', 'result', 'adjust', 'management', 'agreement', 'individual', 'risk', 'recurrence.', 'bullet', 'various', 'mostly', 'prospective', 'retrospective', 'study', 'prognostic', 'gep', 'testing', 'suggest', 'role', 'independent', 'predictor', 'worse', 'outcome', 'though', 'superior', 'addition', 'breslow', 'thickness', 'sln', 'status', 'remains', 'unclear', 'whether', 'gep', 'profile', 'reliably', 'predictive', 'outcome', 'across', 'risk', 'spectrum', 'melanoma', 'prospective', 'validation', 'study', 'performed', 'breast', 'cancer', 'required', 'accurately', 'define', 'date', 'two', 'retrospective', 'one', 'prospective', 'study', 'reported', 'clinical', 'utility', 'molecular', 'testing', 'prior', 'widespread', 'implementation', 'gep', 'prognostication', 'cutaneous', 'melanoma', 'particular', 'determine', 'role', 'guiding', 'showing', 'physician', 'use', 'result', 'guide', 'surveillance', 'imaging', 'slnb', 'adjuvant', 'treatment', 'decision', 'available', 'existing', 'emerging', 'gep', 'platform', 'prognostic', 'technique', 'compared', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'i.e.', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'development', 'fda', 'status', 'decisiondx', 'melanoma', 'performed', 'central', 'laboratory', 'castle', 'bioscience', 'regulated', 'clinical', 'laboratory', 'improvement', 'amendment', 'clia', 'fda', 'clearance', 'required', 'respectfully', 'submitted', 'castle', 'bioscience', 'summary', 'finding', '-gep', 'study', 'design', 'class', 'change', 'decision', 'class', 'change', 'decision', 'ref', 'institution', 'gep', 'directly', 'influenced', 'clinical', 'management', 'patient', 'implemented', 'change', 'reflected', 'predicted', 'recurrence', 'risk', 'retrospective', 'institution', 'gep', 'used', 'guide', 'risk-appropriate', 'patient', 'management', 'significant', 'factor', 'treatment', 'change', 'including', 'directing', 'frequent', 'intense', 'surveillance', 'class', 'patient', 'prospective', 'single', 'center', 'ohsu', 'gep', 'result', 'significantly', 'associated', 'management', 'stage', 'i-ii', 'patient', 'slnb', 'node', 'negative', 'patient', 'class', 'result', 'led', 'aggressive', 'follow', 'management', 'retrospective', 'castle', 'bioscience', 'inc.', 'submission', 'nccn', 'guideline', 'panel', 'melanoma', 'page', 'reference', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'doi.org/./j.jaad', '...', 'litchman', 'gh', 'prado', 'teplitz', 'rw', 'rigel', 'd', 'systematic', 'review', 'meta-analysis', 'gene', 'expression', 'profiling', 'primary', 'cutaneous', 'melanoma', 'prognosis', 'skin', 'cutaneous', 'med', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'interim', 'analysis', 'survival', 'prospective', 'multi-center', 'registry', 'cohort', 'cutaneous', 'melanoma', 'tested', 'prognostic', '-gene', 'expression', 'profile', 'test', 'hematol', 'oncol', 'greenhaw', 'bn', 'zitelli', 'ja', 'brodland', 'dg', 'estimation', 'prognosis', 'invasive', 'cutaneous', 'melanoma', 'independent', 'study', 'accuracy', 'gene', 'expression', 'profile', 'test', 'dermatol', 'surg', 'doi', './dss', 'keller', 'schwartz', 'tl', 'lizalek', 'jm', 'prospective', 'validation', 'prognostic', '-gene', 'expression', 'profiling', 'test', 'primary', 'cutaneous', 'melanoma', 'cancer', 'med', 'podlipnik', 'carrera', 'boada', 'early', 'outcome', '-gene', 'expression', 'profile', 'test', 'ajcc', 'stage', 'ib-ii', 'melanoma', 'patient', 'prospective', 'multicenter', 'cohort', 'study', 'eur', 'acad', 'dermatol', 'venereol', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'decision', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'berger', 'ac', 'davidson', 'r', 'poitras', 'jk', 'clinical', 'impact', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'prospectively', 'consecutively', 'tested', 'patient', 'curr', 'med', 're', 'opin', 'dillon', 'ld', 'gadzia', 'je', 'davidson', 'r', 'prospective', 'multicenter', 'clinical', 'impact', 'evaluation', '-gene', 'expression', 'profile', 'test', 'management', 'melanoma', 'patient', 'skin', 'cutaneous', 'med', 'schuitevoerder', 'heath', 'cook', 'rw', 'impact', 'gene', 'expression', 'profiling', 'decision-making', 'clinically', 'node', 'negative', 'melanoma', 'patient', 'surgical', 'staging', 'drug', 'dermatol', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'doi', './j.jaad', '....', 'ferris', 'lk', 'farberg', 'middlebrook', 'identification', 'high-risk', 'cutaneous', 'melanoma', 'tumor', 'improved', 'combining', 'online', 'american', 'joint', 'committee', 'cancer', 'individualized', 'melanoma', 'patient', 'outcome', 'prediction', 'tool', '-gene', 'expression', 'profile-based', 'classification', 'acad', 'dermatol', '-.e', 'berman', 'ceilley', 'cockerell', 'appropriate', 'use', 'criterion', 'integration', 'diagnostic', 'prognostic', 'gene', 'expression', 'profile', 'assay', 'management', 'cutaneous', 'malignant', 'melanoma', 'expert', 'panel', 'consensus-based', 'modified', 'delphi', 'process', 'assessment', 'skin', 'cutaneous', 'med']}, {'filename': '2020_06_21_DermatologicSurgeryWashington.pdf', 'timestamp': datetime.datetime(2020, 6, 21, 0, 0), 'text': ['submitted', 'gary', 'l.', 'peck', 'md', 'company/organization', 'dermatologic', 'surgery', 'center', 'washington', 'address', 'wisconsin', 'avenue', 'suite', 'chevy', 'chase', 'md', 'phone', 'email', 'garypeck', 'gmail.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'clinical', 'utility', 'dermtech', 'pigmented', 'lesion', 'assay', 'experience', 'director', 'melanoma', 'center', 'washington', 'hospital', 'center', 'washington', 'dc', 'included', 'accruing', 'melanoma', 'patient', 'greater', 'number', 'patient', 'multiple', 'atypical', 'nevus', 'average', 'lesion', 'count', 'many', 'patient', 'nevus', 'including', 'one', 'found', 'upon', 'long-term', 'monitoring', 'high-risk', 'group', 'patient', 'multiple', 'nevus', 'melanoma', 'arose', 'de', 'novo', 'previously', 'uninvolved', 'skin', 'arose', 'pre-existing', 'nevus', 'concluded', 'make', 'good', 'medical', 'sense', 'remove', 'large', 'number', 'nevus', 'order', 'attempt', 'decrease', 'risk', 'melanoma', 'formation', 'many', 'patient', 'melanoma', 'center', 'history', 'numerous', 'biopsy', 'benign', 'mildly', 'atypical', 'nevus', 'patient', 'objected', 'biopsy', 'pain', 'procedure', 'time', 'wound', 'healing', 'appearance', 'scar', 'anxiety', 'caused', 'time', 'waiting', 'biopsy', 'result', 'moreover', 'two', 'patient', 'history', 'biopsy', 'benign', 'lesion', 'prior', 'entry', 'clinic', 'since', 'relied', 'upon', 'dermoscopic', 'evaluation', 'patient', 'nevus', 'determine', 'lesion', 'biopsy', 'routine', 'use', 'dermoscopy', 'increased', 'diagnostic', 'ability', 'reduced', 'number', 'unnecessary', 'biopsy', 'remains', 'room', 'improvement', 'specifically', 'dermoscopy', 'method', 'available', 'rely', 'largely', 'clinician', 'experience', 'education', 'training', 'large', 'disparity', 'within', 'medical', 'community', 'ability', 'utilize', 'diagnostic', 'tool', 'accurately', 'diagnosis', 'early', 'stage', 'melanoma', 'retiring', 'melanoma', 'center', 'washington', 'hospital', 'center', 'continue', 'care', 'high-risk', 'patient', 'large', 'number', 'nevus', 'dermatologic', 'surgery', 'center', 'washington', 'joined', 'july', 'almost', 'year', 'routinely', 'performed', 'pigmented', 'lesion', 'assay', 'pla', 'pre-biopsy', 'tool', 'testing', 'clinically', 'dermoscopically', 'atypical', 'lesion', 'improve', 'diagnostic', 'accuracy', 'able', 'diagnose', 'smaller', 'melanoma', 'earlier', 'stage', 'avoid', 'unnecessary', 'surgical', 'procedure', 'almost', 'melanoma', 'diagnosed', 'since', 'began', 'using', 'pla', 'small', 'le', 'mm', 'melanoma', 'situ', 'since', 'member', 'clinical', 'staff', 'use', 'pla', 'frequently', 'found', 'lesion', 'test', 'reported', 'pla-positive', 'thus', 'patient', 'saved', 'unnecessary', 'surgical', 'biopsy', 'reasonable', 'suggest', 'gene', 'expression', 'change', 'may', 'occur', 'prior', 'development', 'histopathologically', 'diagnosable', 'melanoma', 'therefore', 'quite', 'possible', 'pla', 'test', 'may', 'finding', 'pre-melanoma', 'lesion', 'eventually', 'would', 'evolved', 'pathologically', 'diagnosable', 'melanoma', 'fact', 'pla-positive', 'lesion', 'labeled', 'false', 'positive', 'biopsy', 'reported', 'severely', 'atypical', 'nevus', 'believe', 'pla', 'capable', 'identifying', 'small', 'melanoma', 'situ', 'still', 'dramatically', 'reducing', 'biopsy', 'rate', 'regarding', 'issue', 'false', 'negative', 'diagnosis', 'part', 'problem', 'might', 'difficulty', 'differential', 'diagnosis', 'melanoma', 'situ', 'severely', 'atypical', 'nevus', 'pathologist', 'example', 'pathologist', 'different', 'threshold', 'number', 'cell', 'exhibiting', 'pagetoid', 'spread', 'leading', 'diagnosis', 'mi', 'rather', 'atypical', 'nevus', 'addition', 'variation', 'evaluating', 'pagetoid', 'spread', 'pathologist', 'may', 'vary', 'evaluation', 'criterion', 'degree', 'cytologic', 'atypia', 'highlight', 'value', 'pla', 'brings', 'practice', 'pla', 'provides', 'negative', 'result', 'choose', 'biopsy', 'time', 'monitor', 'closely', 'regular', 'schedule', 'patient', 'informed', 'return', 'clinic', 'immediately', 'lesion', 'change', 'prior', 'next', 'scheduled', 'visit', 'follow-up', 'examination', 'always', 're-examine', 'lesion', 'previously', 'tested', 'pla', 'reported', 'negative', 'change', 'appearance', 'previously', 'pla-', 'negative', 'lesion', 'follow-up', 'examination', 'either', 'repeat', 'pla', 'testing', 'biopsy', 'lesion', 'depending', 'nature', 'change', 'found', 'pla', 'rule-out', 'testing', 'sensitive', 'reliable', 'useful', 'adjunct', 'dermoscopy', 'use', 'pla', 'enables', 'earlier', 'diagnosis', 'melanoma', 'including', 'meet', 'usual', 'clinical', 'dermoscopic', 'criterion', 'malignancy', 'test', 'asset', 'clinician', 'involved', 'diagnosis', 'skin', 'cancer', 'expert', 'dermoscopy', 'creates', 'objective', 'standard', 'provided', 'care', 'patient', 'melanoma', 'year', 'test', 'like', 'pla', 'provides', 'objectivity', 'particularly', 'difficult', 'diagnose', 'case', 'transformative', 'evaluation', 'pigmented', 'skin', 'lesion', 'please', 'allow', 'offer', 'information', 'specific', 'request', 'nccn', 'melanoma', 'guideline', 'panel', 'recommending', 'inclusion', 'pla', 'helpful', 'tool', 'updated', 'cutaneous', 'melanoma', 'guideline', 'specific', 'change', 'me-', 'pre-diagnostic', 'clinical', 'modality', 'recommend', 'deleting', 'last', 'sentence', 'replace', 'clinical', 'utility', 'pre-diagnostic', 'biopsy-guiding', 'noninvasive', 'genomic', 'patch', 'testing', 'established', 'use', 'technology', 'warranted', 'support', 'biopsy', 'decisions.', 'fda', 'pla', 'clia', 'ldt', 'test', 'sample', 'collector', 'fda', 'compliant', 'class', 'device', 'rationale', 'availability', 'abundance', 'peer', 'reviewed', 'evidence', 'clinical', 'validity', 'clinical', 'utility', 'noninvasive', 'pla', 'guiding', 'biopsy', 'decision', 'reducing', 'avoidable', 'pigmented', 'lesion', 'biopsy', 'missing', 'fewer', 'melanoma', 'npv', 'providing', 'key', 'validation', 'gerami', 'jaad', 'ferris', 'jid', 'key', 'utility', 'ferris', 'doj', 'brouha', 'jdd', 'peer', 'reviewed', 'publication', 'facilitate', 'review', 'question', 'regarding', 'use', 'pla', 'please', 'hesitate', 'contact', 'sincerely', 'gary', 'l.', 'peck', 'md', 'director', 'emeritus', 'melanoma', 'center', 'washington', 'cancer', 'institute', 'washington', 'hospital', 'center', 'washington', 'dc']}, {'filename': '2020_06_22_Foundation.pdf', 'timestamp': datetime.datetime(2020, 6, 22, 0, 0), 'text': ['submitted', 'brian', 'alexander', 'md', 'company', 'foundation', 'medicine', 'inc.', 'address', 'second', 'street', 'cambridge', 'phone', 'ext', 'email', 'balexander', 'foundationmedicine.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'panel', 'member', 'behalf', 'foundation', 'medicine', 'respectfully', 'request', 'nccn®', 'cutaneous', 'melanoma', 'guideline', 'panel', 'consider', 'requested', 'update', 'pertaining', 'evaluation', 'management', 'patient', 'melanoma', 'requested', 'update', 'amend', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'include', 'following', 'tumor', 'mutational', 'burden', 'tmb', 'measured', 'reported', 'targeted', 'ng', 'panel', 'validated', 'and/or', 'fda-approved', 'per', 'recommendation', 'outlined', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'remove', 'last', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'use', 'mutation', 'burden', 'guide', 'treatment', 'decision', 'remains', 'investigational', 'time', 'rationale', 'requested', 'update', 'keynote-', 'nct', 'multicohort', 'single-arm', 'open-label', 'phase', 'study', 'evaluating', 'pembrolizumab', 'monotherapy', 'patient', 'selected', 'previously', 'treated', 'advanced', 'solid', 'tumor', 'administered', 'pembrolizumab', 'mg', 'every', 'week', 'intravenous', 'infusion', 'patient', 'evaluable', 'tissue', 'tmb', 'ttmb', 'score', 'efficacy', 'population', 'ttmb-high', 'defined', 'mutations/megabase', 'tmb-high', 'status', 'associated', 'clinically', 'meaningful', 'improvement', 'demonstrated', 'objective', 'response', 'rate', 'orr', 'ci', 'compared', 'ci', 'non-ttmb-high', 'group', 'primary', 'endpoint', 'median', 'follow-up', 'approximately', 'year', 'median', 'duration', 'response', 'reached', 'ttmb-high', 'group', 'month', 'non‒ttmb-high', 'group', 'additional', 'secondary', 'outcome', 'landmark', 'timepoints', 'include', '-year', 'rate', 'ttmb-high', 'group', 'non‒ttmb-high', 'group', '-year', 'o', 'rate', 'ttmb-high', 'group', 'versus', 'non‒ttmb-high', 'group', 'predictive', 'value', 'ttmb', 'independent', 'biomarkers', 'including', 'microsatellite', 'instability', 'msi', '-high', 'pd-l', 'expression', 'additionally', 'predictive', 'value', 'ttmb', 'appear', 'driven', 'particular', 'tumor', 'type', 'increased', 'response', 'rate', 'tmb-high', 'patient', 'observed', 'across', 'tumor', 'type', 'based', 'result', 'keynote-', 'pembrolizumab', 'fda-approved', 'patient', 'unresectable', 'metastatic', 'solid', 'tumor', 'ttmb-high', 'mutations/megabase', 'determined', 'fda-approved', 'test', 'progressed', 'following', 'prior', 'treatment', 'satisfactory', 'alternative', 'treatment', 'option', 'tmb', 'complex', 'continuous', 'biomarker', 'tmb', 'estimation', 'provided', 'next', 'generation', 'sequencing', 'ng', 'targeted', 'panel', 'vary', 'across', 'laboratory', 'due', 'factor', 'difference', 'panel', 'size', 'gene', 'coverage', 'bioinformatics', 'pipeline', 'important', 'role', 'tmb', 'play', 'clinical', 'decision-making', 'potential', 'variation', 'across', 'laboratory', 'friend', 'cancer', 'research', 'convened', 'consortium', 'key', 'stakeholder', 'recommend', 'best', 'practice', 'approach', 'tmb', 'measurement', 'validation', 'alignment', 'reporting', 'stakeholder', 'including', 'fda', 'national', 'cancer', 'institute', 'diagnostic', 'manufacturer', 'academic', 'pharmaceutical', 'company', 'published', 'detailed', 'recommendation', 'around', 'tmb', 'reporting', 'consistency', 'standardization', 'analytical', 'validation', 'study', 'tmb', 'estimation', 'alignment', 'panel', 'tmb', 'value', 'whole', 'exome', 'sequencing', 'wes', '-derived', 'universal', 'reference', 'standard', 'test', 'report', 'tmb', 'value', 'comply', 'recommendation', 'published', 'and/or', 'fda-approved', 'tmb', 'measurement', 'reporting', 'purpose', 'thank', 'review', 'submission', 'sincerely', 'brian', 'alexander', 'm.d', 'chief', 'medical', 'officer', 'foundation', 'medicine', 'reference', 'marabelle', 'fakih', 'lopez', 'association', 'tumour', 'mutational', 'burden', 'outcome', 'patient', 'advanced', 'solid', 'tumour', 'treated', 'pembrolizumab', 'multicohort', 'open-label', 'phase', 'keynote-', 'study', 'lancet', 'oncology', 'submission', 'esmo', 'presentation', 'attached', 'keytruda', 'pembrolizumab', 'fda', 'approved', 'label', 'found', 'http', '//www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf', 'fda', 'label', 'foundation', 'medicine', 'inc.', 'foundationone®', 'cdx', 'technical', 'information', 'attached', 'merino', 'dm', 'mcshane', 'lm', 'fabrizio', 'establishing', 'guideline', 'harmonize', 'tumor', 'mutational', 'burden', 'tmb', 'silico', 'assessment', 'variation', 'tmb', 'quantification', 'across', 'diagnostic', 'platform', 'phase', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'immunother', 'cancer', 'e.', 'chalmers', 'zr', 'connelly', 'cf', 'fabrizio', 'analysis', 'human', 'cancer', 'genome', 'reveals', 'landscape', 'tumor', 'mutational', 'burden', 'genome', 'med', 'published', 'apr', 'doi', './s']}, {'filename': '2020_06_22_SUNY.pdf', 'timestamp': datetime.datetime(2020, 6, 22, 0, 0), 'text': ['june', 'dermtech', 'pigmented', 'lesion', 'assay', '/nccn', 'submitted', 'name', 'daniel', 'm.', 'siegel', 'md', 'm', 'company/organization', 'suny', 'downstate', 'address', 'basic', 'sci', 'bldg', 'clarkson', 'avenue', 'box', 'brooklyn', 'phone', 'email', 'daniel.siegel', 'downstate.edu', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'cutaneous', 'melanoma', 'panel', 'member', 'clinician', 'clinical', 'researcher', 'studied', 'published', 'incorporated', 'use', 'dermtech', 'pigmented', 'lesion', 'assay', 'pla', 'practice', 'rule', 'melanoma', 'guiding', 'biopsy', 'decision', 'via', 'molecular', 'risk', 'factor', 'find', 'non-invasive', 'clia', 'test', 'useful', 'biopsy', 'guidance', 'npv', 'allows', 'miss', 'fewer', 'melanoma', 'find', 'earlier', 'recent', 'work', 'conic', 'jaad', 'e.', 'highlight', 'even', 'relatively', 'small', 'delay', 'managing', 'primary', 'melanoma', 'pla', 'help', 'minimize', 'negatively', 'impact', 'survival', 'stage', 'melanoma', 'patient', 'problem', 'inherent', 'practice', 'dermatology', 'include', 'access', 'specialty', 'care', 'shortage', 'dermatologist', 'dependent', 'geography', 'lack', 'tool', 'supporting', 'provider', 'assessment', 'often', 'difficult', 'ascertain', 'pigmented', 'skin', 'lesion', 'situation', 'helped', 'covid-', 'related', 'closure', 'limited', 'access', 'dermatology', 'office', 'additionally', 'period', 'telemedicine', 'general', 'teledermatology', 'particular', 'lifeline', 'many', 'patient', 'pla', 'lifesaver', 'many', 'patient', 'could', 'obtain', 'sample', 'necessary', 'testing', 'sheltering', 'home', 'either', 'obtain', 'sense', 'relief', 'make', 'high', 'priority', 'waiting', 'list', 'evaluation', 'treatment', 'guided', 'pla', 'clinical', 'circumstance', 'pandemic', 'end', 'pla', 'still', 'paly', 'valuable', 'role', 'expediting', 'management', 'potential', 'high-risk', 'lesion', 'especially', 'useful', 'qualified', 'health', 'care', 'provider', 'high', 'number', 'needed', 'biopsy', 'find', 'melanoma', 'following', 'required', 'format', 'provide', 'information', 'requested', 'category', 'specific', 'change', 'please', 'see', 'regarding', 'requested', 'specific', 'change', 'version', 'page', 'me-', 'bullet', 'point', 'pre-diagnostic', 'clinical', 'modality', 'screen', 'shot', 'recommend', 'following', 'change', 'clinical', 'utility', 'novel/emerging', 'diagnostic', 'imaging', 'molecular', 'technology', 'e.g', 'non-invasive', 'genomic', 'patch', 'testing', 'requires', 'investigation', 'pre-', 'diagnostic', 'molecular', 'genomic', 'patch', 'testing', 'help', 'guide', 'biopsy', 'decision', 'pigmented', 'skin', 'lesion', 'considered', 'fda', 'clearance', 'clia', 'administered', 'laboratory', 'developed', 'test', 'rationale', 'solid', 'evidence', 'multiple', 'utility', 'study', 'demonstrates', 'biopsy', 'guidance', 'pre-', 'diagnostic', 'pre-biopsy', 'test', 'negative', 'predictive', 'value', 'allows', 'clinician', 'miss', 'fewer', 'melanoma', 'find', 'earlier', 'portfolio', 'peer', 'reviewed', 'pla', 'publication', 'public', 'domain', 'attaching', 'recent', 'pdfs', 'pla', 'clinical', 'utility', 'measure', 'appeared', 'question', 'earlier', 'version', 'cutaneous', 'melanoma', 'guideline', 'ferris', 'al.', 'doj', 'missed', 'melanoma', 'month', 'follow-up', 'brouha', 'jdd', 'real-world', 'registry', 'study', 'case', 'reduction', 'biopsy', 'clinician', 'follow', 'guidance', 'test', 'case', 'robinson', 'skin', 'physician-guided', 'pla', 'home', 'sample', 'collection', 'feasible', 'sincerely', 'hope', 'panel', 'recognizes', 'abundance', 'peer', 'reviewed', 'data', 'including', 'clinical', 'utility', 'available', 'pla', 'publication', 'total', 'recommends', 'use', 'biopsy-guiding', 'pre-', 'diagnostic', 'technology', 'pigmented', 'lesion', 'management', 'latest', 'version', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'thank', 'daniel', 'mark', 'siegel', 'md', 'm', 'management', 'policy', 'clinical', 'professor', 'dermatology', 'suny', 'downstate', 'former', 'president', 'american', 'academy', 'dermatology']}, {'filename': '2020_06_23_Northwestern.pdf', 'timestamp': datetime.datetime(2020, 6, 23, 0, 0), 'text': ['submitted', 'name', 'june', 'k.', 'robinson', 'md', 'research', 'professor', 'dermatology', 'company/organization', 'northwestern', 'university', 'feinberg', 'school', 'medicine', 'department', 'dermatology', 'address', 'n.', 'michigan', 'ave', 'suite', 'chicago', 'il', 'phone', 'email', 'june-robinson', 'northwestern.edu', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'june', 'nccn', 'cutaneous', 'melanoma', 'panel', 'submission', 'nccn.org', 'dermtech', 'pigmented', 'lesion', 'assay', 'dear', 'member', 'committee', 'evaluating', 'pigmented', 'lesion', 'assay', 'pla', 'non-invasive', 'melanoma', 'rule-out', 'test', 'favorable', 'inclusion', 'nccn', 'guideline', 'ask', 'consider', 'perspective', 'based', 'year', 'experience', 'managing', 'care', 'patient', 'pigmented', 'skin', 'lesion', 'dermatologist', 'research', 'professor', 'northwestern', 'university', 'feinberg', 'school', 'medicine', 'career', 'focused', 'early', 'identification', 'skin', 'cancer', 'especially', 'melanoma', 'ample', 'opportunity', 'train', 'talented', 'medical', 'student', 'dermatology', 'primary', 'care', 'resident', 'fellow', 'dermatology', 'primary', 'care', 'faculty', 'member', 'perform', 'skin', 'examination', 'detect', 'melanoma', 'research', 'effort', 'included', 'training', 'patient', 'skin', 'self-examination', 'one', 'goal', 'educate', 'make', 'physician', 'aware', 'optimize', 'melanoma', 'detection', 'pathway', 'existing', 'standard', 'care', 'visual', 'examination', 'biopsy', 'histopathology', 'largely', 'subjective', 'relies', 'heavily', 'clinician', 'level', 'education', 'past', 'current', 'experience', 'examining', 'patient', 'melanoma', 'training', 'availability', 'diagnostic', 'tool', 'i.e.', 'dermoscopy', 'proficiency', 'using', 'critical', 'improve', 'diagnostic', 'accuracy', 'clinical', 'histopathological', 'criterion', 'minimize', 'risk', 'harm', 'related', 'screening', 'at-risk', 'patient', 'melanoma', 'histopathologic', 'diagnosis', 'remains', 'gold', 'standard', 'proven', 'limitation', 'landmark', 'study', 'elmore', 'colleague', 'addressed', 'performance', 'dermatopathologists', 'pathologist', 'evaluation', 'pigmented', 'skin', 'lesion', 'bmj', 'demonstrated', 'poor', 'intra-observer', 'reproducibility', 'diagnostic', 'accuracy', 'discordance', 'across', 'spectrum', 'melanocytic', 'skin', 'lesion', 'unexpected', 'poor', 'diagnostic', 'accuracy', 'melanoma', 'situ', 'severely', 'dysplastic', 'nevus', 'accuracy', 'thin', 'invasive', 'melanoma', 'accuracy', 'thick', 'melanoma', 'concerning', 'important', 'department', 'dermatology', 'michigan', 'ave', 'suite', 'chicago', 'il', 'phone', 'june-robinson', 'northwestern.edu', 'june', 'k.', 'robinson', 'md', 'research', 'professor', 'dermatology', 'northwestern', 'university', 'june', 'k.', 'robinson', 'md', 'june', 'page', 'improve', 'diagnostic', 'accuracy', 'decrease', 'false', 'positive', 'may', 'result', 'unnecessary', 'surgery', 'psychological', 'harm', 'critical', 'reduce', 'false', 'negative', 'diagnosis', 'may', 'increase', 'morbidity', 'provides', 'solid', 'rationale', 'additional', 'technology', 'identify', 'marker', 'assist', 'diagnosis', 'genomic', 'test', 'like', 'pigmented', 'lesion', 'assay', 'pla', 'based', 'searchable', 'peer', 'reviewed', 'publication', 'help', 'address', 'deficiency', 'existing', 'care', 'standard', 'request', 'nccn', 'consider', 'available', 'evidence', 'provide', 'feedback', 'required', 'key', 'category', 'requested', 'specific', 'change', 'relative', 'version', 'me-', 'page', 'pigmented', 'lesion', 'assay', 'considered', 'non-invasive', 'test', 'guide', 'decision', 'perform', 'surgical', 'biopsy', 'difficult', 'ass', 'melanocytic', 'lesion', 'recommend', 'deleting', 'last', 'sentence', 'bullet', 'point', 'number', 'fda', 'pla', 'clia', 'fda', 'administered', 'test', 'rationale', 'genomic', 'test', 'like', 'pigmented', 'lesion', 'assay', 'pla', 'based', 'searchable', 'peer', 'reviewed', 'publication', 'help', 'address', 'deficiency', 'existing', 'care', 'standard', 'please', 'see', 'detail', 'recent', 'research', 'demonstrates', 'physician-supervised', 'pla', 'skin', 'sample', 'collection', 'patient', 'viable', 'non-invasive', 'specimen', 'collection', 'option', 'highlighting', 'pla', 'applicability', 'versatility', 'traditional', 'transitioning', 'teledermatology', 'paradigm', 'current', 'coronavirus', 'pandemic', 'many', 'dermatology', 'office', 'unable', 'provide', 'direct', 'patient', 'care', 'pre-biopsy', 'pla', 'support', 'clinician', 'effort', 'provide', 'objective', 'diagnosis', 'regardless', 'setting', 'provides', 'clinician', 'comfort', 'missing', 'fewer', 'melanoma', 'reduces', 'patient', 'anxiety', 'skin', 'biopsy', 'enhances', 'patient', 'trust', 'physician', 'provide', 'care', 'remotely', 'bridge', 'gap', 'providing', 'physician', 'surveillance', 'melanoma', 'survivor', 'clinical', 'office', 'fully', 'support', 'incorporation', 'pla', 'nccn', 'guideline', 'evidence', 'block', 'aide', 'clinician', 'diagnosis', 'pigmented', 'skin', 'lesion', 'pla', 'avoids', 'unnecessary', 'biopsy', 'enables', 'better', 'diagnostic', 'interpretation', 'regardless', 'setting', 'allows', 'consistent', 'objective', 'result', 'appreciate', 'nccn', 'guideline', 'version', 'concentrated', 'management', 'cutaneous', 'melanoma', 'following', 'pathologic', 'diagnosis', 'time', 'reassess', 'position', 'question', 'regarding', 'request', 'include', 'pla', 'pre-diagnostic', 'technology', 'inform', 'decision', 'biopsy', 'next', 'version', 'cutaneous', 'melanoma', 'guideline', 'please', 'hesitate', 'contact', 'email', 'june-robinson', 'northwestern.edu', 'set', 'time', 'speak', 'summary', 'recommendation', 'pigmented', 'lesion', 'assay', 'considered', 'non-invasive', 'test', 'guide', 'decision', 'perform', 'surgical', 'biopsy', 'difficult', 'ass', 'melanocytic', 'lesion', 'sincerely', 'june', 'k.', 'robinson', 'md', 'following', 'article', 'submitted', 'support', 'proposed', 'change', 'pdfs', 'attached', 'june', 'k.', 'robinson', 'md', 'june', 'page', 'elmore', 'bmj', 'pathology', 'comparator', 'ferris', 'doj', 'pla', 'clin', 'utility', 'gerami', 'jaad', 'pla', 'clin', 'validation', 'brouha', 'jdd', 'pla', 'clin', 'utility', 'ferris', 'jid', 'pla', 'clin', 'validation', 'robinson', 'skin', 'pla', 'clin', 'utility']}, {'filename': '2020_06_23_UPMC.pdf', 'timestamp': datetime.datetime(2020, 6, 23, 0, 0), 'text': ['nccn', 'cutaneous', 'melanoma', 'guideline', 'panel', 'submitted', 'name', 'laura', 'k.', 'ferris', 'md', 'phd', 'organization', 'upmc', 'address', 'please', 'see', 'phone', 'please', 'see', 'email', 'ferrlk', 'upmc.edu', 'date', 'request', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'sent', 'via', 'email', 'submission', 'nccn.org', 'regarding', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'pigmented', 'lesion', 'assay', 'dear', 'nccn', 'cutaneous', 'melanoma', 'panel', 'member', 'served', 'lead', 'investigator', 'several', 'clinical', 'study', 'involving', 'dermtech', 'pigmented', 'lesion', 'assay', 'please', 'allow', 'share', 'enthusiasm', 'rationale', 'recommending', 'pla', 'use', 'guide', 'biopsy', 'decision', 'requested', 'change', 'next', 'version', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'based', 'test', 'performance', 'clinical', 'utility', 'evidenced', 'peer', 'reviewed', 'publication', 'number', 'study', 'investigating', 'performance', 'various', 'molecular', 'analysis', 'technique', 'i.e.', 'fish', 'cgh', 'etc', 'however', 'technique', 'fall', 'short', 'truly', 'impacting', 'pigmented', 'lesion', 'management', 'performance', 'characteristic', 'test', 'depend', 'tissue', 'sample', 'surgical', 'biopsy', 'pla', 'different', 'performance', 'characteristic', 'superior', 'npv', 'specificity', 'sensitivity', 'test', 'reduces', 'greatly', 'number', 'exploratory', 'biopsy', 'associated', 'pigmented', 'lesion', 'management', 'specific', 'change', 'recommend', 'deleting', 'last', 'sentence', 'evidence', 'block', 'me-', 'page', 'pre-diagnostic', 'clinical', 'modality', 'based', 'evidence', 'available', 'please', 'correct', 'pre-', 'diagnostic', 'noninvasive', 'genomic', 'patch', 'testing', 'considered', 'guide', 'biopsy', 'decisions.', 'fda', 'clia', 'test', 'fda', 'compliant', 'class', 'device', 'non-invasively', 'obtain', 'sample', 'via', 'adhesive', 'patch', 'rationale', 'rationale', 'recommendation', 'based', 'pla', 'confirmed', 'clinical', 'utility', 'performance', 'npv', 'specificity', 'sensitivity', 'greatly', 'reducing', 'number', 'exploratory', 'biopsy', 'associated', 'pigmented', 'lesion', 'management', 'providing', 'key', 'validation', 'gerami', 'jaad', 'ferris', 'jid', 'key', 'utility', 'ferris', 'doj', 'brouha', 'jdd', 'detailed', 'peer', 'reviewed', 'publication', 'facilitate', 'nccn', 'effort', 'specifically', 'provided', '-month', 'follow', 'study', 'ferris', 'al.', 'impact', 'clinical', 'practice', 'noninvasive', 'gene', 'expression', 'melanoma', 'rule-out', 'test', '-month', 'follow-up', 'negative', 'test', 'result', 'utility', 'data', 'large', 'u', 'registry', 'study', 'doj', 'reviewed', 'record', 'pigmented', 'lesion', 'negative', 'pla', 'result', 'dermatology', 'office', 'lesion', 'negative', 'result', 'biopsied', 'submitted', 'histopathologic', 'review', 'none', 'lesion', 'biopsied', 'histopathologic', 'diagnosis', 'melanoma', 'normal', 'practice', 'lesion', 'likely', 'would', 'biopsied', 'subset', 'subjected', 'wider', 'margin', 'excision', 'pla', 'test', 'result', 'followed', 'unnecessary', 'biopsy', 'downstream', 'complication', 'reduced', 'avoided', 'recent', 'large', 'real-world', 'registry', 'study', 'pla', 'performance', 'impact', 'clinical', 'decision', 'making', 'validated', 'brouha', 'real-world', 'utility', 'non-invasive', 'gene', 'expression', 'test', 'rule', 'primary', 'cutaneous', 'melanoma', 'large', 'u', 'registry', 'study', 'jdd', 'provider', 'evaluated', 'case', 'pla', 'pla', 'test', 'lesion', 'clinically', 'suspicious', 'melanoma', 'negative', 'pla', 'positive', 'pla', 'test', 'result', 'case', 'resulted', 'surgical', 'biopsy', 'pla', 'test', 'result', 'case', 'resulted', 'surgical', 'biopsy', 'avoidance', 'invasive', 'surgical', 'procedure', 'clearly', 'evidence', 'impact', 'pla', 'pigmented', 'lesion', 'management', 'recommend', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'updated', 'reflect', 'available', 'evidence', 'sincerely', 'laura', 'k.', 'ferris', 'md', 'phd']}, {'filename': '2020_09_15_Foundation.pdf', 'timestamp': datetime.datetime(2020, 9, 15, 0, 0), 'text': ['submitted', 'brian', 'alexander', 'md', 'company', 'foundation', 'medicine', 'inc.', 'address', 'second', 'street', 'cambridge', 'phone', 'ext', 'email', 'balexander', 'foundationmedicine.com', 'date', 'request', 'original', 'submission', 'june', 'highlighted', 'update', 'september', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'panel', 'member', 'behalf', 'foundation', 'medicine', 'respectfully', 'request', 'nccn®', 'cutaneous', 'melanoma', 'guideline', 'panel', 'consider', 'requested', 'update', 'pertaining', 'evaluation', 'management', 'patient', 'melanoma', 'requested', 'update', 'amend', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'include', 'following', 'tumor', 'mutational', 'burden', 'tmb', 'measured', 'reported', 'targeted', 'ng', 'panel', 'validated', 'and/or', 'fda-approved', 'per', 'recommendation', 'outlined', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'remove', 'last', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'use', 'mutation', 'burden', 'guide', 'treatment', 'decision', 'remains', 'investigational', 'time', 'rationale', 'requested', 'update', 'keynote-', 'nct', 'multicohort', 'single-arm', 'open-label', 'phase', 'study', 'evaluating', 'pembrolizumab', 'monotherapy', 'patient', 'selected', 'previously', 'treated', 'advanced', 'solid', 'tumor', 'administered', 'pembrolizumab', 'mg', 'every', 'week', 'intravenous', 'infusion', 'patient', 'evaluable', 'tissue', 'tmb', 'ttmb', 'score', 'efficacy', 'population', 'ttmb-high', 'defined', 'mutations/megabase', 'per', 'foundationone', 'cdx', 'panel', 'assessed', 'safety', 'patient', 'enrolled', 'least', 'week', 'data', 'cutoff', 'evaluable', 'tmb', 'included', 'efficacy', 'analysis', 'patient', 'ttmb-high', 'status', 'ttmb-high', 'status', 'associated', 'clinically', 'meaningful', 'improvement', 'demonstrated', 'objective', 'response', 'rate', 'orr', 'ci', 'compared', 'ci', 'non-ttmb-high', 'group', 'primary', 'endpoint', 'median', 'follow-up', 'month', 'iqr', '.-', 'median', 'duration', 'response', 'reached', 'ttmb-', 'high', 'group', 'month', 'non-ttmb-high', 'group', 'additional', 'secondary', 'outcome', 'landmark', 'timepoints', 'include', '-year', 'rate', 'ci', 'ttmb-high', 'group', 'ci', 'non‒ttmb-high', 'group', '-year', 'o', 'rate', 'ci', 'ttmb-high', 'group', 'versus', 'ci', 'non‒ttmb-high', 'group', 'predictive', 'value', 'ttmb', 'independent', 'biomarkers', 'including', 'microsatellite', 'instability', 'msi', '-high', 'pd-l', 'expression', 'additionally', 'predictive', 'value', 'ttmb', 'appear', 'driven', 'particular', 'tumor', 'type', 'increased', 'response', 'rate', 'tmb-high', 'patient', 'observed', 'across', 'tumor', 'type', 'based', 'result', 'keynote-', 'pembrolizumab', 'fda-approved', 'patient', 'unresectable', 'metastatic', 'solid', 'tumor', 'ttmb-high', 'mutations/megabase', 'determined', 'fda-approved', 'test', 'progressed', 'following', 'prior', 'treatment', 'satisfactory', 'alternative', 'treatment', 'option', 'tmb', 'complex', 'continuous', 'biomarker', 'tmb', 'estimation', 'provided', 'next', 'generation', 'sequencing', 'ng', 'targeted', 'panel', 'vary', 'across', 'laboratory', 'due', 'factor', 'difference', 'panel', 'size', 'gene', 'coverage', 'bioinformatics', 'pipeline', 'important', 'role', 'tmb', 'play', 'clinical', 'decision-making', 'potential', 'variation', 'across', 'laboratory', 'friend', 'cancer', 'research', 'convened', 'consortium', 'key', 'stakeholder', 'recommend', 'best', 'practice', 'approach', 'tmb', 'measurement', 'validation', 'alignment', 'reporting', 'stakeholder', 'including', 'fda', 'national', 'cancer', 'institute', 'diagnostic', 'manufacturer', 'academic', 'pharmaceutical', 'company', 'published', 'detailed', 'recommendation', 'around', 'tmb', 'reporting', 'consistency', 'standardization', 'analytical', 'validation', 'study', 'tmb', 'estimation', 'alignment', 'panel', 'tmb', 'value', 'whole', 'exome', 'sequencing', 'wes', '-derived', 'universal', 'reference', 'standard', 'test', 'report', 'tmb', 'value', 'comply', 'recommendation', 'published', 'and/or', 'fda-approved', 'tmb', 'measurement', 'reporting', 'purpose', 'thank', 'review', 'submission', 'sincerely', 'brian', 'alexander', 'm.d', 'chief', 'medical', 'officer', 'foundation', 'medicine', 'reference', 'marabelle', 'fakih', 'lopez', 'association', 'tumour', 'mutational', 'burden', 'outcome', 'patient', 'advanced', 'solid', 'tumour', 'treated', 'pembrolizumab', 'prospective', 'biomarker', 'analysis', 'multicohort', 'open-label', 'phase', 'keynote-', 'study', 'published', 'online', 'ahead', 'print', 'sep', 'lancet', 'oncol', 's-', 'keytruda', 'pembrolizumab', 'fda', 'approved', 'label', 'found', 'http', '//www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf', 'fda', 'label', 'foundation', 'medicine', 'inc.', 'foundationone®', 'cdx', 'technical', 'information', 'attached', 'merino', 'dm', 'mcshane', 'lm', 'fabrizio', 'establishing', 'guideline', 'harmonize', 'tumor', 'mutational', 'burden', 'tmb', 'silico', 'assessment', 'variation', 'tmb', 'quantification', 'across', 'diagnostic', 'platform', 'phase', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'immunother', 'cancer', 'e.', 'chalmers', 'zr', 'connelly', 'cf', 'fabrizio', 'analysis', 'human', 'cancer', 'genome', 'reveals', 'landscape', 'tumor', 'mutational', 'burden', 'genome', 'med', 'published', 'apr', 'doi', './s']}, {'filename': '2020_06_16_DermTech.pdf', 'timestamp': datetime.datetime(2020, 6, 16, 0, 0), 'text': ['submitted', 'dermtech', 'inc', 'name', 'burkhard', 'jansen', 'md', 'chief', 'medical', 'officer', 'company/organization', 'dermtech', 'inc.', 'address', 'torrey', 'pine', 'road', 'suite', 'la', 'jolla', 'ca', 'phone', 'email', 'bjansen', 'dermtech.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'sent', 'via', 'email', 'submission', 'nccn.org', 'behalf', 'dermtech', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'data', 'dermtech', 'pre-biopsy', 'biopsy', 'guiding', 'non-invasive', 'melanoma', 'rule-out', 'test', 'pigmented', 'lesion', 'assay', 'pla', 'pla', 'supported', 'peer', 'reviewed', 'publication', 'covered', 'medicare', 'support', 'test', 'treatment', 'deems', 'experimental', 'investigational', 'benefitted', 'u', 'patient', 'date', 'reducing', 'avoidable', 'biopsy', 'missing', 'fewer', 'melanoma', 'based', 'test', 'high', 'negative', 'predictive', 'value', 'test', 'insert', 'simple', 'non-invasive', 'objective', 'step', 'current', 'diagnostic', 'pigmented', 'lesion', 'paradigm', 'visual', 'inspection', 'surgical', 'biopsy', 'case', 'clinician', 'require', 'information', 'guide', 'biopsy', 'decision', 'greatly', 'appreciate', 'consideration', 'available', 'peer', 'reviewed', 'evidence', 'including', 'large', 'real-world', 'utility', 'study', 'demonstrates', 'pla', 'reduces', 'avoidable', 'biopsy', 'clinician', 'following', 'guidance', 'test', 'case', 'pla', 'positive', 'lesion', 'biopsied', 'pla', 'negative', 'lesion', 'clinically', 'followed', 'biopsied', 'well', 'clarification', 'noninvasive', 'genomic', 'patch', 'test', 'fit', 'diagnostic', 'continuum', 'pigmented', 'lesion', 'management', 'specific', 'change', 'recommend', 'pigmented', 'lesion', 'assay', 'pla', 'useful', 'pre-diagnostic', 'tool', 'support', 'clinician', 'decision', 'whether', 'biopsy', 'assessment', 'pigmented', 'skin', 'lesion', 'suspicious', 'melanoma', 'changed', 'requires', 'investigation', 'see', 'v.', 'me-', 'common', 'follow-up', 'recommendation', 'patient', 'moldx', 'coverage', 'february', 'medicare', 'administrative', 'contractor', 'palmetto', 'gba', 'moldx', 'published', 'effective', 'local', 'coverage', 'determination', 'lcd', 'pigmented', 'lesion', 'assay', 'harmonized', 'medicare', 'administrator', 'coverage', 'determination', 'across', 'moldx', 'region', 'rationale', 'support', 'proposed', 'change', 'v.', 'guideline', 'cutaneous', 'melanoma', 'correctly', 'characterized', 'noninvasive', 'genomic', 'adhesive', 'patch', 'test…', 'pre-diagnostic', 'technolog', 'inform', 'decision', 'whether', 'biopsy', 'affirmatively', 'stated', 'noninvasive', 'genomic', 'adhesive', 'patch', 'testing', 'outside', 'guideline', 'purview', 'however', 'reference', 'noninvasive', 'genomic', 'patch', 'testing', 'removed', 'appropriately', 'principle', 'molecular', 'testing', 'section', 'subsequent', 'version', 'guideline', 'designation', 'requiring', 'investigation', 'see', 'v.', 'me-', 'common', 'follow-up', 'recommendation', 'patient', 'ignores', 'overwhelming', 'evidence', 'pla', 'effectively', 'informs', 'clinical', 'decision', 'making', 'whether', 'biopsy', 'pigmented', 'lesion', 'suspicious', 'melanoma', 'important', 'highlight', 'pre-diagnostic', 'biopsy', 'guiding', 'pla', 'distinct', 'discussed', 'prognostic', 'post-biopsy', 'gene', 'expression', 'test', 'reader', 'previous', 'guideline', 'document', 'confuse', 'portfolio', 'peer', 'reviewed', 'pla', 'publication', 'medicare', 'coverage', 'based', 'full', 'moldx', 'review', 'support', 'proposed', 'change', 'ease', 'use', 'include', 'hyperlinked', 'document', 'peer', 'reviewed', 'publication', 'facilitate', 'review', 'panel', 'highlighting', 'key', 'evidence', 'previously', 'considered', 'brouha', 'al.', 'real-world', 'utility', 'non-invasive', 'gene', 'expression', 'test', 'rule', 'primary', 'cutaneous', 'melanoma', 'large', 'u', 'registry', 'study', 'journal', 'drug', 'dermatology', 'study', 'evaluated', 'case', 'pigmented', 'lesion', 'clinically', 'suspicious', 'melanoma', 'affirmed', 'real-world', 'utility', 'pla', 'clinician', 'followed', 'guidance', 'offered', 'pla', 'positive', 'test', 'case', 'unnecessary', 'surgical', 'procedure', 'avoided', 'case', 'overall', 'clinician', 'followed', 'guidance', 'test', 'case', 'ferris', 'al.', 'impact', 'clinical', 'practice', 'noninvasive', 'gene', 'expression', 'melanoma', 'rule-out', 'test', '-month', 'follow-up', 'negative', 'test', 'result', 'utility', 'data', 'large', 'u', 'registry', 'study.', 'dermatol', 'online', 'paper', 'evaluated', 'long-term', 'follow-up', 'case', 'provided', 'evidence', 'pla', 'missed', 'melanoma', '-month', 'follow-up', 'period', 'palmetto', 'gba', 'moldx', 'local', 'coverage', 'determination', 'lcd', 'pigmented', 'lesion', 'assay', 'policy', 'clearly', 'defines', 'pla', 'fit', 'diagnostic', 'paradigm', 'pre-diagnostic', 'biopsy', 'guiding', 'tool', 'capable', 'reducing', 'biopsy', 'rate', 'non-malignant', 'lesion', 'importantly', 'discus', 'limitation', 'current', 'care', 'standard', 'clinician', 'rely', 'visual', 'inspection', 'plus', 'surgical', 'biopsy', 'study', 'berman', 'colleague', 'consensus', 'panel', 'nine', 'expert', 'dermatologists/dermatologic', 'surgeons/dermatopathologists', 'convened', 'almost', 'two', 'year', 'ago', 'august', 'determine', 'individual', 'level', 'evidence', 'selected', 'publication', 'gene', 'expression', 'test', 'used', 'pigmented', 'lesion', 'management', 'berman', 'al.', 'appropriate', 'use', 'criterion', 'integration', 'diagnostic', 'prognostic', 'gene', 'expression', 'profile', 'assay', 'management', 'cutaneous', 'malignant', 'melanoma', 'expert', 'panel', 'consensus-based', 'modified', 'delphi', 'process', 'assessment', 'skin', 'panel', 'assigned', 'highest', 'evidence', 'level', 'level', 'pla', 'clinical', 'validation', 'study', 'reference', 'within', 'provided', 'hyperlinked', 'document', 'available', 'online', 'unable', 'consider', 'two', 'large', 'real-world', 'utility', 'study', 'highlighted', 'study', 'relevant', 'patient-oriented', 'evidence', 'available', 'time', 'consensus', 'panel', 'convened', 'given', 'limitation', 'panel', 'arrived', 'still', 'high', 'strength', 'recommendation', 'taxonomy', 'sort', 'assessment', 'based', 'fraction', 'key', 'evidence', 'inconsistent', 'limited-quality', 'patient-oriented', 'evidence', 'patient', 'atypical', 'lesion', 'requiring', 'assessment', 'beyond', 'visual', 'inspection', 'help', 'selection', 'biopsy', 'clinical', 'validation', 'study', 'address', 'potential', 'pla', 'niche', 'us', 'patient', 'refuse', 'surgical', 'biopsy', 'patient', 'increased', 'infection', 'risk', 'separately', 'studied', 'received', 'lower', 'sort', 'score', 'new', 'consensus', 'assessment', 'considers', 'evidence', 'available', 'warranted', 'thank', 'review', 'consideration', 'please', 'let', 'know', 'answer', 'question', 'sincerely', 'burkhard', 'jansen', 'md', 'chief', 'medical', 'officer', 'dermtech']}, {'filename': '2021_06_11_Castle.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'submitted', 'name', 'jay', 'braxton', 'pharmd', 'company', 'castle', 'bioscience', 'inc.', 'address', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'texas', 'phone', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'submission', 'requested', 'amendment', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'member', 'nccn', 'guideline', 'melanoma', 'panel', 'behalf', 'castle', 'bioscience', 'thank', 'time', 'attention', 'devote', 'developing', 'clinical', 'practice', 'guideline', 'patient', 'cancer', 'respectfully', 'request', 'additional', 'relevant', 'recent', 'publication', 'included', 'update', 'guideline', 'recognize', 'gene', 'expression', 'profile', 'gep', 'testing', 'may', 'add', 'information', 'multidisciplinary', 'decision-making', 'process', 'adjunct', 'replacement', 'traditional', 'staging', 'please', 'find', 'requested', 'change', 'rationale', 'inclusion', 'well', 'relevant', 'publication', 'previously', 'discussed', 'specific', 'recommended', 'change', 'rationale', 'request', 'gene', 'expression', 'profiling', 'risk', 'recurrence', 'page', 'me-a', 'footnote', 'clinical', 'presentation', 'pathology', 'report', 'preliminary', 'workup', 'footnote', 'page', 'me-a', 'footnote', 'workup', 'primary', 'treatment', 'footnote', 'page', 'me-', 'nccn', 'guideline', 'version', 'melanoma', 'cutaneous', 'footnote', 'footnote', 'similar', 'verbiage', 'therefore', 'request', 'verbiage', 'footnote', 'recommended', 'change', 'use', 'gep', 'testing', 'according', 'specific', 'ajcc-', 'melanoma', 'stage', 'slnb', 'requires', 'prospective', 'investigation', 'large', 'contemporary', 'data', 'set', 'unselected', 'patient', 'prognostic', 'gep', 'testing', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'replace', 'pathologic', 'staging', 'procedure', 'may', 'used', 'conjunction', 'staging', 'provide', 'additional', 'risk', 'stratification', 'moreover', 'since', 'low', 'probability', 'metastasis', 'stage', 'melanoma', 'higher', 'proportion', 'false-positive', 'result', 'gep', 'testing', 'guide', 'clinical', 'decision-making', 'subgroup', 'see', 'principle', 'molecular', 'testing', 'me-c', 'page', 'me-c', 'principle', 'molecular', 'testing', 'bullet', 'prognostic', 'testing', 'arrow', 'recommended', 'change', 'commercially', 'available', 'gep', 'test', 'marketed', 'able', 'classify', 'cutaneous', 'melanoma', 'separate', 'category', 'based', 'risk', 'metastasis', 'however', 'remains', 'unclear', 'whether', 'gep', 'platform', 'may', 'provide', 'clinically', 'actionable', 'prognostic', 'information', 'used', 'addition', 'comparison', 'known', 'clinicopathologic', 'factor', 'multivariable', 'nomogram', 'incorporate', 'patient', 'sex', 'age', 'tumor', 'location', 'thickness', 'ulceration', 'mitotic', 'rate', 'lymphovascular', 'invasion', 'microsatellites', 'slnb', 'status', 'part', 'multidisciplinary', 'decision-making', 'process', 'furthermore', 'impact', 'test', 'treatment', 'outcome', 'follow-up', 'schedule', 'established', 'page', 'me-c', 'principle', 'molecular', 'testing', 'bullet', 'prognostic', 'testing', 'arrow', 'recommended', 'change', 'various', 'mostly', 'retrospective', 'study', 'prognostic', 'gep', 'testing', 'suggest', 'role', 'independent', 'predictor', 'worse', 'outcome', 'though', 'superior', 'breslow', 'thickness', 'sln', 'status', 'remains', 'unclear', 'whether', 'available', 'gep', 'platform', 'reliably', 'predictive', 'outcome', 'across', 'risk', 'spectrum', 'melanoma', 'recent', 'pprospective', 'validation', 'study', 'performed', 'breast', 'cancer', 'required', 'define', 'accurately', 'support', 'clinical', 'utility', 'molecular', 'testing', 'prior', 'widespread', 'implementation', 'gep', 'prognostication', 'cutaneous', 'melanoma', 'adjunct', 'traditional', 'staging', 'process', 'part', 'multidisciplinary', 'decision-', 'making', 'process', 'particular', 'determine', 'role', 'guiding', 'surveillance', 'imaging', 'slnb', 'adjuvant', 'treatment', 'decision', 'existing', 'emerging', 'gep', 'platform', 'prognostic', 'technique', 'compared', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'i.e.', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'development', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'rationale', 'recommended', 'change', 'current', 'staging', 'powerful', 'limitation', 'melanoma', 'diagnosed', 'stage', 'ii', 'many', 'death', 'occur', 'patient', 'initially', 'diagnosed', 'stage', 'sentinel', 'node', 'positivity', 'important', 'prognosis', 'two-thirds', 'patient', 'completely', 'staged', 'die', 'melanoma', 'initially', 'node-negative', 'disease.', 'gene', 'expression', 'profile', 'provide', 'independent', 'information', 'identify', 'patient', 'aggressive', 'tumor', 'biology', 'provide', 'improved', 'risk', 'stratification', 'recent', 'independent', 'publication', 'arnot', 'al.', 'reported', 'outcome', 'patient', 'prospectively', 'enrolled', 'database', 'oregon', 'health', 'science', 'university', 'mean', 'follow-up', 'time', 'month', 'patient', 'underwent', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'patient', 'experienced', 'recurrence', 'melanoma', 'within', 'three', 'year', 'recurrence', 'positive', 'slnb', 'decisiondx-melanoma', '-gep', 'class', 'result', 'demonstrating', '-gep', 'identify', 'completely', 'staged', 'patient', 'still', 'risk', 'metastasis', 'note', 'study', 'slnb', 'identified', 'one-third', 'recurrence', 'consistent', 'mslt-', 'overall', 'cohort', '-gep', 'independent', 'predictor', 'rf', 'hr', 'p=', 'dmfs', 'hr', 'p=', 'specifically', 'low', 'risk', 'stage', 'i-iia', 'population', '-gep', 'could', 'stratify', 'patient', 'group', 'low', 'class', 'high', 'class', 'risk', 'relapse', 'hsueh', 'al.', 'another', 'prospective', 'multi-center', 'study', 'examining', 'unselected', 'patient', 'stage', 'i-iii', 'melanoma', 'median', 'follow-up', 'time', 'year', 'patient', '-gep', 'class', 'result', 'excellent', 'outcome', 'distant', 'metastasis-', 'free', 'survival', 'dmfs', 'compared', 'dmfs', 'among', 'patient', 'high-risk', 'class', 'result', 'molecular', 'testing', 'added', 'clinical', 'factor', 'indicated', 'significant', 'hazard', 'ratio', 'multivariable', 'analysis', 'included', 'ajcc', 'stage', 'breslow', 'thickness', 'ulceration', 'status', 'sln', 'status', 'tumor', 'location', 'head', 'neck', 'sex', 'age', 'mitoses', 'determined', 'accuracy', 'metric', 'sensitivity', 'identification', 'patient', 'developed', 'distant', 'metastasis', 'increased', 'using', 'staging', 'factor', 'combining', '-gep', 'test', 'staging', 'factor', 'sensitivity', 'increased', 'endpoint', 'evaluated', 'study', 'following', 'inclusion', '-gep', 'result', 'ajcc', 'prognosis', 'additionally', 'combined', 'ajcc', '-gep', 'prognosis', 'maintained', 'negative', 'predictive', 'value', 'dmfs', 'similar', 'result', 'seen', 'rf', 'o', 'demonstrating', '-gep', 'test', 'significant', 'independent', 'predictor', 'recurrence', 'distant', 'metastasis', 'death', 'data', 'viewed', '-gep', 'subclass', '-year', 'overall', 'survival', 'patient', 'stage', 'i-iia', 'melanoma', 'class', '-gep', 'result', 'similar', 'survival', 'patient', 'stage', 'iib-iii', 'melanoma', 'suggesting', '-gep', 'identify', 'patient', 'traditionally', 'staged', 'low', 'risk', 'may', 'higher', 'recurrence', 'metastasis', 'risk', 'initially', 'thought', 'result', 'reported', 'article', 'described', 'consistent', 'published', 'prospective', 'studies.', 'addition', 'evidence', 'described', 'prospective', 'study', 'two', 'recent', 'systematic', 'review', 'meta-analyses', 'demonstrated', 'consistent', 'prognostic', 'accuracy', '-gep', 'across', 'multiple', 'study', 'greenhaw', 'al.', 'reviewed', 'result', 'patient', 'reporting', 'group', 'stage', 'patient', 'class', 'result', 'dmfs', 'rate', 'compared', 'patient', 'class', 'result', 'similarly', 'significant', 'separation', 'distant', 'metastasis', 'risk', 'reported', 'stage', 'ii', 'patient', 'patient', 'class', 'result', 'patient', 'class', 'result', 'multivariable', 'cox', 'regression', 'analysis', 'showed', '-gep', 'added', 'independent', 'prognostic', 'information', 'model', 'incorporating', 'clinical', 'pathologic', 'factor', 'incorporated', 'ajcc', 'staging', 'patient', 'age', 'similar', 'study', 'described', 'result', 'meta-analysis', 'demonstrated', '-gep', 'high', 'sensitivity', 'increased', 'combined', 'sln', 'status', 'sensitivity', 'sln', 'status', 'alone', 'indicating', 'using', '-gep', 'conjunction', 'staging', 'factor', 'improve', 'prognostic', 'accuracy', 'growing', 'list', 'study', 'build', 'result', 'ferris', 'al.', 'demonstrates', 'added', 'prognostic', 'value', '-gep', 'combined', 'clinicopathologic', 'factor', 'described', 'ajcc', 'th', 'th', 'edition', 'cancer', 'staging', 'manual', 'recommendation', 'nccn', 'important', 'highlight', 'request', 'comparison', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'limited', 'fact', 'cited', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'currently', 'available', 'use', 'believe', 'request', 'comparison', 'included', 'nccn', 'text', 'limited', 'tool', 'available', 'comparison', 'gene', 'expression', 'profiling', 'sentinel', 'lymph', 'node', 'biopsy', 'page', 'me-f', 'principle', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'bullet', 'arrow', 'recommended', 'change', 'prognostic', 'gep', 'testing', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'replace', 'pathologic', 'staging', 'procedure', 'currently', 'available', 'gep', 'test', 'used', 'determine', 'slnb', 'eligibility', 'however', 'clinical', 'scenario', 'wherein', 'gep', 'add', 'additional', 'information', 'regarding', 'risk', 'slnb', 'positivity', 'adjunct', 'traditional', 'staging', 'important', 'part', 'multidisciplinary', 'discussion', 'rationale', 'recommended', 'change', 'recent', 'nccn', 'guideline', 'recommend', 'sentinel', 'lymph', 'node', 'biopsy', 'discussed', 'offered', 'patient', 'likelihood', 'detecting', 'positive', 'sln', 'procedure', 'discussed', 'considered', 'likelihood', 'sln', 'metastasis', 'procedure', 'performed', 'risk', 'sln', 'positivity', 'le', 't-stage', 'melanoma', 'tumor', 'determined', 'time', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'diagnosis', 'determines', 'likelihood', 'sln', 'metastasis', 'factor', 'including', 'lymphovascular', 'invasion', 'age', 'uncertain', 'microstaging', 'recommended', 'considered', 'determining', 'risk', 'nodal', 'metastasis', 'association', '-gep', 'test', 'result', 'low-', 'high-', 'risk', 'sln', 'metastasis', 'demonstrated', 'specifically', 'class', 'patient', 'year', 'age', 'older', 'thickness', 'tumor', 'risk', 'positive', 'slnb', 'equivalent', 'risk', 'current', 'guideline', 'would', 'recommend', 'procedure', 'thus', 'patient', 'may', 'safely', 'avoid', 'surgical', 'intervention', 'ass', 'nodal', 'status', 'given', 'patient', 'risk', 'group', 'positive', 'node', 'following', 'slnb', 'maintained', '-year', 'ms', 'rate', 'additionally', 'patient', 'year', 'age', 'class', 'score', 'likelihood', 'positive', 'node', 'conversely', 'patient', 'class', 'b-b', '-gep', 'test', 'result', 'risk', 'sln', 'positivityabove', 'threshold', 'nccn', 'guideline', 'recommend', 'discussing', 'slnb', 'procedure', '-gep', 'test', 'validated', 'prospective', 'studies-', 'including', 'academic', 'non-industry-sponsored', 'systematic', 'review', 'meta-analyses', 'including', 'patient', 'multiple', 'retrospective', 'study', 'study', 'consistently', 'demonstrated', '-gep', 'test', 'offer', 'added', 'value', 'prognostication', 'used', 'combination', 'ajcc', 'staging', 'slnb', 'positivity', 'across', 'different', 'patient', 'group', 'early-stage', 'melanoma', 'recently', 'two', 'large', 'prospective', 'study', 'contemporary', 'data', 'set', 'demonstrated', 'added', 'prognostic', 'accuracy', 'offered', '-gep.', 'sum', '-gep', 'shown', 'vetto', 'inform', 'slnb', 'decision', 'improve', 'sensitivity', 'regarding', 'recurrence', 'distant', 'metastasis', 'melanoma-', 'specific', 'survival', 'overall', 'survival', 'used', 'combination', 'slnb', 'evidenced', 'systematic', 'review', 'meta-analysis', 'greenhaw', 'literature', 'summary', 'rationale', 'key', 'article', 'arnot', 'ap', 'han', 'fortino', 'utility', '-gene', 'expression', 'profile', 'predicting', 'outcome', 'patient', 'primary', 'cutaneous', 'melanoma', 'referred', 'sentinel', 'node', 'biopsy', 'surg', 'study', 'design', 'prospective', 'independent', 'unselected', 'large', 'contemporary', 'data', 'set', 'patient', 'undergoing', 'slnb', 'finding', 'risk', 'regional', 'recurrence', 'distant', 'metastasis', '-gep', 'added', 'prognostic', 'value', 'clinical', 'information', 'predicted', 'recurrence', 'slnb', 'patient', 'recurrence', 'slnb+', 'versus', 'patient', 'recurrence', 'class', 'result', 'risk-stratified', 'patient', 'entire', 'cohort', 'stage', 'i-iii', 'stage', 'i-iia', 'subgroup', 'additional', 'rationale', 'publication', 'support', 'added', 'prognostic', 'accuracy', 'offered', '-gep', 'addition', 'slnb', 'identified', 'patient', 'went', 'develop', 'recurrence', 'slnb', 'seminal', 'mslt-', 'trial', 'demonstrated', 'important', 'prognostic', 'information', 'provided', 'slnb', 'however', 'given', 'patient', 'died', 'melanoma', 'sln-negative', 'risk', 'underestimated', 'traditional', 'staging', 'castle', 'bioscience', 'assert', 'take', 'position', 'slnb', 'valuable', 'replaced', 'rather', 'recommend', 'gep', 'used', 'adjunct', 'traditional', 'staging', 'finding', 'slnb', '-gep', 'predicted', 'slnb', 'positivity', 'class', 'patient', 'positive', 'slnb', 'class', 'patient', 'positive', 'slnb', '-gep', 'added', 'clinical', 'information', 'shown', 'significant', 'hazard', 'ratio', 'gep', 'multivariable', 'analysis', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'long-term', 'outcome', 'multicenter', 'prospective', 'cohort', 'evaluating', 'prognostic', '-gene', 'expression', 'profile', 'cutaneous', 'melanoma', 'jco', 'precis', 'oncol', 'study', 'design', 'prospective', 'multicenter', 'contemporary', 'data', 'set', 'demonstrating', 'long-term', 'outcome', 'patient', 'stage', 'i-iii', 'stage', 'i-iia', 'cutaneous', 'melanoma', 'finding', 'statistically', 'significant', 'separation', 'risk', 'profile', 'patient', 'class', 'class', 'gep', 'result', 'patient', '-gep', 'subclass', 'result', 'endpoint', 'rf', 'dmfs', 'o', 'patient', 'class', 'result', 'excellent', 'outcome', 'rf', 'dmfs', 'o', 'compared', 'class', 'result', 'rf', 'dmfs', 'o', 'overall', 'cohort', 'stage', 'i-iia', 'melanoma', 'rf', 'class', 'class', 'dmfs', 'class', 'class', 'o', 'class', '-gep', 'added', 'sensitivity', 'staging', 'maintaining', 'specificity', 'consistently', 'high', 'npv', 'additional', 'rationale', 'provider', 'routinely', 'use', 'gep', 'aid', 'multidisciplinary', 'decision-making', 'process', 'provider', 'routinely', 'use', 'factor', 'included', 'staging', 'i.e.', 'age', 'mitotic', 'rate', 'lvi', 'etc', 'prognostication', 'preponderance', 'evidence', 'demonstrates', 'gep', 'factor', 'included', 'traditional', 'staging', 'aid', 'accurate', 'risk', 'stratification', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'study', 'design', 'multicenter', 'study', 'examining', 'slnb', 'positivity', 'patient', 't-t', 'melanoma', 'prospectively', 'tested', '-gep', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'finding', 'developed', 'validated', 'model', 'predict', 'slnb', 'positivity', 'based', 'incorporation', 'age', 'breslow', 'thickness', 'gep', 'score', 'patient', 'aged', '-years', 'older', 't-t', 'tumor', 'received', 'class', '-gep', 'result', 'risk', 'positive', 'sln', 'maintaining', '-year', 'ms', 'rate', 'additional', 'rationale', 'publication', 'established', 'independent', 'predictive', 'value', 'model', 'incorporating', '-gep', 'age', 'breslow', 'thickness', 'slnb', 'positivity', 'risk', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'study', 'design', 'systematic', 'review', 'meta-analysis', 'examining', 'prognostic', 'value', '-gep', 'across', 'study', 'finding', '-gep', 'accurately', 'consistently', 'identifies', 'patient', 'cutaneous', 'melanoma', 'increased', 'risk', 'metastasis', '-gep', 'independent', 'clinicopathologic', 'feature', 'improves', 'risk', 'stratification', 'identifying', 'patient', 'high', 'risk', 'metastasis', 'previously', 'identified', 'low', 'risk', 'additional', 'rationale', 'study', 'demonstrated', '-gep', 'slnb', 'considered', 'together', 'dmfs', 'sensitivity', 'negative', 'predictive', 'value', 'improved', 'compared', 'either', 'alone', 'support', 'request', 'gep', 'considered', 'adjunct', 'traditional', 'staging', 'additionally', 'multiple', 'study', 'demonstrated', 'age', 'anticorrelated', 'slnb', 'positivity', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'study', 'design', 'multicenter', 'retrospective', 'analysis', 'large', 'cohort', 'patient', 'stage', 'i-iii', 'melanoma', 'examine', 'outcome', 'patient', 'low-risk', 'melanoma', 'traditional', 'ajcc', 'staging', 'slnb-', 'stage', 'i-iia', 'melanoma', 'finding', '-gep', 'independently', 'predicted', 'outcome', 'patient', 'considered', 'low-risk', 'melanoma', 'traditional', 'staging', 'test', 'demonstrated', 'dmfs', 'patient', 'stage', 'iia', 'melanoma', 'class', 'result', 'versus', 'dmfs', 'patient', 'stage', 'iia', 'melanoma', 'class', 'result', 'additionally', 'test', 'identified', 'sln-negative', 'patient', 'went', 'metastasize', 'demonstrated', 'reduced', 'recurrence-free', 'survival', 'patient', 'thin', 'tumor', 'class', 'result', 'class', 'result', 'independent', 'predictor', 'risk', 'patient', 'stage', 'iia', 'melanoma', 'hr', 'p=', 'patient', 'thin', 'tumor', 'hr', 'p=', 'additional', 'rationale', 'publication', 'support', 'addition', 'gep', 'traditional', 'staging', 'process', 'added', 'independent', 'prognostic', 'information', 'traditionally', 'low-risk', 'patient', 'group', 'stage', 'i-iia', 'whose', 'recurrence', 'may', 'missed', 'traditional', 'staging', 'alone', 'additionally', 'provider', 'consider', 'outcome', 'ms', 'outcome', 'reported', 'ajcc', 'version', 'staging', 'ms', 'important', 'outcome', 'publication', 'offer', 'additional', 'information', 'regarding', 'rf', 'dmfs', 'ms', 'kwatra', 'sg', 'hines', 'semenov', 'yr', 'dermatologist', 'guide', 'implementation', 'gene', 'expression', 'profiling', 'management', 'melanoma', 'clin', 'aesthet', 'dermatol', 'suppl', 's-s.', 'study', 'design', 'expert', 'panel', '-gep', 'test', 'user', 'sought', 'provide', 'clarification', 'use', 'option', 'rational', 'clinical', 'workflow', 'guide', 'appropriate', 'application', '-gep', 'test', 'everyday', 'practice', 'specifically', 'considered', 'role', 'gep', 'prognostication', 'finding', 'author', 'found', '-gep', 'test', 'useful', 'actionable', 'patient', 'care', 'applied', 'accordance', 'current', 'nccn', 'guideline', 'stratification', 'patient', 'low-', 'class', 'intermediate-', 'class', 'high-', 'class', 'risk', 'category', 'inform', 'multidisciplinary', 'conference', 'discussion', 'assist', 'determining', 'intensity', 'imaging', 'surveillance', 'follow-up', 'care', 'author', 'suggest', 'clinical', 'workflow', 'integrates', '-gep', 'testing', 'umbrella', 'current', 'national', 'guideline', 'application', 'test', 'appropriate', 'patient', 'population', 'improve', 'risk', 'assessment', 'inform', 'clinical', 'decision-making', 'including', 'slnb', 'referral', 'decision', 'additional', 'rationale', 'recently', 'published', 'consensus', 'statement', 'mpwg', 'author', 'noted', 'gep', 'could', 'important', 'aspect', 'multidisciplinary', 'decision-making', 'process', 'patient', 'cutaneous', 'melanoma', 'castle', 'bioscience', 'fully', 'support', 'thoughtful', 'use', 'gep', 'adjunct', 'traditional', 'staging', 'process', 'grossman', 'already', 'referenced', 'guideline', 'request', 'point', 'recognized', 'well', 'considering', 'gep', 'fda', 'status', 'decisiondx-melanoma', 'performed', 'central', 'laboratory', 'castle', 'bioscience', 'regulated', 'clinical', 'laboratory', 'improvement', 'amendment', 'clia', 'fda', 'clearance', 'required', 'note', 'commercially', 'available', 'prognostic', 'gene', 'expression', 'profile', 'test', 'cancer', 'site', 'breast', 'prostate', 'fda', 'approved', 'request', 'amendment', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'respectfully', 'submitted', 'castle', 'bioscience', 'castle', 'bioscience', 'inc.', 'nccn', 'guideline', 'melanoma', 'panel', 'reference', 'morton', 'dl', 'thompson', 'jf', 'cochran', 'aj', 'final', 'trial', 'report', 'sentinel-node', 'biopsy', 'versus', 'nodal', 'observation', 'melanoma', 'engl', 'med', 'seer', 'data', 'release', 'arnot', 'ap', 'han', 'fortino', 'utility', '-gene', 'expression', 'profile', 'predicting', 'outcome', 'patient', 'primary', 'cutaneous', 'melanoma', 'referred', 'sentinel', 'node', 'biopsy', 'surg', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'long-term', 'outcome', 'multicenter', 'prospective', 'cohort', 'evaluating', 'prognostic', '-gene', 'expression', 'profile', 'cutaneous', 'melanoma', 'jco', 'precis', 'oncol', 'greenhaw', 'bn', 'zitelli', 'ja', 'brodland', 'dg', 'estimation', 'prognosis', 'invasive', 'cutaneous', 'melanoma', 'independent', 'study', 'accuracy', 'gene', 'expression', 'profile', 'test', 'dermatol', 'surg', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'jh', 'interim', 'analysis', 'survival', 'prospective', 'multi-center', 'registry', 'cohort', 'cutaneous', 'melanoma', 'tested', 'prognostic', '-gene', 'expression', 'profile', 'test', 'hematol', 'oncol', 'keller', 'schwartz', 'tl', 'lizalek', 'jm', 'prospective', 'validation', 'prognostic', '-gene', 'expression', 'profiling', 'test', 'primary', 'cutaneous', 'melanoma', 'cancer', 'med', 'podlipnik', 'carrera', 'boada', 'early', 'outcome', '-gene', 'expression', 'profile', 'test', 'ajcc', 'stage', 'ib-ii', 'melanoma', 'patient', 'prospective', 'multicenter', 'cohort', 'study', 'eur', 'acad', 'dermatol', 'venereol', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'berger', 'ac', 'davidson', 'right', 'poitras', 'jk', 'clinical', 'impact', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'prospectively', 'consecutively', 'tested', 'patient', 'curr', 'med', 're', 'opin', 'dillon', 'ld', 'gadzia', 'je', 'davidson', 'r', 'prospective', 'multicenter', 'clinical', 'impact', 'evaluation', '-gene', 'expression', 'profile', 'test', 'management', 'melanoma', 'patient', 'skin', 'cutan', 'med', 'farberg', 'glazer', 'white', 'impact', '-gene', 'expression', 'profiling', 'test', 'cutaneous', 'melanoma', 'dermatologist', 'clinical', 'management', 'decision', 'drug', 'dermatol', 'gastman', 'zager', 'messina', 'performance', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'head', 'neck', 'head', 'neck', 'litchman', 'gh', 'prado', 'teplitz', 'rw', 'rigel', 'd', 'systematic', 'review', 'meta-analysis', 'gene', 'expression', 'profiling', 'primary', 'cutaneous', 'melanoma', 'prognosis', 'skin', 'cutan', 'med', 'mirsky', 'prado', 'svoboda', 'management', 'decision', 'made', 'physician', 'assistant', 'nurse', 'practitioner', 'cutaneous', 'malignant', 'melanoma', 'patient', 'impact', '-gene', 'expression', 'profile', 'test', 'journal', 'drug', 'dermatology', 'drug', 'dermatol', 'schuitevoerder', 'heath', 'cook', 'rw', 'impact', 'gene', 'expression', 'profiling', 'decision-making', 'clinically', 'node', 'negative', 'melanoma', 'patient', 'surgical', 'staging', 'drug', 'dermatol', 'svoboda', 'glazer', 'farberg', 'factor', 'affecting', 'dermatologist', 'use', '-gene', 'expression', 'profiling', 'testa', 'adjunct', 'predicting', 'metastatic', 'risk', 'cutaneous', 'melanoma', 'drug', 'dermatol', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'zager', 'gastman', 'leachman', 'performance', 'prognostic', '-gene', 'expression', 'profile', 'independent', 'cohort', 'cutaneous', 'melanoma', 'patient', 'bmc', 'cancer', 'ferris', 'lk', 'farberg', 'middlebrook', 'identification', 'high-risk', 'cutaneous', 'melanoma', 'tumor', 'improved', 'combining', 'online', 'american', 'joint', 'committee', 'cancer', 'individualized', 'melanoma', 'patient', 'outcome', 'prediction', 'tool', '-gene', 'expression', 'profile-based', 'classification', 'acad', 'dermatol', '-.e', '..', 'rigel', 'ceilley', 'litchman', 'gene', 'expression', 'profile', 'testing', 'skin', 'cancer', 'prognosis', 'data', 'clear', '–it', 'time', 'get', 'board', 'skin', 'cutan', 'med', 'hanna', 'sinnamon', 'aj', 'rose', 'relationship', 'age', 'likelihood', 'lymph', 'node', 'metastasis', 'patient', 'intermediate', 'thickness', 'melanoma', '.-.mm', 'national', 'cancer', 'database', 'study', 'acad', 'dermatol', 'sinnamon', 'aj', 'neuwirth', 'mg', 'yalamanchi', 'association', 'patient', 'age', 'lymph', 'node', 'positivity', 'thin', 'melanoma', 'jama', 'dermatol', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'kwatra', 'sg', 'hines', 'semenov', 'yr', 'dermatologist', 'guide', 'implementation', 'gene', 'expression', 'profiling', 'management', 'melanoma', 'clin', 'aesthet', 'dermatol', 'suppl', 's-s.', 'pmid', 'grossman', 'okwundu', 'bartlett', 'ek', 'prognostic', 'gene', 'expression', 'profiling', 'cutaneous', 'melanoma', 'identifying', 'knowledge', 'gap', 'assessing', 'clinical', 'benefit', 'jama', 'dermatol']}, {'filename': '2020_06_23_Northwestern.pdf', 'timestamp': datetime.datetime(2020, 6, 23, 0, 0), 'text': ['submitted', 'name', 'june', 'k.', 'robinson', 'md', 'research', 'professor', 'dermatology', 'company/organization', 'northwestern', 'university', 'feinberg', 'school', 'medicine', 'department', 'dermatology', 'address', 'n.', 'michigan', 'ave', 'suite', 'chicago', 'il', 'phone', 'email', 'june-robinson', 'northwestern.edu', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'june', 'nccn', 'cutaneous', 'melanoma', 'panel', 'submission', 'nccn.org', 'dermtech', 'pigmented', 'lesion', 'assay', 'dear', 'member', 'committee', 'evaluating', 'pigmented', 'lesion', 'assay', 'pla', 'non-invasive', 'melanoma', 'rule-out', 'test', 'favorable', 'inclusion', 'nccn', 'guideline', 'ask', 'consider', 'perspective', 'based', 'year', 'experience', 'managing', 'care', 'patient', 'pigmented', 'skin', 'lesion', 'dermatologist', 'research', 'professor', 'northwestern', 'university', 'feinberg', 'school', 'medicine', 'career', 'focused', 'early', 'identification', 'skin', 'cancer', 'especially', 'melanoma', 'ample', 'opportunity', 'train', 'talented', 'medical', 'student', 'dermatology', 'primary', 'care', 'resident', 'fellow', 'dermatology', 'primary', 'care', 'faculty', 'member', 'perform', 'skin', 'examination', 'detect', 'melanoma', 'research', 'effort', 'included', 'training', 'patient', 'skin', 'self-examination', 'one', 'goal', 'educate', 'make', 'physician', 'aware', 'optimize', 'melanoma', 'detection', 'pathway', 'existing', 'standard', 'care', 'visual', 'examination', 'biopsy', 'histopathology', 'largely', 'subjective', 'relies', 'heavily', 'clinician', 'level', 'education', 'past', 'current', 'experience', 'examining', 'patient', 'melanoma', 'training', 'availability', 'diagnostic', 'tool', 'i.e.', 'dermoscopy', 'proficiency', 'using', 'critical', 'improve', 'diagnostic', 'accuracy', 'clinical', 'histopathological', 'criterion', 'minimize', 'risk', 'harm', 'related', 'screening', 'at-risk', 'patient', 'melanoma', 'histopathologic', 'diagnosis', 'remains', 'gold', 'standard', 'proven', 'limitation', 'landmark', 'study', 'elmore', 'colleague', 'addressed', 'performance', 'dermatopathologists', 'pathologist', 'evaluation', 'pigmented', 'skin', 'lesion', 'bmj', 'demonstrated', 'poor', 'intra-observer', 'reproducibility', 'diagnostic', 'accuracy', 'discordance', 'across', 'spectrum', 'melanocytic', 'skin', 'lesion', 'unexpected', 'poor', 'diagnostic', 'accuracy', 'melanoma', 'situ', 'severely', 'dysplastic', 'nevus', 'accuracy', 'thin', 'invasive', 'melanoma', 'accuracy', 'thick', 'melanoma', 'concerning', 'important', 'department', 'dermatology', 'michigan', 'ave', 'suite', 'chicago', 'il', 'phone', 'june-robinson', 'northwestern.edu', 'june', 'k.', 'robinson', 'md', 'research', 'professor', 'dermatology', 'northwestern', 'university', 'june', 'k.', 'robinson', 'md', 'june', 'page', 'improve', 'diagnostic', 'accuracy', 'decrease', 'false', 'positive', 'may', 'result', 'unnecessary', 'surgery', 'psychological', 'harm', 'critical', 'reduce', 'false', 'negative', 'diagnosis', 'may', 'increase', 'morbidity', 'provides', 'solid', 'rationale', 'additional', 'technology', 'identify', 'marker', 'assist', 'diagnosis', 'genomic', 'test', 'like', 'pigmented', 'lesion', 'assay', 'pla', 'based', 'searchable', 'peer', 'reviewed', 'publication', 'help', 'address', 'deficiency', 'existing', 'care', 'standard', 'request', 'nccn', 'consider', 'available', 'evidence', 'provide', 'feedback', 'required', 'key', 'category', 'requested', 'specific', 'change', 'relative', 'version', 'me-', 'page', 'pigmented', 'lesion', 'assay', 'considered', 'non-invasive', 'test', 'guide', 'decision', 'perform', 'surgical', 'biopsy', 'difficult', 'ass', 'melanocytic', 'lesion', 'recommend', 'deleting', 'last', 'sentence', 'bullet', 'point', 'number', 'fda', 'pla', 'clia', 'fda', 'administered', 'test', 'rationale', 'genomic', 'test', 'like', 'pigmented', 'lesion', 'assay', 'pla', 'based', 'searchable', 'peer', 'reviewed', 'publication', 'help', 'address', 'deficiency', 'existing', 'care', 'standard', 'please', 'see', 'detail', 'recent', 'research', 'demonstrates', 'physician-supervised', 'pla', 'skin', 'sample', 'collection', 'patient', 'viable', 'non-invasive', 'specimen', 'collection', 'option', 'highlighting', 'pla', 'applicability', 'versatility', 'traditional', 'transitioning', 'teledermatology', 'paradigm', 'current', 'coronavirus', 'pandemic', 'many', 'dermatology', 'office', 'unable', 'provide', 'direct', 'patient', 'care', 'pre-biopsy', 'pla', 'support', 'clinician', 'effort', 'provide', 'objective', 'diagnosis', 'regardless', 'setting', 'provides', 'clinician', 'comfort', 'missing', 'fewer', 'melanoma', 'reduces', 'patient', 'anxiety', 'skin', 'biopsy', 'enhances', 'patient', 'trust', 'physician', 'provide', 'care', 'remotely', 'bridge', 'gap', 'providing', 'physician', 'surveillance', 'melanoma', 'survivor', 'clinical', 'office', 'fully', 'support', 'incorporation', 'pla', 'nccn', 'guideline', 'evidence', 'block', 'aide', 'clinician', 'diagnosis', 'pigmented', 'skin', 'lesion', 'pla', 'avoids', 'unnecessary', 'biopsy', 'enables', 'better', 'diagnostic', 'interpretation', 'regardless', 'setting', 'allows', 'consistent', 'objective', 'result', 'appreciate', 'nccn', 'guideline', 'version', 'concentrated', 'management', 'cutaneous', 'melanoma', 'following', 'pathologic', 'diagnosis', 'time', 'reassess', 'position', 'question', 'regarding', 'request', 'include', 'pla', 'pre-diagnostic', 'technology', 'inform', 'decision', 'biopsy', 'next', 'version', 'cutaneous', 'melanoma', 'guideline', 'please', 'hesitate', 'contact', 'email', 'june-robinson', 'northwestern.edu', 'set', 'time', 'speak', 'summary', 'recommendation', 'pigmented', 'lesion', 'assay', 'considered', 'non-invasive', 'test', 'guide', 'decision', 'perform', 'surgical', 'biopsy', 'difficult', 'ass', 'melanocytic', 'lesion', 'sincerely', 'june', 'k.', 'robinson', 'md', 'following', 'article', 'submitted', 'support', 'proposed', 'change', 'pdfs', 'attached', 'june', 'k.', 'robinson', 'md', 'june', 'page', 'elmore', 'bmj', 'pathology', 'comparator', 'ferris', 'doj', 'pla', 'clin', 'utility', 'gerami', 'jaad', 'pla', 'clin', 'validation', 'brouha', 'jdd', 'pla', 'clin', 'utility', 'ferris', 'jid', 'pla', 'clin', 'validation', 'robinson', 'skin', 'pla', 'clin', 'utility']}, {'filename': '2020_09_15_Foundation.pdf', 'timestamp': datetime.datetime(2020, 9, 15, 0, 0), 'text': ['submitted', 'brian', 'alexander', 'md', 'company', 'foundation', 'medicine', 'inc.', 'address', 'second', 'street', 'cambridge', 'phone', 'ext', 'email', 'balexander', 'foundationmedicine.com', 'date', 'request', 'original', 'submission', 'june', 'highlighted', 'update', 'september', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'panel', 'member', 'behalf', 'foundation', 'medicine', 'respectfully', 'request', 'nccn®', 'cutaneous', 'melanoma', 'guideline', 'panel', 'consider', 'requested', 'update', 'pertaining', 'evaluation', 'management', 'patient', 'melanoma', 'requested', 'update', 'amend', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'include', 'following', 'tumor', 'mutational', 'burden', 'tmb', 'measured', 'reported', 'targeted', 'ng', 'panel', 'validated', 'and/or', 'fda-approved', 'per', 'recommendation', 'outlined', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'remove', 'last', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'use', 'mutation', 'burden', 'guide', 'treatment', 'decision', 'remains', 'investigational', 'time', 'rationale', 'requested', 'update', 'keynote-', 'nct', 'multicohort', 'single-arm', 'open-label', 'phase', 'study', 'evaluating', 'pembrolizumab', 'monotherapy', 'patient', 'selected', 'previously', 'treated', 'advanced', 'solid', 'tumor', 'administered', 'pembrolizumab', 'mg', 'every', 'week', 'intravenous', 'infusion', 'patient', 'evaluable', 'tissue', 'tmb', 'ttmb', 'score', 'efficacy', 'population', 'ttmb-high', 'defined', 'mutations/megabase', 'per', 'foundationone', 'cdx', 'panel', 'assessed', 'safety', 'patient', 'enrolled', 'least', 'week', 'data', 'cutoff', 'evaluable', 'tmb', 'included', 'efficacy', 'analysis', 'patient', 'ttmb-high', 'status', 'ttmb-high', 'status', 'associated', 'clinically', 'meaningful', 'improvement', 'demonstrated', 'objective', 'response', 'rate', 'orr', 'ci', 'compared', 'ci', 'non-ttmb-high', 'group', 'primary', 'endpoint', 'median', 'follow-up', 'month', 'iqr', '.-', 'median', 'duration', 'response', 'reached', 'ttmb-', 'high', 'group', 'month', 'non-ttmb-high', 'group', 'additional', 'secondary', 'outcome', 'landmark', 'timepoints', 'include', '-year', 'rate', 'ci', 'ttmb-high', 'group', 'ci', 'non‒ttmb-high', 'group', '-year', 'o', 'rate', 'ci', 'ttmb-high', 'group', 'versus', 'ci', 'non‒ttmb-high', 'group', 'predictive', 'value', 'ttmb', 'independent', 'biomarkers', 'including', 'microsatellite', 'instability', 'msi', '-high', 'pd-l', 'expression', 'additionally', 'predictive', 'value', 'ttmb', 'appear', 'driven', 'particular', 'tumor', 'type', 'increased', 'response', 'rate', 'tmb-high', 'patient', 'observed', 'across', 'tumor', 'type', 'based', 'result', 'keynote-', 'pembrolizumab', 'fda-approved', 'patient', 'unresectable', 'metastatic', 'solid', 'tumor', 'ttmb-high', 'mutations/megabase', 'determined', 'fda-approved', 'test', 'progressed', 'following', 'prior', 'treatment', 'satisfactory', 'alternative', 'treatment', 'option', 'tmb', 'complex', 'continuous', 'biomarker', 'tmb', 'estimation', 'provided', 'next', 'generation', 'sequencing', 'ng', 'targeted', 'panel', 'vary', 'across', 'laboratory', 'due', 'factor', 'difference', 'panel', 'size', 'gene', 'coverage', 'bioinformatics', 'pipeline', 'important', 'role', 'tmb', 'play', 'clinical', 'decision-making', 'potential', 'variation', 'across', 'laboratory', 'friend', 'cancer', 'research', 'convened', 'consortium', 'key', 'stakeholder', 'recommend', 'best', 'practice', 'approach', 'tmb', 'measurement', 'validation', 'alignment', 'reporting', 'stakeholder', 'including', 'fda', 'national', 'cancer', 'institute', 'diagnostic', 'manufacturer', 'academic', 'pharmaceutical', 'company', 'published', 'detailed', 'recommendation', 'around', 'tmb', 'reporting', 'consistency', 'standardization', 'analytical', 'validation', 'study', 'tmb', 'estimation', 'alignment', 'panel', 'tmb', 'value', 'whole', 'exome', 'sequencing', 'wes', '-derived', 'universal', 'reference', 'standard', 'test', 'report', 'tmb', 'value', 'comply', 'recommendation', 'published', 'and/or', 'fda-approved', 'tmb', 'measurement', 'reporting', 'purpose', 'thank', 'review', 'submission', 'sincerely', 'brian', 'alexander', 'm.d', 'chief', 'medical', 'officer', 'foundation', 'medicine', 'reference', 'marabelle', 'fakih', 'lopez', 'association', 'tumour', 'mutational', 'burden', 'outcome', 'patient', 'advanced', 'solid', 'tumour', 'treated', 'pembrolizumab', 'prospective', 'biomarker', 'analysis', 'multicohort', 'open-label', 'phase', 'keynote-', 'study', 'published', 'online', 'ahead', 'print', 'sep', 'lancet', 'oncol', 's-', 'keytruda', 'pembrolizumab', 'fda', 'approved', 'label', 'found', 'http', '//www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf', 'fda', 'label', 'foundation', 'medicine', 'inc.', 'foundationone®', 'cdx', 'technical', 'information', 'attached', 'merino', 'dm', 'mcshane', 'lm', 'fabrizio', 'establishing', 'guideline', 'harmonize', 'tumor', 'mutational', 'burden', 'tmb', 'silico', 'assessment', 'variation', 'tmb', 'quantification', 'across', 'diagnostic', 'platform', 'phase', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'immunother', 'cancer', 'e.', 'chalmers', 'zr', 'connelly', 'cf', 'fabrizio', 'analysis', 'human', 'cancer', 'genome', 'reveals', 'landscape', 'tumor', 'mutational', 'burden', 'genome', 'med', 'published', 'apr', 'doi', './s']}, {'filename': '2021_06_11_Astro.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['email', 'submission', 'nccn.org', 'date', 'request', 'june', 'american', 'society', 'radiation', 'oncology', 'reviewed', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'gap', 'relative', 'radiation', 'therapy', 'offer', 'two', 'major', 'recommendation', 'supported', 'evidence-based', 'rationale', 'one', 'minor', 'recommendation', 'consideration', 'hope', 'find', 'recommendation', 'useful', 'panel', 'review', 'update', 'guideline', 'sincerely', 'laura', 'i.', 'thevenot', 'chief', 'executive', 'officer', 'american', 'society', 'radiation', 'oncology', 'major', 'recommendation', 'treatment', 'metastatic', 'disease', 'recommend', 'removing', 'page', 'me-', 'me-', 'resectable', 'limited', 'unresectable', 'disseminated', 'sbrt', 'listed', 'alongside', 'resection', 'management', 'limited', 'distant', 'metastatic', 'disease', 'rationale', 'cut', 'point', 'widespread', 'disease', 'limited', 'metastatic', 'disease', 'solely', 'discretion', 'surgeon', 'low-volume', 'brain', 'metastasis', 'low-volume', 'extracranial', 'even', 'unresectable', 'disease', 'effectively', 'managed', 'sbrt', 'sbrt', 'listed', 'alongside', 'resection', 'management', 'limited', 'distant', 'metastatic', 'disease', 'randomized', 'data', 'supporting', 'sbrt', 'oligometastatic', 'disease', 'whereas', 'randomized', 'data', 'practice', 'surgical', 'resection', 'strictly', 'speaking', 'sbrt', 'preferred', 'option', 'based', 'level', 'evidence', 'considered', 'guideline', 'randomized', 'data', 'support', 'use', 'stereotactic', 'body', 'radiotherapy', 'sbrt', 'ablative', 'treatment', 'oligometastatic', 'disease', 'lesion', 'demonstrable', 'benefit', 'progression-free', 'survival', 'overall', 'survival', '..', 'sabrt-comet', 'enrolled', 'histology', 'demonstrated', 'sbrt', 'associated', '-year', 'o', 'versus', 'patient', 'managed', 'standard', 'systemic', 'therapy', 'alone', 'p=.', 'standard', 'consideration', 'patient', 'oligometastatic', 'disease', 'furthermore', 'line', 'intracranial', 'control', 'demonstrated', 'radiosurgery', 'dosing', 'melanoma-specific', 'data', 'demonstrates', 'sufficient', 'sbrt', 'dos', 'achieve', 'metastatic', 'lesion', 'control', 'year', 'approximately', 'year', 'countering', 'long-held', 'belief', 'melanoma', 'metastasis', 'insensitive', 'radiotherapy', 'additionally', 'sbrt', 'modeled', 'cost-effective', 'strategy', 'melanoma', 'pulmonary', 'oligometastases', 'surgical', 'resetion', 'reference', 'palma', 'da', 'clin', 'oncol', 'sep', 'pmid', 'palma', 'da', 'lancet', 'may', 'pmid', 'youland', 'r', 'adv', 'radiat', 'oncol', 'feb', 'pmid', 'lester-coll', 'nh', 'int', 'radiat', 'oncol', 'biol', 'phys', 'jun', 'pmdi', 'major', 'recommendation', 'me-l', 'recommend', 'removing', 'section', 'titled', 'selection', 'initial', 'treatment', 'modality', 'instead', 'propose', 'listing', 'best', 'systemic', 'therapy', 'plus', 'brain-directed', 'therapy', 'first', 'step', 'principle', 'brain', 'metastasis', 'management', 'bullet', 'point', 'heading', 'state', 'highly', 'select', 'patient', 'evaluated', 'multidisciplinary', 'setting', 'systemic', 'therapy', 'alone', 'close', 'observation', 'intracranial', 'response', 'may', 'appropriate.', 'rationale', 'neurosurgeon', 'radiation', 'oncologist', 'illusion', 'resection', 'and/or', 'sr', 'displacing', 'need', 'systemic', 'therapy', 'setting', 'intracranial', 'metastasis', 'either/or', 'choice', 'brain-directed', 'therapy', 'performed', 'context', 'best', 'systemic', 'therapy', 'either', 'ongoing', 'planned', 'shortly', 'thereafter', 'framing', 'presented', 'selection', 'initial', 'treatment', 'modality', 'however', 'make', 'seem', 'systemic', 'therapy', 'indicated', 'almost', 'always', 'local', 'therapy', 'considered', 'parallel', 'decade', 'brain', 'metastasis', 'management', 'clearly', 'contradicts', 'presented', 'dichotomy', 'furthermore', 'presence', 'absence', 'symptom', 'key', 'determinant', 'suggested', 'bullet', 'point', 'page', 'lesion', 'becomes', 'symptomatic', 'sr', 'often', 'feasible', 'craniotomy', 'required', 'avoided', 'asymptomatic', 'window', 'usually', 'ideal', 'time', 'intervene', 'randomized', 'study', 'ipi/nivo', 'nivo', 'alone', 'studied', 'brain', 'metastasis', 'resulted', 'intracranial', 'progression', 'rate', 'craniotomy', 'death', 'ascribed', 'intracranial', 'progression', 'patient', 'offered', 'upfront', 'brain-directed', 'therapy', 'study', 'supported', 'omission', 'brain-directed', 'therapy', 'rather', 'study', 'demonstrated', 'danger', 'omitting', 'brain-directed', 'therapy', 'systemic', 'therapy', 'alone', 'randomized', 'study', 'braf/mek', 'inhibition', 'lieu', 'brain-directed', 'therapy', 'similar', 'concerning', 'finding', 'patient', 'afforded', 'radiosurgery', 'requiring', 'craniotomy', 'tucked', 'away', 'appendix', 'overall', 'recommend', 'strengthening', 'need', 'formal', 'cns', 'specialist', 'evaluation', 'weakening', 'option', 'systemic', 'therapy', 'alone', 'practice', 'brain-directed', 'therapy', 'established', 'standard', 'care', 'brain', 'metastatic', 'management', 'per', 'numerous', 'radiation', 'oncology', 'neurosurgical', 'randomized', 'study', 'always', 'context', 'best', 'systemic', 'therapy', 'systemic', 'therapy', 'alone', 'versus', 'standard', 'never', 'examined', 'randomized', 'fashion', 'reference', 'long', 'gv', 'lancet', 'oncol', 'may', 'pmid', 'kruser', 'tj', 'lancet', 'oncol', 'aug', 'e.', 'pmid', 'davy', 'lancet', 'oncol', 'jul', 'pmid', 'minor', 'recommendation', 'me-', 'me-', 'recommend', 'footnote', 'describing', 'role', 'adjuvant', 'rt', 'desmoplastic', 'histology', 'selected', 'patient', 'positive', 'margin', 'surgery…consider…rt', 'rationale', 'agree', 'note', 'page', 'me-h', 'page', 'adjuvant', 'rt', 'may', 'considered', 'high-risk', 'desmoplastic', 'melanoma', 'however', 'preceding', 'footnote', 'pathway', 'would', 'guide', 'surgeon', 'medical', 'oncologist', 'seeing', 'clinical', 'patient', 'find', 'recommendation', 'reference', 'included', 'reference', 'principle', 'rt', 'melanoma', 'page', 'section', 'me-h', 'nicely', 'support', 'recommendation']}, {'filename': '2020_06_21_DermatologicSurgeryWashington.pdf', 'timestamp': datetime.datetime(2020, 6, 21, 0, 0), 'text': ['submitted', 'gary', 'l.', 'peck', 'md', 'company/organization', 'dermatologic', 'surgery', 'center', 'washington', 'address', 'wisconsin', 'avenue', 'suite', 'chevy', 'chase', 'md', 'phone', 'email', 'garypeck', 'gmail.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'clinical', 'utility', 'dermtech', 'pigmented', 'lesion', 'assay', 'experience', 'director', 'melanoma', 'center', 'washington', 'hospital', 'center', 'washington', 'dc', 'included', 'accruing', 'melanoma', 'patient', 'greater', 'number', 'patient', 'multiple', 'atypical', 'nevus', 'average', 'lesion', 'count', 'many', 'patient', 'nevus', 'including', 'one', 'found', 'upon', 'long-term', 'monitoring', 'high-risk', 'group', 'patient', 'multiple', 'nevus', 'melanoma', 'arose', 'de', 'novo', 'previously', 'uninvolved', 'skin', 'arose', 'pre-existing', 'nevus', 'concluded', 'make', 'good', 'medical', 'sense', 'remove', 'large', 'number', 'nevus', 'order', 'attempt', 'decrease', 'risk', 'melanoma', 'formation', 'many', 'patient', 'melanoma', 'center', 'history', 'numerous', 'biopsy', 'benign', 'mildly', 'atypical', 'nevus', 'patient', 'objected', 'biopsy', 'pain', 'procedure', 'time', 'wound', 'healing', 'appearance', 'scar', 'anxiety', 'caused', 'time', 'waiting', 'biopsy', 'result', 'moreover', 'two', 'patient', 'history', 'biopsy', 'benign', 'lesion', 'prior', 'entry', 'clinic', 'since', 'relied', 'upon', 'dermoscopic', 'evaluation', 'patient', 'nevus', 'determine', 'lesion', 'biopsy', 'routine', 'use', 'dermoscopy', 'increased', 'diagnostic', 'ability', 'reduced', 'number', 'unnecessary', 'biopsy', 'remains', 'room', 'improvement', 'specifically', 'dermoscopy', 'method', 'available', 'rely', 'largely', 'clinician', 'experience', 'education', 'training', 'large', 'disparity', 'within', 'medical', 'community', 'ability', 'utilize', 'diagnostic', 'tool', 'accurately', 'diagnosis', 'early', 'stage', 'melanoma', 'retiring', 'melanoma', 'center', 'washington', 'hospital', 'center', 'continue', 'care', 'high-risk', 'patient', 'large', 'number', 'nevus', 'dermatologic', 'surgery', 'center', 'washington', 'joined', 'july', 'almost', 'year', 'routinely', 'performed', 'pigmented', 'lesion', 'assay', 'pla', 'pre-biopsy', 'tool', 'testing', 'clinically', 'dermoscopically', 'atypical', 'lesion', 'improve', 'diagnostic', 'accuracy', 'able', 'diagnose', 'smaller', 'melanoma', 'earlier', 'stage', 'avoid', 'unnecessary', 'surgical', 'procedure', 'almost', 'melanoma', 'diagnosed', 'since', 'began', 'using', 'pla', 'small', 'le', 'mm', 'melanoma', 'situ', 'since', 'member', 'clinical', 'staff', 'use', 'pla', 'frequently', 'found', 'lesion', 'test', 'reported', 'pla-positive', 'thus', 'patient', 'saved', 'unnecessary', 'surgical', 'biopsy', 'reasonable', 'suggest', 'gene', 'expression', 'change', 'may', 'occur', 'prior', 'development', 'histopathologically', 'diagnosable', 'melanoma', 'therefore', 'quite', 'possible', 'pla', 'test', 'may', 'finding', 'pre-melanoma', 'lesion', 'eventually', 'would', 'evolved', 'pathologically', 'diagnosable', 'melanoma', 'fact', 'pla-positive', 'lesion', 'labeled', 'false', 'positive', 'biopsy', 'reported', 'severely', 'atypical', 'nevus', 'believe', 'pla', 'capable', 'identifying', 'small', 'melanoma', 'situ', 'still', 'dramatically', 'reducing', 'biopsy', 'rate', 'regarding', 'issue', 'false', 'negative', 'diagnosis', 'part', 'problem', 'might', 'difficulty', 'differential', 'diagnosis', 'melanoma', 'situ', 'severely', 'atypical', 'nevus', 'pathologist', 'example', 'pathologist', 'different', 'threshold', 'number', 'cell', 'exhibiting', 'pagetoid', 'spread', 'leading', 'diagnosis', 'mi', 'rather', 'atypical', 'nevus', 'addition', 'variation', 'evaluating', 'pagetoid', 'spread', 'pathologist', 'may', 'vary', 'evaluation', 'criterion', 'degree', 'cytologic', 'atypia', 'highlight', 'value', 'pla', 'brings', 'practice', 'pla', 'provides', 'negative', 'result', 'choose', 'biopsy', 'time', 'monitor', 'closely', 'regular', 'schedule', 'patient', 'informed', 'return', 'clinic', 'immediately', 'lesion', 'change', 'prior', 'next', 'scheduled', 'visit', 'follow-up', 'examination', 'always', 're-examine', 'lesion', 'previously', 'tested', 'pla', 'reported', 'negative', 'change', 'appearance', 'previously', 'pla-', 'negative', 'lesion', 'follow-up', 'examination', 'either', 'repeat', 'pla', 'testing', 'biopsy', 'lesion', 'depending', 'nature', 'change', 'found', 'pla', 'rule-out', 'testing', 'sensitive', 'reliable', 'useful', 'adjunct', 'dermoscopy', 'use', 'pla', 'enables', 'earlier', 'diagnosis', 'melanoma', 'including', 'meet', 'usual', 'clinical', 'dermoscopic', 'criterion', 'malignancy', 'test', 'asset', 'clinician', 'involved', 'diagnosis', 'skin', 'cancer', 'expert', 'dermoscopy', 'creates', 'objective', 'standard', 'provided', 'care', 'patient', 'melanoma', 'year', 'test', 'like', 'pla', 'provides', 'objectivity', 'particularly', 'difficult', 'diagnose', 'case', 'transformative', 'evaluation', 'pigmented', 'skin', 'lesion', 'please', 'allow', 'offer', 'information', 'specific', 'request', 'nccn', 'melanoma', 'guideline', 'panel', 'recommending', 'inclusion', 'pla', 'helpful', 'tool', 'updated', 'cutaneous', 'melanoma', 'guideline', 'specific', 'change', 'me-', 'pre-diagnostic', 'clinical', 'modality', 'recommend', 'deleting', 'last', 'sentence', 'replace', 'clinical', 'utility', 'pre-diagnostic', 'biopsy-guiding', 'noninvasive', 'genomic', 'patch', 'testing', 'established', 'use', 'technology', 'warranted', 'support', 'biopsy', 'decisions.', 'fda', 'pla', 'clia', 'ldt', 'test', 'sample', 'collector', 'fda', 'compliant', 'class', 'device', 'rationale', 'availability', 'abundance', 'peer', 'reviewed', 'evidence', 'clinical', 'validity', 'clinical', 'utility', 'noninvasive', 'pla', 'guiding', 'biopsy', 'decision', 'reducing', 'avoidable', 'pigmented', 'lesion', 'biopsy', 'missing', 'fewer', 'melanoma', 'npv', 'providing', 'key', 'validation', 'gerami', 'jaad', 'ferris', 'jid', 'key', 'utility', 'ferris', 'doj', 'brouha', 'jdd', 'peer', 'reviewed', 'publication', 'facilitate', 'review', 'question', 'regarding', 'use', 'pla', 'please', 'hesitate', 'contact', 'sincerely', 'gary', 'l.', 'peck', 'md', 'director', 'emeritus', 'melanoma', 'center', 'washington', 'cancer', 'institute', 'washington', 'hospital', 'center', 'washington', 'dc']}, {'filename': '2020_06_17_Castle.pdf', 'timestamp': datetime.datetime(2020, 6, 17, 0, 0), 'text': ['submitted', 'name', 'jay', 'braxton', 'pharmd', 'executive', 'director', 'medical', 'affair', 'company', 'castle', 'bioscience', 'inc.', 'address', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'tx', 'phone', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'request', '//', 'nccn', 'guideline', 'panel', 'melanoma', 'castle', 'bioscience', 'inc.', 'would', 'like', 'thank', 'nccn', 'panel', 'updating', 'guidance', 'gene', 'expression', 'profiling', 'gep', 'guideline', 'version', 'appreciate', 'fact', 'panel', 'recognizes', 'gep', 'adjunct', 'staging', 'evidence', 'supporting', 'gep', 'stronger', 'represented', 'guideline', 'respectfully', 'request', 'following', 'recent', 'publication', 'regarding', 'decisiondx-melanoma', 'test', '-gep', 'considered', 'updating', 'language', 'better', 'reflect', 'available', 'evidence', 'two', 'recent', 'meta-analyses', 'multiple', 'prospective', 'clinical', 'validity', 'study', 'prospective', 'retrospective', 'clinical', 'utility-', 'study', 'suggested', 'change', 'included', 'rationale', 'literature', 'summary', 'rationale', 'literature', 'summary', 'clinical', 'validation', '-gep', 'test', 'validated', 'prospective', 'study', 'including', 'academic', 'non-industry-', 'sponsored', 'systematic', 'review', 'meta-analyses', 'including', 'patients-', 'multiple', 'retrospective', 'studies-', 'study', 'consistently', 'shown', '-gep', 'test', 'added', 'impact', 'prognostication', 'combination', 'ajcc', 'staging', 'slnb', 'across', 'different', 'patient', 'group', 'early-stage', 'melanoma', 'summary', 'finding', '-gep', 'study', 'design', 'class', 'class', 'outcome', 'ref', 'gep', 'add', 'prognostic', 'information', 'current', 'staging', 'factor', 'increase', 'identification', 'high-risk', 'patient', 'including', 'diagnosed', 'early', 'stage', 'disease', 'prospective', '-y', 'rf', '-y', 'dmfs', '-y', 'o', 'academic-sponsored', 'gep', 'class', 'patient', 'time', 'likely', 'develop', 'metastasis', 'author', 'offer', 'gep', 'melanoma', 'patient', 'prospective', '-y', 'rf', '-y', 'o', 'sensitivity', 'npv', 'academic-sponsored', 'gep', 'class', 'result', 'significant', 'independent', 'predictor', 'metastasis', 'context', 'clinicopathologic', 'feature', 'used', 'staging', 'gep', 'class', 'result', 'accurately', 'identified', 'slnb-negative', 'patient', 'experienced', 'recurrence', 'prospective', '-y', 'rf', '-y', 'dmfs', 'academic-sponsored', 'gep', 'identified', 'recurrence', 'risk', 'stage', 'ib-ii', 'patient', 'including', 'low-risk', 'ajcc', 'stage', 'prospective', 'rate', 'recurrence', 'sensitivity', 'large', 'study', 'gep', 'identified', 't-t', 'melanoma', 'low', 'risk', 'slnb', 'positivity', 'prospective', 'sln', 'positivity', 'meta-analysis', 'gep', 'consistently', 'accurately', 'predicts', 'recurrence', 'distant', 'metastasis', 'across', 'ajcc', 'stage', 'i-iii', 'across', 'multiple', 'study', 'augments', 'ability', 'identify', 'high-risk', 'patient', 'meta-analysis', '-y', 'rf', '-y', 'dmfs', 'gep', 'identified', 'patient', 'likely', 'recur', 'within', 'traditionally', 'low-risk', 'patient', 'slnb-negative', 'stage', 'i-iia', '≤mm', 'tumor', 'study', 'reporting', 'combined', 'previous', 'cohort', 'retrospective', 'rf', 'dmfs', 'melanoma', 'o', 'gep', 'improved', 'identification', 'high-risk', 'melanoma', 'combined', 'ajcc', 'prediction', 'stage', 'i-ii', 'patient', 'indicating', 'test', 'provides', 'additional', 'prognostic', 'information', 'traditional', 'staging', 'retrospective', 'ajcc', 'low-risk', '-y', 'rf', '-y', 'dmfs', '-y', 'o', 'ajcc', 'high-risk', '-y', 'rf', 'dmfs', '-y', 'o', 'reported', 'disease-free', 'survival', 'class', 'class', 'b.', 'castle', 'bioscience', 'inc.', 'submission', 'nccn', 'guideline', 'panel', 'melanoma', 'page', 'clinical', 'utility', 'prospective', 'retrospective', 'study', 'including', 'total', 'patient', 'prospectively', 'tested', 'showed', 'impact', '-gep', 'test', 'treatment', 'management', 'decisions.-', 'recently', 'expert', 'consensus', 'panel', 'convened', 'national', 'society', 'cutaneous', 'medicine', 'provided', 'evidence-based', 'recommendation', '-gep', 'testing', 'appropriate', 'use', 'criterion', 'statement', 'suggested', 'change', 'based', 'evidence', 'presented', 'please', 'consider', 'following', 'suggested', 'change', 'me-', 'me-', 'me-', 'footnote', 'prognostic', 'gene', 'expression', 'profiling', '-gep', 'differentiate', 'melanoma', 'low', 'versus', 'high', 'risk', 'metastasis', 'may', 'provide', 'information', 'individual', 'risk', 'recurrence', 'adjunct', 'standard', 'ajcc', 'staging', 'however', 'currently', 'available', 'prognostic', 'molecular', 'technique', 'replace', 'pathologic', 'staging', 'procedures.', 'use', 'gep', 'testing', 'according', 'specific', 'melanoma', 'stage', 'sentinel', 'lymph', 'node', 'biopsy', 'slnb', 'requires', 'prospective', 'investigation', 'large', 'contemporary', 'data', 'set', 'unselected', 'patients.', 'me-c', 'prognostic', 'testing', 'bullet', 'commercially', 'available', 'gep', 'test', 'marketed', 'able', 'classify', 'cutaneous', 'melanoma', 'separate', 'category', 'based', 'risk', 'metastasis', 'however', 'remains', 'unclear', 'whether', 'five', 'prospective', 'study', 'two', 'meta-analyses', 'shown', '-gep', 'test', 'provides', 'clinically', 'actionable', 'prognostic', 'information', 'used', 'addition', 'comparison', 'known', 'clinicopathologic', 'factor', 'multivariable', 'nomogram', 'incorporate', 'patient', 'sex', 'age', 'tumor', 'location', 'thickness', 'ulceration', 'mitotic', 'rate', 'lymphovascular', 'invasion', 'microsatellites', 'slnb', 'status', 'furthermore', 'impact', 'test', 'treatment', 'outcome', 'follow-up', 'schedule', 'established', 'three', 'clinical', 'use', 'study', 'showed', 'physician', 'use', '-gep', 'result', 'adjust', 'management', 'agreement', 'individual', 'risk', 'recurrence.', 'bullet', 'various', 'mostly', 'prospective', 'retrospective', 'study', 'prognostic', 'gep', 'testing', 'suggest', 'role', 'independent', 'predictor', 'worse', 'outcome', 'though', 'superior', 'addition', 'breslow', 'thickness', 'sln', 'status', 'remains', 'unclear', 'whether', 'gep', 'profile', 'reliably', 'predictive', 'outcome', 'across', 'risk', 'spectrum', 'melanoma', 'prospective', 'validation', 'study', 'performed', 'breast', 'cancer', 'required', 'accurately', 'define', 'date', 'two', 'retrospective', 'one', 'prospective', 'study', 'reported', 'clinical', 'utility', 'molecular', 'testing', 'prior', 'widespread', 'implementation', 'gep', 'prognostication', 'cutaneous', 'melanoma', 'particular', 'determine', 'role', 'guiding', 'showing', 'physician', 'use', 'result', 'guide', 'surveillance', 'imaging', 'slnb', 'adjuvant', 'treatment', 'decision', 'available', 'existing', 'emerging', 'gep', 'platform', 'prognostic', 'technique', 'compared', 'optimized', 'contemporary', 'multivariable', 'phenotypic', 'model', 'i.e.', 'ajcc', 'th', 'edition', 'melanoma', 'risk', 'calculator/prognostic', 'tool', 'development', 'fda', 'status', 'decisiondx', 'melanoma', 'performed', 'central', 'laboratory', 'castle', 'bioscience', 'regulated', 'clinical', 'laboratory', 'improvement', 'amendment', 'clia', 'fda', 'clearance', 'required', 'respectfully', 'submitted', 'castle', 'bioscience', 'summary', 'finding', '-gep', 'study', 'design', 'class', 'change', 'decision', 'class', 'change', 'decision', 'ref', 'institution', 'gep', 'directly', 'influenced', 'clinical', 'management', 'patient', 'implemented', 'change', 'reflected', 'predicted', 'recurrence', 'risk', 'retrospective', 'institution', 'gep', 'used', 'guide', 'risk-appropriate', 'patient', 'management', 'significant', 'factor', 'treatment', 'change', 'including', 'directing', 'frequent', 'intense', 'surveillance', 'class', 'patient', 'prospective', 'single', 'center', 'ohsu', 'gep', 'result', 'significantly', 'associated', 'management', 'stage', 'i-ii', 'patient', 'slnb', 'node', 'negative', 'patient', 'class', 'result', 'led', 'aggressive', 'follow', 'management', 'retrospective', 'castle', 'bioscience', 'inc.', 'submission', 'nccn', 'guideline', 'panel', 'melanoma', 'page', 'reference', 'greenhaw', 'bn', 'covington', 'kr', 'kurley', 'sj', 'molecular', 'risk', 'prediction', 'cutaneous', 'melanoma', 'meta-analysis', '-gene', 'expression', 'profile', 'prognostic', 'test', 'patient', 'acad', 'dermatol', 'doi.org/./j.jaad', '...', 'litchman', 'gh', 'prado', 'teplitz', 'rw', 'rigel', 'd', 'systematic', 'review', 'meta-analysis', 'gene', 'expression', 'profiling', 'primary', 'cutaneous', 'melanoma', 'prognosis', 'skin', 'cutaneous', 'med', 'hsueh', 'ec', 'debloom', 'jr', 'lee', 'interim', 'analysis', 'survival', 'prospective', 'multi-center', 'registry', 'cohort', 'cutaneous', 'melanoma', 'tested', 'prognostic', '-gene', 'expression', 'profile', 'test', 'hematol', 'oncol', 'greenhaw', 'bn', 'zitelli', 'ja', 'brodland', 'dg', 'estimation', 'prognosis', 'invasive', 'cutaneous', 'melanoma', 'independent', 'study', 'accuracy', 'gene', 'expression', 'profile', 'test', 'dermatol', 'surg', 'doi', './dss', 'keller', 'schwartz', 'tl', 'lizalek', 'jm', 'prospective', 'validation', 'prognostic', '-gene', 'expression', 'profiling', 'test', 'primary', 'cutaneous', 'melanoma', 'cancer', 'med', 'podlipnik', 'carrera', 'boada', 'early', 'outcome', '-gene', 'expression', 'profile', 'test', 'ajcc', 'stage', 'ib-ii', 'melanoma', 'patient', 'prospective', 'multicenter', 'cohort', 'study', 'eur', 'acad', 'dermatol', 'venereol', 'vetto', 'jt', 'hsueh', 'ec', 'gastman', 'br', 'guidance', 'sentinel', 'lymph', 'node', 'biopsy', 'decision', 'patient', 't-t', 'melanoma', 'using', 'gene', 'expression', 'profiling', 'future', 'oncol', 'berger', 'ac', 'davidson', 'r', 'poitras', 'jk', 'clinical', 'impact', '-gene', 'expression', 'profile', 'test', 'cutaneous', 'melanoma', 'prospectively', 'consecutively', 'tested', 'patient', 'curr', 'med', 're', 'opin', 'dillon', 'ld', 'gadzia', 'je', 'davidson', 'r', 'prospective', 'multicenter', 'clinical', 'impact', 'evaluation', '-gene', 'expression', 'profile', 'test', 'management', 'melanoma', 'patient', 'skin', 'cutaneous', 'med', 'schuitevoerder', 'heath', 'cook', 'rw', 'impact', 'gene', 'expression', 'profiling', 'decision-making', 'clinically', 'node', 'negative', 'melanoma', 'patient', 'surgical', 'staging', 'drug', 'dermatol', 'gastman', 'br', 'gerami', 'kurley', 'sj', 'identification', 'patient', 'risk', 'metastasis', 'using', 'prognostic', '-gene', 'expression', 'profile', 'subpopulation', 'melanoma', 'patient', 'favorable', 'outcome', 'standard', 'criterion', 'acad', 'dermatol', 'doi', './j.jaad', '....', 'ferris', 'lk', 'farberg', 'middlebrook', 'identification', 'high-risk', 'cutaneous', 'melanoma', 'tumor', 'improved', 'combining', 'online', 'american', 'joint', 'committee', 'cancer', 'individualized', 'melanoma', 'patient', 'outcome', 'prediction', 'tool', '-gene', 'expression', 'profile-based', 'classification', 'acad', 'dermatol', '-.e', 'berman', 'ceilley', 'cockerell', 'appropriate', 'use', 'criterion', 'integration', 'diagnostic', 'prognostic', 'gene', 'expression', 'profile', 'assay', 'management', 'cutaneous', 'malignant', 'melanoma', 'expert', 'panel', 'consensus-based', 'modified', 'delphi', 'process', 'assessment', 'skin', 'cutaneous', 'med']}, {'filename': '2020_06_15_Castle.pdf', 'timestamp': datetime.datetime(2020, 6, 15, 0, 0), 'text': [\"c/'stla\", 'submitted', 'jay', 'braxton', 'pharnn', 'd.', 'executive', 'director', 'medicalaffairs', 'castle', 'bioscience', 'inc', 's.', 'friendswood', 'drive', 'suite', 'friendswood', 'tx', 'ph', '..', 'email', 'jbraxton', 'castlebiosciences.com', 'date', 'request', 'nccn', 'guideline', 'panel', 'melanoma', 'uveal', 'melanoma', 'appreciate', 'nccn', 'rigorous', 'criterion', 'assigning', 'evidence', 'category', 'guideline', 'recommendation', 'essential', 'clinical', 'decision-making', 'based', 'highest', 'level', 'peer-', 'reviewed', 'science', 'available', 'appreciate', 'current', 'version', 'nccn', 'guideline', 'uveal', 'melanoma', 'v.', 'includes', 'decisiondx-um', 'test', 'one', 'multiple', 'biomarkers', 'aid', 'follow', 'imaging', 'decision', 'um-', 'however', 'would', 'like', 'point', 'within', 'biomarkers', 'distinction', 'made', 'level', 'evidence', 'supporting', 'use', 'whether', 'independent', 'specifically', 'gene', 'expression', 'profiling', 'gep', 'using', 'decisiondx-um', 'test', 'validated', 'biomarker', 'risk', 'uveal', 'melanoma', 'um', 'patient', 'achieving', 'category', 'level', 'evidence', 'reflected', 'guideline', 'concerned', 'could', 'lead', 'confusion', 'provider', 'histologic', 'feature', 'could', 'judged', 'substitute', 'molecular', 'risk', 'assessment', 'histology', 'shown', 'provide', 'independent', 'prognostic', 'value', 'compared', 'directly', 'molecular', 'feature', 'univariate', 'multivariate', 'analysis', 'addition', 'note', 'nccn', 'biomarkers', 'compendium', 'mistakenly', 'omitted', 'use', 'gep', 'uveal', 'melanoma', 'section', 'specific', 'chanqes', 'requested', 'request', 'nccn', 'uveal', 'melanoma', 'panel', 'assign', 'evidence', 'category', 'recommendation', 'gep', 'testing', 'follow', 'section', 'guideline', 'uveal', 'melanoma', 'um-', 'request', 'nccn', 'biomarkers', 'compendium', 'updated', 'reflect', 'inclusion', 'gep', 'biomarker', 'guide', 'follow', 'systemic', 'imaging', 'uveal', 'melanoma', 'guideline', 'vl', 'fda', 'status', 'applicable', 'submission', 'rationale', 'decisiondx-um', 'prognostic', 'test', 'um', 'undergone', 'prospective', 'validation', 'required', 'achieve', 'category', 'level', 'evidence', 'according', 'system', 'outlined', \"nccn's\", 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncologyl', 'decisiondx-um', 'genomic', 'test', 'classifies', 'patient', 'diagnosed', 'uveal', 'melanoma', 'um', 'low', 'class', 'intermediate', 'class', 'high', 'risk', 'class', 'metastasis', 'based', 'rna', 'expression', 'gene', 'primary', 'tumor', 'tissue', 'decisiondx-um', 'class', 'result', 'included', 'um', 'guideline', 'since', 'first', 'iteration', 'v.', 'method', 'risk', 'stratification', 'may', 'used', 'inform', 'frequency', 'follow-up', 'including', 'systemic', 'imaging', 'blood', 'test', 'determine', 'possible', 'eligibility', 'clinical', 'trial', 'however', 'important', 'distinguish', 'decisiondx-um', 'class', 'result', 'risk', 'factor', 'consistently', 'shown', 'independent', 'superior', 'method', 'prognostication', 'listed', 'guideline', 'test', 'undergone', 'prospective', 'validation', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'outline', 'comprehensive', 'system', 'evaluating', 'evidence', 'support', 'clinical', 'biomarker', 'testsl', 'decisiondx-', 'um', 'test', 'prospectively', 'validated', 'marker', 'primary', 'objective', 'study', 'achieves', 'category', 'level', 'evidence', 'outlined', 'system', 'furthermore', 'multiple', 'independent', '.f', 'prospective', 'study', 'confirmed', 'test', 'clinical', 'validity', 'thus', 'decisiondx-um', 'achieved', 'surpilssed', 'threshold', 'needed', 'meeting', 'category', 'evidence', 'according', 'system', 'adopted', 'nccn', 'table', 'table', 'decisiondx-um', 'meet', 'nccn', 'criterion', 'highest', 'level', 'evidence', 'molecular', 'test', 'level', 'evidence', 'la', 'prospeclive', 'marker', 'primary', 'objective', 'w€ll', 'powerod', 'mela-analysisl', 'clinica', 'trial', 'pro', 'pective', 'cftnrcal', 'kial', 'de', 'rgned', 'addfegs', 'tun', 'nratker', 'prospective', 'enrolled', 'tteated', 'patienls', 'ar', 'palreft', 'data', 'followecj', 'prospective', 'raf', 'dorilized', 'conlrol', 't|al', 'spgc', 'nrencollocnon', 'proceasillg', 'specillensrollccled', 'processcd', 'ano', 'archval', 'assayed', 'spccllic', 'ntarker', 'rl', 'roat', 'lrme', 'slalistical', 'desion', 'ana', 'vsis', 'strdy', 'powcrod', 'ilddress', 'tumol', 'ntarkor', 'qucstion', 'result', 'untikety', 'lo', 'play', 'va|dalion', 'ohance', 'altholrgh', 'preferred', 'validation', 'nol', 'roquired', 'rfrlhbo', 'el', 'onken', 'correa', 'augburger', 'plaeseraud', 'aaberg', 'tt', 'il', '\\\\t', 'i.', 'tt', 'prospective', 'study', 'bold', 'onken', 'ot', 'a.', 'ophthalmology', 'gill', 'char', '..', 'odhthahnol', 'chappell', 'ot', 'a|', 'odthahuol', 'rcorrea', 'augsburger', 'el', 'al.', 'graefes', 'arch', 'clln', 'exp', 'ophth', 'correa', 'augsburger', 'al.', 'ophahalmol', 'decatuf', 'el', 'al.', 'jama', 'aphilnlmol', 'walleretal', 'jamaophlh.ilnel.', 'splasseraud', 'al.', 'j.', 'oncol.', 'demirci', '..', 'o.', 'odhtlnlntol.', 'cai', '..', 'odhlhalrnol', 'oaaberg', 'al.', 'ocul', 'oncol', 'pathol', 'press', 'given', 'physician', 'you.s', 'across', 'world', 'follow', 'nccn', 'recommendation', 'important', 'nccn', 'um', 'panel', 'incorporates', 'different', 'level', 'evidence', 'exist', 'biomarkers', 'inform', 'follow', 'surveillance', 'decision', 'um', 'patient', 'presented', 'decisiondx-', 'um', 'test', 'supportr', 'much', 'higher', 'level', 'published', 'evidence', 'method', 'prognostication', 'lack', 'sanre', 'level', 'validation', 'prognostic', 'accuracy', 'thus', 'serve', 'substitute', 'test', 'therefore', 'respectfully', 'urge', 'panel', 'assign', 'evidence', 'category', 'recommendation', \"i'or\", 'gene', 'expression', 'profiling', 'decisiondx-um', 'addition', 'reason', 'test', 'omitted', 'biomarkers', 'compendium', 'question', 'test', 'body', 'scientific', 'evidence', 'associated', 'publication', 'plea', 'feel', 'free', 'contact', 'directly', 'sincerely', \"r'\", 'r.r', 'ja', 'braxton', 'pharmd', 'reference', 'febbo', 'p.', 'g.', 'nccn', 'task', 'force', 'report', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'journal', 'national', 'comprehensive', 'cancer', 'network', 'jnccn', 'suppl', 's-', 'quiz', 's.', 'onken', 'ttl', 'd.', 'collaborative', 'ocular', 'oncology', 'group', 'report', 'number', 'prospective', 'validation', 'multi-gene', 'prognostic', 'assay', 'uveal', 'merlanoma', 'ophthalmology', 'correa', 'z.', 'm.', 'l\\\\ugsburger', 'j.', 'j.', 'sufficiency', 'fnab', 'aspirate', 'posterior', 'uveal', 'melanoma', 'cytologic', 'versus', 'gep', 'classificertion', 'patient', 'relative', 'prognostic', 'significance', 'classification', 'graefes', 'arch', 'clin', 'exp', 'ophthalmol', 'ti', 'avrarav\\\\r/', \"rv'\", 'corra', 'z.', 'm.', 'gsburger', 'j.', 'j.', 'independent', 'prog', 'nostic', 'sign', 'ificance', 'gene', 'expression', 'profile', 'class', 'largest', 'basal', 'diameter', 'posterrior', 'uveal', 'melanoma', 'ophthalmol', '.-e', 'plasseraud', 'k.', 'm.', 'clinical', 'performance', 'management', 'outcome', 'decisiondx-um', 'gene', 'expression', 'profile', 'test', 'prospective', 'multicenter', 'study', 'oncol', 'aaberg', 't.m.', 'gene', 'expression', 'profiling', 'uveal', 'melanoma', 'five-year', 'prospective', 'outcome', 'meta-analysis', 'ocul', 'onr', 'old', 'pathol', 'press']}, {'filename': '2022_09_29_Castle.pdf', 'timestamp': datetime.datetime(2022, 9, 29, 0, 0), 'text': ['c/', 'stlh', 'submitted', 'jay', 'braxton', 'pharm', 'd.', 'vice', 'president', 'medical', 'affair', 'castle', 'bioscience', 'lnc', 's.', 'friendswood', 'drive', 'floor', 'friendswood', 'tx', 'ph', 'ema', 'il', 'jbraxto', 'castlebiosciences.com', 'date', 'request', 'nccn', 'guideline', 'panel', 'melanoma', 'uveal', 'melanoma', 'subcommittee', 'appreciate', 'nccn', 'rigorous', 'criterion', 'assigning', 'evidence', 'category', 'guideline', 'recommendation', 'well', 'panel', 'willingness', 'update', 'recommendation', 'based', 'highest', 'level', 'peer-reviewed', 'evidence', 'available', 'cunent', 'version', 'nccn', 'guideline', 'uveal', 'melanoma', 'v.', 'includes', 'multiple', 'biomarkers', 'elinical', 'risk', 'factor', 'recommended', 'aid', 'follow', 'imaging', 'decision', 'patient', 'diagnosed', 'primary', 'uveal', 'melanoma', 'uiii', 'thank', 'guideline', 'panel', 'recent', 'important', 'update', 'made', 'um', 'guideline', 'including', 'removal', 'several', 'non-evidence-based', 'risk', 'factor', 'listed', 'um-', 'previously', 'submitted', 'request', 'panel', 'increased', 'evidence', 'designation', 'decisiondx-um', 's-gene', 'expression', 'profile', 'gep', 'test', 'believe', 'achieves', 'category', 'evidence', 'according', 'nccn', 'criterion', 'test', 'remains', 'extensively', 'validated', 'test', 'assessing', 'metastatic', 'risk', 'primary', 'um', 'since', 'last', 'submission', 'three', 'new', 'study', 'published', 'supporting', 'test', 'continued', 'clinical', 'performance', 'however', 'note', 'remains', 'distinction', 'level', 'evidence', 'supporting', 'lts', 'use', 'comparison', 'risk', 'factor', 'specific', 'chanoes', 'requested', 'respectfully', 'request', 'thatthe', 'nccn', 'uveal', 'melanoma', 'subcommittee', 'assign', 'evidence', 'category', 'recommendation', 'gep', 'testing', 'follow', 'section', 'guideline', 'uveal', 'melanoma', 'um-', 'based', 'high', 'levelof', 'evidence', 'supporting', 'test', 'including', 'meta-analysis', 'widespread', 'adoption', 'ocular', 'oncologist', 'fda', 'status', 'applicable', 'submission', 'decisiondx-um', 'laboratory', 'developed', 'test', 'exclusively', 'performed', 'castle', 'bioscience', 'laboratory', 'clinical', 'laboratory', 'lmprovement', 'amendment', 'clia', 'certification', 'college', 'american', 'pathologist', 'cap', 'accreditation', 'lt', 'require', 'fda', 'approval', 'clearance', 'test', 'approved', 'new', 'york', 'state', 'department', 'health', 'nysdoh', 'rationale', 'decisiondx-um', 'prognostic', 'test', 'um', 'undergone', 'prospective', 'validation', 'required', 'achieve', 'level', 'evidence', 'according', 'system', 'outlined', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncologyl', 'test', 'extensively', 'utilized', 'across', 'you.s.', 'helping', 'inform', 'management', 'approximately', 'newly', 'diagnosed', 'patient', 'year', 'accurate', 'metastatic', 'risk-stratification', 'essential', 'management', 'um', 'patient', 'prognostic', 'decisiondx-um', 'test', 'multigene', 'expression', 'test', 'us', 'support', 'vector', 'machine', 'learning', 'algorithm', 'classifo', 'patient', 'diagnosed', 'um', 'three', 'risk', 'group', 'increasing', 'probability', 'experiencing', 'distant', 'metastasis', 'within', 'year', 'diagnosis', 'low', 'risk', 'class', 'intermediate', 'risk', 'class', 'high', 'risk', 'class', 'decisiondx-um', 'class', 'result', 'included', 'nccn', 'um', 'guideline', 'since', 'first', 'version', 'released', 'v.', 'method', 'risk', 'stratification', 'may', 'used', 'inform', 'frequency', 'follow-up', 'including', 'systemic', 'imaging', 'blood', 'test', 'determine', 'possible', 'eligibility', 'clinical', 'trial', 'however', 'believe', 'important', 'necessary', 'distinguish', 'decisiondx-um', 'class', 'result', 'risk', 'factor', 'consistently', 'shown', 'independent', '/^/', 'stle', '\\\\vr', 'broscren.es', 'superior', 'method', 'prognostication', 'listed', 'guideline', 'decisiondx-um', 'test', 'test', 'undergone', 'prospective', 'validation', 'nccn', 'task', 'force', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'outline', 'comprehensive', 'system', 'evaluating', 'evidence', 'support', 'clinical', 'biomarker', 'testsl', 'decisiondx-', 'um', 'test', 'prospectively', 'validated', 'marker', 'primary', 'objective', 'study', 'tt', 'achieves', 'level', 'evidence', 'outlined', 'system', 'table', 'furthermore', 'multiple', 'independent', 'prospective', 'study', 'confirmed', 'test', 'clinicat', 'validity', 'recent', 'meta-analysis', 'found', 'class', 'test', 'result', 'independent', 'predictor', 'metastasis', 'associated', 'increased', 'risk', 'metastasis', 'mortality', 'thus', 'decisiondx-um', 'test', 'surpassed', 'threshold', 'required', 'achieve', 'level', 'evidence', 'according', 'system', 'established', 'nccn', 'table', 'decisiondx-um', 'meet', 'nccn', 'criterion', 'highest', 'level', 'evidence', 'molecular', 'test', 'level', 'ofevidence', 'la', 'prospective', 'mrrker', 'primary', 'obiective', 'well', 'powered', 'meta-analysisl', 'patrents', 'patient', 'data', 'trrospectirel', 'enrolled', 'lreated', 'followed', 'praspe.tive', 'randomrzed', '.ontroi', 'trial', 'stalislical', 'desrln', 'afallsrs', 'studr-', 'forered', 'addrcss', 'lumormarkrr', 'question', 'fe.lc', 'st', 'il', 'ln', 'onken', 'corren', 'augburger', 'plassaraud', 'aaberg', '-r.', 'rr', 'il', 'lprospeatrve', 'studres', 'bold', 'onkenet', 'al.', '.ophthalnology', 'gilj', 'char', 'lla/i', 'lrtjr', 'rarrloi', 'chappell', 'ei', 'a/n', 'odlhalltrci', 'corea', 'auosburger', 'al.', 'araefes', 'arch', 'clin', 'exp', 'ophth', 'correa', 'augsburger', 'al.', 'aphhalmol', 'decalur', 'ai', 'ja/', 'ctrirliarrol', \"'€iter\", 'jaira', '-lltai/no', \"'plasseraud\", 'al.', 'j.', 'oncol', 'demrrc', 'ai', 'ophiharrci', 'cai', 'el', 'arn', 'o/rhtilslrncl', 'afshar', 'etal', 'l/ars/yrsscile.rrci', 'iaaberg', '..', 'acul', 'oncol', 'pathol', 'bin', \"i't\", \"ar'/rlr\", \"-t'ti\", \"'rei/a\", 'roelofs', 'bt', 'plltilaitnci', 'stace', 'ea', 'gcr//or.oi', 'fatilol', 'kher', 'etal', 'ad', 'radialo/iio/', 'ong', 'nz', 'cnteild', 'btaclly', 'ltetanf', 'given', 'physician', 'you.s', 'across', 'world', 'follow', 'nccn', 'recommendation', 'feel', 'important', 'nccn', 'um', 'subcommittee', 'incorporate', 'different', 'level', 'evidence', 'exist', 'biomarkers', 'inform', 'follow', 'surveillance', 'decision', 'um', 'patient', 'described', 'decisiondx-um', 'test', 'supported', 'higher', 'level', 'peer-reviewed', 'evidence', 'prognostic', 'factor', 'extensive', 'evidence', 'led', 'use', 'test', 'guide', 'management', 'um', 'patient', 'ocular', 'oncology', 'center', 'you.s', 'therefore', 'respectfully', 'urge', 'panel', 'assign', 'evidence', 'category', 'recommendation', 'gene', 'expression', 'profiling', 'decisiondx-um', 'question', 'test', 'body', 'scientific', 'evidence', 'associated', 'publication', 'please', 'feelfree', 'contact', 'directly', 'sincerely', 'w-', 'jay', 'braxton', 'pharmd', 'specimen', 'collecljof', 'frocessinq', 'archival', 'resuil', 'unlikei', 'b€', 'pla', 'chance', 'although', 'preferred', 'validatron', 'required', 'validatron', 'c/astle', 'i-', 'reference', 'febbo', 'p.', 'g.', 'nccn', 'task', 'force', 'report', 'evaluating', 'clinical', 'utility', 'tumor', 'marker', 'oncology', 'journal', 'national', 'comprehensive', 'cancer', 'network', 'jnccn', 'suppl', 's-', 'quiz', 's.', 'onken', 'm.', 'd.', 'collaborative', 'ocular', 'oncology', 'group', 'report', 'number', 'prospective', 'validation', 'multi-gene', 'prognostic', 'assay', 'uveal', 'melanoma', 'ophthalmology', 'corr€a', 'z.', 'm.', 'augsburger', 'j.', 'j.', 'independent', 'prognostic', 'significance', 'gene', 'expression', 'profile', 'class', 'largest', 'basal', 'diameter', 'posterior', 'uveal', 'melanoma', 'ophthalmol', '-e.', 'plasseraud', 'k.', 'm.', 'clinical', 'performance', 'management', 'outcome', 'decisiondx-um', 'gene', 'expression', 'profile', 'test', 'prospective', 'multicenter', 'study', 'oncol', 'aaberg', 't.m', 'gene', 'expression', 'profiling', 'uveal', 'melanoma', 'five-year', 'prospective', 'outcome', 'meta-analysis', 'ocul', 'oncol', 'pathol']}, {'filename': '2021_05_28_Ilumina.pdf', 'timestamp': datetime.datetime(2021, 5, 28, 0, 0), 'text': ['name', 'david', 'eberhard', 'md', 'phd', 'company/organization', 'illumina', 'inc.', 'address', 'illumina', 'way', 'san', 'diego', 'ca', 'phone', 'email', 'deberhard', 'illumina.com', 'date', 'request', 'may', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'behalf', 'illumina', 'respectfully', 'request', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'consider', 'enclosed', 'information', 'inclusion', 'liquid', 'biopsy-based', 'dna', 'testing', 'complimentary', 'alternative', 'tissue', 'testing', 'assessment', 'genetic', 'variant', 'tumor', 'tissue', 'unavailable', 'specific', 'change', 'red', 'text', 'me-c', 'add', 'new', 'sub-bullet', 'point', 'principle', 'molecular', 'testing', 'section', 'method', 'mutation', 'testing', 'mutation', 'testing', 'may', 'performed', 'using', 'tumor', 'tissue', 'ctdna', 'peripheral', 'blood', 'liquid', 'biopsy', 'liquid', 'biopsy', 'negative', 'tumor', 'tissue', 'testing', 'recommended', 'rationale', 'study', 'demonstrated', 'use', 'ctdna', 'liquid', 'biopsy', 'viable', 'modality', 'molecular', 'biomarker', 'testing', 'tumor', 'tissue', 'unavailable/insufficient', 'patient', 'medically', 'unfit', 'invasive', 'tissue', 'sampling', 'recommendation', 'use', 'ctdna', 'incorporated', 'breast', 'non-', 'small', 'cell', 'lung', 'esophageal', 'gastric', 'cancer', 'guidelines-', 'advanced', 'melanoma', 'patient', 'could', 'benefit', 'le', 'invasive', 'biopsy', 'option', 'tissue', 'available', 'genomic', 'alteration', 'solid', 'cancer', 'may', 'identified', 'evaluating', 'cell-free', 'circulating', 'tumor', 'dna', 'cfdna/ctdna', 'blood', 'le', 'invasive', 'liquid', 'biopsy-based', 'genomic', 'analysis', 'used', 'frequently', 'patient', 'advanced', 'disease', 'may', 'unable', 'clinical', 'biopsy', 'disease', 'surveillance', 'management', 'allows', 'patient', 'matched', 'targeted', 'therapy', 'clinical', 'trial', 'molecular', 'profiling', 'genomic', 'alteration', 'reinforce', 'selection', 'patient', 'targeted', 'therapy', 'braf', 'and/or', 'mek', 'inhibitor', 'clinical', 'trial', 'nras-targeting', 'drug', 'approximately', 'melanoma', 'patient', 'harbor', 'braf', 'nra', 'mutation', 'respectively', 'biomarkers', 'evaluated', 'ctdna', 'testing', 'tumor', 'tissue', 'often', 'unavailable', 'insufficient', 'biomarker', 'testing', 'particularly', 'true', 'cutaneous', 'melanoma', 'patient', 'liquid', 'biopsy', 'assay', 'evaluate', 'spectrum', 'biomarkers', 'including', 'observed', 'melanoma.', 'several', 'melanoma-focused', 'clinical', 'performance', 'study', 'demonstrated', 'good', 'concordance', 'ctdna/cfdna', 'analysis', 'tissue-derived', 'dna', 'testing', 'prospective', 'study', 'metastatic', 'melanoma', 'patient', 'ctdna', 'sequencing', 'braf', 'gene', 'showed', 'sensitivity', 'specificity', 'overall', 'percent', 'agreement', 'respectively', 'compared', 'tissue-based', 'analysis', 'patient', 'braf', 'mutation-positive', 'melanoma', 'comparison', 'cfdna', 'analysis', 'tissue', 'dna', 'testing', 'showed', 'overall', 'positive', 'percent', 'agreement', 'vk', 'overall', 'negative', 'percent', 'agreement', 'vk', 'study', 'stage', 'iii/iv', 'melanoma', 'patient', 'ctdna', 'mutational', 'assessment', 'braf', 'gene', 'showed', 'positive', 'agreement', 'negative', 'agreement', 'overall', 'agreement', 'respectively', 'tissue-based', 'analysis', 'liquid', 'biopsy-based', 'dna', 'sequencing', 'tissue-based', 'method', 'shown', 'good', 'concordance', 'several', 'multi-cancer', 'study', 'ctdna', 'concordance', 'higher', 'tissue', 'metastasis', 'primary', 'tumor', 'ngs-based', 'method', 'used', 'analyze', 'tissue', 'sample', 'observational', 'analysis', 'patient', 'several', 'different', 'cancer', 'melanoma', 'ctdna', 'analysis', 'clinical', 'sensitivity', 'specificity', 'diagnostic', 'accuracy', 'mutated', 'oncogene', 'compared', 'dna', 'sequencing', 'matched', 'tissue', 'similar', 'smaller', 'study', 'showed', 'positive', 'predictive', 'value', 'melanoma', 'total', 'overall', 'concordance', 'melanoma', 'total', 'braf', 'mutational', 'study', 'patient', 'different', 'cancer', 'melanoma', 'overall', 'agreement', 'plasma', 'cfdna', 'tissue', 'dna', 'analysis', 'sensitivity', 'specificity', 'positive', 'predictive', 'value', 'negative', 'predictive', 'value', 'cfdna', 'testing', 'respectively', 'following', 'article', 'submitted', 'support', 'proposed', 'change', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'breast', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/breast.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'esophageal', 'esophagogastric', 'junction', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'nccn', 'guideline', 'gastric', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/gastric.pdf', 'accessed', 'may', 'national', 'comprehensive', 'cancer', 'network', 'nccn', 'nccn', 'clinical', 'practice', 'guideline', 'oncology', 'non-small', 'cell', 'lung', 'cancer', 'version', '..', 'http', '//www.nccn.org/professionals/physician_gls/pdf/nscl.pdf', 'accessed', 'may', 'rothwell', 'dg', 'ayub', 'cook', 'utility', 'ctdna', 'support', 'patient', 'selection', 'early', 'phase', 'clinical', 'trial', 'target', 'study', 'nature', 'medicine', '//', 'lanman', 'rb', 'mortimer', 'sa', 'zill', 'oa', 'analytical', 'clinical', 'validation', 'digital', 'sequencing', 'panel', 'quantitative', 'highly', 'accurate', 'evaluation', 'cell-free', 'circulating', 'tumor', 'dna', 'plo', 'one', 'e.', 'willis', 'lefterova', 'mi', 'artyomenko', 'validation', 'microsatellite', 'instability', 'detection', 'using', 'comprehensive', 'plasma-based', 'genotyping', 'panel', 'clinical', 'cancer', 'research', 'rowe', 'sp', 'luber', 'makell', 'validity', 'clinical', 'utility', 'influence', 'circulating', 'tumor', 'dna', 'melanoma', 'patient', 'management', 'real-world', 'setting', 'mol', 'oncol', 'boyer', 'cayrefourcq', 'dereure', 'clinical', 'relevance', 'liquid', 'biopsy', 'melanoma', 'merkel', 'cell', 'carcinoma', 'cancer', 'tsao', 'chin', 'garraway', 'la', 'fisher', 'de', 'melanoma', 'mutation', 'medicine', 'gene', 'dev', 'santiago-walker', 'gagnon', 'mazumdar', 'correlation', 'braf', 'mutation', 'status', 'circulating-free', 'dna', 'tumor', 'association', 'clinical', 'outcome', 'across', 'four', 'brafi', 'meki', 'clinical', 'trial', 'clinical', 'cancer', 'research', 'haselmann', 'gebhardt', 'brechtel', 'liquid', 'profiling', 'circulating', 'tumor', 'dna', 'plasma', 'melanoma', 'patient', 'companion', 'diagnostics', 'monitoring', 'braf', 'inhibitor', 'therapy', 'clinical', 'chemistry', 'cheng', 'cao', 'macleay', 'clinical', 'validation', 'cell-free', 'dna', 'gene', 'panel', 'journal', 'molecular', 'diagnostics', 'janku', 'huang', 'hj', 'claes', 'braf', 'mutation', 'testing', 'cell-free', 'dna', 'plasma', 'patient', 'advanced', 'cancer', 'using', 'rapid', 'automated', 'molecular', 'diagnostics', 'system', 'molecular', 'cancer', 'therapeutic', 'tae', 'kim', 'suk', 'lee', 'lanman', 'rb', 'prospective', 'blinded', 'study', 'somatic', 'mutation', 'detection', 'cell-free', 'dna', 'utilizing', 'targeted', '-gene', 'next', 'generation', 'sequencing', 'panel', 'metastatic', 'solid', 'tumor', 'patient', 'oncotarget', 'vol', 'perkins', 'yap', 'ta', 'pope', 'multi-purpose', 'utility', 'circulating', 'plasma', 'dna', 'testing', 'patient', 'advanced', 'cancer', 'plo', 'one', 'e-e.', 'thank', 'consideration', 'david', 'eberhard', 'md', 'phd', 'sr', 'medical', 'director', 'oncology', 'illumina', 'inc']}, {'filename': '2021_06_11_PartnerTerapeutics.pdf', 'timestamp': datetime.datetime(2021, 6, 11, 0, 0), 'text': ['hillard', 'lazarus', 'md', 'facp', 'partner', 'therapeutic', 'inc.', 'muzzey', 'street', 'lexington', 'hillard.lazarus', 'partnertx.com', 'june', 'dear', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'panel', 'behalf', 'partner', 'therapeutic', 'respectfully', 'request', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'committee', 'review', 'enclosed', 'data', 'support', 'adding', 'combination', 'ipilimumab', 'sargramostim', 'glycosylated', 'yeast-derived', 'rhu', 'gm-csf', 'guideline', 'second-line', 'subsequent', 'treatment', 'option', 'metastatic', 'unresectable', 'melanoma', 'today', 'patient', 'metastatic', 'melanoma', 'receive', 'pd-', 'pd-l', 'blockade', 'therapy', 'adjuvant', 'first', 'line', 'setting', 'many', 'patient', 'left', 'option', 'experience', 'disease', 'progression', 'ipilimumab', 'fda', 'approved', 'treatment', 'melanoma', 'whereas', 'sargramostim', 'fda', 'approved', 'yet', 'indicated', 'melanoma', 'believe', 'combined', 'ipilimumab/sargramostim', 'important', 'le', 'toxic', 'option', 'patient', 'merit', 'committee', 'consideration', 'specific', 'request', 'request', 'combination', 'ipilimumab', 'sargramostim', 'listed', 'regimen', 'option', 'second-line', 'subsequent', 'therapy', 'page', 'section', 'me-i', 'systemic', 'therapy', 'metastatic', 'unresectable', 'disease', 'based', 'version', 'cutaneous', 'melanoma', 'guideline', 'rationale', 'melanoma', 'metastasizes', 'distant', 'site', '-year', 'survival', 'seer', 'race', 'sex', 'seer', 'summary', 'stage', 'hence', 'death', 'due', 'advanced', 'melanoma', 'represents', 'persistent', 'unmet', 'medical', 'need', 'treatment', 'option', 'unresectable', 'metastatic', 'melanoma', 'dose-limiting', 'severe', 'adverse', 'event', 'particularly', 'immune-related', 'adverse', 'event', 'associated', 'checkpoint', 'inhibitor', 'including', 'ipilimumab', 'nonetheless', 'ipilimumab', 'remains', 'important', 'treatment', 'patient', 'advanced', 'melanoma', 'dose', 'benefit', 'risk', 'relationship', 'established', 'ipilimumab', 'approved', 'mg/kg', 'mg/kg', 'mg/kg', 'dos', 'across', 'several', 'indication', 'recent', 'long-term', 'follow-up', 'data', 'ascierto', 'report', 'mg/kg', 'dose', 'ipilimumab', 'versus', 'mg/kg', 'showed', 'overall', 'survival', 'month', 'month', 'hazard', 'ratio', 'hr', 'p=', 'patient', 'unresectable', 'metastatic', 'melanoma', 'ascierto', 'improving', 'benefit-risk', 'ratio', 'ipilimumab', 'would', 'represent', 'significant', 'advance', 'treatment', 'address', 'serious', 'unmet', 'medical', 'need', 'preclinical', 'translational', 'study', 'demonstrated', 'antitumor', 'activity', 'gm-csf', 'advanced', 'melanoma', 'additive', 'synergistic', 'activity', 'observed', 'combined', 'immune', 'checkpoint', 'inhibitor', 'van', 'elsas', 'li', 'kwek', 'gm-csf', 'improves', 'antigen', 'presentation', 'mature', 'dendritic', 'cell', 'increasing', 'priming', 'activation', 'tumor-infiltrating', 'lymphocyte', 'tumor', 'draining', 'lymph', 'node', 'tumor', 'microenvironment', 'tarhini', 'clinical', 'data', 'supporting', 'sargramostim', 'usage', 'increase', 'survival', 'ameliorate', 'iraes', 'detailed', 'ecog', 'study', 'prospective', 'randomized', 'phase', 'ii', 'trial', 'compared', 'overall', 'survival', 'sargramostim', 'plus', 'ipilimumab', 'versus', 'ipilimumab', 'alone', 'patient', 'advanced', 'melanoma', 'hodi', 'total', 'patient', 'randomized', 'ipilimumab', 'mg/kg', 'every', 'week', 'cycle', 'every', 'week', 'either', 'sargramostim', 'mcg/day', 'day', '-day', 'cycle', 'alone', 'primary', 'analysis', 'median', 'month', 'follow-up', 'summarized', 'following', 'table', 'outcome', 'ipilimumab', 'sargramostim', 'ipilimumab', 'value', 'number', 'death', 'median', 'overall', 'survival', 'month', 'month', 'ne-year', 'survival', 'mortality', 'hazard', 'ratio', 'significant', 'difference', 'secondary', 'clinical', 'outcome', 'progression-free', 'survival', 'clinical', 'response', 'rate', 'observed', 'treatment', 'arm', 'well', 'established', 'ipilimumab', 'improve', 'overall', 'survival', 'without', 'associated', 'progression-free', 'survival', 'response', 'rate', 'benefit', 'finding', 'may', 'due', 'tumor', 'pseudoprogression', 'i.e', 'increased', 'lesion', 'size', 'resembles', 'progressive', 'disease', 'yet', 'actually', 'treatment', 'related', 'pseudoprogression', 'associated', 'influx', 'inflammatory', 'cell', 'follows', 'immune-modulating', 'therapy', 'including', 'ipilimumab', 'additionally', 'posthoc', 'analysis', 'change', 'cd+', 'icos', 'cell', 'found', 'increase', 'function', 'treatment', 'higher', 'sargramostim', 'arm', 'compared', 'ipilimumab', 'alone', 'p=', 'cd+', 'icos', 'cell', 'greater', 'signicant', 'p=', 'hodi', 'addition', 'increased', 'survival', 'fewer', 'patient', 'sargramostim', 'group', 'grade', 'adverse', 'event', 'compared', 'ipilimumab', 'alone', 'arm', 'p=.', 'reduction', 'grade', 'gastrointestinal', 'p=', 'pulmonary', 'p=', 'toxicity', 'favored', 'sargramostim', 'combination', 'arm', 'ipilimumab', 'alone', 'arm', 'correspondingly', 'colonic', 'perforation', 'occurred', 'patient', 'sargramostim', 'combination', 'arm', 'versus', 'ipilimumab', 'alone', 'arm', 'total', 'patient', 'sargramostim', 'combination', 'arm', 'patient', 'ipilimumab', 'alone', 'arm', 'discontinued', 'treatment', 'due', 'adverse', 'event', 'patient', 'discontinued', 'treatment', 'early', 'due', 'adverse', 'event', 'better', 'overall', 'survival', 'sargramostim', 'combination', 'arm', 'compared', 'ipilimumab', 'alone', 'arm', 'p=.', 'additionally', 'rule', 'improved', 'survival', 'benefit', 'due', 'toxicity', 'benefit', 'alone', 'analysis', 'performed', 'censoring', 'treatment-related', 'lethal', 'adverse', 'event', 'overall', 'survival', 'benefit', 'maintained', 'sargramostim', 'arm', 'median', 'o', 'reached', 'ci', 'month', 'reached', 'compared', 'ipilimumab', 'alone', 'month', 'ci', 'month', 'reached', 'p=', 'hodi', 'study', 'result', 'confirmed', 'additional', 'trial', 'kwek', 'conducted', 'prospective', 'single-arm', 'phase', 'ii', 'trial', 'ipilimumab', 'sargramostim', 'metastatic', 'melanoma', 'patient', 'kwek', 'patient', 'received', 'ipilimumab', 'mg/kg', 'day', 'sargramostim', 'mcg/m/day', 'day', '-day', 'cycle', 'cycle', 'followed', 'month', 'sargramostim', 'alone', 'followed', 'maintenance', 'therapy', 'ipilimumab', 'sargramostim', 'every', 'month', 'year', 'primary', 'endpoint', 'disease', 'control', 'rate', 'week', 'median', 'overall', 'survival', 'month', 'grade', 'adverse', 'event', 'occurred', 'patient', 'luke', 'retrospectively', 'evaluated', 'metastatic', 'melanoma', 'patient', 'received', 'ipilimumab', 'mg/kg', 'day', 'sargramostim', 'mcg/day', 'day', '-day', 'cycle', 'cycle', 'luke', 'overall', 'disease', 'control', 'rate', 'week', 'recist', 'criterion', 'immune-related', 'response', 'criterion', 'median', 'overall', 'survival', 'week', 'overall', 'incidence', 'immune-related', 'adverse', 'event', 'grade', 'event', 'including', 'grade', 'colitis', 'ipilimumab', 'dose', 'lower', 'compared', 'dose', 'used', 'adverse', 'event', 'still', 'plague', 'ipilimumab', 'therapy', 'support', 'addition', 'sargramostim', 'enhance', 'patient', 'tolerance', 'following', 'article', 'included', 'support', 'proposed', 'change', 'ascierto', 'del', 'vecchio', 'mackiewicz', 'overall', 'survival', 'year', 'follow-up', 'phase', 'iii', 'trial', 'comparing', 'ipilimumab', 'mg/kg', 'mg/kg', 'patient', 'advanced', 'melanoma', 'immunother', 'cancer', 'e.', 'doi', './jitc', 'van', 'elsas', 'hurwitz', 'aa', 'allison', 'jp', 'combination', 'immunotherapy', 'melanoma', 'using', 'anti-', 'cytotoxic', 'lymphocyte-associated', 'antigen', 'ctla-', 'granulocyte/macrophage', 'colony-', 'stimulating', 'factor', 'gm-csf', '-producing', 'vaccine', 'induces', 'rejection', 'subcutaneous', 'metastatic', 'tumor', 'accompanied', 'autoimmune', 'depigmentation', 'exp', 'med', 'doi', './jem', '...', 'li', 'vanroey', 'wang', 'anti-programmed', 'death-', 'synergizes', 'granulocyte', 'macrophage', 'colony-stimulating', 'factor', 'secreting', 'tumor', 'cell', 'immunotherapy', 'providing', 'therapeutic', 'benefit', 'mouse', 'established', 'tumor', 'clin', 'cancer', 're', 'doi', './-.ccr', 'kwek', 's', 'kahn', 'greaney', 'sk', 'gm-csf', 'ipilimumab', 'therapy', 'metastatic', 'melanoma', 'clinical', 'outcome', 'immunologic', 'response', 'oncoimmunology', 'e.', 'doi', './x', '..', 'tarhini', 'aa', 'joshi', 'garner', 'f.', 'sargramostim', 'rhu', 'gm-csf', 'immune', 'checkpoint', 'inhibitor', 'combinatorial', 'therapeutic', 'study', 'metastatic', 'melanoma', 'immunotherapy', 'press', 'doi', './imt', 'hodi', 'sf', 'lee', 'mcdermott', 'df', 'ipilimumab', 'plus', 'sargramostim', 'ipilimumab', 'alone', 'treatment', 'metastatic', 'melanoma', 'randomized', 'clinical', 'trial', 'jama', 'doi', './jama', '..', 'luke', 'jj', 'donahue', 'nishino', 'single', 'institution', 'experience', 'ipilimumab', 'mg/kg', 'sargramostim', 'gm-csf', 'metastatic', 'melanoma', 'cancer', 'immunol', 're', 'doi', './-.cir', 'combining', 'sargramostim', 'immune', 'checkpoint', 'inhibitor', 'advanced', 'melanoma', 'remains', 'clinical', 'interest', 'ongoing', 'ecog-acrin', 'phase', 'ii/iii', 'trial', 'evaluating', 'combination', 'ipilimumab', 'nivolumab', 'sargramostim', 'compared', 'ipilimumab', 'plus', 'nivolumab', 'alone', 'unresectable', 'stage', 'iii', 'iv', 'melanoma', 'trial', 'recently', 'resumed', 'accrual', 'phase', 'iii', 'portion', 'meeting', 'prespecified', 'efficacy', 'safety', 'threshold', 'believe', 'evidence', 'support', 'adding', 'ipilimumab/sargramostim', 'combination', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'option', 'second', 'line', 'therapy', 'metastatic', 'unresectable', 'disease', 'given', 'improved', 'toxicity', 'profile', 'impact', 'overall', 'survival', 'compared', 'ipilimumab', 'alone', 'please', 'hesitate', 'reach', 'directly', 'hillard.lazarus', 'partnertx.com', 'question', 'sincerely', 'hillard', 'lazarus', 'md', 'facp', 'consultant', 'partner', 'therapeutic', 'professor', 'medicine', 'case', 'western', 'reserve', 'university', 'editor-in-chief', 'bone', 'marrow', 'transplantation', 'editor-in-chief', 'blood', 'review']}, {'filename': '20201_06_01_Merck.pdf', 'timestamp': datetime.datetime(201, 6, 1, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'january', 'nccn', 'guideline', 'panel', 'melanoma', 'panel', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda®', 'pembrolizumab', 'reference', 'unresectable', 'metastatic', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'inclusion', 'pembrolizumab', 'combination', 'dabrafenib', 'trametinib', 'systemic', 'treatment', 'option', 'patient', 'unresectable', 'metastatic', 'melanoma', 'braf', 'v-activating', 'mutation', 'appropriate', 'section', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'v.', 'including', 'page', 'me-i', 'fda', 'clearance', 'keytruda', 'indicated', 'combination', 'therapy', 'dabrafenib', 'trametinib', 'treatment', 'patient', 'advanced', 'melanoma', 'keytruda', 'pembrolizumab', 'indicated', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'keytruda', 'indicated', 'adjuvant', 'treatment', 'patient', 'melanoma', 'involvement', 'lymph', 'node', 'following', 'complete', 'resection', 'please', 'refer', 'keytruda', 'prescribing', 'information', 'fda-approved', 'indication', 'rationale', 'ferrucci', 'published', 'result', 'part', 'keynote-', 'trial', 'nct', 'randomized', 'double-blind', 'phase', 'portion', 'patient', 'previously', 'untreated', 'advanced', 'melanoma', 'randomly', 'assigned', 'receive', 'pembrolizumab', 'mg/kg', 'intravenously', 'every', 'three', 'week', 'combination', 'dabrafenib', 'mg', 'orally', 'two', 'time', 'daily', 'trametinib', 'mg', 'orally', 'daily', 'triplet', 'therapy', 'placebo', 'combined', 'dabrafenib', 'mg', 'orally', 'two', 'time', 'daily', 'trametinib', 'mg', 'orally', 'daily', 'doublet', 'therapy', 'eligible', 'patient', 'year', 'age', 'unresectable', 'stage', 'iii', 'stage', 'iv', 'cutaneous', 'melanoma', 'brafve/k', 'mutation-positive', 'disease', 'primary', 'endpoint', 'progression-free', 'survival', 'assessed', 'based', 'response', 'evaluation', 'criterion', 'solid', 'tumor', 'version', 'recist', 'v.', 'investigator', 'secondary', 'endpoint', 'objective', 'response', 'rate', 'orr', 'duration', 'response', 'dor', 'overall', 'survival', 'o', 'cutoff', 'date', 'june', 'median', 'follow-up', 'time', 'analysis', 'month', 'result', 'updated', 'analysis', 'considered', 'carry', 'statistical', 'significance', 'trial', 'previously', 'demonstrated', 'median', 'follow-up', 'time', 'month', 'triplet', 'therapy', 'improved', 'compared', 'doublet', 'therapy', 'without', 'reaching', 'statistical', 'significance', 'month', 'month', 'hr', 'p=.', 'updated', 'analysis', 'median', 'month', 'ci', '.-', 'triplet', 'arm', 'month', 'ci', '.-', 'doublet', 'arm', 'hr', 'ci', '.-.', '-month', 'kaplan-meier', 'km', 'estimated', 'rate', 'ci', 'triplet', 'arm', 'ci', 'doublet', 'arm', '-month', 'rate', 'ci', 'ci', 'respectively', 'orr', 'recist', 'v.', 'assessed', 'investigator', 'triplet', 'arm', 'doublet', 'arm', 'median', 'km-estimated', 'dor', 'month', 'triplet', 'arm', 'month', 'doublet', 'arm', 'hr', 'ci', '.-.', 'median', 'o', 'reached', 'triplet', 'arm', 'month', 'doublet', 'arm', 'hr', 'ci', '.-.', '-month', 'km-', 'estimated', 'o', 'rate', 'ci', 'triplet', 'arm', 'ci', 'doublet', 'arm', '-month', 'o', 'rate', 'ci', 'ci', 'respectively', 'treatment-related', 'adverse', 'event', 'traes', 'occurred', 'patient', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'grade', 'traes', 'occurred', 'patient', 'including', 'one', 'death', 'pneumonitis', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'adverse', 'event', 'led', 'treatment', 'discontinuation', 'patient', 'triplet', 'arm', 'patient', 'doublet', 'arm', 'median', 'follow-up', 'year', 'result', 'support', 'antitumor', 'activity', 'pembrolizumab', 'dabrafenib', 'trametinib', 'first-line', 'combination', 'therapy', 'patient', 'unresectable', 'metastatic', 'melanoma', 'brafve/k', 'mutation', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'ferrucci', 'pf', 'di', 'giacomo', 'del', 'vecchio', 'keynote-', 'part', 'randomized', 'double-blind', 'phase', 'study', 'pembrolizumab', 'dabrafenib', 'trametinib', 'braf-mutant', 'melanoma', 'journal', 'immunotherapy', 'cancer', 'e.', 'doi', './jitc', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}, {'filename': '2021_06_07_Merck.pdf', 'timestamp': datetime.datetime(2021, 6, 7, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'melanoma', 'panel', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda®', 'pembrolizumab', 'reference', 'resected', 'stage', 'iv', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'inclusion', 'pembrolizumab', 'category', 'adjuvant', 'treatment', 'option', 'patient', 'resected', 'stage', 'iv', 'melanoma', 'evidence', 'disease', 'appropriate', 'section', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'v.', 'including', 'page', 'me-', 'me-a', 'fda', 'clearance', 'keytruda', 'pembrolizumab', 'indicated', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'keytruda', 'indicated', 'adjuvant', 'treatment', 'patient', 'melanoma', 'involvement', 'lymph', 'node', 'following', 'complete', 'resection', 'please', 'refer', 'keytruda', 'prescribing', 'information', 'fda-approved', 'indication', 'rationale', 'grossman', 'presented', 'data', 'phase', 'iii', 'trial', 'ass', 'whether', 'pembrolizumab', 'administered', 'year', 'would', 'improve', 'relapse-free-survival', 'rf', 'overall', 'survival', 'o', 'comparison', 'either', 'ipilimumab', 'high-dose', 'interferon', 'patient', 'high-risk', 'resected', 'melanoma', 'eligible', 'patient', 'age', 'year', 'older', 'completely', 'resected', 'melanoma', 'including', 'lymph', 'node', 'dissection', 'sentinel', 'lymph', 'node', 'positive', 'disease', 'previous', 'immunotherapy', 'allowed', 'prior', 'adjuvant', 'radiation', 'permitted', 'patient', 'randomized', 'treatment', 'stage', 'iiia', 'iiib', 'iiic', 'iv', 'melanoma', 'respectively', 'american', 'joint', 'committee', 'cancer', 'th', 'edition', 'patient', 'randomized', 'either', 'experimental', 'arm', 'control', 'arm', 'follows', 'experimental', 'arm', 'pembrolizumab', 'mg', 'intravenously', 'iv', 'every', 'week', 'qw', 'week', 'control', 'arm', 'investigator', 'choice', 'prespecified', 'enrollment', 'interferon', 'alfa-b', 'million', 'unit', 'per', 'square', 'meter', 'mu/m', 'iv', 'day', 'week', 'followed', 'mu/m/day', 'subcutaneously', 'day', 'week', 'ipilimumab', 'mg/kg', 'iv', 'qw', 'dos', 'every', 'week', 'year', 'primary', 'endpoint', 'rf', 'o', 'total', 'population', 'o', 'patient', 'programmed-', 'death', 'ligand', 'positive', 'pd-l+', 'melanoma', 'baseline', 'pre-specified', 'analysis', 'performed', 'per-protocol', 'year', 'date', 'last', 'patient', 'randomized', 'time-driven', 'including', 'event', 'rf', 'event', 'o', 'patient', 'received', 'pembrolizumab', 'statistically', 'significant', 'improvement', 'rf', 'compared', 'high-dose', 'interferon', 'ipilimumab', 'hr', 'ci', '.-', 'statistically', 'significant', 'improvement', 'o', 'total', 'population', 'hr', 'ci', '.-', 'p=', 'patient', 'pd-l', 'positive', 'melanoma', 'hr', 'ci', '.-', 'p=.', 'treatment-related', 'grade', 'adverse', 'event', 'aes', 'occurred', 'patient', 'received', 'pembrolizumab', 'compared', 'ipilimumab', 'high-dose', 'interferon', 'aes', 'led', 'discontinuation', 'patient', 'received', 'pembrolizumab', 'compared', 'ipilimumab', 'high-dose', 'interferon', 'respectively', 'result', 'study', 'support', 'pembrolizumab', 'treatment', 'option', 'patient', 'completely', 'resected', 'stage', 'iiia', 'iiib', 'iiic', 'iv', 'melanoma', 'specifically', 'subgroup', 'patient', 'resected', 'stage', 'iv', 'melanoma', 'rf', 'hr', 'ci', '.-.', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'grossman', 'kf', 'othus', 'patel', 'final', 'analysis', 'overall', 'survival', 'relapse-free', 'survival', 'swog', 'phase', 'iii', 'randomized', 'trial', 'comparing', 'pembrolizumab', 'either', 'high', 'dose', 'interferon', 'ipilimumab', 'patient', 'high', 'risk', 'resected', 'melanoma', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'virtual', 'scientific', 'program', 'june', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}, {'filename': '2020_06_23_UPMC.pdf', 'timestamp': datetime.datetime(2020, 6, 23, 0, 0), 'text': ['nccn', 'cutaneous', 'melanoma', 'guideline', 'panel', 'submitted', 'name', 'laura', 'k.', 'ferris', 'md', 'phd', 'organization', 'upmc', 'address', 'please', 'see', 'phone', 'please', 'see', 'email', 'ferrlk', 'upmc.edu', 'date', 'request', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'sent', 'via', 'email', 'submission', 'nccn.org', 'regarding', 'nccn', 'guideline', 'cutaneous', 'melanoma', 'pigmented', 'lesion', 'assay', 'dear', 'nccn', 'cutaneous', 'melanoma', 'panel', 'member', 'served', 'lead', 'investigator', 'several', 'clinical', 'study', 'involving', 'dermtech', 'pigmented', 'lesion', 'assay', 'please', 'allow', 'share', 'enthusiasm', 'rationale', 'recommending', 'pla', 'use', 'guide', 'biopsy', 'decision', 'requested', 'change', 'next', 'version', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'based', 'test', 'performance', 'clinical', 'utility', 'evidenced', 'peer', 'reviewed', 'publication', 'number', 'study', 'investigating', 'performance', 'various', 'molecular', 'analysis', 'technique', 'i.e.', 'fish', 'cgh', 'etc', 'however', 'technique', 'fall', 'short', 'truly', 'impacting', 'pigmented', 'lesion', 'management', 'performance', 'characteristic', 'test', 'depend', 'tissue', 'sample', 'surgical', 'biopsy', 'pla', 'different', 'performance', 'characteristic', 'superior', 'npv', 'specificity', 'sensitivity', 'test', 'reduces', 'greatly', 'number', 'exploratory', 'biopsy', 'associated', 'pigmented', 'lesion', 'management', 'specific', 'change', 'recommend', 'deleting', 'last', 'sentence', 'evidence', 'block', 'me-', 'page', 'pre-diagnostic', 'clinical', 'modality', 'based', 'evidence', 'available', 'please', 'correct', 'pre-', 'diagnostic', 'noninvasive', 'genomic', 'patch', 'testing', 'considered', 'guide', 'biopsy', 'decisions.', 'fda', 'clia', 'test', 'fda', 'compliant', 'class', 'device', 'non-invasively', 'obtain', 'sample', 'via', 'adhesive', 'patch', 'rationale', 'rationale', 'recommendation', 'based', 'pla', 'confirmed', 'clinical', 'utility', 'performance', 'npv', 'specificity', 'sensitivity', 'greatly', 'reducing', 'number', 'exploratory', 'biopsy', 'associated', 'pigmented', 'lesion', 'management', 'providing', 'key', 'validation', 'gerami', 'jaad', 'ferris', 'jid', 'key', 'utility', 'ferris', 'doj', 'brouha', 'jdd', 'detailed', 'peer', 'reviewed', 'publication', 'facilitate', 'nccn', 'effort', 'specifically', 'provided', '-month', 'follow', 'study', 'ferris', 'al.', 'impact', 'clinical', 'practice', 'noninvasive', 'gene', 'expression', 'melanoma', 'rule-out', 'test', '-month', 'follow-up', 'negative', 'test', 'result', 'utility', 'data', 'large', 'u', 'registry', 'study', 'doj', 'reviewed', 'record', 'pigmented', 'lesion', 'negative', 'pla', 'result', 'dermatology', 'office', 'lesion', 'negative', 'result', 'biopsied', 'submitted', 'histopathologic', 'review', 'none', 'lesion', 'biopsied', 'histopathologic', 'diagnosis', 'melanoma', 'normal', 'practice', 'lesion', 'likely', 'would', 'biopsied', 'subset', 'subjected', 'wider', 'margin', 'excision', 'pla', 'test', 'result', 'followed', 'unnecessary', 'biopsy', 'downstream', 'complication', 'reduced', 'avoided', 'recent', 'large', 'real-world', 'registry', 'study', 'pla', 'performance', 'impact', 'clinical', 'decision', 'making', 'validated', 'brouha', 'real-world', 'utility', 'non-invasive', 'gene', 'expression', 'test', 'rule', 'primary', 'cutaneous', 'melanoma', 'large', 'u', 'registry', 'study', 'jdd', 'provider', 'evaluated', 'case', 'pla', 'pla', 'test', 'lesion', 'clinically', 'suspicious', 'melanoma', 'negative', 'pla', 'positive', 'pla', 'test', 'result', 'case', 'resulted', 'surgical', 'biopsy', 'pla', 'test', 'result', 'case', 'resulted', 'surgical', 'biopsy', 'avoidance', 'invasive', 'surgical', 'procedure', 'clearly', 'evidence', 'impact', 'pla', 'pigmented', 'lesion', 'management', 'recommend', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'updated', 'reflect', 'available', 'evidence', 'sincerely', 'laura', 'k.', 'ferris', 'md', 'phd']}, {'filename': '2020_06_22_Foundation.pdf', 'timestamp': datetime.datetime(2020, 6, 22, 0, 0), 'text': ['submitted', 'brian', 'alexander', 'md', 'company', 'foundation', 'medicine', 'inc.', 'address', 'second', 'street', 'cambridge', 'phone', 'ext', 'email', 'balexander', 'foundationmedicine.com', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'panel', 'member', 'behalf', 'foundation', 'medicine', 'respectfully', 'request', 'nccn®', 'cutaneous', 'melanoma', 'guideline', 'panel', 'consider', 'requested', 'update', 'pertaining', 'evaluation', 'management', 'patient', 'melanoma', 'requested', 'update', 'amend', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'include', 'following', 'tumor', 'mutational', 'burden', 'tmb', 'measured', 'reported', 'targeted', 'ng', 'panel', 'validated', 'and/or', 'fda-approved', 'per', 'recommendation', 'outlined', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'remove', 'last', 'sub-bullet', 'point', 'somatic', 'mutation', 'burden', 'page', 'me-c', 'use', 'mutation', 'burden', 'guide', 'treatment', 'decision', 'remains', 'investigational', 'time', 'rationale', 'requested', 'update', 'keynote-', 'nct', 'multicohort', 'single-arm', 'open-label', 'phase', 'study', 'evaluating', 'pembrolizumab', 'monotherapy', 'patient', 'selected', 'previously', 'treated', 'advanced', 'solid', 'tumor', 'administered', 'pembrolizumab', 'mg', 'every', 'week', 'intravenous', 'infusion', 'patient', 'evaluable', 'tissue', 'tmb', 'ttmb', 'score', 'efficacy', 'population', 'ttmb-high', 'defined', 'mutations/megabase', 'tmb-high', 'status', 'associated', 'clinically', 'meaningful', 'improvement', 'demonstrated', 'objective', 'response', 'rate', 'orr', 'ci', 'compared', 'ci', 'non-ttmb-high', 'group', 'primary', 'endpoint', 'median', 'follow-up', 'approximately', 'year', 'median', 'duration', 'response', 'reached', 'ttmb-high', 'group', 'month', 'non‒ttmb-high', 'group', 'additional', 'secondary', 'outcome', 'landmark', 'timepoints', 'include', '-year', 'rate', 'ttmb-high', 'group', 'non‒ttmb-high', 'group', '-year', 'o', 'rate', 'ttmb-high', 'group', 'versus', 'non‒ttmb-high', 'group', 'predictive', 'value', 'ttmb', 'independent', 'biomarkers', 'including', 'microsatellite', 'instability', 'msi', '-high', 'pd-l', 'expression', 'additionally', 'predictive', 'value', 'ttmb', 'appear', 'driven', 'particular', 'tumor', 'type', 'increased', 'response', 'rate', 'tmb-high', 'patient', 'observed', 'across', 'tumor', 'type', 'based', 'result', 'keynote-', 'pembrolizumab', 'fda-approved', 'patient', 'unresectable', 'metastatic', 'solid', 'tumor', 'ttmb-high', 'mutations/megabase', 'determined', 'fda-approved', 'test', 'progressed', 'following', 'prior', 'treatment', 'satisfactory', 'alternative', 'treatment', 'option', 'tmb', 'complex', 'continuous', 'biomarker', 'tmb', 'estimation', 'provided', 'next', 'generation', 'sequencing', 'ng', 'targeted', 'panel', 'vary', 'across', 'laboratory', 'due', 'factor', 'difference', 'panel', 'size', 'gene', 'coverage', 'bioinformatics', 'pipeline', 'important', 'role', 'tmb', 'play', 'clinical', 'decision-making', 'potential', 'variation', 'across', 'laboratory', 'friend', 'cancer', 'research', 'convened', 'consortium', 'key', 'stakeholder', 'recommend', 'best', 'practice', 'approach', 'tmb', 'measurement', 'validation', 'alignment', 'reporting', 'stakeholder', 'including', 'fda', 'national', 'cancer', 'institute', 'diagnostic', 'manufacturer', 'academic', 'pharmaceutical', 'company', 'published', 'detailed', 'recommendation', 'around', 'tmb', 'reporting', 'consistency', 'standardization', 'analytical', 'validation', 'study', 'tmb', 'estimation', 'alignment', 'panel', 'tmb', 'value', 'whole', 'exome', 'sequencing', 'wes', '-derived', 'universal', 'reference', 'standard', 'test', 'report', 'tmb', 'value', 'comply', 'recommendation', 'published', 'and/or', 'fda-approved', 'tmb', 'measurement', 'reporting', 'purpose', 'thank', 'review', 'submission', 'sincerely', 'brian', 'alexander', 'm.d', 'chief', 'medical', 'officer', 'foundation', 'medicine', 'reference', 'marabelle', 'fakih', 'lopez', 'association', 'tumour', 'mutational', 'burden', 'outcome', 'patient', 'advanced', 'solid', 'tumour', 'treated', 'pembrolizumab', 'multicohort', 'open-label', 'phase', 'keynote-', 'study', 'lancet', 'oncology', 'submission', 'esmo', 'presentation', 'attached', 'keytruda', 'pembrolizumab', 'fda', 'approved', 'label', 'found', 'http', '//www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf', 'fda', 'label', 'foundation', 'medicine', 'inc.', 'foundationone®', 'cdx', 'technical', 'information', 'attached', 'merino', 'dm', 'mcshane', 'lm', 'fabrizio', 'establishing', 'guideline', 'harmonize', 'tumor', 'mutational', 'burden', 'tmb', 'silico', 'assessment', 'variation', 'tmb', 'quantification', 'across', 'diagnostic', 'platform', 'phase', 'friend', 'cancer', 'research', 'tmb', 'harmonization', 'project', 'immunother', 'cancer', 'e.', 'chalmers', 'zr', 'connelly', 'cf', 'fabrizio', 'analysis', 'human', 'cancer', 'genome', 'reveals', 'landscape', 'tumor', 'mutational', 'burden', 'genome', 'med', 'published', 'apr', 'doi', './s']}, {'filename': '2021_06_07_BrystolMayers.pdf', 'timestamp': datetime.datetime(2021, 6, 7, 0, 0), 'text': ['june', 'mary', 'coffey', 'pharmd', 'senior', 'director', 'ww', 'scientific', 'content', 'market', 'capability', 'bristol', 'myers', 'squibb', 'princeton', 'pike', 'lawrence', 'new', 'jersey', 'nccn', 'guidelines®', 'panel', 'melanoma', 'panel', 'behalf', 'bristol', 'myers', 'squibb', 'respectfully', 'request', 'melanoma', 'panel', 'review', 'data', 'recently', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'meeting', 'use', 'opdivo®', 'nivolumab', 'plus', 'yervoy®', 'ipilimumab', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'specific', 'change', 'respectfully', 'request', 'panel', 'consider', 'following', 'update', 'reflect', 'approximately', 'year', 'minimum', 'follow-up', 'month', 'data', 'checkmate', 'update', 'discussion', 'section', 'ms-', 'ms-', 'ms-', 'ms-', 'm', 'ms-', 'longer-term', 'data', 'update', 'reference', 'me-i', 'pg', 'reflect', 'new', 'longer-term', 'data', 'fda', 'clearance', 'opdivo®', 'indicated', 'adjuvant', 'treatment', 'option', 'patient', 'melanoma', 'lymph', 'node', 'involvement', 'metastatic', 'disease', 'undergone', 'complete', 'resection', 'opdivo®', 'indicated', 'monotherapy', 'combination', 'yervoy®', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma.', 'yervoy®', 'indicated', 'monotherapy', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'adult', 'pediatric', 'patient', 'year', 'older', 'rationale', 'data', 'submitted', 'response', 'standing', 'request', 'nccn®', 'new', 'data', 'please', 'note', 'previous', 'submission', 'nccn', 'regarding', '-year', 'outcome', 'checkmate', 'trial', 'october', 'study', 'summary', 'checkmate', 'phase', 'randomized', 'double-blind', 'study', 'nivolumab', 'combination', 'ipilimumab', 'nivo', 'mg/kg', 'ipi', 'mg/kg', 'qw', 'dos', 'nivo', 'mg/kg', 'qw', 'nivolumab', 'monotherapy', 'nivo', 'mg/kg', 'qw', 'compared', 'ipilimumab', 'monotherapy', 'ipi', 'mg/kg', 'qw', 'dos', 'previously', 'untreated', 'patient', 'unresectable', 'metastatic', 'melanoma', 'co-', 'primary', 'endpoint', 'progression-free', 'survival', 'overall', 'survival', 'nivo+ipi', 'nivo', 'group', 'versus', 'ipi', 'group', 'result', 'minimum', 'follow-up', 'approximately', '.-years', 'recently', 'presented', 'asco', 'meeting', 'median', 'overall', 'survival', 'ci', '.-nr', 'month', 'nivo', 'ipi', '.-', 'month', 'nivo', '.-', 'month', 'ipi', '.-year', 'overall', 'survival', 'rate', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'progression-free', 'survival', 'rate', 'year', 'nivo+ipi', 'nivo', 'ipi', 'respectively', 'additionally', 'patient', 'treated', 'nivo', 'ipi', 'received', 'subsequent', 'therapy', 'compared', 'nivo', 'ipi', 'median', 'time', 'subsequent', 'systemic', 'therapy', 'yet', 'reached', 'compared', 'month', 'nivo', 'month', 'ipi', 'patient', 'alive', 'year', 'treated', 'nivo', 'ipi', 'treated', 'nivo', 'treatment-free', 'study', 'treatment', 'never', 'received', 'subsequent', 'systemic', 'therapy', 'grade', 'treatment-related', 'adverse', 'event', 'reported', 'patient', 'receiving', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'grade', 'adverse', 'event', 'reported', 'patient', 'receiving', 'nivo', 'ipi', 'nivo', 'ipi', 'respectively', 'new', 'safety', 'signal', 'observed', 'additional', 'treatment-related', 'death', 'since', '-month', 'analysis', 'part', 'submission', 'following', 'resource', 'enclosed', 'review', 'product', 'information', 'opdivo®', 'nivolumab', 'injection', 'intravenous', 'infusion', 'bristol', 'myers', 'squibb', 'princeton', 'nj', 'may', 'product', 'information', 'yervoy®', 'ipilimumab', 'injection', 'intravenous', 'infusion', 'bristol', 'myers', 'squibb', 'princeton', 'nj', 'may', 'wolchock', 'jd', 'chiarion-sileni', 'gonzalez', 'checkmate', '.-year', 'outcome', 'patient', 'advanced', 'melanoma', 'presented', 'american', 'society', 'clinical', 'oncology', 'asco', 'anual', 'meeting', 'june', 'thank', 'consideration', 'request', 'sincerely', 'mary', 'coffey', 'pharmd', 'samantha', 'gothelf', 'pharmd', 'senior', 'director', 'vice', 'president', 'ww', 'scientific', 'content', 'market', 'capability', 'u', 'medical', 'oncology']}, {'filename': '2020_06_22_SUNY.pdf', 'timestamp': datetime.datetime(2020, 6, 22, 0, 0), 'text': ['june', 'dermtech', 'pigmented', 'lesion', 'assay', '/nccn', 'submitted', 'name', 'daniel', 'm.', 'siegel', 'md', 'm', 'company/organization', 'suny', 'downstate', 'address', 'basic', 'sci', 'bldg', 'clarkson', 'avenue', 'box', 'brooklyn', 'phone', 'email', 'daniel.siegel', 'downstate.edu', 'date', 'request', 'june', 'nccn', 'guideline', 'panel', 'cutaneous', 'melanoma', 'dear', 'cutaneous', 'melanoma', 'panel', 'member', 'clinician', 'clinical', 'researcher', 'studied', 'published', 'incorporated', 'use', 'dermtech', 'pigmented', 'lesion', 'assay', 'pla', 'practice', 'rule', 'melanoma', 'guiding', 'biopsy', 'decision', 'via', 'molecular', 'risk', 'factor', 'find', 'non-invasive', 'clia', 'test', 'useful', 'biopsy', 'guidance', 'npv', 'allows', 'miss', 'fewer', 'melanoma', 'find', 'earlier', 'recent', 'work', 'conic', 'jaad', 'e.', 'highlight', 'even', 'relatively', 'small', 'delay', 'managing', 'primary', 'melanoma', 'pla', 'help', 'minimize', 'negatively', 'impact', 'survival', 'stage', 'melanoma', 'patient', 'problem', 'inherent', 'practice', 'dermatology', 'include', 'access', 'specialty', 'care', 'shortage', 'dermatologist', 'dependent', 'geography', 'lack', 'tool', 'supporting', 'provider', 'assessment', 'often', 'difficult', 'ascertain', 'pigmented', 'skin', 'lesion', 'situation', 'helped', 'covid-', 'related', 'closure', 'limited', 'access', 'dermatology', 'office', 'additionally', 'period', 'telemedicine', 'general', 'teledermatology', 'particular', 'lifeline', 'many', 'patient', 'pla', 'lifesaver', 'many', 'patient', 'could', 'obtain', 'sample', 'necessary', 'testing', 'sheltering', 'home', 'either', 'obtain', 'sense', 'relief', 'make', 'high', 'priority', 'waiting', 'list', 'evaluation', 'treatment', 'guided', 'pla', 'clinical', 'circumstance', 'pandemic', 'end', 'pla', 'still', 'paly', 'valuable', 'role', 'expediting', 'management', 'potential', 'high-risk', 'lesion', 'especially', 'useful', 'qualified', 'health', 'care', 'provider', 'high', 'number', 'needed', 'biopsy', 'find', 'melanoma', 'following', 'required', 'format', 'provide', 'information', 'requested', 'category', 'specific', 'change', 'please', 'see', 'regarding', 'requested', 'specific', 'change', 'version', 'page', 'me-', 'bullet', 'point', 'pre-diagnostic', 'clinical', 'modality', 'screen', 'shot', 'recommend', 'following', 'change', 'clinical', 'utility', 'novel/emerging', 'diagnostic', 'imaging', 'molecular', 'technology', 'e.g', 'non-invasive', 'genomic', 'patch', 'testing', 'requires', 'investigation', 'pre-', 'diagnostic', 'molecular', 'genomic', 'patch', 'testing', 'help', 'guide', 'biopsy', 'decision', 'pigmented', 'skin', 'lesion', 'considered', 'fda', 'clearance', 'clia', 'administered', 'laboratory', 'developed', 'test', 'rationale', 'solid', 'evidence', 'multiple', 'utility', 'study', 'demonstrates', 'biopsy', 'guidance', 'pre-', 'diagnostic', 'pre-biopsy', 'test', 'negative', 'predictive', 'value', 'allows', 'clinician', 'miss', 'fewer', 'melanoma', 'find', 'earlier', 'portfolio', 'peer', 'reviewed', 'pla', 'publication', 'public', 'domain', 'attaching', 'recent', 'pdfs', 'pla', 'clinical', 'utility', 'measure', 'appeared', 'question', 'earlier', 'version', 'cutaneous', 'melanoma', 'guideline', 'ferris', 'al.', 'doj', 'missed', 'melanoma', 'month', 'follow-up', 'brouha', 'jdd', 'real-world', 'registry', 'study', 'case', 'reduction', 'biopsy', 'clinician', 'follow', 'guidance', 'test', 'case', 'robinson', 'skin', 'physician-guided', 'pla', 'home', 'sample', 'collection', 'feasible', 'sincerely', 'hope', 'panel', 'recognizes', 'abundance', 'peer', 'reviewed', 'data', 'including', 'clinical', 'utility', 'available', 'pla', 'publication', 'total', 'recommends', 'use', 'biopsy-guiding', 'pre-', 'diagnostic', 'technology', 'pigmented', 'lesion', 'management', 'latest', 'version', 'nccn', 'cutaneous', 'melanoma', 'guideline', 'thank', 'daniel', 'mark', 'siegel', 'md', 'm', 'management', 'policy', 'clinical', 'professor', 'dermatology', 'suny', 'downstate', 'former', 'president', 'american', 'academy', 'dermatology']}, {'filename': '2020_01_13_Merck.pdf', 'timestamp': datetime.datetime(2020, 1, 13, 0, 0), 'text': ['name', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'company/organization', 'merck', 'inc.', 'address', 'galloping', 'hill', 'rd', 'phone', 'email', 'suzana.giffin', 'merck.com', 'date', 'request', 'january', 'nccn', 'guideline', 'panel', 'melanoma', 'nccn', 'melanoma', 'panel', 'behalf', 'merck', 'inc.', 'respectfully', 'request', 'nccn', 'melanoma', 'panel', 'review', 'enclosed', 'information', 'keytruda', 'pembrolizumab', 'reference', 'unresectable', 'metastatic', 'melanoma', 'brain', 'metastasis', 'specific', 'change', 'respectfully', 'request', 'nccn', 'panel', 'consider', 'inclusion', 'keytruda', 'combination', 'bevacizumab', 'treatment', 'option', 'patient', 'disseminated', 'unresectable', 'melanoma', 'brain', 'metastasis', 'appropriate', 'section', 'guideline', 'including', 'section', 'me-', 'me-i', 'well', 'section', 'ms-', 'table', 'based', 'data', 'presented', 'annual', 'meeting', 'society', 'neuro-oncology', 'pembrolizumab', 'plus', 'bevacizumab', 'melanoma', 'patient', 'untreated', 'brain', 'metastasis', 'fda', 'clearance', 'keytruda', 'pembrolizumab', 'approved', 'treatment', 'patient', 'unresectable', 'metastatic', 'melanoma', 'rationale', 'ongoing', 'prospective', 'single-arm', 'phase', 'study', 'nct', 'pembrolizumab', 'plus', 'bevacizumab', 'melanoma', 'patient', 'brain', 'metastasis', 'patient', 'brain', 'metastasis', 'response', 'following', 'resource', 'submitted', 'assist', 'committee', 'review', 'kluger', 'hm', 'forsyth', 'khushalani', 'phase', 'trial', 'pembrolizumab', 'bevacizumab', 'melanoma', 'brain', 'met', 'patient', 'neuro-oncology', 'supplement_', 'vi-vi', 'doi', './neuonc/noz', 'kluger', 'km', 'forsyth', 'khushalani', 'phase', 'trial', 'pembrolizumab', 'combination', 'bevacizumab', 'melanoma', 'patient', 'untreated', 'brain', 'metastasis', 'poster', 'presented', 'society', 'neuro-oncology', 'annual', 'meeting', 'november', 'phoenix', 'az', 'keytruda', 'pembrolizumab', 'prescribing', 'information', 'merck', 'inc.', 'thank', 'considering', 'request', 'contact', 'information', 'need', 'contact', 'additional', 'information', 'sincerely', 'suzana', 'giffin', 'avp', 'global', 'medical', 'affair', 'merck', 'inc.', 'galloping', 'hill', 'rd', 'kenilworth', 'nj', 'suzana.giffin', 'merck.com']}]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Using Gensim LdaSecModel"
      ],
      "metadata": {
        "id": "fERY3EnOiB5c"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "#Run for finding optimal number of topics with best coherence score\n",
        "\n",
        "processed_texts = preprocess_text(pdf_texts)\n",
        "\n",
        "# Extract the preprocessed text and timestamps from processed_texts\n",
        "documents = [entry['text'] for entry in processed_texts]\n",
        "timestamps = [entry['timestamp'] for entry in processed_texts]  # Extract timestamps\n",
        "\n",
        "\n",
        "# Convert documents into gensim format\n",
        "dictionary = Dictionary(documents)\n",
        "corpus = [dictionary.doc2bow(doc) for doc in documents]\n",
        "\n",
        "# Convert timestamps to integers for time slices (e.g., year, month, etc.)\n",
        "time_slices = [ts.year for ts in timestamps]  # Access the year attribute of the datetime object\n",
        "\n",
        "# Get unique time slices and their counts\n",
        "unique_time_slices = sorted(set(time_slices))\n",
        "time_slices_lengths = [time_slices.count(year) for year in unique_time_slices]\n",
        "\n",
        "# Function to compute coherence for a given number of topics\n",
        "def compute_coherence_for_topics(num_topics):\n",
        "    ldaseq = LdaSeqModel(corpus=corpus, id2word=dictionary, time_slice=time_slices_lengths, num_topics=num_topics)\n",
        "\n",
        "    # Get the topics for each time slice\n",
        "    topics_per_timeslice = [ldaseq.print_topics(time=t) for t in range(len(unique_time_slices))]\n",
        "\n",
        "    # Flatten the list of topics and convert to the required format for CoherenceModel\n",
        "    topics = [[word for word, prob in topic] for timeslice_topics in topics_per_timeslice for topic in timeslice_topics]\n",
        "\n",
        "    # Compute coherence score\n",
        "    coherence_model_ldaseq = CoherenceModel(topics=topics, texts=documents, dictionary=dictionary, coherence='c_v')\n",
        "    coherence = coherence_model_ldaseq.get_coherence()\n",
        "    return coherence\n",
        "\n",
        "# Test different numbers of topics to find the best coherence score\n",
        "topic_range = range(2, 21, 2)  # Testing with 2, 4, 6, ..., 20 topics\n",
        "best_num_topics = 0\n",
        "best_coherence_score = 0\n",
        "\n",
        "for num_topics in topic_range:\n",
        "    coherence_score = compute_coherence_for_topics(num_topics)\n",
        "    print(f'Num Topics: {num_topics}, Coherence Score: {coherence_score}')\n",
        "\n",
        "    if coherence_score > best_coherence_score:\n",
        "        best_coherence_score = coherence_score\n",
        "        best_num_topics = num_topics\n",
        "\n",
        "print(f'\\nBest Coherence Score: {best_coherence_score} with {best_num_topics} topics')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 411
        },
        "id": "CPYKDOaSuzYx",
        "outputId": "4ffe3f6b-36b9-4ea7-c31d-b610dbcba9b9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "KeyboardInterrupt",
          "evalue": "",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-9-e08696a19d9d>\u001b[0m in \u001b[0;36m<cell line: 39>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     38\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     39\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0mnum_topics\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mtopic_range\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 40\u001b[0;31m     \u001b[0mcoherence_score\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mcompute_coherence_for_topics\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnum_topics\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     41\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mf'Num Topics: {num_topics}, Coherence Score: {coherence_score}'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     42\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-9-e08696a19d9d>\u001b[0m in \u001b[0;36mcompute_coherence_for_topics\u001b[0;34m(num_topics)\u001b[0m\n\u001b[1;32m     19\u001b[0m \u001b[0;31m# Function to compute coherence for a given number of topics\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     20\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0mcompute_coherence_for_topics\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnum_topics\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 21\u001b[0;31m     \u001b[0mldaseq\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mLdaSeqModel\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcorpus\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcorpus\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mid2word\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdictionary\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtime_slice\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtime_slices_lengths\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnum_topics\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mnum_topics\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     22\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     23\u001b[0m     \u001b[0;31m# Get the topics for each time slice\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, corpus, time_slice, id2word, alphas, num_topics, initialize, sstats, lda_model, obs_variance, chain_variance, passes, random_state, lda_inference_max_iter, em_min_iter, em_max_iter, chunksize)\u001b[0m\n\u001b[1;32m    191\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    192\u001b[0m             \u001b[0;31m# fit DTM\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 193\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfit_lda_seq\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcorpus\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mlda_inference_max_iter\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mem_min_iter\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mem_max_iter\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mchunksize\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    194\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    195\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0minit_ldaseq_ss\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtopic_chain_variance\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtopic_obs_variance\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0malpha\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minit_suffstats\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py\u001b[0m in \u001b[0;36mfit_lda_seq\u001b[0;34m(self, corpus, lda_inference_max_iter, em_min_iter, em_max_iter, chunksize)\u001b[0m\n\u001b[1;32m    286\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    287\u001b[0m             \u001b[0;31m# fit the variational distribution. This is the M - Step\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 288\u001b[0;31m             \u001b[0mtopic_bound\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfit_lda_seq_topics\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtopic_suffstats\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    289\u001b[0m             \u001b[0mbound\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0mtopic_bound\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    290\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py\u001b[0m in \u001b[0;36mfit_lda_seq_topics\u001b[0;34m(self, topic_suffstats)\u001b[0m\n\u001b[1;32m    487\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mk\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mchain\u001b[0m \u001b[0;32min\u001b[0m \u001b[0menumerate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtopic_chains\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    488\u001b[0m             \u001b[0mlogger\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0minfo\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"Fitting topic number %i\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mk\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 489\u001b[0;31m             \u001b[0mlhood_term\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msslm\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfit_sslm\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mchain\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtopic_suffstats\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    490\u001b[0m             \u001b[0mlhood\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0mlhood_term\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    491\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py\u001b[0m in \u001b[0;36mfit_sslm\u001b[0;34m(self, sstats)\u001b[0m\n\u001b[1;32m    967\u001b[0m             \u001b[0miter_\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    968\u001b[0m             \u001b[0mold_bound\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mbound\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 969\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mobs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mzeta\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate_obs\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msstats\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtotals\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    970\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    971\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mmodel\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m\"DTM\"\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py\u001b[0m in \u001b[0;36mupdate_obs\u001b[0;34m(self, sstats, totals)\u001b[0m\n\u001b[1;32m   1106\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0mmodel\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m\"DTM\"\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1107\u001b[0m                     \u001b[0;31m# slowest part of method\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1108\u001b[0;31m                     obs = optimize.fmin_cg(\n\u001b[0m\u001b[1;32m   1109\u001b[0m                         \u001b[0mf\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mf_obs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfprime\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdf_obs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mx0\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mobs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mgtol\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mTOL\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0margs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mepsilon\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mSTEP_SIZE\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdisp\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1110\u001b[0m                     )\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_optimize.py\u001b[0m in \u001b[0;36mfmin_cg\u001b[0;34m(f, x0, fprime, args, gtol, norm, epsilon, maxiter, full_output, disp, retall, callback, c1, c2)\u001b[0m\n\u001b[1;32m   1657\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1658\u001b[0m     \u001b[0mcallback\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_wrap_callback\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcallback\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1659\u001b[0;31m     res = _minimize_cg(f, x0, args, fprime, callback=callback, c1=c1, c2=c2,\n\u001b[0m\u001b[1;32m   1660\u001b[0m                        **opts)\n\u001b[1;32m   1661\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_optimize.py\u001b[0m in \u001b[0;36m_minimize_cg\u001b[0;34m(fun, x0, args, jac, callback, gtol, norm, eps, maxiter, disp, return_all, finite_diff_rel_step, c1, c2, **unknown_options)\u001b[0m\n\u001b[1;32m   1777\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1778\u001b[0m             \u001b[0malpha_k\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfc\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mgc\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mold_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mold_old_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mgfkp1\u001b[0m \u001b[0;34m=\u001b[0m\u001b[0;31m \u001b[0m\u001b[0;31m\\\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1779\u001b[0;31m                      _line_search_wolfe12(f, myfprime, xk, pk, gfk, old_fval,\n\u001b[0m\u001b[1;32m   1780\u001b[0m                                           \u001b[0mold_old_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mc1\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mc1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mc2\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mc2\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mamin\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1e-100\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1781\u001b[0m                                           amax=1e100, extra_condition=descent_condition)\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_optimize.py\u001b[0m in \u001b[0;36m_line_search_wolfe12\u001b[0;34m(f, fprime, xk, pk, gfk, old_fval, old_old_fval, **kwargs)\u001b[0m\n\u001b[1;32m   1150\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0mkey\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mkwargs\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1151\u001b[0m                     \u001b[0mkwargs2\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mkwargs\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1152\u001b[0;31m             ret = line_search_wolfe2(f, fprime, xk, pk, gfk,\n\u001b[0m\u001b[1;32m   1153\u001b[0m                                      \u001b[0mold_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mold_old_fval\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1154\u001b[0m                                      \u001b[0mextra_condition\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mextra_condition\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_linesearch.py\u001b[0m in \u001b[0;36mline_search_wolfe2\u001b[0;34m(f, myfprime, xk, pk, gfk, old_fval, old_old_fval, args, c1, c2, amax, extra_condition, maxiter)\u001b[0m\n\u001b[1;32m    311\u001b[0m         \u001b[0mextra_condition2\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    312\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 313\u001b[0;31m     alpha_star, phi_star, old_fval, derphi_star = scalar_search_wolfe2(\n\u001b[0m\u001b[1;32m    314\u001b[0m             \u001b[0mphi\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mderphi\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mold_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mold_old_fval\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mderphi0\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mc1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mc2\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mamax\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    315\u001b[0m             extra_condition2, maxiter=maxiter)\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_linesearch.py\u001b[0m in \u001b[0;36mscalar_search_wolfe2\u001b[0;34m(phi, derphi, phi0, old_phi0, derphi0, c1, c2, amax, extra_condition, maxiter)\u001b[0m\n\u001b[1;32m    441\u001b[0m             \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    442\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 443\u001b[0;31m         \u001b[0mderphi_a1\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mderphi\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0malpha1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    444\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mabs\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mderphi_a1\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m<=\u001b[0m \u001b[0;34m-\u001b[0m\u001b[0mc2\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0mderphi0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    445\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mextra_condition\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0malpha1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mphi_a1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_linesearch.py\u001b[0m in \u001b[0;36mderphi\u001b[0;34m(alpha)\u001b[0m\n\u001b[1;32m    292\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mderphi\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0malpha\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    293\u001b[0m         \u001b[0mgc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 294\u001b[0;31m         \u001b[0mgval\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfprime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mxk\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0malpha\u001b[0m \u001b[0;34m*\u001b[0m \u001b[0mpk\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m)\u001b[0m  \u001b[0;31m# store for later use\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    295\u001b[0m         \u001b[0mgval_alpha\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0malpha\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    296\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdot\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mgval\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mpk\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_differentiable_functions.py\u001b[0m in \u001b[0;36mgrad\u001b[0;34m(self, x)\u001b[0m\n\u001b[1;32m    282\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0marray_equal\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    283\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_update_x_impl\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 284\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_update_grad\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    285\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mg\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    286\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/scipy/optimize/_differentiable_functions.py\u001b[0m in \u001b[0;36m_update_grad\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    265\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_update_grad\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    266\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mg_updated\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 267\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_update_grad_impl\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    268\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mg_updated\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    269\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Extract the preprocessed text and timestamps from processed_texts\n",
        "documents = [entry['text'] for entry in processed_texts]\n",
        "timestamps = [entry['timestamp'] for entry in processed_texts]  # Extract timestamps\n",
        "\n",
        "\n",
        "# Convert documents into gensim format\n",
        "dictionary = Dictionary(documents)\n",
        "corpus = [dictionary.doc2bow(doc) for doc in documents]\n",
        "\n",
        "\n",
        "# Convert timestamps to integers for time slices (e.g., year, month, etc.)\n",
        "time_slices = [ts.year for ts in timestamps]\n",
        "\n",
        "# Get unique time slices and their counts\n",
        "unique_time_slices = sorted(set(time_slices))\n",
        "time_slices_lengths = [time_slices.count(year) for year in unique_time_slices]\n",
        "\n",
        "# Initialize LdaSeqModel\n",
        "num_topics = 10  # from coherence score\n",
        "ldaseq = LdaSeqModel(corpus=corpus, id2word=dictionary, time_slice=time_slices_lengths, num_topics=num_topics)\n",
        "\n",
        "# Print the topics for each time slice\n",
        "for t in range(len(unique_time_slices)):\n",
        "    print(f\"\\nTopics for year {unique_time_slices[t]}:\")\n",
        "    for topic_id in range(num_topics):\n",
        "        topic_terms = ldaseq.print_topic(topic_id, time=t)\n",
        "        print(f\"Topic {topic_id}: {topic_terms}\")\n",
        "\n",
        "# Get the topics for each time slice\n",
        "topics_per_timeslice = [ldaseq.print_topics(time=t) for t in range(len(unique_time_slices))]\n",
        "\n",
        "# Flatten the list of topics and convert to the required format for CoherenceModel\n",
        "topics = [[word for word, prob in topic] for timeslice_topics in topics_per_timeslice for topic in timeslice_topics]\n",
        "\n",
        "documents = [entry['text'] for entry in processed_texts]   # List of tokenized documents\n",
        "coherence_model_ldaseq = gensim.models.CoherenceModel(topics=topics, texts=documents, dictionary=dictionary, coherence='c_v')\n",
        "coherence = coherence_model_ldaseq.get_coherence()\n",
        "print(f'\\nCoherence Score: {coherence}')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5_14z2aWSmM3",
        "outputId": "7c47e911-e0c8-4bca-ce71-a32de22865e9",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n",
            "/usr/local/lib/python3.10/dist-packages/gensim/models/ldaseqmodel.py:298: RuntimeWarning: divide by zero encountered in scalar divide\n",
            "  convergence = np.fabs((bound - old_bound) / old_bound)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Topics for year 201:\n",
            "Topic 0: [('patient', 0.030394853014731674), ('melanoma', 0.027730650373850908), ('risk', 0.015114608626343133), ('-gep', 0.014393449668244618), ('expression', 0.013660857537312302), ('gep', 0.013249962561234107), ('class', 0.012611730986324926), ('test', 0.011887833369276688), ('study', 0.01174611655176095), ('prognostic', 0.011707903183783185), ('cutaneous', 0.011063854693303808), ('slnb', 0.01057396185845648), ('staging', 0.009759443981620312), ('result', 0.00948423045047171), ('prospective', 0.009227270075587903), ('stage', 0.009211555051519516), ('profile', 0.008513605385958703), ('outcome', 0.007753178764732287), ('metastasis', 0.0074930910941936315), ('clinical', 0.00733002337758367)]\n",
            "Topic 1: [('patient', 0.023037378430851522), ('melanoma', 0.019132680416665278), ('clinical', 0.009208239117531785), ('lifileucel', 0.009159778020030806), ('therapy', 0.0076434121424913785), ('lesion', 0.006939961419664312), ('cancer', 0.006890732700604385), ('clin', 0.006664535657861802), ('cell', 0.006608377577289724), ('may', 0.006393397251003606), ('page', 0.006291384525910798), ('lymphocyte', 0.005882470459294243), ('study', 0.005825451360286993), ('care', 0.005789416626131827), ('management', 0.005696220469738797), ('accuracy', 0.005611778999820124), ('tumor-infiltrating', 0.005115701564005591), ('evaluation', 0.005019431762988317), ('center', 0.00500777527912949), ('prior', 0.004811858917283067)]\n",
            "Topic 2: [('tmb', 0.02512627713028841), ('panel', 0.014142821957173288), ('patient', 0.013293932709637359), ('tumor', 0.01140130105938266), ('group', 0.011383867055954107), ('burden', 0.011376012164050748), ('cancer', 0.010181508883734652), ('ttmb-high', 0.008949781511795565), ('research', 0.008631329813989229), ('pembrolizumab', 0.008135615211247444), ('medicine', 0.008031424135247314), ('requested', 0.007771078717806823), ('across', 0.00713665317534374), ('value', 0.006983885240325684), ('guideline', 0.0065854915142057515), ('ci', 0.006565413329728565), ('rate', 0.006558879259149367), ('fda-approved', 0.006558504067518762), ('mutational', 0.006553493309201024), ('foundation', 0.006551483525261367)]\n",
            "Topic 3: [('-gene', 0.07384382250987406), ('melanoma', 0.010697063779567147), ('patient', 0.010075380175104029), ('..', 0.007246201723254092), ('study', 0.0058230621852402185), ('expression', 0.004306888828915283), ('test', 0.004296549029303913), ('-gep', 0.004267374729073247), ('risk', 0.003948569170106444), ('clinical', 0.003810941223010368), ('gep', 0.003660024165096663), ('result', 0.003480185230604665), ('class', 0.0031737785760353535), ('cutaneous', 0.003169921762380255), ('prognostic', 0.0031019701600391346), ('biopsy', 0.00310106091951514), ('nccn', 0.0029092824441306247), ('guideline', 0.002752009017171869), ('profile', 0.002684482971717825), ('stage', 0.002596731719391408)]\n",
            "Topic 4: [('clinical', 0.027913804043923855), ('cancer', 0.024148757343672507), ('patient', 0.02412436261262338), ('melanoma', 0.02307834380862451), ('nccn', 0.020142315586808464), ('dna', 0.019786176418228937), ('testing', 0.01937259705294808), ('tissue', 0.01830915511938433), ('tumor', 0.016256046664254342), ('study', 0.014150833368815991), ('guideline', 0.013445066019380924), ('liquid', 0.012117201757911835), ('braf', 0.012083653702897044), ('ctdna', 0.012049444739332015), ('analysis', 0.011891603259669018), ('may', 0.01091245706490551), ('agreement', 0.010570749695876989), ('biopsy', 0.010293789925963064), ('mutation', 0.00951163777217608), ('molecular', 0.008946007908690566)]\n",
            "Topic 5: [('ipilimumab', 0.04090207945555785), ('melanoma', 0.028558414278274248), ('sargramostim', 0.025956631254639317), ('patient', 0.020993847972638452), ('survival', 0.01881412055131661), ('metastatic', 0.015195276177452885), ('alone', 0.014749914650759352), ('arm', 0.013829231215524937), ('overall', 0.013336815483875128), ('treatment', 0.012891534912485455), ('month', 0.012590467822592993), ('mg/kg', 0.012196322279955311), ('event', 0.011556520364642818), ('adverse', 0.01045171552951963), ('combination', 0.010210832428095219), ('therapy', 0.009721287810876002), ('compared', 0.009303700090248406), ('trial', 0.008667519959521837), ('doi', 0.007813298035453713), ('advanced', 0.007673001309297636)]\n",
            "Topic 6: [('pla', 0.036499317728711046), ('melanoma', 0.0299578279378957), ('lesion', 0.029890262848776595), ('biopsy', 0.02588878777228713), ('test', 0.02062337813009261), ('pigmented', 0.01914273202085553), ('utility', 0.011251724834654961), ('evidence', 0.009898779965433901), ('clinical', 0.009890475833282114), ('assay', 0.009342318556190226), ('guideline', 0.008792632887785805), ('cutaneous', 0.008735284937491882), ('panel', 0.008308768666095954), ('patient', 0.008238966858667856), ('clinician', 0.008197853912546028), ('study', 0.007825275939390247), ('skin', 0.007800077362385536), ('nccn', 0.007649140455108083), ('diagnostic', 0.007586860482219407), ('case', 0.007359404845731021)]\n",
            "Topic 7: [('test', 0.0259441797949926), ('evidence', 0.02188281306879856), ('nccn', 0.017649917370717468), ('decisiondx-um', 0.015473417377459256), ('melanoma', 0.014877654435101974), ('uveal', 0.014141898284304691), ('level', 0.013446003823019649), ('um', 0.01278935074291007), ('prospective', 0.011460629920435898), ('clinical', 0.011428381497391144), ('guideline', 0.011420527935390772), ('risk', 0.011411627772778), ('class', 0.009343454494973893), ('expression', 0.008644444035732102), ('category', 0.007957451250538159), ('patient', 0.00795347905678872), ('gene', 0.007268642940134945), ('prognostic', 0.007268530627390573), ('follow', 0.006742626831444145), ('panel', 0.006584616298254775)]\n",
            "Topic 8: [('patient', 0.02860232693192175), ('melanoma', 0.027092491597906252), ('therapy', 0.014915367069614873), ('pembrolizumab', 0.013619540753817631), ('treatment', 0.011386529821857875), ('arm', 0.01105401915141011), ('nivo', 0.01058030361260068), ('metastatic', 0.010223134915055759), ('ci', 0.010002396905064586), ('panel', 0.009435120942879063), ('request', 0.009110452598930016), ('ipi', 0.009045524531282514), ('information', 0.009032045579302168), ('unresectable', 0.008358127143742884), ('month', 0.008024165772539452), ('nccn', 0.007936878848612614), ('randomized', 0.007923020237842561), ('keytruda', 0.0070611808807542285), ('disease', 0.006946628698384409), ('systemic', 0.006857831934561207)]\n",
            "Topic 9: [('-gene', 0.4586948879130445), ('melanoma', 0.006097151631033407), ('patient', 0.005087672533324227), ('test', 0.0023757096670201294), ('guideline', 0.0023627096798170487), ('study', 0.0022486455615793495), ('nccn', 0.002184538548832866), ('evidence', 0.0021701470444617857), ('expression', 0.001969538625888377), ('clinical', 0.0019232295493440315), ('prospective', 0.0017292804901789507), ('biopsy', 0.00169152734880628), ('pla', 0.0016605275835639014), ('cutaneous', 0.0016252801233606416), ('risk', 0.0016104652388027974), ('class', 0.0015762971625625823), ('gep', 0.0015284904276033347), ('panel', 0.001508348326081721), ('gene', 0.0014760278315637434), ('prognostic', 0.0014755081911821688)]\n",
            "\n",
            "Topics for year 2020:\n",
            "Topic 0: [('patient', 0.030678864919397374), ('melanoma', 0.027992663935013613), ('risk', 0.015174685807574272), ('-gep', 0.014433842999645207), ('expression', 0.013772766505663678), ('gep', 0.013398999608597419), ('class', 0.012666621531388377), ('test', 0.011980176310660789), ('prognostic', 0.011762226152105459), ('study', 0.011762196587893611), ('cutaneous', 0.01112252502805005), ('slnb', 0.010632922969696802), ('staging', 0.009780581437280856), ('result', 0.009491618839765681), ('prospective', 0.009296557484190764), ('stage', 0.00921225083626732), ('profile', 0.008577278443911896), ('outcome', 0.007792979770713302), ('metastasis', 0.007520897617059564), ('clinical', 0.007368312560234186)]\n",
            "Topic 1: [('patient', 0.02310893629508219), ('melanoma', 0.01919858866814279), ('clinical', 0.0092246055648492), ('lifileucel', 0.009172233971146042), ('therapy', 0.00766627638272522), ('lesion', 0.006951393964914276), ('cancer', 0.006891614523679002), ('clin', 0.006670392822934094), ('cell', 0.00661944160689854), ('may', 0.006401489057656233), ('page', 0.006299070279269719), ('lymphocyte', 0.005886811709619093), ('study', 0.005832177818714968), ('care', 0.005794658443071362), ('management', 0.005710434075285537), ('accuracy', 0.005620178926809365), ('tumor-infiltrating', 0.005119817286945457), ('evaluation', 0.005031585976055681), ('center', 0.005018258885211064), ('prior', 0.004818536049746388)]\n",
            "Topic 2: [('tmb', 0.025196398007728434), ('panel', 0.014164759735791652), ('patient', 0.013332412326184904), ('tumor', 0.011424240475522342), ('burden', 0.011413343169786568), ('group', 0.011411860171486243), ('cancer', 0.01020510465555876), ('ttmb-high', 0.0090013027490047), ('research', 0.00864149369200316), ('pembrolizumab', 0.00814755130768784), ('medicine', 0.008040978086354993), ('requested', 0.007787549862648434), ('across', 0.007145286645249132), ('value', 0.006987814730365581), ('guideline', 0.006595002249621114), ('ci', 0.006567822221076369), ('rate', 0.006563741319158805), ('fda-approved', 0.006562288254043499), ('mutational', 0.006561998230406373), ('foundation', 0.00656178025293266)]\n",
            "Topic 3: [('-gene', 0.0738591169938233), ('melanoma', 0.01072293684221026), ('patient', 0.010099273382002725), ('..', 0.0072547720323459805), ('study', 0.005834351758533181), ('expression', 0.004314214104714), ('test', 0.0043038485725594815), ('-gep', 0.004274601772635662), ('risk', 0.003955014467201468), ('clinical', 0.0038170552292552447), ('gep', 0.003665779407806155), ('result', 0.003485519389257507), ('class', 0.003178412415542554), ('cutaneous', 0.00317454693108084), ('prognostic', 0.003106443172967924), ('biopsy', 0.0031055319044003054), ('nccn', 0.0029133304726371573), ('guideline', 0.002755717609081198), ('profile', 0.0026880479786850387), ('stage', 0.0026001121433215308)]\n",
            "Topic 4: [('clinical', 0.028165638282329764), ('patient', 0.024194181577596174), ('cancer', 0.024107662885331647), ('melanoma', 0.023095529104714296), ('nccn', 0.020252132448279076), ('dna', 0.01971457398877975), ('testing', 0.01926296553255894), ('tissue', 0.018285759221160013), ('tumor', 0.016212892335241147), ('study', 0.014232174726471663), ('guideline', 0.013452700800408338), ('braf', 0.012059002086158161), ('liquid', 0.012047114168028674), ('ctdna', 0.012017109249147815), ('analysis', 0.011922244825090198), ('may', 0.010898873624524701), ('agreement', 0.01058877375232151), ('biopsy', 0.010306982321981217), ('mutation', 0.009499488841700321), ('molecular', 0.008958644039107129)]\n",
            "Topic 5: [('ipilimumab', 0.040983697818087084), ('melanoma', 0.028655108357143966), ('sargramostim', 0.026082231407027808), ('patient', 0.02100978462710819), ('survival', 0.01882173918528222), ('metastatic', 0.01521978070276445), ('alone', 0.014791355758261635), ('arm', 0.0138453875523264), ('overall', 0.013351468689687068), ('treatment', 0.012901992087000326), ('month', 0.012623428461292703), ('mg/kg', 0.012213626806269235), ('event', 0.01155687269331228), ('adverse', 0.010464776381133536), ('combination', 0.01023144883345537), ('therapy', 0.009734335502532042), ('compared', 0.00930043672660343), ('trial', 0.008669096854210547), ('doi', 0.007825584403912015), ('advanced', 0.007682310357620731)]\n",
            "Topic 6: [('pla', 0.036799797748523974), ('lesion', 0.030139777541366406), ('melanoma', 0.030132073027118702), ('biopsy', 0.02610326739368211), ('test', 0.020784178953504356), ('pigmented', 0.019274285938810642), ('utility', 0.011317858125765856), ('evidence', 0.009890712153585243), ('clinical', 0.00989037478541809), ('assay', 0.009334748692525345), ('guideline', 0.008783778498016374), ('cutaneous', 0.008731552536272766), ('panel', 0.008314772898761771), ('patient', 0.008228395677355919), ('clinician', 0.008199044329223058), ('study', 0.007825232496078556), ('skin', 0.007773427128645203), ('nccn', 0.007654605464137503), ('diagnostic', 0.007584024111530841), ('case', 0.0073742209224325625)]\n",
            "Topic 7: [('test', 0.026066223526215643), ('evidence', 0.021965409426523894), ('nccn', 0.017719478911780065), ('decisiondx-um', 0.015537027148075842), ('melanoma', 0.014940564380564535), ('uveal', 0.014181174819253491), ('level', 0.013480747615216547), ('um', 0.012812981261161439), ('prospective', 0.011485346869911813), ('clinical', 0.011443551984197473), ('guideline', 0.011438918985633631), ('risk', 0.011435324704573735), ('class', 0.009353127358489944), ('expression', 0.008658934488908738), ('category', 0.007964276401824724), ('patient', 0.007959907585832062), ('gene', 0.007272976673488925), ('prognostic', 0.007272109135601659), ('follow', 0.00674580637366073), ('panel', 0.006587835695945161)]\n",
            "Topic 8: [('patient', 0.028703130849684844), ('melanoma', 0.02683288187473765), ('therapy', 0.015926130478159245), ('pembrolizumab', 0.013677928199678174), ('treatment', 0.01146301513597881), ('arm', 0.011397466971972385), ('metastatic', 0.010394925273124543), ('ci', 0.010170159908297756), ('nivo', 0.010169396409296693), ('panel', 0.00941397083524047), ('information', 0.009063230074635067), ('request', 0.009060238566070862), ('ipi', 0.008640962100836145), ('unresectable', 0.008474200208145601), ('month', 0.008081794873711532), ('randomized', 0.007963267693773384), ('nccn', 0.00794022075416498), ('keytruda', 0.007102394284719164), ('disease', 0.0070341035614992055), ('systemic', 0.00697662786613364)]\n",
            "Topic 9: [('-gene', 0.46020180015044854), ('melanoma', 0.00609512553972723), ('patient', 0.005085257024242682), ('test', 0.00237315817853471), ('guideline', 0.002360161955133642), ('study', 0.002246133310973533), ('nccn', 0.002182048220741817), ('evidence', 0.0021676618398223974), ('expression', 0.0019671328959955446), ('clinical', 0.0019208443939992275), ('prospective', 0.0017269912973161272), ('biopsy', 0.0016892587695447319), ('pla', 0.0016582764256976126), ('cutaneous', 0.001623049327896089), ('risk', 0.0016082431807008246), ('class', 0.0015740956663405723), ('gep', 0.0015263186820551609), ('panel', 0.0015061894654429932), ('gene', 0.0014738900899060848), ('prognostic', 0.001473370793586767)]\n",
            "\n",
            "Topics for year 2021:\n",
            "Topic 0: [('patient', 0.030936318426470977), ('melanoma', 0.028261204738483734), ('risk', 0.015168063871825031), ('-gep', 0.014384858708645613), ('gep', 0.0140046157189668), ('expression', 0.013891451356403677), ('class', 0.012677650727604755), ('test', 0.012115912524821635), ('study', 0.011982868070375236), ('prognostic', 0.011867010991005811), ('cutaneous', 0.011269051726234214), ('slnb', 0.010657121764286959), ('staging', 0.009706251572298609), ('prospective', 0.009703563666903402), ('result', 0.009328712243302234), ('stage', 0.009187493912157941), ('profile', 0.00864202421742184), ('outcome', 0.007817479621841648), ('metastasis', 0.007522938502216563), ('clinical', 0.007430841404208665)]\n",
            "Topic 1: [('patient', 0.023162938725340056), ('melanoma', 0.019280046178879517), ('clinical', 0.009305634270703687), ('lifileucel', 0.008948328982049093), ('therapy', 0.007689927167668348), ('lesion', 0.007012312073274337), ('cancer', 0.006853475053249544), ('clin', 0.006610207477940476), ('cell', 0.006545426130042237), ('may', 0.006427620543479397), ('page', 0.006320028240500125), ('study', 0.005839369208542961), ('lymphocyte', 0.005823105502138024), ('care', 0.005793629490169656), ('management', 0.005790947502946755), ('accuracy', 0.005575267298305778), ('tumor-infiltrating', 0.005097774409117921), ('center', 0.005058962033291352), ('evaluation', 0.005056996625517381), ('prior', 0.004823042230281412)]\n",
            "Topic 2: [('tmb', 0.025334162179397074), ('panel', 0.014191854460998451), ('patient', 0.01329744432861845), ('burden', 0.011447824221824032), ('group', 0.011426032088231479), ('tumor', 0.01142320074507052), ('cancer', 0.010223918726028163), ('ttmb-high', 0.009046905442967112), ('research', 0.00857121078334794), ('pembrolizumab', 0.008173554281401596), ('medicine', 0.00802171256201836), ('requested', 0.007859374498399773), ('across', 0.0071484135973049), ('value', 0.006994513162164502), ('guideline', 0.00660502206963339), ('mutational', 0.006579969206114595), ('foundation', 0.0065793537988123535), ('rate', 0.006571683961467716), ('fda-approved', 0.006568823667956563), ('ci', 0.006512453184684481)]\n",
            "Topic 3: [('-gene', 0.07370938054271961), ('melanoma', 0.01074392700849359), ('patient', 0.01011868901567683), ('..', 0.007270607017449979), ('study', 0.0058436973832010405), ('expression', 0.00432036391557748), ('test', 0.004309977559485355), ('-gep', 0.004280672082704077), ('risk', 0.0039604514017220005), ('clinical', 0.003822223345289401), ('gep', 0.0036706561121479476), ('result', 0.0034900536264091233), ('class', 0.0031823759088187476), ('cutaneous', 0.0031785033476966103), ('prognostic', 0.0031102753641914557), ('biopsy', 0.0031093624392883015), ('nccn', 0.0029168152256517053), ('guideline', 0.002758924318492055), ('profile', 0.002691136912101661), ('stage', 0.0026030495196010537)]\n",
            "Topic 4: [('clinical', 0.028178096379268342), ('patient', 0.02422243867990776), ('cancer', 0.024141957312312112), ('melanoma', 0.02303372614061393), ('nccn', 0.020305377862409938), ('dna', 0.01978801230561779), ('testing', 0.019475681296996693), ('tissue', 0.018389628656508467), ('tumor', 0.016414108740201393), ('study', 0.014231171048357149), ('guideline', 0.013536536726732691), ('ctdna', 0.01210090452198137), ('braf', 0.012054666736663817), ('liquid', 0.012048678174130164), ('analysis', 0.011921047083154697), ('may', 0.010903216344555195), ('agreement', 0.010592936061949247), ('biopsy', 0.010311692961382908), ('mutation', 0.009493288110941063), ('molecular', 0.008954913376117644)]\n",
            "Topic 5: [('ipilimumab', 0.04108930808980319), ('melanoma', 0.028728320363746195), ('sargramostim', 0.02620142244538502), ('patient', 0.020997237982445977), ('survival', 0.018876766805444544), ('metastatic', 0.015195153638198487), ('alone', 0.01482949880677824), ('arm', 0.013886238754850575), ('overall', 0.013389235543021752), ('treatment', 0.012907094331012932), ('month', 0.012644536394724194), ('mg/kg', 0.012244049279870724), ('event', 0.01158300293402381), ('adverse', 0.01047482999108425), ('combination', 0.01024755575402304), ('therapy', 0.009714088662916825), ('compared', 0.009319124688498255), ('trial', 0.008660839753552231), ('doi', 0.007837404706400422), ('advanced', 0.0076629360985395936)]\n",
            "Topic 6: [('pla', 0.037346355203023124), ('melanoma', 0.03086012950014991), ('lesion', 0.030579144802658467), ('biopsy', 0.02644964744259254), ('test', 0.020932107943965033), ('pigmented', 0.019375012039492153), ('utility', 0.011399453921633098), ('clinical', 0.010083975073138289), ('evidence', 0.009755046856774852), ('assay', 0.00920291266775725), ('cutaneous', 0.008811906972992408), ('guideline', 0.008757213547391696), ('panel', 0.00826822815135748), ('patient', 0.008222824736216015), ('clinician', 0.008119367468960114), ('study', 0.0077478163629519274), ('skin', 0.007677957579399925), ('nccn', 0.0076753241787596675), ('diagnostic', 0.007547423694373199), ('case', 0.007362408477960172)]\n",
            "Topic 7: [('test', 0.02617673421886141), ('evidence', 0.02202943929366597), ('nccn', 0.017779100904714042), ('decisiondx-um', 0.015594949520770708), ('melanoma', 0.014999446028786667), ('uveal', 0.014206999424808723), ('level', 0.01350220324826682), ('um', 0.012822864187175518), ('prospective', 0.01149800156612815), ('clinical', 0.011449716496396745), ('risk', 0.01144716115794674), ('guideline', 0.011445803766949479), ('class', 0.009357153025933533), ('expression', 0.008665684088447525), ('category', 0.007967808397089191), ('patient', 0.007963655336497339), ('gene', 0.007275135643831212), ('prognostic', 0.0072740119374640165), ('follow', 0.0067476190655290525), ('panel', 0.006589557105024059)]\n",
            "Topic 8: [('patient', 0.028852400713251902), ('melanoma', 0.026690489919369186), ('therapy', 0.01567363413503011), ('pembrolizumab', 0.013866684422732837), ('treatment', 0.011490073116856665), ('arm', 0.011487465641054531), ('metastatic', 0.01036858567383485), ('ci', 0.01023363308000272), ('nivo', 0.010207450314860742), ('panel', 0.00948310951539232), ('request', 0.009125142112032391), ('information', 0.009118082048012366), ('ipi', 0.008686037847565546), ('unresectable', 0.008534713518909491), ('month', 0.008108705378499333), ('randomized', 0.00796919959967719), ('nccn', 0.007944544063864292), ('keytruda', 0.007137291876917935), ('disease', 0.007076291168366602), ('systemic', 0.007003364769287957)]\n",
            "Topic 9: [('-gene', 0.461233255651777), ('melanoma', 0.006094561100093629), ('patient', 0.005084248817291087), ('test', 0.002371633039307757), ('guideline', 0.002358637612351682), ('study', 0.0022446177722869895), ('nccn', 0.002180539101637523), ('evidence', 0.002166154311602615), ('expression', 0.0019656535152284154), ('clinical', 0.0019193731623289851), ('prospective', 0.0017255614524066781), ('biopsy', 0.0016878384138530442), ('pla', 0.0016568642286826105), ('cutaneous', 0.0016216468178533144), ('risk', 0.0016068448746880972), ('class', 0.0015727073604309084), ('gep', 0.0015249450948812845), ('panel', 0.001504822339096075), ('gene', 0.0014725336593416185), ('prognostic', 0.0014720145383323477)]\n",
            "\n",
            "Topics for year 2022:\n",
            "Topic 0: [('patient', 0.03128104413731951), ('melanoma', 0.02857113937949531), ('risk', 0.01521772892453504), ('-gep', 0.014399645948957323), ('gep', 0.014119424087913262), ('expression', 0.014020512188624806), ('class', 0.012719359771058722), ('test', 0.012218259636654362), ('study', 0.01199328626820738), ('prognostic', 0.01193876834420865), ('cutaneous', 0.011331878455411353), ('slnb', 0.010720628015783273), ('prospective', 0.009734121490114512), ('staging', 0.00972334364822127), ('result', 0.009322050822961255), ('stage', 0.009171513851246033), ('profile', 0.008718175873760553), ('outcome', 0.007858195361786653), ('metastasis', 0.0075451943144381455), ('clinical', 0.007472849301368779)]\n",
            "Topic 1: [('patient', 0.023183718811213488), ('melanoma', 0.019372547189674752), ('clinical', 0.00939344217671469), ('lifileucel', 0.008909776555472709), ('therapy', 0.0077116741086499935), ('lesion', 0.0070231600236412145), ('cancer', 0.006830279792807431), ('clin', 0.006596471401294014), ('cell', 0.006527206765856217), ('may', 0.006418073659031671), ('page', 0.00632458926325876), ('study', 0.005845674517064441), ('management', 0.005821591766159581), ('lymphocyte', 0.005812940886318587), ('care', 0.005803751672098204), ('accuracy', 0.005563037756232605), ('tumor-infiltrating', 0.00509860720782789), ('evaluation', 0.005075421830924893), ('center', 0.0050638364275004755), ('prior', 0.004826578623487907)]\n",
            "Topic 2: [('tmb', 0.025166589639975312), ('panel', 0.014209109991579275), ('patient', 0.013302928470156482), ('burden', 0.011438038160981944), ('group', 0.011400805863546963), ('tumor', 0.011385656280201073), ('cancer', 0.010208303364073338), ('ttmb-high', 0.009089124352378372), ('research', 0.008556010201286482), ('pembrolizumab', 0.008157523553288732), ('medicine', 0.00800250408275238), ('requested', 0.00792117122971158), ('across', 0.007138517964957051), ('value', 0.006988637075188062), ('guideline', 0.006619126177165078), ('foundation', 0.006575652908018424), ('mutational', 0.006575464661754559), ('rate', 0.006559011408220556), ('fda-approved', 0.0065550241300613675), ('melanoma', 0.006505791091109748)]\n",
            "Topic 3: [('-gene', 0.07349314187373834), ('melanoma', 0.010759054187932054), ('patient', 0.010132701693230904), ('..', 0.007293330640156789), ('study', 0.005850551638758357), ('expression', 0.004324927866545303), ('test', 0.004314526535496281), ('-gep', 0.00428517885850316), ('risk', 0.003964502221582013), ('clinical', 0.0038260803883229722), ('gep', 0.00367430289967771), ('result', 0.003493453044132845), ('class', 0.003185362319766275), ('cutaneous', 0.00318148463131185), ('prognostic', 0.0031131666135954692), ('biopsy', 0.00311225248787764), ('nccn', 0.002919454368488956), ('guideline', 0.0027613613643098288), ('profile', 0.0026934882503153066), ('stage', 0.002605290470960906)]\n",
            "Topic 4: [('clinical', 0.028178629196426677), ('patient', 0.02430166370365603), ('cancer', 0.02418044504000895), ('melanoma', 0.023014079297802324), ('nccn', 0.020317117732175365), ('dna', 0.019815352416110793), ('testing', 0.019491233167182962), ('tissue', 0.018378480927768448), ('tumor', 0.016482186691555344), ('study', 0.014242031799180828), ('guideline', 0.013604900510227374), ('ctdna', 0.01212754313085186), ('braf', 0.012063005696405784), ('liquid', 0.012023802599103108), ('analysis', 0.011930143220247573), ('may', 0.010903162392627288), ('agreement', 0.010592949479015176), ('biopsy', 0.010319515259353216), ('mutation', 0.009497670889884421), ('molecular', 0.008953185036949765)]\n",
            "Topic 5: [('ipilimumab', 0.04114345722362082), ('melanoma', 0.0287743960866214), ('sargramostim', 0.026229487594423267), ('patient', 0.021001431418531773), ('survival', 0.018889561489226436), ('metastatic', 0.0151897661037381), ('alone', 0.014842167753120639), ('arm', 0.01389699790521116), ('overall', 0.013401654071018858), ('treatment', 0.012911866430610546), ('month', 0.012653570242367613), ('mg/kg', 0.012253024185933162), ('event', 0.011597088441605528), ('adverse', 0.010480868943681148), ('combination', 0.010256510568588595), ('therapy', 0.009716936995388994), ('compared', 0.009325657268695964), ('trial', 0.008661930956328556), ('doi', 0.007843469027069427), ('advanced', 0.007667688626854855)]\n",
            "Topic 6: [('pla', 0.03773332817042918), ('melanoma', 0.03132766467068082), ('lesion', 0.030841298992903058), ('biopsy', 0.02673765212011798), ('test', 0.02109499361664777), ('pigmented', 0.01952096866949378), ('utility', 0.011486159179164611), ('clinical', 0.01020065736548343), ('evidence', 0.009701693690133835), ('assay', 0.00917966423341223), ('cutaneous', 0.008830574452239831), ('guideline', 0.008732724710705846), ('panel', 0.008253818593266333), ('patient', 0.00817831804750404), ('clinician', 0.008140427165478034), ('study', 0.007724527637016439), ('nccn', 0.0076666526068192705), ('skin', 0.007651418453640808), ('diagnostic', 0.007574777781905742), ('case', 0.0073745703200002845)]\n",
            "Topic 7: [('test', 0.026254410259540444), ('evidence', 0.022066699872001907), ('nccn', 0.017818116612553333), ('decisiondx-um', 0.01563516053589579), ('melanoma', 0.015041458120693114), ('uveal', 0.01421802742193293), ('level', 0.013510098513475554), ('um', 0.012822351068911234), ('prospective', 0.011500035146654953), ('clinical', 0.01145028657335143), ('risk', 0.01144880802790783), ('guideline', 0.011444709988282393), ('class', 0.009357727513723085), ('expression', 0.0086661842273766), ('category', 0.007970585432469297), ('patient', 0.0079660922342876), ('gene', 0.00727662722661525), ('prognostic', 0.007275511566153615), ('follow', 0.006749652024170681), ('panel', 0.006590947516383231)]\n",
            "Topic 8: [('patient', 0.02903588228759148), ('melanoma', 0.02705226877828693), ('therapy', 0.015503425274216092), ('pembrolizumab', 0.01419179639148201), ('treatment', 0.011523871126524289), ('arm', 0.011375349033426876), ('metastatic', 0.01038804536256149), ('nivo', 0.010214617433111518), ('ci', 0.010174101991251683), ('panel', 0.009589337077307379), ('information', 0.009226655564506015), ('request', 0.00922180652393496), ('ipi', 0.008609475648456042), ('unresectable', 0.00860850262537299), ('month', 0.008064830787001744), ('nccn', 0.008013221086579899), ('randomized', 0.007921307197882413), ('keytruda', 0.0072316939328592525), ('disease', 0.007041457857177875), ('systemic', 0.006958220283109023)]\n",
            "Topic 9: [('-gene', 0.4619030132879818), ('melanoma', 0.006094312940244532), ('patient', 0.005083686607708422), ('test', 0.0023706738366267056), ('guideline', 0.0023576786721112436), ('study', 0.002243662335352435), ('nccn', 0.0021795866064686364), ('evidence', 0.002165202575830976), ('expression', 0.0019647163126388545), ('clinical', 0.0019184404063223486), ('prospective', 0.0017246521163570869), ('biopsy', 0.0016869345838407613), ('pla', 0.0016559651622823936), ('cutaneous', 0.0016207534390136975), ('risk', 0.0016059539739572944), ('class', 0.0015718223760980109), ('gep', 0.001524068868996757), ('panel', 0.0015039499748350236), ('gene', 0.001471667708684339), ('prognostic', 0.0014711486930025787)]\n",
            "\n",
            "Topics for year 2024:\n",
            "Topic 0: [('patient', 0.03155375762208152), ('melanoma', 0.028805866555869013), ('risk', 0.015274648875350664), ('-gep', 0.014434360177066856), ('expression', 0.014117334161338842), ('gep', 0.014093590650485177), ('class', 0.012762278034769594), ('test', 0.012284644488061996), ('study', 0.01199628024019126), ('prognostic', 0.011981791809064233), ('cutaneous', 0.011363662137142723), ('slnb', 0.010779910620873422), ('staging', 0.009739637187913895), ('prospective', 0.009686409606658708), ('result', 0.009317061388427701), ('stage', 0.009161109581561137), ('profile', 0.008776930916181178), ('outcome', 0.007893929285490993), ('metastasis', 0.007569353046849511), ('clinical', 0.007499451595489688)]\n",
            "Topic 1: [('patient', 0.023226754255480687), ('melanoma', 0.019428340917660155), ('clinical', 0.009402768009264505), ('lifileucel', 0.008944870449041829), ('therapy', 0.007733163916160492), ('lesion', 0.007025823263921622), ('cancer', 0.006833063260512294), ('clin', 0.00660530692535082), ('cell', 0.006534832894990923), ('may', 0.006418415529180653), ('page', 0.006326566307573412), ('study', 0.005851048607627883), ('management', 0.0058234032100538706), ('lymphocyte', 0.005821839320033054), ('care', 0.005810069227261917), ('accuracy', 0.005568948849325066), ('tumor-infiltrating', 0.00510797243264052), ('evaluation', 0.005087079211865403), ('center', 0.005073212120293498), ('prior', 0.0048332845318360355)]\n",
            "Topic 2: [('tmb', 0.025200529897518396), ('panel', 0.014213011321357326), ('patient', 0.013333838228090738), ('burden', 0.01144712518403588), ('group', 0.011397576242991316), ('tumor', 0.011373818996285997), ('cancer', 0.010214719081249072), ('ttmb-high', 0.009126958518499585), ('research', 0.008564628661340706), ('pembrolizumab', 0.008165311842375228), ('medicine', 0.008002121154173385), ('requested', 0.007938838874744178), ('across', 0.0071422024488880225), ('value', 0.006983305744609681), ('guideline', 0.0066257609340173015), ('foundation', 0.006581207147115492), ('mutational', 0.006580341948613655), ('rate', 0.006558107336467525), ('fda-approved', 0.006553144929349364), ('ci', 0.006497803511922989)]\n",
            "Topic 3: [('-gene', 0.07330412065573817), ('melanoma', 0.010767532840771954), ('patient', 0.010140570151642162), ('..', 0.007305341845823881), ('study', 0.005854478391803521), ('expression', 0.004327579993446714), ('test', 0.004317170291341137), ('-gep', 0.004287799021127784), ('risk', 0.0039668671573288745), ('clinical', 0.003828336669291789), ('gep', 0.0036764411481346377), ('result', 0.0034954522265960367), ('class', 0.003187128783992629), ('cutaneous', 0.0031832482018243928), ('prognostic', 0.0031148793517074896), ('biopsy', 0.003113964547765395), ('nccn', 0.002921024559678308), ('guideline', 0.0027628170407420116), ('profile', 0.0026948952899818464), ('stage', 0.002606634801038481)]\n",
            "Topic 4: [('clinical', 0.028263219094555845), ('patient', 0.024384877852296136), ('cancer', 0.024227248632496652), ('melanoma', 0.022982980410922806), ('nccn', 0.02033052648185063), ('dna', 0.019836813839153714), ('testing', 0.019476254986767673), ('tissue', 0.018367302234375184), ('tumor', 0.016543017613905846), ('study', 0.014244167905580533), ('guideline', 0.013649223836973822), ('ctdna', 0.012155597476549557), ('braf', 0.012060572592964953), ('liquid', 0.012005735155542012), ('analysis', 0.011934975197432076), ('may', 0.010913302499864073), ('agreement', 0.010595391463312584), ('biopsy', 0.01032149488517512), ('mutation', 0.009495438378780178), ('molecular', 0.0089521170315398)]\n",
            "Topic 5: [('ipilimumab', 0.041190739028515944), ('melanoma', 0.028814462214932453), ('sargramostim', 0.026232972108017474), ('patient', 0.02100856883615695), ('survival', 0.018889294577497173), ('metastatic', 0.015190008792880676), ('alone', 0.014847831534493958), ('arm', 0.013897832760126513), ('overall', 0.01340516127092013), ('treatment', 0.012916691647279514), ('month', 0.012662412703695738), ('mg/kg', 0.012254376203616048), ('event', 0.011602651685391095), ('adverse', 0.010486053271533104), ('combination', 0.010262742391161728), ('therapy', 0.00971955350284622), ('compared', 0.00932686152397021), ('trial', 0.008663794516386802), ('doi', 0.007847352176561538), ('advanced', 0.00767110896358886)]\n",
            "Topic 6: [('pla', 0.037947073051279825), ('melanoma', 0.03142230410635709), ('lesion', 0.030992055502840885), ('biopsy', 0.02691757110114778), ('test', 0.021232852809424992), ('pigmented', 0.019644630903459276), ('utility', 0.011542221025907446), ('clinical', 0.010187735999141658), ('evidence', 0.009702891208576005), ('assay', 0.009164738026717457), ('cutaneous', 0.008813566575246472), ('guideline', 0.008712693104343954), ('panel', 0.008259686902875037), ('patient', 0.008172873485643627), ('clinician', 0.008160998097885), ('study', 0.007724841430529378), ('nccn', 0.007663286769775141), ('skin', 0.007635725345357723), ('diagnostic', 0.007571539797696961), ('case', 0.007389609961039004)]\n",
            "Topic 7: [('test', 0.026312623300202384), ('evidence', 0.022096950828078648), ('nccn', 0.01784873928462483), ('decisiondx-um', 0.015666175514506185), ('melanoma', 0.015073570191166084), ('uveal', 0.0142289448396548), ('level', 0.013518731378875323), ('um', 0.0128245964876903), ('prospective', 0.01150428901121358), ('risk', 0.011452670199145306), ('clinical', 0.011451874784672949), ('guideline', 0.011446385254577958), ('class', 0.009358840457659907), ('expression', 0.0086686406427937), ('category', 0.007972577133578258), ('patient', 0.007967789311140089), ('gene', 0.007277504036247624), ('prognostic', 0.0072760087277367515), ('follow', 0.006751041839256641), ('panel', 0.006591529584127105)]\n",
            "Topic 8: [('patient', 0.02920273099493049), ('melanoma', 0.026957959439345945), ('therapy', 0.01558495960006836), ('pembrolizumab', 0.014244798745355575), ('treatment', 0.011549406835327706), ('arm', 0.011380031362242093), ('metastatic', 0.010402635826876798), ('nivo', 0.010266339313871244), ('ci', 0.010160286302337031), ('panel', 0.009635939309954565), ('information', 0.009253648987363802), ('request', 0.009218661921268832), ('unresectable', 0.008632454917174561), ('ipi', 0.008605552269128774), ('month', 0.008065122890989275), ('nccn', 0.00800758970766175), ('randomized', 0.007931135946612884), ('keytruda', 0.007234225030603055), ('disease', 0.0070477131225921774), ('systemic', 0.006959743234028873)]\n",
            "Topic 9: [('-gene', 0.46232020154574804), ('melanoma', 0.006093234038755565), ('patient', 0.005082609951727794), ('test', 0.0023698251681454597), ('guideline', 0.0023568321722662673), ('study', 0.0022428354598359986), ('nccn', 0.002178771243527562), ('evidence', 0.0021643898465387858), ('expression', 0.0019639422554306265), ('clinical', 0.0019176758185008597), ('prospective', 0.0017239295700702372), ('biopsy', 0.0016862206915605298), ('pla', 0.0016552584963902227), ('cutaneous', 0.0016200551243837412), ('risk', 0.0016052592129373827), ('class', 0.0015711359107310474), ('gep', 0.0015233942491865088), ('panel', 0.0015032804309915817), ('gene', 0.001471006417689393), ('prognostic', 0.0014704875357928096)]\n",
            "\n",
            "Coherence Score: 0.5002003308081968\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Dictionary for DLDA for accepted requests"
      ],
      "metadata": {
        "id": "GXnYWgcTHhMU"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "topic_terms_by_year_accepted = { '2020': {\n",
        "'Topic 0': [('melanoma', 0.027093063490646482), ('patient', 0.026437448856950468), ('clinically', 0.007683065755360841), ('therapy', 0.007594842942187769), ('nivolumab', 0.006487550269356947), ('metastatic', 0.004219172367164452), ('treatment', 0.004044256715414212), ('month', 0.003978894296299443), ('data', 0.003911492511098493), ('arm', 0.0038384532686855867), ('group', 0.003724863851710714), ('nivo', 0.0034810633023822624), ('pembrolizumab', 0.0034226388519623795), ('event', 0.003315390067820802), ('panel', 0.0032852263783868063), ('request', 0.003178322109302293), ('stage', 0.0030642782544908972), ('study', 0.003042845707364989), ('ci', 0.00300508228936036), ('``', 0.0029761820430707726)],\n",
        "'Topic 1': [('dosing', 0.029042620778766782), ('mg', 0.022846751933408745), ('cancer', 0.020637658189226436), ('mg/kg', 0.0191517850423742), ('pembrolizumab', 0.016938994780843295), ('week', 0.016721129749501597), ('every', 0.01527075345574962), ('dose', 0.012224995145342721), ('patient', 0.011571305112034254), ('doi', 0.011446276950019917), ('guideline', 0.010517700917552383), ('lung', 0.010070452161797725), ('vial', 0.009392841048037628), ('based', 0.00903198832139347), ('weight', 0.008658987031134035), ('drug', 0.008643397977812564), ('fixed', 0.008630573839126247), ('fda', 0.008396703058177357), ('nccn', 0.008370245149300386), ('pharmacokinetic', 0.007925351738067127)],\n",
        "'Topic 2': [('tecentriq', 0.024914745211440086), ('melanoma', 0.023350996131106493), ('group', 0.023295925517220515), ('patient', 0.02272787256262524), ('treatment', 0.017054450938278048), ('genentech', 0.013840247306065628), ('control', 0.013179567303471888), ('cotellic', 0.011403197506882456), ('zelboraf', 0.0114031768200566), ('information', 0.01110006651087568), ('fda-approved', 0.00983489454879156), ('metastatic', 0.009727239034890003), ('nccn', 0.009607204785923995), ('vemurafenib', 0.008972307231305893), ('http', 0.008941274481973668), ('interferon', 0.00876314259960176), ('month', 0.008505237280379219), ('panel', 0.008230378582838769), ('arm', 0.008126774836733143), ('analysis', 0.00796865081001705)],\n",
        "'Topic 3': [('-year', 0.45931860430539356), ('melanoma', 0.005348744196097864), ('metastatic', 0.0035714094253469), ('patient', 0.0033798792436686626), ('treatment', 0.003061903523298459), ('nivolumab', 0.0024547074933492807), ('arm', 0.0021218976734143874), ('therapy', 0.002019136637288344), ('ci', 0.0018782972578574595), ('information', 0.0018496240752835598), ('pembrolizumab', 0.0018454153246530514), ('unresectable', 0.0018147280580866163), ('o', 0.0017419367710889435), ('group', 0.0016848098689763987), ('rate', 0.00166136291571432), ('study', 0.0016052061292946337), ('request', 0.001576797553971942), ('cancer', 0.0015286188834734231), ('data', 0.0015072478513289812), ('phase', 0.0014829921342462901)],\n",
        "'Topic 4': [('patient', 0.026233600131630553), ('pbo', 0.018381149128318775), ('guardant', 0.016759104242079288), ('tumor', 0.012838307112581477), ('cancer', 0.012600927721197261), ('panel', 0.011280579669098505), ('tissue', 0.010398287997596189), ('melanoma', 0.009779101426136985), ('ctdna', 0.007671917844498137), ('testing', 0.007468525518576633), ('guideline', 0.007380347785998904), ('study', 0.007178706881511591), ('clinical', 0.007087211820271053), ('response', 0.0070704178634306055), ('molecular', 0.006765796150867824), ('trial', 0.006529419867517429), ('mutation', 0.00634882986648436), ('iv', 0.006004067313753284), ('published', 0.005930784025941873), ('cdx', 0.005860593574283725)],\n",
        "'Topic 5': [('melanocytic', 0.02445647136300534), ('gene', 0.022876035886121086), ('expression', 0.02127480788542512), ('melanoma', 0.018100763822408973), ('clarke', 0.01493293477344048), ('signature', 0.014932912776210363), ('test', 0.014930674547918094), ('clinical', 0.013351097762191021), ('lesion', 0.011771160227899539), ('diagnostic', 0.011771160227591978), ('benign', 0.011771160223299418), ('pathol', 0.011771160221134818), ('patient', 0.011769191462234598), ('ambiguous', 0.010193570788169772), ('result', 0.01019349607946623), ('nevus', 0.010193336750924438), ('mypath®', 0.01019061865708835), ('case', 0.010189225253871498), ('neoplasm', 0.01018897819531103), ('outcome', 0.008618341402157033)],\n",
        "'Topic 6': [('patient', 0.036127599516414186), ('lifileucel', 0.027543722502813357), ('therapy', 0.026913757473833223), ('melanoma', 0.02437767730811065), ('lymphocyte', 0.018192377953685942), ('cell', 0.01718748805479317), ('tumor-infiltrating', 0.01461716360841241), ('cancer', 0.01451485357242828), ('efficacy', 0.012382710788400121), ('inhibitor', 0.011786682466678517), ('metastatic', 0.011317282103048353), ('advanced', 0.011130683414718946), ('tumor', 0.011112101298943518), ('response', 0.010000314059351702), ('study', 0.009915999888925064), ('safety', 0.009499494451597638), ('adoptive', 0.008222583080938251), ('analysis', 0.00822207340965763), ('prior', 0.007710281899162737), ('progression', 0.007377351300212422)],\n",
        "'Topic 7': [('nivolumab', 0.0311303503294266), ('patient', 0.030386318677052666), ('melanoma', 0.01944593261895336), ('arm', 0.01500783164513736), ('data', 0.013700210584255211), ('nivo', 0.013648156230117125), ('treatment', 0.012003453483369987), ('ci', 0.011734359865339475), ('o', 0.010546309152570045), ('metastatic', 0.00937971711949526), ('relatlimab', 0.009277545564478113), ('unresectable', 0.008238221787996582), ('grade', 0.007779056009788038), ('ipi', 0.007729827906407275), ('ipilimumab', 0.0076092776445538975), ('request', 0.007587925743366465), ('study', 0.007555229795608821), ('squibb', 0.007391807012598507), ('bristol', 0.007376415400169443), ('myers', 0.007376093096390758)],\n",
        "'Topic 8': [('tebentafusp', 0.02562849847849958), ('melanoma', 0.02253963779928399), ('patient', 0.022152820757129273), ('group', 0.0213542555195257), ('metastatic', 0.01782333647561329), ('ci', 0.017631123179161778), ('uveal', 0.01411180974163244), ('disease', 0.012813852399766132), ('overall', 0.011285341617192352), ('month', 0.010871904139762458), ('treatment', 0.010827212028038786), ('survival', 0.010721059764124156), ('surgery', 0.010622279388216034), ('o', 0.010462026764633153), ('investigator', 0.010365183515295733), ('event', 0.009123888795852613), ('phase', 0.009110085224304126), ('death', 0.008907713104686141), ('pembrolizumab', 0.008518197963120052), ('review', 0.007653904038182959)],\n",
        "'Topic 9': [('melanoma', 0.036442577139357835), ('pembrolizumab', 0.03388224733819849), ('patient', 0.029831067341259003), ('treatment', 0.014102150023209982), ('stage', 0.013356561938500993), ('information', 0.01329856910291806), ('placebo', 0.012622395992512487), ('request', 0.011545006305286374), ('nccn', 0.011155787880963695), ('inc.', 0.010776417007011608), ('merck', 0.010766694461193518), ('keytruda', 0.0106155486703637), ('panel', 0.010492571653513725), ('month', 0.008953613601825486), ('resected', 0.007708510639869248), ('metastatic', 0.007556784265694703), ('unresectable', 0.0074460682978375785), ('trial', 0.007170338334158736), ('adjuvant', 0.007087233365127409), ('iic', 0.0070073648923819455)],\n",
        "},\n",
        "'2021': {\n",
        "'Topic 0': [('melanoma', 0.027139888494719207), ('patient', 0.026511272523144724), ('clinically', 0.007737679491578517), ('therapy', 0.007617839935650938), ('nivolumab', 0.0064986067898939355), ('metastatic', 0.004224931291130161), ('treatment', 0.004049641862556011), ('month', 0.003984141289423778), ('data', 0.003916597927245992), ('arm', 0.0038434063016831613), ('group', 0.003729582087922394), ('nivo', 0.0034852869285857614), ('pembrolizumab', 0.0034267459166139845), ('event', 0.0033192852204689226), ('panel', 0.0032890624203032004), ('request', 0.0031819504282062125), ('stage', 0.0030676881081654218), ('study', 0.0030462148744297593), ('ci', 0.0030083800583360566), ('``', 0.0029812268437373673)],\n",
        "'Topic 1': [('dosing', 0.02930471370603434), ('mg', 0.022898334107350805), ('cancer', 0.020764121203666015), ('mg/kg', 0.019303062446207175), ('pembrolizumab', 0.017010329251459413), ('week', 0.016742137540251778), ('every', 0.015322988346091831), ('dose', 0.012235386058689145), ('patient', 0.011581979750698378), ('doi', 0.011457469453477332), ('guideline', 0.010524801168069694), ('lung', 0.010085953010732186), ('vial', 0.0093995122635853), ('based', 0.00903520870858624), ('weight', 0.008666535038978266), ('fixed', 0.008647956509274432), ('drug', 0.008646131430170133), ('fda', 0.008407816883279766), ('nccn', 0.008372503547995718), ('pharmacokinetic', 0.007926790338255411)],\n",
        "'Topic 2': [('tecentriq', 0.024495287410380786), ('melanoma', 0.0234739350680518), ('group', 0.02303783873548046), ('patient', 0.022950818899163568), ('treatment', 0.01707238795109342), ('genentech', 0.013718429961220963), ('control', 0.013189953495174161), ('zelboraf', 0.011324889762927361), ('cotellic', 0.011324696583054883), ('information', 0.011116154277450116), ('fda-approved', 0.009806856647624982), ('metastatic', 0.009692732677529523), ('nccn', 0.009617196760284613), ('interferon', 0.009018956793806179), ('http', 0.008936145092235693), ('vemurafenib', 0.008924261561759217), ('month', 0.008481263444932826), ('panel', 0.008243211480558107), ('arm', 0.008166339321708042), ('analysis', 0.007976369464701252)],\n",
        "'Topic 3': [('-year', 0.46079348422466504), ('melanoma', 0.005345909550588394), ('metastatic', 0.0035683815633109845), ('patient', 0.0033768671838798883), ('treatment', 0.003058936826644071), ('nivolumab', 0.002451902312331711), ('arm', 0.0021192296623796787), ('therapy', 0.002016519006347013), ('ci', 0.0018757554087319643), ('information', 0.001847098653213388), ('pembrolizumab', 0.0018428923431180093), ('unresectable', 0.0018122231006728945), ('o', 0.0017394762137848414), ('group', 0.00168238582896694), ('rate', 0.0016589543020676639), ('study', 0.0016028355284967114), ('request', 0.0015744467686628857), ('cancer', 0.001526302628335009), ('data', 0.0015049472934193452), ('phase', 0.001480709681478957)],\n",
        "'Topic 4': [('patient', 0.026276341212020125), ('pbo', 0.018393495403922298), ('guardant', 0.016796030299824488), ('tumor', 0.012859241968368133), ('cancer', 0.012620013907775186), ('panel', 0.011295507937620956), ('tissue', 0.010411660325903417), ('melanoma', 0.009789774083971093), ('ctdna', 0.007682697143840279), ('testing', 0.0074763176650092045), ('guideline', 0.0073875039428680225), ('study', 0.007187351571437323), ('clinical', 0.007094253297217391), ('response', 0.007078235439797955), ('molecular', 0.00677391947343512), ('trial', 0.006534687271517437), ('mutation', 0.006353375839591251), ('iv', 0.006008951133599653), ('published', 0.005936856199238471), ('health', 0.005867117532488498)],\n",
        "'Topic 5': [('melanocytic', 0.024503283688202475), ('gene', 0.022928593818582872), ('expression', 0.021315125593083295), ('melanoma', 0.01813279652540107), ('clarke', 0.014955723685979716), ('test', 0.014955703598831858), ('signature', 0.01495568603700432), ('clinical', 0.013372095196174664), ('lesion', 0.011787877185974769), ('diagnostic', 0.011787877185367944), ('benign', 0.011787877176835347), ('pathol', 0.011787877172519785), ('patient', 0.011785602069909017), ('result', 0.010207827687908675), ('nevus', 0.010207046133239663), ('ambiguous', 0.010206955021041346), ('mypath®', 0.010204879523721162), ('neoplasm', 0.010203909156653469), ('case', 0.010203081479991), ('outcome', 0.008629811888543403)],\n",
        "'Topic 6': [('patient', 0.036230126782170344), ('lifileucel', 0.02759984871097426), ('therapy', 0.026945659896125896), ('melanoma', 0.024402177499589162), ('lymphocyte', 0.01821458629952036), ('cell', 0.017206501356074547), ('tumor-infiltrating', 0.014633129058039087), ('cancer', 0.014530933672334349), ('efficacy', 0.012396522743794353), ('inhibitor', 0.011797501950068639), ('metastatic', 0.011329684665240012), ('advanced', 0.011142470983905892), ('tumor', 0.011123725230209077), ('response', 0.0100112513258755), ('study', 0.009926503396182918), ('safety', 0.009508662847525504), ('adoptive', 0.008229811782948283), ('analysis', 0.008229473645505771), ('prior', 0.00771744661319986), ('progression', 0.007382911865379757)],\n",
        "'Topic 7': [('patient', 0.03169680620033185), ('nivolumab', 0.031103473233263772), ('melanoma', 0.01946370374444656), ('arm', 0.01504259501394145), ('data', 0.013724761496000366), ('nivo', 0.013543569465889593), ('treatment', 0.011751192876837287), ('ci', 0.011331497660436613), ('o', 0.010550570240242026), ('metastatic', 0.00937319332445363), ('relatlimab', 0.009207894511838333), ('unresectable', 0.008090123838290457), ('ipi', 0.007852178981506608), ('grade', 0.007705494808074813), ('ipilimumab', 0.007655540109973213), ('request', 0.0076369588673723425), ('study', 0.007515116427037554), ('squibb', 0.0074197133175809594), ('bristol', 0.007404154592662398), ('myers', 0.007403828056329469)],\n",
        "'Topic 8': [('tebentafusp', 0.026479366870681878), ('melanoma', 0.022498984552936536), ('patient', 0.022351741964993472), ('group', 0.02081773429562643), ('metastatic', 0.018162750845306903), ('ci', 0.01781790861600962), ('uveal', 0.014367971267638852), ('disease', 0.012866905711961692), ('overall', 0.01139704843890408), ('month', 0.010985713108038649), ('treatment', 0.010842059412516139), ('survival', 0.010742694852209316), ('o', 0.010599652614120042), ('investigator', 0.01031391830374725), ('surgery', 0.010233879358381203), ('phase', 0.009179874816893014), ('event', 0.008970587575905582), ('death', 0.008854046518108097), ('pembrolizumab', 0.008479419720050741), ('review', 0.0076766162114414995)],\n",
        "'Topic 9': [('melanoma', 0.03717670980842337), ('pembrolizumab', 0.03403018662667252), ('patient', 0.030694171250035138), ('treatment', 0.0142682263277771), ('stage', 0.013549116930427754), ('information', 0.013301276274216253), ('placebo', 0.012342437243290632), ('request', 0.011529495612871322), ('nccn', 0.011034576047271163), ('inc.', 0.010791893347129057), ('merck', 0.010785597588776698), ('keytruda', 0.010723312775373778), ('panel', 0.010421849844153255), ('month', 0.00881482705147863), ('resected', 0.007803955621196374), ('metastatic', 0.007459251523068844), ('unresectable', 0.007371616296045842), ('trial', 0.007212588611565046), ('iic', 0.007130431115642625), ('adjuvant', 0.007127100127667673)],\n",
        "},\n",
        "'2022': {\n",
        "'Topic 0': [('melanoma', 0.02719688070678248), ('patient', 0.02657223124234568), ('clinically', 0.007726370762245956), ('therapy', 0.007635665411431061), ('nivolumab', 0.006506964443448222), ('metastatic', 0.004229302377400506), ('treatment', 0.004053731388543861), ('month', 0.003988126732280862), ('data', 0.003920476699959471), ('arm', 0.003847170252768982), ('group', 0.003733169097630087), ('nivo', 0.0034885011142301715), ('pembrolizumab', 0.0034298722220280887), ('event', 0.0033222517367894515), ('panel', 0.0032919843601244875), ('request', 0.0031847157021892346), ('stage', 0.0030702885822348406), ('study', 0.003048784652555344), ('ci', 0.003010895967220988), ('``', 0.002985560578791686)],\n",
        "'Topic 1': [('dosing', 0.029599031695423463), ('mg', 0.02286104928251538), ('cancer', 0.02087998636000901), ('mg/kg', 0.019514008277177267), ('pembrolizumab', 0.01705996417405717), ('week', 0.01665743468492128), ('every', 0.015323572652157806), ('dose', 0.012297012979588596), ('patient', 0.011585945978284166), ('doi', 0.011480305387992485), ('guideline', 0.010514915279018168), ('lung', 0.010101571773406506), ('vial', 0.009435344400214252), ('based', 0.008993505503624523), ('fixed', 0.008698614563819958), ('drug', 0.008696978563382664), ('weight', 0.008688091623165943), ('fda', 0.00842801526274904), ('nccn', 0.008348829538562124), ('pharmacokinetic', 0.007889531291625024)],\n",
        "'Topic 2': [('tecentriq', 0.02452734395084002), ('melanoma', 0.023497952853876018), ('group', 0.02308068365187094), ('patient', 0.022981129130653942), ('treatment', 0.01708454851191174), ('genentech', 0.013731654744312776), ('control', 0.01319731186932278), ('zelboraf', 0.011329544066601418), ('cotellic', 0.01132923254188974), ('information', 0.011124349924155206), ('fda-approved', 0.009812878133416641), ('metastatic', 0.009698801069328184), ('nccn', 0.009623031712464078), ('interferon', 0.009024626603409908), ('http', 0.008941510446033635), ('vemurafenib', 0.008929901758490878), ('month', 0.008485205306695718), ('panel', 0.008248726380182786), ('arm', 0.00817270331515569), ('analysis', 0.007980698348540486)],\n",
        "'Topic 3': [('-year', 0.46179311723918937), ('melanoma', 0.005344713219523561), ('metastatic', 0.0035667418665727875), ('patient', 0.0033752068734034983), ('treatment', 0.003057256477744909), ('nivolumab', 0.0024502392233111516), ('arm', 0.0021176120889468955), ('therapy', 0.002014921435015626), ('ci', 0.0018741902407222472), ('information', 0.0018455408221971057), ('pembrolizumab', 0.0018413356107711677), ('unresectable', 0.0018106745490558869), ('o', 0.0017379482868554415), ('group', 0.0016808753270373513), ('rate', 0.001657451276728914), ('study', 0.0016013511995970787), ('request', 0.001572972331688292), ('cancer', 0.0015248456522439229), ('data', 0.001503498344366402), ('phase', 0.0014792700570922628)],\n",
        "'Topic 4': [('patient', 0.026321019707719148), ('pbo', 0.018421409715737077), ('guardant', 0.01682443160961275), ('tumor', 0.012868488584398858), ('cancer', 0.012638532111566904), ('panel', 0.01130950043304351), ('tissue', 0.010409888441316503), ('melanoma', 0.009799025176904815), ('ctdna', 0.007688275486028899), ('testing', 0.007484079118355466), ('guideline', 0.007394570908843776), ('study', 0.007194999204051198), ('clinical', 0.007099154631988791), ('response', 0.007082782868127481), ('molecular', 0.0067794781685762235), ('trial', 0.006538349523081275), ('mutation', 0.006359163041105682), ('iv', 0.006010925835019175), ('published', 0.005941982707420192), ('cdx', 0.005869995982357924)],\n",
        "'Topic 5': [('melanocytic', 0.02453541412926357), ('gene', 0.022970157437033553), ('expression', 0.021340543777118862), ('melanoma', 0.018155237255779798), ('test', 0.014976977224476449), ('clarke', 0.014971603028849104), ('signature', 0.014971524657654655), ('clinical', 0.013387492854515598), ('pathol', 0.011802473980081598), ('benign', 0.011802473832268144), ('diagnostic', 0.011802473541747625), ('lesion', 0.011802473521543705), ('patient', 0.01180044676291646), ('nevus', 0.010219958601649174), ('ambiguous', 0.010219395352778516), ('neoplasm', 0.010218471220063998), ('result', 0.010218253707030023), ('mypath®', 0.010217818199505822), ('case', 0.010215178202950337), ('outcome', 0.008638911734475995)],\n",
        "'Topic 6': [('patient', 0.03635870379456244), ('lifileucel', 0.02766382246382135), ('therapy', 0.026992043697300946), ('melanoma', 0.02441651013777421), ('lymphocyte', 0.018232061174969158), ('cell', 0.017219804308170883), ('tumor-infiltrating', 0.014648109360612399), ('cancer', 0.014547800790817904), ('efficacy', 0.012411542017326558), ('inhibitor', 0.011808862135510823), ('metastatic', 0.011339294832955062), ('advanced', 0.011151307846138768), ('tumor', 0.011132177109039923), ('response', 0.010019436647886258), ('study', 0.0099346871079385), ('safety', 0.009515172587923877), ('adoptive', 0.008234644555985045), ('analysis', 0.008234545059993591), ('prior', 0.007724091376120684), ('progression', 0.007384723831355056)],\n",
        "'Topic 7': [('patient', 0.03213974297896357), ('nivolumab', 0.031247523120527903), ('melanoma', 0.01956766542211439), ('arm', 0.014849759447852906), ('data', 0.013783328615477888), ('nivo', 0.013530184203961453), ('treatment', 0.011767487891883368), ('ci', 0.01137217618706181), ('o', 0.010568503262137088), ('metastatic', 0.009369506950490268), ('relatlimab', 0.00914120272470657), ('unresectable', 0.008097387606536522), ('ipi', 0.00789559379578162), ('grade', 0.007741893117853602), ('ipilimumab', 0.007646059550417801), ('request', 0.007633185938072735), ('study', 0.007519958973060182), ('squibb', 0.007470507408037441), ('bristol', 0.007454694111946992), ('myers', 0.007454361935896065)],\n",
        "'Topic 8': [('tebentafusp', 0.026501537481368086), ('melanoma', 0.022525187771777165), ('patient', 0.022392560245296404), ('group', 0.020801677399044143), ('metastatic', 0.018186691313220548), ('ci', 0.01783653854376911), ('uveal', 0.014379955141374072), ('disease', 0.012881203836271149), ('overall', 0.011407887858076837), ('month', 0.01099354192463736), ('treatment', 0.010851026018420192), ('survival', 0.010751142151161654), ('o', 0.010607401993029687), ('investigator', 0.01032571007838662), ('surgery', 0.010242636619578794), ('phase', 0.009187051146279662), ('event', 0.008976528593257647), ('death', 0.008859145629380888), ('pembrolizumab', 0.008486770101247019), ('review', 0.007681588677226731)],\n",
        "'Topic 9': [('melanoma', 0.03635625906822346), ('pembrolizumab', 0.03429044312511816), ('patient', 0.030898410813191036), ('treatment', 0.014147773680949823), ('stage', 0.013882838171040529), ('information', 0.013317268013836413), ('placebo', 0.012668823111921463), ('request', 0.011529728517560213), ('nccn', 0.010976880690602927), ('inc.', 0.01083212712841885), ('merck', 0.010819617416382092), ('keytruda', 0.010589061540612241), ('panel', 0.010384602288302533), ('month', 0.00885907493545884), ('resected', 0.00794989949547396), ('metastatic', 0.007356432317045628), ('unresectable', 0.007302403900527449), ('iic', 0.0072376379054815525), ('trial', 0.007206139771548084), ('adjuvant', 0.007173708045151994)],\n",
        "},\n",
        "\n",
        "'2023': {\n",
        "'Topic 0': [('melanoma', 0.027284613496039996), ('patient', 0.026598517268472587), ('clinically', 0.007709548350525238), ('therapy', 0.00763540592582718), ('nivolumab', 0.006512381999107802), ('metastatic', 0.004232120701606118), ('treatment', 0.004056366419797324), ('month', 0.003990694019867109), ('data', 0.003922974568008491), ('arm', 0.003849593405683159), ('group', 0.003735477133423688), ('nivo', 0.0034905666774828334), ('pembrolizumab', 0.0034318806490159764), ('event', 0.0033241562944739925), ('panel', 0.003293859945923874), ('request', 0.0031864894820385634), ('stage', 0.0030719553003595015), ('study', 0.0030504314327504272), ('ci', 0.003012507760578863), ('``', 0.002988873066308646)],\n",
        "'Topic 1': [('dosing', 0.029913248750350084), ('mg', 0.022843890235326975), ('cancer', 0.02100447098304539), ('mg/kg', 0.019678197317380134), ('pembrolizumab', 0.017112360462621785), ('week', 0.016642845677353257), ('every', 0.01536037186851323), ('dose', 0.012300037169524507), ('patient', 0.011585309531902723), ('doi', 0.011481667871766178), ('guideline', 0.010502373291265223), ('lung', 0.010105706463675049), ('vial', 0.009436503130629307), ('based', 0.008988626866199651), ('fixed', 0.008708572383365466), ('weight', 0.008699767800474002), ('drug', 0.008693757951874345), ('fda', 0.008434079255476635), ('nccn', 0.008341561241926823), ('pharmacokinetic', 0.007880784066383876)],\n",
        "'Topic 2': [('tecentriq', 0.024549090055658467), ('melanoma', 0.02350444306375347), ('group', 0.023157486253171582), ('patient', 0.022997117573365818), ('treatment', 0.017086325352624204), ('genentech', 0.013739712772884528), ('control', 0.01320183325397964), ('zelboraf', 0.01133702018646531), ('cotellic', 0.011336522899786306), ('information', 0.011125746062748952), ('fda-approved', 0.009817614715923545), ('metastatic', 0.009705239018907236), ('nccn', 0.00962577246304769), ('interferon', 0.009025280462049447), ('http', 0.008946386557377181), ('vemurafenib', 0.00893606632239381), ('month', 0.008489832486308324), ('panel', 0.008250289882943159), ('arm', 0.008175974165689083), ('analysis', 0.007982799389111079)],\n",
        "'Topic 3': [('-year', 0.46244067073282946), ('melanoma', 0.005344044423137692), ('metastatic', 0.003565739594433571), ('patient', 0.003374186632850089), ('treatment', 0.0030562157866164206), ('nivolumab', 0.0024491961956826167), ('arm', 0.002116591618391971), ('therapy', 0.0020139118615372835), ('ci', 0.0018731989002278402), ('information', 0.0018445536828788887), ('pembrolizumab', 0.0018403491024719693), ('unresectable', 0.0018096927540662516), ('o', 0.0017369784781401502), ('group', 0.001679915743839446), ('rate', 0.0016564961050704998), ('study', 0.0016004071156366301), ('request', 0.0015720341434332075), ('cancer', 0.0015239179152885878), ('data', 0.001502575429580727), ('phase', 0.0014783527568776262)],\n",
        "'Topic 4': [('patient', 0.026312314126815763), ('pbo', 0.019928537846717758), ('guardant', 0.0165405483388078), ('tumor', 0.01274249762133768), ('cancer', 0.012500657892732072), ('panel', 0.011285023809903282), ('tissue', 0.010305003779516674), ('melanoma', 0.009808207031430514), ('ctdna', 0.007628746408013558), ('testing', 0.007449334338504752), ('guideline', 0.0073595516714190555), ('study', 0.007191470630370123), ('clinical', 0.007057673066887885), ('response', 0.007042363669913704), ('molecular', 0.006731631546883239), ('trial', 0.006549348895521379), ('mutation', 0.006362886034069838), ('iv', 0.006161170940722702), ('ned', 0.005957764571793311), ('published', 0.005934109561217888)],\n",
        "'Topic 5': [('melanocytic', 0.024560320525212873), ('gene', 0.023011098738539574), ('expression', 0.021363851334962672), ('melanoma', 0.018172544626622322), ('test', 0.014992450012598786), ('clarke', 0.014982323162661857), ('signature', 0.014982212130414308), ('clinical', 0.013399105311213747), ('pathol', 0.011811513418564238), ('benign', 0.011811513116400923), ('diagnostic', 0.011811512522372922), ('lesion', 0.011811512481045424), ('patient', 0.011809266762554253), ('neoplasm', 0.010228360242428451), ('nevus', 0.010227927211778077), ('ambiguous', 0.010226927352247858), ('result', 0.010226505074394597), ('mypath®', 0.010226334322370913), ('case', 0.010223003879784557), ('flake', 0.008646281063955678)],\n",
        "'Topic 6': [('patient', 0.03644434387262222), ('lifileucel', 0.027690957601086513), ('therapy', 0.027070722830353146), ('melanoma', 0.02440551838905442), ('lymphocyte', 0.018230670568273412), ('cell', 0.017212875823063332), ('tumor-infiltrating', 0.014648442872198238), ('cancer', 0.014612772905857108), ('efficacy', 0.012414454862499202), ('inhibitor', 0.011844333080675442), ('metastatic', 0.0113429244202144), ('advanced', 0.011154657912122867), ('tumor', 0.011134416906116879), ('response', 0.010023824282612259), ('study', 0.009938426028512689), ('safety', 0.009517497571580644), ('analysis', 0.008236808175800272), ('adoptive', 0.008236309936582092), ('prior', 0.0077283439064788), ('progression', 0.007390257888015184)],\n",
        "'Topic 7': [('patient', 0.032127554425606844), ('nivolumab', 0.031372909958625086), ('melanoma', 0.019676490013236545), ('nivo', 0.014459566071099859), ('arm', 0.014262705414149777), ('data', 0.013817526300784254), ('treatment', 0.011970296440948448), ('ci', 0.011799868248701764), ('o', 0.010537512585352635), ('metastatic', 0.009312075588135585), ('relatlimab', 0.009002401799549368), ('ipi', 0.008306422590523376), ('ipilimumab', 0.008036087307540261), ('grade', 0.007902317618682401), ('unresectable', 0.007900539795758199), ('request', 0.0075750987098583905), ('study', 0.007556795025604108), ('squibb', 0.007517776419156373), ('bristol', 0.007501718798349875), ('myers', 0.007501382264487637)],\n",
        "'Topic 8': [('tebentafusp', 0.025705243655001948), ('melanoma', 0.022621771366652305), ('patient', 0.022267812231077086), ('group', 0.02132995173524659), ('metastatic', 0.017898222181794612), ('ci', 0.017695226059474416), ('uveal', 0.014153546017132103), ('disease', 0.012854297099910835), ('overall', 0.011320250764929282), ('month', 0.010900700751083287), ('treatment', 0.010855932447967743), ('survival', 0.010747677241853998), ('surgery', 0.01064466518885635), ('o', 0.01048785694028287), ('investigator', 0.010396400959115046), ('event', 0.009138657564774388), ('phase', 0.009133740376847103), ('death', 0.008923937258715552), ('pembrolizumab', 0.008538878488819245), ('review', 0.0076688432861556875)],\n",
        "'Topic 9': [('melanoma', 0.03665580198920922), ('pembrolizumab', 0.0344342546085624), ('patient', 0.03050132126273612), ('stage', 0.014227806834219193), ('treatment', 0.014039544787343108), ('information', 0.013324653739036863), ('placebo', 0.012982278726925969), ('request', 0.011534948283443928), ('nccn', 0.01106701034646119), ('inc.', 0.010864831616852044), ('merck', 0.010844721689253406), ('keytruda', 0.010587592240762396), ('panel', 0.010411419039507534), ('month', 0.008788394544198769), ('resected', 0.008081610882125669), ('adjuvant', 0.007341611427744664), ('metastatic', 0.007298591009115489), ('iic', 0.007270323345297888), ('unresectable', 0.00724913272538396), ('trial', 0.007188460861718296)],\n",
        "},\n",
        "'2024': {\n",
        "'Topic 0': [('melanoma', 0.027317651540244937), ('patient', 0.026624454441274106), ('clinically', 0.007693619193424954), ('therapy', 0.007626095275599938), ('nivolumab', 0.006515181682087043), ('metastatic', 0.004233590288413202), ('treatment', 0.004057741982562872), ('month', 0.003992034821125622), ('data', 0.0039242797413469865), ('arm', 0.0038508602256674403), ('group', 0.003736684844432066), ('nivo', 0.0034916498168416615), ('pembrolizumab', 0.0034329344193248677), ('event', 0.003325156658187668), ('panel', 0.003294845409302662), ('request', 0.003187422572292173), ('stage', 0.003072833288781193), ('study', 0.0030512991566581595), ('ci', 0.00301335747007419), ('``', 0.002990619238376872)],\n",
        "'Topic 1': [('dosing', 0.030151157733793968), ('mg', 0.022854667046704056), ('cancer', 0.021105324974419522), ('mg/kg', 0.019789864450088145), ('pembrolizumab', 0.017159286946748772), ('week', 0.01666018484158088), ('every', 0.015404391354646224), ('dose', 0.012300770321673891), ('patient', 0.011583629705369084), ('doi', 0.011479526175148897), ('guideline', 0.010495861832652383), ('lung', 0.010108957914695023), ('vial', 0.009432840804709438), ('based', 0.008987156189970784), ('fixed', 0.008712299448348509), ('weight', 0.008704309719878244), ('drug', 0.008688579601285266), ('fda', 0.008437060284516663), ('nccn', 0.008339843878145414), ('pharmacokinetic', 0.007881669774479662)],\n",
        "'Topic 2': [('tecentriq', 0.024546710046120242), ('melanoma', 0.0235093586811444), ('group', 0.023205509832385448), ('patient', 0.02301619413746053), ('treatment', 0.01709222409641615), ('genentech', 0.013739119070835736), ('control', 0.013205514533873088), ('zelboraf', 0.011339098600137307), ('cotellic', 0.011338453752498399), ('information', 0.0111296403814952), ('fda-approved', 0.00981840262103445), ('metastatic', 0.009707757855593399), ('nccn', 0.00962857527381027), ('interferon', 0.009029242236424075), ('http', 0.008949287341394252), ('vemurafenib', 0.008937691161580457), ('month', 0.008491682498130752), ('panel', 0.00825288420768157), ('arm', 0.008177982148324823), ('analysis', 0.00798530248190869)],\n",
        "'Topic 3': [('-year', 0.4628546594714438), ('melanoma', 0.0053427952854862674), ('metastatic', 0.003564629625833626), ('patient', 0.003373100587131242), ('treatment', 0.0030551741165797787), ('nivolumab', 0.0024482574993067185), ('arm', 0.002115721201230267), ('therapy', 0.002013064479466375), ('ci', 0.001872384726586169), ('information', 0.0018437465129598862), ('pembrolizumab', 0.001839542967712087), ('unresectable', 0.0018088942227532257), ('o', 0.0017361983827413753), ('group', 0.0016791505234912947), ('rate', 0.0016557370965416885), ('study', 0.0015996632438477017), ('request', 0.0015712980713404297), ('cancer', 0.0015231952955937146), ('data', 0.0015018588695256364), ('phase', 0.0014776431446500786)],\n",
        "'Topic 4': [('patient', 0.026327720009305985), ('pbo', 0.019950773785266922), ('guardant', 0.016548189364834973), ('tumor', 0.012741300039847891), ('cancer', 0.012513516488011587), ('panel', 0.011292911108631707), ('tissue', 0.010292781712087208), ('melanoma', 0.009812752379683078), ('ctdna', 0.007629963379967494), ('testing', 0.0074539433527947545), ('guideline', 0.007364630155869799), ('study', 0.007195505883349798), ('clinical', 0.007060379904555594), ('response', 0.0070445120082053255), ('molecular', 0.0067351615361693085), ('trial', 0.006550505234558053), ('mutation', 0.006368103655159124), ('iv', 0.006160611159973924), ('ned', 0.005960063985315324), ('published', 0.005936523323848551)],\n",
        "'Topic 5': [('melanocytic', 0.024576593238614688), ('gene', 0.02304257538428519), ('expression', 0.021382692501323707), ('melanoma', 0.018184120430029337), ('test', 0.015000892671339257), ('clarke', 0.014988460682938094), ('signature', 0.014988336765232044), ('clinical', 0.01340669788664082), ('pathol', 0.011815796470724959), ('benign', 0.011815796163131671), ('diagnostic', 0.011815795558405739), ('lesion', 0.011815795516337012), ('patient', 0.01181315324497628), ('neoplasm', 0.010233377380603715), ('result', 0.010232258128250805), ('nevus', 0.010231499577952137), ('mypath®', 0.010230624142339436), ('ambiguous', 0.010230133861108439), ('case', 0.01022688888758773), ('flake', 0.008651559532246098)],\n",
        "'Topic 6': [('patient', 0.036513277745278384), ('lifileucel', 0.027718436562695056), ('therapy', 0.027093456468429915), ('melanoma', 0.024403360796456202), ('lymphocyte', 0.01823370427900359), ('cell', 0.017212184144744392), ('tumor-infiltrating', 0.014652466981603126), ('cancer', 0.014618081508659226), ('efficacy', 0.012420052173174068), ('inhibitor', 0.011849834542828213), ('metastatic', 0.01134680102140428), ('advanced', 0.011157814633170317), ('tumor', 0.011137157698543461), ('response', 0.010027319822997873), ('study', 0.009941815764915065), ('safety', 0.009519764185085397), ('analysis', 0.008238648600142477), ('adoptive', 0.008238123589146476), ('prior', 0.007731461260121937), ('progression', 0.007392524631140755)],\n",
        "'Topic 7': [('patient', 0.03235731655556669), ('nivolumab', 0.03158861976965604), ('melanoma', 0.019808398118738864), ('nivo', 0.014061017870137181), ('arm', 0.013995377011149274), ('data', 0.013885008873894666), ('ci', 0.01214677684648964), ('treatment', 0.012042227054880046), ('o', 0.010527669861560373), ('metastatic', 0.009280541000701878), ('relatlimab', 0.008940851261827025), ('ipi', 0.008143133575213436), ('grade', 0.008036645306291855), ('ipilimumab', 0.007906922332703431), ('unresectable', 0.007769427946111623), ('study', 0.007631693088094223), ('squibb', 0.007559629076531707), ('request', 0.007549287447537159), ('bristol', 0.0075433522034261844), ('myers', 0.007543011053041763)],\n",
        "'Topic 8': [('tebentafusp', 0.025628790047853338), ('melanoma', 0.022642748628187506), ('patient', 0.02226326547471655), ('group', 0.02137676008195163), ('metastatic', 0.017901279750456606), ('ci', 0.01770720183011366), ('uveal', 0.014156456090140825), ('disease', 0.01285852687813543), ('overall', 0.011323406900656158), ('month', 0.01090556541190941), ('treatment', 0.010860171162799956), ('survival', 0.010749562462602315), ('surgery', 0.010652151453301681), ('o', 0.01048904363942387), ('investigator', 0.01040090537901443), ('event', 0.00914095896288931), ('phase', 0.009138336962533012), ('death', 0.008931037324619875), ('pembrolizumab', 0.008537802860440782), ('review', 0.007668980608022529)],\n",
        "'Topic 9': [('melanoma', 0.03674081080982945), ('pembrolizumab', 0.03449529843258196), ('patient', 0.030587641623007235), ('stage', 0.01445942796476434), ('treatment', 0.01404810803390614), ('placebo', 0.013435297775938146), ('information', 0.013331678675764963), ('request', 0.011536642037142764), ('nccn', 0.01109635481615174), ('inc.', 0.010881678795176491), ('merck', 0.010855809496134343), ('keytruda', 0.010540116918723119), ('panel', 0.01041877346238411), ('month', 0.008797392911670069), ('resected', 0.008179736941489256), ('adjuvant', 0.007390587312963702), ('iic', 0.00735628826149486), ('metastatic', 0.007263983512336333), ('unresectable', 0.007217220601225358), ('trial', 0.007201095489206326)]\n",
        "}\n",
        "}"
      ],
      "metadata": {
        "id": "sVf8pZKXH_DM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### DLDA dictionary for denied topics"
      ],
      "metadata": {
        "id": "HSrtpN4WTKap"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "Topics for year 201:\n",
        "Topic 0: [('patient', 0.030394853014731674), ('melanoma', 0.027730650373850908), ('risk', 0.015114608626343133), ('-gep', 0.014393449668244618), ('expression', 0.013660857537312302), ('gep', 0.013249962561234107), ('class', 0.012611730986324926), ('test', 0.011887833369276688), ('study', 0.01174611655176095), ('prognostic', 0.011707903183783185), ('cutaneous', 0.011063854693303808), ('slnb', 0.01057396185845648), ('staging', 0.009759443981620312), ('result', 0.00948423045047171), ('prospective', 0.009227270075587903), ('stage', 0.009211555051519516), ('profile', 0.008513605385958703), ('outcome', 0.007753178764732287), ('metastasis', 0.0074930910941936315), ('clinical', 0.00733002337758367)]\n",
        "Topic 1: [('patient', 0.023037378430851522), ('melanoma', 0.019132680416665278), ('clinical', 0.009208239117531785), ('lifileucel', 0.009159778020030806), ('therapy', 0.0076434121424913785), ('lesion', 0.006939961419664312), ('cancer', 0.006890732700604385), ('clin', 0.006664535657861802), ('cell', 0.006608377577289724), ('may', 0.006393397251003606), ('page', 0.006291384525910798), ('lymphocyte', 0.005882470459294243), ('study', 0.005825451360286993), ('care', 0.005789416626131827), ('management', 0.005696220469738797), ('accuracy', 0.005611778999820124), ('tumor-infiltrating', 0.005115701564005591), ('evaluation', 0.005019431762988317), ('center', 0.00500777527912949), ('prior', 0.004811858917283067)]\n",
        "Topic 2: [('tmb', 0.02512627713028841), ('panel', 0.014142821957173288), ('patient', 0.013293932709637359), ('tumor', 0.01140130105938266), ('group', 0.011383867055954107), ('burden', 0.011376012164050748), ('cancer', 0.010181508883734652), ('ttmb-high', 0.008949781511795565), ('research', 0.008631329813989229), ('pembrolizumab', 0.008135615211247444), ('medicine', 0.008031424135247314), ('requested', 0.007771078717806823), ('across', 0.00713665317534374), ('value', 0.006983885240325684), ('guideline', 0.0065854915142057515), ('ci', 0.006565413329728565), ('rate', 0.006558879259149367), ('fda-approved', 0.006558504067518762), ('mutational', 0.006553493309201024), ('foundation', 0.006551483525261367)]\n",
        "Topic 3: [('-gene', 0.07384382250987406), ('melanoma', 0.010697063779567147), ('patient', 0.010075380175104029), ('..', 0.007246201723254092), ('study', 0.0058230621852402185), ('expression', 0.004306888828915283), ('test', 0.004296549029303913), ('-gep', 0.004267374729073247), ('risk', 0.003948569170106444), ('clinical', 0.003810941223010368), ('gep', 0.003660024165096663), ('result', 0.003480185230604665), ('class', 0.0031737785760353535), ('cutaneous', 0.003169921762380255), ('prognostic', 0.0031019701600391346), ('biopsy', 0.00310106091951514), ('nccn', 0.0029092824441306247), ('guideline', 0.002752009017171869), ('profile', 0.002684482971717825), ('stage', 0.002596731719391408)]\n",
        "Topic 4: [('clinical', 0.027913804043923855), ('cancer', 0.024148757343672507), ('patient', 0.02412436261262338), ('melanoma', 0.02307834380862451), ('nccn', 0.020142315586808464), ('dna', 0.019786176418228937), ('testing', 0.01937259705294808), ('tissue', 0.01830915511938433), ('tumor', 0.016256046664254342), ('study', 0.014150833368815991), ('guideline', 0.013445066019380924), ('liquid', 0.012117201757911835), ('braf', 0.012083653702897044), ('ctdna', 0.012049444739332015), ('analysis', 0.011891603259669018), ('may', 0.01091245706490551), ('agreement', 0.010570749695876989), ('biopsy', 0.010293789925963064), ('mutation', 0.00951163777217608), ('molecular', 0.008946007908690566)]\n",
        "Topic 5: [('ipilimumab', 0.04090207945555785), ('melanoma', 0.028558414278274248), ('sargramostim', 0.025956631254639317), ('patient', 0.020993847972638452), ('survival', 0.01881412055131661), ('metastatic', 0.015195276177452885), ('alone', 0.014749914650759352), ('arm', 0.013829231215524937), ('overall', 0.013336815483875128), ('treatment', 0.012891534912485455), ('month', 0.012590467822592993), ('mg/kg', 0.012196322279955311), ('event', 0.011556520364642818), ('adverse', 0.01045171552951963), ('combination', 0.010210832428095219), ('therapy', 0.009721287810876002), ('compared', 0.009303700090248406), ('trial', 0.008667519959521837), ('doi', 0.007813298035453713), ('advanced', 0.007673001309297636)]\n",
        "Topic 6: [('pla', 0.036499317728711046), ('melanoma', 0.0299578279378957), ('lesion', 0.029890262848776595), ('biopsy', 0.02588878777228713), ('test', 0.02062337813009261), ('pigmented', 0.01914273202085553), ('utility', 0.011251724834654961), ('evidence', 0.009898779965433901), ('clinical', 0.009890475833282114), ('assay', 0.009342318556190226), ('guideline', 0.008792632887785805), ('cutaneous', 0.008735284937491882), ('panel', 0.008308768666095954), ('patient', 0.008238966858667856), ('clinician', 0.008197853912546028), ('study', 0.007825275939390247), ('skin', 0.007800077362385536), ('nccn', 0.007649140455108083), ('diagnostic', 0.007586860482219407), ('case', 0.007359404845731021)]\n",
        "Topic 7: [('test', 0.0259441797949926), ('evidence', 0.02188281306879856), ('nccn', 0.017649917370717468), ('decisiondx-um', 0.015473417377459256), ('melanoma', 0.014877654435101974), ('uveal', 0.014141898284304691), ('level', 0.013446003823019649), ('um', 0.01278935074291007), ('prospective', 0.011460629920435898), ('clinical', 0.011428381497391144), ('guideline', 0.011420527935390772), ('risk', 0.011411627772778), ('class', 0.009343454494973893), ('expression', 0.008644444035732102), ('category', 0.007957451250538159), ('patient', 0.00795347905678872), ('gene', 0.007268642940134945), ('prognostic', 0.007268530627390573), ('follow', 0.006742626831444145), ('panel', 0.006584616298254775)]\n",
        "Topic 8: [('patient', 0.02860232693192175), ('melanoma', 0.027092491597906252), ('therapy', 0.014915367069614873), ('pembrolizumab', 0.013619540753817631), ('treatment', 0.011386529821857875), ('arm', 0.01105401915141011), ('nivo', 0.01058030361260068), ('metastatic', 0.010223134915055759), ('ci', 0.010002396905064586), ('panel', 0.009435120942879063), ('request', 0.009110452598930016), ('ipi', 0.009045524531282514), ('information', 0.009032045579302168), ('unresectable', 0.008358127143742884), ('month', 0.008024165772539452), ('nccn', 0.007936878848612614), ('randomized', 0.007923020237842561), ('keytruda', 0.0070611808807542285), ('disease', 0.006946628698384409), ('systemic', 0.006857831934561207)]\n",
        "Topic 9: [('-gene', 0.4586948879130445), ('melanoma', 0.006097151631033407), ('patient', 0.005087672533324227), ('test', 0.0023757096670201294), ('guideline', 0.0023627096798170487), ('study', 0.0022486455615793495), ('nccn', 0.002184538548832866), ('evidence', 0.0021701470444617857), ('expression', 0.001969538625888377), ('clinical', 0.0019232295493440315), ('prospective', 0.0017292804901789507), ('biopsy', 0.00169152734880628), ('pla', 0.0016605275835639014), ('cutaneous', 0.0016252801233606416), ('risk', 0.0016104652388027974), ('class', 0.0015762971625625823), ('gep', 0.0015284904276033347), ('panel', 0.001508348326081721), ('gene', 0.0014760278315637434), ('prognostic', 0.0014755081911821688)]\n",
        "\n",
        "Topics for year 2020:\n",
        "Topic 0: [('patient', 0.030678864919397374), ('melanoma', 0.027992663935013613), ('risk', 0.015174685807574272), ('-gep', 0.014433842999645207), ('expression', 0.013772766505663678), ('gep', 0.013398999608597419), ('class', 0.012666621531388377), ('test', 0.011980176310660789), ('prognostic', 0.011762226152105459), ('study', 0.011762196587893611), ('cutaneous', 0.01112252502805005), ('slnb', 0.010632922969696802), ('staging', 0.009780581437280856), ('result', 0.009491618839765681), ('prospective', 0.009296557484190764), ('stage', 0.00921225083626732), ('profile', 0.008577278443911896), ('outcome', 0.007792979770713302), ('metastasis', 0.007520897617059564), ('clinical', 0.007368312560234186)]\n",
        "Topic 1: [('patient', 0.02310893629508219), ('melanoma', 0.01919858866814279), ('clinical', 0.0092246055648492), ('lifileucel', 0.009172233971146042), ('therapy', 0.00766627638272522), ('lesion', 0.006951393964914276), ('cancer', 0.006891614523679002), ('clin', 0.006670392822934094), ('cell', 0.00661944160689854), ('may', 0.006401489057656233), ('page', 0.006299070279269719), ('lymphocyte', 0.005886811709619093), ('study', 0.005832177818714968), ('care', 0.005794658443071362), ('management', 0.005710434075285537), ('accuracy', 0.005620178926809365), ('tumor-infiltrating', 0.005119817286945457), ('evaluation', 0.005031585976055681), ('center', 0.005018258885211064), ('prior', 0.004818536049746388)]\n",
        "Topic 2: [('tmb', 0.025196398007728434), ('panel', 0.014164759735791652), ('patient', 0.013332412326184904), ('tumor', 0.011424240475522342), ('burden', 0.011413343169786568), ('group', 0.011411860171486243), ('cancer', 0.01020510465555876), ('ttmb-high', 0.0090013027490047), ('research', 0.00864149369200316), ('pembrolizumab', 0.00814755130768784), ('medicine', 0.008040978086354993), ('requested', 0.007787549862648434), ('across', 0.007145286645249132), ('value', 0.006987814730365581), ('guideline', 0.006595002249621114), ('ci', 0.006567822221076369), ('rate', 0.006563741319158805), ('fda-approved', 0.006562288254043499), ('mutational', 0.006561998230406373), ('foundation', 0.00656178025293266)]\n",
        "Topic 3: [('-gene', 0.0738591169938233), ('melanoma', 0.01072293684221026), ('patient', 0.010099273382002725), ('..', 0.0072547720323459805), ('study', 0.005834351758533181), ('expression', 0.004314214104714), ('test', 0.0043038485725594815), ('-gep', 0.004274601772635662), ('risk', 0.003955014467201468), ('clinical', 0.0038170552292552447), ('gep', 0.003665779407806155), ('result', 0.003485519389257507), ('class', 0.003178412415542554), ('cutaneous', 0.00317454693108084), ('prognostic', 0.003106443172967924), ('biopsy', 0.0031055319044003054), ('nccn', 0.0029133304726371573), ('guideline', 0.002755717609081198), ('profile', 0.0026880479786850387), ('stage', 0.0026001121433215308)]\n",
        "Topic 4: [('clinical', 0.028165638282329764), ('patient', 0.024194181577596174), ('cancer', 0.024107662885331647), ('melanoma', 0.023095529104714296), ('nccn', 0.020252132448279076), ('dna', 0.01971457398877975), ('testing', 0.01926296553255894), ('tissue', 0.018285759221160013), ('tumor', 0.016212892335241147), ('study', 0.014232174726471663), ('guideline', 0.013452700800408338), ('braf', 0.012059002086158161), ('liquid', 0.012047114168028674), ('ctdna', 0.012017109249147815), ('analysis', 0.011922244825090198), ('may', 0.010898873624524701), ('agreement', 0.01058877375232151), ('biopsy', 0.010306982321981217), ('mutation', 0.009499488841700321), ('molecular', 0.008958644039107129)]\n",
        "Topic 5: [('ipilimumab', 0.040983697818087084), ('melanoma', 0.028655108357143966), ('sargramostim', 0.026082231407027808), ('patient', 0.02100978462710819), ('survival', 0.01882173918528222), ('metastatic', 0.01521978070276445), ('alone', 0.014791355758261635), ('arm', 0.0138453875523264), ('overall', 0.013351468689687068), ('treatment', 0.012901992087000326), ('month', 0.012623428461292703), ('mg/kg', 0.012213626806269235), ('event', 0.01155687269331228), ('adverse', 0.010464776381133536), ('combination', 0.01023144883345537), ('therapy', 0.009734335502532042), ('compared', 0.00930043672660343), ('trial', 0.008669096854210547), ('doi', 0.007825584403912015), ('advanced', 0.007682310357620731)]\n",
        "Topic 6: [('pla', 0.036799797748523974), ('lesion', 0.030139777541366406), ('melanoma', 0.030132073027118702), ('biopsy', 0.02610326739368211), ('test', 0.020784178953504356), ('pigmented', 0.019274285938810642), ('utility', 0.011317858125765856), ('evidence', 0.009890712153585243), ('clinical', 0.00989037478541809), ('assay', 0.009334748692525345), ('guideline', 0.008783778498016374), ('cutaneous', 0.008731552536272766), ('panel', 0.008314772898761771), ('patient', 0.008228395677355919), ('clinician', 0.008199044329223058), ('study', 0.007825232496078556), ('skin', 0.007773427128645203), ('nccn', 0.007654605464137503), ('diagnostic', 0.007584024111530841), ('case', 0.0073742209224325625)]\n",
        "Topic 7: [('test', 0.026066223526215643), ('evidence', 0.021965409426523894), ('nccn', 0.017719478911780065), ('decisiondx-um', 0.015537027148075842), ('melanoma', 0.014940564380564535), ('uveal', 0.014181174819253491), ('level', 0.013480747615216547), ('um', 0.012812981261161439), ('prospective', 0.011485346869911813), ('clinical', 0.011443551984197473), ('guideline', 0.011438918985633631), ('risk', 0.011435324704573735), ('class', 0.009353127358489944), ('expression', 0.008658934488908738), ('category', 0.007964276401824724), ('patient', 0.007959907585832062), ('gene', 0.007272976673488925), ('prognostic', 0.007272109135601659), ('follow', 0.00674580637366073), ('panel', 0.006587835695945161)]\n",
        "Topic 8: [('patient', 0.028703130849684844), ('melanoma', 0.02683288187473765), ('therapy', 0.015926130478159245), ('pembrolizumab', 0.013677928199678174), ('treatment', 0.01146301513597881), ('arm', 0.011397466971972385), ('metastatic', 0.010394925273124543), ('ci', 0.010170159908297756), ('nivo', 0.010169396409296693), ('panel', 0.00941397083524047), ('information', 0.009063230074635067), ('request', 0.009060238566070862), ('ipi', 0.008640962100836145), ('unresectable', 0.008474200208145601), ('month', 0.008081794873711532), ('randomized', 0.007963267693773384), ('nccn', 0.00794022075416498), ('keytruda', 0.007102394284719164), ('disease', 0.0070341035614992055), ('systemic', 0.00697662786613364)]\n",
        "Topic 9: [('-gene', 0.46020180015044854), ('melanoma', 0.00609512553972723), ('patient', 0.005085257024242682), ('test', 0.00237315817853471), ('guideline', 0.002360161955133642), ('study', 0.002246133310973533), ('nccn', 0.002182048220741817), ('evidence', 0.0021676618398223974), ('expression', 0.0019671328959955446), ('clinical', 0.0019208443939992275), ('prospective', 0.0017269912973161272), ('biopsy', 0.0016892587695447319), ('pla', 0.0016582764256976126), ('cutaneous', 0.001623049327896089), ('risk', 0.0016082431807008246), ('class', 0.0015740956663405723), ('gep', 0.0015263186820551609), ('panel', 0.0015061894654429932), ('gene', 0.0014738900899060848), ('prognostic', 0.001473370793586767)]\n",
        "\n",
        "Topics for year 2021:\n",
        "Topic 0: [('patient', 0.030936318426470977), ('melanoma', 0.028261204738483734), ('risk', 0.015168063871825031), ('-gep', 0.014384858708645613), ('gep', 0.0140046157189668), ('expression', 0.013891451356403677), ('class', 0.012677650727604755), ('test', 0.012115912524821635), ('study', 0.011982868070375236), ('prognostic', 0.011867010991005811), ('cutaneous', 0.011269051726234214), ('slnb', 0.010657121764286959), ('staging', 0.009706251572298609), ('prospective', 0.009703563666903402), ('result', 0.009328712243302234), ('stage', 0.009187493912157941), ('profile', 0.00864202421742184), ('outcome', 0.007817479621841648), ('metastasis', 0.007522938502216563), ('clinical', 0.007430841404208665)]\n",
        "Topic 1: [('patient', 0.023162938725340056), ('melanoma', 0.019280046178879517), ('clinical', 0.009305634270703687), ('lifileucel', 0.008948328982049093), ('therapy', 0.007689927167668348), ('lesion', 0.007012312073274337), ('cancer', 0.006853475053249544), ('clin', 0.006610207477940476), ('cell', 0.006545426130042237), ('may', 0.006427620543479397), ('page', 0.006320028240500125), ('study', 0.005839369208542961), ('lymphocyte', 0.005823105502138024), ('care', 0.005793629490169656), ('management', 0.005790947502946755), ('accuracy', 0.005575267298305778), ('tumor-infiltrating', 0.005097774409117921), ('center', 0.005058962033291352), ('evaluation', 0.005056996625517381), ('prior', 0.004823042230281412)]\n",
        "Topic 2: [('tmb', 0.025334162179397074), ('panel', 0.014191854460998451), ('patient', 0.01329744432861845), ('burden', 0.011447824221824032), ('group', 0.011426032088231479), ('tumor', 0.01142320074507052), ('cancer', 0.010223918726028163), ('ttmb-high', 0.009046905442967112), ('research', 0.00857121078334794), ('pembrolizumab', 0.008173554281401596), ('medicine', 0.00802171256201836), ('requested', 0.007859374498399773), ('across', 0.0071484135973049), ('value', 0.006994513162164502), ('guideline', 0.00660502206963339), ('mutational', 0.006579969206114595), ('foundation', 0.0065793537988123535), ('rate', 0.006571683961467716), ('fda-approved', 0.006568823667956563), ('ci', 0.006512453184684481)]\n",
        "Topic 3: [('-gene', 0.07370938054271961), ('melanoma', 0.01074392700849359), ('patient', 0.01011868901567683), ('..', 0.007270607017449979), ('study', 0.0058436973832010405), ('expression', 0.00432036391557748), ('test', 0.004309977559485355), ('-gep', 0.004280672082704077), ('risk', 0.0039604514017220005), ('clinical', 0.003822223345289401), ('gep', 0.0036706561121479476), ('result', 0.0034900536264091233), ('class', 0.0031823759088187476), ('cutaneous', 0.0031785033476966103), ('prognostic', 0.0031102753641914557), ('biopsy', 0.0031093624392883015), ('nccn', 0.0029168152256517053), ('guideline', 0.002758924318492055), ('profile', 0.002691136912101661), ('stage', 0.0026030495196010537)]\n",
        "Topic 4: [('clinical', 0.028178096379268342), ('patient', 0.02422243867990776), ('cancer', 0.024141957312312112), ('melanoma', 0.02303372614061393), ('nccn', 0.020305377862409938), ('dna', 0.01978801230561779), ('testing', 0.019475681296996693), ('tissue', 0.018389628656508467), ('tumor', 0.016414108740201393), ('study', 0.014231171048357149), ('guideline', 0.013536536726732691), ('ctdna', 0.01210090452198137), ('braf', 0.012054666736663817), ('liquid', 0.012048678174130164), ('analysis', 0.011921047083154697), ('may', 0.010903216344555195), ('agreement', 0.010592936061949247), ('biopsy', 0.010311692961382908), ('mutation', 0.009493288110941063), ('molecular', 0.008954913376117644)]\n",
        "Topic 5: [('ipilimumab', 0.04108930808980319), ('melanoma', 0.028728320363746195), ('sargramostim', 0.02620142244538502), ('patient', 0.020997237982445977), ('survival', 0.018876766805444544), ('metastatic', 0.015195153638198487), ('alone', 0.01482949880677824), ('arm', 0.013886238754850575), ('overall', 0.013389235543021752), ('treatment', 0.012907094331012932), ('month', 0.012644536394724194), ('mg/kg', 0.012244049279870724), ('event', 0.01158300293402381), ('adverse', 0.01047482999108425), ('combination', 0.01024755575402304), ('therapy', 0.009714088662916825), ('compared', 0.009319124688498255), ('trial', 0.008660839753552231), ('doi', 0.007837404706400422), ('advanced', 0.0076629360985395936)]\n",
        "Topic 6: [('pla', 0.037346355203023124), ('melanoma', 0.03086012950014991), ('lesion', 0.030579144802658467), ('biopsy', 0.02644964744259254), ('test', 0.020932107943965033), ('pigmented', 0.019375012039492153), ('utility', 0.011399453921633098), ('clinical', 0.010083975073138289), ('evidence', 0.009755046856774852), ('assay', 0.00920291266775725), ('cutaneous', 0.008811906972992408), ('guideline', 0.008757213547391696), ('panel', 0.00826822815135748), ('patient', 0.008222824736216015), ('clinician', 0.008119367468960114), ('study', 0.0077478163629519274), ('skin', 0.007677957579399925), ('nccn', 0.0076753241787596675), ('diagnostic', 0.007547423694373199), ('case', 0.007362408477960172)]\n",
        "Topic 7: [('test', 0.02617673421886141), ('evidence', 0.02202943929366597), ('nccn', 0.017779100904714042), ('decisiondx-um', 0.015594949520770708), ('melanoma', 0.014999446028786667), ('uveal', 0.014206999424808723), ('level', 0.01350220324826682), ('um', 0.012822864187175518), ('prospective', 0.01149800156612815), ('clinical', 0.011449716496396745), ('risk', 0.01144716115794674), ('guideline', 0.011445803766949479), ('class', 0.009357153025933533), ('expression', 0.008665684088447525), ('category', 0.007967808397089191), ('patient', 0.007963655336497339), ('gene', 0.007275135643831212), ('prognostic', 0.0072740119374640165), ('follow', 0.0067476190655290525), ('panel', 0.006589557105024059)]\n",
        "Topic 8: [('patient', 0.028852400713251902), ('melanoma', 0.026690489919369186), ('therapy', 0.01567363413503011), ('pembrolizumab', 0.013866684422732837), ('treatment', 0.011490073116856665), ('arm', 0.011487465641054531), ('metastatic', 0.01036858567383485), ('ci', 0.01023363308000272), ('nivo', 0.010207450314860742), ('panel', 0.00948310951539232), ('request', 0.009125142112032391), ('information', 0.009118082048012366), ('ipi', 0.008686037847565546), ('unresectable', 0.008534713518909491), ('month', 0.008108705378499333), ('randomized', 0.00796919959967719), ('nccn', 0.007944544063864292), ('keytruda', 0.007137291876917935), ('disease', 0.007076291168366602), ('systemic', 0.007003364769287957)]\n",
        "Topic 9: [('-gene', 0.461233255651777), ('melanoma', 0.006094561100093629), ('patient', 0.005084248817291087), ('test', 0.002371633039307757), ('guideline', 0.002358637612351682), ('study', 0.0022446177722869895), ('nccn', 0.002180539101637523), ('evidence', 0.002166154311602615), ('expression', 0.0019656535152284154), ('clinical', 0.0019193731623289851), ('prospective', 0.0017255614524066781), ('biopsy', 0.0016878384138530442), ('pla', 0.0016568642286826105), ('cutaneous', 0.0016216468178533144), ('risk', 0.0016068448746880972), ('class', 0.0015727073604309084), ('gep', 0.0015249450948812845), ('panel', 0.001504822339096075), ('gene', 0.0014725336593416185), ('prognostic', 0.0014720145383323477)]\n",
        "\n",
        "Topics for year 2022:\n",
        "Topic 0: [('patient', 0.03128104413731951), ('melanoma', 0.02857113937949531), ('risk', 0.01521772892453504), ('-gep', 0.014399645948957323), ('gep', 0.014119424087913262), ('expression', 0.014020512188624806), ('class', 0.012719359771058722), ('test', 0.012218259636654362), ('study', 0.01199328626820738), ('prognostic', 0.01193876834420865), ('cutaneous', 0.011331878455411353), ('slnb', 0.010720628015783273), ('prospective', 0.009734121490114512), ('staging', 0.00972334364822127), ('result', 0.009322050822961255), ('stage', 0.009171513851246033), ('profile', 0.008718175873760553), ('outcome', 0.007858195361786653), ('metastasis', 0.0075451943144381455), ('clinical', 0.007472849301368779)]\n",
        "Topic 1: [('patient', 0.023183718811213488), ('melanoma', 0.019372547189674752), ('clinical', 0.00939344217671469), ('lifileucel', 0.008909776555472709), ('therapy', 0.0077116741086499935), ('lesion', 0.0070231600236412145), ('cancer', 0.006830279792807431), ('clin', 0.006596471401294014), ('cell', 0.006527206765856217), ('may', 0.006418073659031671), ('page', 0.00632458926325876), ('study', 0.005845674517064441), ('management', 0.005821591766159581), ('lymphocyte', 0.005812940886318587), ('care', 0.005803751672098204), ('accuracy', 0.005563037756232605), ('tumor-infiltrating', 0.00509860720782789), ('evaluation', 0.005075421830924893), ('center', 0.0050638364275004755), ('prior', 0.004826578623487907)]\n",
        "Topic 2: [('tmb', 0.025166589639975312), ('panel', 0.014209109991579275), ('patient', 0.013302928470156482), ('burden', 0.011438038160981944), ('group', 0.011400805863546963), ('tumor', 0.011385656280201073), ('cancer', 0.010208303364073338), ('ttmb-high', 0.009089124352378372), ('research', 0.008556010201286482), ('pembrolizumab', 0.008157523553288732), ('medicine', 0.00800250408275238), ('requested', 0.00792117122971158), ('across', 0.007138517964957051), ('value', 0.006988637075188062), ('guideline', 0.006619126177165078), ('foundation', 0.006575652908018424), ('mutational', 0.006575464661754559), ('rate', 0.006559011408220556), ('fda-approved', 0.0065550241300613675), ('melanoma', 0.006505791091109748)]\n",
        "Topic 3: [('-gene', 0.07349314187373834), ('melanoma', 0.010759054187932054), ('patient', 0.010132701693230904), ('..', 0.007293330640156789), ('study', 0.005850551638758357), ('expression', 0.004324927866545303), ('test', 0.004314526535496281), ('-gep', 0.00428517885850316), ('risk', 0.003964502221582013), ('clinical', 0.0038260803883229722), ('gep', 0.00367430289967771), ('result', 0.003493453044132845), ('class', 0.003185362319766275), ('cutaneous', 0.00318148463131185), ('prognostic', 0.0031131666135954692), ('biopsy', 0.00311225248787764), ('nccn', 0.002919454368488956), ('guideline', 0.0027613613643098288), ('profile', 0.0026934882503153066), ('stage', 0.002605290470960906)]\n",
        "Topic 4: [('clinical', 0.028178629196426677), ('patient', 0.02430166370365603), ('cancer', 0.02418044504000895), ('melanoma', 0.023014079297802324), ('nccn', 0.020317117732175365), ('dna', 0.019815352416110793), ('testing', 0.019491233167182962), ('tissue', 0.018378480927768448), ('tumor', 0.016482186691555344), ('study', 0.014242031799180828), ('guideline', 0.013604900510227374), ('ctdna', 0.01212754313085186), ('braf', 0.012063005696405784), ('liquid', 0.012023802599103108), ('analysis', 0.011930143220247573), ('may', 0.010903162392627288), ('agreement', 0.010592949479015176), ('biopsy', 0.010319515259353216), ('mutation', 0.009497670889884421), ('molecular', 0.008953185036949765)]\n",
        "Topic 5: [('ipilimumab', 0.04114345722362082), ('melanoma', 0.0287743960866214), ('sargramostim', 0.026229487594423267), ('patient', 0.021001431418531773), ('survival', 0.018889561489226436), ('metastatic', 0.0151897661037381), ('alone', 0.014842167753120639), ('arm', 0.01389699790521116), ('overall', 0.013401654071018858), ('treatment', 0.012911866430610546), ('month', 0.012653570242367613), ('mg/kg', 0.012253024185933162), ('event', 0.011597088441605528), ('adverse', 0.010480868943681148), ('combination', 0.010256510568588595), ('therapy', 0.009716936995388994), ('compared', 0.009325657268695964), ('trial', 0.008661930956328556), ('doi', 0.007843469027069427), ('advanced', 0.007667688626854855)]\n",
        "Topic 6: [('pla', 0.03773332817042918), ('melanoma', 0.03132766467068082), ('lesion', 0.030841298992903058), ('biopsy', 0.02673765212011798), ('test', 0.02109499361664777), ('pigmented', 0.01952096866949378), ('utility', 0.011486159179164611), ('clinical', 0.01020065736548343), ('evidence', 0.009701693690133835), ('assay', 0.00917966423341223), ('cutaneous', 0.008830574452239831), ('guideline', 0.008732724710705846), ('panel', 0.008253818593266333), ('patient', 0.00817831804750404), ('clinician', 0.008140427165478034), ('study', 0.007724527637016439), ('nccn', 0.0076666526068192705), ('skin', 0.007651418453640808), ('diagnostic', 0.007574777781905742), ('case', 0.0073745703200002845)]\n",
        "Topic 7: [('test', 0.026254410259540444), ('evidence', 0.022066699872001907), ('nccn', 0.017818116612553333), ('decisiondx-um', 0.01563516053589579), ('melanoma', 0.015041458120693114), ('uveal', 0.01421802742193293), ('level', 0.013510098513475554), ('um', 0.012822351068911234), ('prospective', 0.011500035146654953), ('clinical', 0.01145028657335143), ('risk', 0.01144880802790783), ('guideline', 0.011444709988282393), ('class', 0.009357727513723085), ('expression', 0.0086661842273766), ('category', 0.007970585432469297), ('patient', 0.0079660922342876), ('gene', 0.00727662722661525), ('prognostic', 0.007275511566153615), ('follow', 0.006749652024170681), ('panel', 0.006590947516383231)]\n",
        "Topic 8: [('patient', 0.02903588228759148), ('melanoma', 0.02705226877828693), ('therapy', 0.015503425274216092), ('pembrolizumab', 0.01419179639148201), ('treatment', 0.011523871126524289), ('arm', 0.011375349033426876), ('metastatic', 0.01038804536256149), ('nivo', 0.010214617433111518), ('ci', 0.010174101991251683), ('panel', 0.009589337077307379), ('information', 0.009226655564506015), ('request', 0.00922180652393496), ('ipi', 0.008609475648456042), ('unresectable', 0.00860850262537299), ('month', 0.008064830787001744), ('nccn', 0.008013221086579899), ('randomized', 0.007921307197882413), ('keytruda', 0.0072316939328592525), ('disease', 0.007041457857177875), ('systemic', 0.006958220283109023)]\n",
        "Topic 9: [('-gene', 0.4619030132879818), ('melanoma', 0.006094312940244532), ('patient', 0.005083686607708422), ('test', 0.0023706738366267056), ('guideline', 0.0023576786721112436), ('study', 0.002243662335352435), ('nccn', 0.0021795866064686364), ('evidence', 0.002165202575830976), ('expression', 0.0019647163126388545), ('clinical', 0.0019184404063223486), ('prospective', 0.0017246521163570869), ('biopsy', 0.0016869345838407613), ('pla', 0.0016559651622823936), ('cutaneous', 0.0016207534390136975), ('risk', 0.0016059539739572944), ('class', 0.0015718223760980109), ('gep', 0.001524068868996757), ('panel', 0.0015039499748350236), ('gene', 0.001471667708684339), ('prognostic', 0.0014711486930025787)]\n",
        "\n",
        "Topics for year 2024:\n",
        "Topic 0: [('patient', 0.03155375762208152), ('melanoma', 0.028805866555869013), ('risk', 0.015274648875350664), ('-gep', 0.014434360177066856), ('expression', 0.014117334161338842), ('gep', 0.014093590650485177), ('class', 0.012762278034769594), ('test', 0.012284644488061996), ('study', 0.01199628024019126), ('prognostic', 0.011981791809064233), ('cutaneous', 0.011363662137142723), ('slnb', 0.010779910620873422), ('staging', 0.009739637187913895), ('prospective', 0.009686409606658708), ('result', 0.009317061388427701), ('stage', 0.009161109581561137), ('profile', 0.008776930916181178), ('outcome', 0.007893929285490993), ('metastasis', 0.007569353046849511), ('clinical', 0.007499451595489688)]\n",
        "Topic 1: [('patient', 0.023226754255480687), ('melanoma', 0.019428340917660155), ('clinical', 0.009402768009264505), ('lifileucel', 0.008944870449041829), ('therapy', 0.007733163916160492), ('lesion', 0.007025823263921622), ('cancer', 0.006833063260512294), ('clin', 0.00660530692535082), ('cell', 0.006534832894990923), ('may', 0.006418415529180653), ('page', 0.006326566307573412), ('study', 0.005851048607627883), ('management', 0.0058234032100538706), ('lymphocyte', 0.005821839320033054), ('care', 0.005810069227261917), ('accuracy', 0.005568948849325066), ('tumor-infiltrating', 0.00510797243264052), ('evaluation', 0.005087079211865403), ('center', 0.005073212120293498), ('prior', 0.0048332845318360355)]\n",
        "Topic 2: [('tmb', 0.025200529897518396), ('panel', 0.014213011321357326), ('patient', 0.013333838228090738), ('burden', 0.01144712518403588), ('group', 0.011397576242991316), ('tumor', 0.011373818996285997), ('cancer', 0.010214719081249072), ('ttmb-high', 0.009126958518499585), ('research', 0.008564628661340706), ('pembrolizumab', 0.008165311842375228), ('medicine', 0.008002121154173385), ('requested', 0.007938838874744178), ('across', 0.0071422024488880225), ('value', 0.006983305744609681), ('guideline', 0.0066257609340173015), ('foundation', 0.006581207147115492), ('mutational', 0.006580341948613655), ('rate', 0.006558107336467525), ('fda-approved', 0.006553144929349364), ('ci', 0.006497803511922989)]\n",
        "Topic 3: [('-gene', 0.07330412065573817), ('melanoma', 0.010767532840771954), ('patient', 0.010140570151642162), ('..', 0.007305341845823881), ('study', 0.005854478391803521), ('expression', 0.004327579993446714), ('test', 0.004317170291341137), ('-gep', 0.004287799021127784), ('risk', 0.0039668671573288745), ('clinical', 0.003828336669291789), ('gep', 0.0036764411481346377), ('result', 0.0034954522265960367), ('class', 0.003187128783992629), ('cutaneous', 0.0031832482018243928), ('prognostic', 0.0031148793517074896), ('biopsy', 0.003113964547765395), ('nccn', 0.002921024559678308), ('guideline', 0.0027628170407420116), ('profile', 0.0026948952899818464), ('stage', 0.002606634801038481)]\n",
        "Topic 4: [('clinical', 0.028263219094555845), ('patient', 0.024384877852296136), ('cancer', 0.024227248632496652), ('melanoma', 0.022982980410922806), ('nccn', 0.02033052648185063), ('dna', 0.019836813839153714), ('testing', 0.019476254986767673), ('tissue', 0.018367302234375184), ('tumor', 0.016543017613905846), ('study', 0.014244167905580533), ('guideline', 0.013649223836973822), ('ctdna', 0.012155597476549557), ('braf', 0.012060572592964953), ('liquid', 0.012005735155542012), ('analysis', 0.011934975197432076), ('may', 0.010913302499864073), ('agreement', 0.010595391463312584), ('biopsy', 0.01032149488517512), ('mutation', 0.009495438378780178), ('molecular', 0.0089521170315398)]\n",
        "Topic 5: [('ipilimumab', 0.041190739028515944), ('melanoma', 0.028814462214932453), ('sargramostim', 0.026232972108017474), ('patient', 0.02100856883615695), ('survival', 0.018889294577497173), ('metastatic', 0.015190008792880676), ('alone', 0.014847831534493958), ('arm', 0.013897832760126513), ('overall', 0.01340516127092013), ('treatment', 0.012916691647279514), ('month', 0.012662412703695738), ('mg/kg', 0.012254376203616048), ('event', 0.011602651685391095), ('adverse', 0.010486053271533104), ('combination', 0.010262742391161728), ('therapy', 0.00971955350284622), ('compared', 0.00932686152397021), ('trial', 0.008663794516386802), ('doi', 0.007847352176561538), ('advanced', 0.00767110896358886)]\n",
        "Topic 6: [('pla', 0.037947073051279825), ('melanoma', 0.03142230410635709), ('lesion', 0.030992055502840885), ('biopsy', 0.02691757110114778), ('test', 0.021232852809424992), ('pigmented', 0.019644630903459276), ('utility', 0.011542221025907446), ('clinical', 0.010187735999141658), ('evidence', 0.009702891208576005), ('assay', 0.009164738026717457), ('cutaneous', 0.008813566575246472), ('guideline', 0.008712693104343954), ('panel', 0.008259686902875037), ('patient', 0.008172873485643627), ('clinician', 0.008160998097885), ('study', 0.007724841430529378), ('nccn', 0.007663286769775141), ('skin', 0.007635725345357723), ('diagnostic', 0.007571539797696961), ('case', 0.007389609961039004)]\n",
        "Topic 7: [('test', 0.026312623300202384), ('evidence', 0.022096950828078648), ('nccn', 0.01784873928462483), ('decisiondx-um', 0.015666175514506185), ('melanoma', 0.015073570191166084), ('uveal', 0.0142289448396548), ('level', 0.013518731378875323), ('um', 0.0128245964876903), ('prospective', 0.01150428901121358), ('risk', 0.011452670199145306), ('clinical', 0.011451874784672949), ('guideline', 0.011446385254577958), ('class', 0.009358840457659907), ('expression', 0.0086686406427937), ('category', 0.007972577133578258), ('patient', 0.007967789311140089), ('gene', 0.007277504036247624), ('prognostic', 0.0072760087277367515), ('follow', 0.006751041839256641), ('panel', 0.006591529584127105)]\n",
        "Topic 8: [('patient', 0.02920273099493049), ('melanoma', 0.026957959439345945), ('therapy', 0.01558495960006836), ('pembrolizumab', 0.014244798745355575), ('treatment', 0.011549406835327706), ('arm', 0.011380031362242093), ('metastatic', 0.010402635826876798), ('nivo', 0.010266339313871244), ('ci', 0.010160286302337031), ('panel', 0.009635939309954565), ('information', 0.009253648987363802), ('request', 0.009218661921268832), ('unresectable', 0.008632454917174561), ('ipi', 0.008605552269128774), ('month', 0.008065122890989275), ('nccn', 0.00800758970766175), ('randomized', 0.007931135946612884), ('keytruda', 0.007234225030603055), ('disease', 0.0070477131225921774), ('systemic', 0.006959743234028873)]\n",
        "Topic 9: [('-gene', 0.46232020154574804), ('melanoma', 0.006093234038755565), ('patient', 0.005082609951727794), ('test', 0.0023698251681454597), ('guideline', 0.0023568321722662673), ('study', 0.0022428354598359986), ('nccn', 0.002178771243527562), ('evidence', 0.0021643898465387858), ('expression', 0.0019639422554306265), ('clinical', 0.0019176758185008597), ('prospective', 0.0017239295700702372), ('biopsy', 0.0016862206915605298), ('pla', 0.0016552584963902227), ('cutaneous', 0.0016200551243837412), ('risk', 0.0016052592129373827), ('class', 0.0015711359107310474), ('gep', 0.0015233942491865088), ('panel', 0.0015032804309915817), ('gene', 0.001471006417689393), ('prognostic', 0.0014704875357928096)]\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 161
        },
        "id": "S9EarQnzOsFg",
        "outputId": "4282c495-4298-4799-c5f5-42ecd6817490"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "SyntaxError",
          "evalue": "invalid syntax (<ipython-input-4-f2e394e8117b>, line 1)",
          "traceback": [
            "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-4-f2e394e8117b>\"\u001b[0;36m, line \u001b[0;32m1\u001b[0m\n\u001b[0;31m    Topics for year 201:\u001b[0m\n\u001b[0m           ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m invalid syntax\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Hyerarchical topic modeling"
      ],
      "metadata": {
        "id": "V7KXuJJEDCst"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install hlda gensim pyLDAvis"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "x8JopJhkDHBX",
        "outputId": "4acb6686-0d1b-4ff4-8705-7d7c96a959ec"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting hlda\n",
            "  Downloading hlda-0.3.1-py3-none-any.whl.metadata (1.9 kB)\n",
            "Requirement already satisfied: gensim in /usr/local/lib/python3.10/dist-packages (4.3.3)\n",
            "Requirement already satisfied: pyLDAvis in /usr/local/lib/python3.10/dist-packages (3.4.1)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from hlda) (1.26.4)\n",
            "Requirement already satisfied: scipy<1.14.0,>=1.7.0 in /usr/local/lib/python3.10/dist-packages (from gensim) (1.13.1)\n",
            "Requirement already satisfied: smart-open>=1.8.1 in /usr/local/lib/python3.10/dist-packages (from gensim) (7.0.4)\n",
            "Requirement already satisfied: pandas>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (2.1.4)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.4.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (3.1.4)\n",
            "Requirement already satisfied: numexpr in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (2.10.1)\n",
            "Requirement already satisfied: funcy in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (2.0)\n",
            "Requirement already satisfied: scikit-learn>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (1.3.2)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from pyLDAvis) (71.0.4)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2024.1)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=2.0.0->pyLDAvis) (2024.1)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn>=1.0.0->pyLDAvis) (3.5.0)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from smart-open>=1.8.1->gensim) (1.16.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->pyLDAvis) (2.1.5)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas>=2.0.0->pyLDAvis) (1.16.0)\n",
            "Downloading hlda-0.3.1-py3-none-any.whl (18 kB)\n",
            "Installing collected packages: hlda\n",
            "Successfully installed hlda-0.3.1\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import fitz  # Assuming you are using PyMuPDF (fitz)\n",
        "\n",
        "# Specify the base folder path, modify for either \"accepted_all\" or \"denied_all \" or \"all\"\n",
        "base_folder_path = '/content/drive/My Drive/thesis/nccn_guidelines/submission_requests/all'\n",
        "\n",
        "# List to hold the text from each PDF\n",
        "pdf_texts = []\n",
        "\n",
        "# List to hold the text from each PDF\n",
        "pdf_count = 0\n",
        "\n",
        "# Walk through all directories and files within the base folder\n",
        "for root, dirs, files in os.walk(base_folder_path):\n",
        "    for filename in files:\n",
        "        # Check if the file is a PDF\n",
        "        if filename.endswith(\".pdf\"):\n",
        "            # Remove \"Copy of \" from the filename, if it exists\n",
        "            filename_cleaned = filename.replace(\"Copy of \", \"\")\n",
        "\n",
        "            # Full path to the PDF file\n",
        "            file_path = os.path.join(root, filename)\n",
        "\n",
        "            # Open the PDF file\n",
        "            doc = fitz.open(file_path)\n",
        "\n",
        "            # Extract text from each page\n",
        "            text = \"\"\n",
        "            for page_num in range(len(doc)):\n",
        "                page = doc.load_page(page_num)\n",
        "                text += page.get_text()\n",
        "\n",
        "            # Append the extracted text to the list\n",
        "            pdf_texts.append({\n",
        "                \"filename\": filename_cleaned,\n",
        "                \"text\": text,\n",
        "                # Calculate and store the word count\n",
        "                \"word_count\": len(text.split())\n",
        "            })\n",
        "\n",
        "            # Increment the counter\n",
        "            pdf_count += 1\n",
        "\n",
        "# Print the total number of PDFs processed\n",
        "print(f\"Total number of PDFs processed: {pdf_count}\")\n",
        "\n",
        "# Display the text and tokenized data extracted from each PDF\n",
        "for pdf in pdf_texts:\n",
        "    print(f\"Text from {pdf['filename']}:\")\n",
        "    print(pdf['text'][:500])  # Print first 500 characters for brevity\n",
        "    print(\"\\n---\\n\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "nBoTd-Y9JHyL",
        "outputId": "777b111f-3bd3-41c1-bb28-4e5e7dbd7254"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Total number of PDFs processed: 46\n",
            "Text from 01_13_20_Melanoma_Merck.pdf:\n",
            " \n",
            "Name: Suzana Giffin, AVP Global Medical Affairs \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd. \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 13, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA (pembrolizumab), in reference to unresectable \n",
            "or metastatic melanoma with brain metastasis. \n",
            " \n",
            "Specif\n",
            "\n",
            "---\n",
            "\n",
            "Text from 03_01_20_Melanoma_Vi3c.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by:  \n",
            "Name: Drs. Daniel Goldstein, Allen Lichter, Mark Ratain, Ian Tannock, Len Saltz \n",
            "Company/Organization: Value in Cancer Care Consortium (Vi3C)  \n",
            "Address: 3930 Ridgmaar Square, Ann Arbor, Michigan 48105 (www.vi3c.org)  \n",
            "Telephone: 1-646-522-9582 \n",
            "Email: danielg3@tauex.tau.ac.il \n",
            "Date of request: March 1, 2020 \n",
            "NCCN Guidelines Panels: Cutaneous Melanoma \n",
            " \n",
            "Specific Change: On behalf of Vi3C, we respectfully request the Cutaneous Melanoma Guideline \n",
            "Panel to amend the NCCN gui\n",
            "\n",
            "---\n",
            "\n",
            "Text from 04_29_20_Melanoma_Merck.pdf:\n",
            " \n",
            " \n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd. Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: April 29, 2020 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request that the NCCN Melanoma \n",
            "Panel review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to updated dosing \n",
            "recommendations for pembrolizumab. \n",
            " \n",
            "Specific\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_10_20_Melanoma_Vi3C.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by:  \n",
            "Name: Drs. Daniel Goldstein, Allen Lichter, Mark Ratain, Ian Tannock, Len Saltz \n",
            "Company/Organization: Value in Cancer Care Consortium (Vi3C)  \n",
            "Address: 3930 Ridgmaar Square, Ann Arbor, Michigan 48105 (www.vi3c.org)  \n",
            "Telephone: 1-646-522-9582 \n",
            "Email: danielg3@tauex.tau.ac.il \n",
            "Date of request: June 10, 2020 \n",
            "NCCN Guidelines Panels: Cutaneous Melanoma \n",
            " \n",
            "Specific Change: On behalf of Vi3C, we respectfully request the Cutaneous Melanoma Guideline \n",
            "Panel to amend the NCCN gui\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_15_20_Uveal_Castle.pdf:\n",
            "C/'STLA\n",
            ":\n",
            "Submitted by\n",
            "Jay Braxton, Pharnn. D., Executive Director of MedicalAffairs\n",
            "Castle Biosciences, Inc\n",
            "820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546\n",
            "Ph: 281.853.9357 ll Email: jbraxton@castlebiosciences.com\n",
            "Date of Request: 0611512020\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations, as it is essential that clinical decision-making be based on the highest level of peer-\n",
            "re\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_16_20_Melanoma_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 16, 2020 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Changes: We respect\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_16_20_Melanoma_DermTech.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: DermTech, Inc  \n",
            "Name: Burkhard Jansen, MD, Chief Medical Officer \n",
            "Company/Organization: DermTech, Inc. \n",
            "Address: 11099 N Torrey Pines Road, Suite 100, La Jolla, CA 92037 \n",
            "Phone: (858)249-9413 \n",
            "Email: bjansen@dermtech.com \n",
            "Date of request: June 16, 2020 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "On behalf of DermTech, Inc., I respectfully request the NCCN Melanoma Panel review the enclosed data on DermTech’s \n",
            "pre-biopsy and biopsy guiding n\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_17_20_Melanoma_Castle_061720.pdf:\n",
            " \n",
            " \n",
            "Submitted by:  \n",
            "Name:  Jay Braxton, PharmD, Executive Director, Medical Affairs \n",
            "Company:  Castle Biosciences, Inc.  \n",
            "Address:  820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546 \n",
            "Phone:  281-853-9357  \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of request:  6/17/20 \n",
            "NCCN Guidelines Panel:  Melanoma \n",
            " \n",
            "Castle Biosciences Inc. would like to thank the NCCN Panel for updating guidance on gene expression profiling (GEP) in the \n",
            "2020 guideline versions. While we appreciate the fact that\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_21_20_Melanoma_DermatologicSurgery.pdf:\n",
            " \n",
            "1 \n",
            " \n",
            "Submitted by: Gary L. Peck, MD \n",
            "Company/Organization: Dermatologic Surgery Center of Washington \n",
            "Address: 5530 Wisconsin Avenue, Suite 820, Chevy Chase, MD 20815 \n",
            "Phone: (301) 652-8081 \n",
            "Email: garypeck1@gmail.com  \n",
            "Date of request: June 21, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Re: Clinical Utility of the DermTech Pigmented Lesion Assay \n",
            " \n",
            "My experience as the director, Melanoma Center, Washington Hospital Center, Washington DC from \n",
            "1996 to 2015 included accruing about 2000 \n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_22_20_Melanoma_Myriad.pdf:\n",
            " \n",
            "Submitted by:   \n",
            " \n",
            "Medical Director, Dermatology \n",
            "Name:  \n",
            " \n",
            " \n",
            "Loren E. Clarke, M.D. \n",
            "Company/Organization: \n",
            "Myriad Genetic Laboratories, Inc. \n",
            "Address: \n",
            " \n",
            " \n",
            "320 Wakara Way, Salt Lake City, UT 84108 \n",
            "Phone:  \n",
            " \n",
            " \n",
            "801.883.3470 \n",
            "Email:   \n",
            " \n",
            " \n",
            "lclarke@myriad.com \n",
            "Date of Request:  \n",
            " \n",
            "June 22, 2020 \n",
            "NCCN Guidelines Panel:  \n",
            "Cutaneous Melanoma \n",
            " \n",
            " \n",
            " \n",
            "Specific Change Requested:  \n",
            "• \n",
            "Modify the existing bullet regarding diagnostic testing from PRINCIPLES OF \n",
            "MOLECULAR TESTING (on page ME-C 1 of 7) as \n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_22_20_Melanoma_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to the evaluation and management of patients with melanoma. \n",
            "Req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_22_20_Melanoma_SUNY.pdf:\n",
            " \n",
            "1 \n",
            "June 22, 2020 \n",
            " \n",
            "Re: DermTech’s Pigmented Lesion Assay /NCCN \n",
            " \n",
            "Submitted by: \n",
            "Name: Daniel M. Siegel MD, MS \n",
            "Company/Organization: SUNY Downstate \n",
            "Address: Basic Sci Bldg 849 450 Clarkson Avenue, Box46, Brooklyn 11203 \n",
            "Phone: 718 270 1229 \n",
            "Email: Daniel.siegel@downstate.edu \n",
            "Date of Request: June 22, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            " \n",
            "Dear Cutaneous Melanoma Panel Members: \n",
            " \n",
            "As a clinician and clinical researcher, I’ve not only studied and published, but also incorporate\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_23_20_Melanoma_UPMC.pdf:\n",
            " \n",
            " \n",
            "NCCN Cutaneous Melanoma Guidelines Panel  \n",
            " \n",
            "Submitted by: \n",
            "Name: Laura K. Ferris, MD, PhD \n",
            "Organization: UPMC \n",
            "Address: Please see above \n",
            "Phone: Please see above \n",
            "Email: ferrlk@UPMC.EDU \n",
            "Date of request: 06232020 \n",
            "NCCN Guidelines Panel – Cutaneous Melanoma \n",
            "Sent via email to: submissions@nccn.org \n",
            " \n",
            "Regarding: NCCN Guidelines for Cutaneous Melanoma – Pigmented Lesion Assay \n",
            "Dear NCCN Cutaneous Melanoma Panel Members: \n",
            "I have served as the lead investigator for several clinical studies invol\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_23_20_Melanoma_Northwestern.pdf:\n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: June K. Robinson, MD – Research Professor of Dermatology \n",
            "Company/Organization: Northwestern University Feinberg School of Medicine, Department of \n",
            "Dermatology \n",
            "Address: 645 N. Michigan Ave, Suite 1050, Chicago, IL 60611 \n",
            "Phone: 312-503-5941 \n",
            "Email: june-robinson@northwestern.edu \n",
            "Date of Request: June 23, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "June 23, 2020 \n",
            "To: NCCN Cutaneous Melanoma Panel; submissions@nccn.org  \n",
            "Re: DermTech’s Pigmented Lesion Assay  \n",
            " \n",
            "D\n",
            "\n",
            "---\n",
            "\n",
            "Text from 07_21_20_Melanoma_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: Tuesday July 21, 2020 \n",
            "NCCN Guidelines Panel: NCCN Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Change\n",
            "\n",
            "---\n",
            "\n",
            "Text from 07_30_20_Melanoma_Genentech.pdf:\n",
            " Genentech, Inc.  All rights reserved.\n",
            "Submitted by: \n",
            "Neda Nguyen, PharmD\n",
            "Medical Science Director, US Medical Affairs\n",
            "Genentech, Inc.\n",
            "1 DNA Way\n",
            "South San Francisco, CA  94080\n",
            "Phone: (800) 821-8590\n",
            "Email:  genentechmedinfo-d@gene.com\n",
            "Date of request: July 30, 2020\n",
            "NCCN Guidelines Panel: Melanoma\n",
            "Dear NCCN Melanoma Panel:\n",
            "On behalf of Genentech, Inc., enclosed is notification of the FDA approval for Tecentriq® (atezolizumab) in \n",
            "combination with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib\n",
            "\n",
            "---\n",
            "\n",
            "Text from 08_12_20_Melanoma_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: August 12, 2020 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Changes: We respe\n",
            "\n",
            "---\n",
            "\n",
            "Text from 09_15_20_Melanoma_Foundation.pdf:\n",
            "Submitted by: Brian Alexander, MD \n",
            "Company: Foundation Medicine, Inc. \n",
            "Address: 150 Second Street, Cambridge, MA 02141 \n",
            "Phone: 617-418-2200 Ext. 2256 \n",
            "Email: balexander@foundationmedicine.com \n",
            "Date of request: Original submission June 22, 2020; highlighted updates September 15, 2020 \n",
            "NCCN Guidelines Panel: Cutaneous Melanoma \n",
            " \n",
            "Dear Panel Members, \n",
            "On behalf of Foundation Medicine, I respectfully request the NCCN® Cutaneous Melanoma Guideline Panel consider the requested \n",
            "updates pertaining to t\n",
            "\n",
            "---\n",
            "\n",
            "Text from 01_06_21_Melanoma_Merck.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 06, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to \n",
            "unresectable or metastatic melanoma. \n",
            " \n",
            "Specific Changes: We resp\n",
            "\n",
            "---\n",
            "\n",
            "Text from 05_28_21_Submission_Melanoma_ctDNA.pdf:\n",
            "Name: David Eberhard MD, PhD \n",
            "Company/Organization: Illumina Inc. \n",
            "Address: 5200 Illumina Way, San Diego CA 92122 \n",
            "Phone: 6503769577 \n",
            "Email: deberhard@illumina.com \n",
            "Date of request: May 28, 2021 \n",
            "NCCN Guidelines Cutaneous Melanoma \n",
            " \n",
            "On behalf of Illumina, I respectfully request the NCCN Guideline Panel for Cutaneous Melanoma to \n",
            "consider the enclosed information for the inclusion of liquid biopsy-based DNA testing as a \n",
            "complimentary alternative to tissue testing for the assessment of genetic v\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_07_21_Submission_Melanoma_nivolumab_ipilimumab.pdf:\n",
            "1 \n",
            "June 07, 2021 \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike  \n",
            "Lawrence, New Jersey 08648 \n",
            "NCCN Guidelines® Panel: Melanoma Panel \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel review the data recently \n",
            "presented at the American Society of Clinical Oncology (ASCO) 2021 Meeting on the use of OPDIVO® \n",
            "(nivolumab) plus YERVOY® (ipilimumab) for the treatment of patients with unresectabl\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_07_21_Submission_Melanoma_pembrolizumab_lenvatinib.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 07, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma Panel to review the enclosed \n",
            "information for KEYTRUDA® (pembrolizumab) and LENVIMA® (lenvatinib), in reference to melanoma. \n",
            " \n",
            "Specific Changes: We respectfully request the inclu\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_07_21_Submission_Melanoma_pembrolizumab.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 07, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IV melanoma. \n",
            " \n",
            "Specific Changes: We respectfully req\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_11_21_Submission_Melanoma_GEP Testing.pdf:\n",
            "Castle Biosciences, Inc.  \n",
            "NCCN Guidelines Melanoma Panel \n",
            " \n",
            "1 \n",
            " \n",
            " \n",
            "Submitted by: \n",
            "Name: Jay Braxton, PharmD \n",
            "Company:  Castle Biosciences, Inc. \n",
            "Address:  505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546 \n",
            "Phone: (336) 944-1365 \n",
            "Email:  jbraxton@castlebiosciences.com \n",
            "Date of Submission of Requested Amendments: 11 June 2021  \n",
            "NCCN Guidelines Panel: Melanoma \n",
            " \n",
            "To the Members of the NCCN Guidelines Melanoma Panel: \n",
            "On behalf of Castle Biosciences, thank you for the time and attention\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_11_21_Submision Melanoma_Guideline Review_RT gaps.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Email: Submissions@nccn.org  \n",
            " \n",
            "Date of Request: June 11, 2021 \n",
            " \n",
            " \n",
            " \n",
            "The American Society for Radiation Oncology has reviewed the 2021 NCCN cutaneous melanoma guideline \n",
            "for gaps relative to radiation therapy. We offer two major recommendations supported by evidence-based \n",
            "rationales and one minor recommendation for your consideration. \n",
            " \n",
            "We hope you find these recommendations useful to your panel as you review and update the guidelines. \n",
            " \n",
            "Sincerely, \n",
            " \n",
            "Laura I. Thevenot  \n",
            "Chief E\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_11_21_Submission_Melanoma_ipilimumab_sargramostim.pdf:\n",
            " \n",
            " \n",
            "Hillard M Lazarus, MD, FACP \n",
            "Partner Therapeutics, Inc. \n",
            " \n",
            "19 Muzzey Street, Lexington, MA 02421 \n",
            "hillard.lazarus@partnertx.com \n",
            "216-978-8003 \n",
            " \n",
            "June 11, 2021 \n",
            " \n",
            "Dear NCCN Cutaneous Melanoma Guideline Panel:  \n",
            " \n",
            "On behalf of Partner Therapeutics, I respectfully request the NCCN Cutaneous Melanoma Guideline \n",
            "Committee review the enclosed data that support adding the combination of ipilimumab and \n",
            "sargramostim (glycosylated yeast-derived rhu GM-CSF) to the Guideline as a second-line or subsequ\n",
            "\n",
            "---\n",
            "\n",
            "Text from 10_29_21_Submission_Uveal Melanoma_tebentafusp.pdf:\n",
            " \n",
            " \n",
            "Immunocore Ltd, 101 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK \n",
            " \n",
            "T: +44 (0)1235 438600  |  www.immunocore.com \n",
            " \n",
            "Registered in England no: 6456207  |  VAT No. GB 939 6694 55 \n",
            " \n",
            "Constance M Pfeiffer, PharmD \n",
            "Head of Medical Affairs \n",
            "Immunocore LLC \n",
            "Six Tower Bridge, Suite 200, 181 Washington Street,  \n",
            "Conshohocken, PA, 19428 \n",
            "215-983-2525 \n",
            "connie.pfeiffer@immunocore.com \n",
            " \n",
            "October 29, 2021 \n",
            "NCCN Guideline: Uveal Melanoma \n",
            " \n",
            "Dear NCCN Panel Members, \n",
            "Based on the NCCN open unsolici\n",
            "\n",
            "---\n",
            "\n",
            "Text from 11_21_21_Melanoma_pembrolizumab.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: November 21, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IIB and IIC melanoma. \n",
            " \n",
            "Specific Changes: We res\n",
            "\n",
            "---\n",
            "\n",
            "Text from 12_02_21_Submission_Melanoma_pembrolizumab.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: December 2, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IV melanoma. \n",
            " \n",
            "Specific Changes: We respectfully \n",
            "\n",
            "---\n",
            "\n",
            "Text from 12_03_21_Submission_Melanoma_pembrolizumab MEL KEYNOTE-716.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: December 03, 2021 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IIB and IIC melanoma. \n",
            " \n",
            "Specific Changes: We res\n",
            "\n",
            "---\n",
            "\n",
            "Text from 12_09_21_Submission_Melanoma_nivolumab+ipilimumab.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "December 09, 2021  \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines® Panel: Melanoma Panel   \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel to review the data recently \n",
            "presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 and published in \n",
            "Lancet Oncology on the use of OPDIVO® (nivolumab) plus YERVOY® (ipili\n",
            "\n",
            "---\n",
            "\n",
            "Text from 12_10_21_Submission_Melanoma_nivolumab_ipilimumab.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "December 10, 2021  \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines® Panel: Melanoma Panel   \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel to review the data \n",
            "recently presented at the November 2021 American Society of Clinical Oncology (ASCO) virtual plenary \n",
            "series on the use of OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) for patient\n",
            "\n",
            "---\n",
            "\n",
            "Text from 01_25_22_Submission_Melanoma_pembrolizumab_lenvatinib HOLD for 2023.pdf:\n",
            "Name: Suzana Giffin, AVP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: January 25, 2022 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab) and LENVIMA® \n",
            "(lenvatinib), in reference to unresectable or metastatic melanoma. \n",
            " \n",
            "\n",
            "---\n",
            "\n",
            "Text from 03_18_22_Submission_Melanoma_Nivolumab and Relatlimab.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "March 18, 2022 \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel to review the following \n",
            "data regarding the use of Opdualag® (nivolumab and relatlimab-rmbw) for the treatment of patients with \n",
            "unresectable or metastatic melanoma: \n",
            "• \n",
            "U.S. Full Prescribing Information1 for Opdualag, which contains data support\n",
            "\n",
            "---\n",
            "\n",
            "Text from 05_12_22_Submission_Melanoma_nivolumab and relatlimab-rmbw.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "May 12, 2022 \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines ® Panel: Cutaneous Melanoma  \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel to review the following \n",
            "data regarding the use of Opdualag® (nivolumab and relatlimab-rmbw) for the treatment of patients with \n",
            "unresectable or metastatic melanoma.   \n",
            " \n",
            "Specific Changes: We respectful\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_10_22_Submission_Melanoma_pembrolizumab.pdf:\n",
            "Name: Suzana Giffin, VP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: June 10, 2022 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "NCCN Melanoma Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma \n",
            "Panel to review the enclosed information for KEYTRUDA® (pembrolizumab), in reference to resected \n",
            "stage IIB and IIC melanoma. \n",
            " \n",
            "Specific Changes: We respectf\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_15_22_Submission_Melanoma_nivolumab and relatlimab-rmbw.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "June 15, 2022 \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines ® Panel: Cutaneous Melanoma  \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Panel to review the following \n",
            "data regarding the use of Opdualag® (nivolumab and relatlimab-rmbw) for the treatment of patients with \n",
            "unresectable or metastatic melanoma.   \n",
            " \n",
            "Specific Changes: We respectfu\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_15_22_Submission_Melanoma_nivolumab_ipilimumab.pdf:\n",
            "1 \n",
            " \n",
            " \n",
            "June 15, 2022  \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines® Panel: Melanoma Cancer Panel \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the Melanoma Cancer Panel review the data \n",
            "recently presented at American Association for Cancer Research (AACR) on OPDIVO® (nivolumab) plus \n",
            "YERVOY® (ipilimumab) in patients with metastatic or unresectable melanoma wi\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_15_22_Submission_Melanoma_NGS.pdf:\n",
            " \n",
            "Submitted by: Mark D. Hiatt, MD, MBA, MS and Julie Wiedower Kaylor, MS, CGC \n",
            "Company: Guardant Health (505 Penobscot Drive, Redwood City, CA 94063) \n",
            "Contact: mhiatt@guardanthealth.com; 903-343-1188 \n",
            " \n",
            "Date of request: June 15, 2022 \n",
            " \n",
            "Guidelines Panel: Melanoma: Cutaneous (v. 3.2022) \n",
            " \n",
            "FDA status: Guardant Health’s Guardant360 CDx is the first plasma-based comprehensive genomic profiling (CGP) test approved \n",
            "by the FDA to profile tumor mutations in all solid malignant neoplasms and serve as a\n",
            "\n",
            "---\n",
            "\n",
            "Text from 06_28_22_Submission_Melanoma_ripretinib.pdf:\n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Deciphera Pharmaceuticals, LLC    200 Smith Street     Waltham, MA 02451   tel 781-209-6400    www.deciphera.com \n",
            " \n",
            "Name: Matthew L. Sherman, MD; Executive Vice President and Chief Medical Officer \n",
            "Company: Deciphera Pharmaceuticals  \n",
            "Address: 200 Smith Street, Waltham, MA 02451 \n",
            "Phone: (781)-209-6408 \n",
            "Email: msherman@deciphera.com  \n",
            "Date of request: June 28, 2022 \n",
            "NCCN Guidelines Panel: Melanoma \n",
            "Attention: NCCN Guideline Panel for Melanoma: Cutaneous \n",
            " \n",
            "Update to Ripretinib\n",
            "\n",
            "---\n",
            "\n",
            "Text from 09_29_22_Submission_UVEAL Melanoma_GEP testing.pdf:\n",
            "C/&STLH\n",
            "Submitted by\n",
            "Jay Braxton, Pharm. D., Vice President of Medical Affairs\n",
            "Castle Biosciences, lnc\n",
            "505 S. Friendswood Drive, 4m Floor, Friendswood, TX 77546\n",
            "Ph : 28 1 . 853.9357 | | Ema il : jbraxto n@castlebiosciences.com\n",
            "Date of Request: 912912022\n",
            "NCCN Guidelines Panel: Melanoma (Uveal Melanoma Subcommittee)\n",
            "We appreciate the NCCN's rigorous criteria for assigning evidence categories to guideline\n",
            "recommendations as well as the panel's willingness to update those recommendations based on th\n",
            "\n",
            "---\n",
            "\n",
            "Text from 10_11_22_Submission_Melanoma_nivolumab_ipilimumab.pdf:\n",
            ", \n",
            " \n",
            " \n",
            " \n",
            "October 11, 2022  \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Senior Director, WW Scientific Content & Market Capabilities \n",
            "Bristol Myers Squibb  \n",
            "3401 Princeton Pike \n",
            "Lawrence, NJ 08648 \n",
            " \n",
            "NCCN Guidelines® Panel: Melanoma Panel   \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully submit the following data on the use of adjuvant \n",
            "OPDIVO® (nivolumab) alone and in combination with YERVOY® (ipilimumab) in patients with stage IV \n",
            "melanoma with no evidence of disease (NED) following complete resection or rad\n",
            "\n",
            "---\n",
            "\n",
            "Text from 05_04_23_Submission_Melanoma_pembrolizumab.pdf:\n",
            "Name: Suzana Giffin, VP \n",
            "Company/Organization: Merck & Co., Inc. \n",
            "Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033 \n",
            "Phone: 908-740-6708 \n",
            "Email: suzana.giffin@merck.com \n",
            "Date of Request: May 04, 2023 \n",
            "NCCN Guidelines Panel: Melanoma Panel \n",
            " \n",
            "On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma Panel to review the \n",
            "enclosed information for KEYTRUDA® (pembrolizumab), in reference to clinically detectable \n",
            "stage IIIB-IV resectable melanoma. \n",
            " \n",
            "Specific Changes: This submissi\n",
            "\n",
            "---\n",
            "\n",
            "Text from 10_16_23_Submission_Melanoma_ nivolumab.pdf:\n",
            ", \n",
            " \n",
            " \n",
            " \n",
            "October 16, 2023  \n",
            " \n",
            "Mary Coffey, PharmD \n",
            "Bristol Myers Squibb \n",
            "3401 Princeton Pike \n",
            "Lawrenceville, New Jersey 08648 \n",
            " \n",
            "NCCN Guidelines® Panel: Cutaneous Melanoma Panel \n",
            " \n",
            "On behalf of Bristol Myers Squibb, we respectfully request the cutaneous melanoma panel to review the \n",
            "recently published data in Nature Medicine on October 16, 2023 and the enclosed Prescribing Information \n",
            "regarding the use of adjuvant OPDIVO® (nivolumab) in patients with completely resected stage IIB/IIC \n",
            "melanoma.\n",
            "\n",
            "---\n",
            "\n",
            "Text from 02_21_2024_Submission_Melanoma__Cutaneous.pdf:\n",
            "Prince, Emily\n",
            "emily.prince@iovance.com\n",
            "6143714737\n",
            "February 21, 2024\n",
            "Company: Iovance, Iovance Biotherapeutics, Inc.\n",
            " \n",
            "Guideline: Melanoma: Cutaneous\n",
            " \n",
            "Panel: Melanoma Panel\n",
            " \n",
            "Algorithm Page Number: MELSYS 1 of 7, page 52\n",
            " \n",
            "Specific Change Recommended:\n",
            "Please consider the inclusion of lifileucel in the guideline as a Preferred Regimen for second-line or \n",
            "subsequent therapy for patients with unresectable or metastatic melanoma along with the accompanying \n",
            "footnote: \"Includes tumor resection for th\n",
            "\n",
            "---\n",
            "\n",
            "Text from 02_21_24_Submission_Melanoma__Cutaneous.pdf:\n",
            "Prince, Emily\n",
            "emily.prince@iovance.com\n",
            "6143714737\n",
            "February 21, 2024\n",
            "Company: Iovance, Iovance Biotherapeutics, Inc.\n",
            " \n",
            "Guideline: Melanoma: Cutaneous\n",
            " \n",
            "Panel: Melanoma Panel\n",
            " \n",
            "Algorithm Page Number: ME-J 3 of 4 page 100\n",
            " \n",
            "Specific Change Recommended:\n",
            "Please consider the addition of the following bulleted point in the first column under BRAF V600-\n",
            "activating mutation present: “For patients with progression on anti-PD-1 containing therapy and BRAF ± \n",
            "MEK inhibitor combination therapy, consider lifi\n",
            "\n",
            "---\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# DESCRIPTIVE STATISTICS: Word Frequencies and Document Lengths\n",
        "import os\n",
        "import fitz\n",
        "from collections import Counter\n",
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# 1. Document Lengths\n",
        "doc_lengths = [pdf['word_count'] for pdf in pdf_texts]\n",
        "avg_doc_length = np.mean(doc_lengths)\n",
        "median_doc_length = np.median(doc_lengths)\n",
        "\n",
        "print(f\"Average document length: {avg_doc_length:.2f} words\")\n",
        "print(f\"Median document length: {median_doc_length:.2f} words\")\n",
        "\n",
        "# 2. Word Frequency Distribution\n",
        "all_words = ' '.join([pdf['text'] for pdf in pdf_texts]).split()\n",
        "word_freq = Counter(all_words)\n",
        "\n",
        "# Top 10 most frequent words\n",
        "print(\"Top 10 most frequent words:\")\n",
        "for word, count in word_freq.most_common(10):\n",
        "    print(f\"{word}: {count}\")\n",
        "\n",
        "# 3. Plotting the document lengths distribution\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.hist(doc_lengths, bins=20, color='blue', alpha=0.7)\n",
        "plt.title('Distribution of Document Lengths')\n",
        "plt.xlabel('Word Count')\n",
        "plt.ylabel('Number of Documents')\n",
        "plt.show()\n",
        "\n",
        "# 4. Plotting word frequencies for top 10 words\n",
        "top_words, top_counts = zip(*word_freq.most_common(10))\n",
        "\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.bar(top_words, top_counts, color='green')\n",
        "plt.title('Top 10 Word Frequencies')\n",
        "plt.xlabel('Words')\n",
        "plt.ylabel('Frequency')\n",
        "plt.xticks(rotation=45)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "lWv3eqPTnhm3",
        "outputId": "107e758b-a9cd-4954-b1f5-55742fcc8d30"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Average document length: 949.20 words\n",
            "Median document length: 900.50 words\n",
            "Top 10 most frequent words:\n",
            "of: 1442\n",
            "the: 1433\n",
            "and: 938\n",
            "in: 909\n",
            "to: 697\n",
            "with: 681\n",
            "for: 672\n",
            "patients: 512\n",
            "a: 502\n",
            "or: 347\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def preprocess_text(pdf_texts):\n",
        "    \"\"\"\n",
        "    Preprocesses text by tokenizing, lowercasing, removing stop words, removing abbreviations, and lemmatizing.\n",
        "    lemmatization, removal of stop words, abbreviations, converted all to lower case, removed contractions, numbers using regex, tokenized.\n",
        "\n",
        "    Parameters:\n",
        "    pdf_texts (dict): Dictionary containing \"filename\" and \"text\".\n",
        "\n",
        "    Returns:\n",
        "    dict: Dictionary with the same structure, but the \"text\" field preprocessed.\n",
        "    \"\"\"\n",
        "    lemmatizer = WordNetLemmatizer()\n",
        "    stop_words = set(stopwords.words('english'))\n",
        "\n",
        "    # Define a list of known abbreviations/low information tokens to remove\n",
        "    abbreviations = {'pfs', 'co.', 'co', 'also', 'vs', 'vs.', 'ok', 'etc.', 'v', 'n=', \"''\", 'et.', 'al', 'et', '--', 'o', \"'s\", \"fig\", \"figure\", 'til', 'le'}\n",
        "\n",
        "    processed_texts = {}\n",
        "\n",
        "    for entry in pdf_texts:\n",
        "        text = entry['text']\n",
        "\n",
        "        # Lowercase the text\n",
        "        text = text.lower()\n",
        "\n",
        "        # Expand contractions\n",
        "        text = contractions.fix(text)\n",
        "\n",
        "        # Remove numbers using regular expression\n",
        "        text = re.sub(r'\\d+', '', text)\n",
        "\n",
        "        # Tokenize the text\n",
        "        words = word_tokenize(text)\n",
        "\n",
        "        # Remove stop words, punctuation, abbreviations, and lemmatize the words\n",
        "        processed_words = [\n",
        "            lemmatizer.lemmatize(word) #Lemmas are always actual words, reduces words to their base dictionary form\n",
        "            for word in words\n",
        "            if word not in stop_words and word not in string.punctuation\n",
        "            and word not in abbreviations and len(word) > 1  # Remove abbreviations and single letters\n",
        "        ]\n",
        "\n",
        "        # Add the processed tokenized text back to the dictionary with the filename\n",
        "        processed_texts[entry['filename']] = processed_words\n",
        "\n",
        "    return processed_texts\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GS73MtFCe5Di",
        "outputId": "f1bba0f0-36a1-4ffe-e699-7525da852450"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Preprocess text test\n",
        "processed_texts = preprocess_text(pdf_texts)\n",
        "\n",
        "# Extract the tokenized texts as a list of lists\n",
        "tokenized_texts = list(processed_texts.values())\n",
        "filenames = list(processed_texts.keys())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ftSFn7hmJdhD",
        "outputId": "f81de92a-f517-45ac-e2f0-677d93a58a35"
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a Dictionaty and a Corpus\n",
        "\n",
        "# Create a Dictionary from the tokenized documents\n",
        "dictionary = Dictionary(tokenized_texts)\n",
        "\n",
        "# Print the dictionary to verify\n",
        "#print(dictionary)\n",
        "\n",
        "# Filter out too rare and too common words\n",
        "dictionary.filter_extremes(no_below=5, no_above=0.5)\n",
        "\n",
        "# Convert the tokenized documents into a bag-of-words corpus\n",
        "corpus = [dictionary.doc2bow(doc) for doc in tokenized_texts]\n",
        "#print(corpus)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Rf4y4tp6JobH",
        "outputId": "5c8f61d6-3e0d-4eb6-f58e-3e060543b518"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import gensim\n",
        "from gensim.corpora import Dictionary\n",
        "from gensim.models import LdaModel, CoherenceModel\n",
        "from sklearn.cluster import AgglomerativeClustering\n",
        "from scipy.cluster.hierarchy import dendrogram, linkage\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# Define a function to compute the coherence score for a given number of topics\n",
        "def compute_coherence_values(corpus, dictionary, texts, start=2, limit=10, step=1):\n",
        "    coherence_values = []\n",
        "    model_list = []\n",
        "\n",
        "    for num_topics in range(start, limit, step):\n",
        "        # Train LDA model for each number of topics\n",
        "        lda_model = LdaModel(corpus=corpus, id2word=dictionary, num_topics=num_topics, random_state=42,passes=15, iterations=150, chunksize=100 )\n",
        "        model_list.append(lda_model)\n",
        "\n",
        "        # Compute coherence score using 'c_v' metric\n",
        "        coherence_model_lda = CoherenceModel(model=lda_model, texts=texts, dictionary=dictionary, coherence='c_v')\n",
        "        coherence_score = coherence_model_lda.get_coherence()\n",
        "        coherence_values.append(coherence_score)\n",
        "\n",
        "        print(f'Coherence score for {num_topics} topics: {coherence_score}')\n",
        "\n",
        "    return model_list, coherence_values\n",
        "\n",
        "\n",
        "# Apply coherence analysis\n",
        "model_list, coherence_values = compute_coherence_values(corpus, dictionary, texts=tokenized_texts, start=2, limit=15, step=1)\n",
        "\n",
        "# Plot coherence score results to visualize the optimal number of topics\n",
        "x = range(2, 15)\n",
        "plt.plot(x, coherence_values)\n",
        "plt.xlabel(\"Number of Topics\")\n",
        "plt.ylabel(\"Coherence Score (c_v)\")\n",
        "plt.title(\"Coherence Score vs. Number of Topics\")\n",
        "plt.show()\n",
        "\n",
        "# Select the optimal model based on the highest coherence score\n",
        "optimal_num_topics = coherence_values.index(max(coherence_values)) + 2  # Adjust for start index\n",
        "optimal_lda_model = model_list[optimal_num_topics - 2]\n",
        "\n",
        "# Get the topic distributions for each document from the optimal model\n",
        "lda_corpus = optimal_lda_model[corpus]\n",
        "\n",
        "# Convert LDA results into a matrix (document-topic distribution)\n",
        "lda_matrix = []\n",
        "for doc in lda_corpus:\n",
        "    doc_topics = [0] * optimal_lda_model.num_topics\n",
        "    for topic_num, prob in doc:\n",
        "        doc_topics[topic_num] = prob\n",
        "    lda_matrix.append(doc_topics)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 752
        },
        "id": "2S7C9M81RVqp",
        "outputId": "2ceecf64-0a65-41e3-ccdb-7c592aa0fea8"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Coherence score for 2 topics: 0.48136209095830484\n",
            "Coherence score for 3 topics: 0.5094689763234207\n",
            "Coherence score for 4 topics: 0.5040262621455351\n",
            "Coherence score for 5 topics: 0.5346411338778412\n",
            "Coherence score for 6 topics: 0.5977827995238134\n",
            "Coherence score for 7 topics: 0.585240425581251\n",
            "Coherence score for 8 topics: 0.5617158453923823\n",
            "Coherence score for 9 topics: 0.5283017280267178\n",
            "Coherence score for 10 topics: 0.5322082006152714\n",
            "Coherence score for 11 topics: 0.5244781807856641\n",
            "Coherence score for 12 topics: 0.5289314719280632\n",
            "Coherence score for 13 topics: 0.5272015718559744\n",
            "Coherence score for 14 topics: 0.5358703779596716\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Hierarchical clustering using the LDA topic distributions\n",
        "linkage_matrix = linkage(lda_matrix, method='ward')\n",
        "dendrogram(linkage_matrix, labels=filenames, leaf_rotation=90)\n",
        "plt.title('Document Hierarchical Clustering Dendrogram')\n",
        "plt.xlabel('Document')\n",
        "plt.ylabel('Distance')\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 961
        },
        "id": "Z1DmKFg8FrKW",
        "outputId": "19f46d5a-c83f-4eff-b4b1-064a3b5e4ac2"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAAjcAAAN5CAYAAAD0DRoGAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzddVxU2fsH8M8gaYAtiigoiIWCoIiFgaJroWsHirmurh2LnYuda68dq2usta6u3a249toYYAsGPc/vD35zvxN3hnuHQXB83q/XvHQuZ845c/OZe08oiIjAGGOMMWYmLDK7AowxxhhjpsTBDWOMMcbMCgc3jDHGGDMrHNwwxhhjzKxwcMMYY4wxs8LBDWOMMcbMCgc3jDHGGDMrHNwwxhhjzKxwcMMYY4wxs8LBDWNfyPjx46FQKDK7GkZ59OgRFAoFZs6cmWbajP6eXbt2hYuLi0nzPHr0KBQKBY4ePWrSfL+U2rVro3bt2pldjSxn9erVUCgUePToUWZXhX1hHNyYEdWBrHrZ2tqiSJEiCAoKwvz58/Hhw4fMrmKWtmjRIqxevVpyeoVCgX79+on+TbUtLl68aKLaMWP9+eefaNSoEfLnzw9ra2sUKVIEbdq0weHDh79YHU6fPo3x48fj/fv3X6zML8XFxUU451hYWCB37tzw9PREr169cO7cucyuHvtGcXBjhiZOnIh169Zh8eLF+OmnnwAAAwcOhKenJ/79999Mrl3WJTe4kWv06NGIi4vLsPyziqzyPYkIoaGhaNmyJV68eIHBgwdjyZIl6Nu3Lx48eIB69erh9OnTX6Qup0+fxoQJEzIsuPnnn3/wzz//ZEjeUnh5eWHdunVYu3YtwsPDUadOHezevRtVq1bF4MGDM61e7NtlmdkVYKbXqFEj+Pr6Cu/DwsJw+PBhNGnSBM2aNcOtW7dgZ2eXiTX8NllaWsLS0nSH3OfPn5E9e/ZMz0Obqb+nsWbNmoXVq1dj4MCBmD17tsajslGjRmHdunVZop7podp+1tbWmVoPJycndOrUSWPZtGnT0KFDB8yZMwfu7u7o06dPJtXOMCJCfHz8FzsnZsQxx3TxnZtvRN26dTFmzBg8fvwY69ev1/jb4cOHUbNmTeTIkQO5c+dG8+bNcevWLZ08nj17hu7du6NIkSKwsbGBq6sr+vTpg8TERAD621qIPfd2cXFBkyZNcPToUfj6+sLOzg6enp5Cm4ft27fD09MTtra28PHxwZUrV3TyvX37Nlq1aoW8efPC1tYWvr6+2LVrl2jZp06dwuDBg1GgQAHkyJEDLVq0wKtXrzTqc+PGDRw7dky4xW7qNgz61s/69evh4+MDOzs75M2bF+3atcOTJ0800tSuXRvly5fHpUuXUKtWLWTPnh0jR44EAOzcuRONGzcWtkvJkiUxadIkpKSkSM4jPj4e48ePR6lSpWBra4vChQujZcuWuH//vk59ly1bhpIlS8LGxgaVK1fGhQsXJH/PKlWqIHv27MiTJw9q1aqlcbdB6veQIi4uDuHh4ShdujRmzpwpWp/OnTujSpUqevNwcXFB165ddZaLtW9ZsGABypUrJ3w3X19fbNy4EUDq+hg2bBgAwNXVVdi/1I+H9O4D2nVStSH6448/MGXKFBQtWhS2traoV68e7t27p/OdFi5ciBIlSsDOzg5VqlTBiRMn0t2Ox87ODuvWrUPevHkxZcoUEJHwN6VSiblz56JcuXKwtbVFoUKF0Lt3b7x7904jD9V54uTJk6hSpQpsbW1RokQJrF27Vqe8GzduoG7durCzs0PRokUxefJkKJVKnXSqPPfv3y+ce5YuXQoAePDgAVq3bo28efMie/bsqFq1Kv766y+dPB4/foxmzZohR44cKFiwIAYNGoT9+/frtNsy5XH777//IiAgANmzZ4ebmxu2bt0KADh27Bj8/PxgZ2cHDw8PHDx4UOIWMm9f988WJkvnzp0xcuRI/PPPP+jZsycA4ODBg2jUqBFKlCiB8ePHIy4uDgsWLED16tVx+fJloeHm8+fPUaVKFbx//x69evVC6dKl8ezZM2zduhWfP3826pfjvXv30KFDB/Tu3RudOnXCzJkz0bRpUyxZsgQjR47Ejz/+CAAIDw9HmzZtcOfOHVhYpMbjN27cQPXq1eHk5ISff/4ZOXLkwB9//IHg4GBs27YNLVq00Cjrp59+Qp48eTBu3Dg8evQIc+fORb9+/bB582YAwNy5c/HTTz8hZ86cGDVqFACgUKFCaX6H+Ph4vH79Wmf5x48fJa2DKVOmYMyYMWjTpg169OiBV69eYcGCBahVqxauXLmC3LlzC2nfvHmDRo0aoV27dujUqZNQv9WrVyNnzpwYPHgwcubMicOHD2Ps2LGIjY3FjBkzNMoTyyMlJQVNmjTBoUOH0K5dOwwYMAAfPnzAgQMHcP36dZQsWVL4/MaNG/Hhwwf07t0bCoUC06dPR8uWLfHgwQNYWVnp/Z4TJkzA+PHjUa1aNUycOBHW1tY4d+4cDh8+jAYNGsj+Hmk5efIk3r59i4EDByJbtmyyPivX8uXL0b9/f7Rq1QoDBgxAfHw8/v33X5w7dw4dOnRAy5Yt8d9//+H333/HnDlzkD9/fgBAgQIFAJhmH9Bn6tSpsLCwwNChQxETE4Pp06ejY8eOGm1hFi9ejH79+qFmzZoYNGgQHj16hODgYOTJkwdFixZN17rJmTMnWrRogRUrVuDmzZsoV64cAKB3795YvXo1QkND0b9/fzx8+BC//vorrly5glOnTmnsS/fu3UOrVq3QvXt3dOnSBStXrkTXrl3h4+Mj5BcdHY06deogOTlZOB8sW7ZM792YO3fuoH379ujduzd69uwJDw8PvHjxAtWqVcPnz5/Rv39/5MuXD2vWrEGzZs2wdetW4Zzy6dMn1K1bF1FRURgwYAAcHR2xceNGHDlyRLQsUxy37969Q5MmTdCuXTu0bt0aixcvRrt27bBhwwYMHDgQP/zwAzp06IAZM2agVatWePLkCXLlypWubffVI2Y2Vq1aRQDowoULetM4ODiQt7e38N7Ly4sKFixIb968EZZdvXqVLCwsKCQkRFgWEhJCFhYWonkrlUoiIho3bhyJ7VKqej18+FBYVrx4cQJAp0+fFpbt37+fAJCdnR09fvxYWL506VICQEeOHBGW1atXjzw9PSk+Pl6jHtWqVSN3d3edsgMDA4V6EhENGjSIsmXLRu/fvxeWlStXjgICAnTqrw+ANF/q60t7/Tx69IiyZctGU6ZM0cj32rVrZGlpqbE8ICCAANCSJUt06vH582edZb1796bs2bNrrB99eaxcuZIA0OzZs3XyUa2zhw8fEgDKly8fvX37Vvj7zp07CQDt3r1b7/e8e/cuWVhYUIsWLSglJUU0fznfo0uXLlS8eHGdtOrmzZtHAOjPP/80mE7lyJEjOvtY8eLFqUuXLjppAwICNPaT5s2bU7ly5QzmP2PGDJ1jgMh0+4B2nVTfp0yZMpSQkCAsV62Xa9euERFRQkIC5cuXjypXrkxJSUlCutWrVxMAScdD8eLFqXHjxnr/PmfOHAJAO3fuJCKiEydOEADasGGDRrp9+/bpLFedJ44fPy4se/nyJdnY2NCQIUOEZQMHDiQAdO7cOY10Dg4Oes89+/bt0yhflceJEyeEZR8+fCBXV1dycXER9t1Zs2YRANqxY4eQLi4ujkqXLq2zD5nyuN24caOw7Pbt2wSALCws6OzZs8Jy1Tl01apVOnl/a/ix1DcmZ86cQq+pqKgoREREoGvXrsibN6+QpkKFCqhfvz727t0LIPUW8o4dO9C0aVONtjwqxnb7LVu2LPz9/YX3fn5+AFIfoRUrVkxn+YMHDwAAb9++xeHDh9GmTRt8+PABr1+/xuvXr/HmzRsEBQXh7t27ePbsmUZZvXr10qhnzZo1kZKSgsePHxtVd5XmzZvjwIEDOi/VYwhDtm/fDqVSiTZt2gjf4fXr13B0dIS7u7vOL0EbGxuEhobq5KP+61S1PmrWrInPnz/j9u3baeaxbds25M+fX2h8rk5727Zt2xZ58uQR3tesWRPA/7aNmB07dkCpVGLs2LHCnTex/OV8j7TExsYCwBf59Zo7d248ffpU5/GcFKbaB/QJDQ3VuKuqvb0uXryIN2/eoGfPnhrtjzp27KixndMjZ86cACCcd7Zs2QIHBwfUr19f4zv7+PggZ86cOt+5bNmyQr2B1DteHh4eGvvc3r17UbVqVY3HjAUKFEDHjh1F6+Tq6oqgoCCNZXv37kWVKlVQo0YNjbr36tULjx49ws2bNwEA+/btg5OTE5o1ayaks7W1Fe6GazPFcZszZ060a9dOeO/h4YHcuXOjTJkywvkR0D1Xfsv4sdQ35uPHjyhYsCAACBd2Dw8PnXRlypTB/v378enTJ3z8+BGxsbEoX768SeuiHsAAgIODAwDA2dlZdLnqefy9e/dARBgzZgzGjBkjmvfLly/h5OSktyzViVv7Gb9cRYsWRWBgoM7yp0+fpvnZu3fvgojg7u4u+nftxzxOTk6ij/9u3LiB0aNH4/Dhw8JFXSUmJibNPO7fvw8PDw9JjWuNWY/379+HhYUFypYtazBvOd8jLfb29gDwRYY/GDFiBA4ePIgqVarAzc0NDRo0QIcOHVC9evU0P2uqfUCftLaX6hzg5uamkc7S0tJkYwmpHtGqAs27d+8iJiZGOA9pe/nypcZ77e8ApH4P9X3u8ePHGhd5FbFzG5Aa3GjTl0eZMmWEv5cvXx6PHz9GyZIldQJ/7XWoYorjtmjRojrlOTg4pHmu/JZxcPMNefr0KWJiYvQehOml7w6Ovgah+tpC6FtO/98gUdVIcOjQoTq/vlS0v2NaeWYGpVIJhUKBv//+W7R+ql+8KmLtB96/f4+AgADY29tj4sSJKFmyJGxtbXH58mWMGDFCp0FlenuEZNR6lPs90lK6dGkAwLVr1xAcHGxUnQztz+rroUyZMrhz5w727NmDffv2Ydu2bVi0aBHGjh2LCRMmGCzDFPuAIVlhv79+/TqA/x2TSqUSBQsWxIYNG0TTq9oiqWTEd/iSvUVNcdwae678lnFw8w1Zt24dAAgBQfHixQGkNq7Tdvv2beTPnx85cuSAnZ0d7O3thZOUPqpfhe/fv9doBJneRz/aSpQoASD1V63YXRNjfenRg0uWLAkigqurK0qVKmVUHkePHsWbN2+wfft21KpVS1j+8OFDWfU4d+4ckpKSDDYKNlbJkiWhVCpx8+ZNeHl5iaYxxfdQV6NGDeTJkwe///47Ro4caVSj4jx58oiOS/P48WNhH1TJkSMH2rZti7Zt2yIxMREtW7bElClTEBYWBltbW737lin2gfRQnQPu3buHOnXqCMuTk5Px6NEjVKhQIV35f/z4EX/++SecnZ2FOyAlS5bEwYMHUb16dZMFGcWLF8fdu3d1loud2wzloe9cqPq76t+bN2+CiDS2q1gvNH1Mvb8zXdzm5htx+PBhTJo0Ca6ursJz6MKFC8PLywtr1qzROIlfv34d//zzD7777jsAgIWFBYKDg7F7927REXdVvxJUvWqOHz8u/O3Tp09Ys2aNSb9LwYIFUbt2bSxduhRRUVE6f1fv4i1Hjhw5vugIsi1btkS2bNkwYcIEnV9aRIQ3b96kmYfqoq3++cTERCxatEhyPb7//nu8fv0av/76q87fTPELMDg4GBYWFpg4caLOL1JV/qb4HuqyZ8+OESNG4NatWxgxYoTo91i/fj3Onz+vN4+SJUvi7NmzwlAHALBnzx6dLtra28na2hply5YFESEpKQlA6r4FQGf/MsU+kB6+vr7Ily8fli9fjuTkZGH5hg0b0v1oIy4uDp07d8bbt28xatQoIRBo06YNUlJSMGnSJJ3PJCcnG3UMfvfddzh79qzG9nz16pXeu0P68jh//jzOnDkjLPv06ROWLVsGFxcX4bFqUFAQnj17pjHsRHx8PJYvXy65LFPv70wX37kxQ3///Tdu376N5ORkvHjxAocPH8aBAwdQvHhx7Nq1C7a2tkLaGTNmoFGjRvD390f37t2FruAODg4YP368kO6XX37BP//8g4CAAPTq1QtlypRBVFQUtmzZgpMnTyJ37txo0KABihUrhu7du2PYsGHIli0bVq5ciQIFCiAyMtKk33HhwoWoUaMGPD090bNnT5QoUQIvXrzAmTNn8PTpU1y9elV2nj4+Pli8eDEmT54MNzc3FCxYEHXr1jVpvdWVLFkSkydPRlhYmND9NleuXHj48CH+/PNP9OrVC0OHDjWYR7Vq1ZAnTx506dIF/fv3h0KhwLp162QFJSEhIVi7di0GDx6M8+fPo2bNmvj06RMOHjyIH3/8Ec2bN0/X93Rzc8OoUaMwadIk1KxZEy1btoSNjQ0uXLiAIkWKIDw83CTfQ9uwYcNw48YNzJo1C0eOHEGrVq3g6OiI6Oho7NixA+fPnzc4QnGPHj2wdetWNGzYEG3atMH9+/exfv16ja7xANCgQQM4OjqievXqKFSoEG7duoVff/0VjRs3FtqZ+Pj4AEgdPLBdu3awsrJC06ZNTbIPpIe1tTXGjx+Pn376CXXr1kWbNm3w6NEjrF69WrRdiT7Pnj0Txs/6+PEjbt68iS1btiA6OhpDhgxB7969hbQBAQHo3bs3wsPDERERgQYNGsDKygp3797Fli1bMG/ePLRq1UrW9xg+fDjWrVuHhg0bYsCAAUJX8OLFi0self3nn3/G77//jkaNGqF///7Imzcv1qxZg4cPH2Lbtm1CY/jevXvj119/Rfv27TFgwAAULlwYGzZsEM6rUtZZRuzvTMsX6pXFvgBVt2fVy9ramhwdHal+/fo0b948io2NFf3cwYMHqXr16mRnZ0f29vbUtGlTunnzpk66x48fU0hICBUoUIBsbGyoRIkS1LdvX42uppcuXSI/Pz+ytramYsWK0ezZs/V2BRfrPgqA+vbtq7FM1Q15xowZGsvv379PISEh5OjoSFZWVuTk5ERNmjShrVu36qwT7S7sYl1/o6OjqXHjxpQrVy5J3WDF6mqoXH1d5bdt20Y1atSgHDlyUI4cOah06dLUt29funPnjpAmICBAb3fjU6dOUdWqVcnOzo6KFClCw4cPF7qEandL1ZfH58+fadSoUeTq6kpWVlbk6OhIrVq1ovv37xOR/m2gWg/jxo1L83uuXLmSvL29ycbGhvLkyUMBAQF04MAB2d9DSldwdVu3bqUGDRpQ3rx5ydLSkgoXLkxt27alo0ePCmnE9gei1G6/Tk5OZGNjQ9WrV6eLFy/qdLteunQp1apVi/Lly0c2NjZUsmRJGjZsGMXExGjkNWnSJHJyciILCwud4yG9+4C+ruBbtmzRSKfajtpdhefPn0/FixcnGxsbqlKlCp06dYp8fHyoYcOGBtZsKlXXagCkUCjI3t6eypUrRz179tTomq1t2bJl5OPjQ3Z2dpQrVy7y9PSk4cOH0/PnzzXyFjtPaH9fIqJ///2XAgICyNbWlpycnGjSpEm0YsUKyeceotRzSqtWrSh37txka2tLVapUoT179uike/DgATVu3Jjs7OyoQIECNGTIENq2bRsB0OianZHHrZxz6LdIQcShImOMsf9RKpUoUKAAWrZsKetxy7ds7ty5GDRoEJ4+farRU5NlDm5zwxhj37D4+HidxyFr167F27dvTT4FibnQnhg2Pj4eS5cuhbu7Owc2WQS3uWGMsW/Y2bNnMWjQILRu3Rr58uXD5cuXsWLFCpQvXx6tW7fO7OplSS1btkSxYsXg5eWFmJgYrF+/Hrdv35bVgJllLA5uGGPsG+bi4gJnZ2fMnz8fb9++Rd68eRESEoKpU6dm+mzjWVVQUBB+++03bNiwASkpKShbtiw2bdqEtm3bZnbV2P/jNjeMMcYYMyvc5oYxxhhjZoWDG8YYY4yZlW+uzY1SqcTz58+RK1euLz7cPmOMMcaMQ0T48OEDihQpIgyqqM83F9w8f/5cZyZVxhhjjH0dnjx5gqJFixpMk2WCm6lTpyIsLAwDBgzA3Llz9abbsmULxowZg0ePHsHd3R3Tpk0T5kCSQjUc+pMnT2Bvb5/eajPGGGPsC4iNjYWzs7NwHTckSwQ3Fy5cwNKlS9Ocgfb06dNo3749wsPD0aRJE2zcuBHBwcG4fPkyypcvL6ks1aMoe3t7Dm4YY4yxr4yUJiWZ3qD448eP6NixI5YvX448efIYTDtv3jw0bNgQw4YNQ5kyZTBp0iRUqlRJdDZjxhhjjH2bMj246du3Lxo3bozAwMA00545c0YnXVBQkMYU9doSEhIQGxur8WKMMcaY+crUx1KbNm3C5cuXceHCBUnpo6OjUahQIY1lhQoVQnR0tN7PhIeHY8KECemqJ2OMMca+Hpl25+bJkycYMGAANmzYAFtb2wwrJywsDDExMcLryZMnGVYWY4wxxjJfpt25uXTpEl6+fIlKlSoJy1JSUnD8+HH8+uuvSEhIQLZs2TQ+4+joiBcvXmgse/HiBRwdHfWWY2NjAxsbG9NWnjHGGGNZVqbdualXrx6uXbuGiIgI4eXr64uOHTsiIiJCJ7ABAH9/fxw6dEhj2YEDB+Dv7/+lqs0YY4yxLC7T7tzkypVLp/t2jhw5kC9fPmF5SEgInJycEB4eDgAYMGAAAgICMGvWLDRu3BibNm3CxYsXsWzZsi9ef8YYY4xlTZneW8qQyMhIREVFCe+rVauGjRs3YtmyZahYsSK2bt2KHTt2SB7jhjHGGGPmT0FElNmV+JJiY2Ph4OCAmJgYHsSPMcYY+0rIuX5n6Ts3jDHGGGNycXDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzK1liVnD2ZRER4pJSMrsajH317KyySZqhmDH2ZXFw840hIrRacgaXHr/L7Kow9tXzLZ4HW37w5wCHsSyGH0t9Y+KSUjiwYcxELj5+x3dBGcuC+M7NN+zi6EBkt9ad5oIxZtjnxBT4Tj6Y2dVgjOnBwc03LLt1NmS35l2AMcaYeeHHUowxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzK5ka3CxevBgVKlSAvb097O3t4e/vj7///ltv+tWrV0OhUGi8bG1tv2CNGWOMMZbVWWZm4UWLFsXUqVPh7u4OIsKaNWvQvHlzXLlyBeXKlRP9jL29Pe7cuSO8VygUX6q6jDHGGPsKZGpw07RpU433U6ZMweLFi3H27Fm9wY1CoYCjo+OXqB5jjDHGvkJZps1NSkoKNm3ahE+fPsHf319vuo8fP6J48eJwdnZG8+bNcePGjS9YS8YYY4xldZl65wYArl27Bn9/f8THxyNnzpz4888/UbZsWdG0Hh4eWLlyJSpUqICYmBjMnDkT1apVw40bN1C0aFHRzyQkJCAhIUF4HxsbmyHfgzHGGGNZQ6bfufHw8EBERATOnTuHPn36oEuXLrh586ZoWn9/f4SEhMDLywsBAQHYvn07ChQogKVLl+rNPzw8HA4ODsLL2dk5o74KY4wxxrKATA9urK2t4ebmBh8fH4SHh6NixYqYN2+epM9aWVnB29sb9+7d05smLCwMMTExwuvJkyemqjpjjDHGsqBMD260KZVKjcdIhqSkpODatWsoXLiw3jQ2NjZCV3PVizHGGGPmK1Pb3ISFhaFRo0YoVqwYPnz4gI0bN+Lo0aPYv38/ACAkJAROTk4IDw8HAEycOBFVq1aFm5sb3r9/jxkzZuDx48fo0aNHZn4NxhhjjGUhmRrcvHz5EiEhIYiKioKDgwMqVKiA/fv3o379+gCAyMhIWFj87+bSu3fv0LNnT0RHRyNPnjzw8fHB6dOn9TZAZowxxti3J1ODmxUrVhj8+9GjRzXez5kzB3PmzMnAGjHGGGPsa5fl2twwxhhjjKUHBzeMMcYYMysc3DDGGGPMrHBwwxhjjDGzwsENY4wxxswKBzeMMcYYMysc3DDGGGPMrHBwwxhjjDGzwsENY4wxxswKBzeMMcYYMysc3DDGGGPMrHBwwxhjjDGzwsENY4wxxswKBzeMMcYYMysc3DDGGGPMrHBwwxhjjDGzwsENY4wxxswKBzeMMcYYMysc3DDGGGPMrHBwwxhjjDGzwsENY4wxxsyKZWZXgDH29SEixCWlZHY1Ms3nxGTR/3+r7KyyQaFQZHY1GBNwcMMYk4WI0GrJGVx6/C6zq5Il+E4+lNlVyHS+xfNgyw/+HOCwLIMfSzHGZIlLSuHAhmm4+PjdN30nj2U9fOeGMWa0i6MDkd06W2ZXg2WSz4kp8J18MLOrwZgODm4YY0bLbp0N2a35NMIYy1r4sRRjjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCo28xxlgGMudJRr+VCUR5YtCvT6YGN4sXL8bixYvx6NEjAEC5cuUwduxYNGrUSO9ntmzZgjFjxuDRo0dwd3fHtGnT8N13332hGjPGmHTf0iSj5jyBKE8M+vXJ1MdSRYsWxdSpU3Hp0iVcvHgRdevWRfPmzXHjxg3R9KdPn0b79u3RvXt3XLlyBcHBwQgODsb169e/cM0ZYyxtPMmoeeCJQb8+mXrnpmnTphrvp0yZgsWLF+Ps2bMoV66cTvp58+ahYcOGGDZsGABg0qRJOHDgAH799VcsWbLki9SZMcaMwZOMfn14YtCvV5Zpc5OSkoItW7bg06dP8Pf3F01z5swZDB48WGNZUFAQduzYoTffhIQEJCQkCO9jY2NNUl/GGJODJxll7MvJ9N5S165dQ86cOWFjY4MffvgBf/75J8qWLSuaNjo6GoUKFdJYVqhQIURHR+vNPzw8HA4ODsLL2dnZpPVnjDHGWNaS6cGNh4cHIiIicO7cOfTp0wddunTBzZs3TZZ/WFgYYmJihNeTJ09MljdjjDHGsp5Mv0dqbW0NNzc3AICPjw8uXLiAefPmYenSpTppHR0d8eLFC41lL168gKOjo978bWxsYGNjY9pKM8YYYyzLyvQ7N9qUSqVGGxl1/v7+OHRIs7vhgQMH9LbRYYwxxti3J1Pv3ISFhaFRo0YoVqwYPnz4gI0bN+Lo0aPYv38/ACAkJAROTk4IDw8HAAwYMAABAQGYNWsWGjdujE2bNuHixYtYtmxZZn4NxhhjjGUhmRrcvHz5EiEhIYiKioKDgwMqVKiA/fv3o379+gCAyMhIWFj87+ZStWrVsHHjRowePRojR46Eu7s7duzYgfLly2fWV2CMMcZYFpOpwc2KFSsM/v3o0aM6y1q3bo3WrVtnUI0YY4wx9rXLcm1uGGOMMcbSg4MbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJkVDm4YY4wxZlY4uGGMMcaYWeHghjHGGGNmhYMbxhhjjJmVTA1uwsPDUblyZeTKlQsFCxZEcHAw7ty5Y/Azq1evhkKh0HjZ2tp+oRozxhhjLKvL1ODm2LFj6Nu3L86ePYsDBw4gKSkJDRo0wKdPnwx+zt7eHlFRUcLr8ePHX6jGjDHGGMvqLDOz8H379mm8X716NQoWLIhLly6hVq1aej+nUCjg6OiY0dVjjDHG2FcoS7W5iYmJAQDkzZvXYLqPHz+iePHicHZ2RvPmzXHjxo0vUT3GGGOMfQWyTHCjVCoxcOBAVK9eHeXLl9ebzsPDAytXrsTOnTuxfv16KJVKVKtWDU+fPhVNn5CQgNjYWI0XY4wxxsxXpj6WUte3b19cv34dJ0+eNJjO398f/v7+wvtq1aqhTJkyWLp0KSZNmqSTPjw8HBMmTDB5fRljjDGWNWWJ4KZfv37Ys2cPjh8/jqJFi8r6rJWVFby9vXHv3j3Rv4eFhWHw4MHC+9jYWDg7O6ervowxxkyDiJCcqMzsaohKSkz53/8TUpBEikysjX6W1hZQKLJm3TJLpgY3RISffvoJf/75J44ePQpXV1fZeaSkpODatWv47rvvRP9uY2MDGxub9FaVMcaYiRERts+4jOgHMZldFVGJICB36v9XDjsJa2TNAKJwSQe0GFqJAxw1mRrc9O3bFxs3bsTOnTuRK1cuREdHAwAcHBxgZ2cHAAgJCYGTkxPCw8MBABMnTkTVqlXh5uaG9+/fY8aMGXj8+DF69OiRad+DMcaYfMmJyiwb2ACANRQY9t4us6uRpqj7MUhOVMLKJltmVyXLyNTgZvHixQCA2rVrayxftWoVunbtCgCIjIyEhcX/2j2/e/cOPXv2RHR0NPLkyQMfHx+cPn0aZcuW/VLVZowxZmKh02vwxVmmpIQUrBpuuJ3qtyrTH0ul5ejRoxrv58yZgzlz5mRQjRhjjGUGK5tsHNwwk8kyXcEZY4wxxkyBgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmZV0Bzfx8fGmqAdjjDHGmEkYFdwolUpMmjQJTk5OyJkzJx48eAAAGDNmDFasWGHSCjLGGGOMyWFUcDN58mSsXr0a06dPh7W1tbC8fPny+O2330xWOcYYY4wxuYwKbtauXYtly5ahY8eOyJbtf7O4VqxYEbdv3zZZ5RhjjDHG5DIquHn27Bnc3Nx0liuVSiQlJaW7UowxxhhjxjIquClbtixOnDihs3zr1q3w9vZOd6UYY4wxxoxlacyHxo4diy5duuDZs2dQKpXYvn077ty5g7Vr12LPnj2mriNjjDHGmGRGBTfNmzfH7t27MXHiROTIkQNjx45FpUqVsHv3btSvX9/UdWSMMca+SkSE5ERlhuSdlJAi+n9Ts7S2gEKhyLD8M4JRwQ0A1KxZEwcOHDBlXRhjjDGzQUTYPuMyoh/EZHhZq4afzLC8C5d0QIuhlb6qAMeoNjcXLlzAuXPndJafO3cOFy9eTHelGGOMsa9dcqLyiwQ2GS3qfkyG3X3KKEbduenbty+GDx8OPz8/jeXPnj3DtGnTRAMfxhhj7FsVOr0GrGyypZ0wC0lKSMnQO0IZyajg5ubNm6hUqZLOcm9vb9y8eTPdlWKMMcbMiZVNtq8uuPmaGfVYysbGBi9evNBZHhUVBUtLo5vxMMYYY4ylm1HBTYMGDRAWFoaYmP89S3z//j1GjhzJvaUYY4wxlqmMus0yc+ZM1KpVC8WLFxcG7YuIiEChQoWwbt06k1aQMcYYY0wOo4IbJycn/Pvvv9iwYQOuXr0KOzs7hIaGon379rCysjJ1HRljjDHGJDO6gUyOHDnQq1cvU9aFMcYYYyzdjA5u7t69iyNHjuDly5dQKjX7v48dOzbdFWOMMcYYM4ZRwc3y5cvRp08f5M+fH46OjhqjFioUCg5uGGOMMZZpjApuJk+ejClTpmDEiBGmrg9jjDHGWLoY1RX83bt3aN26tanrwhhjjDGWbkYFN61bt8Y///xj6rowxhhjjKWbUY+l3NzcMGbMGJw9exaenp463b/79+9vksoxxhhjjMllVHCzbNky5MyZE8eOHcOxY8c0/qZQKDi4YYwxxlimMSq4efjwoanrwRhjjDFmEka1uTGV8PBwVK5cGbly5ULBggURHByMO3fupPm5LVu2oHTp0rC1tYWnpyf27t37BWrLGGOMsa+B0YP4PX36FLt27UJkZCQSExM1/jZ79mxJeRw7dgx9+/ZF5cqVkZycjJEjR6JBgwa4efMmcuTIIfqZ06dPo3379ggPD0eTJk2wceNGBAcH4/LlyyhfvryxX4cxxhhjZsKo4ObQoUNo1qwZSpQogdu3b6N8+fJ49OgRiAiVKlWSnM++ffs03q9evRoFCxbEpUuXUKtWLdHPzJs3Dw0bNsSwYcMAAJMmTcKBAwfw66+/YsmSJcZ8HcYYY4yZEaMeS4WFhWHo0KG4du0abG1tsW3bNjx58gQBAQHpGv8mJiYGAJA3b169ac6cOYPAwECNZUFBQThz5oxo+oSEBMTGxmq8GGOMMWa+jApubt26hZCQEACApaUl4uLikDNnTkycOBHTpk0zqiJKpRIDBw5E9erVDT5eio6ORqFChTSWFSpUCNHR0aLpw8PD4eDgILycnZ2Nqh9jjDHGvg5GBTc5cuQQ2tkULlwY9+/fF/72+vVroyrSt29fXL9+HZs2bTLq8/qEhYUhJiZGeD158sSk+TPGGGMsazGqzU3VqlVx8uRJlClTBt999x2GDBmCa9euYfv27ahatars/Pr164c9e/bg+PHjKFq0qMG0jo6OePHihcayFy9ewNHRUTS9jY0NbGxsZNeJMcYYY18no+7czJ49G35+fgCACRMmoF69eti8eTNcXFywYsUKyfkQEfr164c///wThw8fhqura5qf8ff3x6FDhzSWHThwAP7+/vK+BGOMMcbMklF3bkqUKCH8P0eOHEb3Uurbty82btyInTt3IleuXEK7GQcHB9jZ2QEAQkJC4OTkhPDwcADAgAEDEBAQgFmzZqFx48bYtGkTLl68iGXLlhlVB8YYY4yZF6Pu3JQoUQJv3rzRWf7+/XuNwCctixcvRkxMDGrXro3ChQsLr82bNwtpIiMjERUVJbyvVq0aNm7ciGXLlqFixYrYunUrduzYwWPcMMYYYwyAkXduHj16hJSUFJ3lCQkJePbsmeR8iCjNNEePHtVZ1rp163R1OWeMMcaY+ZIV3OzatUv4//79++Hg4CC8T0lJwaFDh+Di4mKyyjHGGGOMySUruAkODgaQOvN3ly5dNP5mZWUFFxcXzJo1y2SVY4wxxhiTS1Zwo1QqAQCurq64cOEC8ufPnyGVYowxxhgzllFtbh4+fKiz7P3798idO3d668MYY4wxli5G9ZaaNm2aRo+m1q1bI2/evHBycsLVq1dNVjnGGGOMMbmMCm6WLFkizNF04MABHDx4EPv27UOjRo2E2boZY4wxxjKDUY+loqOjheBmz549aNOmDRo0aAAXFxdh5GLGGGOMscxg1J2bPHnyCBNQ7tu3D4GBgQBSx60RG/+GMcYYY+xLMerOTcuWLdGhQwe4u7vjzZs3aNSoEQDgypUrcHNzM2kFGWOMMcbkMCq4mTNnDlxcXPDkyRNMnz4dOXPmBABERUXhxx9/NGkFGWOMMcbkMCq4sbKywtChQ3WWDxo0KN0VYowxxhhLD8nBza5du9CoUSNYWVlpTMMgplmzZumuGGOMMcaYMSQHN8HBwYiOjkbBggWFaRjEKBQKblTMGGOMsUwjObhRTb2g/X/GGGOMsaxEdpsbpVKJ1atXY/v27Xj06BEUCgVKlCiB77//Hp07d4ZCociIejLGGGOMSSJrnBsiQrNmzdCjRw88e/YMnp6eKFeuHB49eoSuXbuiRYsWGVVPxhhjjDFJZN25Wb16NY4fP45Dhw6hTp06Gn87fPgwgoODsXbtWoSEhJi0kowxxhhjUsm6c/P7779j5MiROoENANStWxc///wzNmzYYLLKMcYYY4zJJSu4+ffff9GwYUO9f2/UqBHPCs4YY4yxTCUruHn79i0KFSqk9++FChXCu3fv0l0pxhhjjDFjyQpuUlJSYGmpv5lOtmzZkJycnO5KMcYYY4wZS1aDYiJC165dYWNjI/r3hIQEk1SKMcYYY8xYsoKbLl26pJmGe0oxxhhjLDPJCm5WrVqVUfX4+hEBSZ8zuxZpS1SbGiPxM4BsmVYVWayyAzxAJGOMMQmMmhWcaSECVgYBT85ldk3SRjYA/j9IneEGKL6SR4nOVYFu+zjAYYwxliYObkwh6fPXEdgAyK5IwCPbDpldDfmenE1dz9Y5MrsmjDHGsjgObkxt6D3AOntm18J8JH4GZrpldi0YY4x9RTi4MTXr7Hx3gTHGGMtEssa5YYwxxhjL6ji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2YlU4Ob48ePo2nTpihSpAgUCgV27NhhMP3Ro0ehUCh0XtHR0V+mwowxxhjL8jI1uPn06RMqVqyIhQsXyvrcnTt3EBUVJbwKFiyYQTVkjDHG2NcmU0cobtSoERo1aiT7cwULFkTu3LlNXyHGGGOMffW+yjY3Xl5eKFy4MOrXr49Tp04ZTJuQkIDY2FiNF2OMMcbM11cV3BQuXBhLlizBtm3bsG3bNjg7O6N27dq4fPmy3s+Eh4fDwcFBeDk7O3/BGjPGGGPsS/uqJs708PCAh4eH8L5atWq4f/8+5syZg3Xr1ol+JiwsDIMHDxbex8bGcoDDGGOMmbGvKrgRU6VKFZw8eVLv321sbGBjY/MFa8QYY4yxzPRVPZYSExERgcKFC2d2NRhjjDGWRWTqnZuPHz/i3r17wvuHDx8iIiICefPmRbFixRAWFoZnz55h7dq1AIC5c+fC1dUV5cqVQ3x8PH777TccPnwY//zzT2Z9BcYYY4xlMZka3Fy8eBF16tQR3qvaxnTp0gWrV69GVFQUIiMjhb8nJiZiyJAhePbsGbJnz44KFSrg4MGDGnkwxhhj7NuWqcFN7dq1QUR6/7569WqN98OHD8fw4cMzuFaMMcYY+5p99W1uGGOMMcbUcXDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8yscHDDGGOMMbPCwQ1jjDHGzAoHN4wxxhgzKxzcMMYYY8ysWGZ2BRhjjH09iAjJiUqT5JWUkCL6f1OwtLaAQqEwaZ5fo/RsL1Ntn8zYFhzcMMYYk4SIsH3GZUQ/iDF53quGnzRpfoVLOqDF0ErfdIBjyu2Vnu2TGduCH0sxxhiTJDlRmSGBTUaIuh9jsjtMX6ussr0yY1vwnRvGGGOyhU6vASubbJldDR1JCSkmvwtkDjJje2XmtuDghjHGmGxWNtmyZHDDxH1r2ytTH0sdP34cTZs2RZEiRaBQKLBjx440P3P06FFUqlQJNjY2cHNzw+rVqzO8nowxxhj7emRqcPPp0ydUrFgRCxculJT+4cOHaNy4MerUqYOIiAgMHDgQPXr0wP79+zO4powxxhj7WmTqY6lGjRqhUaNGktMvWbIErq6umDVrFgCgTJkyOHnyJObMmYOgoKCMqiZjjDHGviJfVW+pM2fOIDAwUGNZUFAQzpw5k0k1YowxxlhW81U1KI6OjkahQoU0lhUqVAixsbGIi4uDnZ2dzmcSEhKQkJAgvI+Njc3wejLGGGMs83xVd26MER4eDgcHB+Hl7Oyc2VVijDHGWAb6qoIbR0dHvHjxQmPZixcvYG9vL3rXBgDCwsIQExMjvJ48efIlqsoYY4yxTPJVPZby9/fH3r17NZYdOHAA/v7+ej9jY2MDGxubjK4aY4wxxrKITL1z8/HjR0RERCAiIgJAalfviIgIREZGAki96xISEiKk/+GHH/DgwQMMHz4ct2/fxqJFi/DHH39g0KBBmVF9xhhjjGVBmRrcXLx4Ed7e3vD29gYADB48GN7e3hg7diwAICoqSgh0AMDV1RV//fUXDhw4gIoVK2LWrFn47bffuBs4Y4wxxgSZ+liqdu3aICK9fxcbfbh27dq4cuVKBtaKMcYYY1+zr6pBMWOMMcZYWji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4eCGMcYYY2aFgxvGGGOMmRUObhhjjDFmViwzuwKMsYxDRIhLjjNpnp+TUtT+HwcospksbztLOygUCpPlxxj7NnFww5iZIiKE/B2CiFcRps1XaQVgEgCg9h8BUFgkmSxv74LeWNNwDQc4jLF04eCGMTMVlxxn8sAGABQWSchV5meT5wsAV15eQVxyHLJbZc+Q/Blj3wYObpjpEAFJn02bZ+Jn8f+bilV24Bu4S3C0zVHYWdpldjX0ikuOQ+0/amd2NRhjZoKDG2YaRMDKIODJuYwrY6ab6fN0rgp022f2AY6dpR3fDWGMfTO4txQzjaTPGRvYZJQnZ01/t4kxxlim4js3zPSG3gOss/hdgsTPGXMniDHGWKbj4IaZnnV2wDpHZteCMcbYN4ofSzHGGGPMrHBwwxhjjDGzwsENY4wxxswKt7lhjDGW5RERkhOVaaZLSkgR/b8+ltYWPCK2GeLghjHGWJZGRNg+4zKiH8TI+tyq4SfTTFO4pANaDK3EAY6Z4cdSjDHGsrTkRKXswEaqqPsxku4Isa8L37lhjDH21QidXgNWNumfiT4pIUXSnR32deLghjHG2FfDyiabSYIbZt74sRRjjDHGzAoHN4wxxhgzK1kiuFm4cCFcXFxga2sLPz8/nD9/Xm/a1atXQ6FQaLxsbW2/YG0ZY4wxlpVlenCzefNmDB48GOPGjcPly5dRsWJFBAUF4eXLl3o/Y29vj6ioKOH1+PHjL1hjxhhjjGVlmR7czJ49Gz179kRoaCjKli2LJUuWIHv27Fi5cqXezygUCjg6OgqvQoUKfcEaM8YYYwxIHYMoKSFF70vFUBoiMnm9MrW3VGJiIi5duoSwsDBhmYWFBQIDA3HmzBm9n/v48SOKFy8OpVKJSpUq4ZdffkG5cuVE0yYkJCAhIUF4Hxsba7ovwBhjjH2j5AyuaKjbfUYMpJipd25ev36NlJQUnTsvhQoVQnR0tOhnPDw8sHLlSuzcuRPr16+HUqlEtWrV8PTpU9H04eHhcHBwEF7Ozs4m/x6MMcbYt8ZUgytmxECKX904N/7+/vD39xfeV6tWDWXKlMHSpUsxadIknfRhYWEYPHiw8D42NpYDHMYYY8yEjBlcMSMHUszU4CZ//vzIli0bXrx4obH8xYsXcHR0lJSHlZUVvL29ce/ePdG/29jYwMbGJt11ZYwxxpi4rDa4YqY+lrK2toaPjw8OHTokLFMqlTh06JDG3RlDUlJScO3aNRQuXDijqskYY4yxr0imP5YaPHgwunTpAl9fX1SpUgVz587Fp0+fEBoaCgAICQmBk5MTwsPDAQATJ05E1apV4ebmhvfv32PGjBl4/PgxevTokZlfgzHGGGNZRKYHN23btsWrV68wduxYREdHw8vLC/v27RMaGUdGRsLC4n83mN69e4eePXsiOjoaefLkgY+PD06fPo2yZctm1ldgjBlARIhLjjOYRv3vaaVVsbO0M2nvCmbeiEij0ap2N2VtltYWvH99xTI9uAGAfv36oV+/fqJ/O3r0qMb7OXPmYM6cOV+gVoyx9CIihPwdgohXEZI/U/uP2pLSeRf0xpqGa/gCxNKUVpdlsUatGdE9mX05mT6IH2PMfMUlx8kKbOS48vKK5Ls87NtmTJfljOiezL6cLHHnhjFm/o62OQo7S7t05xOXHCf57g5j2tLqspyR3ZPZl8PBDWPsi7CztEN2q+yZXQ32jctqXZZZxuDHUowxxhgzKxzcMMYYY8yscHDDGGOMMbPCbW4YY1mGqcfE4bFwGPs2cXDDGMsSMmJMHB4LRz7twe7UpTXwnQoPgMcyGwc3jLEsISPGxFGNhcO9tKRJa7A7dYa6S/MAeCyzcXDDGMty0jsmDo+FYxxjBrsToxoAj7tcs8zCwQ1jLMvhMXEyX1qD3YnhAfCYIV9yfi8ObhhjjOngwe6YKX3p+b04uGFfDyIg6bNp8kr8LP7/9LLKDnA7A8YY05Ce+b2MCbI5uGFfByJgZRDw5Jzp857pZrq8nKsC3fZxgMMYY3p8ifm9OLhhX4ekzxkT2Jjak7OpdbXOkdk1YYyxLOlLPPLk4IZ9fYbeA6yzWGPTxM+mvQPEGGPMaBzcsK+PdXa+M8IYY0wvnluKMcYYY2aFgxvGGGOMmRUObhhjjDFmVji4YYwxxphZ4QbFjLGvEhEhLjlO9G/qy/WlAVKneeDJHRkzPxzcMMa+OkSEkL9DJM0ibmgCTe+C3ljTcA0HOIyZGX4sxRj76sQlx0kKbNJy5eUVg3d2GGNfJ75zw5ghUuezMmauKp6HyiSOtjkKO0s7WZ+JS44zeEeHMfZ14+CGMX2Mnc9K6kjFPA+VSdhZ2iG7VRYbsZoZjYiQnKjUWJaUkCL6fwCwtLbgx4pMBwc3jOmT0fNZ8TxUjGkgImyfcdng7NHaEyoWLumAFkMrcYDDNHBww5gUppzPiuehYkxUcqLSYGAjJup+DJITlRk+ESP7unBww5gUPJ8VY19U6PQaBgOWpIQUnbs4jKlwcMOyDkONd6U22OVGuuwLISJQnOGeVsrE/7UPUX6OgzLZ8N0FhR2Pu6NiZZON78Ywo3Fww7IGOY13DT3S4Ua67AsgIjzu0BFxV64YTBefzRpo+gsA4G71GrBNSTSY3q5SJRTfsJ4DHMbSiYMbljWYqvEuN9JlXwDFxaUZ2ACAbUoi/t4xVHK+cZcvg+LioMjOvb8YSw8ObljWY0zj3azcSFf7cZuhR2z8WC1DaE/VYGh6BrlTMrifOgkLO3nj7GhTxsXhbvUa6cqDMfY/HNywrMecGu+m9bhNOyDjx2oml9ZUDdqD+cmdksHCzg4WfKeFsSwlS0y/sHDhQri4uMDW1hZ+fn44f/68wfRbtmxB6dKlYWtrC09PT+zdu/cL1ZRlCURA4ietl9bdEPW/EWVeXeU+blM9VmMmI3eqBp6SgbGvX6bfudm8eTMGDx6MJUuWwM/PD3PnzkVQUBDu3LmDggUL6qQ/ffo02rdvj/DwcDRp0gQbN25EcHAwLl++jPLly2fCN2BflJSGx8beDZHz+AiQ/wjJ0OO2rPxYzYwYmqqBp2RgzHxkenAze/Zs9OzZE6GhoQCAJUuW4K+//sLKlSvx888/66SfN28eGjZsiGHDhgEAJk2ahAMHDuDXX3/FkiVLjK+I1DmExBgzr5CYr6W9hdi6+lLtSIxpeCylkbHcx0eA/EdI5vS47SvFUzUw9m3I1OAmMTERly5dQlhYmLDMwsICgYGBOHPmjOhnzpw5g8GDB2ssCwoKwo4dO4yviLFzCIlJz69vJx+g3SbNi6W+YEnsDoChuwKSPi/hwpuRd07kSqvhsZy7IRkVNGWgz2kE4+qPVt7GvzX4qEX9boZYOn13OzhQkE75Wf/2UqqNl6OMi9N4L0a9AbNYWrEGzhnVLkjfvE/ac0ABMNtxa8S+q/bypIQUvenE1oucdSW1fH1p9ZX1NW+vTA1uXr9+jZSUFBQqVEhjeaFChXD79m3Rz0RHR4umj46OFk2fkJCAhIQE4X1MTOrQ3rGxsf9LlPgJuHfWmK9gWg8uAr9k4qOJsKdppzFmXd07A7yJNhwEJH4CEv6/bUxsLGAtfrBqpItPBpR60gFAYrK0PLXz/SkCsDbQ+yUxDljgJT9fqd8rrTz/X9WNVdNMo9JgQwPJaeU428HwvvA56TNS4lK/S2xsLJKtkrNsWjl5Kj9/xseU/6W1SNafVuWOj2+aaQDgSlV/Senk8rh0Mc00SQkpiEv8BCD1e0m5uC0beEx0+aKB+3WW9ZobYLLys0JaFX3rQJ3Y+jAkrXWV0eVLqcOX3gaq6zZJaUdJmejZs2cEgE6fPq2xfNiwYVSlShXRz1hZWdHGjRs1li1cuJAKFiwomn7cuHEEgF/84he/+MUvfpnB68mTJ2nGF5l65yZ//vzIli0bXrx4obH8xYsXcHR0FP2Mo6OjrPRhYWEaj7GUSiXevn2LfPny8SigjDHG2FeCiPDhwwcUKVIkzbSZGtxYW1vDx8cHhw4dQnBwMIDU4OPQoUPo16+f6Gf8/f1x6NAhDBw4UFh24MAB+PuL38q1sbGBjY2NxrLcuXObovqMMcYY+4IcHBwkpcv03lKDBw9Gly5d4OvriypVqmDu3Ln49OmT0HsqJCQETk5OCA8PBwAMGDAAAQEBmDVrFho3boxNmzbh4sWLWLZsWWZ+DcYYY4xlEZke3LRt2xavXr3C2LFjER0dDS8vL+zbt09oNBwZGQkLi/+NNVitWjVs3LgRo0ePxsiRI+Hu7o4dO3bwGDeMMcYYAwAoiDJz+FbGGGOMMdPKEtMvMMYYY4yZCgc3jDHGGDMrHNwwxhhjzKxwcMMYY4wxs8LBTSZQjcmjPlaPObhx40ZmV8FsZfa6PXDgAACtaUuYWTDXbfv9998DAKZPn26yPN+9e5ch5X9N14TMPhdJ9c0GN3I2kNQdWmq69+/f48WLFzhy5Ag+fPiA2NhYjZex+WYUqeV37twZAFCjRg1J6VVjFx0+fDjNtFK315o1awBA79xk6uSc1OXsL3JOVFLrK2fdylkHUuv6888/AwBq166dZp5y8pWzDeQcBxmxbeWUn1F1lbNvST2+5GxbOeVnxMVdzrq6c+cOiAibNm1KM63UfaBevXoAgDZt2pi0fDnXhJ9++gkAsH79+jTzlZNWKrnn+UyT9gxQ5snb25uIiKpXry45bevWrU2SbuzYsWRnZ0cWFhakUChIoVAI/7ewsDA6XyKifv36ERHRunXr0kx7/fr1NNPIKb9MmTK0adMmKlGiBO3cuVPnpS9f1b9S6pDW9qpUqZLkPOWklbO/lC5dmqKjo6lChQoUGxtLMTExGi9j6iBn3cr5XlLr6unpSVOnTiUnJyeaN2+ezsvYfI3ZBlKOg4zYtnLKz6i6ytm3pB5fcratnPLLlStHSqXSpN9Lzrrq1q0b5ciRgywtLSlPnjzCK3fu3JQnTx6NtFL3gdKlS9PZs2epdOnS9O+//9LVq1c1XsaWL+eaUKFCBcnrQE5aqdcOuef5X375hYiIDh06ZLI6SJHpg/hllvj4eGzevBlRUVHYtWuXzt+bNWsm/D8uLg7nzp3DtWvXcO3aNZ0ZSStUqCAr3YQJEzBhwgRUr14dp06dSrOuUvMFgOPHjwMAZs+ejU6dOhnMt3Pnzrh8+TJq1KiBkydPprv8qVOnYsmSJXj58iXmzJmjkUahUGisUwDInj07GjVqhIcPH6Jly5Y65W7fvl34v5zt1adPHzx79kxjTjGV2bNnC/9PSkrCtGnT8PLlS8yfP18nbf/+/Y0qv02bNnB1dUVCQoIwVLhCoQARQaFQICVFc8ZvKfWVu26lrgOpdV2+fDnWrFmDuLg4XLlyRad8bVLzlbMN5BwHGbFt5ZSfUXWVs29JPb7kbFs55fv5+SFXrlxISEhA3rx5heWqtG/fvpWdr5x1tWLFCvzyyy+oW7cu9u7dq5NWndR9YODAgQgNDcXDhw91jjmFQoEHDx4YVb6ca4KzszPKlCmDyMhIVKpUSefvly9fNiqt1GuH3HPRli1bEBYWhqFDh2qUJ0bO9Sst3+wgfrt27cKSJUtw4sQJ+Pr6avxNoVBo3MpdunQp5s2bhwcPHqBw4cI6aVU7tNR0csnJt0mTJrh//z4iIyPh4eGhk5f6zlW2bFmMGzcOI0eO1NlJgf8d0HK/14ABAzBv3rw0v9e7d+/wzz//YPjw4Zg4caLO37t06SL8X+r2evDgAbZs2YK5c+fihx9+0Mlz3Lhxwv/PnTuHNWvWYPPmzaInqpUrV8ouX52UE5Wc+gLS1q3cPKXWFQCmTZuGESNGpJlOar5ytoGc/TAjtq2c8jOqripStpec4wuQt22l7i8vXrzQe3EvXry47HyNWVcxMTFpzkck9/hu3bo1tmzZYjBPOeXLkZSUhMuXL6NTp0747bffdP4eEBBgVFo51w5A+nm+Ro0ayJUrF86ePYs6dero/F39R6zcOhjyzQY3KlI3ECB9h04rXZ06dQzOSK7vGbmU8uXszBl5QMtx6NAh4Vl2WqRur3Xr1gnPhtMi56QuZ3+RQ059MyPPyMhIg38vVqxYuvKXsw3k7IcZsW3llJ9RdZUjreMro7etqS/ugLR1FRoaavA8KxYImfL4llO+MdeEW7duoUyZMpLqIiWtnGuHHHKCbFPW4ZsPbjLDX3/9BQA4cuQILl++jG7dukGhUGDVqlXw9vbGjBkz0l2GnB3fVAe0hYWFwQNU+3HM2rVrDeYXEhIiuw6q25r61KpVS/h/Rp3U5ZyopNZXzrqVsw6k1rVAgQJCujdv3sDKygpA6skoX758ePnypcbnpOabUdsgoy/YpiSnrnL2LanHl5xtK6f8jLi4y1lXCxcuBABcu3YNx48fR4cOHaBQKPD777+jZs2aWLx4scG8xLi6uhqsp/odOTnly7kmiAUI6saOHWtUWpW0rh1yz/Mqcn7Eyrl+6fPNtrmRs4Gk7tBS0zVu3BgAMGnSJJw8eRKWlqmboXXr1hoXHrnlA8btzGkFNlLL//DhA4gIc+fORVxcHPr06QMAWLJkCezs7HQ+t3v3bgCpPR+OHTuGGjVqQKFQ4OTJkwgICNAIbqRuryFDhgjvIyIiUKJECSgUCty/fx9eXl4atzV9fHwkn9Tl7C9Dhw4FoP9EpU5qfeWsWznrQGpdX716BQAYMWIE3Nzc0L17dwCpF6j79+/rrA+p+crZBnKOg4zYtnLKz6i6ytm3pB5fcratnPJVd4P1XdyNyVfOuurbty+A1GD+7NmzsLe3B5Dag6hJkyYa5UvdB/bs2QMA2LRpEx49eoTevXsDSG23pP2YTU75cq4JHz58AAA8ffoUhw4dQrNmzaBQKLBr1y6d4EFOWqnXDrnnefUgWyzgVj/PG3P90ivdTZK/Uh8/fqQPHz7QpEmTaOTIkfTkyRN68uQJjRo1iiZPnqyR9vr163T9+nUaPXo0derUiU6cOEEnTpygkJAQGjNmjOx0Ku7u7pScnCy8T0pKInd3d510cvIdOnQoDR06lNq1a0cFChSg7t27U48ePahgwYLUvn17jbSqlvj6XsZ+L1WPhrSWqQQHB9O1a9c0ymvZsqVGGjnbi4goNDSU/vnnH+H9gQMHqHv37qLlDx8+nJYtW0YpKSmUkpJCy5cvp59//jld5RMR+fn5UVJSkvA+ISGB/Pz8RNNKra+cdStnHUita8WKFXWWeXl5ieYpJ18p20Dufig1X6nbVk75GVVXueuVSNrxRSRv28opv2bNmho9nmJiYqhmzZrpylfOuipdunSay+Qe376+vhrvlUqlzjI55atIvSYQEdWvX5+ePXsmvH/+/Dk1aNDA6LRyrh1E0s9FrVq1olatWlGDBg3IxsaG6tWrR4GBgWRra0tBQUHpqoMh32xwoyLnYiF1h5aark+fPhQYGEhr166ltWvXUoMGDejHH3/UW1c5B5SUnTmjDmh3d3d68eKF8P7Fixd6D1AiovLly+ss8/T0FE0rdXuJfV7VLVKbnJO6nP1FzolKan3lrFs560BqXcuUKUO3b98W3t+5c4fKlCkjmqecfOVsAznHQUZsWznlZ1Rd5exbUo8vOdtWTvkZcXGXs67atm1LXbp0oePHj9Px48cpNDSU2rZtK5pW6j7g7u5OHz9+FN5/+PBB7/eXU76ca0K5cuUkLZObVmrQJPc8LzXIllMHQ77Zx1IqHz58wMuXL1GwYEEAwMuXL4VbedpiYmLw6dMn5MiRAwDw6dMnxMTEGJ1u/vz5WLp0KXbs2AEACA4ORs+ePfXWVWq+APD8+XMUKVJEeF+4cGE8e/ZMI40qnz///BOXLl0Slk+ePBk+Pj4YNWqUUeUPGTIEFStWxHfffQcA2LdvH8aPH6/3e9nb22P16tVCw7I1a9YgZ86commlbq9s2bLhyJEjQuv8Y8eOwcJCfMzKxMRE3LlzR2id/99//yEhISFd5QNAYGAgGjZsKNx2Xb9+PerXry+aVmp95axbOetAal2nTp2K6tWro2LFiiAiXLt2TbRhptx85WwDOcdBRmxbOeVnVF3l7FtSjy8521ZO+RUrVkTXrl2Fx12rVq1CxYoV05WvnHX122+/YcKECcIAgYGBgRgzZoxoWqn7QIcOHVC1alVhML8tW7bo7bosp3w514SiRYti3Lhx6NGjB4DUrudFixZNd1op1w5A/nn+3r17KF++vPC+XLlyuHv3brrqYJCsUMgMLVmyhBwdHalbt27UrVs3KlKkCC1btkw07bhx46h8+fI0ceJEmjhxInl6etKECROMTqeiVCpJqVSmWVc5+QYFBdHYsWMpMjKSIiMjady4cTq3AFWkRuByyr927RrNnz+f5s+fn+Zggbdv36bKlSuTlZUVWVtbk5+fn8YvSHVSt9epU6fI2dmZSpQoQa6urlSsWDE6c+aMaJ47d+6kfPnyUd26dalOnTqUP39+2rVrV7rKJ0r91fnrr79Sy5YtqWXLlrRo0SKNW+7G1lfqupWTp5y6vnz5knbt2kW7du2iV69e6S1fTr5ytoGc/TAjtq2c8jOqrnK2l5zjS+q2lVP+hw8faOjQoVSpUiWqVKkSDR8+nD58+JCufOWsKznkHN979uyhwYMH0+DBg2nv3r3pLludlGtCVFQUtW7dmvLmzUt58+altm3bUlRUVLrTyrl2yDnPV6tWjVatWiV8t1WrVpG/v3+666AP95YCcP36dRw5cgQAULduXZQrV05v2r/++ktouR8YGIhGjRoZnS4yMhI9e/bEsWPHAKT2GFi6dKnBnhxSy4+Ojkb//v1x6NAhAED9+vUxd+5cODo66qRdunQpxo8frxOBi/1ikFr+p0+fcOXKFSgUCnh5eQm/XA1R/ULKlSuXwXRSt1dSUpIwBUHp0qWFxodiXr16hbNnzwJIHQo+f/786S5fRXWIGWqwKKe+ctatnHUgta6RkZE4fvw4FAoFatWqBWdnZ4N5Ss1XzjaQuh/KzVfqtpVTfkbVFZC+bwHSji+521ZO+XKYcn959+4dwsLCcPDgQSgUCtSvXx9TpkxBnjx5RNPLOb6fPn0KhUIBJycnvWnklG/MNcHU5Fw75JyL7ty5g86dOyMiIgIKhQLe3t5Ys2aN6Hg2cuqgl6xQyEx9/PiRTpw4QSdPntR4jqrPkydP6OnTp+lOFxAQQNOnT6f379/Tu3fvaMaMGRQQEGCy8uWQE4GnVf7BgwepYMGC5O3tTV5eXlSoUCE6fPiwwTx///13ofHY5s2bDaaVur3OnDlDkyZNosmTJ9PZs2cN5vn48WNat24drV+/niIjI01S/uPHj4VGdDY2NtSwYUN6/Phxuuord91KXQdS67phwwbKmzcvtWjRgoKDgyl//vz0+++/m2QdyNkGRNKPg4zYtnLKz4i6yt23pBxfcratnPLfvn1LvXv3ppIlS5Kbmxv16dOH3r59m+58pa6rZs2a0Y8//kgREREUERFB/fr1o2bNmulNL2UfiIiIoNKlSwtTKpQpU4YiIiLSXb6ca0J8fDyFh4cLDXSnTZtG8fHx6U4rlTHneSKi2NhYio2NTVfZUnzzwY2cDSR1h5aarmzZsjrL9DXykpMvkfyd2ZQHdPny5TUupOfOnRNt1KgyZMgQ8vX1pblz59LcuXOpSpUqNGzYMNG0UrfXjBkzqFixYjRw4EAaOHAgFS9enGbNmiWap5yTupz9Rc6JSmp95axbOetAal09PDzowYMHwvuHDx+Sh4eHaJ5y8pWzDeQcBxmxbeWUn1F1lbNvST2+5GxbOeVnxMVdzrqS06BZ6j7g6+tLf/zxh/B+y5YtJuktJeea0LVrV2ratCnt2LGDduzYQc2bN6fQ0NB0p5V67ZB7nieS/iPWFMHYNx/cyNlAUndoqemaNWtGd+7cEd7fuXOHgoOD9dZVzgElZ2c29QEt1iNHrHeDiru7O33+/Fl4//nzZ4M9P6RsL3d3d3r9+rXw/s2bN3rzlHNSl7O/yDlRSa2vnHUrZx1IravYBHyGJuWTmq+cbSDnOMiIbSun/Iyqq9x9S8rxJWfbyik/Iy7uctZV3bp16eXLl8L7ly9fUr169UTTSt0H5PTwlFO+nGuCh4eHRruc5ORkvetATlqp1w6553k5P2LlXL/0+eaDGzkbSOoOLTVd3bp1ydbWlurWrUt169YlOzs7qlevHrVo0YJatGhhdL5E8nZmUx/QQ4cO1Wg4tmbNGr07MRFR5cqVKSUlRXiflJREVapUEU0rdXv5+PhIWkYk76QuZ3+Rc6KSWl8561bOOpBa19GjR9O4cePoyZMnFBkZSRMmTKCxY8eKzgotJ18520DOcZAR21ZO+RlVVzn7ltTjS862lVN+Rlzc5ayr77//ngoVKiQ0EnZ0dKTWrVvToEGDaNCgQRpppe4DISEhdOTIEeH90aNHqWvXrukuX841oVq1avTp0yfh/adPn/TOai4nrdRrh9zzvJwfsXKuX/p8813BGzRooNFNct26dWjQoIFo2kqVKuHo0aOoXbs2gNSutT4+PkanCwkJ0RidMa3pBqTmCwD58uVDXFwcsmfPDgBISEjQ2+DOwsICfn5+wvsqVaogW7ZsRpf/22+/ISYmRhi9MykpCQ4ODli+fLnObMAAULVqVQQFBWl0//T39xdm51WfIE/q9qpbt65G99PVq1cjMDAQ//77LwDNWZkbN26M8ePHo0ePHiAirFq1Ck2bNkVsbCwACCOLyikfAD5+/IiKFSuiWrVqAIAzZ86gWrVqwgzN6hPGSa2vnHUrZx1IreuUKVMA6I4kOmnSJNEZz6XmK2cbyDkOMmLbyik/o+oqZ9+SenzJ2bZyys+TJw88PT2FUXj37t2LmjVrCjPWq89SnxH7i6enJzw9PYX3YpPJqkjdBy5fvoz169fDxcUFAPDo0SOULVtWmHlbfRRwOeXLuSaULl0afn5+Qnf0rVu3onLlysJs6eozpMtJK/XaIfc8nzt3btjY2Ajvrays9DbqlnP90ueb7y2VJ08exMTEaAzjrZrkTXsDeXp64ubNmzo7tOqzqh1aajq55OTbvXt3nD9/XmdnVl3Q1HfmYcOGoVy5choH9PXr1zF9+nSjyn/8+LHB76E9TLnYTLEq2hN4St1erq6uBvNUH/5e39gvqrTqJ3U5+8uaNWv05gtoThgntb5y1q2cdSCnrnJIzVfONpBzHGTEtpVTfkbVVc72knN8SSWn/AkTJhhMqz5LfUbsL3JI3QdUvZn0MXaSSTlCQ0P1/k17hnQ5aaVeO+Se5/v3749bt25pBNllypRB3bp1AWj+iJVz/dL7vb714EbOBpK6Q6dnx9+zZ4/OvCNyywfk7cxf0wEt94Ayt/JZxu2HUretnPKzwjHDdF2+fFm4y6LuSx3f+soXY+iakBHkXDvkkBNkm6QOsh5isQzXo0ePL17mo0ePDL5MYdy4cSbJ52u3e/duk+eZUetWal179uyZIfkyeTJivcrZtnLKv3TpUobkK9V3331n8jyXLl2aIeXLuSboG5gvvWmlykrnef339r5hhoaQ1rZs2TKTplu+fLnksuXkC6QOjCSmePHiBl+mKL9w4cKS6wlA8q8aQPr2kvPrp1evXiYvHwB27twpOa3U+spZt3LWgdS6Nm3aVHKecvKVsw3kHAcZsW21yzd0B8AUdX3//r3OMjn7ltTjS862lVO+vukH0pOvnO36119/SU4rdR+QMz2AvvLXr1+vc56Wc00wNEBketLqu3Zok3uel0NqHVQ4uBEhZwNJ3aENpXv16hUOHz6MqKgoyeXKLR+QtzOb+oBWNTqTSs7JR+r2SuvZvzo5J3U5+4ucE5XU+spZt3LWgdS6yg1uMiJfOcdBRmxb7fL9/f313jo3RV3d3d3Rs2dPXL16VVgmZ9+SenzJWVcZUb6cfA3V9dOnTzh58iROnTqFT58+SS4bEN8HJk+ejLNnz0KpVArLDB1bUss/cuQI/Pz8UK5cOfTv3x+7du0SGklLceXKlQxJK/XaIfc8L+dHrJzrFwB+LCVGvdtkRujcubMwl9OhQ4cof/78VLlyZSpQoAD9+eefGVq2VEuWLDHqc2/evBHmpHn79i1t375d7zw2KupjsaiodwdNi9j2iouL01mmPn+WKWmXf/36dfrnn3900h04cIBu3rwpmofU+h47dkzndfXqVdHPy3Xx4kVau3YtEaVuu+fPn+ukWbNmjc5r586dJh8xWy71rsZZwf379ykgIIAaN25M0dHRJs///fv3NGfOHCpVqhTVqFGDNm/erDGbtjGWLFlC79+/JyKiH3/8kXx8fOjYsWOiaSMjIykhIYGIiE6ePEkLFizQO+qsKh1R6nrZvXt3uusqh7Ej6RoyceJEqlmzJuXLl4+aNm1K8+bNoxs3bpis/Dt37tD8+fPJxcWFLC0tDabNiJGypVIflG/Tpk2yPy92jjGVbz64mTRpksZ7pVJJHTp00JtefTh7fZMQppVOfSyFWrVq0ZUrV4iI6MGDB+Tl5WWwvlLLVzH1zmyo/E2bNpG9vT3Z29vTpk2byNPTkxo2bEiOjo60bds2vXnWqFFDY/TJhw8fUqlSpUTTSt1ezZs31xgn4c2bN3rX7dixYzUCrFevXtH48eONLr9Zs2Z0+fJlnc9euXKFmjdvLpqv1PpWrFiRLCwsyM3Njdzd3cnCwoLKlClDRYoU0Thh7t27lzp37kwBAQEUEBBAnTt3pr/++ku0bCKihQsXUoUKFahEiRJERHTv3j2qXbu2TroGDRqQra0tBQYGUv369cnOzo4CAgKocOHCGiOOKhQKsrCw0PtSuXHjhsYEjX/88Qc1b96cBg8erHdyRRWlUkl//fUXtWjRgnLmzKk33dmzZ2nDhg0aAZk+z58/p1OnTmkEjyonT54U3Y+3bt1Kp06dEs1v3rx5VKxYMerfv78wron22CbG1lXl77//JmdnZypSpAhNnjxZZ4Txd+/e0dSpU6lnz54UGhoqvLSpxt85efIk1apVi/bt20eVK1cWLdPb25vi4uLo6dOnVLRoUWrXrh21atVKNK2vry/FxsbS69evqUiRIlStWjXq3bu33u/i4eFBVlZWZGFhIexHYvbu3Uvz5s2jWbNmCS8xckfSlXPB/vjxI61Zs4ZcXFz01lNO+Xfv3qXFixdTy5Ytyc3NjVq3bq134k7V6Ne5c+eWPFK2lLQqaV075AzKp07qRNFS6mDINx/cNGjQgNavXy+8V50AxEgdzj6tdOoDF2mPVqpvgC855RPJ35mlHNBple/t7U3Pnj2j27dvU86cOenff/8lotQLpb6TJBHR/PnzqWXLlkSUenEpU6aM3gux1O01fPhw6tevHxGlzmXi5+dHy5cvF81TbJAufQOCSSlf3wi0ROKDusmpb7du3XQGDwsNDaULFy4IA/SNGjWKfH19adGiRbR3717au3cvLVq0iHx9fWnUqFGi5VesWJE+f/6sEVCJjQzbsmVLunXrlvD+9u3b1KJFC3r48KHGvvvx40f68OEDTZo0iUaOHElPnjyhJ0+e0KhRo2jy5MlCuipVqggnrytXrlCuXLlo6tSp1KFDB+rWrZtoXe/fv0+jRo0iJycnsrW1pSVLltCbN29E0/7www/k6upKLVq0oFatWlGrVq2odevWomknT55MDg4O5O3tTb6+vuTr66ux3wYGBtK9e/dE6xMYGKizPCUlhSZOnEguLi40ZswYGj9+vPBKb12JiGJiYoS7Nw0bNqRt27ZRv379dAZnq1evHrVr147mzZtHv/76q/DSptrnJ06cSL/99pvGMn1ply5dKgT8YgPgEZGwT61Zs4bCwsKISP9x4O7uTvv27aOYmBj6+PGj8NLWoUMH8vLyotDQUOrRowf16NFDb+NnOQNvSr1gHzhwgEaMGEGVK1cmHx8fGjZsmOjdWrnlKxQKql69Oh05ciTNACCjRsqWeu2QMygf0f/mDbO2tk5z3jBjgjFt33xwExMTQz4+PnT48GEaNGgQtW3bVu9jKanD2aeVrl+/ftS/f3/68OED/fzzz7R+/XpSKpW0d+9eqlOnjt66yhlOX87OLPWATqt89Quj9miSad2RGjx4MPXq1YsqVqxIW7du1ZtOzvZq164dTZ48mQICAmju3Ll68xQLKPUNJS+lfH1Dy6f1Nyn1FTtRqpap/nVzc9N4FKASHx9PJUuWFM1XNWKt+naSOzqvWPpKlSoZXKae36hRo6hPnz5ElDqKrnZZ69evpzp16lDBggVpyJAhdO3aNXJxcRH9Pipubm6SH9mVKFFC9BGpiqEAXXu73Lhxg3x8fKhDhw56J4lMT1179epFhQoVor59++o89tXex8SmNBDj4+NDmzZtonLlygm9JPUdB2XLlqX4+Hhq1aoVnTx5koj0Bzeq8kNDQ+nAgQNEpP/irm8EbW0eHh6SH23JGUlX6gVbFYQcP37cpOX/9ddfNGjQIKpUqRLVqFGDxo0bJ6xfbRk1UrbUa4eckeWJ5M1HJuf6pc83H9wQpd76cnV1pWbNmhk8YKQOZ5/WsoSEBBo4cCDZ29uTi4sLKRQKsrS0pKCgII35Uowti0jeziz1gE6rfPX858+fn2Z9rl69KrwuX75Mvr6+NHToUGGZPoa2l2qo+JiYGHrx4gVVrlyZRowYoXd6ACKiVq1a0bRp0yg5OZmSkpJo6tSp9P333xtVPlHqgSnWzuj27ds661Bufb28vDQelRw7dkwISFQXjJIlS4peJD9//iw8dtLWuHFjunPnjvCLfNWqVdS0aVOddP7+/rRmzRqNE7W/v79G+erc3d012g69ePFCb0AcGBiocddQOz+FQkH169fXyM/V1VX0+6jUrFlT8i1w1ffQx83NTe/ftI+XIkWKaJycpZBT11mzZgntY7Rpt2No2rQpvXv3Ls08z549S82bNxcC6zt37tBPP/0kmnbSpEmUO3duqlKlCimVSnr+/DlVrVpVNG3fvn2pTJkyVKpUKUpMTKS3b9/qPW+NGzdOUrvDoKAgjekEDMmdOzcpFAqytrYma2trUigUlDt3buGugDqpF+wbN27QvHnzqGnTplSmTBnq0qWLxh1dVbl58uQRLV+7XG1xcXG0du1ag4+75EwBISdtWteOnTt30s6dO+mnn36iwMBAWrt2La1du5YaNGhAAwYM0Pud5MxHJuf6pc83O/2Ct7c3FAqF8D4+Ph53795F5cqVAWiOHKoarl7fcPZy01lbW2POnDmYMmUK7t+/j+TkZBQrVgz58uUTravUfNXJGfY9rWGxpZbfrFkzxMbGwt7eHj/99JOw/NatW8IIreqaN2+us2zr1q3YunWrzgi6UrdX7ty5oVAoQETCvxcvXsT06dP1jlw6b948dOrUCaNHj4ZCoUCtWrWwbt06jTRy9pehQ4eiefPmmDdvHqpWrQogdRj5wYMHY+zYsRr5yq3vwoUL0a5dO40BFzdt2oSPHz9i0KBBAICuXbuicuXK6Ny5s9CV//Hjx1i3bp3ewbHmzp2L9u3b4/bt23B2doa9vT327Nmjk27VqlXo3LkzevToAYVCgYoVK2LNmjX49OkTZsyYoZN+yJAhqFixIr777jsAwL59+zR64uXNmxe7du1CkSJFcObMGWzcuBEAkJycjISEBI28Dh06hJUrV6JMmTJo2LAhQkNDQWmMQern54dWrVqhbdu2sLW1FZarj4aqUr9+fQwcOBAdOnTQSKsaFbVw4cI4d+6cxlQlAHD+/HkUKlRIY9nly5d1lumjmgZBal1TUlLw22+/CdMXaNPu3ZM9e3ZUqlQJDRs21MhXfdoDVfk7duwApf7oRalSpYTh+bWNHj0a/fr1g729PRQKBXLlyoWtW7eKpl2wYAGuXr2KEiVKwMrKCikpKTo9oPLkySPs/zExMbCzs4ONjY1wXGgP5T9r1iwEBgaidu3aGt9J+/gCgIiICNF6qVNtA31TVWgrW7YsypYti6ZNm+Lvv//GjBkzsH79enTs2FFWudqmTp2KgwcPIiIiAr6+vvjxxx91zvGqc1FSUhLWrVsnjET+8OFDlC9f3ui0KmldO+bMmaORXr1XoOpaIcbNzQ3//fcfSpUqBQD477//4O7ublQdpPhmRyiWM3Ko1GHs5Qx3L4ecfNV35hs3bujszOo7n+qAPnjwoOiw2HPnzs3Q7yXHlxjpVdVFM0eOHOkuf9WqVRg/fjyePn0KAChatCjGjRuHbt26pbueSUlJuH37NgDAw8MD1tbWOmmOHz+OP/74A5GRkQCAYsWKoXXr1gbXk1KpxJ07d0BE8PDwEJ1fTOXDhw8AgFy5cqVZ3+vXr+PIkSMAUgPkcuXKafytffv2ePbsGUaPHi1csHfs2IHt27dj7dq1OvnFxMRg48aNWLFiBf79918MHToUHTt21MhXRWxUVH1TDojt5+r798GDBxESEoJx48ZpBK2TJ0/GqlWrUL9+feFz2vMzaeepPs6LMdMjBAQE4O+//xbm3jFEXxdl9WkPACAyMhI9e/YU9vU6depg6dKlKFasmM5njx8/LppnrVq1dJap9kFt6vnKHRlY9UOqUqVKGvupWICdmJgoHCMPHjzAzZs30ahRI43Pyd0GvXv3xqFDhwAAgYGBqFevHurVq4e8efMa/B5pGTVqFAIDA1G9enXR4xrIuBGy5Vw75GjRogUUCgViYmJw+vRpnXnDDh48mCF1+GaDG5X4+HjY2NgIv8qVSiUSExM1fg18SaVKlcJ///1n9Ofl7MwZMecMkLoOted+effund5J0nbv3o2aNWsid+7cQtrTp08LE+2pk7q9Lly4gNKlSwsX3w8fPuDOnTvw9fXVSPf27VsolUrkz58f7969w9GjR1GuXDnh14Wx5au8evUKAFCgQAHRv8utr6rM6OhoJCcnC8vELkBSpDWGhvoEhCpRUVF4+PChRvliF7Uv4erVq/jtt9/w+++/4/Xr1xle3sGDBzFx4kRcunQJAODr64vRo0drBDZA6nxtYrZt24bHjx8bPfeRSvfu3XH58mW0bt0aOXPmFJZrz7mTkpKCrl276tyJFFO7dm00btwYvXr1AhHht99+w549e3D06FGdtKo7lkDqMXHnzh2UL19edN68AgUKCHdl4uPj8fnzZ+TLlw8vX77USRsZGYmCBQsKx1N8fDxevXoFZ2dnjXQeHh64c+dOmt9JVdfDhw8jMTERFSpUgIuLCzw9PbFkyRJJnxezfPlyBAYGGvzhp/Ly5UuMGzcOV69eRXx8vLBc3xyDnz59wpUrV6BQKODl5SX6YysjGPMDMikpCQ8fPtT4XuoT8gLy5iEz6Y9YWQ+xzJC/v7/Gs+v379/rnQpeJT4+XqOthNx06m1NtF+Ojo5p1llq+aai6q2gXqZY+RcuXCAXFxeytram4OBgjbFH9PW6INJtW6FUKvWml7q9vL29NdrDJCUl6TznN6brutTy5Y73I6W+RKltYXLlykV58+al/PnzU/78+alAgQI66R48eEDHjh3TaEtFRDo9OlRdbRUKhfAy1AU3rR5F2l68eEE//PAD+fv7k7e3t/BSSUxM1OjptH//fuGZvtSGuESkMZSAtj/++IN69uxJPXv2NNhYnSi1m+6UKVNoypQpdOHCBcnlp+XAgQPk4+ND1apVoxMnToimWbp0qca6eP36td5uwF27dtV56evlaaiRpzo5bSK0nTt3TmgMnpZt27bR2LFjRf9WuXJljfZinz9/Fq1/06ZNJZ/7pPTW+u+//4hI/7lZzOPHj2ndunW0fv16vb1+iIiaNGlCU6dOJXd3d9q1axc1btyYRo8eLZr20KFDVLBgQfLy8kpzTJzPnz/TtGnTqH379tSiRQvhld60Uu3evZscHR3JxsaG8ubNSwqFIs0G/l/SN9vmRuXz58/CJJEA4ODggI8fP4qmPXv2LEJDQ3XurGj/CksrnZeXF1xcXETbC7x580ZvXaWWDwBxcXFYsGABIiIiNKLq7du3i+ZtKAKvWbMmLl++rNE+REW9XcigQYPw66+/omrVqpg7dy5q1aqFgwcPwsnJKc22EeoMzeordXsplUqN286WlpYadxoAYNq0abh16xY+fPgAX19fnD59Gp6enrh//z7at2+Pli1bGlX+5s2bhaHgly1bhilTpsDJyQkRERFYuHChaL5S6gsAkyZNwoULF+Dh4aHzN5UNGzZg4MCBcHR0xPv37/HHH38I7QZGjBihcZdBfYRVKVauXIn79+/rbR+mrXv37qhRowYOHTqEWbNmYenSpfD29hb+Pnr0aNjb22PUqFEAgJ49e6JEiRKIj4/HmTNnEB4eLqQNDQ3VaPekTqFQYMWKFTrLJ06ciB07diAkJAQKhQLh4eG4desWRo8erZN22bJlmDx5Mlq2bAmFQoHvv/8eY8aMQY8ePQD87zGuPmLteCIiIjB8+HA8f/4cU6ZMEW1nprJo0SKNKQTy5cuHRYsWoWfPnjppV61aZbAu6urUqYNevXqha9euGnd5tH9hy2kToa1KlSqSR6dt2bIlfvnlF9HHZdp3Qe3s7HTaXqmWV6pUCQ0aNDDYjkiVJwAcPXoUHTp0AACdR66DBg3Cnj17RLeP2KP3jRs34qeffhLuWA4cOBALFixAu3btdD7/5MkTjBgxAuvXr0fTpk0RFBSEgIAATJo0SSftgAEDsGvXLqFd1/nz59G9e3dcu3ZNJ23Pnj1hb2+P06dPY8iQIVi9erXeO6hy0kq9dowZMwZnz55FcHAwrly5gvXr12uMmC3mjz/+0MlXbJvJvX6JyuTgKtN5enpqDBYWExOj99dKlSpV6OzZs+Tl5UWxsbE0efJkmjlzpux0Li4u9OzZM9EyihYtqreuUssnIurYsSP16dOHihcvTvPnz6dKlSrRwIEDRdOaKgLX7u69bt06KlWqFEVGRhq8c1OjRg2NQdBOnjyp9+6Z1O1VuXJl4dcYUWrPD+2uhMZ0XZdSvjHj/UipL5G0X+EVK1akJ0+eEFHqHQNnZ2c6dOiQwe8l9qtbbFlaPYrE6kL0v1/KCQkJGr1qvLy8NO4uqeqXkpKisw+oj9Giek2fPp1cXV3JxsZGtHxPT0+NXjUfP37U2+vC09NT427jy5cvNdIqFAqqWLEi1alTh2rXrq3x0h7C4eHDh9ShQwcqXrw4rVy5UtKo52JdqfXV9f3799S3b19q0qQJEaX23tm4caNoWhcXF52XWC+zunXrkq2tLdWtW5fq1q1LdnZ2VK9ePdFf+do9HRcvXmxw+ATV6+3bt/T333/rHcLCy8tLozdcVFSU6HpRHzMorfGD5PTWksrDw0OjZ+vDhw91ziEqqmPe19eXXr9+TSkpKXp73skZE0d1TKn2kdjYWKpZs2a600q9dqiGdFC/CyY29IPKTz/9RE2aNKHChQvT4MGDydnZWe9YVnKuX/p888HN1KlTyc/Pj1atWkWrVq0iPz8/mj59umha1QVafWOKXYDSSte/f3+9t6b1jdwpp3z1NFJ2Zi8vL3r06JFwYVm3bh0NHTpUbz30KVWqlM5JfNOmTeTu7k7FihXT+7nTp09ToUKFhNF0ixQpQufOnRNNK3V77dmzhwoWLEhdunShLl26kKOjI/39998aaeR2XZdavjFBk5T6EhH98ssvNGfOHHrx4oXeR5PaJ8h///2XXFxc6J9//klzUDZ1YifVsWPH0oABA+jcuXNp3rYnSvvErn0ynDNnjvB/Q+NaKJVKWr58OTk7O1P79u31DqEgth31bVuxQEJ92dixY6lUqVLUrl07vQO2qVhbW1OJEiVo6tSpNG/ePJ2XmKCgII1Rnjdt2kQNGjQQTdu2bVuaNGmSEFB8/vxZ70VQqtWrVxt8qVMPlNzc3KhRo0Z08eJF0XzVH3VaWlpSmTJlRPdtIqKVK1dSiRIlaNy4cTRu3DgqWbKkMCWIsZRKJV25ckU4Tl69eiU6grhKSkoKPXv2jB4/fiy8tIkdL/qOrY4dO9Lr169p7ty5VLJkSfL29qa2bduKppUzJo7q2PL29haaDugbR0tOWqnXDj8/PyIiatiwIW3fvp0uX75scGiG8uXLU0pKinB+ioqK0rt/y7l+6fPNP5YaMWIEHB0dhYnc+vXrh06dOommVXW/zZcvHy5fvgxnZ2ehwaicdPPmzdNbH0ON3KSWD6TetgVSH298+vQJuXLl0pvWwsICxYsXFx6DdOrUSae7HwD8/fffGDRoEB48eICUlBShm6bqEVL16tWxd+9ejZmn27ZtC4VCoXedqhof37p1C2fOnAEAVKtWTWhcrE3K9iIiVKpUCSdPnsSBAwcApN5CLVmypEY6uV3XpZav/kitb9++Gn8Te9Qktb4AhMc3gwcP1uhCrl6mUqnEhw8fhMbJnp6e+Ouvv9C4cWOdBsSbN2/Gpk2b8PDhQ43HZTExMRqPMFRUvZfUZ2o21GOuVKlSePPmDTp16gQ/Pz/Y29trdOnUnt164MCBwv/1PaLduXMnwsLCUKxYMezcuVPjMZe2KlWqoHPnzsKjnRUrVqBKlSqiad3d3TFq1Cjh8cry5cs1HstMmDAB48ePx8GDB7Fy5Ur069cP7du3R+/evXW6X7dv3x4KhULo1aZO36O1uXPnonnz5hg+fDiA1C7c+mbE/u+//7Bp0yZs27YNQOrxTgYe/W7btg137tzByJEj8fz5c7x58waenp4aadQbdqbl4cOHktPKefQZGhoKV1dX7N27F0Dq47eaNWsKf//999/Rvn17vV3UtRtUA6mPhfLmzYv3798L+5u+x6qrV69G//79YWVlJXSKUCgUQuNn1fHTuHFjjB8/Hj169AARYdWqVXon7ly/fj2A1EdOvr6+ePfuHRo2bKiRRrsrvGofTEpKQu7cuTF9+nSdfPPmzYt3797hu+++Q1BQEPLnz4+iRYuK1kFOWqnXjgEDBuDdu3eYPHky2rVrh/fv3ws9bMXY2trCwsJC6A3l6OiI58+fp6sOBskKhcxMcnIy1atXT3L62bNn0+vXr2n//v2UM2dOsrGxoRkzZhidTi45+QYFBdHbt29p1KhRVL16dWrevLnoEPFE0iNwqUOjy6VvZFNtUreXUqmU3BBSDqnljxo1SrSx482bN4XHCOpMXd/58+eLNkK8efMm1a9fX2NZREQErVq1iooVK6bxK3379u0mb6x+4sQJ2r17NyUlJQnLWrduTatWrdJJu2bNGp2BFFWPK6tUqSJ54sOPHz/S8OHDycfHh3x8fGjEiBF699mXL19S27ZtKV++fJQvXz5q166dwclW9+zZQwUKFNB7p9cYycnJdOPGDbpx44bBAUVVx6zqTuDnz5/1PsIaM2YMNWzYUHgU9Pz5c72PFzdv3kxhYWGS5sGS0/g6MjKSNmzYQBs2bEhzrqDExETRaS6ISGiILKdBtarRff78+SlnzpxkYWEh2gifKHWUakMN/8Ua4Ks3xDckJiaG3rx5I7zUPXr0yOBLjGr/UCqVtG7dOlqwYIHeY1ZOWjnXDjnq1KlDnz59or59+1KbNm2of//+eh+zm6IO33xX8GrVquHkyZM6XZfTkpSUhPj4+DTH+RBLlz9/fnTs2BHdu3fXadRnqvJTUlKQLVs2EBE2bNiA9+/fIyQkRLRr7++//46GDRviwYMHGhG4+oBUQGq314sXLxqsV0pKCo4dO6YxvkpAQIDBMVNatWqFqVOnws3NLa2vLXl7NWzYEOvXr0f+/Pn1prl79y7c3d31jp0gtm2M3V/SIqW+GenVq1dCd3UiwsePHzX2rU+fPiFHjhx6u46L7VdS3L9/HzVq1ECdOnWERpTnzp3D4cOHceLECY07JxYWFnB1dUXTpk1F179Yw0RTe/XqFdasWYM1a9bA2dkZXbt2RXBwsM6YJNqNjxUKBQoWLIgKFSoIv0rFSLnDAgBhYWHImTMn1q9fjwULFmDOnDmoXLmyxgCJKhUrVsTly5fh6+uLK1euAEjdt7X3+/79++Phw4e4dOkS2rdvjy1btqB+/fqiDbW1G19v375do/G1up07dwoNyxUKBU6dOoUVK1aI3ulQNfq1tLREZGQkLly4gHnz5gl3P1Rev36tc6yILROzfft2XL16VbRBs5+fH86dO5dmHnJs3rwZP/30E969e6dxt1XV0DmrkXPt+Pvvv3H37l2NO9L6Bpd88eIFcufODaVSiVmzZuH9+/cYMGCATjd/uXXQ55sPbgYMGIC7d++iU6dOGrfhxXo+AKmPLLQ3pljvF0PpXF1d0aRJE2zYsAElS5ZE9+7d0aFDB0kbTmr5GWH8+PHw8vJCcHCw6N9PnDiBDh06wMnJSRh069GjR3j+/Dk2bNigt3V+3bp1cf78eVSrVk1jG4i1jJe6vVq1aoWzZ8/iu+++00infgFs0qQJ9uzZk+bgbXLLNyZoSqu+AQEBOHbsmHD7WoVERnDds2cPGjZsCEtL6U+du3fvjlmzZiF79uyoXLky7t69i5kzZ+LHH38EkDpi6OXLl4XbyqSnx5yKnPpGRUVh0aJFwrgf3t7e6Nu3r86jnvHjx+t9pANoDkon5/HFsWPHEBAQoLc3lGrbtmjRAv/99x86deqELl26oEiRInrrIjaG1OvXr/Hu3Tvs2LFDdPyisWPH4sKFC7h//z7+++8/REVF4fvvv8fp06d10iYnJ2PGjBnCiMLBwcEYMWKE6I+IqlWr4uzZs/D29haCG09PT50eOJ6enrh69Sq8vb1x9epVREdHo0uXLti/f79OnhUqVMChQ4eEgPjVq1eoV6+e6D5fqVIl/PHHH8KPl3v37qFNmzai47xUrVoVGzZsQKtWrYS6litXDjdu3NDJU/vzYsv00fdDLTw8HHZ2djqjVOs7N8fGxmqci8UG8StRogT++OMP0W2u7fjx4xg6dCju3buH5ORk4XgR+1GhnVa9TulJK1XHjh1x8+ZNeHt7C/udQqHAsmXLjM7TlL75Njeqg1F9OHCFQiEa3AwZMgQbNmxA2bJlNTamdnCRVro8efJgwYIFmDlzJrZt24aVK1di2LBhaNGiBXr06KE3CJBaPiB/Z5YSgc+bN8/g0Oh9+/bFn3/+qXMQX7hwAd26dRPtzgikPuuX+rxf6vby9PQU/cWrTtWdVk77ASnly+1WKqW+mzZtAiBtSPfmzZsjX7586NSpE7p37y46cq+2S5cuIXfu3Ni1axe8vb1x4sQJ1KhRQwhuVBcNqe0n5NS3cOHCot1itYndldBH1dZFdYFUpx0grV+/HgEBAaLtzNS37c6dO+Hg4IDp06drjIQrFrCpRmTWduzYMQwdOlR0YLydO3cKd1iA1PWib1gKS0tLhIWFISwsTPTv6ooXL44TJ04IbR1++eUXeHl56aST0yYC0ByY0tAglSkpKRp3Zd3c3PTuRykpKTptzdTviiUmJiI+Ph4pKSn48OGDEGTHxMQII4xrUz/npaSk4Ny5c3rPg1LatAH/uxvz9u1bYX/SdzfG0dFRUmADpHbZnjJlCqpUqWLwbndGppV67bh06RJu3LiRZn4qN2/exPjx43XyFQuITRGMffPBjb6TkJidO3fiwYMHaQ55LjWdjY0NOnTogA4dOuDRo0dYsWIFOnfurHcocqn5AvJ2Zn0RuLa0LlTx8fGiB3HlypVFx6pQUQU2CQkJGnNciZG6vbSHlhfj6uqKoKAg9OjRAw0bNjR4V0BO+cYETWnVV3UXY926dTpjtEyePFljWYUKFfDbb79hxYoVqFGjBjw8PNC9e3e0b99etJEwAOEiceLECTRp0gT29vai+82PP/6IRYsWpbmscOHCSElJQffu3TWGV9cmZ5oCIHWY/kWLFgm/5MuXL48ff/xRZ4Rm1SOHGTNmiD6+UKcKVNPatnK2pz4BAQF6T9B2dnY661zfjXWx9ZY7d274+/trjB4MAPPnz0eXLl1w7do15MiRA3Xq1NF5zAOkTqXx+fNn1KhRA506dYKjo6Pec01aja/VFSxYEL/99psw9ciqVav0BkO2trb4+PGjcCxeu3ZN4zFeeHg4JkyYAIVCoTHelL29PYYMGSKap/r4XNmyZYO7u7veO3pSg/ewsDDs3btXUtDSq1cv/PLLL2jVqpXG3SCxUcXt7e3RqlUrSXXIqLRSrx0uLi5ISEiQdD0CgHbt2iEkJAT9+vUzaTCml8w2QWYnKSmJZs6cKYzpce/ePWFMEG21a9eWNF5FWun0dQcmIoOzAkstn8hwN1ptHh4eBhsvStWwYUOaMGGCzizQ48eP19vljyi1q3K5cuXIycmJiIguXryot/uj1O0VGRlJjRs3FrrHXrlyhWbPnq2R5sWLFzRz5kwqV64cFS1alEaNGkX37983+B2llJ8jRw5q2bIl7d27V/Isz1LqSyStC6r6e9XswrVr16ZcuXLpbXTZoEED+uGHH6h48eL07t07SkxMFG2gKrXLuIq/v7/BfXbo0KE6ryFDhpCrq6tOA82bN29Snjx5qF27djRnzhyaPXs2tW/fnvLmzUu3bt0SzV9Ol12xMYi0l127do22bdumt8FrWpKTk3Ua0KvGN2rTpg0dP36cvL29KTExkcaPH0+dOnUSzaddu3bk6OhIPXr0oJ49e1LhwoWpRYsW5O7urrer+adPnwx2AIiOjqb4+Hj6/PkzTZ48mYYMGUKRkZGiadUbX+fPn99g4+t79+6Rn58fWVlZkbW1NVWtWlXv+tu/fz/5+/tTwYIFqWPHjlSoUCHR4/uHH37Q+z1Url+/nmYaY8kZ72nJkiVkZ2dHefLkMTiqOBFReHg4rV27lhISEtLMN6PSSr12XL9+nfz9/SksLIwmTJggvPQxdN0ztg6GfPPBTe/evalHjx5Cn/93797pHeDp/Pnz1LJlS1q6dCmtWbNGeMlNd+3aNaPqKrV8Ink7c1BQkMZAZ9ratWtHRKk7p/oQ+tpD6b98+ZK6detGOXPmJFtbW7K1taWcOXNSaGiowV4nAQEBdOLECWHnVyqVokPBE0nfXo0aNaJ169YJF5KkpCS945sQEZ05c4Z69epFuXPnpjp16tCGDRuMLt+YoCmt+u7bt48GDhxIBQsW1OjJ0q1bN4PBjbq7d+/SyJEjRf/26tUrmjNnDp05c4aIUgclU+/FtGnTJgoODqbcuXNrDN9et25dg9OV9O/fnxo1akQbNmwQplXYuXOn3vSGpino0KEDLVmyROczy5Yto/bt22ssS0hIoJiYGKpQoQLFxsYK4wFFRkZSqVKlRMvWXm+JiYkaY4EsXLiQHBwcqEqVKuTg4EDbt2/X+z3EhvA/fPgwdezYkX766SfRcqOjoykoKIgsLS3JysqKGjRoIEzhoS0oKIiio6OF99HR0VS/fn168+aNzrEjJWj7Ej58+KAxAKY+Dx48oEWLFtHChQv1BkGRkZHCue3kyZO0YMECio2N1UijWq9pTadDRFSrVi0iIsqdOzflyZNHeKnea1u1ahVNmTKF7ty5Y3A8HCKiYsWKSQ6Gd+zYIfToMjQNSkamlXrtaNq0KQUEBNCgQYM0fpzoM2jQIDp27JjBPOXWwZBvPrhR/epUjyr1dU3u1q0bubm5UYsWLahVq1bUqlUrat26tdHp1KU1KJjcfOXszGlF4KrBuY4ePSr6EiPW3VEfVXCgvg30RflSt5ecPNU9ePCAKleurHddydlfiKQHTWnV9+jRozR+/HhydHTUGJF19uzZ9PDhQ4280jtnjBhju4xrj+QrNpovUeqdqvr161O5cuVox44donnpGwFWqVTq/G38+PGi3XYdHBxo4sSJGmmnTp1KuXPnJktLS40Lm62tLfXq1UtIV65cOeEC9u+//xq8aIqNCFylShUaM2aMxtxJRLr7ZVp3WFR10bdM+05aWkGbimrbqL9atGhB06dP15m7S84IyXLujk+aNEnSMm9vb4qLi6OnT59S0aJFqV27dtSqVSuNNGXKlKFNmzaRq6urRmAtFmA/f/6ciPR3ydYm525MtWrVRJeLcXV1pUOHDkkabiOj0kq9duj7kaDPqVOnKGfOnFS4cGFydXXVO1K2nDoY8s0HN9rjRSQnJ+v9hV+iRAmNMTr0kZpOnaHpCYzJV87OLDUCX7FihaRlcvn5+VFiYqKwDiIjI/XePZO6vfz8/EipVArp3r59q/fxSXJyMu3cuZOaN29ODg4O1KlTJzpy5Ei6yteWVtAktb4RERFplmWMFy9eUJ8+ffROcKmiPj2BUqnU+bUsl5xpCgwFkfr+JuXxxfv37+nhw4fUsGFDjQua9sSd2kGIlGNWCldXV9q1a5foBVjfXa4GDRrQ+PHjKTIykiIjI2nChAlUv359Sk5OFuopNWhTGTJkCNWvX5/Wr19PGzZsoKCgIGFMkp49e2qklTNCspy741IfI6qWLV26VAh+tPeBnTt3UqNGjShnzpySAmwi6cGVnLsxo0ePpsGDB0sa1Vt1fpEio9JKvXbImbyUKDUYWrFiBV29epWuX78uvNJTB0O++eCmZ8+ewuOAu3fvUo8ePahfv36iaQMDAykxMTHNPKWmUyflroKcfOXszFIjcLGTjPrw+ffu3aPatWuTq6srDRo0SOMXqvp8QtrWrVtH3333nfAIp3jx4hrD0KuTur1mzpxJPXv2pBIlStDy5cvJx8eHFixYoJHmxo0bNGTIECpUqBD5+vrSokWLNGb8Tk/5RPKCJin1JUodkO3du3ekVCrpu+++o3z58qU507U6fcGR1JmLu3XrRu/evaOEhASqUKEC2dnZ0cKFC/WW165dO415w7TJmaZA+xGT+kvqQJDpUbp0afr333+Fi5P2e0Pu379Pc+bMod27d+v8LWfOnKLzVRm6CEdFRVHr1q0pb968lC9fPmrdujU9e/aM4uLihLnMpAZtKv7+/hpt7xITE8nPz4+SkpJ07vSozgVS7mBKudsp57ErUeoM5vHx8dSqVSs6efKkwfL79+8vulyM1OBKzt0YqXN7ERFNmTKFFixYYHB6lYxOK/Xa0aZNGypZsiT16dNH0qCPhuadMrYOhnzzvaVmz56NIUOGIDo6GtWrV0dwcDCmTp0qmrZEiRKoXbs2mjdvrtHqXXvIb6np1InNJmts+UDq2By//vor2rRpk+Z4DR4eHsI0BGLOnz+PM2fO4NWrVxq9DGJiYjR6Qf34449o1aoVqlatinnz5qFevXrYt28fcuXKpTGzq7ZOnTqhRIkS2LlzJxITE7F+/XrUqFFDNK3U7TVkyBD8/vvviImJwT///IPBgwcLMwKr1KxZE506dcL+/ftRsWJFvfWTW/7NmzexcuVKrF+/Hs7OzujWrRvWrFmj0bvDmPoCqT3mJk6ciAMHDsDS0hKnTp1Cu3bt8P3330uqf9OmTYUBFtVJnbk4rS7j2urUqYMff/wRFhYW6Nu3Lzp27KixP8qZpuDatWvInTu3zhg79P/ddcXcvXsX/fv3x9WrVzX2QfVu2yovX77EuHHjdNKqusHHxcXpDDmgeq/dxT8wMBAzZ86El5cXnj9/Dl9fX/j5+WHJkiW4ceMGRowYIaR1c3PD4cOHResvJiUlBXPmzMEff/wh+nfVkAIODg5wcHDAzp07he7UDx48wKlTp9CoUSOdXihv3rzRWI8KhQLv3r2DpaWlxjYDoDNoYVxcnN6eXdqfTUlJ0emVZGtri9y5c8PCwkLjOHF2dtbpMQek7jeOjo4oVaoUqlWrhqioKL29dgxNd6Oyf/9+7Nu3D8+ePdMYAiMmJkY0fd26dTFkyBC0bdtW4/uJjWElp5edqtdj//79DXZFz8i0Uq8dZcuWRdmyZSV/t8aNG2P37t16p6kwpg6GfPOD+MkRGhqqs0yhUGDlypWy0r179w558uQRLUM1AFx6ygegMYJrWjtz27ZtcenSJTRo0EBjR1INILdz507s2LEDu3bt0ji529vbo3PnzkJ3SPVBwgDgl19+wY4dO3DgwAHUqVNH8gBbX4qUrucA0LlzZ6xbt05yvqoxZrp16yY5aJJKtY5Hjx6N0qVLo1OnTjqDl+nr5kpEmDBhguiFvUqVKjh//jwqV66Mffv2IU+ePPDw8MDdu3c10lWsWBFXr17FsGHD4Ofnh1atWulsdzEnT57EokWLcOTIEXTu3Bl9+/YVBnqU4tSpU6hevbrk9Cq1a9dGnz59MHHiRGzatAkLFiyAi4sLRo4cqZO2adOmqFGjBlasWIFZs2Zh6dKl8Pb2ljQGj7YyZcrg1q1bAICZM2fi1KlT+PPPP/Hu3TsEBARojO0hZf1pU20vKSpXrozDhw8jMTERFSpUgIuLCzw9PXXmsfvxxx9x//59Ya60jRs3wsXFBTNmzEBgYCDOnj0rpJUzQnKvXr1Qq1YtzJgxA9u2bcO0adNga2uLBQsW6KS9evWq5GPm/fv3sLe3h4WFBT5+/IiYmBg4OTnppJMS4B47dgxHjx7FkiVL8MMPPwjL7e3t0aJFC5255qQM/Cl3VG+lUonz58+jatWqhr94BpNz7ZAjT548BsdJM3UdvtngRt9opCr6Rig2BfWLUb169XDo0CHRv30pYsOQA7pjr/z9999o1KiR3nxKly6t8wt85syZ2LRpE2JiYnQulGmNrKw+QrHU7aVv6G8VY4bor1SpUpoDyKnvL3KCJkODnwG69a1RowaaNm2K5cuX49SpUyhYsCA8PT1x/fp1IY2VlRU6duwoejdj69at+PDhg87yTp06CcPcL1iwAPb29ihVqpQwGJ9KUFAQSpQogb///hsRERHIkSMHfHx89I7GrPLq1SssWbIEy5YtEy7m/fr107iDYYj6caE9ro++ZeqfU43IS0Tw8/MTDQy8vLwQEREhpE1MTERAQIAwoav2RUqhUOid/kS9vi1btkSjRo2EyTu1j/Fx48bpPQb1GT9+PKysrBAaGqoxdpHYL1vV91q7di1u376NX375RXSE4uTkZCxbtkw4H9WtWxe9e/cWHelazgjJHz9+xJAhQ7Bjxw4AQHBwMGbPno0cOXKI5rtt2zbcv39fY/C2sWPH6qTdsmWLMNFsgwYN9I7jIifAlRJcpaSk4M8//0xz3Bi5o3oD//vx8DXQN0aV2LYCoHf8Njk/cuT4ZoMbCwsLVKhQAXnz5tW5napQKERvE6tmRNYWEhIiK536LzXtX22GfsVJLT8jPX/+HNevX9f4BaQ+PH3v3r11ZrydPXs2hg4dqnMrOlu2bPD19UWHDh1EZwFXH7VY6vaysLBA5cqV0bBhQ9H5h6QM7qetUqVKiIiIkL2/SM1XTn3v3buHX3/9FbVq1ULLli1x7949bN26FT///LOQpkKFCtiyZQs8PDx08nN2dsaTJ08M1uvUqVPCzMXaF7bXr19j/fr1qFq1KqpWrYpHjx7h6NGj6Nq1q2heZ8+exYIFC4Q0P/74I5ycnPDp0yeUKVNG9BGZGPXjQs7Q+6q5gqpVq4aNGzfC0dERZcuWFR0lOq27V2IXKTs7OwQGBmLZsmUoVKiQsNzX1xc7duxA7ty5Ubx4cZw5cwalSpUCIP4jQEXqXD1yftmqpi/o1q0bOnTogMDAQCHgyWpatWqF6OhoncHb1EeEBlIvrDt27EBISAgUCgXWrVuH4ODgdAe4T548QZ8+ffD06VNEREQgIiICR44cwaBBg0TzNDU58+yp9kdtYvuAnLRSDRs2TPh/fHw89u7dC39/f9EBIjPDN9vmZsyYMdi0aRMKFSqEbt26oX79+ml+Zvfu3cL/4+PjcfLkSVStWlUnuEgrnfZzbXWGRsmVWj4gb2eWGoGvWrVKeKzh7u6Oq1evomrVqkJwo/0rX2Xw4MFo27atzvJ79+5h5cqVWLhwISpXroxu3bqhXr16onlI3V6HDh3CypUrsXHjRrRp0wbdunXTGc7dGMbsL1LIra+bmxtmzJghBAVubm4agQ2QOv2Dvkn5Jk+erPH+xo0beP78ucb3qV69Og4cOIC7d++iTJkyGunz58+Ptm3b4s6dOwAAJycn0bZBKr169cKAAQOwYsUKjUeeOXLkEIa6l0KhUMhuFwEAtWrVwps3b9CvXz/4+PjA2tpab/u2UqVK4c2bN+jUqRP8/Pxgb28PHx8f4e9io9e+fv0aixcvRv/+/bF582Zh+ciRI+Ht7Q1LS0vUqVNHCGxOnz6t84hDRepI4frqok+dOnVQtmxZpKSkYOnSpUI7mvSQc4cFSJ0MVTut2Hnr2rVruH37dpqjhW/duhVnz54V2tn06NED/v7+osGNlZUVgNQRmB89egRHR0edUapVevfujQ4dOgjBVPny5dG5c2fR4ObkyZN62wYa6+3bt/Dy8pI0z576Hdi4uDisXbtWb7AiJ63Ua4d2wDl+/Hi9P3KA1Ed5YvmK/dAwSTCW7ibJXzGlUkn//PMPtWvXjkqVKkXjxo0TxjuQ4sGDBzqDh0lJp97rQ7sHiJxeH4bKV+8+9+rVK5o1axZNnz5dNK169+9+/fpRiRIlqGPHjjrpypcvT2/fvhV6PRw7dkzviLdyKJVK2rdvH7Vu3Zo8PDxo//79etNJ3V4xMTG0ZMkS8vPzo9q1a9PZs2eNrp+qt0R69xd9+cqp75EjR6hw4cLk7OxMRKkDO4ptK6maNWtGly9f1ll+5coVat68uc7yLVu2ULFixah48eJElNr7qlGjRkaXL5W3t7essX7EREZGSh5A88SJE7R7927JQy+I9XaMioqiiIgIjVGqnz17pjHYm/r4MaYaKVybUqmkK1euCL1jXr16JbrN5fj++++pevXqkgZw++GHH8jV1VXS+Fz16tXTGVNHjNjwC/qGZBg6dCi9fv2aNmzYQHnz5iVHR0caMGCAaFqp42OVK1eOsmXLRu7u7nqHTtAeEDCtgQGJSGMMKfWXVFWqVEl3WjnXDm36Bl8lIo3u3xcvXqQBAwbojDllijqofNPBjbo9e/ZQgQIFZK9AqcGIejqxwcWMHahITjAkdcd//fq1MDiXOlVXPvWTiKnG+jh//jz16tWLihcvTn/++Wea6aVsr6ioKPrll1/I0dFR1glCm9hQ4MbuL+q0152U+vr5+dG9e/c0TrjaJ5SEhASNC+pff/1FY8aMEe0ybmiYc7GLRaVKlej169cGyycija6hYi+51MuTMtaP+qixYi9TM/Y4UP9cWiOFq1OdK7Rf+mzdupWmTJlCRERPnz4VuosT/W/6BzlKlSoleWoRNzc3nYEL9enduzdVrVqVpk2bpndIAKLUIQk6depEx44do2PHjlFISAh169YtzfzTCnCljjclZUBTfQMC6hsYUJu+Lvv63Lp1i0qUKGHytETi1w717TN79mxq164d1a1bV3KeRPKmsZATuBF9413BX716hTVr1mDNmjVwdnbGr7/+iuDgYL3p1Ru1qmaXFWs4mlY6ObeUjSlfzO3bt/XeitWWL18+0VuFqhbupUqVwty5c1G8eHG9sxZL8fr1a6xbtw5r1qyBo6MjunXrhvnz5+v9TlK2V0pKCnbt2oUVK1bg8ePH6Ny5My5fvixMPGlIQkKCRtd2VePMCxcuSC5fjmzZssmub1qzJgOp7UwOHjyIfPnyYcGCBVi6dCm+++47TJs2DdevX9dox2No+6k/QlCvc758+QyWDwBz58412JZIrn79+gn/X7BgAaZNmybU4/Xr1xg1ahSWLl0qpPHx8RFua79580Z4NJGUlIR8+fLh5cuXQlp9t8BVDN0KT0lJwfLly+Hs7GzU9yK19juzZs1CYGAgateurfEIT+xRj5zHDGPHjsWFCxdw//59jBw5EhYWFujduzdOnz4NILW3pNz2I87OzkhMTJR0/ilcuLDk81RCQgJKly4t9DQDxB/NzZ8/HxMnThQeTwYGBop2GQdSGzCrGjM7OzvD2dlZY5m61q1bo3fv3oiNjcVvv/2GJUuWoEePHjrpAgIChP/fuHED5cqV00mjaigrpwG8unr16hncLnny5BHWTUpKCohItAea3LTa9F071NuGWlpawsvLC7169ZKUJ5B6XEZHR6erDoZ8s8FNixYt8N9//wnjnBQpUiTNz8yZM0f4v6WlJdzc3DSes0tNFxAQgGPHjsmus9TyAXk7s3rX4ZSUFJw/fx6Ojo466SZPnozY2FhMnz4dP/zwA96/f68zG3RKSgoWLlxocEwfFScnJ1SsWBE9e/YULg779+8X/q7eA0nq9nJyckKxYsUQGhoqdB1+9eoVXr16BUB8HIqzZ88iNDQU//33n853kVu+GENBk6Ojo6z6pjVrsqreqgv/unXrcOzYMeTLlw9xcXGoUqWKRnCTM2dO3LlzR6fx8Z07d0R7s+TKlQsvXrwQyj906BDy5s2rk86Ytk9//PEHIiIiNBqrq3qLde/eXVh26dIljQArf/78QgCqolp/I0aMgJubm/D5lStX4v79+xppP3z4ACLC3LlzERcXhz59+gAAlixZorFu1Y8plY8fP8Lf31/WUAHq1PMLCwuDtbU14uPjkZSUZPBz6tsmR44cGDx4MPz8/DQaears3LkTly9fFoZsKFy4sEZQS0b0KXFzc0Pt2rXRokWLNMfcUg0ZoD0mjFiP1FWrVkkqP0eOHJg2bZqktGKN1rX3ARWp402pU/0g0Wf79u06gYzYMm1pbRf1BuGWlpZwdHTUO4O2nLRSrx1St5WKt7e3Rr6PHz/G8OHD01UHQ77p3lKqwaLUTzBkoO+9qRgzroVc6t3u0tqZ1cfPUQVNvXr10hmLJyUlRdL08z4+Prh06VKa6WrXrq33F7N2DySp28vFxUX4u1j3S7E7Un5+fpg/fz5++OEHHD9+HPPnz4etrS2GDBkiu3x1UoImqfVt3749fv/9d+zfvx8TJkzA/fv3Ub9+fRw8eBAbN25E3bp1hc+VLVsW58+fR86cOVGjRg2cOHFCKEPVc0Zl8+bNGDduHObNmyeMr3HmzBkMHjwYY8eO1Wl8e+HCBfTu3RsPHjxA+fLl8fDhQ/z111/w8vLS+f5Aavfp33//HatWrYKdnR2mTp0KPz8/nXT9+/fHw4cPcenSJbRv3x5btmxB/fr1sWLFCp202t2YiUinO7yKWK8gfcef2H6rvky7K6tCoUCBAgV0gks51HvdeHh4CA215bp9+zYaN24setGuWrUqzp49q/G91ddhiRIlMG/ePL0XU7EgRM6YW3Xq1BFNK9bDMCYmBqNGjcLjx4+xe/du3Lx5E1evXkX79u010n3+/Blr1qzR6Vmm/kNt6dKlWLJkCf777z+N4D0mJgblypXTGV4iJSUFQUFBOHjwoE69DNG3P6kawG/cuBEdO3bUKP/KlStp3i1r3bo1tmzZIqsuppDWtcPYYVTUf9BbWlqiRIkSeu9Qy7l+6fPN3rmRM2qkSr169TBmzBjUrl1bWNarVy8sW7ZMVjqlUin8WhSjbxRGqeUDwPHjx9GyZUuNX3h79uxBkyZNdNJKjcCLFi2KTp06ITQ01ODIlPXr18eGDRs0DmgxR48elVTuw4cPJW+vR48eSUqnPhZNUlIS/Pz8kJycjFy5cmHUqFGoXLmyRnBjzP4yYMAArF69WidoMqa+qtv0QUFBKFWqFPbt2ycMyqd9R6Rfv35o1KgRxo0bh8aNG+OHH35A+/bt8ffff6Ny5coaadu2bYvPnz+jV69eePr0KYDU7Txu3DjRXkWVK1fGkSNHcPr0aRARqlWrJtqNX8Xe3h7NmzfH27dvMX/+fNy+fVs0uDly5AiuXr0Kb29vzJo1C8OGDdMYCkBd1apV0a9fPwwbNgxEhJkzZ+od+CwxMVHjztR///2ncRdN3YcPH/Dy5UsULFgQQOqIxeqPf6SOx6E9dpUh6ueAtEYKV6f+y1Z1cdf3y7Z48eJCgJuUlIRffvlFIxh99eoV5syZI3o+UigU6brDAqRuW6l69+6N8uXLC+cGV1dXdOjQQSe4admyJaysrFC5cmW9F72GDRvCw8MDffr00bjrbW9vL3oHN1u2bPj8+TOUSqWsR6m1/o+99w6LIunaxu9RVNxVzIprQFEUFSQoEgyggGFxFRMmVFBRccUcMa+Ys+66sqKiYg4rrmvYFeOqGAAxoJjFHAkqKOn8/uDX/XTPdM9Ujez7fd/rc1/XXMrMmaqa7uruU6fOue9WrRTf52VdloKIVBmoBZw+fRrjx4/H3bt3kZubKy60lEgDeWwNzXPpsdSG2nwB5Ft5hlAo3DdcGTpfIfz9/cX/f/fdd1SvXj2ZsrNSIqEhO2MTiln7JyIyNTUlR0dHevHihUFbS0tLioqKkr3n4+OjY/fgwQOaOXOmqHC8du1aRX2SsmXLkkajoRIlShisDmABT7Km9Hyxtikkqrm7u1NcXBy9evVKrAbihbR/oQ9pYq6+BF59KFmyJJf9/v37qUWLFlS+fHkyMzMjGxsbmj9/vt5KlFevXsmEMaUQ9HsEZWcplN7Lzc2lffv2kY+PD9nY2NDChQv1VpYJx8XOzk7UT1OrfklPT6fAwECqVKkSVa5cmQYPHqwq4BkdHU0VKlSgNm3aUJs2bahixYp04MABRdu1a9eSubk5DRw4kAYOHEjfffcd/fbbb6pjVgOLTpwAqbAnj1aPNDH1yZMnequsXrx4Qe3atSMTExMqVqwYtW3bll6/fm3UeKV4+vQpHT161KDIJ1GBTlVycrJB4UhWzaoGDRoYNWZDGDlyJHXo0IG2bt3K9LseP35MT5480dsmj9jto0ePqG3btlS8eHEqUaIEtW/fXjUBvl69erR792569OgRPXnyRHx9qe2pU6fIycmJypUrR6VLl6ZSpUpR6dKlmX+DGm7cuEF+fn7k4OBAtra24uvfGsNXG7lhhTSEX6VKFRw6dAg+Pj5ISUnB5MmTFVc7huzs7OyM2pZi7R8oIAobO3YsWrZsiQMHDsDa2lrVNj8/HytWrMCjR49E1s6nT5/q2NWqVQuzZs3CrFmzRKrysWPH4uPHjzK7wiYHUxu3EqTni7XNXr164e3btwgNDYW7uztycnJ0+GCM6V9IYq1QoQLi4+NRo0YNMReEF1lZWYq5LaSyLda5c2d07tyZqw99bMkhISGIj4+XUfALEBJTpeDNfSpdujQyMzPRokUL+Pv7w9zcXFUryMzMTHH7Q8Du3bvRo0cPAAUh8qSkJFy4cAEA4OrqiooVKyp+b+jQoWjevLkYaRg7dqxioqghaG+16iO+/PXXX8X3eLR6hJVtbm4url+/jpIlSyrOD6DgvnHkyBFkZmaCiBRzqXixYcMG/PTTT6qcV1IcPHgQQUFBSE1NxbfffovU1FRYWFgoRkNZNausra3x5s0b1XMpxcOHD7Fw4UIdnh2lbTGBaXvdunXie0rRiMTERPTq1QsvXryARqOBubk5tm/frshubGdnh4sXL+rkkynlJ/Xv3x8+Pj7YtWsXiAgRERHo37+/YpTbzMzMIEuyMbZBQUGYO3euDpGiEqQs0e3atdOrcderVy/0798fP/74o8F2ecagCuP9sK8D0hW+8P+MjAxq3749DR06VHFVYcjuS8tGDfUvtY2JiaHatWvTyZMnVft1cHCgDx8+UIcOHWjo0KGUl5endzV3+fJlGj58OFWqVEkxwkNE9PHjRzp79iydPXuWubxVDTzHi9VWzS47O1s1CsDb7rJly+jNmzd09OhRKlWqFJUoUYIWL15sVLumpqZcZaXv3r2j9evX08yZM2nmzJm0fv16evv2rdG/y8LCgnx9fals2bLUpUsX8dWmTRtq3ry5or1UAdmQIvKLFy/o06dPlJmZSXPmzKFx48ZRSkqKUWMtLHoCYyHtf/369WRhYUGlS5cmR0dHKlq0qOLxys3NZYo6Tpw4USzjzsrKIkdHRypbtiyVKlVKUXGciGjQoEG0Y8cOevnypeLnM2bMUHz/xYsXqoraPJxX9vb29PDhQ9F2y5Ytqpw4kydPprCwMLK2tqa///6bvv/+e5o5c6aOXVJSEtWtW5d69+5NgYGB4ksJTk5ONHnyZIqOjqaDBw+Kry9B06ZNadeuXeLfu3fvVo3Kzp07lxwcHKhChQrUtWtXKl26NPn6+iraKtEqNGrUSNF2/vz5tHnzZvr8+bPB8fLYskaXZ8+eTQ4ODrR8+XJasWIFNWnShObMmaNqzxMhNDbCLcV/nRsDkN6opAc8NzeXBg4cqLiNZMju+++/N2osrP0TySfStWvXqG7dulS2bFlFW+E35ubm0uDBg8nHx4esra117JYsWUI2NjbUoEEDWrRokeo2w9mzZ8nc3Jzs7e3J3t6eqlatSufOnWP+nWrjK0xbbbukpCSKjo6mvXv3ii9j8G85TTzbUnv27KHKlSuTn58fTZw4kSZOnEh+fn5UpUoVRa4bFtSvX582btxINWvWlJGL7du3T3FrkhUshG28kM79w4cPU/369alYsWIGt37j4uKoXbt2ZGVlRbVr1xZfvJDOAR4ngIXHo0GDBpSXl0dERBs2bKCmTZvS58+f6cqVK+Tk5KT4nc2bN1O/fv2oWrVqZGtrS2PGjKE///xT/Pzly5f0448/UseOHSkqKoo+f/5MkyZNotKlS6tyx/BwXinZCu9pIycnh+bNm0fNmjUjJycnmjt3ruKWW/Pmzalfv360cuVK+vnnn8WXEtS2PtSwfft2GjRoEA0ePJh27typaKO0ZarWT6NGjSgrK0vky7l16xZ17dpV0bZTp06UnJws/p2cnKzqCO3fv59KlSolchzpm9s8tqyOkK2trWzh+uHDB73HesyYMXTq1Cm9bfKOQR/+69wYgKGHJSshmJLdiRMnaMmSJbRkyRI6fvy4UeNT6//QoUOyv588eUKzZ89WtO3UqZPs79mzZ5NGo9GxCwoKYnJSnJ2dxRwNogJnx9nZ2eD31MDj8bM6N9I2x44dS1WqVKHWrVuTl5cXeXl5kbe3N/c4lfovLKeJx7mpX7++ImPv/fv3qX79+kb1L/wutZwcYyG0e+PGDerRowfTfjxrm0REVlZWdOTIEUpPT5exnirBxsaG1q5dS4mJiTI2VV5IryceJ2DSpEkUFBREZ8+eVc1Nkc7b/v3705IlSwy2KyA/P582b95MtWrVkj3YOnfuTH5+fvTrr7+Sj48PNW/enJo0aUIJCQmqbbm6ulJ+fj517dqVli9fTvv27SMrKytFW+Hab9++Pe3bt4/i4+ONchql0MeEq43evXsz36fHjRtHTZs2pRUrVtCKFSuoWbNmNGHCBB27/v3704kTJ8S/T548SQEBAYptCqzHtra2IvGhNjGgr6+vGAk1NTUVc8RKlixJnp6eiu3Wrl2bYmJimOY2jy2rI8TDEk1U8BwoVaoUVa1aVYzmqs0DHmdMDf/NuTGAokWL4tSpU3B3d1ctgatZsyYAMNu9f/8eHTt2xP3790XtmhUrVqB27dr4888/dZSGWduVQlu9u1q1aqq6L9HR0bK/Z8yYoWirVJWlhKysLDHPAgDc3Nxke828MKQeLgXr/qy0uiY6Ohr3799XzfHggbT/cePGYevWrWjYsKFMK4jn9whQqxxSQl5enqJ+Ue3atRWJ+VhA/3/egyEVc2PbFfbjR4wYYfweuwLMzMzQrl07JtuiRYti6NChTLY5OTl48OCBbF4LeUTS64mH+FLgrBJyGABd+oLc3FxkZ2ejePHi+Oeff0ROHgCq11hERASOHTsmikdOmDBBpiV2+/ZtJCUlASgo8a5UqRJSUlL0VsGxcF4JGDVqFFJTUxEWFoZevXohLS0NK1asULRl1ayys7PD06dPUa1aNdUxCnj9+jXs7Ozg6uoqq1ZU0ms6cOAAEhMTxfL+IUOGwM7ODosWLQLwH66WnJwcbNmyBbVr1wZQUE1pY2Oj2H/JkiWRk5MDe3t7jB8/HtWrV9chXJSSgUo1t/SJIleuXFlGAaEPPLZjxoxBdHQ0mjZtqvdabNasGfr16yeq3a9fvx7NmjVTtQ8MDMTKlSsNtsszBn34r3Pz/0Mf0VpQUBDc3d0VS+CkyWZRUVFMdpMmTYKdnR2OHTsmJp1mZ2dj3LhxmDBhAtauXSv7Lmu7wH8IArUJx0gh8XT79u3o3bu3jBtCCu2Et/j4eISGhuL+/fuyG482d0ypUqVw7NgxeHl5ASggdDOUxKgv4U6pbNIQmzDAnshZo0YNnRJtQ2Dpn9dpYh2vIQgipMOGDRMTTx89eoS1a9eKRG68kDIEFyaEOVq0aFGMHz++UNokSQJqx44dsX//fiYm6ebNm+Py5csGj5F2gmxaWhpq1qypmCDL4wSw0A306NEDrVu3Rvny5WFqaiqW1d+/f19WbizF8OHD0axZMyxbtgyenp46vDzSuV+iRAnUrVtXr2MDFBAnlilTBmXKlBGdMSEZVxve3t4oV64cmjRpIiqsq7HNCkm6hhJJX79+DRsbGyaHxd/fH/7+/np/j4CyZcvK2JSLFSsm4/tSc8r04ddff0V2djaWLl2K0NBQnD17Vof0kWfxIqBTp074+eef4efnJzsGSlQCPLasjhAPSzRQ8FwYOHCgwXZ5xqAPXy2JnwAWorXCRt26dXH79m0dLoXc3FxYW1vj7t27Rrf9/PlzVK1aVYdwTICUP2DmzJmYPXu2IiEXoMtlYWtrixEjRsDV1VV249GuKLl8+TK6desm2uTn52Pfvn1wdHRU7GfevHnYs2cPUlJS4O7ujr///huenp74/fffdWxZz5daNcc///yj0+alS5ewYMECtGvXTnbhK62aeOZL69atERMTw8SZwTNeQ8jKysKSJUuwc+dOkZ3VwsIC3bt3x4QJE2TOllRdWwkCQ/C/BYHEbuzYsfD19VXlDOHB4cOHxchluXLlkJ6ejpIlS4pRFDXSRVtbWyQnJ6Nu3bqyeaBNtubg4CA6TAkJCYiKikJiYqKOSrIx2Lt3L5KTkxEaGopnz57h7du3sLW11bF58uQJevXqhSpVqgAoYG1++/Yt2rZtq9Pm+/fvceLECRw7dgxnzpxB2bJl4eXlJaqyV65cWfbwj4qKkv2tNAek5IP63uO1rV+/PpMq+KZNmxTf1+ckSLmt1DBy5EjcvHlTvPajoqLQoEED8UGrxuFSmNDH1C2F9L4iEIBqNBrFexGP7bx582BmZmbQEWIldRUwY8YMODk54YcffjBoyzoGffjqnRsWdlq1FYkAIRzNategQQOZdooUSp+xtvtvQ4ntVYq///4b3t7eyMjIQMmSJUW21fr164sRKiXY2Njg8uXLcHFxwZUrV8Sb+969e3VsWc4XUPCgOn36NNq0aYOEhAScPn0akZGRiiXEgwYNwunTp2FrayvbPlIi0WLtH+BzmljH++7dO9WSX16cPXvWIBurINWQnp6OsLAwJCcno0mTJpg8eTKzXpA+COyu586dQ7t27VC6dGmYmpqKN18lRumsrCysXr1a5wGgtGpncfIFqEmiaJOPCazFUpZfNVZuFiZdAVINqNu3b+P58+fo1q2bYqn9p0+fUKJECdEJyM/PR3Z2tmoEMicnB//884/IaJ2RkYG3b98CAGbPnq34HQFSuY5Xr17hxYsX6Nmzp1iuDBTMj8GDB8sYlrOzs/Hp0ye0bNkS//zzj8zWy8tLkY3Zy8sLf/75Z6HMLQHXrl1D7969kZaWhidPniAuLg47d+4Ut5qkUGJTFiBlVWaZg8YsHHiYuv8tsDpCVatWRb9+/RAYGIgGDRoYbJdnocHjjKnhq9+WYmGn1ccXIr0Bs9qVLl0aV69e1XFKEhMTFbdvWNsF5PodSpCulnhptA2F7SdPngxvb294eHggPj5edQ9aG6ampjA1NUV+fj6ICPXr11fVfmE5X0ABX0a5cuXEB0qrVq0wevRoxTZPnjyJ5ORkmJgYvhxY+wcKtImuXr0KIpI5TUrOjaHxnjx5En5+fnjz5g0sLCxw4MABnRU9LwTuGhYMGzYM2dnZ6NChA/bv348pU6YUSlRHyH3i2Y8PCgqCmZkZzp07h3HjxiEyMlI14sPDdMrKoCo46tWrV8fvv/+OWrVqITU1VdGWhUlXgCENKCnatGmDw4cPi1tR79+/h4+Pj2Kkr127doiLi4O9vT28vLywa9cu2TUsdV70Yffu3Xj27BlWrFiBZ8+eye4PZcqU0dEJmj9/PmbPng2NRiPbMjMzM1O8XgA+zSrWCEdISAjWrl2LkJAQAAVRo/79+ys6N6xsyixzUG2bUB94mLr/LbAKO58/fx6RkZHw8fFBpUqVMHDgQPTu3Vs1usLDf2asuLQUX71zw0K0xkq9z2o3Y8YM+Pj4YNq0aTI9n7CwMMXcCh7qf549YV4a7dOnT2PdunWqYfucnBwsXLgQr169UlyZqolpsiTcCWAlxuNJ5LS0tGQmCuQh5uNxmgyNd8KECQgPD0f79u2xbds2hIaG4o8//mAasxq0f7O+vKerV6/i+vXr0Gg0CAgIQIsWLZj7Yckl4tmPT0xMxLVr19C4cWOEhIQgICAAPj4+ira1a9dWdPaVIkKtW7dWtNUme+NJkE1JSRGTdQ2hZMmSOg6Q2rzMzMyUPTzLlCmjOr/Hjx+Pli1bcueVaWP+/PmIj4/HqFGjMGfOHIMSAjNnzsTMmTMRHBzMnDPGqgquFuFQwocPH2TzVaPR6JAF3rlzB1ZWVqpRcqWFqKE5yOo0SmFqaiqq1Ofk5MDc3BzPnj2T2fDkVfLY8oKV1FVAoUgqcOCrd2542WkvXrwohvLbtm2rGsXQZ9exY0eYmJhg7ty5YuiySZMmWLdunU6VE2//2qtP4cJQUrHm0XwBgJ9//lnv5+vWrcOmTZuQlZWlw8CsL5rEknAngPV88SRyWlpawsPDA507dza4WuSZLzxOk6Hx5uTkoEuXLgAKttEMnQsWSM+JWt6TcAykWyA8QpGsTLY+Pj74448/mPbjhf5NTEzw8eNHlC5dWtXBPHjwoPj/T58+YcuWLTJFcSmkCc2fPn3Ctm3bUK9ePR07QedImiCrBh4mXUMaUFLk5+fjw4cPKFWqFIACgVK1Sjhvb2/k5+fj2bNnMhulKkt9kM7lAQMGKKptK7XJkwzPqlnFE+EwMTFBTk6OOH8fP36s40SOGTMGBw8eVIySK22P8szBx48fIzg4GE+ePMGVK1dw5coVnDhxAmPGjNGxZWHq3rFjBwC2SAiPrbGOUFxcHHbv3o3jx48rbusJor9quwrS6HFhOmNffc6NFDk5Ofj06ZNOKbaA3377DWFhYejatSs0Gg327duH6dOnY/DgwUbZ8YKn3Zs3b6J79+6ic1O9enXs3r0b1tbWim2z0mjn5OQgJSVFR6xRioULF2LSpEm8P48bhs4XK3gUjnn6Hzp0KK5fv87kNBmCdgKmWkKmsW0aynsyJukUYM8l4tmPb9++PbZv346lS5fi5MmTqFixIj5+/CgrodYHNzc3xTwWbeTm5qJNmzY4ffq0zmeHDx/WyaNRyrG4efMmOnXqBCcnJ9kcUJpbL1++xIABAxATEwONRoPWrVtj69atio7RwoUL8fvvv2PYsGEACrZAu3XrhgkTJujYRkZGYuTIkShWrJiYy6DRaPDq1SuDx0AK6XypVKmSmAvx6dMnZGZmokKFCoptCpEIbShFZ1lVwZ2cnHDp0iXY29vj0qVLKFasmI5avICoqChs374dV69exYABAxAVFYVFixbBz89PZkdEeP78ueJCUBs8c/D7779Hnz59sHjxYiQmJiI3NxcODg6KY3358iXKli2L/Px8LF26FGlpaRg1ahRq1KhhcExfCp5iFABYunQpIiMjkZeXh8DAQPj7+yuqfMfFxaFJkyZMOW28Y9CH/zo3KLgBad+olLhIGjdujJiYGJHr4/Xr1/D09NQJZRqyU7pZSqGWP8DaP1AQYg8KCkKfPn0AFHjw4eHhitGan376Cfv370f//v2h0WiwZcsW+Pr6Ytq0aTK7kydPok+fPjAxMUFKSgouXbqElStXIioqSu/vMYTnz59jxYoVOudALSeI5XzxJHLygnW+8DhNhsZrYmIi28sW1KO/JLwsJPMCQNOmTXH58mU0btwYiYmJ0Gg0sgRynqRTKZSSb5UcM56bmVClQUTYunUr0tLS0L9/f6ZKirdv38LJyUlxW0obnz9/RqNGjXSqF/v27YukpCQ4ODjIcqmUeKBatGgBS0tLnVyiH3/8UbVfVg2oTZs24c8//wRQsM2nVu5cp04dHDp0SFRGNxb6HOp9+/YhMTFRcZ5ItymysrKwefNm5OXlKTpivXr1go2NDXbs2IHr168jKysLrq6uOpGHNm3a4ODBg5g4cSJev34Nc3NzxMbGihpi2jh37hyio6NBROjUqZPitioRwdbWFtevX9d3GADwzUHh2pJeb9L/84Inr5LHlhdDhgxBYGAgXF1djW7j38RXvy3FS7QmJTHTR2imz04pmU6j0eDZs2d4/vy53oxw1v5TU1NFxwYouGksWLBA0XbPnj2IjY0Vw5+DBw+Gq6urjnMzefJknDlzRhRgc3JyMvoClaJr165o0qQJfH19DSZdsp4vnkTO3NxcLF++XBa5GjVqlGKuDM98YQ2xs4xXLcGaBWolsFLuGkN5T8bkDwDsuU8WFhbIzMwUH2L29vaq/EDS426Iv0R6c8/Ly8OjR490El8FdOnSRWZ79epVfP/99zp2cXFxuHHjBlMZbGpqKjZv3mzQ7v3794iKihKFV21tbdGnTx+9UckBAwYwJZtWrFjxix0bQL+AbdeuXTFv3jxF50bqpH377bcYO3YsnJ2dFZ2b27dvY8eOHWLEsGTJkor9bt++HSYmJli8eDGWLVuG1NRU7NmzR3V8bm5uqFmzJjQajSrxn0ajQfXq1Zm2EXnmoImJiew3pKamqh7LpKQkzJo1C3fv3pUtcqQLWJ68Sh5bXkeIldRVel0pQVphVpjO2Ffv3PAQrVlZWWHq1Kkii+m6detgZWXFbSclegMKynvDwsIQFRWld4XM2j9QcPElJSWJKsNJSUmqN2Mikv3+b7/9VvHiy8vL09mO0k7MMwYfP35kziFhPV88iZxjx47FvXv3MHz4cGg0GkRERODRo0eKUR6e+cLjNBkar75wrFoC39WrV9GnTx/VEthBgwaJtobynubPn48pU6YAkKtuAwUO39KlSxXHwJr7dO7cOXTr1g3m5uYACsLze/fuVVwVnj59GuPHj9d5AGRkZOjYSm/uJiYmsLS0VAydA3KWWBMTE4SGhookeVLUqlULnz9/ZpoDLEy6T58+hZubG6pVq4ZmzZqBiLBp0ybMmzcP586dk3136dKlGDduHMaMGaP4EJBuDwrHw9fXFytWrECfPn30coY8efIE1atXVx3nvHnzdNoGCu4LFy5cUDz+Srh165YqiR+LKnheXh7Gjx8vzk+Br0cNgoL3y5cvAUCvgnepUqVgb2+P77//XsxnAnS3XXnmYI8ePTB06FBkZGQgIiICa9eulV17UrAwdbNW9fHasjpCPDk0AJgINHnHwAQusYb/hfDw8BCF6Azh1atX1LNnT6pQoQJVrFiRevXqpai0y2qXlZVF8+bNoypVqtCYMWPozZs3hdI/EdGRI0eoQoUK1Lp1a2rdujVVrFiRjh49qmgbGBhI/v7+dOrUKTp16hT1799fUTCvRYsW9P79e1HD5urVq+Tq6qp3zCwICAig27dvM9mynq8uXbrQ69evmdq0tbWVtZmTk6Oqa8QzX0JCQuj777+n33//nfbv308dO3akkJAQo8br4uIi/l9bPVpNU8jd3Z3OnDkj6hHl5+cb1ORRE7KU9qHdX2GocPPokdWrV492795Njx49oidPnogvfXj69Ck9ffqUaSz5+fmiBpASrl+/Tq6urjRlyhSaPXu2+FKCl5cXlS1bljp06CBTU5diyJAhisrcs2bNoqCgINl7a9euFT9Tekkh6PFoNBrxpU+nx9LSkurXr0/Dhw+nvXv3UmpqquoxkLZlYmJCDRo0oMOHDyvali1blsqVK0flypUjMzMzKl26NEVGRirasqqCs4iMCuBR8GY5rkT8c3Dbtm3k5+dHPXr0oK1bt6rasejojR07loj+o0el/TLWlhWXL18mogI9LaXX/y346iM3ixYtQo8ePQwSreXl5WHJkiVi9rkaWOzy8/MRERGBOXPmoE2bNrhw4YLBRCnW/oX2y5Yti5s3b4p70C4uLqqh1tWrV2POnDkGabSnT5+Otm3b4unTp/D39xcJwaTYv38/5s2bJ0YhbGxsMHnyZL3e+9ixY+Hm5gYrKyvZOdAuwQXYz9fcuXPh6urKlMhJRMjPzxeTLalAUFZxrKz9AwU5SleuXBHb9fHxUWVpNjReaRm1sHUhHb8SWEpgBRiK8kj70O5PrX+APfeJR4/MzMxM3Bo1BJ7E+ufPn2PQoEFiXpqnpyfWrVunE+mZMmUKihcvjk+fPiEnJ0dv/yzU/2fOnFHMmwsNDdUpQRaitizbhLxcIffu3cP9+/dx7Ngx7NixA8HBwbCwsMDFixe/qG1pvoyJiQnMzc1VoxJz5szB4sWLYWZmhtDQUPj6+ioWJ7Ru3RpDhgxBQECALMKiRGj66dMnWaSxe/fu+OmnnxT7N3RcV65ciVGjRnHNQaAg2iEkRb98+RKjRo3CypUrdexat26N06dP62Xq9vDwAMAWEeGxFSKwattIwvaRoIfIGhUSoo1qpIbSqBjrGFjw1Ts3rERrRYsWZSqdZrGzsbHB58+fMW/ePNjZ2SE9PV12c1O6QFn7BwqqE4YMGYLExER07NhRr21eXh6GDRumWnotRdu2bWFlZYUjR46AiDB79mzZNtWhQ4cQHByMWbNmwdnZGUSEixcvYvjw4ShRooRqmbu/vz+Cg4OZCNxYz1dQUBBcXV2Z2mzfvj3atm2LgIAAAMDmzZtVx8pDzMfjNPGMV7sNtT1qlhJYASNHjtRLdCbtQ7s/fXvkrLlPPHpk3bp1w5YtW9CzZ0+D26LDhw/H1KlTZYn1wcHBitfSkCFD0KJFC9FhX7t2LYYMGaLDJ5ScnKzIrqsEISdGOGdKx8rExERxq7JYsWKqHElKD+eyZcuKDrIUw4cP19kKVHoPKGAVFnTTzMzMdLa9b9y4gWfPnulwyhw7dgzVqlWTMdU+efIEL1680KGruHz5MqpWraq4VWdiYoIpU6aIW6BqYBEZFeDo6IiTJ0+KD/pTp06JD2hebNq0CaNGjWKag69fv8bs2bPx6NEj9OrVCz169MDMmTPxyy+/yJwtKbp3726QqVugS2CZWzy2PI4QADx8+BALFy7UETnVXpQKzicLqSHvGPTifzZQ9H8fLC0tKScnh8l25syZFBYWRk+fPqX09HTxxWtnYWFBtWrVUnypScDz9E9E1K1bN7pz5w7T7+IJ8epD27ZtFcOSp0+fJm9vb9XvNW7cmLkP1vNlaPtFiry8PFqzZg1169aNunXrRr/++qvq1hPPfBk/fjy1bt2aNm3aRJs2bSJPT0+aMGGCUeM1Zltoy5Yt9P3331P16tVp6tSpZGFhQTt37lS0bdKkCRHJw+LS/1eqVInGjBlDY8aMkf1/9OjRVLlyZdVxN2jQQO/vEnDp0iWqWbMm1a5dm2rXrk0WFhYUFxenaLt//34qVaoUFSlSRO82CxGRnZ0d03s8tj/88IPqdaeNZ8+eUYcOHcjU1JRMTU3Jx8eHnj17JrPRt62n9lmvXr3I3NycBg8eTEFBQVS1alXq0qULWVlZ0cqVKw22ofS7qlWrRi4uLrRs2TK6evWqYr+dOnWi+Ph4nfcTEhKoc+fOsvf69OlDx48f17E9ceIE9e3bV/bew4cPKSYmRvx75syZ4hy7efOm4lgMwd7enhwcHMjGxoY0Gg1ZWlqSpaUlaTQa1W1nljaJ2OZg586dyc/Pj3799Vfy8fGh5s2bU5MmTSghIUG1/Xr16tH69espMTGRrl+/Lr6U8OjRI2rbti2VKFGCSpQoQe3bt6dHjx59sa0AQ9uzTk5ONHnyZIqOjqaDBw+Kr8KEoTHow1cfueEhWhNWS9ItGyW9C0N2Dx8+NGqsrP0DBUnK9vb2cHNzk4VtlcJ6hkK8rBnsDx48UAxVtmzZUrXUFyiQdbhy5YoqYZkUrOeLJZFTQJEiRRAcHIzg4OBC6x8o4CIJDw8XS9q7d++OIUOGGDXeq1evippSGRkZ4v+JSJWZ1t/fH5aWloiOjkZ2djaioqJUmYUNRXmkpcvaZczDhw9XbBNgJ7Fr2rQp7t69y6RHNmbMGERHRzNFuXgT61+8eCEmNb948ULxXJcsWRKOjo5o27atbAtRieuHJRokPbfa41E7t6mpqbhy5YoonPny5Uv069cPsbGxaNmyJUaOHImdO3dix44dePDggayaLz09XXadC+jTpw9OnDiBXbt24e3bt3j79i2aN28uOw/Pnj2Dg4ODznft7e11KvqSk5MVSd08PDx0VOanT58uI3bcunUr/P398fHjR8yfP19HKFOJQLBs2bKyJOlCTU79/yFcHyxz8Pbt2+L2fGBgICpVqoSUlBS9ius8TN39+/eHj4+PqPEVERGB/v374+TJk19km5KSgqCgIJGXpnXr1ggPD9chaPz06RPmz5/PNFagYM5OmTIFx44dg0ajgbe3N+bOnStTXecdgz7817nhYKdl3Wc2ZNepUyesX79ebym3Me1KwVomChgO8bLeJJRumAL0cXacOXMGERERBtWYAfbz9fr1a9jY2MDV1VVmp+TcpaWlITw8XCe8qpSfwzNfeJwmQ+M1thTczc0Nbm5uBu1GjBgBX19fvH79GtOmTROJzgQYWwrOk/tUtGhRlC9fHrm5uXj+/DkAZcbbypUriyrNhjBv3jy0atVKdNSvXbuGrVu3KtqOHz8eDg4O4pbkkSNHFJW+GzZsKDpLhvD48WOZIzN58mQdJ96Yc/vkyRPRsQGAKlWq4NmzZyhfvrzojFhbW6Nz586Ij4+XMe+amZnB09NTp03hfL99+xbR0dEIDAzE69evZQ6WmrMFQIchOSsrS9VW22m8du2arGS+VKlS4pxr2bKlzvebNGmCd+/eib81JycHpUqVQvXq1bF161bY29vLFlos5KM8YJmD0vleokQJ1K1bV69jA/Axdb9+/VpWTj9+/HhERkZ+sS2rI2RjY4OUlBRmhyMgIADVq1cXy/wjIiIQEBCA6Ohoo8egD1+9c5OdnY169eoZ1DIRkJKSgtOnT0Oj0aBVq1aqzJH67Fq0aAFHR0esWLFClQn4S/tn2WMVYEi7ijVx7M6dO/jjjz8UV7vp6emq3+OREmA9XyyJnAK6d++OSpUqwdXV1WAkgGe+8DhNhsbLw8zJwysh7V9flCc1NRVPnz4VxVDXr18vlqB37dpVtYSYNZeIh0W3U6dO+Pnnn+Hn56e3tBkoKL9nTazv168fHB0dxXyccePGoVGjRjp2PI4eSzSI9dz269dPzI2rVq0aZs+eLa7yN27ciO+++w55eXniubezs4ONjQ3OnDnDtNCJjY3FsWPHcOzYMVy7dg0uLi5iDpSAUqVKITk5WYc3Jzk5WWcBU6RIEZFxVopnz57JVJ8B3YXb6tWrxf+/f/9eZ6yDBg2CtbU1BgwYACJCVFQUrl+/jubNm2PEiBEyAdHCJB8Vzh3LHHzy5IksiVb7b6VI3+rVq5mZuuvWrYvbt2+LEiG3b99WpQbhsWV1hF6/fg07OzumBaTQp9SRWb16taqaOI8zpoov2Q/72rB161YqX748+fr6kq+vL1WsWJG2b99ulN2NGzfIycmJ+vbtS/Hx8ZSYmCi+vrR/Iv491vPnz9OcOXMoLCyMYmNjGY+IHKVKlSIPDw/VlyHwlOuygmXPlic/hweenp7Uq1cvWrlyJf3888/iSx/Uxnvy5EkKDw8X//b29iYHBwdycHCgI0eOyGwjIyP1vpSglmMhIDg4WCxDJiKqXbs2BQQEkJ+fH/3444+q32M9tpaWlnTr1i0mW2lps7TEWQppCfX+/fv1tictNb548aLB/jMyMmj48OFkZWVFVlZWNGLECMrIyFC03bx5M5mbm1NgYCAFBgZS1apVKSoqymAfSpDmzjx//px69OhB5cuXp/Lly1OPHj3o6dOnlJWVpXMunZycmNp3c3OjGTNm0OnTp1Xzynbs2EH169enI0eOUFpaGqWlpdHhw4epQYMGOvein3/+mdzc3GTn9ebNm9SiRQtatWqVzLZu3bqKNARZWVlUp04dnfeVSqaF42NjYyN739nZme7evSv7jrHX/JUrV4iImMrr1crK1crLiQpyj5ReSmjTpg2ZmppSmzZtqE2bNlSyZEny9PRULPPmse3UqRMlJyeLfycnJ5Ovr69O/zz3F2EMr169Ev9+9eoVeXp6KtqyjkEfvnrnJicnhxYtWkTe3t7k7e1NS5YsUb2w69evT/fv3xf/fvDgAdWvX99ou6SkJCpbtizVrFmTKaGYtV2iAo6TRYsWUVpaGqWmptLixYvJ3d1d0Xbx4sVUs2ZNGj16NI0ePZosLCxo6dKlquNQg7F8J0lJSdSwYUMqW7YslS1blmxsbFSTCFnPF0sip4AffvhBL6eHMf0T8d1ADY23Xbt2Ir+E0PbJkyfp4MGD1KFDB8U2lXhH1LhILC0tqWnTpvTLL78oHgs7OzvZ75Q+KJo3b676u3r37m2Qg4ao8JLaBehLwP4SW6ICnqEhQ4ZQQkICXblyhYKDg3W4h6S4du0arV69mlavXq2aHMoCY68vnkIEInWuIwEbNmygmjVrism0NWvWpPXr1yvazpgxg0qWLCle2998840ip8/o0aNp2LBhlJubK76Xm5tLP/74I40cOVLHvkGDBjJurNu3b4vJ69rJ0gKnjVqyvBQvX76kYcOGkaurq7h4KAwep38DPIsYHlseR4gH3bp1oypVqtDAgQNp4MCBZG5uTj169BATxwt7DF/9thQPO+0333yD2rVri3/XqlVLkaWUxW758uVYvnw51q5di549ezKNlbV/gC+s99tvvyE+Pl5US54+fTpcXFxUeQmMQc2aNRWTAAG+cl3W88Va1gsUHFdHR0e0b9/eYIIoz3ypU6cO0tLSDO6zs4z3zZs3svLV4sWLi9uFCxcuVGwzNDQU7du3N/geUJD3cfLkSURGRmLGjBnw9vbGwIEDxZJfjUYjK0uWlurqy61gzX1iZdEV8PjxY5w5cwZAwbapvsRxMpAALv3ckC1QkACcmJgo/r1mzRpFtlsBNjY24nZeYYGH/Zq1EOHatWvo3bu3KteRgMDAQDEfB1CWgTl79iyaN2+O2bNnY9KkSSI3U8OGDXW2rx48eICwsDB8//33qFOnjpiwnJCQgBo1auDw4cM67c+fPx+urq7icb969SoiIiLw4cMHnfupqakpPnz4IG7XXbt2TVXZftCgQWjRogViYmKwdOlShIeHKyZQFzZ4WX8BMOdU8tr2799fRm2hRHNhDGxtbWFrayv+LYi+/ltj+OqFMxs3biwjWsvNzYWjo6OMd0ag1F68eDGKFi2KwYMHg4iwceNG5OXliZIJrHatWrWCmZkZIiIixL14fWBtV4rOnTtj8eLFsj3WSZMm4ffff9exFYTdDL1nCPqE9WrUqIHHjx8rfiYVaNT3HsB2vnjbVJO8UMqtYO0fKKBSv3jxIpPTZGi8DRs2lMkzfPr0SWxT+7Pbt2/j1q1bGDNmDJYvXy6+n56ejrlz5+LWrVuKv1fAx48fMX78ePz222/iA7BOnTq4e/euzo03Pz8fdevWVRWi1K5yEaB9s5XmYAhq02qVgNHR0eJDSKPR4OzZs1i/fr0sCbNBgwZiMmLPnj3F/wuQcknZ2dnhn3/+ARGhZcuW4v8FaDtYNjY2OH/+vKj79OHDB7i4uCgKLsbHxyM0NBT379+X5V2xCHdqQ3p9jRw5Evfu3UNQUJDoZNeuXfuLhGE9PDwQFhaGkJAQJCQkgIhgY2OjQxrJO1Ye25iYGPH/Dg4OOjk/QMGcu3TpEiwtLREbGwugIJdKrUDjr7/+wqxZs3Dv3j14e3uL5KNKCcHCNScIvWZnZ8Pd3R3nz58HUOBInzp1CuXKlZNdC6QnN4YFPMrZPKR4PLb/2/DVR26IgWitbNmy4g0XkBNoaTQa8eHIate/f38MHjyYeYys7QL/SSb98OED7OzsxEqZ8+fP61TNCA/kNm3aICAgQNQ7iYyMVLypGIK+hFF9Ca685bosxHjEWNYL8CeIshLzNWjQQDVhjne8JiYmsuRMwbF59uyZzmr9/PnziIyMxKtXr2TOjZmZmaoGFAC8evUKW7ZswcaNG0FEsoiQh4cH5s2bp6Pjs3DhQr0J56yJ7TyVgLNnz0ZsbCzq1q0LALh79y78/Pxkzk1WVpastFj6f21StGvXrqFs2bLiGMuUKaPXwRowYABcXFzECMGuXbsUFeAF2xEjRjAlqxuC9Ps87NcAW6SLh9HaEHjWzFJbT09PxUou6ecxMTEiSSlLVZEh8lEphN9ramqKt2/foly5cjIdLIEhXmmR9CXgYf3lIcXjsS1sR+jBgweoXbs2tm/fjt69e6s63tJK08Icw1fv3LCw0xZWCbgAKW+EEL4VIJxcY9oF5MyOhsJ60vJQALJVg0ajUVQRFyoqNBoNPD094eLiIn4WExOjKp6n72bHU67LyibMWtYr4OLFi7hy5YqM8l+pvJuHzZjHaTI03iFDhqBHjx7YuHGjWOVw584dDB48GEFBQbK2BBqA9evXqwr0aeOHH37AhQsX0K1bN2zYsAHNmjWTfT5//ny0atUKf/75pygmefHiRbx58wanT59WbZdV0oAHeXl5omMDFFSCaF8jrFxSnz9/5pYpmDBhAmxsbBATEwMAWLJkieJWH1DgkAiSCawQGIIFCJEjqeAuj5OtHekaPXq0TqQL4GO0NgR9i5kvsRUiI1ZWVrh7965sHqghLCwM06ZNk1EyCO9po169enj79i38/f3h7OwMMzMz2XawMG95qhdZwFPhyCrBIUhFsNryOEIs6NatG+Lj48VIcUJCgo6N9m8uzDF89dtS+fn5CA8PF29UXl5eGDJkiE6pohQZGRmyELMSAZc+O2kYVjt8yxLOZe2/sLFkyRKsXr1aJAT7/fffMXLkSNHLLlKkiCzCBBjeYhDw6tUrUcNGX7kuz/m6fv26yIvQunVrxbJeoMC52rNnD1JSUuDu7o6///4bnp6eilt4vPOF1WliGe+0adOwdOlSmJqaQqPR4NOnTxg7dizCwsIU2/vjjz/g7u4OMzMzLFmyBLGxsZg1a5Zi/se2bdvQtWtX2faZNrKysrBt2zbZtkGfPn30qmP/8MMPcHV1FYn+1q5di7Nnz+rkPt25cwcjR45EYmKi7Fgphfm9vb3Rs2dPWRn0jh07ZDxNrODZPhGiBjz48ccfERgYqCNBoITY2FgEBgbi9u3bsveVrpsJEyYgLi5O5mQ7Ojrq5McABb9x165dOpEu7d8dFRWF7du34+rVqxgwYIDIdeTn58f6c2V9GrMtxWrbpk0bXLx4kYmkVKl9lj7Pnj2L1NRUtG/fXoyOshKaAkDt2rX12kqjh2rbtwJ4cmYE/FvnQOo06YODg4OiQ1MYYBnDV+/c8GDnzp0ICQnBu3fvxEmr0WiQnZ3NZSc96doTQN+EYO0fKFgxr1ixQkewUGDL1UZGRgYePnwos9UOc9erVw/nz58XE4/fvXsHFxcXnZvx/2uwsbHB5cuX4eLigitXriA5ORmhoaEi2ZSx4HGaWPHx40cxv0YtOVNIOm/cuLGY/DpgwAAEBwcjKipK3J4AoJMrpNFoULlyZRlBHA+kXCwAe+6Th4cHgoOD8dNPP2HHjh1YvXo1atWqhdDQUJ0+7t27h759+yI+Ph4ajQaOjo6IiooyiqCN5wYs2LJq6gAFSZTJyclMBJXOzs5YtWoVhg0bhtOnT2PVqlUwNTXVieQCfE62nZ2dLAEaUM8/O3fuHKKjo0FE6NSpkyqjtSHwPCx5zoHQLksu19GjR3HkyBFs27YNffv2Fd9PT09HQkKC3vGpLSDVcmIESLeVhFylHTt24OHDh2LEZd26dbCwsFDUBzty5IhOFFDpPRYYM7dZwHpu1ex4iP++ZAxf/bYUD9HalClTcOjQIYOrMEN2xooQsvYPFBCrNWnSBL6+vgZDy8uXL8eMGTNQqVIlmRikttNiZmYmOjZAwQWvVM2SlZWFpKQkaDQaNGzYUG80ACi4eEePHo379+8jLy9Pb6SH9XzxJHKamprC1NQU+fn5ICLUr19flTWWZ75s27ZNdJr27t0rOk1KYB3vt99+qyOMKIUQCgYgrjb/+usvDBkyBEOHDkV4eLjMXntrEiiozKpTpw52796tSvSlBiXFcpbcp4yMDPTs2RNhYWGwtbVFeHg4nJ2dFY9XnTp1EBsbK7Ll6mPGNgRjtk/8/Pzg6emJESNGGLy2eAgqc3Jy4OzsjNzcXJQuXRpTp06Fk5OTonPDw35duXJlREREyCJdasm3rIzWhqBPbkUbUmkIVrBEMkxNTVG2bFkUKVJEts1Ro0YNWeWYFMICMjU1VRZ1FhaQgvOyYcMGHZmEDRs2yJwbIfJ65MgR2ZZi8+bN0axZM0XnhqfC0RD+ra3BL42H+Pr6Mju+XzKGr9654WGnNTc3Z3IsDNm9evVKTK6S/h+AWF75Jf0DBSt81hvr6tWrkZycjO+++07xc57E4xkzZmDJkiViYl5OTg7GjRuneCELGDlyJFavXs10DljPF08iZ8mSJZGTkwN7e3uMHz8e1atXV91C45kvPE5TYSWeSi/6vLw8XLhwAXv37sXGjRsBFJwPKdTYqTdv3oxRo0bh0KFDRo8FYM99EvLQSpcujYcPH8Lc3FyWyKmN58+f48GDBzJHsFWrVl80VlbwaOqwsnsD/zkGFSpUQHx8PGrUqKFzPzBEz6CUcLl27Vr07dtXpC8QIl0Cxo0bh6VLl6rmfagxzuoDz8r8999/V3U2tCFlZN+1a5fOlq/097u7u8Pd3R2+vr56S/WlWxysC8iff/5Zx7n55ZdfFHWh0tPT8fHjRzHK+vHjRx3GdqHCMT09XRZdT09PR2Zmpt6x/E+D1RFSc0AKY7OIZQxfvXPz/PlzHDt2jMl2yJAhmDdvHrp37y6LRmhfyIbsvLy8xBCgt7e3LByor0qJtX+gIPv+zp07TCvvatWqqTo2AHvi8dKlS3HixAnExcWJVUJJSUkYNmyYYqK0ADMzM7Rr187gOAH288WTyPnrr78iOzsbS5cuRWhoKM6ePSvbWjGmf4DPaTIm8VQJ0os+LCwMQ4cOhZeXFxo0aIDk5GSRGsAQ+vfvXyjCg/369YODg4OYS6QmadCqVSu8ffsWI0aMQJMmTVC8eHH06tVLsc25c+di8eLFsLS0lEUahZwtHhhzo+XR1MnKysLq1at1HsJKDkOvXr3w9u1bhIaGwt3dHTk5OTr5VMYkWhqKdHl4eACQFyN8Kb4kEpCTk4MHDx7IjpdQbCDQ948cORIPHjxAXFwcevfujd27d4ucTNrQ59gABfkugnNjaAF58eJFnD9/Hq9fv5YtStPT02VJ4FL06dMHLi4uYu7S7t27daRWjK1w1AdjK9YKC9KInMBxRkTIycnB48ePxT6/dItKFUxUf/+LwcNOu3btWipZsiSVK1eOKlasSBUrVqRKlSpx26kx2hKRKtU2T/9EBXT6FStWJFdXV2rdurX4UsKhQ4coJCSEjh49SqdOnRJfvGjQoAG9fftW5/03b96QtbW16vdmzpxJv//+O1MfrOdr+PDhdOnSJaY2ecAzX65du0YfPnygV69e0eDBg6lbt26UkJCgaFtY4y1MNtXGjRv/H+k/JSWFrl27pvq5paUlvXnz5ov7ISIaNmwYs22nTp2IiMjLy4vKli1LHTp0EBlT1VhT+/btS8HBwWRhYUGrVq0iR0dHGj16tMG+srOzVSUdWPHo0SO9L20U1jEl4psHUts//viDzM3NqUSJElS+fHkqUqQI1apVS+c7NjY2lJeXJ87R58+fU9u2bY0aq5SteOPGjTR37lxKTk5WPFb79++ngIAAKl++PAUEBIivkSNH6r1+Dx48SGPHjqWxY8fSoUOHVO0iIiK4xv7hwwc6c+YM/fPPP/ThwwfZZ4JUhDG2+iA9XhcuXKDw8HBauXKl+FKCh4cHtW7dmjw8PKhUqVLi/9WeSTxjUMNXn1DMQ7RmYWGB48ePG0xcNGTXs2dPUYlbipSUFHh4eKgSfLH2DxSsVjp37qwjWOjj46NjO2PGDKxatYp5JaxWqtqoUSNVwi99n5UrV45ZLI71fLEkchoT4ueZLzzgSTzVB+3EQEPVWkql+2/fvkV4eDiePXsmU2pmgZOTkyy/wFAukRp1gAClnC43NzecO3eOeUzPnj3D9evXZcdAynsjhb6ogQBWYkIAIhmckNz9/v17+Pj4qJbP37x5U6cIQCkn5f3795g8ebKMoXjevHkisSBQwBysVL34+fNnfPjwQSeKWKFCBbRp0waBgYFo37693opRQzC2UsfBwQH79++Hr68vEhISEBUVhcTERJ2tTGGe2dvb49KlSyhWrJh4rL9krOHh4RgzZgxMTU1l90JtAdfDhw+rUkB8KVjmIFBAvdGnTx9Uq1YNRITnz59j+/btaN269RfZAgVbZwkJCdBoNLC3t5cVLiQmJsLOzs7oggnW5GWWMejDV78txUO0Vr16dSbHwpDd58+fERwcjF9//VV87/Hjx2jdujXGjBnzxf0L0JfnIsXmzZvx8OFDgzIBhkpV8/PzkZqainLlysk+f/v2rexmrQ0eQizW88WSb2RMiJ+lf2OcJp7EU32QPgjVbj5S50abIFKj0aBSpUpo166d3m0pFi4WwHAukXb/whhIT1K5t7c3Ro8erSPVoPQA2LBhA3766Se8e/cOVlZWSExMhIuLi6Jzc/DgQQQFBSE1NRXffvst0tLSULNmTZ28JJ6yXIHm38TEBB8/fkTp0qVV8+rGjRuHrVu3omHDhrIHq5JzM3z4cHzzzTfYtWsXNBoNwsPDMXz4cNl2qnY/OTk5+PXXXzF//nz06NFDp82UlBTs3r0bixYtwtChQ+Hv74/AwEDmrUwpeNbMUtsiRYrAwsJCvF/4+/vLtmkElC5dGpmZmWjRogX8/f1hbm6ul5KAFfPmzcO1a9cM3mc7dOjA7DTzVNdpz8HU1FRYWFgo5saNHj0aBw4ckPFODRo0SNHB47E15AgJTgVPwYQULFuWrGPQC6NiQl8ppk2bRmPHjqULFy7oVfE2ZPfp0ydq3bo1hYaGEhHR48ePqU6dOrRixYpC6Z+oQMVZbQtEG61atWKya9asGcXGxpK9vT1lZGRQWFgYLVmyRPx84cKF1LJlSx0V4FatWtHChQuZ+vjfAGPUgHnAGgpu1KgRZWVliUKCt27doq5duxrVpyCmeP78ebK2thZFE4WXGrRFDAsDgsis9KUmOGtjY0Pv3r0Tw9inTp2iwMBARVt7e3t6+PChaLtlyxYaP368ou3OnTtpypQpouiftvCfgHbt2tG7d+9o6tSp1Lx5c+rcuTN5eXkp2tapU4c+fvyo97cLUNoy1LeNuG3bNqpTpw516dKFkpKSDLZ///59CgoK0ntu9UGq/mwI0i0RZ2dnIiJq37497du3j+Lj4xXP7YsXL+jz58+UmZlJYWFhNG7cOEpJSTFqrNItDjc3N6bvbNiwgSwsLKh06dLk6OhIRYsWVRWQdXJyosmTJ1N0dDQdPHhQfKmNhXUOKp1vteuNx9bGxoZiY2PFvy9cuKCjtE5E1KRJEyIisrW1pfz8fL1tStG/f3+DNqxj0IevPnIDsBOtCRUG0mRAbSp3FrsSJUogOjpapBnfs2cPfvzxR4OkRKz9A8CZM2cQERHBtM3h5OQEPz8/nURl7VWIoVLViRMnIi0tDfb29jKiuVGjRmHixImqv+vVq1eYOXOmDoGbWlib5XzxJHI+fvwYwcHBePLkCa5cuYIrV67gxIkTqlE0Q/3zMBPzjpclGiOAp1rLEFxdXREfH49Ro0YhMjJSh4tFDc2bN8fly5eZqvzi4uKQlJSEfv36IS0tDVlZWYpMxmoVXkooXrw4ypUrJ66YW7VqhdGjRyvaskYNeJJZ//zzTxQtWhRz5szB1q1bkZaWpioCWKNGDYO0CQLy8vLw/v17mb6VUpTrr7/+wuTJk1G6dGls2bIFrq6uetvNycnBgQMHsGHDBly6dEm11NwQ6aK01NzQ9S1dhY8aNQqpqakICwtDr169kJaWphhBlPIwjRgxAo8fP5ZVUvFAKijcpk0bjBs3Dj179tQbFVy2bBkSEhLQpk0bxMXF4fTp06rCxDzVdaxzECiQlYiMjBQjiVu2bEHbtm2/2LZIkSJihAcAmjVrphh15SmYkMIQYSHPGPSCyxX6X4i5c+eSg4MDVahQgbp27UqlS5cmX1/ff7VPIeISExNDFStWpICAAIORGF6cPHlS8aUEDw8PnZdSolezZs2IiMjd3Z3i4uLo1atXZGFhoWP34cMHunjxIl28eFEncU0JHTt2pAULFpCVlRUdOHCAfHx8aNq0aYq2rOeLJ5GzQ4cOtGXLFnF1k5OTo7pK4JkvKSkp5OPjI65mEhISaNmyZYq2rOPlica0aNGCsrOzqV+/fjR27FhatmwZ9+pHgLCSFJI/pe00bdpU9Xs2NjZUrFgxatCgATk4OIgvbfzyyy/UuHFjsrS0JCKiu3fvkoeHh94xffr0idLT08WXElxdXSk/P5+6du1Ky5cvp3379pGVlZWiLWvUoDCTWaW4ePEide3alcLDw2nTpk3iSwmLFi2ihg0b0uzZs2n27NnUqFEjWRSViMjb25ssLS0pKipKdpzUjteIESOocuXK1L59e9q5cyd9/vxZdazu7u60Y8cOatiwIV29epWCgoJo7ty5irY81zcr2rVrR6mpqfT+/XuysLAgCwsLmj59uqLty5cvadiwYeTq6qp3DhKxRwUdHR2JSH4dqLXZu3dvxQRuJbDMwbJly1K5cuWobNmypNFoqHjx4lS8eHHSaDRUrlw5o20FjB8/njZu3Ej5+fmUn59PmzZtogkTJujY8RRMCHj06BFt2bKFoqKi9B4T1jHow1fv3PCG7vfs2SNexE+fPqWrV69y2yldQIbC67z9ExVUXNy9e1dvezxYtmwZvXnzho4ePUqlSpWiEiVK0OLFi8XPlW6ghh4+RP8JZQo3is+fP5OLi4uiLev5EtqytbUlIqKMjAxq2bKlYptCeFUanlbLxueZLzxOE+t4eULBxtx81CDcuFkdXAGsTradnR1lZmbKjnujRo0U2+TZGouJiaG0tDS6e/cueXl5UdOmTenvv/9WtN22bRu9e/eOLl++THXr1qWKFStSVFSUjp3gzNnZ2VF2djYRkc55tbe3lz1ItV9KGDhwINWtW5e6dOlC3bt3p+7du1OPHj0UbYmIDh8+TOPGjaNx48bR4cOHdT7XaDTiq0iRIjp/a2Pu3Ln0+PFj1f6k0HZy8/PzycnJSdGW5/omKqjeXLlyJS1dulR8aUOYJzt37qSRI0fS58+fVa+tf8O54nGaearrWObgw4cP9b6MtTXGEeLB1q1bqXz58uTr60u+vr5UsWJF2r59+782hq9+W4ondD9jxgxcunQJ9+7dQ2hoKDQaDYYOHapTuWHIjiesbkz/QIFqcJ8+fWBiYoKUlBRcunQJK1eulJF3CcjNzcXKlStx7949rFmzBvfu3cOjR4/Qpk0bmZ2wTdO2bVu8e/cOnz59klVnSJNDlZJE1UKWhpR4pWA9XzyJnCYmJrKxpqamqiZE8syXV69ewd/fX+SpMDEx0VHw5h0vSyg4Ly8Pnz9/FjWkvv32W6xbtw4fP34U+zEWLFwsUrCS2JUoUUJnbGrHimdrTJjDZcqUMag91bt3bwD/4YhSA0syqzEcQSdPnkRycrLq75ZCYMiVMtdqs+byCoKGhoYiLi4OJ06cQL9+/ZCamopPnz4pbg3ykC7yXN99+/ZFUlISHBwcZEnV2hDIKE+fPo327dujePHiqsft8ePHmDRpEqKiovDDDz+gXbt2cHd3x5w5cxTtL168KHJZtW3bVnFLNSwsDBkZGVi0aBGGDRuGtLQ0rFmzRrE9f39/HV4bNbDMQR7RTh5bXqVzXomfn376CZcvXxblYR4+fIj27dvL+KwKU239q3duePYNo6OjER8fL072qlWrisRYxtjxgqfdyZMn48yZM+jevTuAgrwatfK7ESNGIC8vD//88w+AgpLQnj174vLlyzq2+kpVpTdTHq0SQ0q8UrCer/LlyyM1NRXff/892rVrh4oVK6J69eqKbfbo0QNDhw5FRkYGIiIisHbtWgwePPiL+gf4nCbW8bIQDk6ZMgV169bFkCFDZO9v27YNd+/excKFCxXHoA/CuA05uNpgzSWqVKkSbt++LT7IIiMjVcm9eGQKMjMzsWnTJp05KyVgk+Lw4cM6ttrVb9u3b0fRokWxePFiLFu2DKmpqdizZ4/MRurU5eTkICUlxWAFjqWlJXOVEQ9DriEIgqBr1qxBeHg4Pnz4gH79+uHdu3cYPHiwqOguBQ/pIs/1HRcXhxs3bhjMr7CxsUGHDh1w8+ZNLFq0SC+LL49z9dtvvyEsLAxdu3aFRqNBt27dMH36dJ37AY/TzFJdp+YQCFCqwuLJVWSx5VU655H4AYBvvvlGdGwAoFatWjqLgsJUW//qnRsedtqSJUvqnESlmxGrHS942s3Ly9O5mQoXuTZiY2Nx5coVODg4ACiIwGjT9AN8pao8DKVCNGnUqFFo0qQJ0tLSVLVUWM8XTyLnuHHjsH37dqSnp+Ovv/7C2LFj0adPny/qH+BzmljHqx2NUUJMTIxiAmNgYCDs7e2Ncm5cXFzE/7NysQBAUFAQzMzMcO7cOYwbNw6RkZGKMgkrVqxA7969cevWLdSoUQNmZmY4ePCgYpssMgXScRUrVgxOTk4Gb8CsUQNpMuvUqVP1tskTQbW0tISHhwc6d+4si0RJk8WNYcg1BCEJ+LfffkNsbKyoLVWnTh3V4yrwzvTp0wctW7ZEenq6oto8IL++mzZtKiptK6FWrVr4/PmzwbLuyMhIHDlyBHZ2dvjmm2/w9OlT2Zz//PkzSpQoAYDPufr5558RFxcnJkSHhobC09NTvG7VnGIBSon9gGGpCLWkYaBgDio5N4MGDUKLFi0QExODpUuXIjw8XLyHf4ktq9PEKvEjcFn5+Phg1qxZGDx4MIgIGzduxA8//PBFY9CHr965YXlYCLCwsMCZM2eg0WiQk5ODefPmwd7e3mg7XvC0a2pqig8fPog352vXrqluSWiH9PPy8hRD2tHR0bh//z4Tn4SxzpwhFWLW8yV9OLGEhHv37i2GhAujf4DPaWIdL0soOD8/X/FBbmJiokjMdvPmTWzfvl2kSK9ZsyZ69uwpk0kQOJl4HFyggGxLILELCQlBQECAIpFk3bp1ceHCBSQnJ4vbfWrOCM/WWEpKiqiibgiGogZq2ksClCrxeCKo2dnZqFevHm7evCm+p93f8+fPceXKFWRmZsraMTMzU63WMQShD56tQaDgofXw4UNxHsbHx8PR0VGvvcARlZGRISptS7F06VJ4eXnBw8NDdl+aMWOGzM7U1FQmF1GtWjVUq1ZN/Fuo7gP4nCtAXumlLTCqLxqtNjdYquuUomOGwLPdxmPL6gixSvxoc1lJ+dc0Gg1mz55t9Bj04at1bowhWlu1ahUGDBiAa9eu4dtvv0Xr1q2xdetWo+2UsHfvXnTr1k3xM552p0+fjrZt2+LJkyfw9/fHsWPHsG3bNkXbxo0bIyoqCvn5+eK2haA3IwVPqSpL5KZcuXKKdqTAUMx6vhwcHPT2bSxDsTHzBTDsNPGMF2ALBX/48EG2chXw+fNnnfD9L7/8gsWLF6Nnz55i6eXDhw/h4+OD8ePHY8SIETJ7HgcXMJxLpM1QLDygPn78CECZoZhna8za2hpv3rxBxYoVDY7VUNTAGO0lngiqIG6qD507d0bnzp3/FYZcnq3B5cuXY8aMGahUqZLMydUm+AQMK21LMWXKFBQvXhyfPn1SjB6zQmlxxeJcWVlZYerUqaLO27p162QPb5ZzpI0TJ04gMTERDg4OWLp0KSZMmKC6VcWa/wjwbbfx2LI6QmPHjoWbmxusrKxkzwVtckLe3C+eMejDV+vcGMNOW6VKFRw5cgSZmZkgIhkdtDF2ShgzZoyqc8PTbtu2bWFlZYUjR46AiDB79mzVPf9ly5Zh3LhxePHiBdzc3NClSxfFrYtFixahR48eaNeunWwyC9snUmdFevNQclYAvuQx1vPFk8i5YsUKODk5MVHN88wXHkeIN/GUJRTcsWNHjBw5Er/88ou48s7NzcWYMWN0oiYrV65EQkKCDqv0pEmT4OzsrOPc8Di4gOFcImFVB+g+kLST0AV1ejUoMRTPnTsXrq6ucHJyko17w4YNOraGogbaDyQlB1IbPBHU3NxcLF++XCapMGrUKMXoCQ9DLit4tgZXr16N5ORkvYK7AliVtgEgOTkZycnJ3GPXhnTBwONcrV27FiEhIWIEytvbW8YkLyA9PR1Tp07Fo0eP8McffyApKQmJiYmKCxlTU1MUKVJEjLibm5vj2bNniuPmyX/k2W7jsWV1hPz9/REcHKwj8VMY4HHG1PDVOjfGEK0BwI4dO3Ds2DFoNBp4e3uLSq/G2mnD0HYOT7uVK1eGra0tNBoNzM3NVe1KlSqF8PBwhIeH6+177dq1uHr1KohItloTnBveTHdp8tjz58+RnJwMDw8P5Obm6nj7rOeLJ5EzJiYGGzZswLZt2+Dn54eBAweq2vLMFx6niTfxlCUUHBYWBh8fH1haWoo3sPj4eNSuXRt//vmnzDY/P1/HsQEKnA6lFZchB1cbhnKJWrZsiU+fPmHgwIHo3bu3YqRGgLY6vRRqZJZBQUFwdXVlugGzRg2uXbuG3r17Iy0tDU+ePEFcXBx27tyJRYsW6dgKEdSnT58ajKCOHTsW9+7dw/Dhw6HRaBAREYFHjx4p5nls3LgRs2fPZpKVMASB/E5pa1BbU0lAtWrVmBwbwLDSthT169dHRkaG3nnACx7nqlKlStixY4dBu6FDh8LGxkZUu69duzb69Omj6NzwSEWw5j8CfNttPLY8jhCrxA9gmPjR2DGogqtw/H8heIjWxo0bR02bNqUVK1bQihUrqFmzZorEQqx2SqhRo4bqZzztHjt2jCpXrkwODg5kb29PVapUoePHjyvafvr0iebPn0+enp7k5eVFCxcuFOn2pbC0tNSraG4sdu/eTTVr1hT5Uq5cuUIdOnRQtGU9XydOnKCqVauKx/PixYvUt29fxTbT09Np7dq15OzsTB4eHjLab2P6P378OPn7+1PdunUpNDSUiWuIdbw8au8xMTG0aNEiWrRoEcXExCjajBgxgry8vGjnzp0UGxtLsbGxtHPnTvLy8qIRI0bo2PNysbDg7t27FBoaSlZWVuTv708nTpz4ovakaNiwIbNtvXr1mOzc3d3pzJkzItdKfn6+3n7u379Pa9asoV9++UXvXLC1taW8vDzx75ycHJH3SBs8shJEBZxXycnJqmShL168oMuXL4vX96tXr2jUqFFUpkwZxfYOHTpEISEhdPToUTp16pT4UoIhpW0p/Pz8qE6dOhQcHGxQ2kIfpHxJrq6uXN+NjY2lrVu36iVSFHh+pP2oyV/wSEUIJH5Cu7m5uQaJN9PT0+nt27fiq7BsiYj++ecf+uOPPxTv+zwSP0R8xI+sY9CHr9654SFas7KyoszMTPHvzMxMReImQ3ZSTSDpa8WKFXqJilj7J+LT5ggICKAffviB9u/fT/v376fOnTsr3ii9vLxE0rLChKOjI71580Z2o1B7WLCeL2dnZ7p79y5Tm0QFLLPz5s0jc3NzioyMVLXjmS88ThPreBs3bkzTp09n0qkxhDZt2ojsnz4+PmRra0u2trbk4+NDkZGRsgetAFYH1xgSu7y8PNqzZw9VrlxZkbhNClYyy969e9OTJ08MjpeI6IcfftBLNimAh/SRBzY2NrJjm52drTq3eBhy//jjDzI3N6cSJUpQ+fLlqUiRIlSrVi3x840bN1Lx4sWpSpUqZGNjQ/v376cyZcpQt27d6M6dO4ptTp8+ncqUKUMODg7UtGlTatq0qSqJ39q1a6lkyZJUrlw5qlixIlWsWJEqVaqkaFtYemzDhg2T/T5W52rYsGFUu3Ztg867thOSmZmp6ojyICgoSLy/3LlzhwYPHqy4yCAi2rFjB1WqVIlMTEyoWLFi4r9faivAkCPEyj4ugIf4kXUM+vDVbksJ4CFaK1u2rGyPvVixYqohfX12+jLu9YXeWfsH+LQ5zp8/j5s3b4r71B07dpRVyghgKVU1BkWLFkWFChVk76klXbKeL5ZEzry8PBw4cADr16/Ho0eP0K9fP8THxyuSlvH2DxQkw3bu3Bnv3r3DqlWrcOvWLdk54R2vAJ5QsD68e/dO3FZU21bSBisXC28uUVxcHNavX4/Dhw+jW7duerdXeMgsX79+DRsbG7i6usrmrFJlU8mSJeHo6Ii2bdvKbLWTxU1MTJCTkyNeL48fP9a5tvRVDQHKJa3t27dH27ZtERAQAADYvHmzatJwiRIlQESoV68eVqxYAQsLC1XOq+nTpyM2Nha+vr5ISEhAVFQUEhMTxc+XLFmCS5cuoXHjxjh16hS8vLwQERGhl59l8+bNePjwIcqWLav3dwLsStsA+/bv58+fsXz5cnGL3svLC6NHjxbvj9I8mc+fPyMsLAxLliyRbacrbbkdO3YMSUlJBvPKWrdujblz5+LTp084duwYli9frloxyANp/mPz5s3h6+urSt3As93GY8uao8RSBi4FD/EjT56UGr5654aHaM3FxQXt2rUTHwRRUVFwdXUVy3CFG7IhO2My7nn6B/iE0ipUqICsrCxxH/jz58+K1SUsparGoHTp0nj58qXYVkxMjGIlA8B+vlgSOatVq4aaNWsiMDAQzZs3B1DwMBSqeZQSVFn6N8ZpYk08bd68Oa5cuVIo1AJCX1lZWXj9+rVOZcyNGzd0nFxWB5c1l2jlypXYtGkTKlWqhMDAQCxfvtxgki4PmSUPO2zDhg3RsGFDg3YjRoyAr68vXr9+jWnTpiEqKkon3+b27dto1KgRBg4cCGtra6b+Fy5ciPDwcPF67t69uw4RowAehlxDYowmJibiXHd3d0etWrUMEs9ZWFgwOTYAUL16dSbHBgDev3+PyZMny5Kq582bp1MNN2zYMLx9+xYhISEACu6pycnJioniPM5V1apVDc4/AJgzZw4WL14MMzMzhIaGwtfXF5MmTWL5iarIy8vDnDlzmPIfAb5cJh5bVkdIuMaF5GhDOVg8xI88zpgaNMSyDPtfjKVLlyI5ORkxMTGYMmUK1q5di4CAAJ0qEaDAW1eDRqMRS+AM2Q0YMEC8eZw9e1Z8sArjUWJa5ekfKKhcSk9PF73lnJwcseJHu3Jp0KBBuHjxopicvGfPHjg5OYk3PGMiM9LEZy8vL/Ts2VPV9vLlyxgyZAju378PGxsbPHjwAH/++afiA5z1fP3111+YNWsW7t27B29vbzGRU1pSWatWLfEBryQXoZSgytK/ubm5jtMkhZLTxDJeALC1tUVycjKT2rshODo6YsGCBfDz8wMRoU6dOti1axfq1q0rfq7dbmBgoE47Go1G8aECGCaxK1KkCBwcHFCzZk1FR1kpwuLi4oLY2FgZC7atrS2uXbum+luFc1sYzjgAnDt3DtHR0SAidOrUSYef6cOHD9i5c6e4kAkMDESvXr24KicLC8Lx6tChA4YMGYJatWqhW7du4vy2s7PDP//8Ix6jli1byv5WSu4dP348UlJS0L17d9k8VIq4TZ8+HZmZmQaVtgGgX79++OabbxAcHAyNRoPw8HC8f/9ehyjT2tpaFm3Oy8tDo0aNcOvWLZ02mzdvjrNnzxo8TgAwYcIE3L9/X2es0t+Vl5eHgIAAVfLOL0GzZs1w8eJFJtvIyEg8e/ZM5xwole/z2Lq5uSlGQbVx8+ZNdO/eXXRuqlevjt27dzM5848fP9ZL/Mg6Bn346p0boIBOff/+/SAi+Pr6qhKtGYK2o6KG+vXri+WO2g8QpQeKMf0/evRIr620UknpgSVA+uDavHmzoo32lsb48eNx6tQpccW8bds2uLu7K1aTCEhPT8e5c+dARHBzc9O7KmQ9Xw8ePBBL4du1a8e8etSGdsmvof6NcZpYx3vq1CnF77JqOEnh6OgIExMTREREwNbWFhs2bMCcOXNw8OBB2NjYcEloqMHFxQVbt25F9+7dxbYaNWqEGzduAAA2bdqk9/tKEYSePXtixIgRGDVqFC5cuIB58+bh7t27ig+b58+fY9CgQSJJmqenJ9atW6cYRWONGvAiOTkZ69evx86dO7FkyRL06NFD0S4tLQ3h4eG4d++ejKBRyXHkkZXYvn072rdvj/v376NXr15IS0vDihUr0LdvXwAQy5SVHgVqmnBKCy3tBZYAKeW+1FbpOrCzs5Ntmam917x5c/z9999itDkzMxNt27YVS6il4HGuWH+Xs7MzLly4oGOrBtbF3qxZs1CsWDEEBgaiVKlS4vtKDmZ4eDjGjBkDU1NTg9ttPLasjlDr1q0RFBQk3v927NiB8PBwvYSE2sSPgPIWLo8zpob/OjeFCFbH5JtvvhHJ1LQfIF/yQOFxjAQ9GRbs3r0bPXr0kN2UP336hH/++QcuLi44fPiwzL5evXpITEwUt1WysrJgZ2enSPD1/wK+xOHUBxaeFDWwhoL1oXPnzkhJSZHNt5iYGAwaNAjR0dEIDAzU+d08XCxAASPvpUuXZPPamDm+cuVKjBo1CgDw8uVLDBgwADExMdBoNCKZpdJW6g8//ABXV1cMHz4cQAGdwdmzZ/HHH3/o2BqKGhjKqVCKMuXk5GD//v2IiIjAs2fPsGrVKtUIrJeXFypVqgRXV1dZDs+PP/6oY9u+fXtFWQlDchD/t8PGxgbnz58XHcoPHz7AxcUF169fB/Af5y0xMVEx2hwREaHTJo9zxYrJkyfj3bt3CAgIkDkhSg4Tz2JPSh0hzTVRcjAtLCxw/PhxpkUbjy2rI2Rvb69D/6H0ngAe4kceZ0wNX23OjbGMs/pgjJ+oHSb/krA5T/9K3AJqmD9/Pnr06IHdu3fL3n/w4IHizZQ18Vktr0a4oI1hKDYmkdMQiOhfmS+urq4GbbTHyxsKzsnJwYMHD2S8EsINODo6Gg0aNJA5WZ6enti0aRM6deqkmLzHw8UC8JHY6cOmTZtE54aHzPLx48cyR2by5Mmq+UpXr16VRQjWrFkDOzs78e/o6Gg0bdoUffr0MZhvkpiYiA0bNuDgwYPw9vbGnDlz0KxZM73fef78uahGbQg8shIAmyAoL3bv3i1zctXIRwE2pW2gIFLn4uIiRjZ27doliyxLneKmTZuKDoqjo6MqE+6DBw84fpX+a0bAzp07AUAmmqnmMB04cEC22BsyZAjs7OwUnRseNl+eXCYeW9YcpaJFiyIpKUnMU0tKStLLJcVD/MiTJ6WGr9a54SFaYwWrY5Kbmys+DF69eiV7MKgJ1RVm/7y2ak5T7dq1xe0F4D/6RmqJz9ooU6YMKlWqhEGDBqFt27Z6zwPr+TImkdMQNBrNvzJfiAh37tzhGu/w4cMxdepUWSg4ODhYMRR88OBBBAUFITU1Fd9++y3S0tJQs2ZN2c2+a9euOHnyJNq1aye+5+7uji1btiiKfJ48eRJXrlwRj4GPj49eh5KHxE4fiMgohmIiwosXL0QSyxcvXugVm33//r0saiBdMd+9excbNmzAL7/8AicnJwwcOBCenp6KbTk4OKBp06YYPHgwvv32W8TGxiI2Nlb8XCmPrU6dOkhLS2NK1OWRlWAVBOXBTz/9hP3796N///7QaDSYP38+bt68iWnTpunYsiptAwU5LzY2NmJUecmSJTKyOWOLMVidK+1rJjU1FRYWFjoOEo/DxFPlyoM2bdpg3LhxTNttPLasjtC8efPQqlUrsY1r167plRniIX7kccbU8NVuS504cQIbNmxAbGysQXZaVrBuX1SoUEFvqauxFzDP9okxtlJxxry8PFy4cAHHjx8XE+B4Ep4FCCzBly9fhp+fHwIDA2Fpaaljx3q+/o1ETkdHRyxduvRfmS+nT5/mGi9PKNjBwQH79+/XKQEWFJ15IORz2draIiEhQdyGysnJgaOjo95k3sLIfXJ0dMSVK1dQvXp1nYo1QH3VvGXLFkycOFEsqT5y5AgWL14s5ptIsXjxYkRGRupEDbQT/IkIf/31F9avX4+rV69i1apVOpWIAQEBqg6EWgJ2r169cPHiRbRv315vKTpQEMHr1KkTk6yEtbW1XkFQY9C4cWPExsaKOS8fP36Eq6urogPauHFjxMTEiCKUr1+/hqenp0Fn1RBY5Se0nat9+/apOleFec0I98tjx47h5s2bssVegwYNuOkStMGz3cZjy5Oj9OrVK/H+7+LiotfZPnz4MA4fPoyOHTvK2m3VqtUXjUENX61zIyAjIwPbt2/Hxo0bUbJkSSxYsECVi8QQWHMJCiNR80vbNca5kTovJiYmqFu3LiZOnKh44fAiPT0dW7duxU8//YSwsDDFGw/Ad75YEzkNQXpcC3O+aJ8DlvE2adIEW7ZskYWC+/Xrh7i4OEXbuLg4WSWR8J6xY50wYQLi4uJkXCyOjo56k8ULA46OjrC1tcW5c+fQvXt3DBw40KAasYDr16+LNPmtW7dW5HAScPjwYTFq4OXlpUpRf+nSJURERODo0aNYsWKFUaKagLwIQEkdGVDmfmnRogUsLS11ZCXU8nP27dvHLHbKAqXqNLWKtcaNG+s4MkrvAQWirQsXLtRJqtZeGG3YsAE//fSTjvyEUkIxj3NVmNeMMYu9/xvwb+QoAQX8VKtWrYKlpaUsgqhUHVYYY/hqt6UE8BCtGYJS+bgSOnfurHfVwuOdGtM/8B89GRYI/q++LHgAouaR2m9T+12vXr1CZGQkNm3aBEdHR73bHKznKycnR8yhMDMzYwrfq8HFxYW7fxZI1xWs4+UJBQs0ANWrV8fvv/+OWrVqITU19YvGysrFUti5T0SETZs24f3799ixYwcGDBgAExMTDBw4EH5+fnof3DY2Nqolp9ro0KGDKnHemzdvsGXLFmzatAnm5uYYOHAgVq1aZXRSOACEhISIx4JHvyw1NVW1elEbhgRBBQhikA8fPsTBgwf1ikE2a9YM/fr1Q1BQEABg/fr1qjlFhpS2pfDz84OnpydGjBihN9K0fPlyJCQkoE2bNoiLi8Pp06cRGRmpai84Ntr/10ZhXjOG7pdfipSUFMX3lSqKeGxZt9yOHDmC0aNH4/79+8jLy9Ob/AzwET/y5kkp4auN3CgRrfXr108v0RpQEKq+cuWKLBSqFDbWZ1ekSBHu8Dpv/wBbYhwLDh8+jA4dOsDT0xPTp0+Hh4eH+NmQIUPw22+/AShgNj548CCz1x0dHY0NGzbg3r178Pf3R//+/VX3ZFnPl3Yi58CBA/Umct68eRPbt28XL/6aNWuiZ8+eOqt7Y+eLPgQHB2PYsGFc4wXYQ8GGSoB5wFsxVqpUKb25RLyl64mJibLkXqCAG8jf3x/jx4/HxIkTFb8XHx+P0NBQ3L9/XxYJULrGDEUNSpQoATs7OwwYMEBxcWCMaKV2tPXixYs617dSfk6fPn2wePFiVKtWzWAfnTp1QkZGBhwdHWUOg/ZWS69evWBjY4MdO3bg+vXryMrKgqurq+KW58ePH/HTTz/JolzTp09X3E59/fo1QkJCxJwXb29vrFy5EpUrV9axVYvoaEMpwqI2R7t16wZra2uZc5WUlIS9e/fq2BbmNSOFoXuxIdZxbUcUKHDShIqqT58+ITMzExUqVFCsKOKxZXWE6tWrh9WrV+tU96ltqbu7u6tSWRg7Bn34ap0bY4jWRo4ciQcPHiAuLg69e/fG7t274e3tjfXr13PZDRgwwKjwOmv/AFsyqYCsrCysXr1a56aqXdparVo1lCpVCjNnzhQTWr+kTLpIkSJo2rQpmjdvrpifIHXaWM+X0GaXLl0ULzLpg+KXX37B4sWL0bNnT9SqVQtAwQNu586dGD9+/BcR87E6TTzj/T8J4TyzcrHw5j6xOiG5ubmIjo7G+vXr8fjxY/Tr1w+BgYGqq3FbW1uMGDFC5wastDXVrFkzeHp66tj6+PgAADw8PPTm0RizzSC9fubNm4c9e/YgJSUF7u7u+Pvvv+Hp6Ynff/9d53ve3t64fPkyk6yElFeLZSxSh0uJY+bfRJ8+fbBgwQKDDzE3NzecPXsW3bt3R8uWLWFhYYFJkyYplhXzOFeGEBgYqDcZWynniSVJecKECQCAJ0+eICYmBp06dYJGo8GBAwfg6enJlIS/b98+JCYmqm5vstqyOkJNmzbF5cuXDfYlgIf4kccZU8NX69wYQ7Rma2uLxMREODg4IDExES9evMCAAQNw9OhRbjshvL5x40bm8Dpr/wBfYpy/vz/MzMxw6NAhjBs3DpGRkWjVqpWMoh0ouPkdOnQIPj4+6NGjByZPnqya55Ofn48XL17IHlTaN6xZs2bpvVFIw/Ss54snkbNevXq4cOGCTuXCu3fv4OzsjDt37nD3D/A5TbyJp7yh4MIqARbOMw8XiwCWXCIWJ2TMmDH4448/4OnpicDAQNl2oRr08W5ogzVqYAgPHjxgzkOTOjc2Nja4fPkyXFxccOXKFSQnJyM0NFQxwqBGfqhEetipUydERUUpEsFJoc38nJWVBWdnZ8Vjkpubi7179+o4uUoRBgC4cOGCjq2Snhmr03b8+HE0adIEb968EeUn5s+fDy8vL72/UQ3SYgklCA/gX375BUDBdvDp06fRp08faDQabN++HS1btpRpWgnguRcLsjlCBPv58+cICAhQvMcrgcfhYLVVc4RmzZoFe3t75nwzHuJH1jHow1ebc/Pw4UMmOykHiKmpqcjmmZOTA3Nzc5FvRAoWu9KlSyMoKAhBQUFieP3Vq1eq4XWe/gHDejJSJCYm4tq1a2jcuDFCQkIQEBAgrla1YW5ujpMnT8LPzw8PHz5U5GWIjIzEyJEjUaxYMbFkWImAadasWaq/VYrdu3czn6/w8HCmHIizZ88iPz9fVfhU+3fxzJeVK1ciISFBp+1JkybB2dlZ5tzoyxPQHm/z5s0xcuRIxVCwEgqzBFgYMw8XC8CeS1S0aFFx20ANK1euhJWVFS5evIhLly7pfK4UQWzevDkuX77MpFFjY2ODlJQUrtC3Erp168Yc4W2/8QABAABJREFUzZQ6yaampjA1NUV+fj6ICPXr18e9e/d0vpOXl4ctW7YwnwdWQVAeMchevXrhxYsXegV5BQQHB+Po0aOwt7eXzUMl54ZVC0yQJSlTpoyMa0YNhpwrtXujMFbBuRGc+FatWiE2NlZ0GENCQtCxY0fF7/Pci589eybbmq9atSqePn2qaJuRkSH+X6helb5nrK02unbtinnz5uk4FitXrkR6ejpKliwpCrlq85NJ8SU5SGpj0Iev1rlhhaurq3ijKl26NDIzM9GiRQv4+/vD3NxcMdLCYqcdXh8/frxeGQSe/gG+xDiBXMrExAQfP35E6dKlFfl2hBtT6dKlcfDgQQwZMkRkDpVizpw5uHTpEurXr6/397BCIBFkgfR86UNISAg6dOgAb29vBAUFiXIUjx49wrp16/D9998bNVZXV1cup4kVQuKpmZmZjJNGH+Li4gyWAGuzJO/ZswdnzpyBg4ODWBEFFOiPAexcLLwkdixOiDE3x9OnT2PdunVMWlyvX7+GnZ0d01aPPvAEw6WObsmSJZGTkwN7e3uMHz8e1atXV4zIFS1aFJmZmcjPz2fiXGIVBOURg7x27Rpu3brF5CyzKm0DypEnJfDIT7A4V7xz6/Xr17JImJmZmSpHGc+9uHr16pg5c6ZYLbp+/XpUr15d0bZs2bJiFLlo0aKwsrJSJdPksWV1hFgjogJOnz6t+L5SKfiXOGMCvtptKVZIt11evnwpPqCWLl2KtLQ0jBo1Sie50JCdMeF1nv4BvsS49u3bY/v27Vi6dClOnjyJihUr4uPHj0wrIqWVLq/uiiHwlLjzlOPHx8djy5Yt2LVrlyw3pkePHujXr59RZH0ODg5o0aIFbt26peg0WVtbY/Xq1Ua1m5CQwBUKZikBlm6L/Prrr1i7di169+6NgwcPol27dpg+fbrMnpWLhTeXqDAFQSdNmoSFCxcC4NPi4tnq0QdHR0dcunQJv/32m07eVa9evTB06FBFh/P69euoXbs2MjMzERoaitTUVEybNk2RUXnUqFG4c+cO/P39ZfT/xiQ1GwMvLy/8+eefTFHSVq1a4dSpU8xRQ5aiCR75CSsrK1y7do3JucrNzcXKlStx7949rFmzBvfu3cOjR490BGx79eoFU1NT0enfuHEjMjMzsWPHDp02ee7FL168wMiRI8VEbW9vb6xYsUIkofyfgFRrTHCEli1bpkqLwAonJyfx/58+fUJycjJsbGwUr/HCGMN/nRsD+Dd0hYoUKQIrKyt88803ihf8v6FjpA95eXkoWrQoiAhbt25FWloa+vfvL65MTp06BXd3d9V9ae0b6vz581GyZEn06dNHdkMxtOevhn+DnPDf0otydHREXFxcoTtNwngFtXeWUPCNGzcQFBSktwRY6gw6Oztj3759qFatGt6/fw83Nzcd3hJWLhbeXKLCFgT9n76GtPt3cnLCixcvMGzYMFne1dq1a1GlShWxwtBY8OQvsAqC8uTRDBs2DImJiejSpYtsbiklwLMobUu/z1I00bBhQ2b5CR7natiwYcjLy8M///yDmzdvIi0tDV5eXjq5KR8+fFCsFpM6mv/b8erVK8ycOROJiYkyR5T12rt48SIiIyOxZs2af2V8/92W4kBSUhJmzZqFu3fvyi5+7YQ7Q3bG7j2y9i+ANZlUGqpV2u+OioqCu7u74j6xdD9agLB6Gjt2rEHxt//TyMrKwuvXr3WiTzdu3NBL9qYPQshbKafgS8ETCp4yZQqKFy+OT58+IScnR9FGesPPy8sTS4tLly6tKIbJysXCm0skODGFIQgqXa+xVgIK4KFa0Nf/8ePHZQnpANCgQQO0b98e9erVk71vjG4Zzz1k+PDh+Oabb7Br1y5REHT48OE6Kuo8eTSfP3+GtbU1bt68Kb6n5jwIjoE02VbpviH8LqFoYunSpZgwYYJi5IxHfsLZ2Rndu3dncq5iY2Nx5coVODg4ACjYzlG6dkqVKsVFXMmT2G8oP6hcuXKKx1ppocNjy4tBgwahRYsWiImJwdKlSxEeHi4eNxY0a9bMYJ7dl+C/zo0BSG+UvXr1Qv/+/Q0STBmyM2Y1ytM/wJdMevr0aYwfP17HaRL2ONetWweA/YZqbF6JGniCi6y2AoW+n58fiAh16tTBrl27ULduXQAFCtHGimwChe80Ce0K21wsSE5ONlgCfOvWLTg6OoKIcP/+fVFbiYhUHSJWLhYWCLlEvIKg+iCd50FBQTAzM8O5c+dklYBKUIsa8KJr167YsmULXr9+rVOi/vr1a505WqZMGe4+WLdPAMOCoAJ48mh4JGJ4HDHWoom5c+fC1dWVSX6Cx7nS3rrKy8tTvJ/xRLl47sUs+UE8CxweW15H6PHjx5g0aRKioqLwww8/oF27dnB3d8ecOXMU25cuwoU8Gu17TGE6Y/91bgxAmg9TtGhRjB8/3uB3WO14wdMuSzKpgKCgIMydO1d1xWaMYCEvhBuI0pbNvHnzmNthzV8aMWIEpk2bhtOnT8PW1hYbNmyAl5cXDh48CBsbG6MU3oX+/w2nSUg85QkF169fHxkZGXq3Aw8fPiz7W7ixvHz5EsHBwTr2alwsxjo3wnHmEQTlAU8lIEvU4PDhw4p5NNIE9OnTp+O7776Dvb09OnfuLMu7OnDggM7WHg8zsYARI0aI2ydAgV5dz549FUt7DQmCCqhRoways7OZGZdZtZ0AdkJR1qKJoKAguLq66shPKIFnDjVu3BhRUVHIz8/H3bt3sXDhQhlpqQCeKBfPvZgl+Vq6wMnMzBQdGHt7e51jxWPLmyBcvHhxAAUO4du3b1GuXDm8efNG1b5z587i/01MTGBlZaWT58Y7Br2grxhJSUk0ffp0GjBgAA0YMICmT59O169fV7UfM2YMnTp1ymC7rHa84Gm3Xbt29PHjRybbpk2b6v28Vq1aqq/atWuLdq1atSIiorJly1K5cuXEl/C3Nt6/f08TJkyg6tWrk4mJCZmYmFCNGjVowoQJlJGRoWPPcr5yc3NpzZo11LJlS7KwsCALCwtq2bIl/fLLL5Sbmyuztbe3l/197NgxsrCwoCtXrpCDg4P+gybBH3/8IfvbycmJEhMTKT8/nyIiIsjCwoKuXbum2CfPeImIOnbsSAsWLCArKys6cOAA+fj40LRp0xTH5efnR3Xq1KHg4GAaM2aM+PoSNGrUiLKyssjOzo6IiG7dukVdu3Y1uj3hOAvtSaH0Hgukx9jJyUns58OHD0REZG1trfg94Tqws7Oj7OxsIiKysbERP586dSo1bdqU1qxZQ4cOHaJDhw7RmjVrqGnTpjR16lSd9u7fv0+LFy+mkJAQCgkJocWLF9P9+/dVx52SkkI+Pj7i705ISKBly5Yp2go20t/auHFjRdtFixZRw4YNafbs2TR79mxq1KgRLVmyRMdu6NCh5OLiQgsXLqSVK1eKLyWsX7+eLCwsqHTp0uTo6EhFixal5s2bK9r+8ccfZG5uTiVKlKDy5cuTRqOhWrVqKdq+ePGCPn36RJmZmRQWFkbjxo2jlJQUHbuGDRsqfl8N2dnZlJycTImJieJLCe/fv6chQ4ZQ5cqVqXLlyjRkyBBx3khRr149ys/PZ+qb517csmVL5nbPnj1L5ubmZG9vT/b29lS1alU6d+7cF9sSEX38+JHOnj1LZ8+eVR1737596c2bN7RixQqqU6cOOTg4UM+ePZnGzgKWMejDV+vc/Pzzz2RhYUETJ06kNWvW0Jo1a2jixIlkYWFBq1evVvzO2bNnqVSpUlS1alWqXbu2zsOd144XPO1ev36dXF1dacqUKeJNbfbs2Yq28+fPp82bN9Pnz5+/aHzPnj0jIqKHDx8qvrTRrVs3GjFiBCUlJVFmZiZlZmbSjRs3aMSIEdSlSxeZLev5GjJkCHXq1IkOHTpESUlJlJSURIcOHaJOnTpRUFCQrE1ra2v69OmT7L2TJ09SzZo1ydzcnPl316hRQ/Y3j9PEM16i/zzUhIfu58+fycXFRXFcs2bNUnyxIjQ0VOe9Jk2aEBGRra2teBM21gkh+o9z4+joSDdu3BDfv3HjBjk6OhrV5qtXr8T/t2vXjt69e0dTp06l5s2bU+fOncnLy0vxe61bt6aPHz/Sjz/+SH5+fjRy5Ehq1qyZ+HndunUVr5FPnz5RnTp1jBqrFB06dKAtW7aITkpOTo7MuZLC2dmZiP4z13Jzc1VtiYgOHTpE48aNo3HjxtHhw4cVbQICAnRegYGBirY2Njb07t07sf9Tp06p2trb29PDhw9F2y1bttD48eNVx8qC3r1705MnT5hseZwrVnh6eurcO9TAcy8eP348de3alXbu3EnR0dHiSwnOzs70zz//iH+fPXtWnBdfYsvrCBERnTlzhv744w/KycnR+Sw9PV3vq7DGoI2vtlqKh51WQP369TFp0iSdUKh2DgWrHVCQwHbs2DFoNBp4enrq3VbhaZdVTwYo0Hjy9/dHZmYmgP/sbyqFri9evCiSh7Vt21aRlyQsLAzTpk0z+J4+Wvh69erJqNRZz5eVlZXiuSMi1KtXT/bZ1KlT0apVKx3emNOnT2Pw4MGy/tWS/4gIGzZsQHp6uvhegwYNcOXKFVl4/9SpU+jfvz+ys7Px/Plz8X2e8QIFSXgXL16Ek5MTjhw5gnLlyqF+/fqKbXwpatasqaPx0rJlSxw/fhyDBg1CpUqVUL16dWzYsEFRDZoFQrXW0aNH0bdvXx1B0LZt2+p8h4el2VAloBRSqoVly5YhNTVVRrVQt25dXL9+XWfLICsrCzY2NjqEe6dPn8bDhw/h7e0t0yDbtGmTYpKswBgrrWBTozYYMmQIWrVqhcWLF2Pv3r1YuHAhTE1NjaIZMAY82k4sSttdunTRm+ujnQDOIz/BwhDMylAsgKdajOdezFMFpySNocbIzWPr4uKCpUuXijIz586dw9ixYxEbG6tjywJpWbc21K7bwhjDV5tzYwzRWqlSpTBw4ECDbbPaLVmyBKtXrxZZQHv16oWRI0eqPkhZ2wXYkkkFjBkzBtHR0Qb3r3/77TeEhYWha9eu0Gg06NatG6ZPny4STgnYt2+fjiOj9F6RIkVEJXEpbt++rTMO1vOl0WiYEznnzp2r+DtbtWolc2zOnj2LNWvWYOLEiYrHR/um3LVrV5w8eVLmNLm7u2PLli06x4pnvECBk/f27Vv4+/vD2dkZZmZmaNKkieLvYCkBVlPvJiJFHZdff/0V2dnZWLp0KUJDQ3H27FmdqhseCLlE7dq1Q1JSEpMgKA9Ls6FKQCmqVKki/l+JLyUgIABOTk7o16+fLI9my5YtOgScy5Ytw6+//gpra2uMGzcO4eHh4nW+cuVKRedGW0g3NTVVNfdr2bJlGDduHF68eAE3Nzd06dJF5PbRhiFBUF6qBwAiDUG9evWwYsUKWFhY4MOHD4rfZyGxY6XwF8DKZAywMQT7+vqicePGKF++vKKYsfYx4KkW47kX8+QHlSpVCseOHRMlJ2JiYlS123hss7KyZPp5bm5uslwp3qRfYwpMDI2BBV+tc2MMO62Pjw/++OMP/PDDD3rbZrX77bffEB8fjwoVKgAoSER0cXFRdW5Y2wXYkkkFVK5cWbHKQhs///wz4uLixAdxaGgoPD09xQf20aNHceTIETx9+lT2G6RRDSkWL16Mli1bwtHRUTwHDx8+REJCAiIiImS2rOdr0qRJzImcrAgJCYGNjQ169OgBW1tbnc+1x8rjNPGONyoqCkABiVuTJk2QlpamSmzFUgJ8//59bN++XSe5kIjQs2dPnTZtbGwAFCj/ClV0SsjLy2MisRNI0ICCeahGYS8FC0uzg4OD3kiANMLAGjWYNm0aWrVqhV27domJvDVr1sTPP/+sUwEZGRmJuLg4mJmZISkpCb6+vsjMzIS/v7+qw9KjRw8MHToUGRkZiIiIwNq1a3WcYQGlSpVCeHg4wsPDVcctwM/PD56enqpVlrxUD0BBJDYjIwOLFi0StZ3U+EpGjRqF1NRUhIWFyUjspNB29rSZs7XBQ6zI4lxNnz4dO3bsQJUqVTBw4ECDVXI81WI892KAPfl65cqV6Natm3hO8/PzVSkOeGwNOUJfkvT7+PFjnDlzBkDBgk9N1Z7HGVPDV7stRUTcRGusBGqsdkrCZfrEzHgI3Hr27Im4uDiDejJAQQWMmZkZ/Pz89JLuKQkLSt87deoUTp48ibVr12LYsGGydrp06SKSmUnx8eNHHD58WHYO2rdvr0OGxXO+Hjx4gL1798rsunXrxixmqA0HBwfMnTsX9erVE6uepDh+/DiTc6gNIYxf2OMVoBSK1n5P0BNyc3PT+X6NGjXw+PFjAPxcLEOHDmUisXN3d8epU6d0VoP65jYLS7MaKaAAqTOixkwsgJehGNC9Vp48eQJvb29MnjwZK1euVK2Y2759O/bv3w8igq+vr1g9JsWjR4+wZs0a3LhxA0ABu3NwcLCqJlZhCYL+T+DatWvo3bs30tLS8OTJE8TFxWHnzp06nDJqEWylUnBWhmAiwrFjx7BhwwbEx8ejd+/eGDp0qGxLUQrWajGeezGLgrgUOTk5YlSofv36oiP3JbaXL19WdISUorzPnz9HcnIyPDw8kJubi/z8fLGKShvR0dEiN45Go8HZs2exfv16xcU6zxjU8NU6N8bg0aNHiu9rc48YshNuNFFRUXj16pW4eo2MjESlSpWwYMGCL+ofYGeSBZTLr5X2Qrt16wZra2uReGndunVISkrSUS1OTExU5NH4fxX/FuMtj6yEMfwPNjY2OH/+vKwE2MXFRaYH9ujRI5iZmSlu+WVlZYm6Y4aiXtrzijWX6Pnz56hatSrX3OZx8oGCm3pKSgrq1Kmj9zcI0Bc1ePDgAR4/fgwnJyfx2ADA33//LVvtOzg44OjRo6hcubL43rNnz+Dl5YXHjx/j/fv3TGPRxs2bN9G8eXO0a9cOzs7OICJcunQJR48exdmzZxV5gfr06YMFCxaoOj88VA9qekQCpDknvHksAODh4YGwsDCEhIQgISEBRAQbGxvRkRMgqHMDBVT+e/fuhaOjI37++We9fbLizz//RGBgICZMmIAJEybofL5hwwb89NNPePfuHaysrJCYmAgXFxcxoicFz72YR0F83LhxGDRoEJNuGI8twOYI7dmzB+PGjYNGo8HDhw+RmJiIKVOm4NChQ4ptOjo6ymgx7t69Cz8/P9V7K4/jpoSvdlsK4Cdas7CwMMgVwGInrfcH5KtMjUaj6tyw9g/wcWew7omuXbsWISEhcHR0hEajgZeXl4wYS4CdnR0z0dvmzZvx8OFD/PDDDzJ2y/nz52PKlCkyW9bzxZvIyYrCJuYTnBWW8RoTCh4wYABcXFzE7aVdu3bp5IboIwWUPrwzMzNVczqUwJpLJPzeqlWriiu++/fvIykpCR06dFBsm+dYnDx5En369IGJiQlSUlJw6dIlrFy5Utzek8JQ1GDr1q0YPXo0zM3NkZaWhl27dsHV1RVAwXao1LmZPHky7t27J3NuvvvuO8TExOhcmzxRsbCwMMyfP1+H2XXdunX46aefsG3bNp3vGxIE1b4fSaHRaHD//n3xb33OuLbzzaq0LcWHDx/QokULmZ1SJEBQ5xYQHBys0x6vc/X69Wts2rQJmzZtQo0aNfDzzz+rRgeXL1+OhIQEtGnTBnFxcTh9+rQqKzfPvZhHQdzMzAwdO3ZExYoVERgYiD59+qgSQvLYCo6QsAWthvnz5yM+Pl7cOrKzs1NdpAAFW9XSyHfdunVVnz2sY9ALrtqq/0U4evQolSlThszMzMjBwYHu3LkjfqbGccJanlYYZWxf0j8RUUZGBg0fPpysrKzIysqKRowYocgdIyAlJYW2bt1KW7duVSyxzM3NpYkTJzKNc+7cueTg4EAVKlSgrl27UunSpcnX11fHbtKkSdSiRQsaMWIEmZub04oVK8TPtM8B6/launQp1a1blzp27EgVK1akvXv3qrbJCnt7e6PmiyE4ODgYNd5nz57RiRMniKigXFhfCT9LCTDrWInYuVgiIiLou+++o+DgYFqwYAEtWLCAgoODqVq1ahQREaFj37RpU8rIyKA3b97Qd999R25ubjR06FDV8bByYDg7O9Pdu3dl5flqHCnu7u505swZ0TY/P19ma2dnR48fPyYior///ptq1KhBMTExRKRb/s+KFStWkEajoWbNmtGMGTMMlu7Xr19fsZ38/HzVzyIjIxVf/zfC2dmZsrOzZfNNoB/Qh7y8PJ3f7+Hhofpq3bq1zNbX15caNmxI8+bNo6dPnxrsT6ApkJbfq12v0vJvQ6XgQnl2+/btad++fRQfH2+QRuT48eM0YMAAqlSpEvXp0+eLbWfNmkW1a9cmJycnWrNmDaWlpSnaCRxS0rmv7zrw8vKidevWUV5eHuXl5VFERIQqLQPrGPThq3VueIjWBLByBfBwChAV8GQYqvvnbdff35+GDBlCCQkJdOXKFQoODiZ/f39F2/3791OFChWoc+fO5OvrS5UqVaIDBw7o2AmT2RBYid5sbGzEB/Pz58/JycmJ5s2bR0S654D1fNna2orH8MaNG2RlZUVbtmxRbJMVERERRs0XQ7C3t+ce7+7du6lmzZpkYWFBRERXrlyhDh06GNU/71iJ+LhYeEjshPY3bdpEU6ZMISJSbZfHyReI+VhuwMJDVM1WmyTv6tWrVKtWLfrrr7++yME9fvw4+fv7U926dSk0NJTu3r2raq9G1GfoM1bs2bOH5s6dS0RET58+patXryrapaWl0Y8//kgdO3YkooK5u23bNkXbnJwcWrJkCQUHBxMR0d27d0WnUBtbtmyh77//nqpXr05Tp04lCwsL2rlzp46dlJRy5MiR5ObmRt26deP+vQI0Gg2VLVuWmYDU1dWV8vPzqWvXrrR8+XLat28fWVlZKbY9fvx48TVixAiytLSkvn37Ktpu27aN3r17R5cvX6a6detSxYoVaevWrQbHf/HiRerXrx8VL1680GwNOUJt2rShFy9eiHP/2LFj1KZNG9X27ty5Q87OzlS8eHEqXrw4ubi40L17975oDPrw1To3xrDTKt08lAjMWO3Onz9P1tbWVKRIEdlLDaztqtmq3fy0IxF37txRPAYzZ86ksLAwevr0qV5njJXorVGjRrK/09PTyc3NjebMmaPTP+v5srW1ldk9fvyYrK2tKTIykusBpE1gV1hsxlJERERwj9fR0ZHevHnDFIl48OABDRs2jLy9val169biyxgIYzHkABgL4TcEBgbS33//TUTqc5vHyW/RogW9f/9eHP/Vq1fJ1dVVtV19UQMbGxud6OeNGzeoVq1aVL58eYZfqQvpsUtPT6e1a9eSs7MzeXh4UGxsrI5948aNKSMjQ5EMTZ9zs3PnTpoyZYpepurp06dT+/btxYf0s2fPVI9Vz549ac6cOeI1nJmZqXq+hg4dSoMHDxaZoVNTU/VGY86ePUsTJ06kCRMm0JkzZxRtpJGtsLAw2rFjh8gqrQ0W50qNeFSNgDQmJobS0tLo7t275OXlRU2bNhXnrSG8efNGdAq/BC9fvqQlS5ZQo0aNqGHDhrR48WJ6/vz5F9tKoc8RunTpEjk4OFCZMmWoefPm9N1331FCQoLBNt+/f0/v3783aMcyBn34ap0bY9hp3dzcZBP42LFj5ObmZrRds2bNKDY2luzt7SkjI4PCwsIUadF52yUqcBykN+L379/rOBMCWJ0mjUaj81Jyxlq0aEHZ2dnUr18/Gjt2LC1btkxxFd6sWTN68OCB7L3379+Tm5ubzkRmPV/29vb08uVLmd3Tp0+pQYMGVKpUKZ0xqEGbdZhnvvBKQPCMlycU7OTkRJMnT6bo6Gg6ePCg+DIGwgPf2dmZ8vPzxT7fvXun+lA7deoUbdq0SWSuFqC0JfLjjz9SgwYNqF69epSdnU3v3r1TfQDyOPlHjx4lV1dXqly5MvXt25eqVKlidNRg1apVdPz4cZ3vJSUlkbe3t2KbhqDtwD5//pzmzZtH5ubmisdJuOa0r0G1a5GIKCQkhDp27EhVq1alsWPHUo0aNWjgwIE6do0bN6bc3FydSKi+cbPIP/BIRfwb4HWu9EEt+s0LXvkIJVSoUIGGDh1K58+fL1RbHkcoLS2NDh06RH/++Selpqbqbbdr1670559/Ul5eXqGOQQ1frXMTGhpKR44c0Xn/1KlTquHFS5cuUc2aNal27dpUu3ZtsrCwoLi4OKPthBuE9MGvT+eJtV0idj0ZIr69UBZcu3aNPnz4QK9evaLBgwdTt27dFD3648eP05UrV3Te//DhgxgaF8B6vnbs2KG4RfHs2TMdOQMHBwfFl729PZUoUcKo/on4JBV4xkvEFwpWezAZA+HBtGTJEgoKCiJLS0tat24dNWnSRFGuhDeXKD8/nxISEsRI4Js3byg+Pl5xLDxOPlHB9tiaNWvol19+0bvlQ8QWNTCEXbt2Mds6ODhQbm4u7du3j3x8fMjGxoYWLlyo4xB+CWxsbCgvL090KJ4/f05t27bVsdOWdBC+qwRt28zMTNX5xiIV0aVLF70vbXz8+JHWrFlDY8aMEbc9Q0JCFPsvTOfKmCitVKdr2bJl1KtXL73bN6zIzMz8V2x5HCEeREZGkru7O3333Xc0ceJEunXr1r86hv+WghvA2bNnZUyJrOVpLHbOzs64cOECPDw8sGzZMtSoUQNOTk54+PCh6nh4yuMOHz6MmJgYAICXl5cq2du9e/fQt29fxMfHQ6PRwNHREVFRUYqlsykpKTh9+jQ0Gg1atWolUtNL8fbtW5GYsDAwadIk5kod7fOlhpUrV2LmzJl6CexevnzJPdazZ88iICCAS1KBBStXrsSoUaNw+fJlDBkyBPfv34eNjQ0ePHiAP//8E/b29jrfMVQCrITXr1/j2rVraNCggaxyS1r5xMLF0rhxY/zzzz8yErsZM2bA399fsQT+0qVLaNSokUg6ePHiRYwdOxbfffedTtuFwYHxb4KHOsDBwQHPnz9HzZo1ERgYqDh3lQjcDMHT01O89p2cnHDp0iXY29vj0qVLKFasmEwKQUDPnj0xYsQIjBo1ChcuXMC8efNw9+5dRQbqKVOmoFSpUoiKisLq1auxfPlyODk5YdasWTq2LFIRRYsWRdOmTdGnTx+ULVtWpw3tKsf27dujWLFicHJykhETKjFLu7i4IDY2Vpx3eXl5sLe3N0oyxBhaCGmFoomJCerWrYshQ4Yo0i+wYPv27ejdu7dqWb60KpXHVoCUAkIJ5cuXV3yfDFAyCLh//z42b96MLVu2wNzcHGfPnuUeAwu+6lJwFoSEhMgmc9GiRVG+fHnk5uaKGkFKDw8Wu169euHt27cIDQ2Fu7s7cnJyEBYWpnc8rP0DBay+auW0UtSpUwexsbEifbo2gZ6Abdu2ISQkBK1atQIAjB49GqtXr0avXr1kdvXq1UObNm0QGBiI9u3bK/Lo8ODvv/9mdm60z5caNm3aBAcHB5QpU0aRwE6NiIqlf15JBRZs2rQJo0aNQtOmTXHixAmcO3cORAQ3NzfFh4HQn74SYADo378/lixZgsqVK+P48ePo2bMnateujYcPH+K3334TS2Glv6V3797o3bu3wTELJJANGzbE8ePH4e3tjby8PEW+nsGDByM+Ph537tzB1KlT0b17dwQGBuLo0aM6tk2bNsXdu3f1OvmGHB3pHBFkEdSgxuSqBp5zHBkZic6dO+P169dYtGiRjgaPdik2K6QPmNKlSyMzMxMtWrSAv78/zM3NFSkkVq1ahQEDBuDatWv49ttv0bp1a2zdulWx/Tlz5mDx4sUwMzNDaGgofH19MWnSJEVbqVRE8+bN4evrq0N3cffuXWzYsAG//PILnJycMHDgQHh6eqr+vpSUFCQlJbEcCjRu3BhRUVHIz8/H3bt3sXDhQnh4eDB9tzDAw2YMFBCbJiQkQKPRwN7eXoeZ99atWwCUy/K1ry0eW8ERUmMeFxyhMmXKoFKlShg0aBDatm3LfX+vUaMGGjVqhHr16uHSpUtGjYEF/43cGIB0lRkZGYmRI0eiWLFi4gnVaDQ6GjysdlLk5OTg06dPMt0fbfC0a0hPRhvPnz/HgwcPZLaCEyPA2toahw8fFplzHz58iPbt24sXkICPHz9i9+7diIyMxL179+Dv74/AwEDUq1dP9bfpAw/ZHautQJbFQmDHO9YRI0ZgxowZqpIKUskBnnZZj4EANeZd6SpYyljs7u6OlStXwt7eHg8ePEDXrl3FPnkZinlJ7IQV8apVq5Cbm4uxY8fq/OaPHz/i22+/RUZGhuIYpIzapUqVQqNGjTBw4EBFYjspQzFv1MAQHB0dcf78eSxcuBAPHz6Er6+vjFMlJCTEKIFLQ5IE2mMQHDhDgqDayMzMBBFx090XBogIf/31F9avX4+rV69i1apViuKpXbt2xW+//aaqPybFhw8fMG7cOOzfvx9AgY7UsmXLjPp90uMqjWK3bNlSZ5FpDIlhTEwM+vTpg2rVqoGI8Pz5c2zfvl1RULOwMXPmTMyePVuHCwsoeM5I2Z9jYmKwYcMGXL58GX5+fggMDISlpaXe9uPj47Fx40bs3LkTTk5OCAgIQOfOnWULSZ4xGMJ/nRsDkE7mOnXq4NChQ6hfv77e77DaAQWMo3fu3JE5FWorSZ52mzVrBk9PTx1xQR8fHx3buXPnYvHixbC0tJQJDQoihgKUQrKGwrQPHjzA/PnzsX79ekX1VxbwhIJZbf8t1mGh3YcPH2LPnj2FJqlgYmKiqE3DGgpWg1R9Xdi+ECCl7S9SpAicnJxUI3HaRGU7d+5EzZo1RZI7Ac+fP8fMmTNF+QUBjRo1wvHjx+Hv74+FCxfC0dFRRzZAOLZKKsPajNofPnzAzp07xVVzYGAgevXqpfhAe/DgATZs2CDedA1FDQzB0dERjo6O+PDhA5ycnBAREYH27duLZGzGzr1/4zoACkgk9UG6yPm3GYqBgi3KiIgIHD16FCtWrFAk0rt58yY6deoEJycnWVSS5+FnDIRrRIhiu7u7g4jwzz//6ESx9Tkkakrftra2iIiIgLOzMwDg4sWLGDRokOoW2oULF3QWsP379/9iW1akp6dj69at+OmnnxAWFqaqhQYURFgDAwPRr18/VU2pwsR/nRsDkN4khBwZQ2C1GzduHLZu3YqGDRvKnIq//vrri9oF+PRk6tSpg4sXL6rmyQgr5cWLF6No0aIYPHgwiAgbN25EXl6eIr14Tk4ODhw4gA0bNuDSpUvw8/Mzmhr933JuLl26xCTu+G+NlQclSpSAnZ2daihYjWl4165dOkzR0ihLSEgIihQpgrlz52Lu3LmwsbFBnz59cOTIESxevFi8AZ84cQIbNmxAbGws/Pz8MHDgQGY5A30QcokiIiIwfvx4eHl5Yc+ePbh37x4GDhxoUCOKBcnJyVi/fj127tyJJUuWoEePHop2rFEDQ3BwcEBeXh4SExOh0Wjw8eNH9OrVC9WqVcPatWuNisIJ7bJ+TxCjZREEdXJyAlDAIHvlyhVYWlpCo9Hg3r17sLe3l81nwclt1KiRonq21LkoUqSIXqVt6cP9zZs32LJlCzZt2gRzc3MMHDgQnTt3Vo1UtWjRApaWlmjatKnsOpUyFxvrXOXn5+PFixcyJ0A7KsMaxeaFkh6cvb29Iit3cHAwjh49Cnt7e9nzY9euXV9kC7A5Qq9evUJkZCQ2bdoECwsLhIWFFWre25c6Y//NuTEA6UXp6+uLFStWoE+fPnoFJlntoqOjcf/+fVUJBW2wtgsU6AqlpKQwJZNWqVJFbwJw2bJlZSvln376SfxMo9HoODchISHYvXs3HBwcEBgYiN9//93oHBaAL4eB1ZaIMHz4cLx48QJTpkzREXe8cuWKTnShMPqfOnWqqmq4PjRs2BDz58/Hhg0bsGzZMqZQ8MiRI/HgwQPExcWhd+/e2L17t47a8dKlSzFp0iRUq1YN5cuXx6NHjxAQEABPT0+sX79etGvdujVat26NjIwMbN++HX379kXJkiWxYMECcZVpDIRcosGDB8tWfbVr18bff/+t+J3Hjx+jSpUqKF68OM6ePYuEhAQMGDBAcUs3JycHV69eRWJiIszMzPRuY2g0GpQvXx7lypXDp0+fkJmZadRvmjdvnqi5AxQoqO/btw89e/ZEUFCQUW0K42NFjRo19AqLSiFE6wYOHIiFCxeKc+TYsWPYsWOHzHb9+vXYuHEjbt68iYEDB6J3796qOXo8StvVqlWDnZ0dgoKCxO0yab6VtiOSmpqKzZs36/1dvr6+ep0rJeeGdev/m2++kUVha9Wqpfc+vnv3bnE+t2vXDt26dVO0a9u2LSIjI8Wt0C1btqg62MeOHUNSUpLsWaAGHls1R0hwLKKjo7FhwwYx5eDvv/9WTPwXsHTpUowbN051a1tJQNTQGFjw38iNAaxfv17MkZCuloWHvZLAJKtd69atERMTw5yQxdouAHh7e+Py5ct6k0kFzJw5E+np6TpOkzFVGkDBzb1///6oXr06k31qaioePXokVhJoX4BKyblqkJ4vfUhMTET37t0LvarJUP81a9YUo0Q8kIqRsoaCbW1tkZiYCAcHByQmJuLFixcYMGCAYpLu1atXcerUKeTl5aFVq1Z6V2AvXrzAxo0bsWrVKixYsOCL9LoEgU21VbbSA8jR0RHnzp3D27dv4eLighYtWiA3Nxe7d+8WbRITE7FhwwYcPHgQ3t7eGDhwIJo1a6bYB2vUID09HbNmzRId+rVr1yIqKgqNGzfGqlWrZLlb7u7u+OWXX2TaOLm5uejZsyf2799v1BatdlQwJycHDx48kEXl9F2zhnJ2lKK9SpEEALhz5w42bNiAPXv2oHnz5pg8ebJibhMxKm17eHioOm9KWzh9+vTB4sWL9W5vzJw5Ezt27ICjo6NB50qAoa1/Y6LYP/30E/bv34/+/ftDo9Fgy5Yt8PX1xbRp00QbQRiXiJCeni4myOfk5KBs2bKK286tWrXCqVOnmJxeHlsrKytcu3ZN1REqUqQImjZtiubNmyu2p+2shIeHY+jQoVwCoobGwIKv1rnJycnBmjVroNFoMHz4cOzbtw9bt25F48aNMX369C+KNLDi0qVLWLBgAdq1ayc7iV+6DwqwJZMKUMoD0VelkZGRIQsVqpUGGsKTJ08wbNgwHD58GEBBhCgrKwsjRozA3LlzZRUw+/fvR8uWLVGhQgW8efMGwcHBuHDhAuzs7LB27VrxJvf582fmRM569erh7NmzOo7Tq1ev4Obmhrt373L3D6hX6hARbt68KXsY6UObNm10buo8oWCWEuCkpCQEBATgyZMn4oo5JSUFNWrUwMaNG0VB0Ly8PBw4cADr16/Ho0eP0K9fP/Tr10/nIcWLihUr4s2bN4r5CWp5CcJD/rfffsOrV68wbdo0nYewcAPu0qWLYp6NNDdE2PIbMGCAYpKtMId69uyJqlWr4uPHj7h79y6sra0REBCA3bt3482bNzLhxOvXr8PU1FQmFAgUHMedO3cqls8bgnRb6uDBgwgKCkJqaiq+/fZbpKWloWbNmnjw4IHO9wwJgkrbX7ZsmXguTp06hdGjR6tuhWVnZ2PXrl0YO3Yspk+fjpCQEL3jN6S0zYIHDx6gdu3azIs3VudKgKGtf6V8LwFqC83GjRsjNjZWjOx8/PgRrq6uMkdSn+AkoLztPGHCBNy/fx89e/aUHQOlBQGPrSFHSHDw1cAjFKoGHmdMDV+tcxMcHIyXL18iKysLZcuWxefPn9GzZ0/8/vvvMDc3x4oVK/71MQwaNAinT5+Gra0t0z7o/2ns3LkTISEhePfunTjpNBoNsrOzZXZHjhzB6NGjcf/+feTl5alGmLy9vREQEIDvv/8eW7ZsQWpqKoYNG4ZJkyahbNmysnPQqFEjXL9+HRqNBgEBAfjuu+/g7++PP//8EydPnsSff/4JoKCkmDWRc/369cxVTaz9AwVOGit/jlrlj9Dn48ePAeiGgvv37683FAwUOEcHDx7ExIkT8fr1a5ibmyM2NlZ283Z2dsbEiRN1wuR79uzBokWLxKRyc3PzQudiAYzLUWrUqBHi4+Ph7++P0aNHo3nz5jrOTUBAgN5IgDQ3hDVqIDiGeXl5qFy5Ml6+fAkTExMQEezs7Jhz3IxFcHAwfv31VwD/qfbz9fVFQkICoqKikJiYiMWLF+t8z8PDA2FhYQgJCUFCQgKICDY2Nrhx44bM7ty5c+jVq5e4qMjNzcXOnTvh4uIis0tISMD69etx+PBhtGvXDgEBAapRMW2l7YCAAPj6+hq9eBTmC8/iTQCLczV//nyULFmSaeufFUqcQkrv8YJnQcBjy+MI6cPu3btl+W25ubnYu3evTh7NjBkz/pUxfLXOjTC5Pn36hMqVK+PFixf45ptvkJ2djSZNmihOvDt37mDkyJFITEyUrb61Q4asdnXq1EFycjJMTNhSn1jbFWAomVQbnz9/xufPn8W/tS9oS0tL7Nq1C02bNtU7znr16mH16tU6lVraK2jtMHizZs1w8eJF5OXlwdraWrYt1LBhQ5HXQjuxUppw17hxY65ETtaqJtb+gYIbydy5cxX5c2rUqCE6LIDySlBpy5E3FAywlQDXr19f5IvRhvSzWrVqyRzawuBiAeTHkrVyMCwsDEuXLkW9evUQGxuLFy9eoGvXrjh//jx3/6ykj0BBHtv169d1xg0oJ31u3rwZDx8+RMeOHWXRtfnz52PKlCky25s3b+oktvfs2VOMnGmjSZMmiIuLkz0khfe00bRpU1y+fFk2ZrXk5JycHDEp1traWpE/yMTEBIGBgejatasOXYL0ntGlSxfcvn0b/v7+GDBggEFnnAW8ydi8zpVSioBaRIYVgwYNQnZ2tphvtX79epiYmMhy2gS8evUKM2fO1LnHG1OkwDO3pbY8jpA+aC9cunfvjhcvXqBZs2ay54KSQ14oYzCa2/j/cUhptLV1adS0etzd3WnHjh3UsGFDunr1KgUFBenIBPDYeXl5qYq9fUn/ROx6MkTsAp5qInraYNVtsbOzE3WV7ty5Qy4uLuJn2torHh4eokxBx44dRZ2RjIwMGZV7gwYNZN/Lzs6mLl260ODBg40WeJw4cSJz/0QFInzv3r1TbEubBv27776j169fK9pWr15d/P/MmTNlYoHaL2Ph5uZGmzdvlum95OXlUWRkJPP5/hII8htjx46lKlWqUOvWrcnLy4u8vLz06jWlpqaKY/7w4QM9efLEqP556PRLliwp6otJr9vMzEwdOv+JEydSixYtaMSIEWRubk4rVqxQ7fPnn38mCwsLmjhxIq1Zs4bWrFlDEydOJAsLC0VpC6L/SBq0b9+e9u3bR/Hx8VS7dm1VW32CoB8+fCAiUhTj1BbG1da0El5K2la8Stss+O6774hIrgquJgbq6+tLDRs2pHnz5tHTp0+N6k8Nt2/fpvbt21PVqlVlv00JHz58oIkTJ1KTJk2oSZMmNGnSJPGYa6Njx460YMECsrKyogMHDpCPjw9NmzbNqDHyzG0eW6lorT5o32/r1asnCil/KVjG8NU6N/b29qKIoVT1NScnR1VPRVsLKj8/XxQyNMZuyJAh5ObmRgsXLpTpj6iBtV3BhkVPhohdwHPjxo00d+5cSk5OpkePHokvbcycOZN+//131d8hYPPmzWRubk7t2rWjSpUqifpDz58/pw4dOshsr169SpaWltS3b18KDAykmjVr0oABA6hhw4YUFRUl2rVq1YquXbsm+25OTg517dpVr+K6Pjg4ODD3z4OJEydS9+7dVYUcfXx8uNvctWsX+fr6Muv03Llzh9q0aUNlypQha2trsra2pjJlylDr1q0pOTnZqN9FRPTp0yeaPXs2BQYGUnR0tOyzESNG6NjXqVOHPn78yNT2gQMHxIfu4sWLqVu3bjrnnBU8Dm+DBg0UFyOPHj2iP/74Q/aejY0Nff78mYgK5rOTkxPNmzdPsU8rKytFZ/jt27dUt25dxbFs27aN3r17R5cvX6a6detSxYoVVeehIUFQ4b6iLcKpT4yTBbxK2ywQBG1ZnHxjnauUlBTaunUrbd26VdVp5lloaovl6oOw0Bbu8Z8/f5Yt+njAM7d5bFkdIW07T09PHfFhY8Eyhq+2FPzXX39FTk4OihYtKkvWevTokSrFsxCiLV26NB4+fAhzc3O8efPGaLvs7GzUq1cPN2/eFN/Tl0DF2i4AmJqailseOTk5MDc3x7NnzxRtc3Jy4OzsjNzcXJQuXRpTp06Fk5MTxo0bJ7P7/PkzwsLCsGTJElmOkHaZ5MqVK5Geno6SJUuiRIkSqkRz/fr1g5OTE27cuAE7Ozsx+dLc3ByHDh2S2dra2uL69evYtm2bqFVUs2ZNzJkzR7bN8ssvv+hk2JuYmGDXrl3YuXOn4u83BCJi7p8Hf//9t95w88GDB7nbnD9/PkaNGsVsX7duXcTExOD169fidlmNGjWYq9PU8OOPP4q5T5MmTcKJEyfE3CclLZkaNWowV0ZMnTpVLO+OiopCcHAwgoODcebMGe5x8iQsmpqaKmq51axZU4dygYjErQ9zc3McO3YMHTp0UJSfyM/PV2TJFrYUlSDIXzRp0sRgVZ+/vz8sLS0RHR2N7OxsREVFoUWLFuLnwhxU68sYSLWtDKFfv36K+lVKECgrWJJWlZKrDSE6OhqDBg1CixYtoNFoMHr0aKxfvx4//PCDzC4jIwM9e/ZEWFgYbG1tER4eDmdnZ4SGhuq0Wb16dfTr1w+BgYFo0KCB3v6FOWNqaoq3b9+iXLlyqvd4Q+CZ2zy2ZGQmS926deHh4YEuXbrIrnUeSQWeMXy1zo12kpyAOnXqqJKTtWrVCm/fvsWIESPQpEkTFC9eXEdXiceOV3OEtV2AXU8G+I/TVKFCBcTHx6NGjRp4/fq1jt28efNw7do1g+RtSoRTarC2tlYsIVVCyZIlDZZ5S0tvpShatKhRFSrAfy58lv55YOxNwlCb2kmVLLT9lSpV+mKHRoqLFy+KuU/Dhg1Dr169MGzYMKxdu1bxdy9atAg9evRgqhwUctT++usvDBkyBEOHDkV4eHihjV0fWPNovv32Wzx8+FDkTzIzM8PRo0fRrl07nUTeDh06wNvbG0FBQbLE9nXr1uH7779XHcvhw4d1cpTUuETc3NwUc8D+LfAwZmsfD3347rvv9LIkSx+UasSW+jB79mzExsaKC627d+/Cz89Px7nhWWieP38ekZGR8PHxQaVKlUR+IKUk5Xr16uHt27fw9/eHs7MzzMzM0KRJE+7f8W+C1RHSvs4/f/4Ma2tr5sX8l47hq3Vu9EGNaE1IfOrTpw9atmyJ9PR0xYcpq50aCZVaKThru0CBAFnRokWxePFiMZl0z549irasAp7Vq1dnYqW1sLDA8+fPkZycDA8PD+Tm5iquCnnKtvWBlRhvwIABqlUWhpCXl1fobMYajabQjoG0TQGsJcBfir179+pUW+Xm5nKR2K1duxZXr14FERkk7crLy8OFCxewd+9ecYGQk5Nj1Nh5HMynT59i3bp1sLe3h4+PDyZPnixGyXbv3i1zbhYsWID09HTZ90uVKoW//voLK1eulL2/atUqbNmyBZs3b5bNLX9/f/Tr109xLH379kVSUhIcHBxkx0sKXkFQIdKrDWOSaY15aB0+fFjx+pI6eJUrV1ZNKP6SsmEBeXl5svL9unXrKt67eBaatWrVwqxZszBr1iycPHkSa9euxdixY/Hx40cd26ioKAAQRXJTU1PRvn17o34Lz9z+NxZa8+bNk/1taDGvXV31xSiUDbD/ZRD2dQWoJdppJ9yx2gno3r27+OrYsSOVLVuW2rdvr2PH2+6XIDs7mzIyMhQ/mzZtGo0dO5YuXLhAiYmJ4ksbu3fvppo1a5KFhQURFSSNaufQEBENGjSIevbsSUuWLCFra2saPXq0+BlPgpv2+fpSO23Y29vTkCFDqFOnTnTo0CFKSkqipKQkOnToEHXq1ImCgoKMatfBwaHQjoHSd9zd3enMmTPifnp+fr5OonZhQOm48uY+WVpaUk5ODlN/Bw4cIDs7Oxo7diwREd26dYu6du1qxMiJIiIimG0rV67MnEfDiokTJxr1vfr16xvM5ShSpAg1a9aMVqxYQZGRkTovbXz48EF8vX79mpYuXUqLFi0yany8yaz/H3vnHRbF2f397wpqjAIWiFiQIk0EKVIEFURQNNaosaKCokhELBgxliR2jRpFNLELohFrrNiNqCh2EUGxYK9YEBFQgfP+wTvz29md2Z1ZwDzP436ua65rd/bMPffuTjlz3+d8z+TJk8nV1ZX++OMPSkxMpMTERPrjjz/I1dWVJk+erFEfNMHf359WrVpFxcXFVFxcTKtXryZ/f3+V2zx48EBUzNeFCxfohx9+ICMjI7XxdG/fvqVXr16xiyZIObal2DLH+t27d2nEiBHUrl078vX1ZRdNkXLMiDnfvthUcClCa1LSdcXYCXH37l1MnjwZf/31F2e9lHa/++47UfVkAKjV5VDULhEr9te8eXMcOnQI/v7+7FNW06ZNlYafpaRti/2/hAQFiQjv3r3jDOHz8ebNG6X4h+zsbHh5eZW7mnFF1CCS30ZKCnBZUExvB6SL2LVr1w6JiYm8MS2aIHWkTcyogXwqOFAad9GxY0d07NgRO3bsKFMxzIKCAmRnZyvF7qSnp/Omg3fo0AE7duxQKflfHgVBpdSzk0dqPbh3794hPT1dKUX7w4cPaNq0KSuomZSUBB8fH0mK1lK4c+cOBgwYgEuXLkEmk8HFxQUbNmzgHbHOzc3FvXv3ONcUvuvUwoULERsbi+LiYgQHByMwMFBQRJDREnvz5g3nGq+oJcYgRe5DqjSIEIwKu5TizGKQcm0So0T/xU5LZWVlqRRak0dsoF1ZA/LMzc1555+ltCu2ngwAdOvWTfAzPqdFbICejo6OUq0qPl0JKVMXYv8vHR0dHD16FAYGBkp2ipoPV65cQVBQECpVqoT4+HhMmDAB//zzDwwNDbF3717WuTMyMoJMJuMtA5Gdna12SDc7OxtpaWlo0qQJ56J26NAh+Pj4lGsNIvmhYF1dXXz69Ilt/+HDhxpNn6mDz5mWGvtkYWGBNm3aoFu3boLBhps2bUK/fv0EYy7kbaXUDZsyZQoOHjzIxkIwtr/88gtOnz7NTtFKiaMRC/3/Yp29e/cGEaFx48bYsmUL6xQOHDiQ10lYuHAh/P390aZNG87vJS+IZm5ujhkzZmD69Ok4dOgQVqxYgZEjR4ouCHrjxg2Ng1mlBNnr6OiAiHivcyUlJZzza8OGDfDx8WGD0+VRrBcl9eENKI25TElJQV5eHgAI1s1atGgRfv75ZxgZGXGmBW/evKlkm5mZiZUrV8LT01NlfwDgp59+QmJiolotMUBc7ThNbAHVjhDjVBQWFmLOnDlq+ykWxeuImD6o4ot1bpydnWFgYMAbZKdKPfPixYvIyMjAwIEDkZOTg4KCAl4vXIyd/NMHE0egLvBTXbtSgkk1ySbYvn07MjMzMWnSJDx58gSvXr2Cg4MDx0ZPTw/Pnz9nD9ajR4/yjqgYGRnh2rVr7I2wcuXK2LJlC/r06aN0YRL7fzVv3hyvX7/mvXApFk0cPXo0fv31V+Tk5ODbb7/FzJkzsW/fPuzcuRPjx4/nVGePioqCk5OToJqxPIMGDcKCBQvwzTff4NixY+jTpw/Mzc1x7949rFy5knVAmSBesb8BUHrTnTdvnpLKJyNu1bFjR3ZdeHg4unfvjuzsbEyZMgUbNmzQON5GyKEgIvZGoIgUETsxmYOMuJyYp7tjx44pjaY1adIEHTp0gLW1NWf95s2beUcNhgwZgqZNm7LOjZQ4GrHIZDJMmTKFVSpfu3Yt/P39sXfvXtjb2ws6zj/99BOqVKmCwsJCtfFGYguCMvWNALDK4qpivp4+fYq7d+9yjkNvb28ApVlH8qiqtH3+/HnMnDkTbm5uGDhwIOf8io+PR3BwMLvNqlWrAJRWqVeHlIe3W7duwcrKStAhUryexMTEIDMzU5QwoZQCvMbGxqIcG6D0N2Bqxy1cuBA//vijoEKzFFuxjpCU4sxSkeqM8SJ6kut/DClCawzLli2jZs2akYWFBRER3b59m9q0aaOxXZs2bdjF39+fRowYQVlZWYJ9FtsuUakuTNOmTalBgwZEVDrf++OPPwq2vW3bNlan4fHjx3T16lUlm6lTp1KHDh3IysqKiIiePHnCK/R2/vx5cnZ2JgMDA2rZsiXVr1+fLl++rGSXlpZGt27dUlpfVFREGzdu5KwT+3/l5eWxcRHqkJ+3VYwbURR2JCqdY54/fz6NGjWKRo0aRfPnz+f9v+QF3by9vdnvnpWVpTRXLOU3ICJyc3OjiRMn0q5du2jv3r3sIkRycjJNmDCBfvzxRzp58qSgnTqCgoJULopIEbGrCKysrOjFixdK658/f06NGzfmrGvcuDEVFBQo2ebn57PnmhSkxNE4OzsrHRNHjhwhU1NTunLliuBvZW1trbbt7Oxs+v3338nR0ZECAgJo8+bNKnVG5DVoHj16pDKmZ+bMmWRgYEDOzs7k6upKrq6ugppb69atIz09PapduzYZGhqSoaEhGRkZKdklJSXRyJEjqUuXLtSlSxcaOXIkHT9+XLAPmzZtoqFDh1JISAhHt0cTmBgYMzMzpYVPHLFVq1Zq2+zbty8RlV5nnJ2dlRY+xGqJERG5uroSUem1itFfEtJok2IrViPN39+fatasSR07dhTU0ZKC/HkgRadNiC/WuRGL/IXK0dGR8vPzOX9C06ZNlbYRaycVKe1KCSYV67Q0a9aMioqKOPt3cHDgbTMnJ4cSExNp37599ObNG1HfT4jAwEDRtmJvLIGBgRwHZtCgQZzPFRVnpeyf+R2J/u+iwiD0e6mD+Q003b4i4QsEliJiR1Qq+jdnzhzy8/Mjf39/mjdvnsobcWJiIkVHR9PChQvZRZ7Vq1dT/fr1KSwsjObOnUtz586lsLAwatCggVLw5IwZM8je3p7mzZtHCQkJlJCQQPPmzSN7e3uaMWOG5N9DamCkra2t0nc9fvw4NWrUiIyNjXm369Kli9pkgipVqpCbmxstXbqUdu3apbSUBQsLC3r58qVo2xs3bpRpf4pERkaSq6srLV68mBYvXkzu7u4qH96ISo+x8krESExMpFGjRtHBgwcpKSmJXeS5cOECEZX+l3wLH8uXL6dq1apRrVq1VDqCRES+vr70/v17GjlyJPXu3ZsiIiLI3d29zLZiHSG+IHW+QHWxJCYmSu6DKr7YaSmxHD58GPPmzQNQWj1YsZYKX10osXZ+fn6YOnUq2rRpw64bPny44DCm2HYBIC8vjyPUJZPJBKfbdu3ahUuXLrHDofXq1eOdaqhWrZpSzAYJDJsbGBhwpkjKgpR4Bvn/S12bdevWRW5uLvT19Tkp4k+fPhUtKMe3/4CAAIwePRqzZs2Cv78/Nm7ciP79++PAgQNKU2NiYX4DMUPBUlOANSUjIwOrV6/Gxo0bOcVAAWkidgAwYsQIvHr1iq0svW7dOly/fp03fbR///64fv26yjTooUOHom3btti+fTsbJGxhYYGTJ08qBcZPmTIF3t7e2LJlC06dOgWgdMpk6dKl8PHxkfy78J0TquKuFi9ejOPHjyMgIIBd7+Pjg/j4eISEhPDuo1q1anBxcUH79u05x6p8gKinpydkMhmvBIR8fMrff/+NrKwsVrTT1taWFeb8448/eFOc69atqxRXJ4ShoSFsbGzU2t29excPHz6Em5sb5zp3+PBhpSmJ3bt3IzU1lbUbPnw4HB0deaddU1JSEBwcrBQPw5fgcf78eTRt2hRff/01tmzZgnPnzmHcuHFK009nzpzB+vXrcerUKc4xyBSaBcDq00g5hsRqiQFcuY+FCxciJydHUO5Diq1YjTRmWos53tWl4hcUFCAmJkYpjoa5HsnfL6TotAmhdW7UIH+hMjIyws2bN9k/MTY2lvcmI9buxo0bCA0NxS+//MIGWV64cEGwL2LbBaQFk4p1WkxNTXHy5ElW9Xj27NlwcnJiP5efs1dsi0+huCIQcrb4OHjwIIDSYGX5LBlDQ0Ns3bpV4/0vXLgQUVFRaNCgAWrXro379+8jKCgIfn5+vMXypJCdnQ1HR0d4enpybmryDsuuXbvg6uqK/v37o2bNmmXanyJ5eXlISEjA6tWrcfnyZYwbNw5HjhxRspMafHvmzBlcv36dPX46d+4sWDTy0qVLSE9PVxscbW5ujvHjx4v6Xt7e3my8SFlh9HnExl0JaTR5e3tzbsjyxQ3t7OxgZ2ensh/Hjx8X1d+5c+ey+ipAaQzb5cuXkZeXh9GjR/M6N+3atcOYMWOUqmfzxbp1794dixcvVllpe+PGjRgzZgyMjY2Rk5ODLVu2sAG4UVFRSs5NzZo1ObGElStX5lV5Bkpj62JjYzFixAicOHECS5YsEXx4CQkJwaVLl3Dr1i1MnjwZvXr1QnBwMHutYGDiyVSdX8HBwSqrzfNdC8RqiQGlDibDlClTys1WrCP09OlTDB06lI1/8vPzw6pVqwQzwYYNGwZ9fX2cPn0akZGRiI2NFTznpDhjgmg8hvSFID/EfOvWLXJ1daVq1apRw4YNyc7OjjfmQqyds7MzPX36lFxcXGjOnDlEpDp/X2y7ROrrycjTu3dvOnHiBDk7O9PHjx/p119/5Z0KevbsGQUEBJCuri5VrlyZ2rdvzyn6WBG1ZIgqpgCcs7MzZWRkkJubGxkbG5O7uzu5u7uTsbExubm50bVr18rc19TUVFqyZAktWrSILl68qFF7iu2KGQrOysqiKVOmkJWVFfXv35+OHDlSpn0TlRaqCw4Oppo1a1LPnj1p7969rI4RH8eOHWOLYsqTl5fHW4PHy8uLU1vq/fv31LJlS962AwICRNWhSkpKori4OHry5AlnPd/QeVZWFiUlJSnF2x06dEjtfhRxdnaWFHclpd2K4Ouvv+a8l9cqEfoPxMamEHGLbcoX3ZTH0dGRHj58SEREhw8fJhMTE7bmGt/vNWrUKPL396f169fT+vXrqX379jR69GjeKTfFmnxEytPFirbMlKfQ/r29vXm3l2fp0qVKy2+//Ubm5uZUtWpV3m3EaokREaWnp9P3339Pzs7O5ODgwC5ltRVL586dadasWfTmzRt68+YNzZkzhzp37ixoz/z+zH5zc3OpdevWZeqDKrTOjRoULyjFxcWUkZFB6enpKgPuxNgxbefm5lKHDh0oNDRUbayH2P0TiQ8mVee0KPL+/XvBqrZiaNu2rST7inJu3N3dadu2bUqfbd26VTA4Uky76enp5ObmRvXq1asQp4moNIZKXYXdkpISOnDgAH3//fdkY2NDBw8e1GjfRKU3qHbt2rHV0IlI8GYmBT8/P4qOjqYhQ4aQvb09TZ8+naZPn07NmjWjoUOH8m5z7do18vT0pJ9++ommTZvGLvIsXLiQLC0tqXPnzmRoaMgWZSVS/i03bNhAhoaGZG9vTw0bNmSrv/PZisHJyalC4q7kb7K5ubn0ww8/kJWVFVlZWVF4eLig+KY6hG60ROICl8sDxeve1atXyczMjA4dOsT7H8gnYyguikJyTGyJj48PXbx4kV68eCHomNvZ2dGzZ8/I39+ffSDh+78iIyPp+++/p82bN4uKYyopKaFVq1aRiYkJ9evXT/ChVIrT6ODgQPPnz6ekpCQ6deoUu5TVVqwjxJd0wbeOgbmmOjs7s/cPW1vbMvVBFdppKTUQEXJzcznrGjRoAACsfDYzvCrWjoEZVtfT08PevXsxfPhwjkgYg9R2GcTWk6lbty4OHDiA/Px8EBGqV68uaJuQkIAjR45AJpOhXbt26N27t9r2FZE6PSVFm4VETkvp6OggJydHqWwAAPTq1QuTJ08WvU/F/QcHByMqKkqp7W3btiE4OJgzLy8W5jeQMhQsNgVYDGvWrMHatWvh5uaGQYMGISgoSOO25Ll8+TKrieLq6sqm57q4uAjqO4lJg46NjcXFixehr6/PFjrNz89HYGCg0jEyf/58XL58GQ0bNsSRI0fQp08fxMbGom3btiqPJ1VxNNOnTy/3uCv5KY4ffviBjQuRyWRYsWIFfvjhB9EFKOXR0dFBZmamUlxMZmam4LUFKK0fxkxJtm/fXmUK88OHD9nCpj4+Puw1jKGkpATv3r2Dnp4egNJCufv27UOnTp2Urn+AuFRwBrHlZQBg7NixsLGxgb+/P1xcXHDnzh3e6a6LFy8CKC3AzKCos8Owa9cu/PTTT2jUqBF27doFZ2dnwb5KkefQ0dERPe0qxbZv374YNGgQwsPDVV57iQjPnj2DsbExAODZs2cqz5fatWvjzZs3+PbbbxEQEABDQ0M0bNiwTH1QiSRX6AvkxYsX7DBqpUqVVA6virVTBV/an5R25VPy+BZ55Ic9+RZFNMlQ4EPV0/Dy5ctFtfHixQs6evSo0pTDixcvKC8vj83gefXqFR05coQd8pbHy8uL1q9fT8XFxey64uJiio2N5c0WE9svVU+7ip9JzSQTMxQsNQVYCjdu3KAJEyaQsbExVatWjVauXCmYoi8GTaZoxIwmKD7lPXz4kGxtbSk2Nlbp+BM7ajBw4EB6/vw5EREdPXqUDA0Nyc3NjYyMjOjvv//mtPHhwwcaM2YM6evrk5mZGclkMtLV1aWAgACVcg+qkO8L3wivphl+ZmZm1KRJEzp06BDl5ORQTk4OHTp0iJo2bUp//fUX7zYrVqwgExMTGj16NI0ZM4YaNWpEq1at4rXduXMn1alTh7p160bdu3cnIyMj2r17N8dmyZIldOzYMaVtMzIyqF27duz7mzdvEpHwtUsdqsrL8FFcXCxaWkKRU6dOUcuWLcnd3Z33u/Ehn/6tLhV87NixShlaQkixFXtOrl+/noyNjSk4OJiCg4OpXr16tGHDBkF7ZqahpKSE4uPjKSYmRjBrTdOpW3m+2PILqrC2tuYE8vn4+KCwsFBlNVcpdlIlxMW2C5R66KqCSeWFmypVqoSGDRtCV1dXyePmUyi2trbmZCgUFBTA0dGRV5VTFYw0O9/3l88Wk/8dxAZorl+/HqGhoTA0NERcXBwCAwPRsGFDZGVlYdmyZRw149u3byM0NBQXL15kn7yfPn0KFxcXLF++XEnsTQjF46Vly5YYMWIEBgwYgEqVKgEofTKNj4/HihUrcPr0ada2SpUq6NixI0JCQtCpUyfWXggnJyelquuK66pWrQpHR0cMHjyYVym2rBL1QGmmyd69e7FmzRocO3ZMUMhPHcyxIKWIbNeuXbFhwwaV54GzszMOHjyIb775hl335MkT+Pv74+HDh3j37h273sHBAadPn2ZHDYDSTDBm1ODVq1cAAEdHR6SmpgIoPSejo6Ph5OSEu3fvokePHrziglevXkVSUhKKi4vh7e0tWEZEDPLy9Pb29jhz5gzb57y8PLRo0YJ35FdMuyNHjsS0adPw5MkTAKWjw1OnThVUym7WrBmOHj3KKnZnZ2fDz8+PVwTPxcWFo7rMVNrWpFxF8+bNcfHiRdGlYIBSJfTo6Gjcvn0bf/75J+7cuYP79++jbdu2SrYrVqxA3759YWBggJEjR+Ls2bP4/ffflQJfT5w4wds/ebtKlSrB3NwcXbp04T2v+UofMGroRMSOttapU4fNXpPn9OnTCAgIgJ6eHr766is2cYPvN5BiO27cOHTv3l1UgP21a9fYwHVfX1/BJACpSOmDEF/stJQqaW75Cx9Q6ozcuXMHa9euhaurKzw8PDB06FBOCrcUOykS4lLaBUovHGvXrsWyZcvU1pMZOHAgTp8+jV69emHIkCGwsrIS/E0AaRkKYujevTs8PT05Kepv377FokWLlH6H1NRU9kY1bdo0HD58mHNjYZybBQsW4MaNG3j79i28vb1x5MgRuLq64vbt2+jZsyfHubG0tMTRo0eRnZ3N1kYyMTFRKrEASDte4uLiEBoailGjRik5TbGxsRxbc3NzeHt7IyoqCqGhoRg0aBCGDBki6FiRiKFgsSnAZUFHRwfdunVDt27d8PTp0zK3t2fPHvZ1YWEhTp06hRYtWvA6N2LSoCdOnIg7d+5wnJv69evj6NGj+OWXXzjtDR8+HBcuXICvry+7zs7ODomJiWzVb6DUmWfIz89nMwXNzc2V0oozMjIQFBSER48esQ7mvHnzYGJignXr1ml0EwgPD2dfDx48GC1atGCP5y1btnCUfKXQo0cPhISEICQkBNnZ2QDAew7IZ2sp2vDZM4ittC0G5lhXN31z9+5d1gEKDw9HcXExm+Zfp04d9OnThzczddmyZQgNDUVycjKuXbuGWbNmYfz48UpTyUzaPFB6vGZmZsLe3p7jsP3888+SK5Uzvz/Djh07WIdakeDgYERHR8PV1VXt1I0U2169eol2hOzt7QVLrShy4sQJjB8/Hrdv3+YoVfNNO0rpgyBlHvv5L0Umk5G5uTlvAFflypUFtysuLqZt27bRN998oyQcpomdVMS2KzaYNDc3l1auXEmenp7UunVrWrdunWAmipQMBVV07dqViIjWrl1LXl5edOnSJfYzMzMz3m3EBmjKD2cqBg2WZahTk+PlxYsXdPHiRTaIkQ/5qYbk5GQaOnQo6enpUevWrSkuLk7JXupQsCqkTI/IV91WFEoUkzkihNB/kpWVRf369eP97Ndff+VdNEFeOVkdHTp0oIiICHr37h1NnDiRNmzYQCUlJZSYmMgbxCo2WP3vv/9mBfGys7OpV69eZGJiQp07d6ZHjx4J9icxMZEiIyMpMjKS9u/fL2gzcOBA8vHxIR8fHxo4cCDt27dP9HeWR/5Y7dGjB02aNImdNpkyZYpgZXZNKm0LIfYclu8rE+Qqv63QFB6z3fTp01mxRzFB5WfPnqWwsDBRfVNky5YtKj9v3rw573oXFxfR+5Bia21tTWvWrKHU1FS6du0auzBoorzMtLt161a6f/8+PXr0iF006YMYvljnxszMjB4/fsz7WcOGDXnXX7hwgcLCwsjMzIzCwsJ4ZfPF2EmNdZG6f4Zz587R8OHDydTUVCkmgI+DBw+SkZERzZs3j/dzKRkK8tLoCQkJgvu8d+8e+fv707Rp06ioqEgwMyA8PFzUjcXFxYWuXbtGJ0+eJENDQzYj4Pr162VKfdTkeBED38UgLy+PVq9eLZiGm5aWRjExMRQTE6Nx9pXQvoWQvzEobifmhqMqRkoITWNIpCDlN3B0dBQdRyMl7srOzo7NfBs8eDD99NNPlJ6eTr/99ht9++23Er4Nl8mTJ5Orqyv98ccflJiYSImJifTHH3+Qq6srTZ48WXJ78v/zixcvqE+fPlSnTh2qU6cO9e3bl41HUuT27dvk4eFBlStXpipVqlCLFi3o9u3bGn0nsf+XfF89PDw464qKigTVbps3b04JCQnUtGlTVr5CrLp8eaT4yysov379mvbv3895sJNn6tSpSrFLQkixVecIaaK8TCScfq9JH8TwxTo3ERERgunRoaGhnPeLFy8mZ2dnat++PW3atEkwOFOsHd/Tv6q0P7HtEkkPJv306RNt27aNOnbsyErQq7rhqIJxJKQGHpeUlNCCBQvI09OT6tevz2sjNkBz3759bA2bI0eOUJs2bcja2pr09fVVOlnqkHK8SKE8Auc+x77lbRW347vhSAm+JSJOOu2OHTsoKipKMB3/9evXFBoaSo0bNyZLS0sKCwvTOKhZk99AjH6RlGD1Jk2aCPZHKLX27t27NGLECGrXrh35+vqyizyWlpa8wbCFhYVK9bXEUFadnXfv3tG7d+/K1IYUqQeGYcOGUXx8PDVr1oxu3bpFISEhFB4ezrvdmTNnqFu3buyIXmZmJo0aNUrJTv5h9NKlS/Tnn39qXGJH/j9nkkSY61uTJk0ER+Vq1qxJMpmMvv76a6pVqxbVrFmTatWqVWZbKY4QQ05ODqWlpam0mTNnDq1fv15UgLYmfVDkiw8oVlSntbCwULKpVKkSnJ2d0ahRI945VEYdVqydVKS0KyWYdOzYsdizZw/8/PwQHByMFi1aaNQ/BiY4VGrgMfMfpKWloVKlShg5cqTgPsQGaN6+fRuPHj1CUVERateujYYNG3LiLzRFzPEihdevX6N27dpq2+3Xrx82bdoEZ2dn3mNAk+BM5v+Saqu4HV87UoNv5eNddHV1YWlpiQkTJvAGjnbr1g0NGzbE8OHDAQCrV6/GgwcPlCpRS/1e6mjSpAn09PQ4cTQPHjzgjaOREqzu6+uL2bNnw9PTE126dMGqVatgbGyMd+/ewcvLC2lpaUp9cXd3h5+fHzw9PTkxFJ06dWJfW1pa4tq1a0pqvAUFBbC3t8edO3dEfW8GFxcXLFq0SHQyhNRK22KQD6pW11fmf83Ly0NkZCR27twJoDTWb9GiRZLl/OWRPy51dXVhZWWFGTNmsCUXpCDlGJTn/v37vOuZquqa2taqVQtv375FtWrVULVqVUGF+Q4dOiAhIQG6urps3M2gQYMwffp03n3t2rULgYGBrCQF0y5fGQyxfVDFFxtQfP36dQwePBgPHz5kSxgwF6rY2FiOtDlffRs+xNrJI0YrQkq7UoJJo6OjYWVlhXPnzuH8+fNK9lJPOMZPFht4LP8fmJqagojw4MEDxMXFKd0sxAZoMm3y3YAU/1cpSDlepPD8+XN06NCBt13578VoVCxevFij/ZSVGzdusI6k/Gsi4nVapQTfAtJ0S27evMlxZGJiYtCkSRPR22vKgwcPsH79elH6RVKC1ZcsWcIG1xsZGcHDwwO+vr44f/48Jk2axNuXwsJCzJkzR2V/g4KC4ObmhoEDB7I3sfv37yM+Pl6j4GMikpQMMXbsWOzduxfdunXjtRUKDmWCjfkyjGbPni26rww1atTAihUrsGLFCkH7hQsXIjIyEuPGjeP9XDGzSYoeTUVhamqK/Px8NlPSyclJ0GGTYquYjSnE8+fPUbNmTWzZsgXdunXDggUL4OLiIujcjB07li0Noy6oWWwfVFKmcZ//YipCnVZscCJjJ0Urojz3T1QasCk0Z6pu7lQICwsL2rVrl2DgsSJS/gOxthXxv/6ntitmKFgVUqZkpB4rYmOkXrx4wQlgT05OptGjR1NMTAxnSkeetm3bcqZOX7x4QX5+fqK/izxSfoOKVPLNz8+n1atX07hx4ygiIoIWLFhADx48ELTv16+foP6JPElJSTRy5Ejq0qULdenShUaOHKnRuU1EStXUy5N3797Rjz/+SA0bNiRdXV3S1dUlExMT+vHHHzVSXp4+fTr72tnZmZYtW6ZSU4rR11IXrC4fE8O3aIKTkxM7TaS4qJo+Sk5OJmNjY3JyciInJyeqV68eR11bU1uiUhX65ORkSk5OFkwwYabhRo4cSXv27GG/ixBM7JNYxPRBFV+scyMl4E8sUueDHRwclC7SZQl6rYgyBUTK2TFC1KhRQ3TAMZG0/0CsbUX8r/9J7QYEBNCbN2/o3bt3ZGpqSqampjR16lSN9i1/A1DH33//rbbchzxiY6RatWrFCrPdvHmTatSoQSNGjCAfHx8aP348p82xY8fS2LFjqWfPnlS3bl0aMmQIDRkyhIyNjen7778X3Td5+OpfCdGkSZNyF33UFH9/f6pZsyZ17NhRUKRTEzZv3kw//fQT+1uPHTuW12737t3szXz+/PnUs2dPweD2c+fOsTenzZs3U2RkpFJwfs+ePSk8PJwyMjIoPz+f8vPzKT09ncLDwwW/19mzZ2nFihUUHR3NLnwcP36cBg8eTHXq1KHevXvTgQMH1JYuEUI+JkZToVZFEhMTNarL5+HhwSmhkJycLOhASLEV6wj16dOHOnToQKampvT+/Xt6//69Sudm1qxZFBMTQ8+fP1frEEp1xvj4Yp2bilCnFfsUyNjxOTJlcW40DRBVhyYZCmKQ8h+Ita2I//U/qV3mN968eTNFRETQx48feTM/yjMFmKg0sLVu3br0448/0o0bN0Rvpy741s7Ojn09Y8YMGjhwIBGVjmQoBmgKPVXzpYIXFhbStGnTKDg4WEmmQDGYVN7ZKikpofnz51PXrl3pl19+oY8fP7Kf3bp1i9q2bUsGBgZka2tLtra2ZGBgQL6+vpSZmSn6N5HCpEmTeNeLKaBKJK0g6KhRo6hz585Ur149GjduHJmYmNCQIUN4989cp65cuUKOjo60fPlyatWqFa9ts2bNqKioiG7evEmWlpY0ceJEat++PcdGlZPPly00a9YscnZ2pjp16lCPHj1IT0+PunfvLtgGUWkW4rp168jHx4dMTEx4bd6/f09//PEHjR07lkaNGsUuZSE/P5/mzZtH/fr1E+WIih2x4MsmFApAl2Ir1hEqKCigv//+mz1/Hj16JBj8TCSugKrUPqjii3VuKuJCJXXkRopWRHnuX6qtWKdFftj648ePlJmZqTLFXcp/INa2om5A/yntihkKLu8UYIbz58/TDz/8QLVq1aKWLVvS2rVrBS++YouHyh+H3377LUfbpyyZZEOHDqU+ffrQggULyNbWlsaMGcO7T8X306dPp3bt2tGmTZvo+++/p4iICKW2xegXlRdCN2ExSC0Iam9vT8XFxeyN8OnTp0pOiOL2v/32Gy1btkywTfn1qipt29rasiN48mRmZvIWV2zatCkVFBSwN+gbN26ovXY+e/aMfvvtN2rSpIlgKnhAQAB17tyZpk2bRjNnzmQXPh48eEAbN26kjRs3qtQjGjBgAIWFhZGpqSktWbKEXFxcOMejPFJGLLy8vOjw4cPs+yNHjpCXl1eZbcU6Qg8ePGAzn06dOkUxMTEaF2/VtA+q+GKdG4byvFBJdW7ktSIMDQ1VakWU5/7LYitm2HrPnj1kbGxMVatWpdq1a5NMJhMU5yOS9h+Ita2oG9C/3a6YoeDyTgHma2fjxo3k7+9PBgYGNGzYMCUbsbFEnp6edOXKFXr69Cnp6elx4kxsbGx49y9fCVyoKriDgwM79ZCXl0edO3dmU/YVfy/5982bN2djMwoLCwVvguUJnxCas7MzOTk5qYzzUXcuOjo6sjXVDh8+TCYmJnT06FEi4nccGR0SR0dHdsRK6Ps3a9aMUlJSyMPDgzIyMlTaiqm0vWfPHqpbty517NiRRowYQSNGjKAOHTpQ3bp1WSdeHkbYTv5/Frr5bd++nTp37kxGRkb0ww8/0Llz53jtiLhp+aoQUy+LgfldmO+cm5tLrVu35rWVMmJx/vx5atSoEZmbm5O5uTmZmpoKShNIsRXrCDk7O1NBQQE9evSIGjZsSH379qVevXrxtskg1iGU4owJ8cVmSzEYGRmplA6XAonMqiciFBcXY8GCBUhISCiXfUvZv1RbhoiICNy9excXL15Ev379sHXrVrRr107JburUqUhJSUH37t1x+fJlbNiwQVBCHJD2H4i1Lc//9T+p3djYWBw4cACOjo74+uuv8fjxY6WsGSLilbcvKSnR6H9XpGrVqujduze++uorvHnzBgkJCWw9MAaxFdfnzJmDtm3b4t27dxg5ciSb4XbgwAHY2try7l++3EVhYSESExPh6enJsSkqKmJT5qtXr44dO3agT58+vLWS5FPrdXR02JpsVatWha5uxV8is7KysGnTJqXsFSLilAuRR8y5SERs1WV/f3/s27cPXbt2xcqVK3nlBPT09JCfn49WrVohMDAQxsbGghk1M2fORGhoKPz9/dGkSRNkZmYKlgwRU2m7c+fOuHPnDvbv389KIvj5+aFDhw6oUaOGUpvVqlXDp0+f4OTkhPHjx6Nhw4a8WXgAsHz5cgQHB2Pr1q1KafGK2Nra4uXLl2ort0+bNg0pKSlK9bK6dOnC21egNGX8/fv30NPTUyqzwFBQUMApceHl5YXCwkJeW6asTGZmJgDAxsYGlStXLrNtdHQ0evbsyWY0lZSUCMqYfPXVV9i3bx9CQ0MxZcoUODo68toBpangQ4cORatWrSCTyTBmzBisWbOG9zeT0gdBJLlCWlQiNjiRsStLlk1Z9k8kLZiUecoTO2zNqEvKP8mVh+KkFnFDwTNmzGAFGRMSEighIYHmzZtH9vb2NGPGjDLtPy0tjcaMGUPffPMNeXl50erVq3mF2aTEEhUVFSllsuTl5XHaVVUq4uXLl0qV0b29vZUyyT59+kQ9evRQmufX0dFhM1OqVKlC2dnZrP3nGLlp06YNJScn834mpH4t5ly0t7dXOjbS09PJzMyMateurdTms2fPqLCwkPLz82nGjBkUGRmpMmNLU8pSaZshLS2N8vLy6MWLFxQSEkI9e/aky5cvl7lvGRkZZGlpSf369WNLnAQHByvZSZk2CQgIoNevX9PkyZOpZcuW1K1bN8HyE1JHLIqLi+nx48dqK4hLtf348SOlpaVRWloaJ+5MHjs7OyosLKRevXqxo02qVMWdnZ05qvq3bt1SOYMgpg+q0Do3Erh48SIFBASQlZUVO7zHpygs1u6XX36hmTNn0uPHj0WlE4ptV4g///xTtK08zDSJ2GFrZhi1Q4cOtGPHDrp06ZKkfmoRRuxQcHmmABMRLVu2jJo3b05169al8ePHs1MRQpR3jJK6aVT5wGSi0psfX3mSoqIi2rhxI2edYmYKc2y/ePGCduzYIbmvUrl3756gwrJiIDCDmHNxyZIldOzYMaVtMzIyqF27dmXpMk2dOpXevHlDJSUl9O2331KdOnV4pyGJStOsc3JyiIjohx9+oObNm1NSUhLHJicnh8aMGUNjx46l3Nxc+u2336hZs2YUGBhYJvVp+Wk+FxcX6tChA/3++++CmX8tW7akgQMHUnR0NC1dupRdFJFSL4vZV0lJCcXHx1NMTIzgdV7K9NG6detIT0+PVWQ3NDQkIyOjMtsSiXOEZsyYQTVr1iR3d3cqKSmhJ0+eUIsWLQTblBpHI8UZ4+OLVyiWgoODA8LDw5VUQRUr/Iq14xOpElJslNKuEI0aNWKHfOU5cOAAxowZg6ysLBQXFwsqR7Zt2xZ79+7FhAkTkJ2dDWNjY6SkpODs2bMcu02bNqFDhw7IyspC3759kZOTg8WLF2PAgAGi+qlFGEbNdOXKlXjx4gU7FKxq2q886NSpE4YOHYquXbtKmqoRI2InBnll2iVLlrDri4uLce7cObx48QJHjx7VqO3/FqKiojBv3jwA4s9FMWzduhXff/89MjIy8OuvvypVbeZTGGaOucOHD2Pp0qX47bff0LdvX1714GbNmuHq1atITk7GpEmTMGnSJEydOpUjetinTx/Uq1cP79+/x+3bt2Fra4ugoCBs3boVL1++RGxsLKfNp0+fYvHixbh16xanr/LKyUlJSUp9efnyJdasWQNHR0deEcSmTZsiPT1d9Q+G0mmowMBA9vu6uLhg48aNZVYsB4BPnz6Jmj5q3LgxEhMTYWNjo7ZNKbaxsbGIiIhA5cqV2XuUTCbDixcvlGxzcnKgr6+PSpUqIS8vD2/fvkWDBg14223Xrh369OmDIUOGACgVp01ISMDhw4fL1AdBJLlCXzhio7WlRnWX5/7lUw3ll+7du9PXX3/Nu42VlRUdOHCA3r59S3l5eeyiyOcattYijNihYCkpwGJQFCsrr6wIsciP3AQFBbFLSEgIzZ07l/fpPi4ujqZNm6b05Dt79mzR+x00aJDmnS5n5H8D+XNx5syZZToX5XW35s+fT0lJSXTq1Cl24YOZqp48eTLFx8cr9Y+vfVWVtplRp6KiIqpduzZ9+vSJiEpHO/jkMVq0aEEjR46kuLg42rBhA7uIobCwUPBa2q9fP5WBroqIqZeVlJREbm5uVKtWLdLT02MXPsaNG0fp6emi9u3u7i66n1JsLSwsVMo9MFltUgs/Symgqq4PYvjiA4ql0LJlS1y4cIG3RIImdkCppPuJEycgk8ng7e3NWw9KSrsHDx7E4sWLUaVKFc56IsLJkyd5t9HX10dAQIDavtatW5d9PWXKFJW2+/fvV3qqEpI21yKefv36wdjYGNbW1vDy8sLTp0+Vgj43btyIMWPGwNjYGDk5OdiyZQsbcBsVFcUbBK6OmjVrQiaTcQKSq1WrBn9/f6xcuZJzbFQ0YsqRREVF4fTp03ByckKnTp0wceJEjB49GkDpSMVPP/0kal9SykJUNPK/vfzvLR+gXZZ2dXR02DIf6qhevTrmzZuHhIQEJCcng4jw8eNHXttKlSph8+bN2Lx5M/bt2wcASrbM6ISOjg4aNWrEjg7KZDLeEe73799j6dKl4r6gAlWrVuVtEygdabS3t4enpycn+FgxmLVnz54YOnQoOnToINgWw7BhwzBr1iy4u7urLTugr6+Pzp07w9DQEMHBwejfvz8MDAx4bbt3747Fixejf//+nL7q6+uXydbQ0FDlCI+mZTUaN26MlJQU5OXlAQBvoLjYPohBOy0lAQcHB2RmZsLS0pJzgCjWYBJr99dff2HUqFHw9vYGAJw6dQoxMTHo27evxvtv2bIloqOjeR0gExMTdopAnl9//RVOTk7o3r27im8P0cPWAwYMQEZGBpydndmTWSaTKWXUaNEMdUPBTk5O2Lt3Lxo2bIgjR45gyJAhiI2NRdu2bUUXHhTDy5cv8eeff+LatWvYvHlzubQphLOzMzZu3IhvvvmGzWTZunUrNm7cCEtLS/z666+ci6WDgwMuXryIKlWq4NmzZ+jatSu+++47/PTTT0q/Qe3atXn3SUR49+4d51j/N3FxcYGpqSlvphODJsV5manOcePGoXv37uz1SBW3b9/G0qVL4e3tjR49euD27dvYtm0bJk6cqGSbkpKCuXPnwtfXF6NHj8bNmzexdOlSzvSiq6srkpOTUbVqVXz69Il1dgoKCtCiRQuladfg4GBMmjQJVlZWkr/v1atXERYWhuTkZKXP4uLieLcZPHiwkt26detw69YtBAYGYsiQIYI3Yzc3N97afar4559/EBcXh8TERLRr1w4bN25UspF3qpgHD6GwBim2c+bMQbVq1UQ5QlJ5+vQp7t69yzmn+I638uiD1rmRAN8cLlBa9VgTO1tbW+zfv5+tMHvv3j106NABN27c0Hj/Fy5cQP369VG/fn0lu5s3b/Kma4qtwNqsWTMMGjRI6QlEPnWR+V7p6elqn1K0iEdKhWXFGJy0tDQ2BTgqKkqjCsSqKE+HSYgZM2Zg79692LFjBxo0aIArV67A29sbkydPxtWrV/HVV19hzZo1rL29vT2uXbvGvs/NzUXHjh3RsWNH7Nixg/MbGBkZ4ejRo0pPyESEli1b4vHjxxX63cTi4uLCjj4JoXgTFtvupUuXcPr0aQQEBEBPTw9fffUVex0QehIvT+7du4cGDRooxZc8ePAAV69eRefOnTnr09LS0LZtW1hZWXFufseOHWNff/fdd0qO4MuXL3Hz5k1s2bJFpRPH3BZVOZJAaRr/+vXrER8fD2NjY16Hae7cuWjQoAH69OmjNKKuivPnzyMmJgabN2/Ghw8fRG9XVqQ4Qrm5ubh37x7HWWGK6ioya9YszJ8/HxYWFpyHXvnYK036IIR2WkoCjBPx5MkTAOB1IKTYff3116xjAwBmZmaCuhJi21U1ZSWkQyG2AqvYYWszMzN8+PBB5XfRIg0pQ8ElJSV49+4d9PT0AJSOYuzbtw+dOnVCbm5uufdN3Q1AHXfv3sXDhw/h5ubGaoIAwOHDh9kptKlTp2LLli3sCNW2bdsQGBiIqKgoFBUVwdnZmdNm9erVce/ePZiZmQEofeI7ePAgAgIClAJGmzdvjtevX3McRAZ1eiefEyJScl4+fPiAqlWrlrldoHQ0hBn1FXowiYyMxMKFC3kdB4A7ciSl0jbzPynSqFEjNGrUiH0/cOBAxMfHIzAwEGFhYSr7qjgSLZPJ2KrrQqN1Dx48wLBhw9gHSV9fX6xYsYLTB3lMTEzQtGlTWFtbC47ONGnSBIGBgQgKCgIAlTfqFy9eID4+HuvWrQMRITg4GL/99htvuxUFn0YWH4sWLcLPP/8MIyMjjrNy8+ZNXvu1a9fizp07qFOnTrn1QRVa50YC169fR69evVjnomHDhti6dauS2Jg6O+YG06lTJ/z6668ICQkBEWHdunW8gkZS9y/mZiGPqakp8vPzWSfHycmJ1zHx9fXFiRMn1A5bL1y4EP7+/mjTpg3nqernn39WuZ0WYfbu3Qug9L9Vx/Dhw3HhwgX4+vqy6+zs7JCYmKj2yV8KxcXFWLVqlco4MXVIiQ+Sz9I6e/YsQkJC2PWKN7i5c+fi7du3nHU1atTAoUOHEB0dzVm/fft2wYyUis5C4yM7OxtpaWlo0qQJ6tWrx64/dOgQ+zotLQ39+vVDTk4OHj16hIsXL2Lz5s0a3Qhnz54NoPT3YTJZhGjTpg0AZceBD2aaUChmRBPkHdPp06ertBU7iiWfhTZo0CB06tQJW7ZsARFh9erVGDRoEI4fP87Z5tKlS1i3bh02b94MNzc3DBkyBLt27eJtf+zYsdi1a5dKR4zBzs4OvXr1wurVq9GiRQuVtrdu3UJERARSU1M5Qn+KI+5SbcUSExODzMxMwYd3RerWrSvKsSk3yhSO/IXRpk0bjkbGpk2bqE2bNpLtNK0sK2b/UuvJEImvZ5KcnEw1atSgevXqkbm5OZmZmfHq13Tp0oV8fHxo7NixNH78eHbRUj68ffuWUlNT2XINQjoY6tiyZYto25o1a1KtWrU4S+XKlcnb21uy/oQ8UkoEtG3blnbt2kXnz5+n6tWrs/pLnz594q0/JAaxFe+JiAIDAzXahzoGDhzIll05evQoGRoakpubGxkZGdHff//Nu42Pjw+dPHmS/Y1KSkqUtH6kasdMnTpVsITAfwrMNSwsLKxcRPvk2yRS1ksiIqUCrkSlhT7nzJkjKrNKSsFHIV0jPnx8fCghIYHs7Ozo6tWrNGzYMJo1a1aZbW/evEkdOnSgevXqcc53RYQKpQrx888/0+jRo+ns2bNqs6vE9kEVWudGAnzpg2VZVxH7l1pPhkh8PRNra2tas2YNpaam0rVr19iFz05LxfD7779TjRo1yNzcnCwtLcnS0pK3arIYpNQXUxS6u3//vqQLsRCKaexXr14lMzMzOnTokFL/0tLSyN7enmrVqsUWYCQi+vvvv9lq4lKpqHpsUpD/Dby9vdmbdlZWluA5y9RWkv9c0bZ37940evRoCgkJoTZt2tCIESMoJSWFIiMjafDgwUpt1qxZk2QyGX399desYrPQDeXJkyc0YcIE+u6771ihyC5duvDalmelbeY/sLe3p8qVK1OTJk04Qn2aIP+7de3alSMymZmZqbbauDpmzZpFMTEx9Pz5c0Gx1r/++ouISouL8i18yP8WRKUOrpDqvRRbsY5QYmIijRo1ig4ePEhJSUnsIoSZmZnSIiTuKsUZE0I7LSUBHR0dZGRkwM7ODkBp9hDfMKNYO4bc3FxOQJbQfLCYdkliPRlAfD0TMcPWQKnwVG5ubrlE12vhInUoWBUkIZfA1NRUlJ2fn58kMT0p8UH29vZIS0tTaqN79+6caZLk5GSlIHchpPwGFUVBQQH7Oj8/H05OTgAAc3NzwQBKXV1dfPr0iT2nHz58qHQtyMjIwObNm1FcXIxvvvkGhw8fhq6uLtzd3XlrAImNvQOAHj16oHnz5ujevbvaqZYePXqgcuXKcHNzK7ckA03TwPmQyWRsDFFeXh4cHR3h5eUFADhz5gz7GpAWR8TAyGZERERw9in/3zJJJHyB+ULXbWYqVU9PD/fu3YOxsTFevnxZZtvc3Fz06dMHM2fOhIODA1asWAEPDw9MmjSJY3fmzBmsX78ep06dUhsgDIibUpfaB1VonRsJzJ49G97e3mzgYVpaGm+Knli7zZs3Y9SoUXj9+jV7AMtkMkG9CDHtahJMWqNGDRw5cgT+/v4AgKNHj6J69epKdp06dcKePXtUxgUBpfonLi4uaN++PSfmhu/E1yKNBg0alItjA5Q9EJgPqXP4FREfNGrUKNEZYRXxG0glICAAo0ePxqxZs+Dv74+NGzeif//+OHDggGBAc3h4OLp3747s7GxMmTIFGzZsUIq3kaodIzb2DpCmM/PgwQNkZGSIslUHcxMVm7QhFnnneNCgQbyvAc3iiMQEx06bNg2AOA0nBm9vb7x69Qrh4eFo3rw5qlSpIigjIsVWrCO0fv163Lt3jy00K5YPHz5wsr/4HoKlOGOCSBrn0ULPnz+nPXv20J49e9gCe5ramZub0/nz58t1/5rUkxFbz0TssPWvv/7Ku2gpO1KHglVREdMsFTV1IwWhqRw+/hOmpT58+EBjxowhfX19MjMzI5lMRrq6uhQQEKCyYGhycjJNmDCBfvzxRzp58qTS582bN6fCwkIiIk7hwfz8fF5Va7Gxd0SlKtGMUq06vvvuO5XXSiJSKpyqjoyMDLKzs6OaNWtSzZo1yd7enq5fvy6pDQYpx4umPHjwgDZu3EgbN25UG6eTkpJCGzdupLi4OHYR075ioVhNbcePH08vX76kjRs3Uu3atcnY2JjGjBmjZOft7S1qfwxnzpwhW1tbqlSpEmcpSx9UodW5+Rfx8vLC6dOn/5V9M/VkGMTUM7l//z5vW2KnLLSUnZ9//hlLliwRpRWhjorQp2E0U6RQUFCA7OxspXTb9PR00XXTNO2DlN9AEzE2KVy9ehVJSUkoLi6Gt7e3oF6IWKRqx7Ro0QILFy5kp/ROnz6NcePGISUlRaltMTozDNevX0fXrl3h5ubGsV27di37ukqVKujYsSNCQkLQqVMntaq/vr6+GDZsGPr37w8ASEhIwIoVKzRSlM7OzmZrnglNu8v3FQCKioqwfft23LlzhxNSwJcRumvXLgwdOhStWrWCTCZDcnIy1qxZwzsCHhYWhoMHD8LJyYlzfm/ZsoW1USfnID8SIsWWj4cPH+Lt27ewt7dX+mz8+PF48OABevXqxflfu3btytuWh4cHlixZghEjRuDEiRNYsmQJvvrqK0RGRmrcB1VonRsR+Pj4ICkpCbVq1eIMY5OC2J1YO4bY2Fg8efJE6eBQvMhLbVcMLi4uOHnyJKpXry54AvAd+GKGrYVSNLWp4GXHzMwMV65ckTwUzMf+/fvRsWPHsndKDqnOzaFDh9C7d28QERo3bowtW7bA0tJSo7ZU9UEovVr+xnblyhXcu3cPurq6sLOzK5ciiGLIyMhAUFAQHj16xKbVP3jwACYmJli3bh3HwevRo4fKtjRRKGbgK8Dq5OTEG4vj6OiIbt26KaU3d+rUScm2VatWsLCwULIdOXIk+9rGxgbDhw/HmjVrkJOTg0GDBmHIkCGC2lx8/RLqq9jCwACwbNky9nVhYSG2b98OFxcXpSm4Xr164dmzZ0qCpvPnz1dq08XFhXNc3759G7179+Y9tq2srJCWlsa5HyhSqVIlpVIoQkJ3UmylOkLyU8nybfM5uMD/nZcODg5s7JziA0NZnTEOksZ5vlCePHlCRMoZI8wi1Y5h+fLlVK1aNapVq5bKMvRS2xWDk5MTO8zOl5rON1wodthaPv07PDycLCwsaMCAARr1UwsXMUPBPXv2pL///puKioo+Q4+4dO3aVZK9m5sbpaamUklJCa1evZpMTU3ZIXNNpwucnJwkpVenpqaSvb096evrU6VKldiMrF69eilltVQE7u7utG3bNqX1W7duVcpoqVSpErm7u9PixYspNjZWaVFESvFQLy8vOnz4MPv+yJEj5OXlxdtnvmktIfjSqxWRn/JLTk6moUOHkp6eHrVu3Zp3WsbFxYVTYDI9PZ1cXFx42xZbGJiP9+/fk5+fn9J6a2trKikpEdUG328llD3bunVr0e2WN0L3AXUSJWJhinf6+PjQxYsX6cWLF2RqalphfdA6NxL48OED+/rOnTu0Z88e3huIWLtGjRoJVkUty/7FoEn8gNiUcUVevnxJnTt3lrw/LcpERkbS999/T5s3b6Zdu3axizyMzlHdunVp/PjxGsciCPHkyRNKTk4uc8wPkbIDc+TIETI1NaUrV65oHOOyevVqSenVnp6ebMzKrl27aNSoUfThwweaPHnyZ6kKrko6QfGzrKwsmjJlCllZWVH//v3pyJEjgttOmDCBWrVqReHh4WRsbEyLFy9mP+P7bcXG3hFJ05kRU2mbrz95eXm0evVqatmypdJnBw4coDp16pCvry/5+vqSoaEhHTx4kLdtJm1eE4qLi8nGxkZpvZ+fHxvPpA5/f39atWoVFRcXU3FxMa1evZr8/f15bcePH089evRQeX7Lc+HCBVq/fj0RlcYtMQ/CZbUVy6ZNm2jo0KEUEhJCmzdvVmn7+++/08uXL+ngwYNUo0YNqlq1Ks2fP7/MfRBC69xIwNXVlXJzc+nly5dUv3598vLyotDQUI3thJ6Kyrp/MchfTB48eMA6TqdOnaKYmBjKzc1V2kbKE4giYp7etKinTZs2Souvry/Hhrl5p6Sk0PDhw0lfX5+8vLxozZo1op9YhZg5cyYZGBiQs7Mzubq6kqurq6BehhhsbW2VbhLHjx+nRo0akbGxseh2Jk2axHkvr/3j6urK+czBwYHzXvEYlrfXVENICl5eXrR+/XoqLi5m1xUXF1NsbCx5enryblNSUkIHDhyg77//nmxsbHhv7Pb29ux5/fTpU3Jzc2NHbIRGxT5+/EhpaWmUlpbGCULma1uszoy/vz/VrFmTOnbsSN999x27yKPJKJ3Y5I5ffvlFUAxRkbFjx7JLREQEeXl5Uc+ePZXsQkNDqUWLFjRv3jy1ejS3b98mDw8Pqly5MlWpUoVatGgh+FAr5vxmWLZsGTVr1owsLCzY/fCJykq1JRLnCEVGRpKrqystXryYFi9eTO7u7vTjjz8KtinPx48fee8xUvugCm0quASKioqgp6eH9evXY/DgwZg9ezYcHBw0tmvbti0iIyPRp08fzhwrX40bKe2KgeTmYLt164bTp0/j8ePH6Nu3L1q1aoWkpCRs3bqVs43YlHH5ar/FxcU4d+4cjI2NNeqnFi5iAiaZuCwPDw94eHhg0aJF2LJlC9auXYuxY8cqlSWQgpT6MGLo0aMHjh8/joCAAHadj48P4uPj2fIKYoiPj8esWbPY91LSqytXrowbN27A1tYWKSkpnGP6cxR/jYuLQ2hoKEaNGsXGAz19+hQuLi6IjY3l3UYmk6F27dqoVasWCgsLkZ+fr2RDRGyhRmNjYxw5cgQdO3ZEcXGxYAq8jo4OateujaKiIjx9+hSAcgwgIE1nJjAwEIGBgSptGG2krKwsPHjwgN2vqrinb775Rikomo/o6GhRhYEBboq3rq4uIiIieOOcPnz4AFtbW1y/fp1dJ/SbNm7cGCkpKcjLywMATvV6RdSd3/IaTitXrkRKSgqrw9O4cWNkZ2fzbifF9o8//sCKFSuQl5eHgQMH4tWrVwgJCVHq2+7du5GamsqW+Bk+fDgcHR2VJAmEiv0y8N3vxPZBFVrnRgKM/szx48fZKH2+i59Yuw0bNgDgBgGqqsIrtl0xMPVkGL766ivs27cPoaGhmDJlCq/IV3R0NHr27Mnus6SkhDeAUT77RFdXF05OThg+fLhG/dSiTEJCAo4cOQKZTIZ27dqhd+/enM9JIUfg66+/RlBQEIKCggSL2omlvOvDyDsk8nh7e3P6mpycjFGjRvHaEhFevHjBWbdw4UJERUWhQYMGqF27Nu7fv4+goCD4+flxqocDpRXHW7VqBUNDQ7x69Qrbtm0DADx79gytW7cuy9cThaWlJY4ePYrs7Gw8fPgQQGlBRibQWZ6XL18iPj4ecXFxMDY2xpAhQ7BkyRLe4plSiocCpQkOERERqFy5MputJJPJlH5b4P90Zh49egSZTMYWNOWDqfFEKiptP3/+HB06dMDDhw9ZZ0ooqBqQFiQsRZzwl19+EWWnTo9GMRv16dOnuHv3LiezSl2NPj7kNZyqVq3KqR0IcOuvySPFVqwjVLNmTc5xV7lyZdSqVUvJjq/YL4PQ/U6KMyaE1rmRgK+vL+zs7FBcXIwVK1bgzZs3vAeIWDspio1S2hVi8ODBiIuLAwBOlgwjqnT48GGMGTNGcHtXV1fcvn1bbcq4FCEqLdIYP348kpKS2CfhhQsX4sKFC5ynJVXid0LZJ2Jp164dxowZg/79+4sabSwvRo0ahaysLGzatEkpQ4+I0KdPH866KlWqYNGiRQgODlabXt2hQwfcvn0bd+7cwePHj0FEyMrKgoWFBVauXFmh30seIyMjXodGngYNGsDR0RHDhg1jM6sOHjzIfi6fhiuleChQ6uSdP38eNjY2avuampqKvn374tmzZ5DJZDA2NkZCQgLvcSCm0nZQUBCioqLQs2dPzrbbtm1DcHCwktRBREQEYmJi4OnpqfYBT4w44fHjx2Fpacmquy9cuBDx8fFo3Lgxli5dysmwE8OcOXNY52bWrFmYP39+ucg3yD+4GBkZ4ebNm6yzGBsbK1i9XIqtOkdo9+7dAEqlAwICAlihww0bNrBFb+WRep8T0wdRSJrE+sIpKSmhy5cvsxkUL1++pEuXLmlsR0S0bds2tmbG48eP6erVq2XevxAmJia862fMmEE1a9Ykd3d3KikpoSdPnlCLFi14bYuLi+nx48d0//59dlHEwsKCNmzYwFnXqVMn0f3UIoyVlRWnplN+fv5niQthkFIfpjxxcnKiNm3aUHJyMu/nDRs25LxPT08nNzc3qlevHrm7u5O7uzsZGxuTm5ubUj20jIwM1tbDw4NjK5+R85+Aj48Pb1yGqtgMdTDFQ5lsFjG4urpyCq9u3bpVKbZJvs+//fYb5eTk0Js3b2j+/Pnk4+PDsZESVE0kLUhYTJans7MzvXr1ioiITpw4QbVr16aEhASKioqiXr16id4Xg3wMkYWFBb18+VJyG3zIxzXdunWLXF1dqVq1atSwYUOys7MTFH2UYtupUyfKzMxk97Vu3TpO3TCh40/MMSj2fqeuD2LQOjcSOHfuHL1//56IiDZv3kyRkZH0+PFjje2mTp1KHTp0YG9OT548EQwgFNuuYuVmZqlZsybp6OgItv3mzRs2oDEvL483u2HdunWkp6dHtWvXVpm6bmZmRq6urpxCZ59DBfRLwM3NjRN4+unTJ0k3JcXA2/8WnJ2d6d69e7zVrImUqylLSa+WYvvfgiplY0WYG8js2bNp0aJFKgs8MjAFGOVRDNRmEFNpW2pQtZQgYTFZnvJ9j4yMpMjISCIqfaAU+l6qkHdCVF3Ty9IuUelvlJGRQenp6WozZ8XaSnGEpCDlflcefdA6NxJo1qwZFRUV0c2bN8nS0pImTpxI7du3L7Od/I1f1Ykkpl1DQ0NKTU1V0sK5e/cu1a9fn7fd3bt3sxex+fPnU8+ePXnluS0sLOjGjRuC/WNwdnamvLw86tixI4WGhlJxcbHWuSkjTEroqFGjyN/fn9avX0/r16+n9u3b0+jRo0W3IzR6J4WzZ8/SrFmzaNasWZLLh2iK1LRwKSMBUkcN/huQ8nsx56YUbZFBgwbRP//8w74/fvw4BQUF8dqKqbR969Ytatu2LRkYGJCtrS3Z2tqSgYEB+fr6crZlkFLBXEyWp7xNq1atOI6TFE0fBvnf/+eff6bRo0fT2bNnKTU1lV00wcnJieN48i3ySLGVR4wjJC8FIUYWQur9Torjxoc25kYCOjo60NHRwf79+xEWFoZx48bB2dlZY7tq1arxVvUuy/6bN2+O169f8859CxXhmzx5Mq5evYrU1FRs2LABYWFhCAsLw8mTJ5W2FzMfD5QGM+7ZswcjRoxA165deauMaxHPokWLOO/l5eAVsxGEZPuJJ/BWKitXrsTMmTPRo0cPyGQy9OzZE1OnTpWU2aQJzHlx4sQJ3Lt3D/7+/pxiiXFxcWzgKlB6rMbHx2PAgAFscGxJSQni4+OVAqKl2P63oOo6oggThyGmwKOzszNkMhk+ffqE+Ph4mJubAyiNq1CUxxdbaRuQFlQNSAsSFpPlaWZmhujoaDRo0ACpqams+m5BQQE+ffokel8M8r//+vXrAZSWYWBQlTiiivDwcNSsWZP9zxT/Z8Wgaim2iurATJD4+/fvASirA8uXTSgsLERmZibs7e0FVcXF3O+k9kEVWudGAh8+fMDz58+xZ88ezJs3DwB4o/PF2pmamuLkyZPsxWL27NlwcnIq0/63b9/OG+QLQElanYEJ1Dp06BCGDx+O0NBQrFixQsmue/fuWLx4sVIwqeIBxwQ66ujoYNWqVZg+fToSExMFv5cW9UhJgZQSeCuVpUuX4uLFi+xNZ9KkSfDz86tw5yY8PBy///47/vzzT9ja2iIyMhIrVqxg03Sjo6M5zo2U9GpNUrH/06moaueLFy8WbSu20rY8YoKqAWn17MRkeS5btgxhYWF49OgRVq5cyaaEHzt2TFS6uSLy2ahSA2q3bNmCK1eucB4If//9dwDA0KFDsX79ehQWFmLIkCHo16+fyht+69atRdtKcYQAKNVZO3funMrzRcz9TmofVCJ5rOcLZtWqVWRgYMCKOt2+fZtXDl+s3bNnzyggIIB0dXWpcuXK1L59e5ViVGLblUqzZs0oJSWFPDw8KCMjg4j459QrSpZbi3jEDAVLCbyVCt8wsiYxCQyKAn5bt26liIgIWrduHe9+mKH09PR0srKyovj4eCISjul68eIFXbx4kZV7V4UU2/90NJmWunnzJnXo0IHq1avHidf7T+T58+c0YsQI8vT0VCsiSCRenFAdTBB1fn4+zZs3j/r16ycoTKhIYWGh2imhUaNGUefOnalevXo0btw4MjExoSFDhijZ3b59myZNmkRWVlYUGBjImSLU1Nbb25vc3d1p+fLlGpcdURV+IOZ+Vx59YNA6N2WguLiYUxJBU7v3799rpBwr1K6UejJEpTE3jo6ONG7cOCIiunHjBvXo0UNyf/766y8iIo5ipzr1Ti3SYFSBXV1dWZVYxYu6lMBbqfTo0YMmTZrEZspNmTJFo2OFQb7vf/zxBzVr1ozmzJlDLVu2pOnTp3NsFZ2ohw8fkq2tLcXGxmpcquF/Fb6bzIsXL+jo0aNKSq+MI+fj40MJCQlkZ2dHV69epWHDhnGSAuRhMmMUFz6Cg4N5l7LQuXNnmjt3LllZWdHu3bupU6dONGXKFI4Nc02VGm+iCuY4GzBgAIWFhZGpqSktWbKEXFxcaMyYMbzbnDlzhmxtbalSpUqchQ97e3sqLi5m43yePn3KG6/JUFxcTNu2baNvvvmGFi5cqLLvYmylOE3y8UOXLl2iP//8UylQnA919zspfVCF1rkRwfHjx4mIOLU++Op+iLWTR0xtDintSq0nU578/PPPREQUFBTEu2gpf86ePUthYWEabcukAEvhxYsX1KdPH6pTpw7VqVOH+vbtyxao1AT5m7C7uzubpZebm6s0eujk5KS0r8ePH1OTJk2oRo0aGvfhf5Hp06dLKh5K9H/XB+Z3LykpEcwW27t3L7ts27aNevToQRMnTuS1Xbp0KbssWLCAPD09aeTIkWX6fkxAMNPXDx8+KMlXSC0MLAbmeGX2yzjcubm51Lp1a95t3N3dKSUlhZycnCg3N5dmzpxJCxYs4LVl0ukdHR3ZESa+UXSi0vIEYWFhZGZmRmFhYXTr1i3BfkuxJRLnCMnLQVhaWlLHjh3pwoULSnbyThDfUpY+qELr3IggJCSEiNTX/RBrxyC2NoeUdqXUk5E60vLfNGz9JaFpJtp/wmiHfB8UtUsUv1dCQgJvFfonT57QsGHDKqaD/4EkJibSwIEDycfHh3x8fGjgwIG0b98+JTspxUOJ/k/nxtPTk+7evUsFBQWiNYw+ffokeHNXRKjSthQYp8vV1ZVevnxJxcXFZGlpWaY2xcAcr8z+mcxQotI6aaq2kXdShDSBfH196f379zRy5Ejq3bs3RUREKEk9LF68mJydnal9+/a0adMmlQU8pdgySHWE1CGTycjExITMzc1Fa2SVRx+0AcUiWLVqFQD1QZ1i7RjE1uaQ0i5JqCdz48YNANxyCaoYNmwYwsLCMH36dCQkJCAmJoaVdme+jyrk1VO1aIZ8ZlRxcTHOnj2rUTYHIC2jJikpCT4+PoL/sab/7Y0bN+Di4sKqAr979w56enogIqXvJRQMXa9ePY6ScHR0tEqV5v9mpkyZgoMHD7IBogBw7949/PLLLzh9+jRmzpzJ2hYUFLCv8/Pz2eBNc3Nz3sBMb29vvHr1CuHh4WjevDmqVKmCvn37iupXcXExnjx5Isr2q6++wqNHj0TZCmFtbY1Xr14hMDAQHh4e0NfXR/PmzXltHz58iLp166JKlSpITk7G5cuXMXjwYOjp6Wm8/9q1a+PNmzf49ttvERAQAENDQ1bdWBEmwaNOnTq4dOkSTExMBEsJbNq0CTo6Opg/fz4WLlyInJwcthwIw9ixY+Hs7Iyvv/4aW7ZswZYtWzifywdLS7GNjo5GXFwcjIyMEBwcjEWLFvGW9VAkKysLu3fvhqWlJW/w9cCBA3H69Gn06tULQ4YMgZWVlWBbmvaBDxlJucJpwfXr13Hr1i1OjRC+wmpi7Nzd3ZGSksKmnxYVFaFly5Y4e/asxvv38PDA5s2bOU5HXl4eAgICcOHCBXz48EH8l1XAxcUFly5dgoODA9LS0kBE8PDwYGXEmfRJPmQyGY4dO6bxvrWUwqTeAqVZblZWVpgxY4bghV0VzP8phmHDhmHVqlW8/3FZ/ltGkp+hefPmqFGjBp49e4bt27dj5MiRktuU8r3+27CyskJ6ejr7AMPw4cMHNG3aFLdv32bXjRo1CpUqVcKsWbMwa9Ys2Nvbs8VD58+fr/I/e/jwId6+fauU3s3ApHkDpY7N1atX8e2332LZsmVKtuPGjWNfFxcX48KFC6hXr57STVtTTp06hZycHHTo0IFXot/FxQWnT5/Gq1ev0KJFC7Rq1QpFRUVKhYHF4OzsjMuXL6O4uBg6OjogImzcuBE5OTkYNGgQbzbSokWLMGjQIFy8eBE9e/bEp0+fMHPmTIwfP16j78uU0BFCMWtQrG2lSpXg7OyMRo0a8WbbMY6Qv78/FixYACcnJzx58gT29vbw8PDA3bt3ERwcjKioKKVt3717h4SEBKxbtw66uroYMmQIevfurZTRKbYPYtA6NxKIjIzExo0bYWdnx6kRcujQIY3sIiIicP36dU5tjiZNmqBt27YAlJ+GxbT7zz//oHbt2kqFL9+/f4/o6GhMmjSJ97vt379fyWmSvygBpY7T2bNn4eXlhb/++gvGxsaws7PTSK9By7/P/6oTwNyA/hextLTEtWvXOFIMQOkojb29Pe7cucOu+/jxI6KiorB27Vq2eKiOjg78/Pzw559/so6yoraIInw3bPmbpq6uLiwtLeHh4cG7/bRp05Rse/ToIShZUd4wx/nKlSvx4sULtjCwkDSGKvbv38+pyyeVT58+obCwUHDUKCMjA7/++itu377NuRarq6zNh5QRzOjoaNSsWVOlDeMINWnShK2GvmDBAiQnJ+Pvv//Gmzdv4OPjo7avhw4dQmBgIMaPH48JEyZwPpPijKlDOy0lgV27diErK0vJ29TULi0tDQBXkC01NRWpqamQyWRKzo2YdoVGT6pXr85xbKKiolitnP79++P69etwdnbmOE2KSBm23rp1Kw4fPgwACAgIUCqIp6VsqBsKFoMmzzV79uyBj48P9PX1sWDBAqSkpGDatGlKVZvLg8mTJwtWDVdFRWm8/CcQFBQENzc3DBw4kNV6uX//PuLj4xEcHMyxFVs8lNEWkT8emPdC2iJSbjJiK22LoVatWrz/L9PX169fK30mtjDw+vXrce/ePXTu3JnzG82ZMwc//fQTgP8rOHzixAmMHz9eyQmRdxTV3eT5hFb79u2LQYMGITw8XG1BUHXExcWJdm7i4uJEP+jk5eWxr0+fPo1vv/0WQOl/I1TcsqioCLt27cKaNWvw8OFDjB8/Xul4BcQfV6IcN+nhQV8ubdq04dQ+KaudOuTroZRnu0TcQE4bGxvJ8tYPHjzgLdFARDRt2jRydnamRYsW0eLFi6l58+Y0Y8aMMvX3S8fPz48NCH38+DHVqlWLOnToQDY2NjR37lyV26pLAZYCkx1y5coVcnR0pOXLl1OrVq0ktyMGTUtF/CcESlckSUlJNHLkSOrSpQt16dKFRo4cyWZUyiOleKhYNm3aRLdv32bfh4eHk4GBAbm4uLAaWQz//PMPPXz4kH2/YMECcnR0pB49eigdi2JRLCujuPAhpjBwVFSUpCxTa2tr2rp1K92/f58ePXrELvLwFZlVF0hbnmVqpLQlxbZatWr08OFDevfuHdWuXZtTHsPGxkbJfsyYMdS4cWMaPnw4nTlzRvR+VCHmHNc6NxI4d+4c9ejRg1asWEFxcXHsoqmdOhT/wPJql4h7MAcEBLAFOfmQWp/EwcGB015eXl6ZhN60cDMx5s+fz9bmef36tdJvKzUFWArMMfnbb7/RsmXLOOs0bY9vcXJyoqpVq2rUpraOWSmaFAS9cOECrV+/nohKi+kqOiEODg5sdtDevXupYcOGlJKSQkuXLqUOHTpwbMu70rYiT548YTVQPn36pFJLTF1hYClZpkTC2U5lZezYsSrrM0lBynkpxdbMzIwMDQ3J2NiYFZQlKi1IGhAQoGQvk8nI2tqanJyceM91TRBzjmunpSSwfPlyXL16FUTEmb5RlBMXa6cOUpg2KK92me0YFi5cCH9/f7Rp04Yzl//zzz8DkD5sTUScqbPq1atrNAWi5f9gMuoA9UPBqamp+OabbwCUxjscPnwYTk5OuHv3Lnr06MGRxZcKk6G1fft2rFu3DgA0ztYCyl4qoqioSOn7/7eWTBDL3bt38fDhQ7i5uXGOi8OHD6Ndu3bs+5ycHN7p4F69emHy5MlK6//44w+sWLECeXl5GDhwIF69eoWQkBBOlqZMJmPrMh04cADBwcHw8PCAh4cHm9XJUFRUhNq1awMonVIPDg5Gnz590Lt3b6WYQKls27YNkZGRkMlkuHfvHtLT0/HTTz/xlnlhplIrVarETqX++uuvbN0iQFqWKQD07NkT8fHx6NOnj1JwNx/bt29HZmYmJk2ahCdPnuDVq1dwcHBQsuvVqxcCAgKgp6eHr776ir3G/ifFNdaqVQtnzpzB8+fPOVNrZmZmnKzFDx8+oGrVqpJKx4hF1NSzRm7TF4qFhQV9+vSp3OzUoejVlle7im136dKFfHx8aOzYsTR+/Hh20ZTg4GAKDAxkSwMMGjSIV0Jci3iaN28ueijYysqKfa34hFnWETRGzToyMpKINFezZpBSKuLcuXPk7u5OPXv2pCdPnlCrVq1IJpORra0tXbp0SeM+/DexYcMGMjQ0JHt7e2rYsCFH90fxeuHl5UXr16/nTGUXFxdTbGwseXp6KrXt6OhI+fn5nKdiRcVZRa2W/fv3s+8Vj63yrrQtj4uLC718+ZLTVzs7O15bMVOp7u7udPfuXc66d+/ekZeXF1WpUkWpzZ07d1KNGjVYtWFVwoBTp06lDh06sOflkydPeH9/otLprjVr1lBqaipdu3aNXTShoqalxI62SB2VkSIqqp2WKmf8/f1F1SURa6cOxT+wvNol4h7M1tbWordTN2xNVDrsGxUVRc2bN6fmzZtTVFSURuUltPwf27dvFz0UHB4eThEREfTu3TuaOHEibdiwgUpKSigxMVFQIv/fQkqpCE9PT9qwYQMtXbqULC0taenSpfT+/XtKSEigli1bfo7u/us4OjqycSyHDx8mExMTOnr0KBEp36Bu3bpFbdu2JQMDA7K1tSVbW1syMDAgX19fjnPMwIjFybfDKAEzBAYG0rhx42j+/PlUp04d9j968+aNknPTtWtXWrx4MW3dupX09PQoJyeHiEr/1yZNmpThV/g/ET35vgrdoMVMpR47doyuXLmitG1eXh5vCQpzc3M6evQovX37lvLy8tiFj2bNmlFRURGnf0IPGS4uLrzrNYHv+5SHrVhHSOr0sCb10FShdW4kMHz4cPLy8qJ58+apVPIVa6cOxT+wvNol4gaTdunSRVStlWXLllGzZs3IwsKCiEprgLRp04ZjU1RURIGBgRr1SYtqnj59SleuXKGSkhJ23ePHj+n+/fvs+8LCQvrw4QONGTOG9PX1yczMjGQyGenq6lJAQABlZWWVqQ9Tp06lN2/eUElJCX377bdUp04d3riO8mbChAmc80Ex2PhLibNRHPG4evUqmZmZ0aFDhwRvDmILgnbq1IkyMzPZdtatW0ddunTh2OTk5FB4eDh1796dU/Pn0KFDShL5Dx8+pM6dO5OTkxNt2rSJXb93715eJXYptG3blp49e8b29ciRI9S2bVteW7GFgaXg4eEh2Vb+GBXa/9SpU2n37t2i2r148SIFBASQlZUVmZubs0tZbdUh1hGSOnIj5RwW0wdtzI0EPn78CGtrazbHH+Cf+xNrp47w8PBybdfa2ho3b94EABgZGbHrq1WrBhcXF7Rv354Tc/P7779ztl+5ciVSUlLg5eUFAGjcuLGS0qaOjg67Dy3li7GxMYyNjTnr6tevz3nv6emJS5cuiUoB1oRdu3Zh+vTpOHz4MHR1dZGcnIy+fftWeKr/4cOH8fHjRxQUFODdu3d49eoVnj9/jrp16+L9+/coLCys0P3/p1BSUsKqOAOAg4MD9u3bh06dOgnq1RgZGXHOdyEWL16Mfv364caNGzAxMYG+vj727t3LsTEwMEBMTIzStu3atePE+zCpunv27FGy7dSpEzp16sS+37p1K77//nu1/ZNn3rx56NixI7KystCqVSvcvXsX+/bt47WdOXMmQkND4efnhyZNmiAzMxPW1tZKdidOnMC9e/fg7+/POa/i4uKUUpS7du2KpUuXonfv3pxrJp8mkKmpKU6ePAmZTIZPnz5h9uzZrFq0IjExMXj79i2qVauGqlWrqkxxHzx4MMLDw+Hp6ak2bVyK7aVLlzBp0iRkZWVx0tyZuJ+yxksJIX8vK48+aEX8/mW2bNmCK1eucC7Oik6FFFRpKwQEBODp06dK6+VFtuRR1KdgRPzkRdKcnJxw5coVjt3EiRPx+vVrBAUFoUaNGux6Pl0HLeWLs7MzNm7ciKCgIDx69AgmJiYAgAcPHsDExATr1q0rkyYN899PmTIFtra2CAwM/CxigM7Ozujbty/+/PNPFBUVYcyYMdixYweaNWuG5ORkdO3aVSNNnP82YmJiYG9vr6Rndf36dYwePVpJKFQqJSUlyMzMBBHBxsZGY60VKceEpsfP27dvcfr0aRARvLy81IrQqeL333/Hn3/+CVtbW6SkpGDFihWs8jtf/xhVeXmENIGeP3+OwYMH4+jRo5DJZPD19cXGjRthaGioZHv//n3e/jGaRvLwXXuFkGLr4ODA6whJvW5IFdOU/53Low/akRsJfPjwAYsWLcKRI0cgk8nQrl07jB49Wqn2hVi7iIgI3L17FxcvXkS/fv2wdetWztOPJvt3cnKCmZkZb3bSq1eveNsVK7JlZGSEmzdvsh52bGwsGjVqpGS3efNmAGBF/AD8x0X8/68ik8lYCXTF0ZRt27YhODiYLZehCdWrV8e8efOQkJCA5ORkEBE+fvxY1m6rRSaTISoqCh06dIBMJkOzZs3Qq1cvbN++HQEBAfjuu+8qvA//CYwaNYp3fZMmTTiOjZTREMURHyaL6P379wD4RyPUIeWZWdPnawMDA5VqwZs2bUK/fv2wZMkS3s8jIiLY17Gxsbh48SL09fWRkZGB7t27Iz8/H4GBgbz9KykpEd3PunXr4sCBA8jPzwcRsdlmfJiamiI/P591RJycnARFW1u2bIkLFy7A1dVVbR+k2Oro6CA0NFStnTpatGghyV7+dy6PPmidGwmMGDECr169Yi8w69atw/Xr19mUWKl2//zzD1JTU+Hs7IyFCxfixx9/VKnQKKZdU1NTnDp1Smm6AgD7FK/Imzdv8NNPP3GcplmzZqFWrVocOzHD1kBpqqqWfw+pKcBSiI2NxdKlS/Hbb7+hbt26uH37NgIDA8vUphTkh6PNzMwQGRn52fb938ScOXNEOzeM1AOg7GgIjUaoQ8p0uRRbJrVcEb7pG6mFgRknzs7ODseOHUO7du0EU8GB0vpbJ0+eBAD4+PhwUssBzRSKT58+jZ49e7LTz8+fP8f27dvh6empZHvixAmsWrUKlpaWnKkxvlEwKbZiHCGmdIWjoyNu3bqFvXv3olmzZvDz82Nt/vzzT8Ht+ZB3zqU4Y4JIivj5wrGxseEEcxYVFfEqMoq1Y9J0HR0d2SwoVYFuYtqNiIigkydP8m4fGhrKu75r1670ww8/0JUrV+jKlSsUHh5OXbt25bUtLi6mjIwMSk9PV6lqfObMGZoxYwbNnDmTUlJSBO20lC9OTk6SU4D/G2CCDePi4mjatGl08eJFzueM4JqWUqQEZ3p7e5O7uzstX75cVGKBGCpSQM7NzY2WL19OWVlZohSKxeDk5MQKXzI8fvyYmjRpQjVq1FCy37lzJ9WpU4e6detG3bt3JyMjI6VAYJlMRiYmJmRubi5aodjDw4OjTJ+cnCwYvHz8+HHepay29vb2VLlyZWrSpAmv2N6SJUuoUaNGVL9+ffr999/J2dmZRowYQdbW1rR8+XLeNomI9u/fTzY2NlS5cmW16fPq+iAG7ciNBOrUqYOCggJ2mPDDhw+886Zi7fT09JCfn49WrVohMDAQxsbGKutGiWk3OjpacPvly5fzrr958yZ27drFvo+JiUGTJk3Y91KHrRcsWICYmBh2zrpPnz6IiIhQKsSppfxp0aIFIiMjERoailGjRqFevXoAgKdPn8LFxUVjgbvIyEgsXLiQUw1aHinVelWRnZ2NtLQ0NGnShO07UPpUN3HiRCQnJ8PJyQmdOnXCxIkT2foyW7duZev/aJE2GpKUlIQ7d+5g7dq1cHV1hYeHB4YOHYo2bdpovH+qoGmpu3fv4ujRo1i7di1+//139O7dG8HBwbCwsFC5nbrCwBMnTsSdO3dY8UugNFj/6NGjvNP206ZNQ0pKCiwtLQEAt2/fRu/evdGlSxfWZuDAgTh9+jR69eqFIUOGwMrKSu33KygoQMuWLdn3Xl5egsHyPj4+AIAnT56w/RVCiu3SpUtV9nHVqlVIT0/Hu3fvYGFhgczMTDRq1AjZ2dlo37694HRSREQEYmJiRAU1q+uDKCS5Ql8oTMr1kCFDyN7enqZPn07Tp0+nZs2a0dChQyXbMTx79owKCwspPz+fZsyYQZGRkfTgwQON968OeXE3edq2bctJEX3x4gX5+fmx7xkPm/G25Rc+z9vKyopevnzJvn/16pXgvrWUnT179vCuF5sCLAbmqTQ2NpZ30RQppSKkSuR/yWgqa19cXEzbtm2jb775Rim1Wwi+tFyhVF356wJDYmKitE7+f3JycmjZsmVUt25dWrVqlaBdv379yMnJiYKDgykkJIRCQkJo2LBhGu2TqTnFJ0KoqAlERJSbm0srV64kT09Pat26Na1bt05lqRsvLy86fPgw+/7IkSPk5eXFa5uRkUF2dnZUs2ZNqlmzJtnb29P169fLbMvw+PFjevz4sdJ6VSKPqo675s2bq9yflD6IQTtyIwL5OVtXV1c2MNbFxYUTWCbWjqFu3brs6ylTppR5/4Dqed53795x3jNPLrVq1YKDgwObnpmYmIjWrVuzdq1bt0ZhYSGGDBmCfv36qQ0w1NfXR506ddj3tWvX1igoUYs4fvjhB97K4GJTgMXAPJFKqQYtBimlIkiiRP6XDGkQpHvx4kWsWbMG+/fvR8+ePdG1a1clG750827duiEtLQ1ExJ7nQqm6bm5uSokFqoKChXjx4gViY2MRFxcHFxcXlTIHly5dQnp6epmrbAP/V2n7m2++werVqzFkyBAApfGPfOeanp4ehg0bhmHDhuHQoUMIDAzEixcvMGHCBN72o6Oj0bNnT7avJSUlgqOiP/zwAyZPnoz+/fsDABISEhAWFsZb7kCK7fXr19GrVy92lKdhw4bYunUrbG1tAYATg6WYafvhwwfevgJA586dsXPnTlHlX9T1QQzaVPB/kYyMDPz666+4ffs2Z7hUXSCaKipVqiSYLfX48WNOZotQCjiD/HAsM2y9detWwWFrpt8bNmzAixcvMHToUAClQahGRkaYO3eupl/ri0doSo+IsHbtWrx9+/az9OPp06dYvHix0hD/7t27NWpPXnvJzc0N58+fZz9r1qwZ51zw8PDA5s2bYWZmxq7Ly8tDQEAALly4oPLC+qWxf/9+0U5DdHQ04uLiYGRkhODgYHz33XdKmZ0MlSpVUqozx6AYfMwX/Pv27VsYGBgAAK92izp27dqFtWvX4s6dOwgMDMSgQYNUTrEAQIcOHbBjxw6VU/5iYdKb79y5gwEDBuDSpUuQyWRwcXHBhg0b0LhxY459UVERdu3ahTVr1uDhw4cYOHAggoODVT50fPr0CZmZmQAAGxsbVK5cmdeOL71bKOVbiq2vry+GDRvGcYRWrFjBOkJ//PEHBg4cyGotMVy/fh3R0dGC4Q+1atUSreGjrg9i0Do3Eli/fj3vesXClWLtmjVrhkGDBsHd3Z3zVCE/5yq1XXNzcyQnJwtmSz18+JC3DbGUlJTg77//xg8//ICoqCjOTdfc3FxwO20qeNn46quvMGHCBN6nz0WLFiEnJ+ez9MPT0xPNmzdXOmYHDBigUXujRo1CpUqVMGvWLMyaNQv29vbo378/Dhw4gPnz5+PYsWOs7T///IPatWsrjQq8f/8e0dHRmDRpkmZf6n+EwYMHIy4uTvJ2lSpVgrOzMxo1aqQ2niooKAhVqlTBokWL2JRmc3Nz3gzJtm3bwsrKChMnTkSlSpVARGjdujVOnToFgF+7RUxfXV1d0bJlS96+8mmEpaenY9iwYYKFgaWgqHmTl5cHABw9L4axY8diz5498PPzQ3BwsOjU6JKSEjx79ozz8MAnudG8eXPEx8fDzs4OQOnD8sCBA3Hx4sUy2UpxhKRQVg0fqX3QTktJQF5ts7CwEKdOnUKLFi2UnBaxdjo6Ohg/fny57r9r167IysridW7kVUHlmT59Ou96xZNf3bC1NgW84rC3t8f333/PW0l49erVn60f79+/L59gv//PwoULERUVhQYNGqB27dq4f/8+goKC4OfnhzVr1nBsFYXrGKpXr85xbKKiojBv3rxy6+N/C5pWX1aUqFBFbGws/v77b/j6+mL+/Pnw8fERnBI8duwYq5S9cuVKWFtbo3Llyho5NQw///yz5CnIn376CVWqVEFhYWGZKtgr8vTpU9y9e5fjhHh7e7Ovo6OjYWVlhXPnznFGJBn40rBjY2MRERGBypUrs0KBMpkML168ULKdPXs2vL292ZTytLQ0bNy4kbevUmx1dHSQkZHBcYQUH6oKCgqQnZ2t5HSlp6cLCu1J0fAR0wd1aEduysDdu3cxefJk/PXXXxrZjRs3Dt27d+ecEBWxf3X8+OOP7OvCwkIkJibC09MTGzZsACBt2JohNzcX9+7d45z45SH//6WSmJgIa2trNjtDnmPHjqFt27afpR/BwcGYNGmSqMwPKVy9erXcSkV8DsXkfwtVOi/v3r3jnG8VyfPnzzF8+HCYmppi165dgk/lQOkNb/jw4ejZsydiYmI+y0OQvIihjY0NO81TVphpqVmzZmH+/PmwsLBgb7oymYwjkJmUlKSyLSaDSZ7GjRsjMTERNjY2ovrz4sULdp8tWrTgzcqVanvw4EEMGDBAyRFq3749gNLMxd69e4OI0LhxY2zZsoW9Lqk696Ro+Kjrgyg0CkPWwsIXNS/WLjk5mWrUqEH16tVjtRCkFjMTu38pvHz5kjp37sy+l8lk5OLiQt27d6fvvvtOaVHk999/pxo1apC5uTlZWlqSpaWlNlvqf4SrV6+SoaEheXp6kq+vL7toSnp6Orm5uVG9evXI3d2d3N3dydjYmNzc3OjatWsatfm/nDllaGhIqampSvoud+/epfr163/2/qxevZoGDBig1u7Tp080ZcoUat269WfoFTdrR2xhYEU+ffqktI7JArOwsODN/NKECRMmsK+Zyuz/Ns+fP6c9e/bQnj17KDs7m/OZm5sbpaamUklJCa1evZpMTU0pLS2NiFSfe1I0fNT1QQzaaSkJyAdNFhcX4+zZs7wjGGLtgoODER0dDVdXV1FDbmLbLSt16tThxMdIGbYGSnVyMjMz1Qb6aZGGJkPB5U1gYCDCwsJEH7PqqIhSEf/LmVPNmzfH69evedVtVT21VxRDhw5lEwdUoaurixkzZnyGHpVCchMSYgoDnz9/HuHh4TAxMUFMTAx69+6N5ORk2NjY4K+//oKzszOA/8sCq1u3LicjtCwcPnyYnUbt3r07Fi9ejP79+wsW5PTx8UFSUhJq1arFOdaJJ0BXiq0833zzDW8GJlAa8Mwcf0OHDoWZmRk6d+6MXbt2qTz3pGj4qOuDGLTOjQQWLVrEvtbV1YWlpSVbR0kTuxo1arCphOW5f6nI114pLi7GuXPnONWnxab/MpWAGzRooHVsyhlVQ8EDBw78rNMwQjFamlCRpSL+F9m+fbtg9gwjiV/RrF+/Hvfu3UPnzp0504dz5sxRElKUUmm7PJG/ydrZ2bGxG0KMHj0aERERyMnJgbe3N8aMGYODBw9iz549GDVqFBsEzdCuXTuMGTNGyQnRpDiwvCPGHPPjxo1js9IUs9ASEhIAQFRwrRRbsY5QYWEhPnz4wD5Y+/n5IS4uDl27dlVZZ65GjRo4cuQI/P39AQBHjx5VqrOlqTPGi+SxHi3lxtSpU5Uku/8NgoKC2CUkJITmzp1Lr1+/ltwOMxScmJhIo0aNooMHD1JSUhK7aNEcTYeCy5uwsDC6fPlyubVXEaUi/penpf5toqKiqFWrVhQeHk7GxsasqB2RsoDbwoULydLSkjp37kyGhoa0fft2QdvyRmr78seMiYmJ4GcMiuUUNAkp0LSvDIygJRHRnTt3aM+ePYIlccTYPnnyhIhIacpTsbTFpEmT6MCBA0r7SEpKUhl+cP78eWrUqBGZm5uTubk5mZqaKpVREdsHMWidGxG8ePGCoyqZnJxMo0ePppiYGM5FWawdQ82aNUkmk9HXX39NtWrVopo1a1KtWrU03v+/DXMRmDp1KhkYGJCzszO5urqSq6srubm5/cu9++9G8QJ75MgRMjU1pStXrlT4jUKe8qj5Is+tW7eobdu2ZGBgQLa2tmRra0sGBgbk6+tLmZmZGrVZVjXm/3Qqqr6WmNo/UlSiHRwc2FiX9PR0srKyovj4eF7b8ka+/devX1NoaCg1btyYLC0tKSwsTOnhzc7OjvLz8+n58+f09ddf07Nnz4iIKC8vj2xtbSu0r5qeP66urpSbm0svX76k+vXrk5eXl2D9QCm2UpwmVcjH1zB8/PiR0tLSKC0tja2nWFF90Do3ImjVqhXdvHmTiIhu3rxJNWrUoBEjRpCPjw+NHz9esh2DWO9UartiSU9P5wRqbdmyhbp160aRkZH07t07ye0xJ6mpqSm9efNG435pUcbW1pYKCws5644fP06NGjUiY2Pjz9YPKQX4pCCmVMSWLVvY19nZ2fTtt9+Svr4++fj40P3798vch/8GJkyYIHrkRCpWVlZ04MABevv2LeXl5bGLPIpy+2/fviUvLy+aMWOG0v4dHBw47x8+fEi2trYUGxtb4Q65fEkHMYWB586dS6amptSgQQOaP38+eXp6UmhoKNnb29OkSZME91NYWEhv375lF02Qd8Ru3rxJHTp0oHr16lGtWrXYRdV2cXFx9NNPPxGRcOFlKbZSHCFVMP8xcwzJ/07qfrPy6IPWuRGBnZ0d+3rGjBk0cOBAIiLKz8/nnOxi7eR5//49JScnU3JysmDNEU3aFYO7uzs9evSIiIguX75Menp6NHfuXOrfvz8NGTJEcnvMwezt7a1xn7Two+lQcEXx8OFD9tj5XMjfEENCQigqKoqePn1KCxcupO7du3/WvvxbVGR9LTG1f9zd3enu3bucde/evSMvLy+qUqUKZ73USttSuHv3Lo0YMYLatWunNmuPb+SFb92VK1coNTWVbX/BggW0Y8cO3jbPnDlDtra2bM09ZtEEeWfex8eHEhISyM7Ojq5evUrDhg2jWbNm8W7H3BeCg4PZelR89a2k2kpxhFTBtMOct8xIoLrahOXVB21AsQjkM5LOnDmDPn36ACiNwpcP7hNrxyA2719qu2LJz89nK3xv27YNgYGBiIqKQlFREZsdIAX6/4Fxbm5u6N27N3r16sUJtuOrVaNFHLNmzeJd7+3tzZYvAIDk5GRBhevyIDU1FX379sWzZ88gk8lgbGyMhIQEjQIppUJygZfnzp3DpUuXoKOjg3HjxmmkzPvfCFVgfS0xtX/mzp2rVOqjRo0aOHToEKKjoznrpVbalkLv3r3h5+eH8PBwtVl79evXR3Z2NlvyIDs7m73uySOvfG1mZobIyEjBNkePHo3Y2FiMGDECJ06cwJIlSzjXOnkOHDiAMWPGICsrC8XFxUpBwvKlGHJzc9GnTx/MnDkTDg4OWLFiBTw8PHjVt319fWFnZ4fi4mKsWLECb968ga4u/y1dii0TFHz8+HG2/IEmmZHM8cgkO/DVVxSiXPog2R37AvH09KQrV67Q06dPSU9Pj1O528bGRrIdg9i8f6ntikX+Sc/f358SEhLY90JevSoYDYg2bdooLWXRQtEinooe7nd1deVMD23dupVcXV0rdJ8Mtra2dPXqVUpNTVU6PjU5Xv8bkTJyIhWxMYDljfzUmlgUp7z4GDt2LI0dO5Z69uxJdevWpSFDhtCQIUPI2NiYvv/+eyV7KbFMzHkmP5ogdB6Ime5jYHRuPD096e7du1RQUCAYqFxSUkKXL19mp3ZevnxJly5dKrPtyJEjqUmTJmRtbU0fP36k169fa1TRW/Fa9ODBA3bU8dSpUxQTE0O5ubkV1gftyI0I5syZg7Zt2+Ldu3cYOXIkTExMAJR65PJVSsXaMYjN+5farlhq166N3bt3o379+jhz5gyrdFxUVMRbhPDSpUuYNGkSsrKyOEqojCYO8+SjqQy8lrJDFSw4XlhYyCq/AqUp2+WZGq6KgoICdvRPJpPh0aNHaNiwId6+fctK1f+vI2XkRCpi0oWLi4uxcuVKbNq0CQ8ePABQWveob9++CA0N1egJn6m0LQV7e3s8ePCAt+YSA1Og08HBgVO2ZMSIEUq2EydORHJyMpycnNCpUydMnDiR7dPWrVuVUtyZEfM6derg0qVLMDExQXZ2Nm8/9PX1ERAQIOp7eXt749WrVwgPD0fz5s1RpUoV9O3bl9f2woULaNq0Kb7++mts2bIF586dEyywK8U2JiYGqampsLCwQOXKlVFSUoJVq1aJ6r88iteibt264fTp03j8+DH69u2LVq1aISkpCVu3bq2YPkh2x75QioqKlIJk8/LyOIG3WVlZou2IStNgmflPotIMGC8vrzLtXwppaWlkb29PtWrVooULF7Lr//77bzauRx57e3tavnw5paam0rVr19hFkU+fPtGCBQsoLCyMiIhu375NR48eldQ3LZpR0SM3gwYNon/++Yd9f/z4cQoKCqrQfSpy+/ZtOnbsGP3zzz90584dys/Pl3zs/68jr3orBXUxgMOHD6euXbtSYmIiZWRkUEZGBiUmJlLXrl1p2LBhGu1Tk1ghf39/qlmzJnXs2FGlWrpYpMYy/f777/Ty5Us6ePAg1ahRg6pWrUrz58/nbfuXX36hv//+W3KfHjx4wMo98NGsWTMqKiqimzdvkqWlJU2cOJHat29fZttz586x//3mzZspMjKSHj9+LLn/q1ev5rxnrk0rVqygGTNmsP2qqD5oa0uVI2Jr2jB2Fy5cQM+ePdmnnZKSEuzYsUPjujoVVVOHieMQW5V1xIgRKC4uxqlTp3D9+nXk5OTA398fFy5cKPe+aeFSUceAs7MzZDIZPn36hPT0dLYC/N27d2Fvb4+rV6+W+z4VuX79OgYPHoxHjx6hUaNGICI8ePAAJiYmWLdu3WdTaf5vQJPjQEwMoJWVFW7duqW0LRHB2tqa97OK6KtQjBWfMKCYwsD29va4du0a+z43NxcdO3ZEx44dsWPHDpX9+/TpEwoLC6Gnp8f7ea1atfD27VtUq1YNVatW5RWky83NFWwf4CoUMzC/25IlS1BUVIRx48axta/KYuvo6IhLly4hKysL3377LXr16oVLly7h4MGDAICdO3eidevWqFOnDl6+fImwsDCcPXsWjo6OWL58OW88EwA0bdoUly5dQmBgIMaMGYOWLVvC0dGRV3xSXR/EoJ2WKkfE+omMnaurK27fvs0WdbOxsSlTgHBF+amjRo3CpUuX0LJlS1y4cAGurq4q7VNSUnDlyhU2KLlmzZrlWo1XizAVdQwsXry4QtqVQlBQULmXavhfRZPjYNy4cdi2bRs7VX769GmMHTsWKSkprI1MJuME5zJkZ2dX+JSoPIwTw+xTVTD1u3fv2NfyhYHlqV69Ou7duwczMzMApc7EwYMHERAQgPT0dNZOnRPPF1gv5oGwZs2arCIxg5BCMcOHDx/w/Plz7Nmzhy3fwGcn1VZHRwc6OjrYv38/wsLCWEeIYfLkyawjOH78eFhZWWHatGnYt28fhg8fjn379vG2269fPxgbG8Pa2hpeXl54+vSpyqrgqvogBq1zU46IzVaQt9PR0UHt2rVRVFSEp0+fAoDKeeTy2L9UmBPuxIkTWLVqFSwtLTmZAYpPNYpZA8XFxZIi5bVoTnh4eIW0y1fB+HOjLdUgHk2uBWJiAKOiouDk5IRu3brB1NQUAHD//n3s3r0b06ZN06ivmjhFT58+xdChQ9n4Pj8/P6xatQr16tVTsp0/fz7n/a+//oqgoCDOOrGxTN26dRPsk0wm49TkYzA1NUV+fj7r5Dg5OSnd1DW5Po4dOxY2Njbw9/eHi4sL7ty5g1q1apXZVp0jxDhcQGn2ZGxsLIDSMhcbN24U7O+UKVMQHh4OfX19yGQy6OvrY9u2bRr1QQxa5+ZfJDY2FhEREahcuTIbECmTyfDixYt/uWdcmAN56dKlouybNWuGDRs2oKSkBLdv38a8efPQpk2bCuzhl83kyZPZVHExRQzLgq+vL++N89ixYxW6X6C0MGR8fDwGDBjAni8lJSWIj48vtyKGXzJiav8MHToUbdu2xfbt29mAYgsLC5w8eZKdqpQKc3OUwvDhw9GqVSs2CWL58uUYPnw49uzZo3ZbxcLAQOlxzUf16tU5adi9e/dmb7ZiESv5wXDx4kVkZGRg4MCByMnJQUFBAa/TFhISgpCQEPa9ubk5Dh8+zNumFFt1jlDdunVx5swZeHp6omHDhnj27BmMjY3x7t07lQ7Inj174OPjg0qVKmHBggVISUnBr7/+yjuNJcUZE0Ibc1OOCM1hCtk1btwYiYmJsLGx+az7l4rinPiTJ08AQLA4Zl5eHiIjI7Fz504QEb777jssWrRIcAhSS9lo1KgRe6OpaOSHnAsLC/HXX3/B2toac+bMqfB93759G6Ghobh48SJ7sX/69ClcXFywfPlyWFtbV3gf/lvQ5FpQ3jGAqmjbtm2ZHGK++D+hmEC+wsAvXrzA0aNHJe9X/lq4fft2ZGZmYtKkSXjy5AlevXrFycpiaNGiBRYuXMiZ7hs3bhxnuo/hjz/+wIoVK5CXl4c7d+7gzp07CAkJ4WSgJiUlwcfHB7t37+bto7yemBRbIUpKSlBUVMTqK6WlpaF79+7w9PRElSpVcPToUfj6+uL8+fOYNGkSBgwYwNtOs2bNcPXqVaSmpmLw4MEICwvDhg0bcPLkScl9EIN25KYc6dGjhyQ7Q0PDcnNspOxfKoz/e/36dfTq1Yt1bho2bIitW7cqpaPXqFEDK1aswIoVKyqkP18iQjcYIvqsI32dOnXivO/WrRvatm37WfZtaWmJo0ePIjs7Gw8fPgQAmJiYKMV/fElkZ2cjLS0NTZo04TzdHzp0SHJbYmMAmUrf7dq14+xTsdK3qiBZTQKP5SEidsQAAJ49eyY4vSXv5Onq6sLJyQnDhw/XeL9AaTDy+fPncefOHUyaNAkymQyhoaE4ffq00jZiJT8AYOXKlUhJSYGXlxcAoHHjxkop5hs2bICPjw8WLVqktL1MJuM4LFJsxTpCDg4OuHbtGv766y9kZGSge/fuaNSoEWbMmMHKlPDBiAYeOnQIw4cPR2hoqNI9ojycMRZJuVValPjzzz8573fu3Em7du0iIqKTJ09SRESEUkocw+zZs2nRokX0/PlztbU2srKyKCkpifLz8znrDx06VA7fQjVM/9u0aUMbN25k12/atInatGmjZF9YWEhz5swhPz8/8vf3p3nz5inVRdIiDQMDA0pMTFSq6fTPP//QN99886/1q7CwkBo3bvyv7f9LY+DAgWxJg6NHj5KhoSG5ubmRkZGRRunGRNJq/0ip9C0kt69Kdl8s69evJ2NjYwoODqbg4GCqV68ebdiwoUxtioH5jkxqtXyauJCwoBTJD0bET77dzyVQGRISQkQVJ8LarFkzSklJIQ8PD8rIyCAi5ZIK5dkHrXNTRkxMTNjXU6ZMIXd3d3JycqJx48aRt7c3zZ07l1q3bk3Tp09X2lbsSb9hwwYyNDQke3t7atiwIZ0+fZr9rKJ0TfiKxfGdZHzrgoKCqEuXLrRz507auXMndevWjYKDgyugl18Obdq0oeTkZN7PGjZs+Nn60b17d1ZTpGvXrmRmZkY//PDDZ9v/l468Loi3tzddvnyZiEoffjStLSWl9o+USt/169fnFOaVpzyO2bS0NIqJiaGYmBheva3yLgxM9H+/FaMkL/+dhWofnT9/nho1akTm5uZkbm5OpqamSirIDJ06daLMzEx2P+vWraMuXboI9icjI4N27dpF27dvZ5fysNUUVUVGd+/eTY6OjjRu3DgiIrpx4wb16NGj3PvAoJ2WEoHQdA8R4dWrV+z7v//+G1euXEF+fj6MjY3x8OFD1KlTBz/88ANatmyJqVOncrYXGyE/f/58XL58GQ0bNsSRI0fQp08fxMbGom3bthWWfhkfH69Uz0hHRwcZGRmws7MDAGRkZPAqkp45cwbXr19nA087d+6s1SApI7GxsbxaFwA4taUqGvm6Q7q6upg0aRI8PDw+2/6/dAoKCtjX+fn5cHJyAlAaICo1m4RBau0f5ji0s7PDsWPH0K5dO97aVl5eXrh69SrvtKV8HSdNsbe3h729veDnwcHB2LFjB4DSdOyhQ4di8uTJuHr1KkaPHo01a9ZI3idzvTU1NcXJkydZ7afZs2ez/4UiUiQ/Fi9ejH79+uHGjRswMTGBvr4+9u7dy2sbGRmJjRs3ws7Ojr0Oy2Qy3vuVFFugNATh1q1bHCV6MWEPfPcNhi5duqBLly7sexsbG2zfvl2wLU37wKB1bkRw8OBBLF68WCmYiYg4wVBVqlSBrq4u9PX1YWlpyWZw6OnpaSRLLr+fhg0bAgD8/f2xb98+dO3aFStXrixT+rfUOI7Zs2fD29ub1XJIS0vjTf2rU6cOCgoK2ADiDx8+wNDQUON+agGbdstHtWrVPls/+ETStHw+AgICMHr0aMyaNQv+/v7YuHEj+vfvjwMHDpT5HHv48CHq1q2LKlWqIDk5GZcvX8bgwYM54nQ6Ojp48eIFWwyzYcOGOHr0KPz9/dk4KAY+WX0GoRu2Ovr164dNmzaxopKKyCc+lKUwsLpYpiVLlmDw4MFIS0tD9erV4evrq3QtfP/+PapXr87GHjESHwUFBSgoKOB9WLG0tMTZs2eRmZkJIoKNjY3gvWPXrl3IysoSlaghxVadIyT1vrFp0yb069ePE9gtT0REhOQ+iEHr3IjAyckJzs7OvOJ18qMx8k9O8oFSRMRWOZXn1q1biIiIQGpqKifATF65Eih9onr37h17kXFwcMC+ffvQqVMntcqWqsjKysKmTZuUDngiYiuPyxMQEICMjAxWLK1Fixa8F1RbW1t4eHigd+/eAEovLG5ubuzBzXcwa9Ec+VTwiiIhIQFubm5o3LgxgFJhx/j4eDRu3BgbNmxAkyZNKnT/WkpZuHAhoqKi0KBBA9SuXRv3799HUFAQ/Pz8NBqJkEdM7Z+KrPQthvHjxwMQJyopX/X67NmzbCq0rq6uksMwaNAgLFiwAN988w2OHTuGPn36wNzcHPfu3cPKlSvZEUsmeL1u3bo4cOAA8vPzQURKKfMA0Lp1a1y6dElQoE/+fqF4HWecsvfv3wPgVyg2MTERrEReFlt1jpDU+8aNGzcAQFL2nhRnTAhtKrgILly4gPr16/OmPt+8eZNNQd25cyfatWundKBnZmZi8+bNHLlvAGjTpg3CwsIwffp0JCQkICYmBmZmZkrl7WNiYmBvb6+kxXD9+nWMHj1ao8wIoFTbYdasWWxkvjwmJiZKT2JiCQ4OFvxMJpNh7dq1GrWrhZ/PkQrerFkznDlzBtWrV8e+ffswYsQIbNu2DRcuXMDevXuxf//+Ct2/Fi5Xr15FUlISiouL4e3tXS7p2kya88qVK/HixQtMmTJFUB5fHdHR0RgxYgTmzZuHe/fuoXv37pxMl1GjRiEmJqbMfQaAt2/f4uHDh0pTVH5+fhg9ejTq16+PNm3a4O7duzAyMkJRUREcHBxw/fp11lb+e/r4+CA6OhpOTk64e/cuevTowd6YNVEoFkOlSpXYkSjFW7KQQvH58+cxd+5cBAQEcByXQYMGlcnW19cXR48eFSxGW1H3DSl9EIPWufkXYS4mDg4OSEtLAxHBw8Pjs8nI379/H/r6+rziSAUFBex0h4+PD5KSklCrVi3OUDDx1EgRw9atWzmVpbWoR9VQ8PXr1wVTS8sL+Yv/qFGjUKtWLbZmj9iaY1rKTkZGBoKCgvDo0SM27ba86mtJqf2jDhcXF7i4uCAvLw9ubm5YvXo1OnTowKYkl7UGWocOHZCQkABdXV3WqRk0aBCnjtS1a9fQr18/PH78GFOmTGGrYO/cuRM7duzA+vXrWVtra2s2ds3NzQ3nz59nP2P0WYBSJ6Rhw4bQ1dXldUL4FIrFTPf5+PigsLAQQ4YMQb9+/QTj6+QZOnQoTpw4AQcHB87UzZYtW8pkq84REnvf4GP//v1KcTR81cmlOGOCVFio8v8YYlOxpaRsM2l/np6edPfuXSooKCBzc3Pe/efn59P9+/eV1vNlCZQ3T548ISKie/fu8S5SqejK1f+L/Nup4PKZIK6urrR//372vVAKrJbyx93dnbZt26a0fuvWreTm5lamtmfMmEE1a9Ykd3d3KikpoSdPnlCLFi00asvJyYkcHByopKSEiErTzTt37kyhoaHs52WB2X7z5s0UERFBHz9+FMxWUsepU6coPDycIiIi6N27dzRx4kTasGEDlZSUUGJiIicFedCgQWxV7Zs3b4pq39nZmQoKCujRo0fUsGFD6tu3L/Xq1UvJ7vbt2zRp0iSysrKiwMBA+ueff1S2a2FhQZ8+fRLVBym2Q4YMIUtLS/ruu++oV69e1KtXL/r+++9FbSuPYmX6fv36kZOTEwUHB1NISAiFhIQIVpIvjz5onRsRiE3FlpqyPX78eHr58iVt3LiRateuTcbGxjRmzBglu4MHD5KBgQHp6+uTs7Mz3bp1S2W7UkhKSqK4uDilcvKxsbFKth8+fGBf37lzh/bs2UNFRUWS91nWC9uXyL+dCh4YGEjjxo2j+fPnU506dVjn/c2bN1rn5jNibW2t0WdiefPmDRUXFxMR0bt37+jRo0catePs7ExNmjThrPv48SN99913FBISUuZrQNOmTYmIaOTIkbRnzx4i0vy64uzsTB8+fKAxY8aQvr4+mZmZkUwmI11dXQoICKCsrCyOfW5uLq1cuZI8PT2pdevWtG7dOnr//r3K9omIVqxYQTNmzCAibkq/IsXFxbRt2zb65ptvaOHChYJ2/v7+9PHjR1HfUYqtFEdIFYr3JhsbG9H3i/Log9a5EYGjoyM9fPiQiIgOHz5MJiYmdPToUSJSFlsSY8fHgwcPKC0tjfczNzc3Sk1NpZKSElq9ejWZmpqytmW5SEgR5CIqfWLPzc2lly9fUv369cnLy4t9EpOCduRGOvfu3aPXr1/zfqY4SlgR5OTkUHh4OHXv3p3zRHno0CGVF2At5YuXlxetX7+edUCISm+GsbGx5OnpqVGbzAhEamoq76IJzs7O5O3trXRN+/TpE/Xo0aPMIn59+vShDh06kKmpKb1//57ev3+v8bVQfrvU1FRasmQJLVq0SFCLRp6DBw+SkZERzZs3T9DGzs6OCgsLqVevXnTq1CkiEnZuLly4QGFhYWRmZkZhYWGcB1lFhg8fTl5eXjRv3jyKjo5ml7LaSnGEVKH4fwQEBKh0Asu7D9psKRGQyFRssXZ8GU4GBgYwMDBAbm6u0nzrp0+f2EC1oUOHwszMDJ07d8auXbvKlAoeGxuLixcvQl9fn5XRzs/PR2BgIK9+TlFREfT09LB+/XoMHjwYs2fP5q2loqX8EZsKHhUVJbmwnxgMDAx4A0DbtWuHdu3ase+jo6MxevToct+/llLi4uIQGhqKUaNGKdXX0qQAJVBapHDv3r28Fa+F4kjUQURYtmyZUoaOrq4utmzZgs2bN2vUV4bY2FgcOHAAjo6O+Prrr/H48WON65vJZDLeWKZ58+bxxjIVFRVh165dWLNmDR4+fIjx48erTKLo168fjI2NYW1tDS8vLzx9+lQpCyg6OhpxcXEwMjJCcHAwFi1ahKpVq6rs98ePH2Ftbc0JjBa6H0ixtbCwQJs2bdCtWzfO/yc1y1Wx/YULF8Lf3x9t2rThtKuYaFNefdAGFIvAwcEBp0+f5gSAZWRksKnYjJCfWDsmMp4UUgPp/wfoKkbGN2nSBFeuXOEc7ElJSRg0aBA+fvyIp0+favS95APlAODRo0do164dJk6ciOjoaKWAv6ZNmyI9PR1DhgxB//794e/vr1EwaUUV+NRS9kDN//b9fyn8p9fXSk1NFS3UN3DgQMTHx0tqX0yQrlhcXFxQuXJlTJgwAT179uR8tm3bNvz2229sksfYsWOxZ88e+Pn5ITg4GC1atBC1j5ycHOjr66NSpUp4//49cnJyONWwK1WqBGdnZzRq1IjX6WDECD8HfI6aJlmuiteCrl27Ijc3Fy4uLpxU/Pnz51dIH7TOjQjEpmJXVMr25MmT4e3tjYCAAM76EydOICQkRGOFWmdnZxw8eJCjWfHkyRNWkOvdu3cc+/DwcBw7dgzFxcW4du0a8vLy0K5dO1y4cEHSfvfv34+OHTtq1Gctqvm3Hcd/e/9aykZubi7u3bvHyWYRm2auaaVvTRxiFxcXnD59Gq9evUKLFi3QqlUrFBUVqRQOFMLZ2Rn5+fmsgrAiNjY27GeVKlWClZUVvv76a7Uiggx79uyBj48P9PX1sWDBAqSkpODXX3/lpK7HxcWp7COfeOaHDx+waNEiHDlyBDKZDO3atcPo0aN5R3yk2JYXitcC+d/xc6B1bsoRsSnO8nYXL15ERkYGBg4ciJycHBQUFHAUMaWQnJzMqT6rjs2bN6NRo0bw9PTkrH/69Cl++eUXrFy5krOeiJCamgoLCwvo6+vj1atXePDggZLaZ0FBAWJiYnDlyhVOivLnfPr4Uvm3R07+7f1r0ZxFixbh559/hpGRESddWP7hSZVoaNOmTTXSONHUuSkvTZ41a9Zg7dq1GDFiBAYMGMBqq5SUlCA+Ph4rVqxgq30nJSWpbMvHx0dpHTNCnpqaisGDByMsLAwbNmzgqNuLRX7aNzg4GK9evcLQoUMBAOvWrUOtWrWwbt06pe2k2Ip1hLKyslh9rUaNGsHCwoLzeXZ2NmdEsWvXrtiwYYOoNPdyccbKFLGjhYPYQFnGbtmyZdSsWTOysLAgotJUQL4q2+W9f6ksXryYiIjOnTvHBoRt3ryZIiMjlbKsiIgGDBhAYWFhZGpqSkuWLCEXFxfeLDAt5c+/Haz9b+9fi+aYm5vzns/yVESlb02OGSlBunwoFni8desWtW3blgwMDMjW1pZsbW3JwMCAfH19KTMzU3L/5NOgme/322+/0bJlyzjrpCK/nY2NDZtqT0RUVFRENjY2vNtJseUrfBwUFMR+npGRQW5ubmRsbEzu7u7k7u5OxsbG5ObmplKapHfv3tS4cWMKCwujsWPHsosmfRCDNqC4HCGRg2CM3cqVK5GSksIqPTZu3BjZ2dkVvn+pxMXFYfTo0QgJCcGlS5dw69YtTJ48Gb169UJwcDAOHjzIsU9NTUVaWhqaNWuGUaNGISgoCJ06daqQvmnhUlHHwH/L/rVoToMGDXhV2OWpV68eUlNTecuuMIG4nwMxQbqqUCzwaGlpiaNHj5ZbLNPhw4fZwP7i4mKcPXsW27dvZ0dKPn36pFG78ueXlBp+UmzVFT4OCgpCVFQUb3xScHCwoAitnZ0dW3RZHeVRfFnr3JQjYjOXGLuqVasqqTnK10OpqP1LhTmhdHR0oKOjg/379yMsLAzjxo3jLUDHfCddXV28f/8eenp6ZXLatCijrrDfv4WmGTta/n0mTZqEiIgIdO7cmZOh4u3tzb6uiErfmhQVnjJlCsLDw6Gvrw+ZTAY9PT1s27aNYyO1wCNQWjuqPIKz5Z2QmTNnIjQ0FH5+fmjSpAkyMzPZkj1SkclkbI0+oRp+8kixZVDnCOXk5Cg5NgDQq1cvTJ48WbDvUmqPlUfxZa1z8y9iZGSEmzdvsk5JbGwsWzn2Pwmmfx8+fMDz58+xZ88ezlOJIrVr18abN2/w7bffIiAgAIaGhmyKvBbNkFrYr7z58OGDqDpBmt7gtPz7nDlzBuvXr8epU6c4MTfyT+IVUelbvtSBOm7dugUrKyvBGk/yGUhSCzyWJ/IPml26dEGXLl3Y9zY2Nti+fbvGbcsH6bq6urKp+i4uLigpKdHYVqwjZGhoiPj4eN74pDp16gj2+82bN/jpp584cTSzZs3ilHHQxBkTQuvclCNSp6UWL16Mfv364caNGzAxMYG+vr7GFwgp+9eUsWPHwsbGBv7+/nBxccGdO3d464vs27cPOjo6mDFjBjZu3IicnBxpNUG0KJGamspmtU2bNg2HDx/mFPZjnJuKYuTIkWydoKioKPzzzz9snaDk5OQK3beWz8P69etx79491KxZs1zau3PnDkJCQnD//n10794ds2fPZkeEPD09cebMGcltStHkcXZ2hoGBAW+BxypVqkjet1Q2bdqEfv36sTdsRaTqxgCl13i+IGAhpNiKdYQ01VoKCgpCw4YNWcdu9erVCAoKwq5duyT3QQzabKlyhC/F+dWrV0rerLxdSUkJMjMzQUSwsbHRaIiWYc2aNWw0fHkilN5bUlKCoqKiz3Kh+NIRW9ivomjWrBlSU1Mhk8nw/v179O3bFw0aNMDy5cu16d//IzAFclUhdgQPAAICAtC1a1e0aNEC0dHRuHPnDg4cOAA9Pb3PcsyUpcBjWXF2dkbXrl0xbdo0QYE/KY4Hg7x+kHzhT3n4HiSl2IpFanxSkyZNOCKCQuvKC61zI4JevXohMDAQXbp0kex8WFhYKCl8qkqnBKCUKldcXIyVK1di06ZNnNS7vn37IjQ0tEwOkRgYp2n37t28n8tf4IBS/Z3x48fj9u3bHL0Mdd9bizCjRo1CpUqVMGvWLMyaNQv29vbo378/Dhw4gPnz52ukLyIFOzs7ZGRksO8/ffqEPn36oE6dOrhw4YLWufkfYPz48Xjw4AF69erFibmRP79DQkJEV/pWdGBmz56NnTt34vDhw/D19S2zZEBZNHkqGsU0aLFcunQJkyZNQlZWFud78alEy8uOFBYW4tSpU2jRogX2799fJtuKcIQAwM/PDwkJCezvkp2djX79+uHIkSMV0getcyMCIyMjGBsbIzs7GwMHDsTQoUNha2urZFe7dm2ldW/fvoWBgQEA4PXr1wD+T6EYUJ5K4lMoDg0NxbNnzzBixAiYmZkBAO7du4fly5ejbt26Sno0YhH7FDZs2DCsWrVKSZyQ6a/ijdXGxgazZs2Cu7s7x/GSnw/XIo2PHz8iKioKa9euRe3atXH//n3o6OjAz88Pf/75J8zNzSt0/z4+Pli2bBlHeKyoqAh9+vTBzp07eWOvtPx3Ieb8ljKCZ2trixs3bnDaW7BgARISEvD27VvcunVL476K0eQBSh+07t27B39/f04mWFxcHK8wnlgOHDiAMWPGICsrC8XFxYLq8gz79+/HrVu3OA7LuHHjlOwcHBwQHh4OT09PzrVTTKbQ3bt3MXnyZPz1119lspXiCCkiP8LMwHzPBw8e4NSpU2zmbGJiIlq3bo0tW7aUax8YtM6NCJiT9uzZs1i7di0SEhJgb2+PoUOHok+fPqhevTqAUoVOKysrTJw4EZUqVQIRoXXr1jh16hSA/6sP5OPjg8LCQgwZMgT9+vVTK2pkZWXFeyEgIlhbW2t8kZDyFCYFxWkTLeVHfn4+7ty5g6KiIjRq1EhlAF95cu3aNXz11VewtLTkrC8uLsbmzZvRv3//z9IPLf8uUkbwvvvuO4SGhqJDhw6cNn7//XeMHz9ecgyFPBYWFjh16pTK1PXff/8df/75J2xtbZGSkoIVK1agR48eAMouNmltbY2YmBglJ4S5F8jTv39/XL9+Hc7OzhxHjO+hVJNyNvJIETIUa6voCKmaAg8ICFAqBzRt2jSV7YvJopLiuDFoA4pFwIyyeHh4wMPDA4sWLcKWLVuwdu1ajB07Fm/fvgUAHDt2DIsWLUJwcDBWrlwJa2trVK5cWanoYVJSEu7cuYO1a9fC1dUVHh4eGDp0KNq0aSO4f75hzuzs7DIFEZ87d459ChsxYgT69u2LESNGYPny5YLtXr9+XekJhLlgMPTs2RPx8fHo06ePNh6nnHn27Blbo+zt27efzbmRH7GRR0dHR+vY/A+RkJDAyWZhslUYjIyMcO3aNfZ4qFy5MrZs2YI+ffoo3fQSEhLYIF/56fRx48aVOVtJjCaP1MLAUtDX11cqhyPEpUuXkJ6eLip8oGXLlrhw4QJcXV3V2sqHCTBaOkIKvlJsFTE3N0d6ejr73snJCWZmZry/IXNtkkdKCrjYPohB69yIQPFP/PrrrxEUFISgoCClIbixY8eiffv2CA4ORs+ePQVPosaNG2PWrFmYMWMG/v77b/Tp0wdRUVG8Q5VRUVFwcnJCt27dWEfp/v372L17t1qvWBVFRUWs41a9enXs2LEDffr0wbBhw3jtIyMjsXHjRtjZ2XGeQBSdmyZNmiAwMBBBQUEAoHbIVot6rl+/jsGDB+Phw4esXMCDBw94qxZXFEw2TefOnTmxDXPmzMFPP/1U4fvXUrGMHz8eSUlJCAwMBFBaxfnChQv47bffWBsplb6zsrIEj9nY2NgyTVOL0eQB/i9+0c7ODseOHUO7du1QXFxcZk2wzp07Y+fOnaKyFM3MzPDhwwdRIoMnTpzAqlWrYGlpyflefKNMzCg7UPofWFpaClZbl2KrzhEyNTUVHDVTJeQ4ffp03vV8VcHL4owxaKelRBAbG8veqMVSVFSEX3/9FSdOnMCJEyd4bS5evIg1a9aw2VPjxo1TGvZnuHfvHrZt28Z5AurZs2eZYi2kxlFYWlri6tWrak9SCwsLrF69Gq6urmqHbLWIw8PDQ1TV4ooiKioKp0+fhpOTE7Zt24aJEyeyNW609aT+N7C2tkZqaiqbRVRQUABHR0eNCvMOHDgQN2/erLBj9ueff8aSJUtgYWEhqMkjtTCwFGrVqoW3b9+iWrVqqFq1KvsAx8RVypOeno5hw4ahTZs2HIeF76YulK3GV7OqopCPvWIcoQkTJrD3mtGjR+P7779Hq1atlLZlRv75+PHHH9nXhYWFSExMhKenJzZs2CC5D2LQOjf/AtHR0YiLi4ORkRGCg4Px3XffVWh1ViGkxlH4+vri6NGjrHCTEC1atEBKSkq59/dLRlVF3c9RbdfBwQEXL15ElSpV8OzZM3Tt2hXfffcdfvrpJ20q+P8I7u7uSElJYc/voqIitGzZEmfPnpXclouLC96/f19hx6yZmRmuXLmiUpNHamFgKdy/f593vWIIAlCabZabmwsXFxfOw978+fMF23/y5AkA8I6OZGdno3r16uxD5unTp7FlyxZYWlrihx9+4Fyfpdh+bl69eoWgoCDs2bOnQtrXOjciEJuKzdj99ddfbP4/n12lSpXg7OyMRo0a8Q6PSqmePXnyZE6NFE1hgvtUHeznz/+/9u49Lsb8/x//Yyp2nRJyiE5sqJQOFLJEh43ljcVuzrJ5q3Xct+0jtOu9ixzX7mbfu1pvS4m3pdjFIqWWRYikrNocCmmj1iFlOqhe3z/6zfWbq5mYa5rpmup5v93mZua6Xl3Xs8zhOa/r9Xq+LmPDhg3w8fHhfQOpPT1v3bp1MDQ0xAcffMBrp8pqsES5oUOHqrRqsbbY2dnhjz/+4B4/f/4co0ePxujRo3Ho0CHquWnEZJcATp06hczMTO71vGfPHtjY2OCbb74RfExnZ2e0atVKa89ZVWryqEp+pW0hpFIpN/jX0dGxzh5tIYlcZmYmJk+ezCU3pqamiI6O5s3OHTZsGHbu3MlNNHF2dsaMGTOQmZkJFxcXXtIkpK0YiVC/fv14Y2k0GQMlNypQdSq2qu0iIyNfeT4hUxTNzc25hEuokpISrF69Gvv27cPDhw8B1CyMN2XKFHz22Wdo164dr72/vz9+//132Nvb87qCa0/lU/YEpDE39XP79m0EBAQgJSVFoSpoeHi42mvVqGrQoEHYv38/97wGap4/Pj4+uHLlCsrLy7V6fqI9yqaAyygr9aAKZ2dnHDhwQGvPWVVq8giJVWhynpSUhEmTJqFbt24AgEePHuHgwYMKvUSymPbs2aPSl7uRI0fin//8J9dr/tNPP+GHH37Ab7/9xrWRTwjWrl2LmzdvYvfu3SgtLYWLiwvvS4iQtkISIXXIV2quqqpCcnIyCgoKkJCQoJUYKLlRgapTsTU9ZVv2jeJVC8BlZmairKxM0HFlJk+eDBMTE8yfP5/70MrJycG2bduQl5en0IP01ltvISsrq16Le5L60dSqxUL99ttv6Nixo8LaUS9evEBYWBhWrlzZIHGQxkE+YdDGc1bVmluqUOey6uDBg7FlyxYMHToUQE2ys3TpUqWX4319fZGSkoJ33nmHl4h99dVXCm2VTQWvvU3+bztmzBj4+vpyvW21fxchbYUkQuqQr9QsG0czb948XgVpTcZAn1IqUHUqtqanbEdGRmLJkiVaWwDu+vXrCivp2tra4ttvv1X6rapXr14q/x65ubk4e/YsgJouZCrgpxmaWrVYqLq+3bdp04aX2AQHB3OLqpLGpa6JD7VnIKlCfmyJNp6z8j0Z9aXOzKnS0lIusQFqVkuv60umra0tbG1tVTquvr4+MjIyuPYZGRkKU8jffPNNpKWloWvXrjh79ixvAG9paanabeXHfV64cIH7bGnVqhVatGihUvyvospyE5qMgZIbFag6FVvTU7ZliYS2FoDT09PjVtmVd/PmTaU1GXr16oURI0Zg/PjxvG8gtReAO3z4MPz9/fH2229DIpHg448/xo8//shbGZc0TfHx8ZTcNFKffPIJd7+srAxZWVmws7NTazxVQxTxfF1NHm1q27YtTp06BS8vLwBAQkJCnbNBhdR5WbduHYYPH47+/fsDqPkCunfvXl6b9evXw8PDA8XFxViwYAE3/To2Nlahcr6QtkISISEyMjLQpUsXGBsbA6hZWX7v3r2wsrLC559/jrZt22olBrospSJVp2Jrcsq2rEtRWwvA/frrr5g7dy6cnZ25ZOzu3btITU3Fjh07MHbsWF57ZQvASSQS7Ny5UyFu2SAwoGa8yAcffECDTpsBmjnVdCQnJyMiIgLff/89t00bK32ro3ZNnv/9739wd3fn1eRRlTrP2StXrmDSpEncl8Dq6mocOnRI6RCCp0+fYsWKFbxELDQ0VOn7OQAUFBRwU9oHDx7MJQXyqqqqUFxczJst9uLFCzDGuGQhJycHPXv2VLnt/fv3MXHiRC4RktXGiY2NRXh4OH755RdBfyOZQYMG4dChQ+jRoweuXbuG4cOHIyQkBOnp6XjzzTfx448/cm3PnDmjuRgY0Zhly5ZptJ2Tk5NWzi+vpKSERUdHsy1btrAtW7aw6OhoVlxcLPg48vr376+wzcHBoV7HJI2D0Ocs0W2Ojo68x++88w77z3/+w65cucJmzpzJ3Nzc2PPnz5W21abevXszqVTKPZZKpax37951tn/69Gmd72vXrl1TK4aKigp2/fp1dv36dVZRUVFnu3HjxrH58+eza9eusWvXrrGFCxeycePGqXVOIYS8FmVtKysr2dOnT3n7SkpKeH+77OxsQXHY2dlx90NCQthHH33EGGPs5cuXvH0ymopBvEnuTVB8fLxG2zGBnWqqHldemzZtMHnyZCxduhRLly7F5MmTed2EQE1BLqBmoc0NGzbAy8sL3t7e2LRpk9JZMl26dMGOHTtQXV2N6upq/Pjjj6KMEyGEqC49PZ27paamIjw8HC9fvuS1KSgowIIFCzBgwADs3r0bY8aMgaenJ4qKiupd9VcIIyMj3viMFi1aKPSEPH/+HAsXLkT79u3RqVMntG/fHhYWFryeKAAKg+Rf5cWLF9yxS0tLYW5uDnNzc5SWluL58+dKf+bmzZv47rvv4ODgAAcHB3z77bcKhRFlRfo6dOiAjh07cjfZY3UI+fyQtdXX11eoHdSmTRveZ0LtooyvIz8B5dKlS9zvamBgoHT4g6ZioDE3GqTqk0nVdhEREVo5v1Cy0euBgYF4/PgxFi1aBKBmgFhmZqbCQLHw8HBMnz4d8+fPh0QigbOzs9IqlKTp0dZzkGjf+PHjufsGBgbo3bu3QtmK2uMeVq5ciZYtW8LT07NeFX9VJavJM3jwYPj4+PBq8tSehj1nzhw4Ozvj9OnT2LNnD7p27Qp3d3esWrUKT58+RUhIiODzDxs2DFevXoWRkREkEonChBJl5S66d+/Om2hSWFioMMHip59+AoB6LZpZm5BkU0hboa/xjh074siRI+jevTsuXLjALX5ZWVmpdgkJVWKg5EaDVH2CyNpdvXoVK1euRHZ2Nm8hyuzsbADCvlEIOb+6Lly4gMzMTO48Y8eOVbqm0VtvvYWLFy+ipKQEABR6gkjj9fTpU9y7d4+byll7naG4uDiRIiP1lZOT89o2NjY2iI2N5a30HRQUBD09PQQFBWkzPAD8NZIA8Mb71V64MysrCwcPHgRQM65myJAhWLZsGX7++Wc4OTmpldzIxg2qsqK5bJ3ADh06wN7eHmPGjAEAHD9+HMOGDeO1ldUBMjEx4SaJZGdnIyMjA6NHjxYcpzYJ/ZwJCwvD1KlTkZeXh9WrV3NJ3q+//goXFxetxUDJjYhmz56NhQsXYsiQISqtGCu2Tp06obS0lJuSXl5ernSwG1BTrCsnJ4eXtKkzpZTohgcPHiAwMBAnTpwAUHNZoLS0FAsXLkRoaCg3TZMuPzZ+2dnZOHLkCKysrBQmFWhzpW9VCJkCLpFIIJVK0bp1axQUFHDvRa1bt67XLFOgptRF165d0bJlS5w/fx6pqamYPXs2r/Bp+/btAdQsXWJvb89tDwwMrPO4Q4cORWJiIioqKjBs2DBYWlri119/rXO9pldR57KUNtjZ2eH69esK2ydMmMBbePT8+fO86fX1RcmNBgm9LKWvr4+AgIAGP79QBQUF2Lp1K6ytrTFo0CBuymVMTIzSzDs0NBSbN29+5aJ2pHGZM2cO/Pz8EBUVhaioKDx9+hSBgYEIDg7G//3f/6lVop/oBi8vL3z55ZdwdHTEX3/9hYEDB2LQoEEIDw/HjRs3EBwczLXV5krfQqhSk2fWrFlwdXXF22+/jVOnTnE9Sw8fPqx3L/f48eORlJSEvLw8TJkyBW+//TbOnDmD6Ohoro2QKeAylZWVaNeuHXbv3o3Zs2dj3bp1vMRIiIkTJ2qlrbY+ZxYtWqTyjFpVYqCp4GooLCzE9evXYWNjw3Unyrar8s1V1m7BggWYM2cOBg4c2KDnF8rY2LjOGjXKpoK/9dZbSE5ORqdOnTQeCxFH//79ed3+rq6uSE5ORlVVFaytrQVX3ya6w8bGBpmZmQCAL7/8EufPn8fPP/+Mp0+fwt3dnff/Lvbq9DLyX6peVZMnPj4e6enpGDBgAEaMGKGx88vKdGzfvh0FBQX49NNP4eDggLS0NIW2q1evVnoMZauCyyr0fvjhh5g2bRq8vLyUVi2uS3h4uELPUE5ODnJzc+Hi4sIrGxIfHw9vb2+VjitvzZo1+OyzzwT/3OsImZKvUgyqTOVq7mbOnMkePXrEGGMsISGBGRsbMxcXF9a5c2f2888/c+0OHDjA3S8sLGTvvvsuMzQ0ZO7u7uzevXsKx7Wzs2MtWrRgNjY2zMnJibupe35dMWTIELFDIBrm4ODAPQdv3brFBg8ezO2ztbUVKyyiAfLvOe+99x7bvn270n2MMdanT586j/Oqfdp26dIlbopxQ7C1tWVlZWVs8uTJ7Ny5c4wx5SUwGGMsKCiIuy1cuJD16tWLTZ8+XWnbBQsWMBsbG9anTx9WUVHBnjx5wgYMGKByXGZmZrzHe/bsYcbGxszOzo6ZmpqypKQkbp+yz5rs7Gx25swZ3jR7xhiLi4tTOQZ1vW7q+rZt2wQdj5IbFcg/aYcPH85SU1MZYzVPBPnaDvL/OXPnzmXBwcEsPz+fbdmyhU2YMEHhuKdPn1Z6U/f8Qt2+fZuNGDGC9ezZk/3rX/9ipaWl3D75Dy+ZyMhIpbfaVq1axZYsWcIuXbrE0tLSuBtpvHbv3s26devGfHx8WOfOndnBgwcZY4zl5+ez0aNHixwdqY8BAwaw3NxcVlxczDp27MiysrK4fX379uW1dXNzY7t372ZVVVXctqqqKhYRESH6lxpl74WRkZHsiy++YFevXuVtX7duXb3OtWbNGmZkZMRcXV1ZdXU1++uvv5S+Zyrz999/s7FjxyrdV11dzVJTU1lRURHXtnbs7733ntLbhAkTWOvWrXltHRwcWG5uLmOMsfj4eGZmZsYSEhIYY4p/L6GJkKa97hy1E7fXoTE3KpCf/iiVSuHo6AgAXPVHGSZ3hS85ORlXr16Fvr4+li5dqnQlcNl8f9ny9t27d6/X+YWaP38+Jk+ejMGDByMsLAyenp6IjY1Fu3btlK6TcvToUe5+WVkZzp07h8GDB3PTMWV2794NoGYZBhnZIETSOM2cORMuLi64ceMGHBwcuOrT3bp1w/Hjx0WOjtTHypUr4eTkBAMDA4wcOZJbVy4pKYm3CjxQs95dQEAAFi1apLDSt9DSFfUhf6msqqoKly5dUqjJs3z5cpw/fx6Ojo549913sXz5cixZsgRAzRIAK1asUPv8n376KRYuXAhDQ0NIJBIYGhoqrNNXl06dOtX5XnjlyhX069cPrVu3xoEDB5CcnMzNupI5efIkvvnmG4VB0Ywxbj0/+W2mpqYAasZWHTt2DOPGjcP27dsVxh1t3rwZqampMDU1xalTp+Dr64uIiAh4eHg0SIkHxlidY38YY3j8+LHgA5LXWLhwIVu8eDErLi5my5cvZ3v27GHV1dXs+PHjbOTIkVw7a2trlp6eztLS0hQq8iqr0JuRkcFsbW2ZkZERMzIyYnZ2diwzM1Pt8wtVO3MPDQ1lLi4u7NmzZypl6tnZ2Wzq1Klqn58Qohvy8/PZtWvXWHV1NbctLy+Pdzm9rKyMu19QUMBSUlJYSkoKKygoaNBYGWPM0tKSu1lZWbHRo0ezK1eu8NrY2dmx8vJyxljN7+fi4sL12NS3mvKRI0e43pXNmzezSZMmsevXryttGxYWxt2++uorNmXKFObh4aG0bf/+/VllZSW7efMms7KyYsuXL2fvvPMOr42bmxu7fPmy0p83NTXlPbazs+MqSMvcuHGDWVpaso4dOyqcW156ejqztLRkcXFxDdJzs2PHDta6dWu2fft2FhERwbvt2rWLderUSdDxKLlRQXl5Ofv444+ZoaEhs7S0ZBKJhBkYGDAfHx9eGWgLCwvuBdezZ0+uO7CuZGHEiBFs79693ON9+/axESNGqH1+oWp3OTNW80IdMGAAs7KyUukYdV1nZqzmzbCoqIi7kcarrKyMffHFF2zOnDns8OHDvH0LFy4UKSrSkBrb0hr9+vXjPS4qKmJubm5szZo19f5d7O3tGWM1Szc4ODiw8PBw9vbbbytt6+fnx93mzp3LNmzYwJ48eaK0rSyusLAwtmXLFsaYYiJ2+fJllpeXp/Tn5S8pMsbY1q1bWWJiokK7jIwM5u3tzdsmJBHSlJUrV/IeC0ncXoeSGwHS0tLY1q1b2ddff81SUlLqbHf79m2WmJjIfvvtN3bnzh0mlUqVJiHKenNetQaTqudX1YQJE9iJEycUtm/ZsoVJJBKF7YcPH+Zuhw4dYsHBwczFxUWh3YULF5i1tTXT09Pj3Ujj5e/vz3x9fdmXX37JrK2t2ccff8zta2wfekQ9Dbl2lKru3LnDvv76a3b06FGFfa6uriwnJ4e3rbi4mLm5ubGWLVvW67yy5/ymTZvYd999x9tWH7a2tuzhw4fMy8uLe4+XJVLaJiQR0pTa42iEJG6vQ8mNCm7cuMFcXFyYiYkJc3V1Za6urqxbt27MxcWF/fHHH1y7jIwMrt2gQYPqbCfj7OzMbty4wTuPs7Oz2ucXqqysjNfVLO/BgwcK20aMGMHdvLy8WGBgoNKkzdXVlV28eJE5Ojqy58+fs7Vr17Ivv/xS7TiJ+Ozt7blLFiUlJWzs2LEsICCAMaabH3pE83QhifX09OQmVOTl5bEOHTqwUaNGsb59+7INGzbw2iYmJipdFLOkpISFhobWK47+/fuzixcvskGDBrGMjAzGGFNYBPLGjRussLCQe3zgwAE2fvx49sknn9S5iOd///tf1r59ezZp0iTGWM0X5eHDhyu0EzKrSSqVKp2tW5/PDiHkZwLL3xwdHdkbb7yhtfNScqMCV1dXFhMTo7A9Ojqa13OhajuZ2NhY1qlTJzZy5Eg2cuRIZmxszE6ePKn2+TXpVSvsvo7sTVD+xT5w4MB6x0TEY2Njw3tcUVHB3nvvPTZ37lxKbpoJXUhurK2tufubN2/mZqE+efJE7R6OZcuWCf6ZI0eOMAcHB7Z06VLGGGN//vknmzhxIq+Nq6sr9yUxNTWVtWvXjm3YsIFNmzaNffjhhyqdp6qqihs3JCNkVtPJkydZ+/btmaGhIXNycmK3bt2qsy1j2kmE2rdvz44fP64wK/i3335jXbp0UWivqenolNyoQNXaDurUgHj06BE7evQoO3r0KC/LV+f8QslP065969atG9euoKCAvXjxgnt8/vx5tmTJEvbtt9/ypoTKuLq6MsYYc3d35wYcWlhYqB0nEd/w4cMVBky+fPmSTZw4kS45NhO6kMQKqcmjzjE1Sf7LXUhICFeH5+XLlwq9PLISIPKX/uVv8oRM73ZxcWFpaWmsurqa7dixg1lYWHCv49pthSZCqhoxYgQ7f/680n21x9Focjo6TQVXgbGxMaKiojB9+nTo6ekBqFk4LSoqileFV9V28rp06aKwfou65xfK0dERlpaWSqf5yU+7mzhxInbu3InevXvj1q1b8PHxwYwZMxATE4N79+5h8+bNvJ+dMmUKHj9+jJUrV8Ld3R0vX77E2rVr1Y6TiO+7775TWCTTwMAABw4cwP79+0WKijSkwYMHix0C9PT08ODBAxgZGeHMmTPYsGEDt08qlap1TGXvf3XZt28fpk6diq1btyrdv3jxYu6+gcH///F66dIlzJ07l9teey3BPXv2wN3dXWFhUKCmjMa4ceN48ao6vfvly5fo378/AMDf3x+WlpYYO3YsDh8+rND2008/xe+//w57e3vs3LkTXl5e+PXXX2FnZ1evqeAREREwNDRUuu/mzZu8xxqdji4oFWqmbt26xTw8PFj79u2ZtbU1s7a2Zu3bt2cjR47kDXJStZ3sGqqRkRHr0KEDd5M9Vvf8QllaWtY5eEs+o5avQLtmzRo2c+ZMxlhNF2btGQm1VVRUKIzAJ03XjBkzxA6BaJCygbpiOnjwIDM2NmbdunXjxqUwVtOb7OPjo9YxhfQIrFq1ijHGnwElf5Pn4eHBDh8+zC5fvszatGnDTZl/+fIl7/KaUEJmNVlbWyuMqzx9+jQzNzfn9c4zptiTc+rUKWZhYcGuXbvWYJckNTkdnZIbAVSt7fC6dn/99RdjjLG7d+8qvdX3/KpavHgxO3v2rNJ9ssGijPFf/O+++y6vKrH8C+JVl7moQnHzoAvjMojmCK0K2xCE1uR5HW09Z69fv87s7OxYhw4duGndjDH2888/c18QlcnIyGCHDx9mBw8e5G7yhMxqWrlyJYuNjVVoe+bMGYVxlUISIaHOnDnDIiMjFb5MR0RE8B5rcjo6LZwpooqKCq7KZHZ2NjIyMjB69GiFLkuxubm5Ydu2bejatSv69OmDGzduwMzMDABgbW2NP//8E0BNxeS6UIXi5kG2oCBpPGpXwJVhjGHnzp0oKipq4IjqT8jzUMiCjfJOnDiBW7duobKykttW19/yVc6fP4+hQ4cCAD755BPs3bsXtra23OeARCJBXFyc4ONGR0fj/fffVzmG48ePY/jw4fDx8eHt+/333zF37lyFS0iq+uqrr7Bt2zZYW1vj4sWL+OGHH7hKxLX/n7799lvY2dlh5MiRvGNkZmZiyZIlgv4ONOZGREOHDkViYiIqKiowbNgwWFpa4tdff0V4eLjYofGsX78eHh4eKC4uxoIFC7jEJjY2FtbW1ly7nJwcsUIkhKjp+++/x7Jly5R+qao9LqOxkP/Onp2djfv37wMAzM3N0atXL15bdRKHadOmITMzE05OTrwkRB2LFi3iPuAPHz6M7OxstG7dWq1jyVu/fr3KyY18DLUNHz6cl9jIJ2OqiIiIQEpKCgwNDZGRkYEJEyZAKpVixowZCuNoFi1apPQYNjY2vP8nVRI3Sm5EVFlZiXbt2mH37t2YPXs21q1bB3t7e7HDUuDu7o6CggIUFxfDyMiI2z5s2DC8/fbb3OOcnByu9+bgwYPIysrCypUr8ddff+Hx48c6+bsR0tzZ2dnh/fffV/r63LFjhwgR1Z9EIkFmZiZmz56N3NxcmJubAwDu378PMzMz7Nq1C/369QMAdO7cWfDxr169ihs3bmikl13+A97MzExh4L4mjqvJtq9KhOoiG1Bsa2uLxMREeHt7o6qqSu2EUJXEjZIbEVVUVAAATp8+jWnTpgGAzl2SktHX1+clNgDQpk0b3uNJkybh6tWrWLVqFS5fvow7d+5g5cqVkEgkCAgIQFJSUgNGTMSgq89fUrfVq1ejVatWSvcpW/C3sfDz80NwcDAmTZrE2x4TE4M5c+YgOTlZ7WNbWlqivLxcIz0s8h/wmzZtwvvvvw8fHx9eklN7cWKhx9VkW6EjWfT19VFQUIAuXboAAExNTZGQkAAvLy/k5uYKOpaQGCi5EdHIkSNha2uLqqoq/PDDD3j69Clv+mBjI3vCHT58GFevXsXAgQMBACYmJigpKREzNKIh165dw927d2FgYABbW1uFLv7Lly+LFBlR17vvvlvnPg8PjwaMRHMYY3j27JlCYgMAkydPRkhISL2Ov2XLFnh5eWHEiBG8JGTVqlX1Om54eDjS09PBGONd7lInudEWob0ty5cvx507d7jkBgC6d++OhIQE/Pvf/9ZaDI33k7QJ+Pbbb5GWloZevXqhRYsWqK6uxn//+1+xw1Kb7AnXqlUrhW/wNG69cUtPT8f06dNx//59lJSUwNbWFnl5efD09MSPP/5YZx0L0jiUlpaisLCQu3wjc+PGDe7yTWMyePBgpKena6U+GACsWLECLVu2RFlZGV6+fFmvY8m/N54+fRpZWVka+ZKrrctSQvn6+irdbmJigu3bt3OPw8LCsGTJEs2dWNDcKqJRycnJXOXf/fv3s08++aTOujONgWxK5QcffMB+//135uTkxCoqKtjnn39O9U8auSFDhnBlAw4fPswWLVrEysvLWUhICJs1a5bI0ZH60FZl2oZWuyaPtuqDMVa/yvC17dixg7vv5eXFKioqNHLc48ePqxXD62irUrWQ55oqMVByI6L+/fuzyspKdvPmTWZlZcWWL1/O3nnnHbHDUpvsCffw4UPm4+PDDAwMWIsWLdg777xT59ISpHGovVq9/Fph9VmHjIhPSIl+XVZXTR5N1wdjjLF//OMfrKio6LXtVK3vIjNv3jzm5ubGNm7cyMLCwribvEmTJrGff/6ZVVZWvvb8tevWREdHs8WLF7Ndu3a99mfrIiQREqL2c62qqkrp8j6MqZa40WUpEenr60NfXx8nTpzARx99hKVLl8LJyUnssNQmq13QtWtXxMbGQiqVgjGmMPCYND4tWrTAn3/+ydWqkP8/pUHEjZuQEv1ie1VNnrrq8XTu3FmtGVGv0qpVKzg7O+Odd97hjbn56quvePdl9V0++eQTXn2XsLAwzJ49W+G4FRUV6NOnDzIzM7lttf8Pzpw5g6ysLAQGBmLmzJnw9/fnleSQN2TIEG5m07Zt2xAeHo6pU6dix44dyM3NxWeffabS7xsSEoLQ0FAANc8RbZBIJCgpKcHq1auxb98+PHz4EEDN5aspU6bgs88+Q7t27QAAo0ePfu3xKLkRUXl5OR49eoSjR49i48aNAICqqiqRoxImPDwcgYGBAIDx48cjPT29zrayN1DS+KxZswZvv/02jI2N8fjxY8TExAAAHj58iGHDhokcHamPsrIylJeX44033gAAeHp6IjIyEuPGjeNmdOoKTdXk6dOnj9pF6YCaKc22travbCOkvovMrl27XntuU1NTpKam4tKlS9i5cycGDRoEOzs7+Pv7w9fXl/fFQ/48EREROH78OHr06IEFCxbAzc1N5eQmKiqKS260yc/PDyYmJoiLi4OlpSWAmhIj27Ztw+zZs3Ho0CGVj0UVikW0Y8cOBAUFwcvLCzExMbhz5w4+/PBDnDlzRuzQVGZubs4VyNLT04OpqSkMDAwUXrxUobjxe/bsGe7cuYPevXvTAOImJCQkRCuVabVh4MCB2LVrl9KaPGZmZrypxa/6ouXj44P8/HytxCjTv39/XgwPHjyAt7c3li9fjrCwMKW1YsrLy/H111/j1KlTkEgk8Pb2xpIlS7jEE1Cs6iuVSnHgwAHs3LkTaWlpvB4s+bYDBw7ElStXuH21KzM7Ozsr/T0YY8jMzERZWZkafwXVOTk5QSqVIisrS+l+oQkpJTc6pLq6GpWVldySDLpC1pVaG2MMcXFxePHiBQBg9uzZSEpKwuTJk/Hhhx+id+/eDRkmaQCvq/ZKmi6hlWm14fjx4+jTpw+srKwU9iUmJvKmruvp6cHS0lJpL0leXl69eqWePn2KFStW8JKQ0NBQdOjQgWvj5OSEkydP8qZA//XXX1x9l+LiYoXjzpkzB48fP+Yu/ezatQsdOnTg9ei8armImzdvok+fPtzj1q1bw9raGowxZGdn48GDB2jXrh0YY7C3t8cff/zBtTUyMsK+ffsUavcwxuDr64tHjx4J/CspevbsGQwMDNC2bVuFfWlpaZgyZQqOHDmi8Nlx8+ZNjB8/nne57nXospQIzpw5A3d3dxw5ckTpfvnl7XXByZMn8c033ygkXYwxnD17lnscGRmJ4uJi/PTTT5g9ezYMDAzw4Ycf4oMPPtBIsSsinoyMDPj5+eHBgwfc8hvKqr2SpkudyrSaJqQmj4WFBc6dO4fu3bsrtJU9h9Xl5+cHU1NTHDx4EEBNL7yfnx8OHz7MtVGnvsuFCxeQmZnJXWIbO3aswmvrVdOl5RMboGb9K3my4z569AgfffQRb5+TkxPat28PNzc3hePW5wv38+fPsXLlSkRFRXH1zkxNTREcHIz58+dz7RwcHLB582YMGzYMzs7OsLCwAADcvXsXqampwqtlqzWsmdTL3LlzGWOMjRgxQuE2cuRIkaNT5Obmxi5fvqx0n6mpaZ0/d/LkSda5c2e2ceNGbYVGGoirqyuLiYlR2B4dHc1cXFxEiIg0NF2ZOSWVSnkrgMv88ccfvMeLFy/myhfUFhAQUK8YrK2tVdomlJubG1cehDHGXrx4wYYOHVrv46ri7t277MmTJ0r3SaVStY87ceJEtnbtWnb16lW2dOlStnHjRnbx4kX2zjvvsLVr1yq0LykpYdHR0WzLli1sy5YtLDo6mhUXFws+LyU35LUuX75cZ/2d2vUiXr58yWJiYtjo0aOZnZ0d27hxo8amXxLxvKquhyZrfhDdpQs1b3SlJo+Hhwfvfa2goIB5enoqtMvOzmZnzpxRSA7i4uJ4j2VTvj/88ENmZ2fHVq9ezVavXs369+/P/P39eW0rKyvZ999/z4YNG8YsLCyYhYUFGzZsGPvuu+9Umh4us3LlSpXb1ke/fv14jwcPHswYq0nctPneQZelRJaZmYlbt26hsrKS21bXGBexyJZRUEa+G/Rf//oXjh49Ck9PT6xatQqDBw9uiPBIAzA2NtZatVdCVPXpp5/i999/h729PXbu3AkvLy/8+uuvsLOza5Aq6LKp6B06dIC9vT3GjBkDoGYsUO1Zg3v37sXHH3+Mbt264dmzZzhw4ACGDBkCAAgODoa3tzfXVn4MzcCBA7nJF87OzqiuruYdd/78+Xj48CFWrFjBzSi6e/cuwsPDce3aNV7V31cRMgNKfiq4UBKJBFKpFK1bt0ZBQQH3Wde6dWtBl7tmz54taK0zSm5E9Mknn2Dv3r2wtbXlrSOia8kNUDMdLzc3Fy4uLrxF9uLj47kXaVhYGHr37o3k5GSlawyJfb2eqC8yMhIBAQFYtGgRTExMAAD5+flwdnZGRESEuMGRBtEQycPriF2Tp3379gAAe3t73owtWTkMeZs3b0ZqaipMTU1x6tQp+Pr6IiIiAh4eHgp/S1WmgMskJibi1q1bvG02NjYYNWqUwpibV82AKigoUPmc9ZkKPmvWLLi6uuLtt9/GqVOnEBQUBKCmjISQ/7PffvtN0HlptpSIrKyskJ6ervODbV/1DUR+quHrprC7u7trPVaiXYWFhdx0WzMzM40XRyO668cff9RaATdV2djY4Nq1a7yp0WfOnMGsWbNQUVGh9endQjg4OCAtLY17fP36dYwbNw7bt29HcHCw0i97u3fvVnos+YUz+/Tpg/Pnzyu89goKCuDm5obbt29z24TMgNLmVPD4+Hikp6djwIABGDFiRJ3tOnbsWGcMxcXFvCscr0M9NyIyMzPjVbfUVap+A1E1eQkODuaKFpLGRRvVXonuaojKtEJMnDgRp0+f5tXkcXd3R1RUFObOndtgcaxevVrpdvlVwaurq1FcXMxV1bW3t8exY8cwZswYPH/+XOnPHz16lCF9OJAAACo4SURBVLtfVlaGc+fOYfDgwbzkJjg4GI6Ojhg/fjw3o+jevXs4cuQIvvjiC97xhMyAys7OfmUiVB/e3t7w9vZGdXU1qquruUvbtenr6yMhIYHrIZOPQWgZAkpuRLRp0ya8//778PHx4SU5urS8PVDzxDI1NQUAeHl54dixY9w3EHW6guPj4ym5IaQRaKjKtKqqK5bhw4fzCrxpuyaPfI2asrIyHD9+nOvNlpk3bx6uXLmCkSNHcttsbW1x/PjxOqdzR0dH8x7n5OQgJCSEt83f3x+enp6IiYnhak716tULZ8+eRc+ePXltIyIi6iy4WbsgnramgsuWVPjpp5+4njVlSyoAwIABA/DkyROl1eyNjY0FnZcuS4nI39+fGxwnP+bmwIEDIkfGZ29vj6SkJN6TMCMjg/sG8vjxY0HHe1URKkJIwxK7Mq021K7iq22PHz+Gn58fr+dFVdHR0Xj//ffr3F/78paqhPSQy2rOGBoa8goRypSWlvLGWgoxefJkmJiYYP78+QpLKuTl5fGWVHjx4gVatGihkUK2lNyI6K233kJWVhYMDHS7A+3bb7+FnZ0d7xsIUDPTa8mSJYiLixN0vIZ+4yGE1K0hKtM2NDG+QPXr1w83btwQ/HPy74fyhV2rqqpw6dIlJCYmIjk5uV7H1WRbocMK+vbtq7ElFWRmzpyJqKioV7bR7U/VJq5Xr146MQPhdRYtWqR0u42NDS+xed03EEKI7tHW5QgxaXvm1NatW7n7VVVVSE5ORrdu3dQ6lvxnwNdff83dNzAwgJWVFfbv31/v42qyrdBhBXp6erh165bSJRWULYCqClWSSEpuRNSrVy+MGDEC48eP5425Wbx4sYhRqW/9+vUqJTeNIaEjpLkQMi6D1JDvFTIwMICjoyPmzZun1rHkEzGh051VPa4m2wp9/9bokgoCUHIjooqKCvTp04e3GFhD1GrQFlWf9EIvYxFCtEf2gaOMuuMsxKbtL1BC6tKoorCwEG3atOEuDSYlJeHAgQOwsrLC/Pnz65xdJAahn1Fjx47FnTt3cOLECW4AtKenJ0aNGqV0AU1NoeRGRJp+gYhN9qSPjY3Fxx9/jOzsbFRVVYExBolEgqqqKgCgqcSENBL1qUwrpoULF2rluBkZGejSpQs3cyc6Ohp79+6FlZUVPv/8c7U+rBljmDhxInbu3InevXvj1q1b8PHxwYwZMxATE4N79+5h8+bNah1XG23V0aZNG0yePPmVbVQZRyOE7qSDzVB5eTk2bNgALy8veHt7Y9OmTSgvLxc7rHpbvHgxwsLC8Pfff+P58+coLi6us64DIUR3afLDRtvkp0xrqybPnDlzuPfoa9euwd/fH0OGDEF+fv4rV+t+lXXr1uHJkyfcmJT9+/fjvffew7Zt23DixAmFlb1rKywsRGJiokIBQ2U95ELa1kVbiZCQwdiqjNWh5EZEgYGBSEpKwqJFi7Bw4UIkJSUpLePdWMie9IaGhvDx8YGhoSHatGnD3QghusfZ2VnpzcnJSVCJfrE1RCImlUrRo0cPAEBMTAxmzJiB4OBgREZGKsxoys7OxpQpUxAUFASpVIqZM2fCzMwMo0ePxt27d7l2o0eP5lVcvnDhAry8vADUXBZs0aIF77izZs3i/l8SExNha2uL5cuXw8HBAb/88gvXrnPnzoLaysd9+vRpnD59mlvjSp4uDCtQtrxPbXRZSkQXLlxAZmYmdzln7Nix6Nevn8hRqW/dunUAan6PX375BRMmTBA3IELIa2mzMq2maWqtJHXJl+24dOkSVxXZwMBAoTfhn//8Jzw8PPD8+XO4u7vDw8MDJ0+exNGjRxEYGIjY2Fiu7Ztvvom0tDR07doVZ8+eRXh4OLevtLSUd9y0tDR06dIFAPDFF18gPj4ejo6OyMnJwcSJE3nvu0LaZmZmYvbs2cjNzYW5uTkA4P79+zAzM8OuXbu4zyZtDiu4c+cO5s6di3v37mHChAlYt24dN9lmyJAhuHDhgsrHouRGRJ06dUJpaSn3plJeXi64CmNDmDx5MmbMmIF//OMfr+wOHD16NICaBTSLiorQqlUrvPHGG9yYmydPnjRUyIQQFTWmqeBiJ2IdO3bEkSNH0L17d1y4cAH/+9//AACVlZUKQwr+/vtvhISEgDGGHj16cNOnbW1tsW/fPl7b9evXw8PDA8XFxViwYAHMzMwA1IxftLa25rWVT3akUikcHR0BAD179uTGNarT1s/PD8HBwZg0aRJve0xMDObMmaNWrR2h5s+fj8mTJ2Pw4MEICwuDp6cnYmNj0a5dO8HFJCm5EYGsRoK1tTUGDRqEDz74AEDNk8jFxUXM0JQ6c+YMsrKyEBgYiJkzZ8Lf31/hBSfv2rVrDRccIaReGtNUcLETsbCwMEydOhV5eXlYvXo114vx66+/Krx3V1ZWorq6GlKplBt72K5dO7x8+RIVFRW8tu7u7igoKEBxcTGMjIy47cOGDcPbb7/NPc7JyYGPjw+WLFmC0NBQeHl5Ye/evZg2bRpiY2MVvhwLafvs2TOFxAao+XJbewkIbdDX10dBQQEWLFgAoGYR0XXr1sHT0xPx8fGCZ2lRhWIRzJkzp859EokEO3fubMBoXk9W7fPSpUvYuXMnfvrpJ9jZ2cHf3x++vr5Kx9NIpVIuyXF0dNT5lc8JIa+mCwve3rt3TytLBGja+fPncejQISQlJaG8vBzu7u64ceMGPDw8kJiYCEtLS2zfvl3wcZ2dnXHx4kUEBwdj586d6NixI+7duwd9fX14enpi27ZtvPWlKioqVG47dOhQBAYGYvr06dzU8+rqakRFReGHH35AUlJS/f8wr2FtbY0///yTt+3LL7/ETz/9hKKiIty6dUvlY1FyQ16rdmluqVSKAwcOYOfOnUhLS0NRURGvfVJSEiZNmsRV7Hz06BEOHjyosLAcIaTxoGVTVOfs7IyUlBQcOXIEEokE//jHP3DlyhXs3r0bvXr1woIFC9TqaZJfViI9PR1nzpxBVVUVhg8fXud4JFXb3r59GwEBAUhJSYGJiQkAID8/H87OzggPD0efPn0ExwsIG0fz3nvvISAgAKNGjeId46uvvkJQUBCqq6tVPi8lNyLavXu30u26tir4q9ZpuXnzpsKTfvDgwdiyZQu3Km9SUhKWLl2Kixcvaj1WQoh26PqCt7pUk0dbfytnZ2fs2bMHfn5+ePDgATc2R9nAX6CmLo+qbWUKCwuRm5sLADAzM6v3AGIfHx+MGzeOG0dz584dbhxN7b+TbNyS/Owxmby8PG6mmkoYEc3kyZO529ixY5mRkREbNWqU2GEp2LVrl6D2/fv3V9jm4OCgmWAIIaJwcnISO4RXMjMzEzsEzuv+VitXrlT7uK6uriwmJkZhX3R0NHNxceFtE9L2VXr37i082P+Po6Mj73FoaChzcXFhz549E/ScEhoDDSgWUXR0NO9xTk5OgwzcEsrPz09Q+7Zt2+LUqVNcrYaEhASqc0MIqTexp4JrSlRUlFq9TIwxQQN/hbRNT0+v87zFxcWCY5WpPZV95cqVaNmyJTw9PRWOq8kYKLnRIT179hRUpbGhVFVVYfv27di3bx+3Noi5uTmmTJmCgIAAhenhYWFhmDRpEre9uroahw4davC4CSGaw3RgBIPYU8FVxRjTSiI2ceJExMbGIioqSunA306dOvHaGxsbq9zW0dERlpaWSv+fHz9+rFa8AGBjY4PY2FjeOJqgoCDo6ekhKChIazHQmBsRHTlyhLtfVVWFS5cuITExsUHqCQgREBCAhw8fIjAwEJaWlgBqVnUNDw9H165dlY76f/nyJbKysgAAffv2VaiySQjRTYWFhbh+/TpsbGy4gaWy7WKvCzdy5EiEhoYqnQpuZmbGjRUR248//ohPPvnklYnYo0ePeNtzcnKQm5sLFxcX3qyv+Ph4eHt7c4+FDPwV0rZnz544f/48unfvrvD71OdvK2QcjUZjEHQRi2jUiBEjuJuXlxcLDAxk2dnZYoelwMrKSun26upq3r6SkhLGGGNFRUVKb4QQ3TNz5kz26NEjxhhjCQkJzNjYmLm4uLDOnTuzn3/+Wdzgarl79y578uSJ0n1SqbRBYjhz5gyLjIxkeXl5vO0RERG8xyNGjGDnz59XegxTU1Pe4z179jBjY2NmZ2fHTE1NWVJSErevrnEpBQUFLCUlhaWkpLCCgoJXxqxK28WLF7OzZ88q3RcQEPDK46ur9jgaTcZAyQ15rd69eyt9QTx69Ii99dZb3GPZi1AikTA9PT0mkUi4m56eXoPFSwhRnfwEgOHDh7PU1FTGGGPZ2dkKg0Ebi2XLlmnluFu2bGFWVlZs7NixzNjYmB08eJDbVzsJEZKIOTg4sNzcXMYYY/Hx8czMzIwlJCQwxhQH5DY2aWlpdd66deumtfPSmBsRFBYWok2bNlx3ZVJSEg4cOAArKyvMnz+fuzaqK4KDg+Ho6Ijx48fDwsICQE0xrSNHjuCLL77g2slqYAipRUAIEZeQEv2NRXx8vFYKDkZERCAlJQWGhobIyMjAhAkTIJVKMWPGDIVxIrL3SmXkLzsFBweDMQZTU1MAgJeXF44dO4Zx48Zh+/btgivz6hptjeV5Hd36FG0mJk6ciLy8PADArVu34OPjg/LycsTExCA4OFjk6BT5+/vj/Pnz6NWrF/Ly8pCXl4devXrh7Nmz8Pf3V2ifm5vLlRc/f/48/vOf/9RrtD0hRHtkJfpLSkq4Ev2MMZw4cUIn17pThbIPUk2RLVVha2uLxMREhIaGIjIyUu0kJD4+HtXV1bz3SHt7exw7dgzz5s3DvXv3NBK3WCwsLHDu3Dnk5OQo3Lp27aq9E2utT4jUydbWlru/Zs0aNnPmTMZYTVdlv379xAqr3mRdwU5OTqy0tJQ9ePCAmZqasilTprDJkyeLHB0hRJny8nL28ccfM0NDQ2ZpackkEgkzMDBgPj4+OjkGUBXaqsnj6OjIjU+SycvLYzY2Nqxt27ZqH3Pr1q0sMTFRYV9GRgbz9vZW67i6QoyxPIwxRrOlRCBfxnzMmDHw9fXlqhLrehXQV5H9XrJ/t2/fjoKCAnz66adwcHBAWlqa2CESQuoglUpx584dVFZWwtzcXGGqcGOiraUi9u/fD3Nzc4WlZPLz8/Hvf/9b7fWiaFkLzaPLUiJ48803kZaWhocPH+Ls2bMYOXIkt692waPGRJYnl5eXo7y8HPHx8bzfjRCiux4+fIjHjx+jqKhIYb24xkZb39l9fX2VrpFnYmKiVmIjr7S0lKsjJk8Xa581BpTciGD9+vXw8PCAubk5/P39uTU/YmNjYW1tLXJ06pNdc546dSq6deuG+/fvw83NDfn5+bQqOCE6KjMzE66urhg6dCiCg4MRHByMoUOHwtXVVec/WAsLC5GYmIj8/Hze9ri4OK2dMycnB7///rvCF9H4+Hi1jscYQ1xcHExMTGBvbw9nZ2fcvn2b2z9z5sx6xdtsae2CF3mlyspK9vTpU962kpISVlxczD1ubNe75a9zP336lFVVVTHGan6vBw8eiBUWIeQVNLX+UEMQuyaPOvVo5CmbGl5QUMBcXFxYWloaq66uZjt27GAWFhbs+vXrjLHGPxVcLJTc6DBdX6iuNtmL8MiRI1zRvs2bN7NJkyZxL1RCiG7p06ePWvvEIHZNHiH1aFJTU5mDgwNzcnJif/zxB3v33XdZq1atmJmZGUtLS+O1rf2zp06dYhYWFuzatWuN7nNAV9BlKR3GdHSs9+u6gkNCQmBoaIi0tDTs2bMH3t7e+Oijj8QIlRDyGrL1h+TrU1VXVyMyMlLnBhWLXZOHKalH4+/vj/j4eIWp4EuWLMHnn3+OxYsX491338WUKVMglUqxdetWhTWVysrKuGUKAMDT0xORkZEYN26cwvssUQ0lNzpMV4o3zZo1i1voLTExEba2tli+fDkcHBzwyy+/cO1k684YGNTUhoyLi8O8efMQEBCAFy9eNHjchJDXi4yMREREBDp27AgbGxvY2NigY8eO3HZdInZNHiH1aJ4/f44JEybAz88PjDFu7MyECRMUFs6cOHEiTp8+zdvm7u6OqKgotGvXTju/TFMnbscReRVd6Y4U2hXcv39/dvHiRTZo0CCWkZHBGGPMzs6uQWIlhKhHyFpFYhG7Jo+QejQODg7c/VmzZvH2yb+nCnHu3Dm1fq45ouUXdBjTkctSQruC165di4CAAHh6esLGxgZZWVm81WcJIbqnc+fOoq/6/TotW7bE119/jTlz5uDMmTOoqqrC8OHD4ezs3CDnX7RokdLtNjY2vBla0dHR6Nq1K54/fw5DQ0NERkZy+/Lz8/Hmm2+qfX6qiaMaKuKnw9asWYPPPvtM7DCwaNEi6OnpITQ0FKGhobCzs8O0adMQGxuLzZs3IzExUewQCSHNQEZGBvz8/PDgwQOuhMb9+/dhZmaGXbt2oV+/fiJHWONVhflkdYTMzc0FH7cxF3ltaJTc6Jjw8HAEBgaKHQZPRUUFgoODsXPnTnTs2BH37t2Dvr4+PD09sW3bNvTs2RMAsG/fPkydOhVbt25VepzFixc3ZNiEkCZm0KBBWLZsGSZNmsTbHhMTg02bNiE5OVmkyPjkk5Ds7GyuOJ+5uTl69eql9nGpmrHq6LKUjlm3bp3OJTeqdgX/+eefAEDfLAghWvHs2TOFxAYAJk+ejJCQEBEiUk4ikXC9TLm5uVwvjS72MjVVlNyIYOLEiUq3M8a0ugS8upR1BW/cuFHhRfrFF18AAHbt2iVarISQpks2bX369OnQ06uZ7FtdXY2oqCidm7Y+Z84cBAcHK+1lmjNnjlq9THShRXV0WUoEbdq0wTfffIOWLVvytjPGEBQUhL///lukyJRTpyv4xIkTuHXrFiorK7ltS5cu1XqshJCm6/bt2wgICEBKSgpMTEwA1AzQdXZ2Rnh4uM5MXHBycoJUKkVWVpbS/X379q1z36v8+OOP8Pf3r294zQIlNyIYOnQowsLCMHDgQIV9ZmZmyM3NFSGqur3qhahs37Rp05CZmQknJyfo6+sDqOmmre/CcoQQAtQUEpW9T5qZmencLK8TJ05g7dq1CAwMVNrL9MMPPyApKYlrX15ejjfeeIN7HBMTg7Nnz8LJyQl+fn4NHX6TQJelRBAWFobu3bsr3ZeQkNDA0bye0K7gq1ev4saNG1xiQwghmiTmtPXdu3fj7t27GDt2LG/c4fr167FixQoAwOjRo9G7d28EBARg0aJFCr1MtYsjDhkyhBsovG3bNoSHh2Pq1KnYsWMHcnNzdWLWbGNDPTfktYR2BY8aNQqHDh2ilcAJIU3K8uXLcf78eTg6OiImJgbLly/HkiVLANQ9k0mVXib52VWDBg3CoUOH0KNHDxQXF8PNzQ3Xr1/X4m/VNFHPjUhycnKQm5sLFxcXtGrVitseHx8Pb29vESNTZGVlhYSEBJW7grds2QIvLy+MGDGCV6xq1apVDRIvIYRow7Fjx5CSkoKWLVsiJCQE48aNg1QqxYoVK+oc7KtKL5P8UjtVVVXo0aMHAKBdu3bccjZEGPqriWDv3r34+OOP0a1bNzx79gwHDhzAkCFDAADBwcE6l9zIqNoVvGLFCrRs2RJlZWV4+fJlA0RGCCHaxxjjJoJ069YNp06dwujRo1FVVVWvtQD//PNPODs7gzGG7OxsFBcXo127dmCM0Xuomii5EcHmzZuRmpoKU1NTnDp1Cr6+voiIiICHh0eTmOqXlZWl1kwAQgjRZW3atMHdu3dhaWkJADA0NMTJkyfh4+ODGzduqH3cEydO8B7LEqVHjx7ho48+Uvu4zRklNyJgjMHU1BQA4OXlhWPHjmHcuHHYvn27zqwEXh99+/bl1lQhhJCmYsOGDSgqKuJta9u2LeLi4hAWFqb2cd3d3ZVu79atGxYsWKD2cZszGlAsAnt7eyQlJfGWss/IyMCYMWPw/PlznSzkJ4Svry9SUlLwzjvv8MbcfPXVVyJGRQghjU9ISAhCQ0PFDqPR0RM7gOZo3rx5uHLlCm+bra0tjh8/jgEDBogUlebY2tpi5syZ6Nq1K9q3b8/dCCGkqdLW8g9RUVFaOW5TRz03Oiw6Ohrvv/++2GEQQgh5DXNzc26BTKFqr9MnwxhDZmYmysrK6hNas0TJjQ5rrCvAPn36FCtWrMCpU6cgkUjg7e2N0NBQdOjQQezQCCFEbdpKQoyMjLBv3z6F2mCMMfj6+uLRo0dqHbc5owHFOqyx5p1+fn4wNTXFwYMHAQA7duyAn58fDh8+LHJkhBCivuzs7FcmIepycnJC+/bt4ebmprCv9hqERDWU3Oiwxjpz6ubNm7xE5ttvv4WNjY2IERFCSP1pKwmJiIioc3bpzZs31T5uc0YDionGde/eHYWFhdzjwsJCruImIYQ0VhEREXV+UatPEmJhYVHnZXv5CvbBwcFqn6O5oeRGhzW2y1JLly7F0qVL0aFDB9jb28Pf3x/+/v7o378/OnbsKHZ4hBBSL2InIfHx8Vo5blNEl6V02Lp168QOQRDZdG97e3vY29tz2wMDA8UKiRBCGlx8fDw2btyo8eM2ti+8YqLZUiIoKirC559/DolEgi+++ALh4eHYs2cP+vfvj61bt9KsIkIIacTkV/nWpMY6g1YM1HMjgnnz5sHExAQlJSUYN24crK2tsX37dkRHR+Nf//oXIiIixA6xXlavXq10O60KTghpDhrrZJCmhJIbEWRkZGD//v2oqqpCly5dEB8fDwMDA7i6usLBwUHs8OqtuLiYu19WVobjx49zq54TQghRD11oUR0lNyJo0aIFAEBfXx/m5uYwMKj5b5BIJNDTa/xjvDdv3sx7/Pnnn8PPz0+cYAghpIHVNwkpLCzE9evXYWNjAxMTE257XFxcfUNrNhr/J2kjpKenh/LycgBAcnIyt720tLRJZuadOnVCdna22GEQQkiDEJqEzJo1CwUFBQCAxMRE2NraYvny5XBwcMAvv/zCtevcubMmw2zSaECxCO7evYvu3bsrFH26f/8+0tPTMXbsWJEi04ytW7dy96uqqpCcnIyCggIkJCSIGBUhhNSP/Hp/f//9N2bPno1z587ByckJu3fvhrm5uVrHdXBwQFpaGgDA3d0dYWFhcHR0RE5ODiZOnKiVwclNHfXciMDS0pJLbKqrq1FdXQ2gZuG1xp7YAEBqaip3y8jIgKOjI2JiYsQOixBC6mX9+vXc/RUrVsDe3h5ZWVkYN24clixZovZxS0tLuftSqRSOjo4AgJ49e6Kqqkrt4zZn1HMjgpKSEqxevRr79u3Dw4cPAQAmJiaYMmUKPvvsM7Rr107kCAkhhNQmP8XbwcEBV69ehb6+PvdY1vsi1KJFi6Cnp4fQ0FCEhobCzs4O06ZNQ2xsLDZv3ozExESN/Q7NBfXciMDPzw+lpaWIi4vD8+fP8fz5c8TGxqK0tBSzZ88WOzy1ZWRk4O+//+YeR0dHY8KECQgKCkJJSYmIkRFCSP2VlZXh+vXrSE9Ph0Qi4RIboH7Tv7ds2QI9PT306NEDP/30E2bOnImWLVsiLCwMP/74oyZCb3ao50YEffv2RVZWltJ9ffr0abQLpQ0aNAiHDh1Cjx49cO3aNQwfPhwhISFIT0/Hm2++SS9SQkijZmlpCT09PW7ix9mzZ2FqaoqioiKMHDmy3gX2pFIp7ty5g8rKSpibm6NTp06aCLtZoqngItDT08OtW7fQu3dv3vabN2/yvgk0NlKplFsgMyYmBjNmzEBwcDAqKyvh5OQkcnSEEFI/d+/eVbq9RYsWOHjwYL2P//DhQzx+/BhATSV7Sm7UR8mNCDZv3oxhw4bB2dkZFhYWAGpeNKmpqdixY4fI0alPVq8HAC5duoS5c+dy2xtz0kYIIfKys7Nx//59ADUTQXr16oWePXuqfbzMzEzMnj0bubm53Iyr+/fvw8zMDLt27UK/fv00EndzQpelRPLixQucOHGC9wIZNWoU2rZtK3Jk6vP09MSSJUvQvXt3jBgxAjk5OejcuTMqKythb2+PzMxMsUMkhBC1ZWRkwM/PT+NJyKBBg7Bs2TJMmjSJtz0mJgabNm3i1UMjqqHkRofNnDkTUVFRYoehsj/++ANTp05FXl4ePv30UyxduhQA8Msvv+DQoUPYvXu3yBESQoj6tJWEvGoc5qv2kbpRcqPDmuoKsOfPn8fQoUPFDoMQQgTRVhIydOhQBAYGYvr06dwSPNXV1YiKisIPP/yApKQktWNurmgqOGlwixYtEjsEQggRzNjYGFFRUVzhVaAmCYmMjKzX4N/IyEhERESgY8eOsLGxgY2NDTp27MhtJ8LRgGLS4KizkBDSGEVGRiIgIACLFi3iFrTMz8+Hs7NzvZIQKysrJCQkoLCwELm5uQAAMzMzWkuqHii5IQ2uPsWuCCFELNpOQjp37kwJjYZQcqPDaPo0IYToHkpCdB+NudFhly9fFjsEraDLUoQQQrSJkhsR3LlzByNHjkSvXr2wdOlSlJWVcfuGDBkiYmQNY+HChWKHQAghpAmj5EYE8+fPx+TJkxEdHY2///4bnp6eKC4uBgBeotMY/f7779i9ezf++usv3vbIyEjuvr+/f0OHRQghpBmh5EYEBQUFWLBgAQYMGIDdu3djzJgx8PT0RFFRUaMebPvVV1/B398f0dHRcHBwwKFDh7h9YWFhIkZGCCGkOaEBxSIoLS3lPV65ciVatmzJ68FpjCIiIpCSkgJDQ0NkZGRgwoQJkEqlmDFjBo2zIYQQ0mAouRGBjY0NYmNjMWrUKG5bUFAQ9PT0EBQUJGJk9WdoaAgAsLW1RWJiIry9vVFVVdWoe6QIIYQ0LrT8ggjKy8sBAG+88YbCvry8PPTo0aOhQ9IIJycnnDx5El26dOG2/fXXX/Dy8kJubm6j7pUihBDSeNCYGxG88cYbShMbAI02sQGA5cuX486dO7xt3bt3R0JCAqZOnSpSVIQQQpob6rnRMX369MHNmzfFDoMQQghptGjMjQjS09Pr3NfYL93k5OQgNzcXLi4uaNWqFbc9Pj4e3t7eIkZGCCGkuaCeGxHo6enB0tJS6QyivLw8VFRUiBBV/e3duxcff/wxunXrhmfPnuHAgQNcUUJnZ2dcvXpV5AgJIYQ0B9RzIwILCwucO3cO3bt3V9hnZmYmQkSasXnzZqSmpsLU1BSnTp2Cr68vIiIi4OHhQVPBCSGENBgaUCyCcePGITs7W+m+MWPGNHA0msMYg6mpKQDAy8sLx44dg7+/P+Lj42kqOCGEkAZDl6WIxtjb2yMpKQnt2rXjtmVkZGDMmDF4/vw5Hj9+LGJ0hBBCmgvquSEaM2/ePFy5coW3zdbWFsePH8eAAQNEiooQQkhzQz03pMFFR0fj/fffFzsMQgghTRQlN6TB0cwpQggh2kSXpUiDo3yaEEKINlFyQxoczZwihBCiTZTcEEIIIaRJoeSGNDi6LEUIIUSbKLkhDW7dunVih0AIIaQJo9lSRGNycnLQs2dPADW9M1u2bMHZs2fh5OSEkJAQtGjRQuQICSGENAfUc0M0ZtKkSdz9tWvXIi4uDlOnTkVGRgaCgoJEjIwQQkhzQgtnEo2R7wQ8fPgwTp06BSMjI7z33nsYOHCgiJERQghpTqjnhmiM/BRvfX19GBkZAQDeeOMNGBhQHk0IIaRh0CcO0Zj09HR07NgRjDFIpVL8/fffMDY2RmVlJSorK8UOjxBCSDNByQ3RmDt37vAet2/fHgDw9OlTrF69WoyQCCGENEM0W4oQQgghTQqNuSEatXv3bqxevVphYcz169eLFBEhhJDmhpIbojHBwcH473//i8LCQowZMwZhYWHcvujoaBEjI4QQ0pzQmBuiMcePH0dKSgpatmyJkJAQjBs3DlKpFCtWrKAlFwghhDQYSm6IxjDG0LJlSwBAt27dcOrUKYwePRpVVVW0EjghhJAGQ5eliMa0adMGd+/e5R4bGhri5MmTOHHiBG7cuCFeYIQQQpoV6rkhGrNhwwYUFRXxtrVt2xZxcXG88TeEEEKINtFUcNLggoODsXHjRrHDIIQQ0kTRZSnS4OLj48UOgRBCSBNGyQ1pcNRZSAghRJsouSENjmZOEUII0SZKbgghhBDSpFByQxocXZYihBCiTTRbijS4wsJCdO7cWewwCCGENFHUc0MaRJ8+fbj7lNgQQgjRJiriRzQmPT29zn3FxcUNGAkhhJDmjC5LEY3R09ODpaWl0jE1eXl5qKioECEqQgghzQ313BCNsbCwwLlz59C9e3eFfWZmZiJERAghpDmiMTdEY8aNG4fs7Gyl+8aMGdPA0RBCCGmu6LIUIYQQQpoUuixFNC47Oxv3798HAJibm6NXr14iR0QIIaQ5oeSGaExGRgb8/PyQm5sLc3NzAMD9+/dhZmaGXbt2oV+/fiJHSAghpDmgy1JEYwYNGoRly5Zh0qRJvO0xMTHYtGkTkpOTRYqMEEJIc0LJDdGYvn37IisrS/A+QgghRJNothTRGGNjY0RFRaG6uprbVl1djcjISHTq1EnEyAghhDQn1HNDNOb27dsICAhASkoKTExMAAD5+flwdnZGeHg4bwkGQgghRFsouSEaV1hYiNzcXAA1xftoLSlCCCENiZIbQgghhDQpNOaGEEIIIU0KJTeEEEIIaVIouSGEEEJIk0LJDSGEEEKaFEpuCCEa4efnB4lEAolEghYtWqBr167w9vbGzp07ebWPmrKIiAgYGRmJHQYhzR4lN4QQjRk1ahTy8/Nx9+5dnDhxAiNHjsSSJUswduxYVFZWih0eIaSZoOSGEKIxb7zxBrp164YePXrA2dkZK1euxOHDh3HixAlEREQAqFlMdfz48Wjbti0MDQ3xwQcf4NGjR7zjHD16FC4uLnjzzTdhbGyM9957j9snkUjwyy+/8NobGRlxx7979y4kEgkOHDiAYcOGoVWrVnBxccHNmzdx+fJlDBw4EG3btsXo0aNRWFjIO86OHTtgY2ODN998E9bW1vj++++5fbLjHjp0CCNHjkTr1q3h4OCACxcuAABOnz6NOXPmoKioiOvB+vzzzzXzhyWECELJDSFEqzw8PODg4IBDhw6huroa48ePx5MnT3DmzBnEx8cjOzsbvr6+XPtjx47hvffew7vvvovU1FQkJCTA1dVV8Hn//e9/49NPP8XVq1dhYGCAadOmYdmyZQgLC8PZs2dx+/ZtrFq1imu/d+9erFq1CqGhocjMzMS6devw2WefITIyknfckJAQBAUF4dq1a+jTpw+mTp2KyspKuLm54ZtvvoGhoSHy8/ORn5+PoKAg9f9whBD1MUII0YDZs2ez8ePHK93n6+vLbGxsWFxcHNPX12f379/n9t24cYMBYMnJyYwxxoYMGcKmT59e53kAsJ9//pm3rX379mzXrl2MMcZycnIYALZjxw5u/759+xgAlpCQwG1bv34969u3L/f4rbfeYv/73/94x12zZg0bMmRInceVxZ6ZmckYY2zXrl2sffv2dcZOCGkY1HNDCNE6xhgkEgkyMzNhZmYGMzMzbp+trS2MjIyQmZkJALh27Ro8PT3rfc7+/ftz97t27QoAsLe3520rKCgAALx48QJ37tyBv78/2rZty93Wrl2LO3fu1Hlc2RpqsuMQQnSDgdgBEEKavszMTPTs2VOltq1atXrlfolEAlZr1ZiXL18qtGvRogXvZ5Rtk83iKikpAQD897//xaBBg3jH0dfXf+1xm8tsMEIaC+q5IYRoVWJiIq5fv45JkybBxsYGubm53MKqAJCRkYFnz57B1tYWQE3PSEJCQp3H69y5M/Lz87nHt27dglQqrVeMXbt2Rffu3ZGdnQ0rKyveTdWkDABatmyJqqqqesVCCKk/6rkhhGhMeXk5Hj58iKqqKjx69AixsbFYv349xo4di1mzZkFPTw/29vaYPn06vvnmG1RWVmL+/Plwd3fHwIEDAdQMBPb09MRbb72FKVOmoLKyEsePH0dwcDCAmgHK//nPfzBkyBBUVVUhODiY15uiri+++AKLFy9G+/btMWrUKJSXl+PKlSt4+vQpli5dqtIxLC0tUVJSgoSEBDg4OKB169Zo3bp1vWMjhAhDPTeEEI2JjY2FiYkJLC0tMWrUKPz222/YunUrDh8+DH19fUgkEhw+fBgdOnTA8OHD4eXlhV69emH//v3cMUaMGIHo6GgcOXIEjo6O8PDwQHJyMrd/y5YtMDMzw7BhwzBt2jQEBQVpJIGYO3cuduzYgV27dsHe3h7u7u6IiIgQ1HPj5uaGwMBA+Pr6onPnzti0aVO94yKECCdhtS9eE0IIIYQ0YtRzQwghhJAmhZIbQgghhDQplNwQQgghpEmh5IYQQgghTQolN4QQQghpUii5IYQQQkiTQskNIYQQQpoUSm4IIYQQ0qRQckMIIYSQJoWSG0IIIYQ0KZTcEEIIIaRJoeSGEEIIIU3K/wN5Txt25WcX7gAAAABJRU5ErkJggg==\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pyLDAvis\n",
        "import pyLDAvis.gensim_models as gensimvis\n",
        "from gensim.models.ldamodel import LdaModel\n",
        "from gensim.corpora import Dictionary\n",
        "\n",
        "# Prepare the pyLDAvis visualization data\n",
        "lda_vis_data = gensimvis.prepare(optimal_lda_model, corpus, dictionary)\n",
        "\n",
        "# Show the pyLDAvis visualization in a notebook or save as an HTML file\n",
        "pyLDAvis.display(lda_vis_data)  # For displaying in a Jupyter notebook\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 916
        },
        "id": "ldRGYqUHjuxY",
        "outputId": "25ce6f0c-9206-446d-9c06-f6c7dc9302c8"
      },
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
              "\n",
              "\n",
              "<div id=\"ldavis_el17371330341875897767298211158\" style=\"background-color:white;\"></div>\n",
              "<script type=\"text/javascript\">\n",
              "\n",
              "var ldavis_el17371330341875897767298211158_data = {\"mdsDat\": {\"x\": [0.19836748185574204, -0.11356550111372263, -0.07952548213474293, -0.16858047869090062, 0.29276666057204465, -0.1294626804884202], \"y\": [-0.021003943887278533, -0.19600424195680624, -0.08329442995167699, 0.0957550423914703, 0.04241026399880561, 0.16213730940548612], \"topics\": [1, 2, 3, 4, 5, 6], \"cluster\": [1, 1, 1, 1, 1, 1], \"Freq\": [25.56369524948337, 22.357435021324083, 18.256082686037285, 13.195434870523929, 10.632556404392924, 9.994795768238413]}, \"tinfo\": {\"Term\": [\"pembrolizumab\", \"nivolumab\", \"lesion\", \"pla\", \"test\", \"nivo\", \"arm\", \"biopsy\", \"therapy\", \"ipilimumab\", \"ipi\", \"pigmented\", \"expression\", \"gep\", \"risk\", \"class\", \"merck\", \"keytruda\", \"advanced\", \"gene\", \"mg/kg\", \"tumor\", \"placebo\", \"prognostic\", \"cell\", \"diagnostic\", \"prospective\", \"utility\", \"o\", \"resected\", \"gep\", \"profiling\", \"class\", \"prognostic\", \"biomarkers\", \"sensitivity\", \"validated\", \"identified\", \"me-c\", \"profile\", \"decision-making\", \"biomarker\", \"prospectively\", \"showed\", \"prospective\", \"risk\", \"expression\", \"drive\", \"factor\", \"analytical\", \"superior\", \"important\", \"gene\", \"blood\", \"sequencing\", \"method\", \"predictive\", \"according\", \"used\", \"molecular\", \"independent\", \"testing\", \"test\", \"outcome\", \"validation\", \"laboratory\", \"tumor\", \"metastasis\", \"evidence\", \"across\", \"level\", \"cancer\", \"value\", \"available\", \"management\", \"group\", \"stage\", \"recurrence\", \"status\", \"may\", \"iic\", \"iib\", \"resected\", \"merck\", \"suzana\", \"pembrolizumab\", \"giffin\", \"galloping\", \"suzana.giffin\", \"hill\", \"merck.com\", \"keytruda\", \"kenilworth\", \"dosing\", \"rd\", \"completely\", \"keynote-\", \"keytruda\\u00ae\", \"avp\", \"intravenously\", \"aes\", \"investigator\", \"placebo\", \"iv\", \"sp\", \"considering\", \"jj\", \"randomization\", \"luke\", \"contact\", \"qw\", \"adjuvant\", \"stage\", \"rf\", \"prescribing\", \"complete\", \"mg/kg\", \"nj\", \"hr\", \"arm\", \"compared\", \"group\", \"randomized\", \"cell\", \"dor\", \"inhibitor\", \"activity\", \"immunother\", \"ann\", \"immune\", \"anti-ctla-\", \"mutation-positive\", \"checkpoint\", \"daily\", \"incidence\", \"pd-\", \"regimen\", \"re\", \"february\", \"first-line\", \"advanced\", \"therapy\", \"duration\", \"immunotherapy\", \"braf\", \"second-line\", \"pyrexia\", \"reduction\", \"approved\", \"antibody\", \"suppl\", \"de\", \"control\", \"safety\", \"clin\", \"oncol\", \"efficacy\", \"progression\", \"combination\", \"cancer\", \"orr\", \"systemic\", \"alone\", \"tumor\", \"-month\", \"approval\", \"randomized\", \"ipilimumab\", \"arm\", \"indication\", \"mutation\", \"dose\", \"o\", \"pembrolizumab\", \"tissue\", \"prior\", \"ipi\", \"opdivo\\u00ae\", \"yervoy\\u00ae\", \"guidelines\\u00ae\", \"nivo\", \"summarized\", \"ratio\", \"hazard\", \"product\", \"injection\", \"table\", \".-nr\", \"ms-\", \"princeton\", \"intravenous\", \"squibb\", \"myers\", \"bristol\", \"undergone\", \"nr\", \"ipilimumab\", \"plus\", \"reflect\", \"stratified\", \"coffey\", \"mary\", \"pharmd\", \"standing\", \"pike\", \"street\", \"infusion\", \"market\", \"ww\", \"senior\", \"mg/kg\", \"group\", \"nivolumab\", \".-\", \"death\", \"o\", \"randomized\", \"combination\", \"alone\", \"nj\", \"therapy\", \"adjuvant\", \"hr\", \"stage\", \"outcome\", \"progression\", \"pigmented\", \"pla\", \"lesion\", \"peer\", \"dermtech\", \"pre-diagnostic\", \"case\", \"dermatology\", \"brouha\", \"reviewed\", \"diagnosis\", \"care\", \"ferris\", \"biopsy\", \"assay\", \"diagnostic\", \"genomic\", \"proposed\", \"useful\", \"registry\", \"skin\", \"center\", \"via\", \"fewer\", \"guiding\", \"sample\", \"see\", \"utility\", \"npv\", \"demonstrates\", \"negative\", \"surgical\", \"number\", \"md\", \"test\", \"publication\", \"large\", \"management\", \"evidence\", \"decision\", \"testing\", \"gene\", \"oral\", \"presentation\", \"nivolumab\", \"blinded\", \"myocarditis\", \"accessed\", \"untreated\", \"landmark\", \"traes\", \"monotherapy\", \"asco\", \"observed\", \"james\", \"content\", \"annual\", \"phd\", \"baseline\", \"follow\", \"senior\", \"ww\", \"market\", \"smr\", \"significance\", \"mary\", \"coffey\", \"lawrence\", \"virtual\", \"england\", \"pike\", \"standing\", \"arm\", \"meeting\", \"capability\", \"bristol\", \"myers\", \"squibb\", \"cohort\", \"per\", \"o\", \"orr\", \"-year\", \"previously\", \"society\", \"princeton\", \"combination\", \"director\", \"treatment-related\", \"new\", \"prior\", \"nivo\", \"therapy\", \"nj\"], \"Freq\": [208.0, 128.0, 66.0, 65.0, 129.0, 73.0, 116.0, 68.0, 124.0, 105.0, 47.0, 34.0, 81.0, 53.0, 77.0, 57.0, 56.0, 59.0, 68.0, 62.0, 73.0, 88.0, 64.0, 51.0, 38.0, 32.0, 58.0, 34.0, 97.0, 44.0, 53.036019810245875, 31.758351453380055, 55.39913685085208, 49.29730600283009, 14.549351020557054, 16.344459468866297, 11.676758425459793, 11.658619670158854, 10.733522108854865, 37.59726321996559, 10.72759146142167, 9.765583709730906, 7.846539676402262, 10.258446341016935, 52.09777890685082, 68.36153252343134, 71.30161870145318, 5.847232739192284, 23.19958266683328, 4.9267906708238325, 4.895999045375173, 14.540484796965957, 51.70157044706137, 5.553104115385029, 13.375052355675598, 8.633922003059833, 12.511635994547554, 7.788936793968179, 16.363225099550437, 28.381051619785254, 28.72830285346726, 43.359797766830354, 89.12199676494748, 42.63878659691934, 24.87792977061975, 13.301300176621984, 53.28554523476812, 34.12728160228511, 38.68159220745397, 21.326046593904053, 18.44967243110165, 44.38555453680137, 19.68233435503941, 19.942457165958675, 21.153085581057276, 32.84233217676666, 33.24057507935066, 19.557060855429008, 18.481701119661835, 19.671561385491074, 29.699674165213057, 28.716187725118242, 40.665286283868, 50.90975522023464, 25.048516894078826, 183.07257653826218, 25.0233201843878, 25.022558724439445, 25.02077183176064, 25.003090731759865, 25.002116063025973, 52.13116743579209, 23.85001193196769, 37.95974294137208, 26.074568945286618, 13.979291651151465, 32.857154139856284, 11.463111975911906, 20.350317896435207, 8.94045100741194, 11.299344784819452, 16.074408087849733, 50.360311103500806, 29.473710925539066, 5.090118625761583, 12.332494911845817, 8.58293667796043, 7.062130467159446, 9.86194572401136, 24.13588684037816, 23.59084396214581, 36.87397212461472, 64.32854254890243, 32.69138684729949, 23.10191306750766, 22.138539322848693, 31.364207844915697, 24.083973039299224, 21.69351674703245, 32.21888572014698, 23.394709646848668, 27.641447924812706, 24.350181975443544, 36.14392778108535, 11.56448156289031, 28.205834263742695, 7.562117553043952, 9.994858247677156, 8.334591138381361, 12.429721782982574, 9.67535233235607, 8.091699719109993, 14.62492246143512, 8.502488819626612, 6.716732655031079, 9.595945552102652, 10.306589913194504, 12.512806357497986, 5.824135407403642, 4.897405348137898, 50.26053948922388, 90.04202859783288, 10.943717768077784, 9.55636133536003, 26.295913940991397, 4.706175072723622, 3.941294386388076, 3.96287979511734, 19.71955561507782, 7.816432000252749, 9.570820693865967, 8.248676455066429, 13.941587458524802, 30.18015588325526, 17.909407249485174, 25.88683212873813, 28.258869528532838, 25.18632475932585, 34.38464883356333, 51.790883257041564, 20.308993390519888, 14.954059658771126, 18.224087160895834, 31.443630028777875, 14.842052222082653, 12.499965684435056, 21.70405775046241, 26.215694709145584, 27.48254923361512, 14.352942891688413, 13.968546550586149, 14.338006839646122, 18.447248131068527, 19.150424984284385, 13.634038260643802, 13.605505043622195, 46.75415924001668, 23.538637280425572, 20.7535731681112, 5.76741747497849, 62.70765200490569, 6.43420741315227, 10.177522898206483, 9.848326226150695, 13.425371921149376, 10.971986007753243, 12.112425494991966, 6.451289725746621, 9.525628862451532, 15.417722651279105, 12.789729526908046, 19.866480870223963, 19.85945799190753, 19.854668712475437, 5.77347111219622, 9.559252690056566, 56.684131669785806, 18.80751381231086, 3.899395135598656, 5.9112995933190104, 9.00541079902125, 9.002266383153886, 12.570505766253428, 4.585157556314688, 4.578894191502185, 3.260512824531628, 11.458464144374242, 7.726864192569536, 7.72491597301951, 7.712539048819341, 29.409075946065595, 30.820605577173694, 38.73114695016501, 20.44150300125009, 16.198721249241366, 22.34816053420937, 16.70546506373454, 16.605460954329256, 12.003482495886562, 13.34483952086462, 17.479311950715005, 13.459612947104745, 12.65083892532315, 14.73916549698425, 13.061232384722851, 12.356211353103125, 33.18970338493928, 63.398094037445034, 64.21125131487791, 11.482856568891703, 9.595760560217373, 8.651948503801917, 18.754952201100213, 14.242597317839753, 5.818970270418306, 13.361456437894851, 14.89324940194555, 13.382712177536794, 10.52120605938813, 49.118741877402, 19.04933858214837, 22.95080068349659, 12.537518593096298, 4.600544957898737, 5.16936292722114, 5.79988368087782, 17.16770166158414, 8.656394839026579, 4.892832803915519, 4.878772860624337, 4.878989534215439, 8.99351601197341, 5.848891143061537, 20.63382245943153, 3.915518423353755, 3.893314208646581, 14.786884999975566, 12.705069444422318, 10.08955363886452, 15.876498466132142, 39.24153801457992, 10.508192365874596, 9.553335991788972, 14.213196099686604, 18.357012742837938, 11.432940767558655, 12.483738879979851, 9.777070486352224, 8.346826134533954, 12.858920751556228, 89.16082647077339, 6.097200611913416, 3.619984932191729, 5.232697401122154, 12.8133923944444, 7.435839723830804, 14.3579354417223, 19.791504989260385, 15.082101156769523, 15.082031940595067, 4.319008722886808, 8.415810264600553, 10.123596255255778, 5.855644105906102, 4.047275099508616, 11.078701169025512, 7.373749411270758, 7.36520631983683, 7.361816429325624, 4.428759477670165, 3.8053569106224927, 7.937219565098865, 7.935012023010313, 3.7573796058300584, 10.929409823566353, 2.884074877642047, 4.044634105311184, 4.038899942399595, 49.49817477335706, 14.610549515271604, 7.367632290016898, 12.865324949730368, 12.859300873170037, 12.857059857685643, 13.317134095829307, 9.30204508478783, 25.656130177474836, 12.761058158408318, 9.500668840225368, 11.343933010770497, 11.123429568711266, 8.985185352393618, 13.10454285679422, 8.54242366804902, 9.02629068248865, 9.06357834342052, 8.978992206816995, 9.474173796397205, 9.74729401264726, 8.891774153547114], \"Total\": [208.0, 128.0, 66.0, 65.0, 129.0, 73.0, 116.0, 68.0, 124.0, 105.0, 47.0, 34.0, 81.0, 53.0, 77.0, 57.0, 56.0, 59.0, 68.0, 62.0, 73.0, 88.0, 64.0, 51.0, 38.0, 32.0, 58.0, 34.0, 97.0, 44.0, 53.907068232422574, 32.71716184191762, 57.73200008150845, 51.948220416043455, 15.389629154062265, 17.31049660480865, 12.501967222012887, 12.501283399005837, 11.539886882261975, 40.43577385642575, 11.540844335116539, 10.576672232333904, 8.651953531266255, 11.526216502779166, 58.696956433854666, 77.03797763836016, 81.61356716574772, 6.723285050100371, 26.824567536022077, 5.76070803973469, 5.760664308979373, 17.280670447604532, 62.37636058754347, 6.717408172128192, 16.23741822725863, 10.554471905112505, 15.350878334888973, 9.605005062570244, 20.228379540536963, 35.47253202473063, 37.252263694926455, 58.41192928664972, 129.2169747886879, 60.349264813191944, 34.49561583718014, 17.275257697799795, 88.1131562440801, 54.693612706453386, 69.97171465444835, 31.476486275616974, 26.81345916666829, 121.83738542801864, 32.62132938289703, 33.451728671185606, 37.25372055338681, 94.10848520688174, 116.60638036814001, 36.795385959220695, 31.399692421814958, 54.34339653774813, 30.543541496436564, 29.557141982301808, 44.21410079178487, 56.99729352118231, 28.479910130156505, 208.3135305764891, 28.479214795650183, 28.479121789987005, 28.47901871110477, 28.47853159140135, 28.478485911675406, 59.90359482620234, 27.48626142737495, 44.1687977230914, 30.421121417138327, 16.684250014425057, 39.280621448702, 13.722642546721538, 24.508509682295802, 10.777664825987156, 13.708502745136448, 20.511374094585484, 64.4196454312805, 38.98271364998635, 6.842016399285704, 16.621985209376376, 11.718246108793263, 9.676836728120099, 13.668827593620188, 34.17300825348063, 33.99602706774159, 55.37031848475144, 116.60638036814001, 55.422899200888395, 37.904509689266945, 39.51238705845597, 73.0169798052605, 49.752264544486124, 45.12626699284376, 116.88881104698493, 55.058248394022456, 94.10848520688174, 68.9186972773496, 38.11774740918323, 12.390267694185118, 31.415061682250816, 8.580395404069337, 11.443475595619407, 9.543619912817544, 14.27937532321207, 11.394184788499029, 9.536024526776146, 18.067060002673973, 10.523972264681124, 8.609793179756371, 12.357483595739636, 13.30766661843939, 16.244157701387607, 7.613364909207915, 6.626994004003463, 68.22156370848391, 124.38803797707348, 15.277380026484758, 13.371938905884571, 36.915984707975824, 6.651019620492099, 5.673541481861421, 5.707341122168483, 28.76530717939188, 11.459641261505574, 14.336450939918429, 12.39504863514737, 21.078859839362202, 48.808805578393574, 28.601423356414266, 44.038607394650136, 50.80512120647363, 45.46506849194107, 71.74995173756257, 121.83738542801864, 37.49557819648945, 25.62452611382713, 35.975194106525386, 88.1131562440801, 29.403128476922582, 22.099098200207873, 68.9186972773496, 105.62822051862938, 116.88881104698493, 32.023141156192914, 32.48616030919844, 36.81120595378964, 97.3703898148626, 208.3135305764891, 35.321783247594816, 37.8035945157643, 47.846995466725495, 24.395887489501508, 21.582173835575524, 6.576304585237845, 73.84500345994806, 8.418385273346784, 14.152650669944437, 14.20245166936677, 19.574809193652314, 16.74749302842643, 18.947835948565267, 10.324370458675695, 15.257520561269736, 25.074953691731388, 21.49901813541063, 33.4023490414494, 33.402308306105326, 33.402150763967995, 10.427486000437113, 17.787619918176535, 105.62822051862938, 35.919081051766916, 7.571193445034312, 11.499121978917081, 17.602700542070206, 17.602653680319666, 25.23421272111911, 9.275981702616974, 9.275833012278888, 6.642798427716139, 23.36411515583881, 15.74366441150881, 15.74354546151324, 15.743342147006665, 73.0169798052605, 94.10848520688174, 128.7052673322487, 56.22799827264805, 43.80281367680335, 97.3703898148626, 68.9186972773496, 71.74995173756257, 35.975194106525386, 49.752264544486124, 124.38803797707348, 55.37031848475144, 45.12626699284376, 116.60638036814001, 60.349264813191944, 45.46506849194107, 34.01039461906082, 65.19980854871437, 66.13527217622776, 12.284503642640557, 10.395284783288854, 9.450681701235307, 20.793718158925397, 16.081678907521855, 6.616905656604784, 16.099167549328882, 19.954934301791955, 18.069225742989538, 14.22858331324024, 68.28586507446428, 26.55899375513509, 32.277747433192374, 18.006237413931494, 6.624012099231875, 7.579544094295442, 8.542779756215314, 25.60208891288274, 13.2824560995338, 7.538324479830619, 7.578915358900448, 7.597556929412318, 14.051489040027969, 9.485263292884955, 34.25248745130337, 6.653369093294, 6.653203918380221, 25.639579538929294, 22.87202128493641, 18.044967971020682, 31.989977145268412, 129.2169747886879, 21.88032347656207, 19.108458039193252, 37.25372055338681, 69.97171465444835, 29.593760753060184, 58.41192928664972, 62.37636058754347, 9.149752813721017, 17.57530714778581, 128.7052673322487, 9.25278133128704, 5.593906048638635, 8.300768385944284, 20.447833311185047, 12.070492848687039, 24.103714211348546, 33.24862955981489, 27.03772027783698, 28.885637189995506, 8.32988146274991, 16.650459497673296, 20.573132441225553, 12.053718261551623, 8.482149095311215, 23.402991555333166, 15.743342147006665, 15.74354546151324, 15.74366441150881, 9.473129065142329, 8.425177136338345, 17.602653680319666, 17.602700542070206, 8.346318473995431, 24.660849260555832, 6.567860812226625, 9.275833012278888, 9.275981702616974, 116.88881104698493, 34.750444440453386, 17.715755409901696, 33.402150763967995, 33.402308306105326, 33.4023490414494, 36.67431422213191, 23.56302368556294, 97.3703898148626, 37.49557819648945, 25.36876920839071, 35.80371237850122, 36.209524398913814, 25.074953691731388, 71.74995173756257, 25.22437850893028, 30.253174930220755, 34.82183216356026, 37.8035945157643, 73.84500345994806, 124.38803797707348, 49.752264544486124], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -4.0734, -4.5862, -4.0298, -4.1465, -5.3668, -5.2505, -5.5868, -5.5883, -5.671, -4.4174, -5.6716, -5.7655, -5.9843, -5.7163, -4.0913, -3.8196, -3.7775, -6.2784, -4.9002, -6.4497, -6.456, -5.3674, -4.0989, -6.33, -5.451, -5.8887, -5.5177, -5.9917, -5.2493, -4.6987, -4.6865, -4.2748, -3.5544, -4.2916, -4.8304, -5.4565, -4.0687, -4.5143, -4.389, -4.9844, -5.1293, -4.2515, -5.0647, -5.0515, -4.9926, -4.5527, -4.5406, -5.071, -5.1276, -5.0652, -4.5192, -4.5529, -4.205, -3.9803, -4.6895, -2.7005, -4.6906, -4.6906, -4.6907, -4.6914, -4.6914, -3.9566, -4.7386, -4.2738, -4.6494, -5.2728, -4.4182, -5.4712, -4.8973, -5.7198, -5.4856, -5.1331, -3.9912, -4.5269, -6.2831, -5.3981, -5.7606, -5.9556, -5.6217, -4.7267, -4.7495, -4.3029, -3.7464, -4.4232, -4.7704, -4.813, -4.4647, -4.7288, -4.8333, -4.4378, -4.7579, -4.591, -4.7178, -4.1202, -5.2598, -4.3682, -5.6845, -5.4056, -5.5873, -5.1876, -5.4381, -5.6169, -5.025, -5.5673, -5.8031, -5.4464, -5.3749, -5.1809, -5.9457, -6.119, -3.7905, -3.2074, -5.3149, -5.4505, -4.4383, -6.1588, -6.3362, -6.3307, -4.7261, -5.6515, -5.449, -5.5976, -5.0728, -4.3005, -4.8224, -4.454, -4.3663, -4.4814, -4.1701, -3.7605, -4.6966, -5.0027, -4.805, -4.2595, -5.0102, -5.182, -4.6302, -4.4413, -4.3941, -5.0437, -5.0709, -5.0448, -4.7928, -4.7554, -5.0951, -5.0972, -3.5382, -4.2244, -4.3504, -5.6308, -3.2446, -5.5214, -5.0629, -5.0958, -4.7859, -4.9877, -4.8888, -5.5188, -5.1291, -4.6476, -4.8344, -4.394, -4.3944, -4.3946, -5.6298, -5.1256, -3.3456, -4.4488, -6.0223, -5.6062, -5.1852, -5.1856, -4.8517, -5.8602, -5.8616, -6.2012, -4.9443, -5.3384, -5.3386, -5.3402, -4.0018, -3.9549, -3.7264, -4.3655, -4.5981, -4.2763, -4.5673, -4.5733, -4.8979, -4.7919, -4.5221, -4.7834, -4.8453, -4.6926, -4.8134, -4.8689, -3.6649, -3.0177, -3.0049, -4.7263, -4.9058, -5.0093, -4.2357, -4.5109, -5.406, -4.5747, -4.4662, -4.5732, -4.8137, -3.2729, -4.2201, -4.0338, -4.6384, -5.6409, -5.5244, -5.4093, -4.3241, -5.0088, -5.5794, -5.5822, -5.5822, -4.9706, -5.4009, -4.1402, -5.8022, -5.8079, -4.4734, -4.6251, -4.8556, -4.4023, -3.4974, -4.815, -4.9102, -4.513, -4.2571, -4.7306, -4.6427, -4.8871, -4.9834, -4.5512, -2.6148, -5.2974, -5.8188, -5.4503, -4.5548, -5.099, -4.441, -4.12, -4.3918, -4.3918, -5.6422, -4.9752, -4.7904, -5.3379, -5.7072, -4.7002, -5.1073, -5.1085, -5.109, -5.6171, -5.7689, -5.0337, -5.034, -5.7815, -4.7138, -6.0461, -5.7079, -5.7093, -3.2033, -4.4235, -5.1082, -4.5507, -4.5512, -4.5514, -4.5162, -4.875, -3.8605, -4.5589, -4.8539, -4.6766, -4.6962, -4.9097, -4.5323, -4.9602, -4.9051, -4.901, -4.9104, -4.8567, -4.8283, -4.9201], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 1.3477, 1.3343, 1.3227, 1.3116, 1.3078, 1.3066, 1.2957, 1.2942, 1.2916, 1.2912, 1.2909, 1.2842, 1.2663, 1.2475, 1.2447, 1.2445, 1.2289, 1.2244, 1.2188, 1.2076, 1.2014, 1.1913, 1.1763, 1.1737, 1.1701, 1.1631, 1.1595, 1.1544, 1.1519, 1.141, 1.1042, 1.066, 0.9925, 1.0166, 1.0371, 1.1026, 0.861, 0.8923, 0.7713, 0.9747, 0.9901, 0.3542, 0.8588, 0.8467, 0.798, 0.3113, 0.109, 0.732, 0.834, 0.3478, 1.47, 1.4691, 1.4143, 1.3851, 1.3696, 1.3688, 1.3686, 1.3686, 1.3685, 1.3679, 1.3678, 1.359, 1.3561, 1.3465, 1.3438, 1.3211, 1.3194, 1.3181, 1.3121, 1.3111, 1.3047, 1.2543, 1.2518, 1.2184, 1.2022, 1.1995, 1.1866, 1.183, 1.1716, 1.1503, 1.1326, 1.0915, 0.9032, 0.9701, 1.0029, 0.9187, 0.653, 0.7725, 0.7656, 0.2093, 0.6421, 0.2729, 0.4576, 1.6475, 1.6317, 1.5929, 1.5743, 1.5653, 1.5652, 1.5619, 1.5372, 1.5364, 1.4893, 1.4874, 1.4524, 1.4478, 1.4451, 1.4397, 1.4328, 1.3982, 1.3951, 1.3775, 1.3671, 1.3647, 1.3614, 1.3548, 1.3364, 1.3359, 1.3231, 1.3181, 1.2966, 1.2934, 1.2873, 1.2199, 1.2325, 1.1693, 1.1141, 1.11, 0.9651, 0.8452, 1.0875, 1.1621, 1.0206, 0.6702, 1.017, 1.1309, 0.5452, 0.3071, 0.253, 0.8982, 0.8567, 0.7578, 0.0371, -0.686, 0.7487, 0.6787, 2.0022, 1.9895, 1.9861, 1.8941, 1.8618, 1.7565, 1.6956, 1.6592, 1.6482, 1.6024, 1.5778, 1.5551, 1.5542, 1.5389, 1.5059, 1.5057, 1.5054, 1.5051, 1.4341, 1.4043, 1.4029, 1.3783, 1.3618, 1.3599, 1.3551, 1.3547, 1.3285, 1.3207, 1.3193, 1.3137, 1.3128, 1.3136, 1.3133, 1.3117, 1.1159, 0.909, 0.8244, 1.0135, 1.0305, 0.5535, 0.6081, 0.5618, 0.9277, 0.7094, 0.0629, 0.6109, 0.7536, -0.043, 0.4948, 0.7225, 2.2168, 2.2132, 2.2117, 2.1738, 2.1612, 2.1529, 2.1381, 2.1198, 2.1127, 2.0549, 1.9487, 1.941, 1.9394, 1.9118, 1.9089, 1.9002, 1.8793, 1.8767, 1.8585, 1.854, 1.8416, 1.8131, 1.809, 1.8008, 1.7984, 1.795, 1.7578, 1.7344, 1.7111, 1.7054, 1.6909, 1.6533, 1.6599, 1.5407, 1.0495, 1.5078, 1.548, 1.2777, 0.9032, 1.2902, 0.6982, 0.3881, 2.2113, 1.9906, 1.936, 1.886, 1.8679, 1.8417, 1.8357, 1.8187, 1.785, 1.7843, 1.7194, 1.6533, 1.6463, 1.6208, 1.594, 1.5811, 1.5632, 1.5553, 1.5446, 1.5434, 1.543, 1.5428, 1.5083, 1.5066, 1.5063, 1.505, 1.4893, 1.4801, 1.4731, 1.4716, 1.4438, 1.4367, 1.4257, 1.349, 1.3485, 1.3484, 1.2901, 1.3737, 0.9694, 1.2253, 1.3209, 1.1537, 1.1228, 1.2768, 0.6029, 1.2203, 1.0936, 0.9571, 0.8656, 0.2497, -0.2433, 0.5812]}, \"token.table\": {\"Topic\": [2, 3, 4, 5, 6, 1, 2, 3, 4, 6, 2, 3, 4, 6, 3, 4, 6, 4, 6, 1, 3, 1, 3, 5, 6, 3, 1, 2, 3, 4, 1, 3, 4, 6, 2, 3, 4, 1, 3, 4, 6, 1, 2, 3, 2, 4, 6, 3, 6, 2, 3, 6, 1, 2, 3, 6, 1, 2, 3, 2, 3, 4, 6, 2, 3, 4, 6, 1, 5, 6, 1, 2, 5, 6, 2, 3, 1, 2, 6, 1, 1, 1, 4, 5, 6, 3, 6, 1, 1, 3, 4, 6, 4, 6, 5, 1, 2, 3, 4, 5, 6, 2, 4, 6, 1, 2, 5, 3, 5, 3, 5, 1, 3, 5, 3, 4, 1, 5, 1, 3, 5, 4, 6, 1, 3, 4, 6, 1, 2, 3, 4, 6, 1, 2, 3, 4, 6, 2, 3, 4, 6, 1, 2, 1, 2, 3, 1, 2, 3, 5, 4, 6, 1, 2, 3, 6, 2, 3, 1, 3, 5, 1, 2, 3, 4, 6, 1, 3, 5, 1, 1, 5, 1, 5, 5, 1, 2, 5, 1, 5, 1, 4, 5, 6, 3, 2, 3, 4, 6, 2, 3, 1, 1, 2, 3, 6, 1, 2, 3, 4, 6, 2, 4, 6, 1, 2, 4, 5, 1, 5, 6, 1, 5, 6, 3, 5, 1, 5, 3, 5, 3, 6, 1, 5, 6, 2, 3, 1, 5, 1, 5, 6, 1, 2, 3, 1, 2, 3, 4, 5, 6, 4, 1, 5, 1, 2, 4, 2, 3, 1, 2, 3, 4, 6, 1, 2, 2, 3, 4, 1, 3, 2, 3, 6, 1, 5, 2, 3, 1, 2, 3, 6, 2, 3, 1, 3, 4, 6, 3, 4, 4, 6, 1, 3, 4, 6, 2, 3, 2, 3, 4, 5, 4, 2, 3, 4, 2, 3, 4, 4, 6, 2, 3, 2, 3, 1, 2, 3, 1, 2, 3, 2, 3, 1, 3, 5, 1, 5, 6, 1, 2, 5, 4, 6, 3, 5, 1, 3, 4, 5, 2, 3, 1, 3, 5, 4, 6, 4, 6, 1, 2, 3, 4, 5, 6, 1, 4, 5, 6, 1, 1, 2, 3, 4, 6, 2, 3, 2, 3, 1, 2, 3, 6, 1, 5, 2, 3, 4, 1, 5, 6, 1, 4, 6, 2, 4, 1, 3, 4, 6, 1, 3, 4, 6, 2, 6, 1, 5, 6, 1, 2, 3, 4, 5, 6, 3, 4, 6, 4, 6, 2, 3, 4, 6, 1, 5, 3, 4, 6, 1, 3, 5, 1, 2, 3, 4, 6, 1, 2, 3, 4, 6, 1, 2, 3, 4, 6, 1, 3, 4, 6, 1, 2, 4, 6, 3, 4, 5, 1, 2, 3, 1, 2, 3, 4, 6, 1, 4, 6, 4, 5, 6, 5, 4, 6, 1, 5, 2, 3, 4, 2, 3, 4, 5, 6, 5, 1, 5, 2, 3, 6, 1, 2, 3, 6, 1, 2, 3, 4, 5, 6, 4, 6, 1, 2, 3, 4, 5, 6, 3, 4, 6, 1, 2, 5, 1, 1, 5, 2, 3, 4, 6, 3, 5, 1, 2, 3, 1, 1, 5, 6, 3, 6, 2, 4, 2, 6, 2, 3, 4, 6, 1, 3, 4, 2, 3, 1, 2, 3, 1, 2, 4, 3, 5, 1, 4, 5, 3, 4, 1, 5, 2, 4, 1, 5, 1, 2, 4, 1, 2, 5, 2, 3, 4, 4, 5, 6, 3, 4, 1, 3, 5, 4, 6, 1, 1, 6, 1, 4, 1, 3, 6, 1, 5, 6, 2, 6, 1, 2, 3, 4, 6, 1, 2, 4, 6, 1, 2, 3, 4, 5, 4, 6, 1, 2, 3, 4, 6, 2, 4, 1, 4, 4, 6, 1, 1, 3, 1, 2, 3, 4, 5, 2, 3, 2, 3, 1, 3, 4, 6, 1, 2, 4, 1, 5, 1, 4, 5, 6, 2, 3, 4, 6, 1, 3, 6, 3, 4, 6, 2, 3, 4, 6, 1, 3, 6, 1, 4, 2, 3, 4, 6, 1, 2, 5, 1, 4, 5, 1, 5, 1, 1, 3, 5, 1, 2, 4, 5, 4, 5, 2, 3, 6, 4, 6, 4], \"Freq\": [0.06801997282601153, 0.5101497961950865, 0.23806990489104038, 0.13603994565202307, 0.03400998641300577, 0.23651127694502036, 0.03941854615750339, 0.23651127694502036, 0.07883709231500678, 0.3941854615750339, 0.35569468262093445, 0.12449313891732706, 0.35569468262093445, 0.14227787304837378, 0.1937164118630958, 0.5811492355892873, 0.0968582059315479, 0.24094154986743227, 0.6023538746685807, 0.832899092492435, 0.10411238656155437, 0.6671646833804158, 0.1270789873105554, 0.0635394936552777, 0.1270789873105554, 0.9323579652525011, 0.03612043518497703, 0.6682280509220752, 0.05418065277746555, 0.2347828287023507, 0.043974365829831094, 0.7329060971638516, 0.10260685360293922, 0.11726497554621625, 0.802421694367944, 0.07294742676072218, 0.07294742676072218, 0.08339079397644843, 0.5003447638586905, 0.3335631759057937, 0.055593862650965616, 0.8679488641868882, 0.10478204382982097, 0.8382563506385677, 0.24303542565937747, 0.24303542565937747, 0.48607085131875494, 0.8776406724677416, 0.08776406724677416, 0.17452553307390697, 0.6981021322956279, 0.08726276653695349, 0.04525071525274247, 0.31675500676919727, 0.5430085830329096, 0.04525071525274247, 0.13905639787033774, 0.13905639787033774, 0.6952819893516887, 0.27376444086797325, 0.23098874698235242, 0.059885971439869144, 0.419201800079084, 0.18492683364649412, 0.11095610018789648, 0.1479414669171953, 0.5547805009394824, 0.22591217330437907, 0.7153885487972004, 0.037652028884063174, 0.597876426554525, 0.0597876426554525, 0.2690443919495363, 0.0597876426554525, 0.8160430911246875, 0.1632086182249375, 0.11789465013681294, 0.23578930027362588, 0.47157860054725176, 0.9454769685902754, 0.974682355879939, 0.2343091060287856, 0.0292886382535982, 0.717571637213156, 0.0146443191267991, 0.21615122290173097, 0.6484536687051929, 0.8932016406112024, 0.08126560956538266, 0.7043019495666497, 0.05417707304358844, 0.16253121913076532, 0.5987638383326699, 0.3891964949162354, 0.906768255643934, 0.36113709963018814, 0.12311492032847324, 0.42679839047204055, 0.049245968131389296, 0.024622984065694648, 0.008207661355231549, 0.1128938593768437, 0.4515754375073748, 0.3951285078189529, 0.11068542883061583, 0.11068542883061583, 0.7194552873990029, 0.048091447251378885, 0.9137374977761988, 0.944441958060905, 0.026234498835025138, 0.15057456128691424, 0.15057456128691424, 0.6775855257911141, 0.8302402271194074, 0.16604804542388146, 0.9526778895993331, 0.034642832349066656, 0.17481647461012392, 0.6293393085964462, 0.17481647461012392, 0.5112851848209385, 0.45447571984083424, 0.32720448233380567, 0.2999374421393219, 0.027267040194483807, 0.3544715225282895, 0.04181187481453648, 0.05574916641938197, 0.47386791456474675, 0.23693395728237338, 0.18118479086299139, 0.2179509946288595, 0.4177394063719807, 0.1816258288573829, 0.14530066308590633, 0.018162582885738292, 0.5567874187771155, 0.07592555710597028, 0.3037022284238811, 0.07592555710597028, 0.11987353331859793, 0.8391147332301855, 0.06016128563487742, 0.7219354276185291, 0.12032257126975485, 0.058525722557547843, 0.7023086706905741, 0.1463143063938696, 0.058525722557547843, 0.48046722080660326, 0.48046722080660326, 0.04744089612155501, 0.23720448060777505, 0.6641725457017702, 0.04744089612155501, 0.09502115502109792, 0.8551903951898813, 0.16135475211680936, 0.6454190084672374, 0.16135475211680936, 0.04565916734840117, 0.3196141714388082, 0.11414791837100294, 0.36527333878720936, 0.1369775020452035, 0.50686359618721, 0.101372719237442, 0.3716999705372873, 0.9531365020260385, 0.30060704955619594, 0.6012140991123919, 0.062182562265453004, 0.8705558717163421, 0.9619746075716653, 0.15033875605045713, 0.10022583736697142, 0.7516937802522857, 0.27882986626089573, 0.7125652137778447, 0.19822093924850642, 0.3567976906473116, 0.11893256354910385, 0.3567976906473116, 0.9685020772902045, 0.5433128168934939, 0.38031897182544566, 0.054331281689349385, 0.027165640844674693, 0.8603358469984715, 0.1358425021576534, 0.8924208858153987, 0.06545624958379036, 0.13091249916758071, 0.7200187454216939, 0.06545624958379036, 0.019683055098637953, 0.2755627713809314, 0.5511255427618628, 0.09841527549318976, 0.059049165295913864, 0.3045131523306389, 0.3045131523306389, 0.45676972849595837, 0.5573680764091528, 0.11433191310956979, 0.07145744569348113, 0.25724680449653203, 0.869953397035167, 0.11027578272276765, 0.012252864746974183, 0.8574229563669142, 0.03727925897247453, 0.07455851794494905, 0.7880877997511133, 0.13134796662518555, 0.21084319738342366, 0.7730917237392201, 0.26389000342262176, 0.6597250085565545, 0.7544898934538687, 0.15089797869077376, 0.4272958000414763, 0.08545916000829527, 0.470025380045624, 0.8778360577393144, 0.10534032692871773, 0.8336491502581248, 0.1603171442804086, 0.22214524378675496, 0.7219720423069537, 0.05553631094668874, 0.9831734823991594, 0.8778331909564591, 0.10533998291477509, 0.3506591348001727, 0.2975289628607526, 0.010626034387884021, 0.3294070660244046, 0.010626034387884021, 0.010626034387884021, 0.9123665004003153, 0.26324251579575897, 0.6581062894893974, 0.14082075732838398, 0.14082075732838398, 0.70410378664192, 0.8778542503065138, 0.10534251003678165, 0.08864017049392386, 0.4875209377165813, 0.022160042623480966, 0.2880805541052526, 0.11080021311740483, 0.959901445075175, 0.9811503432018085, 0.9822043721910906, 0.8403728964594974, 0.07003107470495812, 0.08738603858977972, 0.8738603858977972, 0.14956694119503214, 0.7478347059751607, 0.07478347059751607, 0.8680218771303123, 0.11573625028404164, 0.11614680853789065, 0.8130276597652345, 0.7784761816756288, 0.026844006264676857, 0.08053201879403057, 0.13422003132338428, 0.530866098271949, 0.43718384563572266, 0.04280067930370969, 0.17120271721483876, 0.47080747234080655, 0.2568040758222581, 0.8912922178287401, 0.06366372984491, 0.6568147233337612, 0.29855214696989146, 0.09302750420521938, 0.04651375210260969, 0.6046787773339259, 0.23256876051304845, 0.8350602978763227, 0.09278447754181364, 0.7800550039318731, 0.04875343774574207, 0.09750687549148414, 0.04875343774574207, 0.98229783378322, 0.20827767325797103, 0.24614634112305667, 0.5396285170774704, 0.7439194782688032, 0.025652395802372524, 0.2052191664189802, 0.3601491826042891, 0.48019891013905214, 0.768033024434133, 0.17067400542980732, 0.8731634916379423, 0.10914543645474278, 0.12728922852021787, 0.8401089082334379, 0.025457845704043573, 0.016693488978437594, 0.8680614268787549, 0.11685442284906315, 0.8015948795975888, 0.14574452356319795, 0.7525213358557136, 0.11577251320857132, 0.05788625660428566, 0.24853997575801748, 0.08284665858600583, 0.5799266101020408, 0.3663299249809869, 0.10466569285171054, 0.5233284642585527, 0.47925321954377526, 0.47925321954377526, 0.015120524450785412, 0.9677135648502664, 0.6713046566694286, 0.11188410944490476, 0.037294703148301585, 0.14917881259320634, 0.731591640285771, 0.21947749208573128, 0.5637020863434496, 0.026842956492545225, 0.37580139089563314, 0.508140912489973, 0.44462329842872633, 0.5112865459633674, 0.45447692974521553, 0.3680299958083694, 0.07360599916167389, 0.22081799748502165, 0.16561349811376624, 0.1288104985329293, 0.036802999580836944, 0.1250391640430301, 0.21881853707530263, 0.5001566561721204, 0.1562989550537876, 0.9532155828068092, 0.028776610374395346, 0.2589894933695581, 0.05755322074879069, 0.2589894933695581, 0.4316491556159302, 0.8947793280929472, 0.08772346353852424, 0.877855658391961, 0.10534267900703533, 0.6216448012399862, 0.12798569437293833, 0.1462693649976438, 0.09141835312352739, 0.8527191204744663, 0.09474656894160736, 0.42455878184332413, 0.16434533490709322, 0.397167892692142, 0.7893431452956063, 0.16914495970620136, 0.028190826617700226, 0.06015285521473791, 0.3308407036810585, 0.6015285521473791, 0.3277072431212833, 0.6554144862425666, 0.4617350852557591, 0.43095274623870855, 0.06156467803410122, 0.03078233901705061, 0.10486550209598414, 0.8389240167678731, 0.5987610142603339, 0.38919465926921704, 0.17876596269316425, 0.715063850772657, 0.3510197968080969, 0.5850329946801616, 0.039002199645344106, 0.08615284761321053, 0.08615284761321053, 0.2584585428396316, 0.28717615871070173, 0.028717615871070176, 0.2584585428396316, 0.013541877624020676, 0.8531382903133026, 0.12187689861618609, 0.3030179013522632, 0.6915023902654212, 0.4823901026362395, 0.06029876282952994, 0.26129463892796306, 0.1808962884885898, 0.3005995867591084, 0.6011991735182168, 0.22487550433391837, 0.5621887608347959, 0.22487550433391837, 0.16625133415686025, 0.22166844554248033, 0.5541711138562009, 0.13351081396221012, 0.18486112702459861, 0.18486112702459861, 0.22594137747450943, 0.26702162792442025, 0.10385784396125577, 0.06923856264083718, 0.20771568792251155, 0.10385784396125577, 0.5192892198062788, 0.3860249223517722, 0.02270734837363366, 0.5903910577144752, 0.9837723677947001, 0.8743405601081549, 0.026669811431088312, 0.5333962286217663, 0.10667924572435325, 0.3467075486041481, 0.7125190361987722, 0.06628084057662997, 0.21541273187404741, 0.016570210144157493, 0.8092262411295127, 0.16184524822590254, 0.8954370742191051, 0.02400228149445188, 0.8784835026969389, 0.09120866967891715, 0.08487875014213052, 0.21219687535532628, 0.25463625042639154, 0.08487875014213052, 0.38195437563958734, 0.1981436890961683, 0.5151735916500376, 0.31702990255386926, 0.2488858570362688, 0.2488858570362688, 0.4977717140725376, 0.9702915937795514, 0.5390351457794947, 0.4312281166235958, 0.015337468349356346, 0.9662605060094498, 0.7761607451462517, 0.031046429805850068, 0.17075536393217536, 0.08352106769313981, 0.2784035589771327, 0.5289667620565521, 0.02784035589771327, 0.05568071179542654, 0.9523122547682038, 0.8468570798619403, 0.13028570459414465, 0.6067879571203816, 0.34296710619847653, 0.026382085092190505, 0.11379601978972902, 0.05689800989486451, 0.05689800989486451, 0.7396741286332387, 0.13965032304868788, 0.11172025843895031, 0.19551045226816302, 0.08379019382921273, 0.11172025843895031, 0.30723071070711333, 0.5982064886104391, 0.35892389316626344, 0.07935753301842723, 0.10581004402456963, 0.3703351540859937, 0.10581004402456963, 0.07935753301842723, 0.23807259905528166, 0.05108606628586083, 0.6641188617161907, 0.2554303314293041, 0.9397619082282341, 0.02473057653232195, 0.02473057653232195, 0.9780799494350153, 0.9432469410418352, 0.0384998751445647, 0.06598472408617984, 0.5498727007181653, 0.26393889634471934, 0.08797963211490646, 0.15096590782434724, 0.7548295391217361, 0.885906240447042, 0.017036658470135423, 0.08518329235067712, 0.9246466674941979, 0.4570316344139919, 0.5027347978553911, 0.04570316344139919, 0.7050270122794005, 0.17625675306985011, 0.7059648456031882, 0.2941520190013284, 0.7233768840656958, 0.20667910973305595, 0.34823641403749656, 0.3192167128677052, 0.24666745994322672, 0.08705910350937414, 0.14131628389919498, 0.07065814194959749, 0.7065814194959749, 0.8546693477694217, 0.13148759196452642, 0.18468178253057307, 0.06156059417685769, 0.8002877242991501, 0.5435464115572927, 0.3533051675122402, 0.10870928231145853, 0.7008517476663836, 0.1752129369165959, 0.26415914670780627, 0.5283182934156125, 0.13207957335390313, 0.7514465373023235, 0.1502893074604647, 0.23411583314493115, 0.7023474994347935, 0.927305978540175, 0.06785165696635427, 0.12423002579927638, 0.8074951676952964, 0.2526031694815342, 0.595421756635045, 0.16238775180955772, 0.8826815303902811, 0.05192244296413418, 0.05192244296413418, 0.20488106360108815, 0.6146431908032645, 0.1639048508808705, 0.07116683485652917, 0.6405015137087625, 0.2135005045695875, 0.7517644339214951, 0.150352886784299, 0.10542669919875769, 0.21085339839751538, 0.6325601951925461, 0.508151314079207, 0.4446323998193061, 0.9242946846224729, 0.8006198903084358, 0.12317229081668243, 0.8675873819990134, 0.08675873819990133, 0.23738373302252222, 0.23738373302252222, 0.47476746604504444, 0.27341518982373597, 0.6640083181433588, 0.03905931283196228, 0.4222469653367804, 0.4222469653367804, 0.027617043211702535, 0.44187269138724056, 0.0828511296351076, 0.11046817284681014, 0.30378747532872785, 0.14615574439494158, 0.730778721974708, 0.5987602840501351, 0.3891941846325878, 0.2830033819402946, 0.5488550437629957, 0.008575860058796807, 0.1286379008819521, 0.02572758017639042, 0.5390265052581314, 0.43122120420650517, 0.5732540229436925, 0.03184744571909403, 0.15923722859547015, 0.06369489143818806, 0.19108467431456416, 0.43481580673439124, 0.5217789680812694, 0.45161689499457386, 0.45161689499457386, 0.712725755020554, 0.118787625836759, 0.8679554530206359, 0.27900908089200765, 0.6975227022300191, 0.13116462085385563, 0.13116462085385563, 0.13116462085385563, 0.04372154028461855, 0.568380023700041, 0.8778117587361438, 0.10533741104833726, 0.8778392350383827, 0.10534070820460592, 0.11707533581981772, 0.5853766790990886, 0.23415067163963543, 0.03902511193993924, 0.26388237757455363, 0.05277647551491072, 0.6333177061789287, 0.6887639967236825, 0.30181793114857997, 0.7361509973242369, 0.01711979063544737, 0.20543748762536845, 0.01711979063544737, 0.056275507788700725, 0.7235422429975807, 0.13666909034398747, 0.08039358255528675, 0.509600545188377, 0.3963559795909599, 0.08493342419806284, 0.3318990562970344, 0.0414873820371293, 0.5808233485198102, 0.26443505577355364, 0.165271909858471, 0.23138067380185942, 0.29748943774524783, 0.6014992795535096, 0.35182033332375084, 0.034047129031330725, 0.38360156991170474, 0.5754023548675571, 0.14671481101907202, 0.04890493700635734, 0.14671481101907202, 0.6357641810826454, 0.7909679550918333, 0.09887099438647916, 0.04943549719323958, 0.13193405666082547, 0.13193405666082547, 0.6596702833041274, 0.3795344796047893, 0.6130941593615827, 0.9598489411227182, 0.7247297777781502, 0.05797838222225201, 0.20292433777788205, 0.6130957989249132, 0.12261915978498264, 0.1532739497312283, 0.09196436983873697, 0.2653109461328121, 0.6632773653320302, 0.4866012469081339, 0.04055010390901116, 0.44605114299912274, 0.5081447517369481, 0.4446266577698295, 0.9730252457416554], \"Term\": [\"-month\", \"-month\", \"-month\", \"-month\", \"-month\", \"-year\", \"-year\", \"-year\", \"-year\", \"-year\", \".-\", \".-\", \".-\", \".-\", \".-nr\", \".-nr\", \".-nr\", \"accessed\", \"accessed\", \"according\", \"according\", \"across\", \"across\", \"across\", \"across\", \"activity\", \"adjuvant\", \"adjuvant\", \"adjuvant\", \"adjuvant\", \"advanced\", \"advanced\", \"advanced\", \"advanced\", \"aes\", \"aes\", \"aes\", \"alone\", \"alone\", \"alone\", \"alone\", \"analytical\", \"ann\", \"ann\", \"annual\", \"annual\", \"annual\", \"anti-ctla-\", \"anti-ctla-\", \"antibody\", \"antibody\", \"antibody\", \"approval\", \"approval\", \"approval\", \"approval\", \"approved\", \"approved\", \"approved\", \"arm\", \"arm\", \"arm\", \"arm\", \"asco\", \"asco\", \"asco\", \"asco\", \"assay\", \"assay\", \"assay\", \"available\", \"available\", \"available\", \"available\", \"avp\", \"avp\", \"baseline\", \"baseline\", \"baseline\", \"biomarker\", \"biomarkers\", \"biopsy\", \"biopsy\", \"biopsy\", \"biopsy\", \"blinded\", \"blinded\", \"blood\", \"braf\", \"braf\", \"braf\", \"braf\", \"bristol\", \"bristol\", \"brouha\", \"cancer\", \"cancer\", \"cancer\", \"cancer\", \"cancer\", \"cancer\", \"capability\", \"capability\", \"capability\", \"care\", \"care\", \"care\", \"case\", \"case\", \"cell\", \"cell\", \"center\", \"center\", \"center\", \"checkpoint\", \"checkpoint\", \"class\", \"class\", \"clin\", \"clin\", \"clin\", \"coffey\", \"coffey\", \"cohort\", \"cohort\", \"cohort\", \"cohort\", \"combination\", \"combination\", \"combination\", \"combination\", \"combination\", \"compared\", \"compared\", \"compared\", \"compared\", \"compared\", \"complete\", \"complete\", \"complete\", \"complete\", \"completely\", \"completely\", \"considering\", \"considering\", \"considering\", \"contact\", \"contact\", \"contact\", \"contact\", \"content\", \"content\", \"control\", \"control\", \"control\", \"control\", \"daily\", \"daily\", \"de\", \"de\", \"de\", \"death\", \"death\", \"death\", \"death\", \"death\", \"decision\", \"decision\", \"decision\", \"decision-making\", \"demonstrates\", \"demonstrates\", \"dermatology\", \"dermatology\", \"dermtech\", \"diagnosis\", \"diagnosis\", \"diagnosis\", \"diagnostic\", \"diagnostic\", \"director\", \"director\", \"director\", \"director\", \"dor\", \"dose\", \"dose\", \"dose\", \"dose\", \"dosing\", \"dosing\", \"drive\", \"duration\", \"duration\", \"duration\", \"duration\", \"efficacy\", \"efficacy\", \"efficacy\", \"efficacy\", \"efficacy\", \"england\", \"england\", \"england\", \"evidence\", \"evidence\", \"evidence\", \"evidence\", \"expression\", \"expression\", \"expression\", \"factor\", \"factor\", \"factor\", \"february\", \"february\", \"ferris\", \"ferris\", \"fewer\", \"fewer\", \"first-line\", \"first-line\", \"follow\", \"follow\", \"follow\", \"galloping\", \"galloping\", \"gene\", \"gene\", \"genomic\", \"genomic\", \"genomic\", \"gep\", \"giffin\", \"giffin\", \"group\", \"group\", \"group\", \"group\", \"group\", \"group\", \"guidelines\\u00ae\", \"guiding\", \"guiding\", \"hazard\", \"hazard\", \"hazard\", \"hill\", \"hill\", \"hr\", \"hr\", \"hr\", \"hr\", \"hr\", \"identified\", \"iib\", \"iic\", \"immune\", \"immune\", \"immunother\", \"immunother\", \"immunotherapy\", \"immunotherapy\", \"immunotherapy\", \"important\", \"important\", \"incidence\", \"incidence\", \"independent\", \"independent\", \"independent\", \"independent\", \"indication\", \"indication\", \"infusion\", \"infusion\", \"infusion\", \"infusion\", \"inhibitor\", \"inhibitor\", \"injection\", \"injection\", \"intravenous\", \"intravenous\", \"intravenous\", \"intravenous\", \"intravenously\", \"intravenously\", \"investigator\", \"investigator\", \"investigator\", \"investigator\", \"ipi\", \"ipilimumab\", \"ipilimumab\", \"ipilimumab\", \"iv\", \"iv\", \"iv\", \"james\", \"james\", \"jj\", \"jj\", \"kenilworth\", \"kenilworth\", \"keynote-\", \"keynote-\", \"keynote-\", \"keytruda\", \"keytruda\", \"keytruda\", \"keytruda\\u00ae\", \"keytruda\\u00ae\", \"laboratory\", \"laboratory\", \"laboratory\", \"landmark\", \"landmark\", \"landmark\", \"large\", \"large\", \"large\", \"lawrence\", \"lawrence\", \"lesion\", \"lesion\", \"level\", \"level\", \"level\", \"level\", \"luke\", \"luke\", \"management\", \"management\", \"management\", \"market\", \"market\", \"mary\", \"mary\", \"may\", \"may\", \"may\", \"may\", \"may\", \"may\", \"md\", \"md\", \"md\", \"md\", \"me-c\", \"meeting\", \"meeting\", \"meeting\", \"meeting\", \"meeting\", \"merck\", \"merck\", \"merck.com\", \"merck.com\", \"metastasis\", \"metastasis\", \"metastasis\", \"metastasis\", \"method\", \"method\", \"mg/kg\", \"mg/kg\", \"mg/kg\", \"molecular\", \"molecular\", \"molecular\", \"monotherapy\", \"monotherapy\", \"monotherapy\", \"ms-\", \"ms-\", \"mutation\", \"mutation\", \"mutation\", \"mutation\", \"mutation-positive\", \"mutation-positive\", \"myers\", \"myers\", \"myocarditis\", \"myocarditis\", \"negative\", \"negative\", \"negative\", \"new\", \"new\", \"new\", \"new\", \"new\", \"new\", \"nivo\", \"nivo\", \"nivo\", \"nivolumab\", \"nivolumab\", \"nj\", \"nj\", \"nj\", \"nj\", \"npv\", \"npv\", \"nr\", \"nr\", \"nr\", \"number\", \"number\", \"number\", \"o\", \"o\", \"o\", \"o\", \"o\", \"observed\", \"observed\", \"observed\", \"observed\", \"observed\", \"oncol\", \"oncol\", \"oncol\", \"opdivo\\u00ae\", \"oral\", \"orr\", \"orr\", \"orr\", \"orr\", \"outcome\", \"outcome\", \"outcome\", \"outcome\", \"pd-\", \"pd-\", \"peer\", \"pembrolizumab\", \"pembrolizumab\", \"pembrolizumab\", \"per\", \"per\", \"per\", \"per\", \"per\", \"pharmd\", \"pharmd\", \"pharmd\", \"phd\", \"phd\", \"phd\", \"pigmented\", \"pike\", \"pike\", \"pla\", \"pla\", \"placebo\", \"placebo\", \"placebo\", \"plus\", \"plus\", \"plus\", \"plus\", \"plus\", \"pre-diagnostic\", \"predictive\", \"predictive\", \"prescribing\", \"prescribing\", \"prescribing\", \"presentation\", \"presentation\", \"presentation\", \"presentation\", \"previously\", \"previously\", \"previously\", \"previously\", \"previously\", \"previously\", \"princeton\", \"princeton\", \"prior\", \"prior\", \"prior\", \"prior\", \"prior\", \"prior\", \"product\", \"product\", \"product\", \"profile\", \"profile\", \"profile\", \"profiling\", \"prognostic\", \"prognostic\", \"progression\", \"progression\", \"progression\", \"progression\", \"proposed\", \"proposed\", \"prospective\", \"prospective\", \"prospective\", \"prospectively\", \"publication\", \"publication\", \"publication\", \"pyrexia\", \"pyrexia\", \"qw\", \"qw\", \"randomization\", \"randomization\", \"randomized\", \"randomized\", \"randomized\", \"randomized\", \"ratio\", \"ratio\", \"ratio\", \"rd\", \"rd\", \"re\", \"re\", \"re\", \"recurrence\", \"recurrence\", \"recurrence\", \"reduction\", \"reduction\", \"reflect\", \"reflect\", \"reflect\", \"regimen\", \"regimen\", \"registry\", \"registry\", \"resected\", \"resected\", \"reviewed\", \"reviewed\", \"rf\", \"rf\", \"rf\", \"risk\", \"risk\", \"risk\", \"safety\", \"safety\", \"safety\", \"sample\", \"sample\", \"sample\", \"second-line\", \"second-line\", \"see\", \"see\", \"see\", \"senior\", \"senior\", \"sensitivity\", \"sequencing\", \"sequencing\", \"showed\", \"showed\", \"significance\", \"significance\", \"significance\", \"skin\", \"skin\", \"skin\", \"smr\", \"smr\", \"society\", \"society\", \"society\", \"society\", \"society\", \"sp\", \"sp\", \"squibb\", \"squibb\", \"stage\", \"stage\", \"stage\", \"stage\", \"stage\", \"standing\", \"standing\", \"status\", \"status\", \"status\", \"status\", \"status\", \"stratified\", \"stratified\", \"street\", \"street\", \"summarized\", \"summarized\", \"superior\", \"suppl\", \"suppl\", \"surgical\", \"surgical\", \"surgical\", \"surgical\", \"surgical\", \"suzana\", \"suzana\", \"suzana.giffin\", \"suzana.giffin\", \"systemic\", \"systemic\", \"systemic\", \"systemic\", \"table\", \"table\", \"table\", \"test\", \"test\", \"testing\", \"testing\", \"testing\", \"testing\", \"therapy\", \"therapy\", \"therapy\", \"therapy\", \"tissue\", \"tissue\", \"tissue\", \"traes\", \"traes\", \"traes\", \"treatment-related\", \"treatment-related\", \"treatment-related\", \"treatment-related\", \"tumor\", \"tumor\", \"tumor\", \"undergone\", \"undergone\", \"untreated\", \"untreated\", \"untreated\", \"untreated\", \"used\", \"used\", \"used\", \"useful\", \"useful\", \"useful\", \"utility\", \"utility\", \"validated\", \"validation\", \"validation\", \"validation\", \"value\", \"value\", \"value\", \"value\", \"via\", \"via\", \"virtual\", \"virtual\", \"virtual\", \"ww\", \"ww\", \"yervoy\\u00ae\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [4, 2, 1, 3, 6, 5]};\n",
              "\n",
              "function LDAvis_load_lib(url, callback){\n",
              "  var s = document.createElement('script');\n",
              "  s.src = url;\n",
              "  s.async = true;\n",
              "  s.onreadystatechange = s.onload = callback;\n",
              "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
              "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
              "}\n",
              "\n",
              "if(typeof(LDAvis) !== \"undefined\"){\n",
              "   // already loaded: just create the visualization\n",
              "   !function(LDAvis){\n",
              "       new LDAvis(\"#\" + \"ldavis_el17371330341875897767298211158\", ldavis_el17371330341875897767298211158_data);\n",
              "   }(LDAvis);\n",
              "}else if(typeof define === \"function\" && define.amd){\n",
              "   // require.js is available: use it to load d3/LDAvis\n",
              "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
              "   require([\"d3\"], function(d3){\n",
              "      window.d3 = d3;\n",
              "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "        new LDAvis(\"#\" + \"ldavis_el17371330341875897767298211158\", ldavis_el17371330341875897767298211158_data);\n",
              "      });\n",
              "    });\n",
              "}else{\n",
              "    // require.js not available: dynamically load d3 & LDAvis\n",
              "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
              "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "                 new LDAvis(\"#\" + \"ldavis_el17371330341875897767298211158\", ldavis_el17371330341875897767298211158_data);\n",
              "            })\n",
              "         });\n",
              "}\n",
              "</script>"
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Extract the most salient terms from the prepared pyLDAvis data\n",
        "term_info = lda_vis_data.token_table # Access the 'token_table' attribute using dot notation\n",
        "\n",
        "# Sort the terms by relevance and frequency\n",
        "top_terms = term_info.sort_values(by='Freq', ascending=False).head(10)\n",
        "\n",
        "# Display the most salient terms and their frequency\n",
        "print(\"Top 10 most salient terms and their frequency:\")\n",
        "print(top_terms[['Term', 'Freq']])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "DD3P5tiPrhk0",
        "outputId": "cef85806-bf4f-41cf-fe30-22efbf383cdf"
      },
      "execution_count": 26,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Top 10 most salient terms and their frequency:\n",
            "            Term      Freq\n",
            "term                      \n",
            "527      opdivo®  0.983772\n",
            "229          gep  0.983173\n",
            "307          ipi  0.982298\n",
            "562          iic  0.982204\n",
            "561          iib  0.981150\n",
            "265    profiling  0.978080\n",
            "202   biomarkers  0.974682\n",
            "536      yervoy®  0.973025\n",
            "345    pigmented  0.970292\n",
            "471          dor  0.968502\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from collections import defaultdict\n",
        "\n",
        "# Initialize a dictionary to store word frequencies\n",
        "word_counts = defaultdict(int)\n",
        "\n",
        "# Loop through the corpus and count the occurrences of each word\n",
        "for doc in corpus:\n",
        "    for word_id, freq in doc:\n",
        "        word_counts[word_id] += freq\n",
        "\n",
        "# Convert the word IDs back to words and print the 10 most frequent words\n",
        "most_common_words = sorted(word_counts.items(), key=lambda x: x[1], reverse=True)[:10]\n",
        "\n",
        "print(\"Top 10 words by frequency in the corpus:\")\n",
        "for word_id, count in most_common_words:\n",
        "    print(f\"{dictionary[word_id]}: {count}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "X6C7uXFtr3nr",
        "outputId": "807fa559-e974-418e-da2a-ea34f1b9a4fd"
      },
      "execution_count": 27,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Top 10 words by frequency in the corpus:\n",
            "pembrolizumab: 211\n",
            "nivolumab: 139\n",
            "test: 134\n",
            "therapy: 130\n",
            "cancer: 126\n",
            "arm: 123\n",
            "stage: 119\n",
            "ipilimumab: 110\n",
            "o: 102\n",
            "group: 97\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    }
  ]
}